@ARTICLE{Han2021-zr,
  title     = "{COVID-19} and cancer: From basic mechanisms to vaccine
               development using nanotechnology",
  author    = "Han, Hyun Jee and Nwagwu, Chinekwu and Anyim, Obumneme and
               Ekweremadu, Chinedu and Kim, San",
  abstract  = "Coronavirus disease 2019 (COVID-19), caused by severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global
               pandemic which has induced unprecedented ramifications, severely
               affecting our society due to the long incubation time,
               unpredictably high prevalence and lack of effective vaccines.
               One of the interesting notions is that there is an association
               between COVID-19 and cancer. Cancer patients seem to exhibit
               exacerbated conditions and a higher mortality rate when exposed
               to the virus. Therefore, vaccines are the promising solution to
               minimise the problem amongst cancer patients threatened by the
               new viral strains. However, there are still limitations to be
               considered, including the efficacy of COVID vaccines for
               immunocompromised individuals, possible interactions between the
               vaccine and cancer, and personalised medicine. Not only to
               eradicate the pandemic, but also to make it more effective for
               immunocompromised patients who are suffering from cancer, a
               successful vaccine platform is required through the
               implementation of nanotechnology which can also enable scalable
               manufacturing and worldwide distribution along with its faster
               and precise delivery. In this review, we summarise the current
               understanding of COVID-19 with clinical perspectives,
               highlighting the association between COVID-19 and cancer,
               followed by a vaccine development for this association using
               nanotechnology. We suggest different administration methods for
               the COVID-19 vaccine formulation options. This study will
               contribute to paving the way towards the prevention and
               treatment of COVID-19, especially for the immunocompromised
               individuals.",
  journal   = "Int. Immunopharmacol.",
  publisher = "Elsevier BV",
  volume    =  90,
  number    =  107247,
  pages     = "107247",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; Cancer; Nanotechnology; Pharmaceutics; Vaccine
               development",
  language  = "en"
}

@ARTICLE{Sonani2021-zn,
  title     = "{COVID-19} vaccination in immunocompromised patients",
  author    = "Sonani, Bhavin and Aslam, Fawad and Goyal, Amandeep and Patel,
               Janki and Bansal, Pankaj",
  journal   = "Clin. Rheumatol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  40,
  number    =  2,
  pages     = "797--798",
  month     =  feb,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ortega_Rodriguez2021-ru,
  title     = "The century of {mRNA} vaccines: {COVID-19} vaccines and allergy",
  author    = "Ortega Rodr{\'\i}guez, N R and Aud{\'\i}cana Berasategui, M T
               and de la Hoz Caballer, B and Valero Santiago, A",
  journal   = "J. Investig. Allergol. Clin. Immunol.",
  publisher = "Esmon Publicidad, SA",
  volume    =  31,
  number    =  1,
  pages     = "89--91",
  month     =  feb,
  year      =  2021,
  keywords  = "Allergy; COVID-19 vaccine; Coronavirus; PEG; Vaccine excipients",
  language  = "en"
}

@ARTICLE{Kanwugu2021-zt,
  title     = "{HIV/SARS-CoV-2} coinfection: A global perspective",
  author    = "Kanwugu, Osman N and Adadi, Parise",
  abstract  = "Since its first appearance in Wuhan, China, severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly
               spread throughout the world and has become a global pandemic.
               Several medical comorbidities have been identified as risk
               factors for coronavirus disease 2019 (COVID-19). However, it
               remains unclear whether people living with human
               immunodefeciency virus (PLWH) are at an increased risk of
               COVID-19 and severe disease manifestation, with controversial
               suggestion that HIV-infected individuals could be protected from
               severe COVID-19 by means of antiretroviral therapy or
               HIV-related immunosuppression. Several cases of coinfection with
               HIV and SARS-CoV-2 have been reported from different parts of
               the globe. This review seeks to provide a holistic overview of
               SARS-CoV-2 infection in PLWH.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  2,
  pages     = "726--732",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; HIV; antiretroviral therapy/coinfection;
               immunodeficiency",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Fung2021-bs,
  title     = "Treatment of immunocompromised {COVID-19} patients with
               convalescent plasma",
  author    = "Fung, Monica and Nambiar, Ashok and Pandey, Suchi and Aldrich, J
               Matthew and Teraoka, Justin and Freise, Christopher and Roberts,
               John and Chandran, Sindhu and Hays, Steven R and Bainbridge,
               Emma and DeVoe, Catherine and Roque Gardner, Annelys and Yokoe,
               Deborah and Henrich, Timothy J and Babik, Jennifer M and
               Chin-Hong, Peter",
  abstract  = "Immunosuppressed patients such as solid organ transplant and
               hematologic malignancy patients appear to be at increased risk
               for morbidity and mortality due to coronavirus disease 2019
               (COVID-19) caused by SARS coronavirus 2 (SARS-CoV-2).
               Convalescent plasma, a method of passive immunization that has
               been applied to prior viral pandemics, holds promise as a
               potential treatment for COVID-19. Immunocompromised patients may
               experience more benefit from convalescent plasma given
               underlying deficits in B and T cell immunity as well as
               contraindications to antiviral and immunomodulatory therapy. We
               describe our institutional experience with four immunosuppressed
               patients (two kidney transplant recipients, one lung transplant
               recipient, and one chronic myelogenous leukemia patient) treated
               with COVID-19 convalescent plasma through the Expanded Access
               Program (NCT04338360). All patients clinically improved after
               administration (two fully recovered and two discharged to
               skilled nursing facilities) and none experienced a transfusion
               reaction. We also report the characteristics of convalescent
               plasma product from a local blood center including positive
               SARS-CoV-2 IgG and negative SARS-CoV-2 PCR in all samples
               tested. This preliminary evidence suggest that convalescent
               plasma may be safe among immunosuppressed patients with COVID-19
               and emphasizes the need for further data on the efficacy of
               convalescent plasma as either primary or adjunctive therapy for
               COVID-19.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  2,
  pages     = "e13477",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; convalescent plasma; immunocompromised; transplant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Metawea2021-ha,
  title     = "{COVID} 19 and liver: An {A-Z} literature review",
  author    = "Metawea, Marwa Ibrahim and Yousif, Walid Ibrahim and Moheb,
               Islam",
  abstract  = "The coronavirus pandemic has changed the priorities of the whole
               medical society. During the clinical course of COVID-19, it has
               been observed that hepatic injury occurs in a significant
               proportion of patients, particularly in those with severe or
               critical illness. In this literature review, we summarize the
               most recent studies, which covered the pathophysiology of
               COVID-19 induced liver injury including; hepatic pathological
               findings, therapy related liver damage, and the effects of the
               viral infection on pre-existing liver diseasesin context of the
               most recent recommendations. Conclusions: This review sheds
               light on the impact of COVID-19 infection on the liver, as well
               as the prognostic effect of liver laboratory markers on disease
               outcome. Temporal variations in liver parameters during disease
               course as well as different patterns of derangement are
               depicted. More intensive surveillance and individualized
               therapeutic approaches should be tailored for immunocompromised
               patients with advanced liver disease, hepatocellular carcinoma,
               and liver transplant patients. Despite the limited studies on
               COVID-19 infected patients with preexisting liver disease, this
               comprehensive overview provides a perspective on the management
               of liver disease during COVID-19.",
  journal   = "Dig. Liver Dis.",
  publisher = "Elsevier BV",
  volume    =  53,
  number    =  2,
  pages     = "146--152",
  month     =  feb,
  year      =  2021,
  keywords  = "Covid -19; Drug hepatotoxicity; Inflammatory response; Liver
               function; Liver pathology",
  language  = "en"
}

@ARTICLE{Zivkovic2021-tv,
  title     = "{Doctor-Should} {I} get the {COVID-19} vaccine? Infection and
               immunization in individuals with neuromuscular disorders",
  author    = "{\v Z}ivkovi{\'c}, Sasha A and Gruener, Gregory and
               Narayanaswami, Pushpa and {AANEM Quality and Patient Safety
               Committee}",
  abstract  = "The clinical course of neuromuscular disorders (NMDs) can be
               affected by infections, both in immunocompetent individuals, and
               in those with reduced immunocompetence due to
               immunosuppressive/immunomodulating therapies. Infections and
               immunizations may also trigger NMDs. There is a potential for
               reduced efficacy of immunizations in patients with reduced
               immunocompetence. The recent vaccination program for coronavirus
               disease-2019 (COVID-19) raises several questions regarding the
               safety and efficacy of this vaccine in individuals with NMDs. In
               this Practice Topic article, we address the role of
               vaccine-preventable infections in NMDs and the safety and
               efficacy of immunization in individuals with NMDs, with emphasis
               on vaccination against COVID-19.",
  journal   = "Muscle Nerve",
  publisher = "Wiley",
  volume    =  63,
  number    =  3,
  pages     = "294--303",
  month     =  mar,
  year      =  2021,
  keywords  = "AANEM, COVID-19 vaccine, immunization, immunosuppression,
               infection, neuromuscular disorders",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Machado2021-kl,
  title     = "Invasive pulmonary aspergillosis in the {COVID-19} era: An
               expected new entity",
  author    = "Machado, Marina and Valerio, Maricela and {\'A}lvarez-Ur{\'\i}a,
               Ana and Olmedo, Mar{\'\i}a and Veintimilla, Cristina and
               Padilla, Bel{\'e}n and De la Villa, Sof{\'\i}a and Guinea,
               Jes{\'u}s and Escribano, Pilar and Ruiz-Serrano, Mar{\'\i}a
               Jes{\'u}s and Reigadas, Elena and Alonso, Roberto and Guerrero,
               Jos{\'e} Eugenio and Hortal, Javier and Bouza, Emilio and
               Mu{\~n}oz, Patricia and {COVID-19 Study Group}",
  abstract  = "OBJECTIVES: Information on the recently COVID-19-associated
               pulmonary aspergillosis (CAPA) entity is scarce. We describe
               eight CAPA patients, compare them to colonised ICU patients with
               coronavirus disease 2019 (COVID-19), and review the published
               literature from Western countries. METHODS: Prospective study
               (March to May, 2020) that included all COVID-19 patients
               admitted to a tertiary hospital. Modified AspICU and European
               Organization for Research and Treatment of Cancer/Mycoses Study
               Group (EORTC/MSG) criteria were used. RESULTS:
               COVID-19-associated pulmonary aspergillosis was diagnosed in
               eight patients (3.3\% of 239 ICU patients), mostly affected
               non-immunocompromised patients (75\%) with severe acute
               respiratory distress syndrome (ARDS) receiving corticosteroids.
               Diagnosis was established after a median of 15 days under
               mechanical ventilation. Bronchoalveolar lavage was performed in
               two patients with positive Aspergillus fumigatus cultures and
               galactomannan (GM) index. Serum GM was positive in 4/8 (50\%).
               Thoracic CT scan findings fulfilled EORTC/MSG criteria in one
               case. Isavuconazole was used in 4/8 cases. CAPA-related
               mortality was 100\% (8/8). Compared with colonised patients,
               CAPA subjects were administered tocilizumab more often (100\%
               vs. 40\%, p = .04), underwent longer courses of antibacterial
               therapy (13 vs. 5 days, p = .008), and had a higher all-cause
               mortality (100\% vs. 40\%, p = .04). We reviewed 96 similar
               cases from recent publications: 59 probable CAPA (also putative
               according modified AspICU), 56 putative cases and 13
               colonisations according AspICU algorithm; according EORTC/MSG
               six proven and two probable. Overall, mortality in the reviewed
               series was 56.3\%. CONCLUSIONS: COVID-19-associated pulmonary
               aspergillosis must be considered a serious and potentially
               life-threatening complication in patients with severe COVID-19
               receiving immunosuppressive treatment.",
  journal   = "Mycoses",
  publisher = "Wiley",
  volume    =  64,
  number    =  2,
  pages     = "132--143",
  month     =  feb,
  year      =  2021,
  keywords  = "Aspergillus infection; COVID-19; SARS-CoV-2 infection;
               antifungal therapy; fungal diseases; fungal infections;
               intensive care; invasive pulmonary aspergillosis",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Abdelgawad2021-bc,
  title     = "Clinical review of {COVID-19}; Pathogenesis, diagnosis, and
               management",
  author    = "Abdelgawad, Hussien Ahmed H and Sayed, Ahmed and Munir, Malak
               and Elberry, Mostafa H and Sayed, Ibrahim M and Kamal, Md Amjad
               and Negida, Ahmed and Ebada, Mahmoud A and Bahbah, Eshak I",
  abstract  = "Severe acute respiratory syndrome-coronavirus (SARS-CoV-2, or
               COVID-19 virus) is a worldwide pandemic pathogen infecting 210
               territories. It belongs to the family coronaviriadae and the
               order Nidovirales. The SARS-CoV-2 virus is a positive-sense
               single-stranded RNA enveloped virus that includes spike proteins
               projecting from the envelope. The spike (S) protein interacts
               with the human angiotensin-converting enzyme 2 (ACE2) receptor,
               which plays a role in the viral entry into the cell. The
               SARS-CoV-2 virus is zoonotic; the wet animal market where live
               animals are sold is expected to be the source of infection. It
               is the third zoonotic coronavirus, after SARS-CoV and MERS-CoV.
               Transmission of the virus among humans is confirmed by direct
               contact, droplet infection, fecal-oral, and blood transmission.
               The symptoms of COVID 19 include fever, dry cough, headache, and
               difficulty in breathing. COVID 19 complications, including the
               development of acute respiratory distress syndrome (ARDS), acute
               organ injury, secondary infection, and shock, are common in
               immunocompromised and elderly patients. Up till now, there is no
               established treatment for COVID-19, and supportive measures
               including mechanical ventilation and the use of nonspecific
               anti-viral therapies such as Remdesevir, Liponavir, and
               chloroquine, are currently applied in severe cases. Also, until
               now, there is no approved vaccine for COVID-19. In this review,
               we have provided an update on the SARS-COV2 virus, focusing on
               the epidemiology, pathogenesis, clinical presentations,
               treatment options, and preventive measures associated with
               COVID-19 cases.",
  journal   = "Curr. Pharm. Des.",
  publisher = "Bentham Science Publishers Ltd.",
  volume    =  27,
  number    =  41,
  pages     = "4232--4244",
  year      =  2021,
  keywords  = "COVID-19; SARS-COV2; coronavirus; diagnosis; management.;
               pandemic; pathogenesis",
  language  = "en"
}

@ARTICLE{Raja2021-sw,
  title     = "{COVID-19} in solid organ transplant recipients: A systematic
               review and meta-analysis of current literature",
  author    = "Raja, Mohammed A and Mendoza, Maria A and Villavicencio, Aasith
               and Anjan, Shweta and Reynolds, John M and Kittipibul,
               Veraprapas and Fernandez, Anmary and Guerra, Giselle and
               Camargo, Jose F and Simkins, Jacques and Morris, Michele I and
               Abbo, Lilian A and Natori, Yoichiro",
  abstract  = "Severe acute respiratory virus syndrome 2 (SARS-CoV-2) has led
               to a worldwide pandemic. Early studies in solid organ transplant
               (SOT) recipients suggested a wide variety of presentations,
               however, there remains a paucity of robust data in this
               population. We conducted a systematic review and meta-analysis
               of SOT recipients with SARS-CoV-2 infection from January 1st t
               October 9th, 2020. Pooled incidence of symptoms, treatments and
               outcomes were assessed. Two hundred and fifteen studies were
               included for systematic review and 60 for meta-analysis. We
               identified 2,772 unique SOT recipients including 1,500 kidney,
               505 liver, 141 heart and 97 lung. Most common presenting
               symptoms were fever and cough in 70.2\% and 63.8\% respectively.
               Majority (81\%) required hospital admission. Immunosuppressive
               medications, especially antimetabolites, were decreased in
               76.2\%. Hydroxychloroquine and interleukin six antagonists were
               administered in59.5\% and 14.9\% respectively, while only few
               patients received remdesivir and convalescent plasma. Intensive
               care unit admission was 29\% from amongst hospitalized patients.
               Only few studies reported secondary infections. Overall
               mortality was 18.6\%. Our analysis shows a high incidence of
               hospital admission in SOT recipients with SARS-CoV-2 infection.
               As management of SARS-CoV-2 continues to evolve, long-term
               outcomes among SOT recipients should be assessed in future
               studies.",
  journal   = "Transplant. Rev. (Orlando)",
  publisher = "Elsevier BV",
  volume    =  35,
  number    =  1,
  pages     = "100588",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; Meta-analysis; SARS-CoV-2; Solid
               organ transplant; Systematic review",
  language  = "en"
}

@ARTICLE{Mohammed2021-tf,
  title     = "{COVID-19} in chronic Liver Disease and liver transplantation: A
               clinical review",
  author    = "Mohammed, Abdul and Paranji, Neethi and Chen, Po-Hung and Niu,
               Bolin",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has brought
               challenges to clinicians caring for patients with chronic liver
               disease. In the past 6 months, COVID-19 has led to over 150,000
               deaths in the United States and over 660,000 deaths around the
               world. Mounting evidence suggests that chronic liver diseases
               can have an adverse effect on the clinical outcomes of patients
               with COVID-19. We present a comprehensive review of the latest
               literature on preexisting liver diseases and its
               interrelationship with COVID-19 infection in cirrhosis,
               hepatocellular carcinoma, nonalcoholic fatty liver disease,
               autoimmune hepatitis, and viral hepatitis B. As social
               distancing and telemedicine gain new footing, we synthesize
               recommendations from 3 major hepatology societies [American
               Association for the Study of Liver Disease (AASLD), the European
               Association for the Study of Liver (EASL), and the Asian Pacific
               Association for the Study of Liver (APASL)] to present the best
               approaches for caring for patients with liver diseases as well
               as those requiring liver transplantation.",
  journal   = "J. Clin. Gastroenterol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  55,
  number    =  3,
  pages     = "187--194",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Goldman2021-nr,
  title     = "{COVID-19} in immunocompromised populations: implications for
               prognosis and repurposing of immunotherapies",
  author    = "Goldman, Jason D and Robinson, Philip C and Uldrick, Thomas S
               and Ljungman, Per",
  abstract  = "SARS-CoV-2 is the virus responsible for the COVID-19 pandemic.
               COVID-19 has highly variable disease severity and a bimodal
               course characterized by acute respiratory viral infection
               followed by hyperinflammation in a subset of patients with
               severe disease. This immune dysregulation is characterized by
               lymphocytopenia, elevated levels of plasma cytokines and
               proliferative and exhausted T cells, among other dysfunctional
               cell types. Immunocompromised persons often fare worse in the
               context of acute respiratory infections, but preliminary data
               suggest this may not hold true for COVID-19. In this review, we
               explore the effect of SARS-CoV-2 infection on mortality in four
               populations with distinct forms of immunocompromise: (1) persons
               with hematological malignancies (HM) and hematopoietic stem cell
               transplant (HCT) recipients; (2) solid organ transplant
               recipients (SOTRs); (3) persons with rheumatological diseases;
               and (4) persons living with HIV (PLWH). For each population, key
               immunological defects are described and how these relate to the
               immune dysregulation in COVID-19. Next, outcomes including
               mortality after SARS-CoV-2 infection are described for each
               population, giving comparisons to the general population of
               age-matched and comorbidity-matched controls. In these four
               populations, iatrogenic or disease-related immunosuppression is
               not clearly associated with poor prognosis in HM, HCT, SOTR,
               rheumatological diseases, or HIV. However, certain individual
               immunosuppressants or disease states may be associated with
               harmful or beneficial effects, including harm from severe CD4
               lymphocytopenia in PLWH and possible benefit to the calcineurin
               inhibitor ciclosporin in SOTRs, or tumor necrosis
               factor-$\alpha$ inhibitors in persons with rheumatic diseases.
               Lastly, insights gained from clinical and translational studies
               are explored as to the relevance for repurposing of
               immunosuppressive host-directed therapies for the treatment of
               hyperinflammation in COVID-19 in the general population.",
  journal   = "J. Immunother. Cancer",
  publisher = "BMJ",
  volume    =  9,
  number    =  6,
  pages     = "e002630",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; HIV; autoimmunity; hematologic malignancies;
               hematopoietic stem cell transplant; immunocompromised;
               rheumatology; solid organ transplant",
  language  = "en"
}

@ARTICLE{Marr2021-tk,
  title     = "Aspergillosis complicating severe Coronavirus disease",
  author    = "Marr, Kieren A and Platt, Andrew and Tornheim, Jeffrey A and
               Zhang, Sean X and Datta, Kausik and Cardozo, Celia and
               Garcia-Vidal, Carolina",
  abstract  = "Aspergillosis complicating severe influenza infection has been
               increasingly detected worldwide. Recently, coronavirus
               disease-associated pulmonary aspergillosis (CAPA) has been
               detected through rapid reports, primarily from centers in
               Europe. We provide a case series of CAPA, adding 20 cases to the
               literature, with review of pathophysiology, diagnosis, and
               outcomes. The syndromes of pulmonary aspergillosis complicating
               severe viral infections are distinct from classic invasive
               aspergillosis, which is recognized most frequently in persons
               with neutropenia and in other immunocompromised persons.
               Combined with severe viral infection, aspergillosis comprises a
               constellation of airway-invasive and angio-invasive disease and
               results in risks associated with poor airway fungus clearance
               and killing, including virus- or inflammation-associated
               epithelial damage, systemic immunosuppression, and underlying
               lung disease. Radiologic abnormalities can vary, reflecting
               different pathologies. Prospective studies reporting poor
               outcomes in CAPA patients underscore the urgent need for
               strategies to improve diagnosis, prevention, and therapy.",
  journal   = "Emerg. Infect. Dis.",
  publisher = "Centers for Disease Control and Prevention (CDC)",
  volume    =  27,
  number    =  1,
  pages     = "18--25",
  month     =  jan,
  year      =  2021,
  keywords  = "Aspergillus; COVID-19; SARS-CoV-2; aspergillosis; complications;
               coronavirus disease; fungal infections; fungi; respiratory
               infections; severe acute respiratory syndrome coronavirus 2;
               severe viral pneumonia; zoonoses",
  language  = "en"
}

@ARTICLE{Gresham2021-ne,
  title     = "An evidence-based guide to {SARS-CoV-2} vaccination of patients
               on immunotherapies in dermatology",
  author    = "Gresham, Louise M and Marzario, Barbara and Dutz, Jan and
               Kirchhof, Mark G",
  abstract  = "Immune-mediated diseases and immunotherapeutics can negatively
               affect normal immune functioning and, consequently, vaccine
               safety and response. The COVID-19 pandemic has incited research
               aimed at developing a novel severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) vaccine. As SARS-CoV-2 vaccines are
               developed and made available, the assessment of anticipated
               safety and efficacy in patients with immune-mediated
               dermatologic diseases and requiring immunosuppressive and/or
               immunomodulatory therapy is particularly important. A review of
               the literature was conducted by a multidisciplinary committee to
               provide guidance on the safety and efficacy of SARS-CoV-2
               vaccination for dermatologists and other clinicians when
               prescribing immunotherapeutics. The vaccine platforms being used
               to develop SARS-CoV-2 vaccines are expected to be safe and
               potentially effective for dermatology patients on
               immunotherapeutics. Current guidelines for the vaccination of an
               immunocompromised host remain appropriate when considering
               future administration of SARS-CoV-2 vaccines.",
  journal   = "J. Am. Acad. Dermatol.",
  publisher = "Elsevier BV",
  volume    =  84,
  number    =  6,
  pages     = "1652--1666",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunomodulatory therapy;
               immunosuppressive therapy; vaccine",
  language  = "en"
}

@ARTICLE{Patel2021-os,
  title     = "{COVID-19} in immunocompromised cancer patients: A case series
               and review of the literature",
  author    = "Patel, Raj H and Vanaparthy, Rachana and Greene, John N",
  abstract  = "The global pandemic of the novel coronavirus disease 2019
               (COVID-19), caused by severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2), has presented newfound challenges to
               the oncology community regarding management of disease
               progression in immunocompromised and cancer patients. Further,
               the large influx of COVID-19 patients has overwhelmed healthcare
               facilities, limited access to intensive care unit beds and
               ventilators, and canceled elective surgeries causing disruptions
               to the cancer care continuum and re-organization of oncological
               care. While it is known that the potential threat of infection
               is greatest in elderly patients (>60 years of age) and patients
               with underlying comorbidities, there is still insufficient data
               to determine the risk of COVID-19 in cancer patients. Given the
               immunosuppressive status in cancer patients arising from
               chemotherapy and other comorbidities, management of COVID-19 in
               this patient population carries a unique set of challenges. We
               report three cases of COVID-19 in immunocompromised cancer
               patients and discuss the challenges in preventing, diagnosing,
               and treating this vulnerable group.",
  journal   = "Cancer Control",
  publisher = "SAGE Publications",
  volume    =  28,
  pages     = "10732748211044361",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; cancer; comorbidities; immunocompromised",
  language  = "en"
}

@ARTICLE{Rhee2021-fv,
  title    = "Duration of Severe Acute Respiratory Syndrome Coronavirus 2
              ({SARS-CoV-2}) infectivity: When is it safe to discontinue
              isolation?",
  author   = "Rhee, Chanu and Kanjilal, Sanjat and Baker, Meghan and Klompas,
              Michael",
  abstract = "Defining the duration of infectivity of Severe Acute Respiratory
              Syndrome Coronavirus 2 (SARS-CoV-2) has major implications for
              public health and infection control practice in healthcare
              facilities. Early in the pandemic, most hospitals required 2
              negative RT-PCR tests before discontinuing isolation in patients
              with Covid-19. Many patients, however, have persistently positive
              RT-PCR tests for weeks to months following clinical recovery, and
              multiple studies now indicate that these generally do not reflect
              replication-competent virus. SARS-CoV-2 appears to be most
              contagious around the time of symptom onset, and infectivity
              rapidly decreases thereafter to near-zero after about 10 days in
              mild-moderately ill patients and 15 days in severely-critically
              ill and immunocompromised patients. The longest interval
              associated with replication-competent virus thus far is 20 days
              from symptom onset. This review summarizes evidence-to-date on
              the duration of infectivity of SARS-CoV-2, and how this has
              informed evolving public health recommendations on when it is
              safe to discontinue isolation precautions.",
  journal  = "Clin. Infect. Dis.",
  volume   =  72,
  number   =  8,
  pages    = "1467--1474",
  month    =  apr,
  year     =  2021,
  keywords = "COVID-19; SARS-CoV-2; isolation; transmission-based precautions",
  language = "en"
}

@ARTICLE{Luxi2021-lz,
  title     = "{COVID-19} vaccination in pregnancy, paediatrics,
               immunocompromised patients, and persons with history of allergy
               or prior {SARS-CoV-2} infection: Overview of current
               recommendations and pre- and post-marketing evidence for vaccine
               efficacy and safety",
  author    = "Luxi, Nicoletta and Giovanazzi, Alexia and Capuano, Annalisa and
               Crisafulli, Salvatore and Cutroneo, Paola Maria and Fantini,
               Maria Pia and Ferrajolo, Carmen and Moretti, Ugo and Poluzzi,
               Elisabetta and Raschi, Emanuel and Ravaldi, Claudia and Reno,
               Chiara and Tuccori, Marco and Vannacci, Alfredo and Zanoni,
               Giovanna and Trifir{\`o}, Gianluca and {Ilmiovaccino COVID19
               collaborating group}",
  abstract  = "To date, four vaccines have been authorised for emergency use
               and under conditional approval by the European Medicines Agency
               to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen,
               Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria
               (previously COVID-19 Vaccine AstraZeneca). Although the
               benefit-risk profile of these vaccines was proven to be largely
               favourable in the general population, evidence in special
               cohorts initially excluded from the pivotal trials, such as
               pregnant and breastfeeding women, children/adolescents,
               immunocompromised people and persons with a history of allergy
               or previous SARS-CoV-2 infection, is still limited. In this
               narrative review, we critically overview pre- and post-marketing
               evidence on the potential benefits and risks of marketed
               COVID-19 vaccines in the above-mentioned special cohorts. In
               addition, we summarise the recommendations of the scientific
               societies and regulatory agencies about COVID-19 primary
               prevention in the same vaccinee categories.",
  journal   = "Drug Saf.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  44,
  number    =  12,
  pages     = "1247--1269",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Avanzato2020-ra,
  title     = "Case study: Prolonged infectious {SARS-CoV-2} shedding from an
               asymptomatic immunocompromised individual with cancer",
  author    = "Avanzato, Victoria A and Matson, M Jeremiah and Seifert,
               Stephanie N and Pryce, Rhys and Williamson, Brandi N and Anzick,
               Sarah L and Barbian, Kent and Judson, Seth D and Fischer,
               Elizabeth R and Martens, Craig and Bowden, Thomas A and de Wit,
               Emmie and Riedo, Francis X and Munster, Vincent J",
  abstract  = "Long-term severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) shedding was observed from the upper respiratory
               tract of a female immunocompromised individual with chronic
               lymphocytic leukemia and acquired hypogammaglobulinemia.
               Shedding of infectious SARS-CoV-2 was observed up to 70 days,
               and of genomic and subgenomic RNA up to 105 days, after initial
               diagnosis. The infection was not cleared after the first
               treatment with convalescent plasma, suggesting a limited effect
               on SARS-CoV-2 in the upper respiratory tract of this individual.
               Several weeks after a second convalescent plasma transfusion,
               SARS-CoV-2 RNA was no longer detected. We observed marked
               within-host genomic evolution of SARS-CoV-2 with continuous
               turnover of dominant viral variants. However, replication
               kinetics in Vero E6 cells and primary human alveolar epithelial
               tissues were not affected. Our data indicate that certain
               immunocompromised individuals may shed infectious virus longer
               than previously recognized. Detection of subgenomic RNA is
               recommended in persistently SARS-CoV-2-positive individuals as a
               proxy for shedding of infectious virus.",
  journal   = "Cell",
  publisher = "Elsevier BV",
  volume    =  183,
  number    =  7,
  pages     = "1901--1912.e9",
  month     =  dec,
  year      =  2020,
  keywords  = "COVID-19; SARS-CoV-2; asymptometic; chronic lymphocytic
               leukemia; convalescent plasma; immunocompromised; infectious
               virus; long-term shedding; within host evolution",
  language  = "en"
}

@ARTICLE{Messika2021-ap,
  title     = "{COVID-19} in lung transplant recipients",
  author    = "Messika, Jonathan and Eloy, Philippine and Roux, Antoine and
               Hirschi, Sandrine and Nieves, Ana and Le Pavec, J{\'e}r{\^o}me
               and S{\'e}n{\'e}chal, Agathe and Saint Raymond, Christel and
               Carlier, Nicolas and Demant, Xavier and Le Borgne, Aur{\'e}lie
               and Tissot, Adrien and Debray, Marie-Pierre and Beaumont,
               Laurence and Renaud-Picard, Benjamin and Reynaud-Gaubert,
               Martine and Mornex, Jean-Fran{\c c}ois and Falque, Lo{\"\i}c and
               Boussaud, V{\'e}ronique and Jougon, Jacques and Mussot, Sacha
               and Mal, Herv{\'e} and {French Group of Lung Transplantation}",
  abstract  = "BACKGROUND: A concern about the susceptibility of
               immunocompromised patients to the worldwide pandemic of
               coronavirus disease 2019 (COVID-19) has been raised. We aimed at
               describing COVID-19 infections in the French cohort of lung
               transplant (LT) patients. METHODS: Multicenter nationwide cohort
               study of all LT recipients with COVID-19 diagnosed from March 1
               to May 19, 2020. Recipient main characteristics and their
               management were retrieved. Hospitalization characteristics,
               occurrence of complications and survival were analyzed. RESULTS:
               Thirty-five LT patients with a COVID-19 infection were included.
               Median age was 50.4 (40.6-62.9) years, 16 (45.7\%) were female,
               and 80\% were double-LT recipients. Infection was
               community-acquired in 25 (71.4\%). Thirty-one (88.6\%) required
               hospitalization, including 13 (41.9\%) in the intensive care
               unit. The main symptoms of COVID-19 were fever, cough, and
               diarrhea, present in 71.4\%, 54.3\%, and 31.4\% of cases,
               respectively. Extension of pneumonia on chest CT was moderate to
               severe in 51.4\% of cases. Among the 13 critically ill patients,
               7 (53.9\%) received invasive mechanical ventilation. Thrombotic
               events occurred in 4 patients. Overall survival rate was 85.7\%
               after a median follow-up of 50 days (41.0-56.5). Four of 5
               nonsurvivors had had bronchial complications or intensification
               of immunosuppression in the previous weeks. On univariate
               analysis, overweight was significantly associated with risk of
               death (odds ratio, 16.0; 95\% confidence interval, 1.5-170.6; P
               = 0.02). CONCLUSIONS: For the 35 LT recipients with COVID-19,
               the presentation was severe, requiring hospitalization in most
               cases, with a survival rate of 85.7\%.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  1,
  pages     = "177--186",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Kooman2021-xj,
  title     = "{COVID-19} in {ESRD} and acute kidney injury",
  author    = "Kooman, Jeroen P and van der Sande, Frank M",
  abstract  = "The COVID-19 pandemic has greatly affected nephrology. Firstly,
               dialysis patients appear to be at increased risk for infection
               due to viral transmission next to an enhanced risk for mortality
               as compared to the general population, even in the face of an
               often apparently mild clinical presentation. Derangements in the
               innate and adaptive immune systems may be responsible for a
               reduced antiviral response, whereas chronic activation of the
               innate immune system and endothelial dysfunction provide a
               background for a more severe course. The presence of severe
               comorbidity, older age, and a reduction of organ reserve may
               lead to a rapid deterioration of the clinical situation of the
               patients in case of severe infection. Secondly, patients with
               COVID-19 are at increased risk of acute kidney injury (AKI),
               which is related to the severity of the clinical disease. The
               presence of AKI, and especially the need for renal replacement
               therapy (RRT), is associated with an increased risk of
               mortality. AKI in COVID-19 has a multifactorial origin, in which
               direct viral invasion of kidney cells, activation of the
               renin-angiotensin aldosterone system, a hyperinflammatory
               response, hypercoagulability, and nonspecific factors such as
               hypotension and hypoxemia may be involved. Apart from logistic
               challenges and the need for strict hygiene within units,
               treatment of patients with ESRD and COVID-19 is not different
               from that of the general population. Extracorporeal treatment of
               patients with AKI with RRT can be complicated by frequent filter
               clotting due to the hypercoagulable state, for which regional
               citrate coagulation provides a reasonable solution. Also, acute
               peritoneal dialysis may be a reasonable option in these
               patients. Whether adjuncts to extracorporeal therapies, such as
               hemoadsorption, provide additional benefits in the case of
               severely ill COVID-19 patients needs to be addressed in
               controlled studies.",
  journal   = "Blood Purif.",
  publisher = "S. Karger AG",
  volume    =  50,
  number    = "4-5",
  pages     = "610--620",
  year      =  2021,
  keywords  = "COVID-19; Dialysis; Kidney; Pathophysiology",
  copyright = "https://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Baang2021-rn,
  title     = "Prolonged severe acute respiratory syndrome Coronavirus 2
               replication in an immunocompromised patient",
  author    = "Baang, Ji Hoon and Smith, Christopher and Mirabelli, Carmen and
               Valesano, Andrew L and Manthei, David M and Bachman, Michael A
               and Wobus, Christiane E and Adams, Michael and Washer, Laraine
               and Martin, Emily T and Lauring, Adam S",
  abstract  = "We describe a case of chronic coronavirus disease 2019
               (COVID-19) in a patient with lymphoma and associated B-cell
               immunodeficiency. Viral cultures and sequence analysis
               demonstrate ongoing replication of infectious severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119
               days. The patient had 3 admissions related to COVID-19 over a
               4-month period and was treated twice with remdesivir and
               convalescent plasma with resolution of symptoms. The patient's
               lack of seroconversion and prolonged course illustrate the
               importance of humoral immunity in resolving SARS-CoV-2
               infection. This case highlights challenges in managing
               immunocompromised hosts, who may act as persistent shedders and
               sources of transmission.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  223,
  number    =  1,
  pages     = "23--27",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; antibody; evolution; immunocompromise",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Fardanesh2021-oq,
  title     = "{COVID-19} and rheumatology: Reflecting on the first wave and
               preparing for the second wave",
  author    = "Fardanesh, Armin and Byravan, Swetha and Moorthy, Arumugam and
               Tahir, Hasan",
  journal   = "Int. J. Rheum. Dis.",
  publisher = "Wiley",
  volume    =  24,
  number    =  1,
  pages     = "7--9",
  month     =  jan,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Parente2021-ha,
  title     = "{COVID-19}, liver transplant, and immunosuppression: Allies or
               foes?",
  author    = "Parente, Alessandro and Manzia, Tommaso Maria and Angelico,
               Roberta and Tirotta, Fabio and Muiesan, Paolo and Tisone,
               Giuseppe and Framarino Dei Malatesta, Marialuisa",
  abstract  = "Liver transplant (LT) recipients are considered at a
               particularly high risk for developing critical COVID-19
               infection. To date, available data are heterogeneous and scarce
               and mortality in LT recipients seems to be higher compared to
               normal population, but whether this is caused by altered
               immunological status, immunosuppression (IS), or underlying
               comorbidities has not yet been fully clarified. Some evidences
               show that IS might play a role in the pathophysiology of this
               new disease. We searched all available data regarding LT
               recipients infected by COVID-19, focusing on the role of IS. To
               date, 244 LT recipients have been reported as COVID-19-positive.
               Trends among transplant physicians are to reduce overall IS,
               especially antimetabolite drugs, but the current available
               observations are still not enough to build strong evidences for
               recommendation and IS should be meticulously tailored case by
               case.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  1,
  pages     = "e13417",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; liver transplant; liver transplantation",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Belsky2021-tx,
  title     = "{COVID-19} in immunocompromised patients: A systematic review of
               cancer, hematopoietic cell and solid organ transplant patients",
  author    = "Belsky, Jennifer A and Tullius, Brian P and Lamb, Margaret G and
               Sayegh, Rouba and Stanek, Joseph R and Auletta, Jeffery J",
  abstract  = "BACKGROUND: The clinical impact of severe coronavirus disease
               2019 (COVID-19), caused by severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2), in immunocompromised patients has
               not been systematically evaluated. METHODS: We reviewed current
               literature reporting on COVID-19 in cancer (CA), hematopoietic
               cell (HCT), and solid organ transplant (SOT) patients and
               compared their clinical data and outcomes to the general
               population. For adult CA, HCT and SOT patients, an extensive
               search strategy retrieved all articles published until July 20,
               2020 by combining the terms coronavirus, coronavirus infection,
               COVID-19, and SARS-CoV-2 in PubMed, Cochrane, and Web of
               Science, and following the Preferred Reporting Items for
               Systematic Reviews and Meta-analysis guidelines. For the
               pediatric CA cohort, a global COVID-19 registry was used. For
               the general population cohort, a large meta-analysis was used to
               compare pooled prevalence estimates, and two large meta-analyses
               were utilized to serve as pooled comparators for hospitalized
               COVID-19 patients. FINDINGS: Compared to the general population,
               adult CA and SOT patients with COVID-19 had higher
               comorbidities, greater levels of inflammatory markers at
               diagnosis, and higher rates of intensive care and hospital
               mortality. Pediatric CA patients and HCT patients with COVID-19
               tended to have clinical presentations and outcomes similar to
               the general population. INTERPRETATION: To our knowledge, this
               is the first systematic review evaluating COVID-19 phenotype and
               outcomes in immunocompromised patients and comparing them to the
               general population, which shows that hospital outcomes appear to
               be worse in adult CA and SOT patients, potentially due to their
               higher co-morbidity burden. FUNDING: None.",
  journal   = "J. Infect.",
  publisher = "Elsevier BV",
  volume    =  82,
  number    =  3,
  pages     = "329--338",
  month     =  mar,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Wang2021-cy,
  title     = "Convalescent plasma may be a possible treatment for {COVID-19}:
               A systematic review",
  author    = "Wang, Ying and Huo, Pengfei and Dai, Rulin and Lv, Xin and Yuan,
               Shaofei and Zhang, Yang and Guo, Yiming and Li, Rui and Yu, Qian
               and Zhu, Kun",
  abstract  = "INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic
               has spread globally. Therapeutic options including antivirals,
               anti-inflammatory compounds, and vaccines are still under study.
               Convalescent plasma(CP) immunotherapy was an effective method
               for fighting against similar viral infections such as SARS-CoV,
               and MERS-CoV. In the epidemic of COVID-19, a large number of
               literatures reported the application of CP. However, there is
               controversy over the efficacy of CP therapy for COVID-19. This
               systematic review was designed to evaluate the existing evidence
               and experience related to CP immunotherapy for COVID-19.
               METHODS: A literature search was conducted on Pubmed, Cochrane
               Library, Clinical Key, Wanfang Database; China National
               Knowledge Infrastructure(CNKI) were used to search for the
               proper keywords such as SARS-CoV-2, COVID-19, plasma, serum,
               immunoglobulins, blood transfusion, convalescent, novel
               coronavirus, immune and the related words for publications
               published until 15.10.2020. Other available resources were also
               used to identify relevant articles. The present systematic
               review was performed based on PRISMA protocol. Data extraction
               and risk of bias assessments were performed by two reviewers.
               RESULTS: Based on the inclusions and exclusions criteria, 45
               articles were included in the final review. First, meta-analysis
               results of RCTs showed that, there were no statistically
               significant differences between CP transfusion and the control
               group in terms of reducing mortality(OR 0.79, 95\% CI 0.52-1.19,
               I2 = 28\%) and improving clinical symptoms(OR 1.21, 95\%CI
               0.68-2.16; I2 = 0\%). The results of controlled NRSIs showed
               that CP therapy may reduce mortality in COVID-19 patients(RR
               0.59, 95\% CI 0.53-0.66, I2 = 0\%). Second, limited safety data
               suggested that CP is a well-tolerated therapy with a low
               incidence of adverse events. But, due to lack of safety data for
               the control group, it is really not easy to determine whether CP
               transfusion has an impact on moderate to serious AEs. Thirdly,
               for children, pregnant, elderly, tumor and immunocompromised
               patients, CP may be a well-tolerated therapy, if the disease
               cannot be controlled and continues to progress. Studies were
               commonly of low or very low quality. CONCLUSIONS: Although the
               results of limited RCTs showed that CP cannot significantly
               reduce mortality, some non-RCTs and case report(series) have
               found that CP may help patients improve clinical symptoms, clear
               the virus, and reduce mortality, especially for patients with
               COVID-19 within ten days of illness. We speculate that CP may be
               a possible treatment option. High-quality studies are needed for
               establishing stronger quality of evidence and pharmacists should
               also be actively involved in the CP treatment process and
               provide close pharmaceutical care.",
  journal   = "Int. Immunopharmacol.",
  publisher = "Elsevier BV",
  volume    =  91,
  number    =  107262,
  pages     = "107262",
  month     =  feb,
  year      =  2021,
  keywords  = "Convalescent plasma(CP); Coronavirus disease 2019(COVID-19);
               SARS-CoV-2",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Coll2021-pv,
  title     = "{COVID-19} in transplant recipients: The Spanish experience",
  author    = "Coll, Elisabeth and Fern{\'a}ndez-Ruiz, Mario and
               S{\'a}nchez-{\'A}lvarez, J Emilio and
               Mart{\'\i}nez-Fern{\'a}ndez, Jos{\'e} R and Crespo, Marta and
               Gayoso, Jorge and Bada-Bosch, Teresa and Oppenheimer, Federico
               and Moreso, Francesc and L{\'o}pez-Oliva, Mar{\'\i}a O and
               Melilli, Edoardo and Rodr{\'\i}guez-Ferrero, Marisa L and Bravo,
               Carlos and Burgos, Elena and Facundo, Carme and Lorenzo,
               Inmaculada and Ya{\~n}ez, {\'I}{\~n}igo and Galeano, Cristina
               and Roca, Ana and Cabello, Mercedes and G{\'o}mez-Bueno, Manuel
               and Garc{\'\i}a-Cos{\'\i}o, Mdolores and Graus, Javier and
               Llad{\'o}, Laura and de Pablo, Alicia and Loinaz, Carmelo and
               Aguado, Beatriz and Hern{\'a}ndez, Domingo and
               Dom{\'\i}nguez-Gil, Beatriz and {Spanish Group for the Study of
               COVID-19 in Transplant Recipients}",
  abstract  = "We report the nationwide experience with solid organ transplant
               (SOT) and hematopoietic stem cell transplant (HSCT) recipients
               diagnosed with coronavirus disease 2019 (COVID-19) in Spain
               until 13 July 2020. We compiled information for 778 (423 kidney,
               113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1
               multivisceral) recipients. Median age at diagnosis was 61 years
               (interquartile range [IQR]: 52-70), and 66\% were male. The
               incidence of COVID-19 in SOT recipients was two-fold higher
               compared to the Spanish general population. The median interval
               from transplantation was 59 months (IQR: 18-131). Infection was
               hospital-acquired in 13\% of cases. No donor-derived COVID-19
               was suspected. Most patients (89\%) were admitted to the
               hospital. Therapies included hydroxychloroquine (84\%),
               azithromycin (53\%), protease inhibitors (37\%), and
               interferon-$\beta$ (5\%), whereas immunomodulation was based on
               corticosteroids (41\%) and tocilizumab (21\%). Adjustment of
               immunosuppression was performed in 85\% of patients. At the time
               of analysis, complete follow-up was available from 652 patients.
               Acute respiratory distress syndrome occurred in 35\% of
               patients. Ultimately, 174 (27\%) patients died. In univariate
               analysis, risk factors for death were lung transplantation (odds
               ratio [OR]: 2.5; 95\% CI: 1.4-4.6), age >60 years (OR: 3.7; 95\%
               CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95\% CI:
               1.9-4.9).",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  5,
  pages     = "1825--1837",
  month     =  may,
  year      =  2021,
  keywords  = "antibiotic: antiviral; clinical decision-making; clinical
               research/practice; complication: infectious; infection and
               infectious agents - viral; infectious disease",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Islam2021-ke,
  title     = "Preventive behaviors and mental health-related symptoms among
               immunocompromised adults during the {COVID-19} pandemic: An
               analysis of the {COVID} impact survey",
  author    = "Islam, Jessica Yasmine and Vidot, Denise Christina and Havanur,
               Amoghvarsha and Camacho-Rivera, Marlene",
  abstract  = "The COVID-19 pandemic has disrupted the continuity of care of
               U.S. adults living with chronic diseases, including
               immunocompromised adults. Disruption in care may be a barrier to
               identifying COVID-19 associated sequelae, such as mental health
               symptoms, among the immunocompromised. Our objectives were to
               evaluate COVID-19-related preventive behaviors, with a focus on
               canceling doctor's appointments as a proxy for continuity of
               care, and to compare COVID-19-related mental health symptoms
               among the immunocompromised with the general population. We used
               nationally-representative data of 10,760 U.S. adults from the
               publicly-available COVID-19 Household Impact Survey. We defined
               immunocompromised as adults with a self-reported diagnosis of
               ``a compromised immune system'' (n = 854, 7.6\%). We adherence
               to self-reported COVID-19 preventive behaviors among
               immunocompromised adults to others using $\chi$2-tests. We
               focused on continuity of care and estimated determinants of
               canceling doctor's appointments among the immunocompromised
               using multivariable Poisson regression to estimate adjusted
               prevalence ratios (aPRs) with 95\% confidence intervals (95\%
               CIs). We evaluated associations of mental health symptoms with
               being immunocompromised using multinomial logistic regression
               and estimated conditional odds ratios (cOR) with 95\% CIs.
               Immunocompromised adults were more likely to adhere to
               recommended COVID-19 preventive behaviors, including washing or
               sanitizing hands (96.3\% vs. 89.8\%, $\chi$2 <0.001),
               maintaining social distance (91.9\% vs. 83.7\%, $\chi$2 <0.001),
               and canceling a doctor's appointment (47.1\% vs. 29.7\%, $\chi$2
               <0.001). Hispanic immunocompromised adults (aPR: 1.47, 95\% CI:
               1.12-1.92) and immunocompromised women (aPR: 1.25, 95\% CI:
               1.00-1.56) were more likely to cancel doctor's appointments
               compared to non-Hispanic White immunocompromised adults and men,
               respectively. Immunocompromised adults reported higher odds of
               feeling nervous/anxious/on edge (cOR: 1.89, 95\% CI: 1.44-2.51),
               depressed (cOR: 2.81, 95\% CI: 2.17-3.64), lonely (cOR: 2.28,
               95\% CI: 1.74-2.98), and hopeless (cOR: 2.86, 95\% CI:
               2.21-3.69) 3-7 days in the last week. Immunocompromised adults
               were more likely to cancel their doctor's appointments and
               report COVID19-related mental health symptoms. The continuity of
               care of immunocompromised adults should be prioritized through
               alternative interventions, such as telehealth.",
  journal   = "AIDS Res. Hum. Retroviruses",
  publisher = "Mary Ann Liebert Inc",
  volume    =  37,
  number    =  4,
  pages     = "304--313",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; immunocompromised; mental health symptoms; preventive
               behaviors",
  language  = "en"
}

@ARTICLE{Rao2021-yk,
  title     = "Clinical profile and outcome of {COVID-19} among
               immunocompromised children",
  author    = "Rao, Sunil Kumar and Kumar, Ashutosh and Prasad, Rajniti and
               Gupta, Vineeta and Mishra, Om Prakash",
  abstract  = "This retrospective study describes the clinical profile, risk of
               infection and outcome of coronavirus disease-19 in
               immuno-compromised children. It was found that children on
               immuno-suppressant medication has 2.89 times increased risk of
               infection (P=0.01). Disease manifestation was asymptomatic
               (P=0.01) or mild with predominant gastrointestinal symptoms
               (P=0.02) without alteration in immunosuppressive treatment
               regime.",
  journal   = "Indian Pediatr.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  58,
  number    =  7,
  pages     = "686--687",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Al-Rahimi2021-ne,
  title    = "Levels and predictors of fear and health anxiety during the
              current outbreak of {COVID-19} in immunocompromised and chronic
              disease patients in Saudi Arabia: A cross-sectional correlational
              study",
  author   = "Al-Rahimi, Jehan S and Nass, Nada M and Hassoubah, Shahira A and
              Wazqar, Dhuha Y and Alamoudi, Soha A",
  abstract = "Coronavirus disease 2019 (COVID-19) infection has become a
              clinical threat to healthy people as well as immunocompromised
              patients and those with pre-existing chronic diseases around the
              world. This study, which used a cross-sectional correlational
              design, aimed to assess the levels of fear and health anxiety and
              to investigate their predictors during the current outbreak of
              COVID-19 in immunocompromised and chronic disease patients in
              Saudi Arabia. Sociodemographic and clinical data, fear of
              COVID-19, and health anxiety measurements were collected by
              online surveys from June 15 to July 15, 2020. Univariate and
              multiple linear regression analysis was used to identify
              predictors. A total of 1,030 patients in 13 provinces in Saudi
              Arabia completed the questionnaire. A significant number of
              patients with chronic diseases experienced considerable levels of
              fear and anxiety during the COVID-19 outbreak. It was found that
              21.44\% of participants met the criteria for anxiety cases, and
              19.4\% were considered borderline anxiety cases. In regression
              analysis, significant predictors of fear and health anxiety were
              female gender, lower education, middle-aged, divorced or widowed,
              receiving immunosuppressants, type of chronic disease (Crohn's
              disease, hypertension, and cardiovascular diseases), and media
              use as a source of knowledge about COVID-19. Immunocompromised
              and chronic disease patients are vulnerable to fear and anxiety
              during epidemic infectious diseases such as COVID-19. Optimizing
              this population's compliance with appropriate infection
              prevention and control strategies is crucial during the
              infectious outbreaks to ensure their safety, to decrease the risk
              of infection and serious complications, and reduce their fear and
              health anxiety. Effective positive psychological interventions
              and support strategies also need to be immediately implemented to
              increase psychological resilience and improve the mental health
              of these patients. Due to the COVID-19 outbreak, chronic disease
              patients in Saudi Arabia need special attention from health
              authorities, policymakers, and healthcare professionals to manage
              maladaptive forms of health anxiety and fear.",
  journal  = "PLoS One",
  volume   =  16,
  number   =  4,
  pages    = "e0250554",
  month    =  apr,
  year     =  2021,
  language = "en"
}

@ARTICLE{Lewis2021-tm,
  title     = "Household transmission of severe acute respiratory syndrome
               Coronavirus-2 in the United States",
  author    = "Lewis, Nathaniel M and Chu, Victoria T and Ye, Dongni and
               Conners, Erin E and Gharpure, Radhika and Laws, Rebecca L and
               Reses, Hannah E and Freeman, Brandi D and Fajans, Mark and
               Rabold, Elizabeth M and Dawson, Patrick and Buono, Sean and Yin,
               Sherry and Owusu, Daniel and Wadhwa, Ashutosh and Pomeroy, Mary
               and Yousaf, Anna and Pevzner, Eric and Njuguna, Henry and
               Battey, Katherine A and Tran, Cuc H and Fields, Victoria L and
               Salvatore, Phillip and O'Hegarty, Michelle and Vuong, Jeni and
               Chancey, Rebecca and Gregory, Christopher and Banks, Michelle
               and Rispens, Jared R and Dietrich, Elizabeth and Marcenac,
               Perrine and Matanock, Almea M and Duca, Lindsey and Binder,
               Allison and Fox, Garrett and Lester, Sandra and Mills, Lisa and
               Gerber, Susan I and Watson, John and Schumacher, Amy and
               Pawloski, Lucia and Thornburg, Natalie J and Hall, Aron J and
               Kiphibane, Tair and Willardson, Sarah and Christensen, Kim and
               Page, Lindsey and Bhattacharyya, Sanjib and Dasu, Trivikram and
               Christiansen, Ann and Pray, Ian W and Westergaard, Ryan P and
               Dunn, Angela C and Tate, Jacqueline E and Nabity, Scott A and
               Kirking, Hannah L",
  abstract  = "BACKGROUND: The evidence base for severe acute respiratory
               syndrome coronavirus-2 (SARS-CoV-2) is nascent. We sought to
               characterize SARS-CoV-2 transmission within US households and
               estimate the household secondary infection rate (SIR) to inform
               strategies to reduce transmission. METHODS: We recruited
               patients with laboratory-confirmed SARS-CoV-2 infection and
               their household contacts in Utah and Wisconsin during 22 March
               2020-25 April 2020. We interviewed patients and all household
               contacts to obtain demographics and medical histories. At the
               initial household visit, 14 days later, and when a household
               contact became newly symptomatic, we collected respiratory swabs
               from patients and household contacts for testing by SARS-CoV-2
               real-time reverse-transcription polymerase chain reaction
               (rRT-PCR) and sera for SARS-CoV-2 antibodies testing by
               enzyme-linked immunosorbent assay (ELISA). We estimated SIR and
               odds ratios (ORs) to assess risk factors for secondary
               infection, defined by a positive rRT-PCR or ELISA test. RESULTS:
               Thirty-two (55\%) of 58 households secondary infection among
               household contacts. The SIR was 29\% (n = 55/188; 95\%
               confidence interval [CI], 23\%-36\%) overall, 42\% among
               children (aged <18 years) of the COVID-19 patient and 33\% among
               spouses/partners. Household contacts to COVID-19 patients with
               immunocompromised conditions and household contacts who
               themselves had diabetes mellitus had increased odds of infection
               with ORs 15.9 (95\% CI, 2.4-106.9) and 7.1 (95\% CI: 1.2-42.5),
               respectively. CONCLUSIONS: We found substantial evidence of
               secondary infections among household contacts. People with
               COVID-19, particularly those with immunocompromising conditions
               or those with household contacts with diabetes, should take care
               to promptly self-isolate to prevent household transmission.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  73,
  number    =  7,
  pages     = "1805--1813",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; contact tracing; household; transmission",
  language  = "en"
}

@ARTICLE{DAmico2021-kg,
  title     = "{SARS-CoV-2} vaccination in {IBD}: more pros than cons",
  author    = "D'Amico, Ferdinando and Rabaud, Christian and Peyrin-Biroulet,
               Laurent and Danese, Silvio",
  journal   = "Nat. Rev. Gastroenterol. Hepatol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  18,
  number    =  4,
  pages     = "211--213",
  month     =  apr,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Waheed2021-th,
  title     = "Imaging trend and disease course in admitted {COVID-19} patients",
  author    = "Waheed, Khawaja B and Naseer, Jawad and Ul Hassan, Muhammad Z
               and Sarfraz, Saulat and Ahmed, Zubair and Amin, Muhammad S and
               Ali, Imran and Shams, Tamer M O and Muthaian, Jebasingh and
               Arulanantham, Zechariah J",
  abstract  = "OBJECTIVES: To describe radiographic imaging findings and
               disease course in admitted Coronavirus disease 2019 (COVID-19)
               patients. METHODS: This retrospective study was carried in the
               Radiology Department, King Fahad Military Medical Complex,
               Dhahran between March to August 2020 (6 months). All laboratory
               confirmed COVID-19 admitted cases were evaluated for their
               symptoms, duration of hospital stays (in a ward or intensive
               care unit [ICU]), and imaging findings (ground-glass opacity
               [GGO], air-space shadowing/consolidation, and others such as
               atelectasis, reticulation, peribronchovascular thickening,
               lymphadenopathy and pleural effusion) on chest radiograph (CXR)
               and computed tomography (CT) studies. Cavitation, nodularity,
               bronchiectasis, and embolism detected on CT scans were
               considered as complications. Disease course in terms of recovery
               (radiographic regression or resolution of findings), worsening
               (shifting from ward to ICU), and unfavorable outcome (persistent
               ICU stay or death) were recorded. Imaging findings were
               interpreted by 2 experienced radiologists and consensus
               reporting was made. Chi-square test was used to determine
               association. Results: Out of 106 patients, majority were males
               (n=82, 77.4\%). Forty-six patients (43.3\%) had abnormal imaging
               with mostly peripheral GGO (56.5\%), followed by consolidations
               (34.7\%), and others (26\%). Complications were detected in 6
               ICU patients. All patients with unfavorable outcomes were above
               60 years having comorbidities or complications (p less than
               0.0005). Fatality rate was calculated as 2.8. Conclusion:
               Coronavirus disease 2019 is seen mostly affecting males, with
               peripheral opacities as common imaging findings. Elderly
               patients with co-morbidities may show unfavorable outcomes.",
  journal   = "Saudi Med. J.",
  publisher = "Saudi Medical Journal",
  volume    =  42,
  number    =  1,
  pages     = "30--37",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Patel2021-mx,
  title     = "{COVID-19} and {AIDS}: Outcomes from the coexistence of two
               global pandemics and the importance of chronic antiretroviral
               therapy",
  author    = "Patel, Raj H and Acharya, Arpan and Mohan, Mahesh and Byrareddy,
               Siddappa N",
  abstract  = "The outbreak of coronavirus disease 2019 (COVID-19), caused by
               severe acute respiratory syndrome 2 (SARS-CoV-2), has created a
               worldwide pandemic, raising multitude of challenges and
               uncertainties regarding disease management specific to
               immunocompromised patient populations. Despite over ~16 million
               confirmed cases of COVID-19 worldwide as of July 25, 2020, there
               is a dearth of reports describing the co-infection of Human
               Immunodeficiency Virus (HIV) and SARS-CoV-2. There are various
               unknowns regarding the simultaneous impact from these two
               diseases, despite the fact that the majority of patients with
               acquired immunodeficiency syndrome (AIDS) are immunocompromised
               and have comorbidities which can predispose them to severe
               clinical symptoms, and poorer prognosis, from COVID-19. A large
               majority of reports indicate that HIV patients with normal CD4
               T-cell counts and suppressed viral loads and receiving regular,
               chronic antiretroviral therapy (cART) do not present with a
               severe clinical course of COVID-19 and may not be at an
               increased risk of developing SARS-CoV-2 infection. These
               favorable indications for HIV patients may be the byproduct of a
               potential protective factor conferred by antiretroviral therapy
               which has also been used successfully in previous coronavirus
               epidemics. This article is protected by copyright. All rights
               reserved.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  2,
  pages     = "641--643",
  month     =  feb,
  year      =  2021,
  keywords  = "AIDS; COVID-19; HIV; SARS-CoV-2; antiviral; cART; co-infection",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Tekin2021-hn,
  title     = "Kidney transplantation and {COVID-19}: Two case reports",
  author    = "Tekin, Sabri and {\"O}zdo{\u g}an, Hatice and Demir, Mustafa
               Kemal and Soultan, Hagar and Zafar, Sadia",
  abstract  = "Immunocompromised populations are at great risk of the current
               2020 global emergency of coronavirus disease 2019 (COVID-19),
               and treatment of kidney transplant recipients with COVID-19 is
               currently not declared. Hence, the purpose of the study is to
               set a clear treatment regimen. We report here a therapeutic
               course of 2 patients who underwent transplant surgery in March
               2020 and got infected soon after. Since the transplant, these 2
               patients have received triple maintenance immunosuppressive
               therapy with oral tacrolimus, mycophenolate mofetil (MMF), and
               prednisone, and they have been regularly followed up at our
               hospital. The tacrolimus trough level was between 10 and 12
               ng/mL. After the diagnosis of COVID-19, MMF was stopped and the
               tacrolimus dose was reduced so that blood level was between 4
               and 6 ng/mL. The first patient was a 30-year-old man who,
               despite being treated with hydroxychloroquine, favipiravir,
               oseltamivir, and azithromycin therapy, died because of the
               presence of other comorbidities. The second case was a
               58-year-old man who fully recovered from COVID-19 pneumonia with
               treatment with methylprednisolone, MMF, azithromycin,
               favipiravir, hydroxychloroquine, and reduction in
               immunosuppression dosage. This reflects the importance of using
               glucocorticoids in the treatment of COVID-19 along with other
               medications and the decreased mortality rate associated with
               their use.",
  journal   = "Transplant. Proc.",
  publisher = "Elsevier BV",
  volume    =  53,
  number    =  4,
  pages     = "1207--1210",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Nakajima2021-hg,
  title     = "Prolonged viral shedding of {SARS-CoV-2} in an immunocompromised
               patient",
  author    = "Nakajima, Yukiko and Ogai, Asuca and Furukawa, Karin and Arai,
               Ryosuke and Anan, Ryusuke and Nakano, Yasushi and Kurihara, Yuko
               and Shimizu, Hideaki and Misaki, Takako and Okabe, Nobuhiko",
  abstract  = "The duration of viral shedding of SARS-CoV-2 is usually less
               than 10 days. We experienced a COVID-19 case with prolonged
               viral shedding for 2 months. His cell mediated immunity has been
               depressed (CD4+T cell <100/$\mu$l) due to advanced malignant
               lymphoma and chemotherapy which had been completed 4 months
               prior to the onset of symptoms of COVID-19. We administered
               several treatments against COVID-19, however the results of
               Polymerase Chain Reaction (PCR) from nasopharyngeal specimens
               remained positive to SARS-CoV-2 for 2 months. Moreover, virus
               isolation assays performed on Day 59 also remained positive. He
               was finally discharged on Day 69 with two consecutive negative
               PCR results for SARS-CoV-2. Immunocompromised status may prolong
               viral shedding and it is therefore important for the clinician
               to take into account this when assessing such patients.",
  journal   = "J. Infect. Chemother.",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  2,
  pages     = "387--389",
  month     =  feb,
  year      =  2021,
  keywords  = "Bendamustine; Follicular lymphoma; Immunocompromised state;
               SARS-CoV-2 PCR; Viral replication",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Madhusoodhan2021-my,
  title     = "Characterization of {COVID-19} disease in pediatric oncology
               patients: The New {York-New} Jersey regional experience",
  author    = "Madhusoodhan, P Pallavi and Pierro, Joanna and Musante, Jordan
               and Kothari, Prachi and Gampel, Bradley and Appel, Burton and
               Levy, Adam and Tal, Adit and Hogan, Laura and Sharma, Archana
               and Feinberg, Shari and Kahn, Alissa and Pinchinat, Ashley and
               Bhatla, Teena and Glasser, Chana L and Satwani, Prakash and
               Raetz, Elizabeth A and Onel, Kenan and Carroll, William L",
  abstract  = "PURPOSE: Pediatric oncology patients undergoing active
               chemotherapy are suspected to be at a high risk for severe
               disease secondary to severe acute respiratory syndrome
               coronavirus-2 (SARS-CoV-2) infection; however, data to support
               this are lacking. We aim to describe the characteristics of
               coronavirus disease 2019 (COVID-19) in this population and also
               its impact on pediatric cancer care in the New York region
               during the peak of the pandemic. PATIENTS AND METHODS: This
               multicenter, retrospective study included 13 institutions.
               Clinical and laboratory information on 98 patients $\leq$21
               years of age receiving active anticancer therapy, who tested
               positive for SARS-CoV-2 by nasopharyngeal swab polymerase chain
               reaction (PCR), was collected. RESULTS: Of the 578 pediatric
               oncology patients tested for COVID-19, 98 were positive, of whom
               73 were symptomatic. Most experienced mild disease, 28 required
               inpatient management, 25 needed oxygen support, and seven
               required mechanical ventilation. There is a slightly higher risk
               of severe disease in males and obese patients, though not
               statistically significant. Persistent lymphopenia was noted in
               severe cases. Delays in cancer therapy occurred in 67\% of
               SARS-CoV-2-positive patients. Of four deaths, none were solely
               attributable to COVID-19. The impact of the pandemic on
               pediatric oncology care was significant, with 54\% of
               institutions reporting delays in chemotherapy, 46\% delays in
               surgery, and 30\% delays in transplant. CONCLUSION: In this
               large multi-institutional cohort, we observed that mortality and
               morbidity from COVID-19 amongst pediatric oncology patients were
               low overall, but higher than reported in general pediatrics.
               Certain subgroups might be at higher risk of severe disease.
               Delays in cancer care due to SARS-CoV-2 remain a concern.",
  journal   = "Pediatr. Blood Cancer",
  publisher = "Wiley",
  volume    =  68,
  number    =  3,
  pages     = "e28843",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; chemotherapy; immunocompromised;
               immunotherapy; pediatric oncology",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Freeman2021-aj,
  title     = "Immunocompromised seroprevalence and course of illness of
               {SARS-CoV-2} in one pediatric Quaternary care center",
  author    = "Freeman, Megan Culler and Rapsinski, Glenn J and Zilla, Megan L
               and Wheeler, Sarah E",
  abstract  = "BACKGROUND: The burden of coronavirus disease 2019 (COVID-19) is
               poorly understood in pediatric patients due to frequent
               asymptomatic and mild presentations. Additionally, the disease
               prevalence in pediatric immunocompromised patients remains
               unknown. METHODS: This cross-sectional study tested convenience
               samples from pediatric patients who had clinically indicated lab
               work collected and an immunocompromising condition, including
               oncologic diagnoses, solid organ transplant (SOT), bone marrow
               transplant, primary immunodeficiency, and rheumatologic
               conditions or inflammatory bowel disease on systemic
               immunosuppression, for the presence of antibodies to severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RESULTS:
               We tested sera from 485 children and observed SARS-CoV-2
               seroprevalence of 1.0\% (Confidence Interval [CI] 95\%:
               0.3\%-2.4\%). Two patients were positive by nasopharyngeal (NP)
               swab Reverse transcriptase polymerase chain reaction (RT-PCR),
               but only 1 seroconverted. Patients with oncologic diagnoses or
               SOT were most likely to be tested for COVID-19 when presenting
               with respiratory illness as compared with other groups.
               CONCLUSIONS: Seroprevalence of antibodies to SARS-CoV-2 in
               immunocompromised children was similar to that of an
               immunocompetent pediatric population (0.6\%, CI 95\%:
               0.3\%-1.1\%), suggesting an adequate antibody response. However,
               none of the patients who tested positive for antibodies or via
               NP RT-PCR had more than a mild illness course and 2 patients did
               not have any reported illness, suggesting that SARS-CoV-2 may
               not cause a worse clinical outcome in immunosuppressed children,
               in contrast to immunocompromised adults.",
  journal   = "J. Pediatric Infect. Dis. Soc.",
  publisher = "Oxford University Press (OUP)",
  volume    =  10,
  number    =  4,
  pages     = "426--431",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunocompromised; pediatric; serology",
  language  = "en"
}

@ARTICLE{Gatechompol2021-tv,
  title    = "{COVID-19} and {HIV} infection co-pandemics and their impact: a
              review of the literature",
  author   = "Gatechompol, Sivaporn and Avihingsanon, Anchalee and Putcharoen,
              Opass and Ruxrungtham, Kiat and Kuritzkes, Daniel R",
  abstract = "Coronavirus disease 2019 (COVID-19) was first detected in
              December 2019. In March 2020, the World Health Organization
              declared COVID-19 a pandemic. People with underlying medical
              conditions may be at greater risk of infection and experience
              complications from COVID-19. COVID-19 has the potential to affect
              People living with HIV (PLWH) in various ways, including be
              increased risk of COVID-19 acquisition and interruptions of HIV
              treatment and care. The purpose of this review article is to
              evaluate the impact of COVID-19 among PLWH. The contents focus on
              4 topics: (1) the pathophysiology and host immune response of
              people infected with both SARS-CoV-2 and HIV, (2) present the
              clinical manifestations and treatment outcomes of persons with
              co-infection, (3) assess the impact of antiretroviral HIV drugs
              among PLWH infected with COVID-19 and (4) evaluate the impact of
              the COVID-19 pandemic on HIV services.",
  journal  = "AIDS Res. Ther.",
  volume   =  18,
  number   =  1,
  pages    = "28",
  month    =  may,
  year     =  2021,
  keywords = "COVID-19; Clinical; Co-infection; HIV; Outcome; Pathophysiology",
  language = "en"
}

@ARTICLE{Khade2021-ho,
  title     = "An update on {COVID-19}: {SARS-CoV-2} life cycle,
               immunopathology, and {BCG} vaccination",
  author    = "Khade, Shankar M and Yabaji, Shivraj M and Srivastava, Jyoti",
  abstract  = "The causative agent of novel coronavirus disease (COVID-19) is
               severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
               The SARS-CoV-2 possesses RNA as a genetic material with 79\% of
               the match with the bat SARS-CoV genome, which became epidemic in
               2002. The SARS-CoV-2 peripheral Spike-Fc protein binds
               specifically to the ACE2 receptors present on bronchial
               epithelial cells and alveolar pneumocytes to downmodulates its
               expression which leads to severe acute respiratory failure. The
               disease is super infectious from human to human and the symptoms
               are similar to flu. The old aged and immunocompromised
               population are severely affected, and healthcare providers
               globally applied various strategies for treatment including the
               repurposing of drugs including antimalarial drug,
               hydroxychloroquine and anti-viral drugs.Herein, we described the
               SARS-CoV-2 pandemic, immune responses, possible drug targets,
               vaccines under the trials and correlated the possibility of
               trained immunity induced by BCG vaccination over control of
               SARS-CoV-2 infection. The countries with constraint BCG
               vaccination policy are struggling badly compared to countries
               with BCG vaccination policy. The BCG vaccination policy supports
               either lowering the total number of COVID-19 cases or the
               increasing recovery rate.",
  journal   = "Prep. Biochem. Biotechnol.",
  publisher = "Informa UK Limited",
  volume    =  51,
  number    =  7,
  pages     = "650--658",
  year      =  2021,
  keywords  = "BCG vaccination; ; COVID-19; ; SARS-CoV-2; ; hydroxychloroquine;
               ; immunopathological response",
  language  = "en"
}

@ARTICLE{Chiotos2021-bc,
  title    = "Multicenter interim guidance on use of antivirals for children
              with Coronavirus disease 2019/severe acute respiratory syndrome
              Coronavirus 2",
  author   = "Chiotos, Kathleen and Hayes, Molly and Kimberlin, David W and
              Jones, Sarah B and James, Scott H and Pinninti, Swetha G and
              Yarbrough, April and Abzug, Mark J and MacBrayne, Christine E and
              Soma, Vijaya L and Dulek, Daniel E and Vora, Surabhi B and
              Waghmare, Alpana and Wolf, Joshua and Olivero, Rosemary and
              Grapentine, Steven and Wattier, Rachel L and Bio, Laura and
              Cross, Shane J and Dillman, Nicholas O and Downes, Kevin J and
              Oliveira, Carlos R and Timberlake, Kathryn and Young, Jennifer
              and Orscheln, Rachel C and Tamma, Pranita D and Schwenk, Hayden T
              and Zachariah, Philip and Aldrich, Margaret L and Goldman, David
              L and Groves, Helen E and Rajapakse, Nipunie S and Lamb,
              Gabriella S and Tribble, Alison C and Hersh, Adam L and Thorell,
              Emily A and Denison, Mark R and Ratner, Adam J and Newland, Jason
              G and Nakamura, Mari M",
  abstract = "BACKGROUND: Although coronavirus disease 2019 (COVID-19) is a
              mild infection in most children, a small proportion develop
              severe or critical illness. Data describing agents with potential
              antiviral activity continue to expand such that updated guidance
              is needed regarding use of these agents in children. METHODS: A
              panel of pediatric infectious diseases physicians and pharmacists
              from 20 geographically diverse North American institutions was
              convened. Through a series of teleconferences and web-based
              surveys, a set of guidance statements was developed and refined
              based on review of the best available evidence and expert
              opinion. RESULTS: Given the typically mild course of COVID-19 in
              children, supportive care alone is suggested for most cases. For
              children with severe illness, defined as a supplemental oxygen
              requirement without need for noninvasive or invasive mechanical
              ventilation or extracorporeal membrane oxygenation (ECMO),
              remdesivir is suggested, preferably as part of a clinical trial
              if available. Remdesivir should also be considered for critically
              ill children requiring invasive or noninvasive mechanical
              ventilation or ECMO. A duration of 5 days is appropriate for most
              patients. The panel recommends against the use of
              hydroxychloroquine or lopinavir-ritonavir (or other protease
              inhibitors) for COVID-19 in children. CONCLUSIONS: Antiviral
              therapy for COVID-19 is not necessary for the great majority of
              pediatric patients. For children with severe or critical disease,
              this guidance offers an approach for decision-making regarding
              use of remdesivir.",
  journal  = "J. Pediatric Infect. Dis. Soc.",
  volume   =  10,
  number   =  1,
  pages    = "34--48",
  month    =  feb,
  year     =  2021,
  keywords = "COVID-19; SARS-CoV-2; antiviral; pediatric",
  language = "en"
}

@ARTICLE{Shapiro_Ben_David2021-ht,
  title     = "Reactogenicity of a third {BNT162b2} {mRNA} {COVID-19} vaccine
               among immunocompromised individuals and seniors - A nationwide
               survey",
  author    = "Shapiro Ben David, Shirley and Shamir-Stein, Na'ama and Baruch
               Gez, Sharon and Lerner, Uri and Rahamim-Cohen, Daniella and Ekka
               Zohar, Anat",
  abstract  = "BACKGROUND: Since July 13, 2021, a third SARS-CoV-2 vaccine
               BNT162b2 was approved in Israel to immunocompromised and seniors
               60 years of age or older. We aimed to evaluate vaccine's
               reactogenicity. METHODS: A retrospective cohort, using
               electronic surveys sent to booster vaccine recipients, during
               July 20-August 10, 2021. RESULTS: 17,820 participated in the
               survey, with a response rate of 30.2\%. 3195 (17.9\%) were
               immunocompromised. Fatigue, myalgia and fever were the most
               frequent systemic side effects reported (19.6\%, 9.2\% and 8.1\%
               respectively among immunocompromised; 21.3\%, 9.9\% and 9.2\%
               respectively among seniors). 67.3\% of immunocompromised and
               62\% of seniors reported experiencing a better or a similar
               response to the third dose, compared to the second. CONCLUSIONS:
               Local and systemic reactions after third BNT162b2 vaccine,
               reported by immunocompromised and seniors, were similar to those
               observed following previous vaccines and mostly self-resolved.
               These findings may aid promoting confidence among vaccine
               providers and recipients.",
  journal   = "Clin. Immunol.",
  publisher = "Elsevier BV",
  volume    =  232,
  number    =  108860,
  pages     = "108860",
  month     =  nov,
  year      =  2021,
  keywords  = "Booster; Elderly; Immunocompromised; SARS-CoV-2; Side-effects;
               Vaccine",
  language  = "en"
}

@ARTICLE{Fung2021-dt,
  title    = "{COVID-19} in immunocompromised hosts: What we know so far",
  author   = "Fung, Monica and Babik, Jennifer M",
  abstract = "The coronavirus disease 2019 (COVID-19) pandemic caused by severe
              acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused
              significant morbidity and mortality for patients and stressed
              healthcare systems worldwide. The clinical features and outcomes
              of COVID-19 among immunosuppressed patients, who are at presumed
              risk of more severe disease but who may also have decreased
              detrimental inflammatory responses, are not well characterized.
              We review the existing literature on COVID-19 among
              immunocompromised populations ranging from patients with cancer
              and solid-organ transplant recipients to patients with HIV and
              those receiving immunomodulatory therapy for autoimmune disease.
              Patients with malignancy and solid-organ transplant recipients
              may be at increased risk of severe COVID-19 disease and death,
              whereas for those with other types of immunocompromise, current
              evidence is less clear. Overall, further prospective controlled
              studies are needed to determine the attributable risk of
              immunocompromising conditions and therapies on COVID-19 disease
              prognosis.",
  journal  = "Clin. Infect. Dis.",
  volume   =  72,
  number   =  2,
  pages    = "340--350",
  month    =  jan,
  year     =  2021,
  keywords = "COVID-19; biologics; cancer; immunocompromised; transplant",
  language = "en"
}

@ARTICLE{Greiner2021-ft,
  title     = "Characteristics and mechanisms to control a {COVID-19} outbreak
               on a leukemia and stem cell transplantation unit",
  author    = "Greiner, Jochen and G{\"o}tz, Marlies and Malner-Wagner,
               Waltraud and Wendt, Constanze and Enders, Martin and Durst,
               Christine and Michel, Detlef and von Harsdorf, S and Jung,
               Susanne",
  abstract  = "Immunosuppressed patients like patients with leukemia or
               lymphoma, but also patients after autologous or allogeneic stem
               cell transplantation are at particular risk for an infection
               with COVID-19. We describe a COVID-19 outbreak on our leukemia
               and stem cell transplantation unit (LSCT-Unit) originating from
               a patient with newly diagnosed acute myeloid leukemia. The
               patient was treated with intensive induction chemotherapy and we
               characterize the subsequent outbreak of COVID-19 on a LSCT-Unit.
               We describe the characteristics of the 36 contacts among the
               medical team, the results of their PCR and antibody tests and
               clinical aspects and features of infected employees. Of these 36
               close contacts, 9 employees of the LSCT-Unit were infected and
               were tested positive by PCR and/or antibody-testing. 8/9 of them
               were symptomatic, 3/9 with severe, 5/9 with mild symptoms, and
               one person without symptoms. Due to stringent hygiene measures,
               the outbreak did not lead to infections of other patients
               despite ongoing clinical work. Moreover, we demonstrate that
               incubation period and clinical course of a COVID-19 infection in
               an immunosuppressed patient could be unusual compared to that of
               immunocompetent patients. Consistent PCR and antibody testing
               are helpful to understand, control, and prevent outbreaks. For
               the safety of health-care workers and patients alike, all
               employees wore FFP2 masks and were trained to adhere to several
               further safety guidelines. The implementation of rigorous
               hygiene measures is the key to controlling an outbreak and
               preventing infections of other patients.",
  journal   = "Cancer Med.",
  publisher = "Wiley",
  volume    =  10,
  number    =  1,
  pages     = "237--246",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19 infection; acute myeloid leukemia; health-care
               facilities; immunocompromised individuals; management of disease
               control",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tenforde2021-mx,
  title     = "Association between {mRNA} vaccination and {COVID-19}
               hospitalization and disease severity",
  author    = "Tenforde, Mark W and Self, Wesley H and Adams, Katherine and
               Gaglani, Manjusha and Ginde, Adit A and McNeal, Tresa and
               Ghamande, Shekhar and Douin, David J and Talbot, H Keipp and
               Casey, Jonathan D and Mohr, Nicholas M and Zepeski, Anne and
               Shapiro, Nathan I and Gibbs, Kevin W and Files, D Clark and
               Hager, David N and Shehu, Arber and Prekker, Matthew E and
               Erickson, Heidi L and Exline, Matthew C and Gong, Michelle N and
               Mohamed, Amira and Henning, Daniel J and Steingrub, Jay S and
               Peltan, Ithan D and Brown, Samuel M and Martin, Emily T and
               Monto, Arnold S and Khan, Akram and Hough, Catherine L and
               Busse, Laurence W and Ten Lohuis, Caitlin C and Duggal, Abhijit
               and Wilson, Jennifer G and Gordon, Alexandra June and Qadir,
               Nida and Chang, Steven Y and Mallow, Christopher and Rivas,
               Carolina and Babcock, Hilary M and Kwon, Jennie H and Halasa,
               Natasha and Chappell, James D and Lauring, Adam S and Grijalva,
               Carlos G and Rice, Todd W and Jones, Ian D and Stubblefield,
               William B and Baughman, Adrienne and Womack, Kelsey N and
               Rhoads, Jillian P and Lindsell, Christopher J and Hart, Kimberly
               W and Zhu, Yuwei and Olson, Samantha M and Kobayashi, Miwako and
               Verani, Jennifer R and Patel, Manish M and {Influenza and Other
               Viruses in the Acutely Ill (IVY) Network}",
  abstract  = "Importance: A comprehensive understanding of the benefits of
               COVID-19 vaccination requires consideration of disease
               attenuation, determined as whether people who develop COVID-19
               despite vaccination have lower disease severity than
               unvaccinated people. Objective: To evaluate the association
               between vaccination with mRNA COVID-19 vaccines-mRNA-1273
               (Moderna) and BNT162b2 (Pfizer-BioNTech)-and COVID-19
               hospitalization, and, among patients hospitalized with COVID-19,
               the association with progression to critical disease. Design,
               Setting, and Participants: A US 21-site case-control analysis of
               4513 adults hospitalized between March 11 and August 15, 2021,
               with 28-day outcome data on death and mechanical ventilation
               available for patients enrolled through July 14, 2021. Date of
               final follow-up was August 8, 2021. Exposures: COVID-19
               vaccination. Main Outcomes and Measures: Associations were
               evaluated between prior vaccination and (1) hospitalization for
               COVID-19, in which case patients were those hospitalized for
               COVID-19 and control patients were those hospitalized for an
               alternative diagnosis; and (2) disease progression among
               patients hospitalized for COVID-19, in which cases and controls
               were COVID-19 patients with and without progression to death or
               mechanical ventilation, respectively. Associations were measured
               with multivariable logistic regression. Results: Among 4513
               patients (median age, 59 years [IQR, 45-69]; 2202 [48.8\%]
               women; 23.0\% non-Hispanic Black individuals, 15.9\% Hispanic
               individuals, and 20.1\% with an immunocompromising condition),
               1983 were case patients with COVID-19 and 2530 were controls
               without COVID-19. Unvaccinated patients accounted for 84.2\%
               (1669/1983) of COVID-19 hospitalizations. Hospitalization for
               COVID-19 was significantly associated with decreased likelihood
               of vaccination (cases, 15.8\%; controls, 54.8\%; adjusted OR,
               0.15; 95\% CI, 0.13-0.18), including for sequenced SARS-CoV-2
               Alpha (8.7\% vs 51.7\%; aOR, 0.10; 95\% CI, 0.06-0.16) and Delta
               variants (21.9\% vs 61.8\%; aOR, 0.14; 95\% CI, 0.10-0.21). This
               association was stronger for immunocompetent patients (11.2\% vs
               53.5\%; aOR, 0.10; 95\% CI, 0.09-0.13) than immunocompromised
               patients (40.1\% vs 58.8\%; aOR, 0.49; 95\% CI, 0.35-0.69) (P <
               .001) and weaker at more than 120 days since vaccination with
               BNT162b2 (5.8\% vs 11.5\%; aOR, 0.36; 95\% CI, 0.27-0.49) than
               with mRNA-1273 (1.9\% vs 8.3\%; aOR, 0.15; 95\% CI, 0.09-0.23)
               (P < .001). Among 1197 patients hospitalized with COVID-19,
               death or invasive mechanical ventilation by day 28 was
               associated with decreased likelihood of vaccination (12.0\% vs
               24.7\%; aOR, 0.33; 95\% CI, 0.19-0.58). Conclusions and
               Relevance: Vaccination with an mRNA COVID-19 vaccine was
               significantly less likely among patients with COVID-19
               hospitalization and disease progression to death or mechanical
               ventilation. These findings are consistent with risk reduction
               among vaccine breakthrough infections compared with absence of
               vaccination.",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  326,
  number    =  20,
  pages     = "2043--2054",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Schmidt2020-tr,
  title     = "Myths, misconceptions, othering and stigmatizing responses to
               Covid-19 in South Africa: A rapid qualitative assessment",
  author    = "Schmidt, Tenielle and Cloete, Allanise and Davids, Adlai and
               Makola, Lehlogonolo and Zondi, Nokubonga and Jantjies, Monalisa",
  abstract  = "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is
               a new strain of virus in the Coronavirus family that has not
               been previously identified. Since SARS-CoV-2 is a new virus,
               everyone is at risk of catching the Coronavirus disease 2019
               (Covid-19). No one has immunity to the virus. Despite this,
               misconceptions about specific groups of people who are immune to
               Covid-19 emerged with the onset of the pandemic. This paper
               explores South African communities' misconceptions about who is
               most vulnerable to Covid-19. A rapid qualitative assessment was
               conducted remotely in Gauteng, KwaZulu-Natal and the Western
               Cape provinces of South Africa. Recruitment of study
               participants took place through established relationships with
               civil society organizations and contacts made by researchers. In
               total, 60 key informant interviews and one focus group
               discussion was conducted. Atlas.ti.8 Windows was used to
               facilitate qualitative data analysis. The qualitative data was
               coded, and thematic analysis used to identify themes. The
               results show a high level of awareness and knowledge of the
               transmission and prevention of SARS-CoV-2. Qualitative data
               revealed that there is awareness of elderly people and those
               with immunocompromised conditions being more vulnerable to
               catching Covid-19. However, misconceptions of being protected
               against the virus or having low or no risk were also evident in
               the data. We found that false information circulated on social
               media not only instigated confusion, fear and panic, but also
               contributed to the construction of misconceptions, othering and
               stigmatizing responses to Covid-19. The study findings bring
               attention to the importance of developing communication
               materials adapted to specific communities to help reduce
               misconceptions, othering and stigmatization around Covid-19.",
  journal   = "PLoS One",
  publisher = "Public Library of Science (PLoS)",
  volume    =  15,
  number    =  12,
  pages     = "e0244420",
  month     =  dec,
  year      =  2020,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Taramasso2021-pe,
  title     = "Duration of isolation and precautions in immunocompromised
               patients with {COVID-19}",
  author    = "Taramasso, L and Sepulcri, C and Mikulska, M and Magnasco, L and
               Lai, A and Bruzzone, B and Dentone, C and Bassetti, M",
  journal   = "J. Hosp. Infect.",
  publisher = "Elsevier BV",
  volume    =  111,
  pages     = "202--204",
  month     =  may,
  year      =  2021,
  keywords  = "SARS-CoV-2; immunocompromised; infectivity; viral shedding;
               virus viability",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Pellegrino2021-qc,
  title     = "{COVID-19} and systemic sclerosis: analysis of lifestyle changes
               during the {SARS-CoV-2} pandemic in an Italian single-center
               cohort",
  author    = "Pellegrino, Greta and Mohammad Reza Beigi, Davide and Angelelli,
               Carlotta and Stefanantoni, Katia and Cadar, Marius and Mancuso,
               Silvia and Conti, Fabrizio and Riccieri, Valeria",
  abstract  = "The outbreak of SARS-CoV-2 has changed the habits and lives of
               people worldwide. Patients affected by systemic sclerosis (SSc)
               experienced constant fear because of their immunocompromised
               status. The aim of this study was to investigate the prevalence
               of SARS-CoV-2 infection and to analyze the lifestyle changes in
               a single-center cohort of SSc patients and if these changes were
               more severe than in the general population. During the Italian
               lockdown, we supplied two surveys to our 184 SSc patients. In
               the first one, filled by 110 patients, we asked if SARS-CoV-2
               had infected them or if they experienced signs and symptoms
               consistent with COVID-19. The second survey, performed by 79 SSc
               patients and 63 healthy subjects, included questions about the
               lifestyle adopted during this specific period. Among our
               patients, COVID-19 was diagnosed only in one case, while three
               other subjects reported signs and symptoms suggestive for the
               disease. Regarding the second survey, our patients greatly
               changed their lifestyle during the pandemic, adopting more
               restrictive isolation measures, because of their awareness of
               frailty. To date, we do not dispose of enough data to speculate
               about the risk of COVID-19 among immunocompromised patients,
               although in our SSc patients their frailty seems to have been
               their shelter. Pending more accurate epidemiological studies, it
               is essential to share as much data as possible to better
               understand the impact of COVID-19 on SSc patients' health. Key
               points  The lifestyle adopted by SSc patients during the first
               months of COVID-19 pandemic was characterized by more stringent
               isolation rules than general population.  The prudential
               behavior of patients with SSc during Italian lockdown should be
               considered as a possible bias when analyzing the risk of
               SARS-CoV-2 disease in these subjects, as well as a protective
               factor against infection.",
  journal   = "Clin. Rheumatol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  40,
  number    =  4,
  pages     = "1393--1397",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Lifestyle changes during SARS-CoV-2 pandemic; Systemic
               Sclerosis",
  language  = "en"
}

@ARTICLE{Erdinc2021-kp,
  title     = "Hematological manifestations and complications of {COVID-19}",
  author    = "Erdinc, Burak and Sahni, Sonu and Gotlieb, Vladimir",
  abstract  = "The virus SARS-CoV-2 commonly causes self-resolving, flu-like
               illnesses in the majority of patients, but a critical illness
               can be seen in 5\% of cases - especially in the elderly
               population or in patients with multiple comorbidities. When
               COVID-19 is severe, it can cause pneumonia and hypoxemic
               respiratory failure, and can progress to viremia involving
               multiple organ systems. It causes significant cytopenia, mainly
               severe lymphopenia, and excessive exhaustion of CD8+ T cells,
               resulting in an immunocompromised state and cytokine storm.
               Furthermore, COVID-19 can commonly be complicated with acute
               thrombotic events, including venous thromboembolism, acute
               stroke, acute myocardial infarction, clotting of hemodialysis
               and extracorporeal membrane oxygenation (ECMO) catheters, and
               acute limb ischemia. This makes SARS-COV-2 a unique virus with
               an undiscovered pathophysiology. Therefore, patients with
               COVID-19 need close monitoring of their symptoms and laboratory
               parameters, and early hospitalization and treatment in severe
               cases. Early identification of severe cases and the
               abovementioned complications of COVID-19 could decrease the
               morbidity and mortality caused by the disease. In the study, we
               summarize what is currently known about the hematological
               manifestations and complications of COVID-19.",
  journal   = "Adv. Clin. Exp. Med.",
  publisher = "Wroclaw Medical University",
  volume    =  30,
  number    =  1,
  pages     = "101--107",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; cytokine storm; hypercoagulable state; lymphopenia;
               thromboembolism",
  copyright = "https://creativecommons.org/licenses/by/3.0/",
  language  = "en"
}

@ARTICLE{Lai2021-yi,
  title     = "{COVID-19} vaccines: concerns beyond protective efficacy and
               safety",
  author    = "Lai, Chih-Cheng and Chen, I-Tzu and Chao, Chien-Ming and Lee,
               Ping-Ing and Ko, Wen-Chien and Hsueh, Po-Ren",
  abstract  = "INTRODUCTION: Several vaccine candidates have been developed
               using different platforms, including nucleic acids (DNA and
               RNA), viral vectors (replicating and non-replicating),
               virus-like particles, peptide-based, recombinant proteins, live
               attenuated, and inactivated virus modalities. Although many of
               these vaccines are undergoing pre-clinical trials, several large
               clinical trials investigating the clinical efficacy and safety
               of coronavirus disease 2019 (COVID-19) vaccines have produced
               promising findings. AREAS COVERED: In this review, we provide a
               status update on COVID-19 vaccines currently undergoing clinical
               trials and discuss issues of concern beyond vaccine efficacy and
               safety, including dosing regimens, the mixed vaccine strategy,
               prior severe acute respiratory syndrome coronavirus-2 infection,
               antibody levels, cellular immunity and protection, variants of
               concern, COVID-19 vaccine distribution, vaccination willingness,
               herd immunity, immunity passports, and vaccine indications.
               EXPERT OPINION: Four vaccines have obtained emergency use
               authorization, 87 are at the clinical development stage, and 186
               are in pre-clinical development. While the knowledge and
               development of COVID-19 vaccines is rapidly expanding, the
               benefits of COVID-19 vaccines must outweigh the potential risks
               of adverse events. To combat the COVID-19 pandemic, clinicians
               should consistently update COVID-19-associated information, and
               healthcare authorities and manufacturers should work together to
               provide adequate and appropriate vaccinations for the prevention
               of COVID-19. PLAIN LANGUAGE SUMMARY: What is the context?Severe
               acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a
               global pandemic: the coronavirus disease 2019 (COVID-19)
               outbreak. The development and implementation of the COVID-19
               vaccine could be an important measure to control the COVID-19
               pandemic.What is new?Several phase 3 clinical trials have
               demonstrated the effectiveness and safety of COVID-19 vaccines
               for the prevention of SARS-CoV-2 infections. Several COVID-19
               vaccines have obtained emergency use authorization and been
               implemented in many countries. Although concerns regarding
               unusual blood clots and low platelet counts have been raised,
               the benefits of COVID-19 vaccines outweigh the potential risks
               of adverse events.What is the impact?Except for children, the
               COVID-19 vaccine is recommended for all people, including those
               pregnant or immunocompromised. Healthcare authorities should
               advise people receiving the vaccine that they must seek medical
               attention if they have associated thromboembolism and
               thrombocytopenia symptoms. More studies are necessary to
               determine the appropriate vaccine dose and regimen strategy, as
               well as the effectiveness of COVID-19 vaccines against variants
               of concerns. A global effort must be made to achieve widespread
               vaccination and herd immunity.",
  journal   = "Expert Rev. Vaccines",
  publisher = "Informa UK Limited",
  volume    =  20,
  number    =  8,
  pages     = "1013--1025",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; cellular immunity; protective efficacy; safety;
               sars-cov-2; vaccination willingness; vaccine; variants of
               concern",
  language  = "en"
}

@ARTICLE{Fedeli2021-il,
  title     = "Intravescical instillation of {Calmette-Gu{\'e}rin} bacillus and
               {COVID-19} risk",
  author    = "Fedeli, Ugo and Porreca, Angelo and Colicchia, Michele and
               Schievano, Elena and Artibani, Walter and Biasio, Luigi Roberto
               and Pal{\`u}, Giorgio",
  abstract  = "It has been theorized that Calmette-Gu{\'e}rin bacillus may
               prevent or reduce the severity of COVID-19 through a nonspecific
               stimulation of the immune system. A preliminary assessment of
               SARS-CoV-2 infection rates and outcomes among 2803 individuals
               affected with high risk non-muscle-invasive bladder cancer and
               treated with intra-bladder instillation of BCG, showed no
               evidence of a protective effect. However, the interpretation of
               these data need some caution, due to the low prevalence of
               infection (<1\%) observed within this population, along with the
               fact that intra-bladder administration cannot mirror the usual
               intradermal administration of BCG, in particular in patients
               partially immunocompromised. Confirmation by larger prospective
               studies is required.",
  journal   = "Hum. Vaccin. Immunother.",
  publisher = "Informa UK Limited",
  volume    =  17,
  number    =  2,
  pages     = "416--417",
  month     =  feb,
  year      =  2021,
  keywords  = "BCG; Covid-19; bladder Cancer; epidemiology",
  language  = "en"
}

@ARTICLE{Baek2021-ze,
  title     = "{COVID-19-related} outcomes in immunocompromised patients: A
               nationwide study in Korea",
  author    = "Baek, Moon Seong and Lee, Min-Taek and Kim, Won-Young and Choi,
               Jae Chol and Jung, Sun-Young",
  abstract  = "BACKGROUND: Given the rapid increased in confirmed coronavirus
               disease 2019 (COVID-19) and related mortality, it is important
               to identify vulnerable patients. Immunocompromised status is
               considered a risk factor for developing severe COVID-19. We
               aimed to determine whether immunocompromised patients with
               COVID-19 have an increased risk of mortality. METHOD: The
               groups' baseline characteristics were balanced using a
               propensity score-based inverse probability of treatment
               weighting approach. Odds ratios (ORs) and their 95\% confidence
               intervals (CIs) were calculated for the risks of in-hospital
               mortality and other outcomes according to immunocompromised
               status using a multivariable logistic regression model. We
               identified immunocompromised status based on a diagnosis of
               malignancy or HIV/AIDS, having undergone organ transplantation
               within 3 years, prescriptions for corticosteroids or oral
               immunosuppressants for $\geq$30 days, and at least one
               prescription for non-oral immunosuppressants during the last
               year. RESULTS: The 6,435 COVID-19 patients ($\geq$18 years)
               included 871 immunocompromised (13.5\%) and 5,564
               non-immunocompromised (86.5\%). Immunocompromised COVID-19
               patients were older (60.1$\pm$16.4 years vs. 47.1$\pm$18.7
               years, absolute standardized mean difference: 0.738). The
               immunocompromised group had more comorbidities, a higher
               Charlson comorbidity index, and a higher in-hospital mortality
               rate (9.6\% vs. 2.3\%; p < .001). The immunocompromised group
               still had a significantly higher in-hospital mortality rate
               after inverse probability of treatment weighting (6.4\% vs.
               2.0\%, p < .001). Multivariable analysis adjusted for baseline
               imbalances revealed that immunocompromised status was
               independently associated with a higher risk of mortality among
               COVID-19 patients (adjusted odds ratio [aOR]: 2.09, 95\% CI:
               1.62-2.68, p < .001). CONCLUSIONS: Immunocompromised status
               among COVID-19 patients was associated with a significantly
               increased risk of mortality.",
  journal   = "PLoS One",
  publisher = "Public Library of Science (PLoS)",
  volume    =  16,
  number    =  10,
  pages     = "e0257641",
  month     =  oct,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Negahdaripour2021-aq,
  title     = "Administration of {COVID-19} vaccines in immunocompromised
               patients",
  author    = "Negahdaripour, Manica and Shafiekhani, Mojtaba and Moezzi, Seyed
               Mohammad Iman and Amiri, Sogand and Rasekh, Shiva and Bagheri,
               Ashkan and Mosaddeghi, Pouria and Vazin, Afsaneh",
  abstract  = "Since the beginning of vaccination programs against COVID-19 in
               different countries, several populations such as patients with
               specific immunological conditions have been considered as the
               priorities for immunization. In this regard, patients with
               autoimmune diseases or those receiving immunosuppressive agents
               and anti-cancer therapies, need special attention. However, no
               confirmed data is presently available regarding COVID-19
               vaccines in these populations due to exclusion from the
               conducted clinical trials. Given the probable suppression or
               over-activation of the immune system in such patients, reaching
               a consensus for their vaccination is critical, besides gathering
               data and conducting trials, which could probably clarify this
               matter in the future. In this review, besides a brief on the
               available COVID-19 vaccines, considerations and available
               knowledge about administering similar vaccines in patients with
               cancer, hematopoietic stem cell transplantation, solid organ
               transplantation, multiple sclerosis (MS), inflammatory bowel
               disease (IBD), and rheumatologic and dermatologic autoimmune
               disorders are summarized to help in decision making. As
               discussed, live-attenuated viruses, which should be avoided in
               these groups, are not employed in the present COVID-19 vaccines.
               Thus, the main concern regarding efficacy could be met using a
               potent COVID-19 vaccine. Moreover, the vaccination timing for
               maximum efficacy could be decided according to the patient's
               condition, indicated medications, and the guides provided here.
               Post-vaccination monitoring is also advised to ensure an
               adequate immune response. Further studies in this area are
               urgently warranted.",
  journal   = "Int. Immunopharmacol.",
  publisher = "Elsevier BV",
  volume    =  99,
  number    =  108021,
  pages     = "108021",
  month     =  oct,
  year      =  2021,
  keywords  = "Cancer; Hematologic malignancies; Inflammatory bowel disease;
               Multiple sclerosis; Transplantation; Vaccination",
  language  = "en"
}

@ARTICLE{Pasero2021-fl,
  title     = "A challenging complication following {SARS-CoV-2} infection: a
               case of pulmonary mucormycosis",
  author    = "Pasero, Daniela and Sanna, Silvana and Liperi, Corrado and
               Piredda, Davide and Branca, Gian Pietro and Casadio, Lorenzo and
               Simeo, Raffaella and Buselli, Alice and Rizzo, Davide and Bussu,
               Francesco and Rubino, Salvatore and Terragni, Pierpaolo",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 infection might
               induce a significant and sustained lymphopenia, increasing the
               risk of developing opportunistic infections. Mucormycosis is a
               rare but severe invasive fungal infection, mainly described in
               immunocompromised patients. The first case of a patient
               diagnosed with coronavirus disease (COVID-19) who developed a
               pulmonary mucormycosis with extensive cavitary lesions is here
               reported. This case highlights how this new coronavirus might
               impair the immune response, exposing patients to higher risk of
               developing opportunistic infections and leading to worse
               outcomes.",
  journal   = "Infection",
  publisher = "Springer Science and Business Media LLC",
  volume    =  49,
  number    =  5,
  pages     = "1055--1060",
  month     =  oct,
  year      =  2021,
  keywords  = "Mucormycosis; Opportunistic infections; SARS-Cov-2",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Osman2021-mf,
  title     = "A comparative systematic review of {COVID-19} and influenza",
  author    = "Osman, Molka and Klopfenstein, Timoth{\'e}e and Belfeki, Nabil
               and Gendrin, Vincent and Zayet, Souheil",
  abstract  = "BACKGROUND: Both SARS-CoV-2 and influenza virus share
               similarities such as clinical features and outcome, laboratory,
               and radiological findings. METHODS: Literature search was done
               using PubMed to find MEDLINE indexed articles relevant to this
               study. As of 25 November 2020, the search has been conducted by
               combining the MeSH words ``COVID-19'' and ``Influenza''.
               RESULTS: Eighteen articles were finally selected in adult
               patients. Comorbidities such as cardiovascular diseases,
               diabetes, and obesity were significantly higher in COVID-19
               patients, while pulmonary diseases and immunocompromised
               conditions were significantly more common in influenza patients.
               The incidence rates of fever, vomiting, ocular and
               otorhinolaryngological symptoms were found to be significantly
               higher in influenza patients when compared with COVID-19
               patients. However, neurologic symptoms and diarrhea were
               statistically more frequent in COVID-19 patients. The level of
               white cell count and procalcitonin was significantly higher in
               influenza patients, whereas thrombopenia and elevated
               transaminases were significantly more common in COVID-19
               patients. Ground-grass opacities, interlobular septal
               thickening, and a peripheral distribution were more common in
               COVID-19 patients than in influenza patients where
               consolidations and linear opacities were described instead.
               COVID-19 patients were significantly more often transferred to
               intensive care unit with a higher rate of mortality.
               CONCLUSIONS: This study estimated differences of COVID-19 and
               influenza patients which can help clinicians during the
               co-circulation of the two viruses.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  3,
  pages     = "452",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; clinical features; imaging; influenza;
               laboratory; systematic review",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Harrington2021-du,
  title     = "Evaluation of 2 commercial {anti-SARS-CoV-2} antibody assays in
               an immunocompetent and immunocompromised inpatient population
               with {COVID-19}",
  author    = "Harrington, David and Azim, Tahira and Rosmarin, Caryn and
               Cutino-Moguel, Teresa and Hopkins, Mark",
  abstract  = "INTRODUCTION: During the COVID-19 pandemic, widespread
               introduction of SARS-CoV-2 antibody testing was introduced
               without a full understanding of the assays performance or the
               antibody kinetics following infection with SARS-CoV-2. METHODS:
               We performed an evaluation of 2 anti-SARS-CoV-2 antibody assays
               with a more detailed look into the effect of immune status on
               antibody sensitivity. RESULTS: Both assays demonstrated 100\%
               specificity. The overall sensitivity of the Roche was 92.1\% at
               $\geq$14 days and 94.8\% at $\geq$21 days, and the overall
               sensitivity of the Abbott was 94.4\% at $\geq$14 days and 98.2\%
               at $\geq$21 days. 7/41 (17\%) of patients included in this
               cohort were immunocompromised. Seroconversion was seen less
               commonly in the immunocompromised (4/7 [57.1\%] seroconverted)
               and after excluding these patients 100\% sensitivity was seen in
               both assays at $\geq$21 days. DISCUSSION: Performance of both
               assays in the immunocompetent appeared excellent after 21 days
               postsymptom onset. Both assays are highly specific.",
  journal   = "Diagn. Microbiol. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  101,
  number    =  2,
  pages     = "115449",
  month     =  oct,
  year      =  2021,
  keywords  = "Anti-SARSCoV-2 Antibody; Antibody waning; COVID-19;
               Immunocompromised; Immunosuppressed; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Passaro2021-mv,
  title     = "Severity of {COVID-19} in patients with lung cancer: evidence
               and challenges",
  author    = "Passaro, Antonio and Bestvina, Christine and Velez Velez, Maria
               and Garassino, Marina Chiara and Garon, Edward and Peters,
               Solange",
  abstract  = "Cancer patients are highly vulnerable to SARS-CoV-2 infections
               due to frequent contacts with the healthcare system,
               immunocompromised state from cancer or its therapies, supportive
               medications such as steroids and most importantly their advanced
               age and comorbidities. Patients with lung cancer have
               consistently been reported to suffer from an increased risk of
               death compared with other cancers. This is possibly due to the
               combination of specific pathophysiological aspects, including
               underlying pulmonary compromise due to smoking history and the
               increased specific pressures on respiratory healthcare services
               caused by the related pandemic. Rationally and safely treating
               patients with lung cancer during the pandemic has become a
               continuous challenge over the last year. Deciding whether to
               offer, modify, postpone or even cancel treatments for this
               particular patient's population has become the crucial recurrent
               dilemma for lung cancer professionals. Chemotherapy,
               immunotherapy and targeted agents represent distinct risks
               factors in the context of COVID-19 that should be balanced with
               the short-term and long-term consequences of delaying cancer
               care. Despite the rapid and persistent trend of the pandemic,
               declared by WHO on March 11, 2020, and still ongoing at the time
               of writing (January 2021), various efforts were made by
               oncologists worldwide to understand the impact of COVID-19 on
               patients with cancer. Adapted recommendations of our
               evidence-based practice guidelines have been developed for all
               stakeholders. Different small and large-scale registries, such
               as the COVID-19 and Cancer Consortium (CCC19) and Thoracic
               Cancers International COVID-19 Collaboration quickly collected
               data, supporting cancer care decisions under the challenging
               circumstance created by the COVID-19 pandemic. Several
               recommendations were developed as guidance for prioritizing the
               various aspects of lung cancer care in order to mitigate the
               adverse effects of the COVID-19 healthcare crisis, potentially
               reducing the morbidity and mortality of our patients from
               COVID-19 and from cancer. These recommendations helped inform
               decisions about treatment of established disease, continuation
               of clinical research and lung cancer screening. In this review,
               we summarize available evidence regarding the direct and
               indirect impact of the COVID-19 pandemic on lung cancer care and
               patients.",
  journal   = "J. Immunother. Cancer",
  publisher = "BMJ",
  volume    =  9,
  number    =  3,
  pages     = "e002266",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; lung neoplasms",
  language  = "en"
}

@ARTICLE{Chong2021-my,
  title     = "A systematic review and meta-analysis comparing the clinical
               characteristics and outcomes of {COVID-19} and influenza
               patients on {ECMO}",
  author    = "Chong, Woon Hean and Saha, Biplab K and Medarov, Boris I",
  abstract  = "BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is a
               valuable rescue therapy to treat refractory hypoxemia caused by
               influenza. The present meta-analysis aimed to compare the
               clinical characteristics and outcomes of ECMO between COVID-19
               and influenza. METHODS: We searched the PubMed, Cochrane
               Library, SCOPUS, and Web of Science databases from inception to
               May 1, 2021. The included studies compared the clinical
               characteristics and outcomes of ECMO between adults with
               COVID-19 and those with influenza. RESULTS: The study included
               four retrospective cohorts involving a total of 129 patients
               with COVID-19 and 140 with influenza who were treated using
               ECMO. Clinical characteristics were similar between the COVID-19
               and influenza groups, including body mass index (BMI), diabetes
               mellitus, hypertension, and immunocompromised status. A higher
               proportion of patients with COVID-19 on ECMO were male (75.9\%
               vs. 62.9\%; P = 0.04). There was no difference between the
               groups in terms of illness severity based on sequential organ
               failure assessment (SOFA) score or serum pH. Patients with
               COVID-19 had a longer mean duration of mechanical ventilation
               before ECMO (6.63 vs. 3.38 days; P < 0.01). The pooled mortality
               rate was 43.8\%. The mean ECMO duration (14.13 vs. 12.55 days; P
               = 0.25) and mortality rate (42.6\% vs. 45.0\%; P = 0.99) were
               comparable between the groups. CONCLUSION: Clinical
               characteristics, ECMO duration, and mortality were comparable
               between patients with COVID-19 and those with influenza who
               required ECMO to treat refractory hypoxemia. The duration of
               mechanical ventilation before ECMO did not influence outcomes.
               Patients with COVID-19 benefit from ECMO salvage therapy
               similarly to those with influenza.",
  journal   = "Respir. Investig.",
  publisher = "Elsevier BV",
  volume    =  59,
  number    =  6,
  pages     = "748--756",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; ECLS; ECMO; Influenza; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Abid2021-jr,
  title    = "Overlap of immunotherapy-related pneumonitis and {COVID-19}
              pneumonia: diagnostic and vaccine considerations",
  author   = "Abid, Muhammad Bilal",
  abstract = "The clinically indistinguishable overlap between pneumonitis
              caused due to immune checkpoint inhibition (ICI) and pneumonia
              associated with COVID-19 has posed considerable challenges for
              patients with cancer and oncologists alike. The cancer community
              continues to face the challenges that lay at the complex
              immunological intersection of immune-based cancer therapy and
              immune dysregulation that results from COVID-19. Is there
              compounded immune dysregulation that could lead to poor outcomes?
              Could ICIs, in fact, ameliorate SARS-CoV-2-driven T-cell
              exhaustion?A little more is known about the kinetics of the viral
              replication in immunocompromised patients now as compared with
              earlier during the pandemic. Working knowledge of the diagnostic
              and therapeutic nuances of SARS-CoV-2 infection in patients with
              active cancers, issues related to viability and replication
              potential of the virus, unclear role of corticosteroids among
              those with diminished or dysfunctional effector T-cell
              repertoire, and the type of immunotherapy with differential risk
              of pneumonitis will inform decision making related to
              immunotherapy choices and decision for ICI continuation in the
              era of COVID-19.",
  journal  = "J. Immunother. Cancer",
  volume   =  9,
  number   =  4,
  month    =  apr,
  year     =  2021,
  keywords = "COVID-19; autoimmunity; cellular; immunity; immunotherapy;
              vaccination",
  language = "en"
}

@ARTICLE{Kelly2021-qg,
  title     = "Safety and efficacy of {COVID-19} vaccines in multiple sclerosis
               patients",
  author    = "Kelly, Hannah and Sokola, Brent and Abboud, Hesham",
  abstract  = "COVID-19 vaccination is recommended for multiple sclerosis
               patients. Disease-modifying therapies can influence the safety
               and efficacy of COVID-19 vaccines. RNA, DNA, protein, and
               inactivated vaccines are likely safe for multiple sclerosis
               patients. A few incidences of central demyelination were
               reported with viral vector vaccines, but their benefits likely
               outweigh their risks if alternatives are unavailable.
               Live-attenuated vaccines should be avoided whenever possible in
               treated patients. Interferon-beta, glatiramer acetate,
               teriflunomide, fumarates, and natalizumab are not expected to
               impact vaccine efficacy, while cell-depleting agents
               (ocrelizumab, rituximab, ofatumumab, alemtuzumab, and
               cladribine) and sphingosine-1-phosphate modulators will likely
               attenuate vaccine responses. Coordinating vaccine timing with
               dosing regimens for some therapies may optimize vaccine
               efficacy.",
  journal   = "J. Neuroimmunol.",
  publisher = "Elsevier BV",
  volume    =  356,
  number    =  577599,
  pages     = "577599",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Zavaglio2021-wn,
  title     = "Robust and persistent {B-} and T-cell responses after {COVID-19}
               in immunocompetent and solid organ transplant recipient patients",
  author    = "Zavaglio, Federica and Frangipane, Vanessa and Morosini, Monica
               and Gabanti, Elisa and Zelini, Paola and Sammartino, Jos{\`e}
               Camilla and Ferrari, Alessandro and Gregorini, Marilena and
               Rampino, Teresa and Asti, Annalia and Seminari, Elena and Di
               Matteo, Angela and Cattadori, Barbara and Pellegrini, Carlo and
               Tonello, Stelvio and Mallela, Venkata Ramana and Minisini,
               Rosalba and Rizzi, Manuela and Sainaghi, Pier Paolo and Meloni,
               Federica and Lilleri, Daniele and Baldanti, Fausto",
  abstract  = "The development and persistence of SARS-CoV-2-specific immune
               response in immunocompetent (IC) and immunocompromised patients
               is crucial for long-term protection. Immune response to
               SARS-CoV-2 infection was analysed in 57 IC and 15 solid organ
               transplanted (TX) patients. Antibody responses were determined
               by ELISA and neutralization assay. T-cell response was
               determined by stimulation with peptide pools of the Spike,
               Envelope, Membrane, and Nucleocapsid proteins with a 20-h
               Activation Induced Marker (AIM) and 7-day lymphoproliferative
               assays. Antibody response was detected at similar levels in IC
               and TX patients. Anti-Spike IgG, IgA and neutralizing antibodies
               persisted for at least one year, while anti-Nucleocapsid IgG
               declined earlier. Patients with pneumonia developed higher
               antibody levels than patients with mild symptoms. Similarly,
               both rapid and proliferative T-cell responses were detected
               within the first two months after infection at comparable levels
               in IC and TX patients, and were higher in patients with
               pneumonia. T-cell response persisted for at least one year in
               both IC and TX patients. Spike, Membrane, and Nucleocapsid
               proteins elicited the major CD4+ and CD8+ T-cell responses,
               whereas the T-cell response to Envelope protein was negligible.
               After SARS-CoV-2 infection, antibody and T-cell responses
               develop rapidly and persist over time in both immunocompetent
               and transplanted patients.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  11,
  pages     = "2261",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; T-cell response; antibody response;
               cytokines; immunocompetent patients; membrane protein;
               nucleocapsid protein; spike protein; transplanted patients",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Neurath2021-ey,
  title     = "{COVID-19}: biologic and immunosuppressive therapy in
               gastroenterology and hepatology",
  author    = "Neurath, Markus F",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic is an ongoing
               global health crisis causing major challenges for clinical care
               in patients with gastrointestinal diseases. Although triggering
               of anti-viral immune responses is essential for clearance of
               infection, some patients have severe lung inflammation and
               multiorgan failure due to marked immune cell dysregulation and
               cytokine storm syndrome. Importantly, the activation of
               cytotoxic follicular helper T cells and a reduction of
               regulatory T cells have a crucial, negative prognostic role.
               These findings lead to the question of whether immunosuppressive
               and biologic therapies for gastrointestinal diseases affect the
               incidence or prognosis of COVID-19 and, thus, whether they
               should be adjusted to prevent or affect the course of the
               disease. In this Review, data on the use of such therapies are
               discussed with a primary focus on inflammatory bowel disease,
               autoimmune hepatitis and liver transplantation. In particular,
               the roles of corticosteroids, classic immunosuppressive agents
               (such as thiopurines and mycophenolate mofetil), small molecules
               (such as Janus kinase (JAK) inhibitors), and biologic agents
               (such as tumour necrosis factor (TNF) blockers, vedolizumab and
               ustekinumab) are reviewed. Finally, the use of severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines for the
               prevention of infection in patients with gastrointestinal
               diseases and concomitant immunosuppressive or biologic therapy
               will be discussed.",
  journal   = "Nat. Rev. Gastroenterol. Hepatol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  18,
  number    =  10,
  pages     = "705--715",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Vaid2021-kt,
  title     = "Clinical characteristics and outcomes of immunosuppressed
               patients hospitalized with {COVID-19}: experience from London",
  author    = "Vaid, N and Ardissino, M and Reed, T A N and Goodall, J and
               Utting, P and Miscampbell, M and Condurache, D and Cohen, D L",
  abstract  = "BACKGROUND: Coronavirus disease 2019 (COVID-19) is a global
               health emergency. Despite the widely hypothesized role of a
               cytokine storm in disease severity, no study thus far has
               explored the association between immunosuppression and disease
               severity in patients hospitalized with COVID-19. OBJECTIVE: This
               study aimed to examine the association between the use of
               immunosuppressant medication and outcomes of patients
               hospitalized with COVID-19. METHODS: Nine hundred and eighty-one
               consecutive patients hospitalized between 12 March 2020 and 15
               April 2020, who tested positive for severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2), were enrolled in this
               cohort study and subdivided by immunosuppression status. The
               patients were followed up for a minimum of 28 days (median 37
               days) for the primary end-point of mortality. Secondary
               end-points included the composite of intubation or death, and
               the composite of mortality, intubation or continuous positive
               airway pressure (CPAP) requirement. RESULTS: During the
               follow-up period, 354 (36.1\%) of study patients died. The
               immunosuppressed cohort (n = 31) had significantly higher
               mortality rates (aHR: 2.067, 95\% CI: 1.20-3.57, P = 0.009).
               There was no association between immunosuppression and the
               composite end-point of mortality or intubation (aHR: 1.49 95\%
               CI: 0.88-2.51, P = 0.14) and of the composite end-point of
               mortality, intubation or CPAP (aHR: 1.36 95\% CI: 0.81-2.30 P =
               0.245). CONCLUSION: In this cohort study of 981 confirmed
               COVID-19 patients consecutively hospitalized at a large North
               West London hospital, immunosuppressant use was associated with
               significantly higher mortality rates. These results support the
               current UK government's early isolation ('shielding') policy for
               these individuals and should be used to guide future research.",
  journal   = "J. Intern. Med.",
  publisher = "Wiley",
  volume    =  289,
  number    =  3,
  pages     = "385--394",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; coronavirus disease 2019; immunosuppression;
               mortality; outcomes",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Brehm2021-qh,
  title     = "Comparison of clinical characteristics and disease outcome of
               {COVID-19} and seasonal influenza",
  author    = "Brehm, Thomas Theo and van der Meirschen, Marc and Hennigs,
               Annette and Roedl, Kevin and Jarczak, Dominik and Wichmann,
               Dominic and Frings, Daniel and Nierhaus, Axel and Oqueka, Tim
               and Fiedler, Walter and Christopeit, Maximilian and Kraef,
               Christian and Schultze, Alexander and L{\"u}tgehetmann, Marc and
               Addo, Marylyn M and Schmiedel, Stefan and Kluge, Stefan and
               Schulze Zur Wiesch, Julian",
  abstract  = "While several studies have described the clinical course of
               patients with coronavirus disease 2019 (COVID-19), direct
               comparisons with patients with seasonal influenza are scarce. We
               compared 166 patients with COVID-19 diagnosed between February
               27 and June 14, 2020, and 255 patients with seasonal influenza
               diagnosed during the 2017-18 season at the same hospital to
               describe common features and differences in clinical
               characteristics and course of disease. Patients with COVID-19
               were younger (median age [IQR], 59 [45-71] vs 66 [52-77]; P <
               0001) and had fewer comorbidities at baseline with a lower mean
               overall age-adjusted Charlson Comorbidity Index (mean [SD], 3.0
               [2.6] vs 4.0 [2.7]; P < 0.001) than patients with seasonal
               influenza. COVID-19 patients had a longer duration of
               hospitalization (mean [SD], 25.9 days [26.6 days] vs 17.2 days
               [21.0 days]; P = 0.002), a more frequent need for oxygen therapy
               (101 [60.8\%] vs 103 [40.4\%]; P < 0.001) and invasive
               ventilation (52 [31.3\%] vs 32 [12.5\%]; P < 0.001) and were
               more frequently admitted to the intensive care unit (70 [42.2\%]
               vs 51 [20.0\%]; P < 0.001) than seasonal influenza patients.
               Among immunocompromised patients, those in the COVID-19 group
               had a higher hospital mortality compared to those in the
               seasonal influenza group (13 [33.3\%] vs 8 [11.6\%], P = 0.01).
               In conclusion, we show that COVID-19 patients were younger and
               had fewer baseline comorbidities than seasonal influenza
               patients but were at increased risk for severe illness. The high
               mortality observed in immunocompromised COVID-19 patients
               emphasizes the importance of protecting these patient groups
               from SARS-CoV-2 infection.",
  journal   = "Sci. Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  11,
  number    =  1,
  pages     = "5803",
  month     =  mar,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Speich2021-ye,
  title     = "A trial platform to assess approved {SARS-CoV-2} vaccines in
               immunocompromised patients: first sub-protocol for a pilot trial
               comparing the {mRNA} vaccines Comirnaty\textregistered{} and
               {COVID-19} {mRNA} Vaccine Moderna\textregistered{}",
  author    = "Speich, Benjamin and Chammartin, Fr{\'e}d{\'e}rique and Smith,
               Daniel and Stoeckle, Marcel P and Amico, Patrizia and
               Eichenberger, Anna L and Hasse, Barbara and Schuurmans, Mac{\'e}
               M and M{\"u}ller, Thomas and Tamm, Michael and Dickenmann,
               Michael and Abela, Irene A and Trkola, Alexandra and Hirsch,
               Hans H and Manuel, Oriol and Cavassini, Matthias and Hemkens,
               Lars G and Briel, Matthias and Mueller, Nicolas J and Rauch,
               Andri and G{\"u}nthard, Huldrych F and Koller, Michael T and
               Bucher, Heiner C and Kusejko, Katharina and {study groups from
               the Swiss HIV Cohort Study and the Swiss Transplant Cohort
               Study}",
  abstract  = "BACKGROUND: Late 2019, a new highly contagious coronavirus
               SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months
               a pandemic with the highest disease burden in elderly and people
               with pre-existing medical conditions. The pandemic has
               highlighted that new and more flexible clinical trial
               approaches, such as trial platforms, are needed to assess the
               efficacy and safety of interventions in a timely manner. The two
               existing Swiss cohorts of immunocompromised patients (i.e.,
               Swiss HIV Cohort Study (SHCS) and Swiss Transplant Cohort Study
               (STCS)) are an ideal foundation to set-up a trial platform in
               Switzerland leveraging routinely collected data. Within a newly
               founded trial platform, we plan to assess the efficacy of the
               first two mRNA SARS-CoV-2 vaccines that reached market
               authorization in Switzerland in the frame of a pilot randomized
               controlled trial (RCT) while at the same time assessing the
               functionality of the trial platform. METHODS: We will conduct a
               multicenter randomized controlled, open-label, 2-arm sub-study
               pilot trial of a platform trial nested into two Swiss cohorts.
               Patients included in the SHCS or the STCS will be eligible for
               randomization to either receiving the mRNA vaccine
               Comirnaty\textregistered{} (Pfizer/BioNTech) or the COVID-19
               mRNA Vaccine Moderna\textregistered{}. The primary clinical
               outcome will be change in pan-lg antibody response (pan-Ig
               anti-S1-RBD; baseline vs. 3 months after first vaccination;
               binary outcome, considering $\geq$ 0.8 units/ml as a positive
               antibody response). The pilot study will also enable us to
               assess endpoints related to trial conduct feasibility (i.e.,
               duration of RCT set-up; time of patient recruitment; patient
               consent rate; proportion of missing data). Assuming vaccine
               reactivity of 90\% in both vaccine groups, we power our trial,
               using a non-inferiority margin such that a 95\% two-sided
               confidence interval excludes a difference in favor of the
               reference group of more than 10\%. A sample size of 380 (190 in
               each treatment arm) is required for a statistical power of 90\%
               and a type I error of 0.025. The study is funded by the Swiss
               National Science Foundation (National Research Program NRP 78,
               ``COVID-19''). DISCUSSION: This study will provide crucial
               information about the efficacy and safety of the mRNA SARS-CoV-2
               vaccines in HIV patients and organ transplant recipients.
               Furthermore, this project has the potential to pave the way for
               further platform trials in Switzerland. TRIAL REGISTRATION:
               ClinicalTrials.gov NCT04805125 . Registered on March 18, 2021.",
  journal   = "Trials",
  publisher = "Springer Science and Business Media LLC",
  volume    =  22,
  number    =  1,
  pages     = "724",
  month     =  oct,
  year      =  2021,
  keywords  = "Organ transplant; Platform trial; Protocol; Randomized
               controlled trial, HIV; SARS-CoV-2; Vaccine",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Scharringa2021-pf,
  title     = "Vaccination and their importance for lung transplant recipients
               in a {COVID-19} world",
  author    = "Scharringa, Samantha and Hoffman, Thijs and van Kessel, Diana A
               and Rijkers, Ger T",
  abstract  = "INTRODUCTION: Lung transplant patients are immunocompromised
               because of the medication they receive to prevent rejection, and
               as a consequence are susceptible to (respiratory) infections.
               Adequate vaccination strategies, including COVID-19 vaccination,
               are therefore needed to minimize infection risks. AREAS COVERED:
               The international vaccination guidelines for lung transplant
               patients are reviewed, including the data on immunogenicity and
               effectivity of the vaccines. The impact on response to
               vaccination of the various categories of immunosuppressive
               drugs, used in the posttransplant period, on response to
               vaccination is described. A number of immunosuppressive and/or
               anti-inflammatory drugs also is used for controlling the
               immunopathology of severe COVID-19. Current available COVID-19
               vaccines, both mRNA or adenovirus based are recommended for lung
               transplant patients. EXPERT OPINION: In order to improve
               survival and quality of life, infections of lung transplant
               patients should be prevented by vaccination. When possible,
               vaccination should start already during the pre-transplantation
               period when the patient is on the waiting list. Booster
               vaccinations should be given post-transplantation, but only when
               immunosuppression has been tapered. Vaccine design based on mRNA
               technology could allow the design of an array of vaccines
               against other respiratory viruses, offering a better protection
               for lung transplant patients.",
  journal   = "Expert Rev. Clin. Pharmacol.",
  publisher = "Informa UK Limited",
  volume    =  14,
  number    =  11,
  pages     = "1413--1425",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; efficacy; immune status;
               immunosuppression; influenza; lung transplantation; vaccination",
  language  = "en"
}

@ARTICLE{Mousavi2021-bt,
  title     = "{COVID-19} and cancer: A comparative case series",
  author    = "Mousavi, Seied Asadollah and Rostami, Tahereh and Kiumarsi,
               Azadeh and Rad, Soroush and Rostami, Mohammadreza and Motamedi,
               Fatemeh and Gandomi-Mohammadabadi, Alireza and Mirhosseini,
               Amirhossein",
  abstract  = "BACKGROUND: Cancer patients, with an incidence of more than 18
               million new cases per year, may constitute a significant portion
               of the COVID-19 infected population. In the pandemic situation,
               these patients are considered highly vulnerable to infectious
               complications due to their immunocompromised state. MATERIAL \&
               METHODS: In this retrospective case series, the documents of
               solid cancer patients infected by SARS-CoV-2, hospitalized in
               Shariati hospital between 20 February and 20 April 2020, were
               evaluated. The diagnosis of COVID-19 was based on
               laboratory-confirmed COVID-19 and/or features of chest CT scan
               highly suggestive for SARS-CoV-2. RESULTS: A total of 33
               COVID-19-infected cancer patients were included. Mean age was
               63.9 years, and 54.5\% of the patients were male. LDH level was
               significantly higher (1487.5 $\pm$ 1392.8 vs. 932.3 $\pm$ 324.7
               U/L, P-value=0.016) and also serum albumin was significantly
               lower in non-survivors (3.6 $\pm$ 0.5 vs. 2.9 $\pm$ 0.6 g/dL,
               p-value=0.03). Among 16 patients with stage IV cancer, thirteen
               patients died, which was significantly higher compared to stage
               I-III cancer patients (81.3\% vs. 18.8\% P-value= <0.001). In
               terms of developing complications, sepsis, invasive ventilation
               and mortality was significantly higher in patients who received
               cytotoxic chemotherapy within the last 14 days. CONCLUSION: In
               this study, we showed that the mortality rate among cancer
               patients affected by COVID-19 was higher than general population
               and this rate has a significant correlation with factors
               including the stage of the disease, the type of cancer, the
               activity of cancer and finally receiving cytotoxic chemotherapy
               within 14 days before diagnosis of COVID-19.",
  journal   = "Cancer Treat. Res. Commun.",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  100339,
  pages     = "100339",
  month     =  feb,
  year      =  2021,
  keywords  = "Cancer; Covid-19; SARS-CoV-2",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Hasan2021-wo,
  title     = "Predictors of disease severity and outcome of hospitalized renal
               transplant recipients with {COVID-19} infection: a systematic
               review of a globally representative sample",
  author    = "Hasan, Irtiza and Rashid, Tasnuva and Suliman, Sarah and Amer,
               Hatem and Chirila, Razvan M and Mai, Martin L and Jarmi, Tambi
               and Khouzam, Samir and Franco, Pablo Moreno and Heilig, Charles
               W and Wadei, Hani M",
  abstract  = "Introduction. COVID-19 presents a special challenge to the
               kidney transplant population.Methods. A systematic review of
               articles that examined COVID-19 in kidney transplant recipients
               was performed. Patients' demographics, clinical, laboratory and
               radiological presentations, immunosuppression modification, and
               COVID-19 specific management were abstracted and analyzed.
               COVID-19 severity was classified into mild, moderate, and
               severe. Disease outcome was classified by whether the patient
               was discharged, still hospitalized, or died.Results. 44 articles
               reporting individual data and 13 articles reporting aggregated
               data on 149 and 561 kidney transplant recipients respectively
               with COVID-19 from Asia, Europe and America fulfilled all
               inclusion and exclusion criteria. Among studies reporting case
               specific data, 76\% of cases had severe disease. Compared to
               patients with mild/moderate disease, patients with severe
               disease had higher CRP, LDH, Ferritin, D-dimer and were more
               likely to have bilateral lung involvement at presentation and
               longer time since transplantation (P < 0.05 for all).
               Recipients' age, gender and comorbidities did not impact disease
               severity. Patients with severe disease had a more aggressive CNI
               reduction and more antiviral medications utilization. Outcome
               was reported on 145 cases, of those 34 (23\%) died all with
               severe disease. Longer duration from transplant to disease
               diagnosis, hypoxia and higher LDH were associated with mortality
               (P < 0.05). Different immunosuppression reduction strategies,
               high dose parenteral corticosteroids use and various antiviral
               combinations did not demonstrate survival advantage. Similar
               finding was observed for studies reporting aggregated
               data.Conclusion. COVID-19 in kidney transplant patients is
               associated with high rate of disease severity and fatality.
               Higher LDH and longer time since transplantation predicted both
               disease severity and mortality. None of the COVID-19 specific
               treatment correlated with, or improved disease outcome in kidney
               transplant recipients.",
  journal   = "Rom. J. Intern. Med.",
  publisher = "Walter de Gruyter GmbH",
  volume    =  59,
  number    =  1,
  pages     = "10--42",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; Severe Acute Respiratory Syndrome
               Coronavirus 2; coronavirus disease 2019; coronavirus pandemic;
               immunosuppression; novel coronavirus; renal transplant;
               transplant recipient",
  language  = "en"
}

@ARTICLE{Lindsay2021-dm,
  title     = "Factors associated with {COVID-19} viral and antibody test
               positivity and assessment of test concordance: a retrospective
               cohort study using electronic health records from the {USA}",
  author    = "Lindsay, Lisa and Secrest, Matthew H and Rizzo, Shemra and
               Keebler, Daniel S and Yang, Fei and Tsai, Larry",
  abstract  = "OBJECTIVES: To identify factors associated with COVID-19 test
               positivity and assess viral and antibody test concordance.
               DESIGN: Observational retrospective cohort study. SETTING: Optum
               de-identified electronic health records including over 700
               hospitals and 7000 clinics in the USA. PARTICIPANTS: There were
               891 754 patients who had a COVID-19 test identified in their
               electronic health record between 20 February 2020 and 10 July
               2020. PRIMARY AND SECONDARY OUTCOME MEASURES: Per cent of viral
               and antibody tests positive for COVID-19 ('positivity rate');
               adjusted ORs for factors associated with COVID-19 viral and
               antibody test positivity; and per cent concordance between
               positive viral and subsequent antibody test results. RESULTS:
               Overall positivity rate was 9\% (70 472 of 771 278) and 12\% (11
               094 of 91 741) for viral and antibody tests, respectively.
               Positivity rate was inversely associated with the number of
               individuals tested and decreased over time across regions and
               race/ethnicities. Antibody test concordance among patients with
               an initial positive viral test was 91\% (71\%-95\% depending on
               time between tests). Among tests separated by at least 2 weeks,
               discordant results occurred in 7\% of patients and 9\% of
               immunocompromised patients. Factors associated with increased
               odds of viral and antibody positivity in multivariable models
               included: male sex, Hispanic or non-Hispanic black or Asian
               race/ethnicity, uninsured or Medicaid insurance and Northeast
               residence. We identified a negative dose effect between the
               number of comorbidities and viral and antibody test positivity.
               Paediatric patients had reduced odds (OR=0.60, 95\% CI 0.57 to
               0.64) of a positive viral test but increased odds (OR=1.90, 95\%
               CI 1.62 to 2.23) of a positive antibody test compared with those
               aged 18-34 years old. CONCLUSIONS: This study identified
               sociodemographic and clinical factors associated with COVID-19
               test positivity and provided real-world evidence demonstrating
               high antibody test concordance among viral-positive patients.",
  journal   = "BMJ Open",
  publisher = "BMJ",
  volume    =  11,
  number    =  10,
  pages     = "e051707",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; epidemiology; infectious diseases; molecular
               diagnostics; public health",
  language  = "en"
}

@ARTICLE{Ferreira-Silva2021-ul,
  title     = "Implications of {COVID-19} for the busy gastroenterologist",
  author    = "Ferreira-Silva, Joel and Peixoto, Armando and Rodrigues-Pinto,
               Eduardo and Macedo, Guilherme",
  abstract  = "Coronavirus disease 2019 (COVID-19) is an infection caused by a
               novel coronavirus (SARS-CoV-2) originated in China in December
               2020 and declared pandemic by WHO. This coronavirus mainly
               spreads through the respiratory tract and enters cells through
               angiotensin-converting enzyme 2 (ACE2). The clinical symptoms of
               COVID-19 patients include fever, cough, and fatigue.
               Gastrointestinal symptoms (diarrhea, anorexia, and vomiting) may
               be present in 50\% of patients and may be associated with worst
               prognosis. Other risk factors are older age, male gender, and
               underlying chronic diseases. Mitigation measures are essential
               to reduce the number of people infected. Hospitals are a place
               of increased SARS-CoV-2 exposure. This has implications in the
               organization of healthcare services and specifically endoscopy
               departments. Patients and healthcare workers safety must be
               optimized in this new reality. Comprehension of COVID-19
               gastrointestinal manifestations and implications of SARS-CoV-2
               in the management of patients with gastrointestinal diseases,
               under or not immunosuppressant therapies, is essential. In this
               review, we summarized the latest research progress and major
               societies recommendations regarding the implications of COVID-19
               in gastroenterology, namely the adaptations that
               gastroenterology/endoscopy departments and professionals must do
               in order to optimize the provided assistance, as well as the
               implications that this infection will have, in particularly
               vulnerable patients such as those with chronic liver disease and
               inflammatory bowel disease under or not immunosuppressant
               therapies.",
  journal   = "Eur. J. Gastroenterol. Hepatol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  33,
  number    =  3,
  pages     = "319--324",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Fakhar2021-aq,
  title     = "Obstetrics and {COVID-19} experience: Challenges and strategies
               adapted by a tertiary care hospital in a developing country",
  author    = "Fakhar, Shazia and Asghar, Irram and Ashraf, Muhammad and Khan,
               Ejaz and Azam, Sumeyya",
  abstract  = "Novel coronavirus disease 2019 (COVID-19) pandemic has produced
               profound effects on the global healthcare systems including
               every specialty. Pregnant women are physiologically
               immunocompromised and may be affected more by the pandemic than
               the general population. New and unique challenges were
               encountered by hospitals and healthcare providers (HCPs) related
               to medical, surgical and strategic management involved in
               obstetric care. Data of obstetric patients presenting in labour
               and delivery unit from April to July 2020 was studied. In all
               533 patients presented, 46 (8.6\%) were COVID-19 positive.
               Overall, 41\% cesarean sections were performed with one
               mortality and one COVID-19-positive neonate. The challenges
               faced by HCPs regarding delivery of care and collective
               successive measures taken to overcome those challenges as well
               as challenges faced by patients related to healthcare provision
               are also addressed. Strategies adopted for timely intervention
               to overcome those challenges were implemented for smooth and
               safe care to all patients and staff. We believe that planning
               and preparing proactively is the key to address any pandemic
               like COVID-19. Key Words: COVID-19, Pregnancy, Obstetric care,
               Challenges.",
  journal   = "J. Coll. Physicians Surg. Pak.",
  publisher = "College of Physicians and Surgeons Pakistan",
  volume    =  31,
  number    =  2,
  pages     = "S112--S116",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Kharmoum2021-xk,
  title     = "La vaccination {anti-COVID-19} et patients atteints de cancer :
               {\'e}tat de l'art et synth{\`e}se des recommandations",
  author    = "Kharmoum, Saoussane and El M'Rabet, Fatima Zahra",
  journal   = "Bull. Cancer",
  publisher = "Elsevier BV",
  volume    =  108,
  number    =  5,
  pages     = "553--555",
  month     =  may,
  year      =  2021,
  language  = "fr"
}

@ARTICLE{Kiley2021-we,
  title     = "Viral infections in burns",
  author    = "Kiley, John L and Chung, Kevin K and Blyth, Dana M",
  abstract  = "Background: Viral infections after burns are less common than
               bacterial infections but usually occur in the more severely
               burned patients and have been associated with poor outcomes.
               Methods: Retrospective reviews and case series were examined to
               provide an overview of the management of viral infections in the
               burn patient. Results: The most common viral pathogens in these
               patients are the herpesviruses, which include herpes simplex,
               varicella zoster, cytomegalovirus, and human herpesvirus 6.
               Established viral infections that may complicate patient
               management include human immunodeficiency virus, hepatitis B and
               C, and, more recently, the novel coronavirus SARS-CoV-2.
               Herpesvirus infections can occur as primary or nosocomial
               pathogens but clinical manifestations most commonly are
               re-activation of latent viral infection. Because of the paucity
               of data in the burn population, much of the evidence for
               specific treatments is extrapolated from patients with severe
               immunosuppression or critical illness. Antiviral therapy is
               employed for the burn patient with herpesvirus infections. This
               is an area of active study, and further research is needed to
               better understand the risks, clinical manifestations, and
               attributable morbidity and mortality of viral infections.
               Conclusions: Major burn injury results in immunosuppression and
               viral infection in a small number of patients. Recognition and
               antiviral therapy are employed, but additional studies are
               necessary to improve outcomes in these patients.",
  journal   = "Surg. Infect. (Larchmt)",
  publisher = "Mary Ann Liebert Inc",
  volume    =  22,
  number    =  1,
  pages     = "88--94",
  month     =  feb,
  year      =  2021,
  keywords  = "SARTs-Co-V-2 virus; antiviral drugs; burns; cytomegalovirus;
               herpes simplex virus; human immunodeficiency virus; varicella
               zoster virus",
  language  = "en"
}

@ARTICLE{Agut2021-hp,
  title     = "{COVID-19} - The vaccine miracle must include strictness and
               caution",
  author    = "Agut, Henri",
  abstract  = "Outside of SARS-CoV-2 vaccines, there is little positive outlook
               for the control of Covid-19 epidemic. Schematically, two
               antagonistic and extreme strategies have been proposed,
               zero-covid and herd immunity. Between the two, often oscillating
               measures, based on medical but also societal and political
               considerations, have been taken without any major effect on the
               course of the epidemic. Vaccines are a game-changer by providing
               a real opportunity to sustainably protect everyone against
               infection and eliminate the circulation of the virus. The
               Pfizer, Moderna and AstraZeneca vaccines, the three currently
               authorized in France, overall induce remarkable protection rates
               of 95 \%, 94 \% and 70 \% respectively. The surprise came from
               that this efficacy was obtained after a rapid development, by
               targeting only the viral protein S as antigen, and by using the
               administration of expression vectors innovative in vaccinology,
               consisting of either messenger RNA or recombinant adenovirus.
               However, bringing the epidemic under control requires a
               well-organized mass vaccination campaign. It also requires
               careful monitoring of many parameters such as the occurrence of
               adverse events, duration of induced immunity, vaccine efficacy
               against emerging variants of SARS-CoV-2, interest or not of
               vaccinating people already infected, vaccination of
               immunocompromised patients. Vaccination must be accompanied by
               the maintenance of barrier measures and gestures and an
               amplification of clinical and biological investigations both to
               validate its effectiveness on the Covid-19 epidemic and to
               prepare for future developments in vaccinology.",
  journal   = "Virologie",
  publisher = "John Libbey Eurotext",
  volume    =  25,
  number    =  3,
  pages     = "141--147",
  month     =  jun,
  year      =  2021,
  keywords  = "Covid-19; SARS-CoV-2 variant; mRNA vaccine; recombinant
               adenovirus vaccine",
  language  = "fr"
}

@ARTICLE{Razavi2021-rh,
  title     = "{COVID-19} in patients with cancer: Risks and precautions",
  author    = "Razavi, Azadehsadat and Hamblin, Michael R and Rezaei, Nima",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
               a member of the coronavirus family, which causes coronavirus
               disease 2019 (COVID-19). The phenotype of the disease varies
               from asymptomatic, to a mild phenotype, through to the severe
               form of acute respiratory distress syndrome (ARDS), which often
               leads to death, especially in those with underlying diseases. It
               has been reported that those who suffer from cancer (especially
               lung cancer and hematological malignancies) are at higher risk
               of serious complications and death from COVID-19. Some cancer
               treatments such as CAR T cell therapy can produce a cytokine
               storm, which is also a hallmark of severe COVID-19. Therefore,
               patients receiving CAR T cells are at higher risk if they become
               infected with COVID-19, and could be treated with anti-cytokine
               approaches.",
  journal   = "Am. J. Emerg. Med.",
  publisher = "Elsevier BV",
  volume    =  48,
  pages     = "357--360",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Connelly2021-vd,
  title     = "Impact of {COVID-19} on pediatric immunocompromised patients",
  author    = "Connelly, James A and Chong, Hey and Esbenshade, Adam J and
               Frame, David and Failing, Christopher and Secord, Elizabeth and
               Walkovich, Kelly",
  abstract  = ".",
  journal   = "Pediatr. Clin. North Am.",
  publisher = "Elsevier BV",
  volume    =  68,
  number    =  5,
  pages     = "1029--1054",
  month     =  oct,
  year      =  2021,
  keywords  = "Autoimmune; COVID-19; Cancer; HIV; Immunocompromised;
               Immunodeficiency; Pediatric; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Antoon2021-ey,
  title     = "Factors associated with {COVID-19} disease severity in {US}
               children and adolescents",
  author    = "Antoon, James W and Grijalva, Carlos G and Thurm, Cary and
               Richardson, Troy and Spaulding, Alicen B and Teufel, 2nd, Ronald
               J and Reyes, Mario A and Shah, Samir S and Burns, Julianne E and
               Kenyon, Ch{\'e}n C and Hersh, Adam L and Williams, Derek J",
  abstract  = "BACKGROUND: Little is known about the clinical factors
               associated with COVID-19 disease severity in children and
               adolescents. METHODS: We conducted a retrospective cohort study
               across 45 US children's hospitals between April 2020 to
               September 2020 of pediatric patients discharged with a primary
               diagnosis of COVID-19. We assessed factors associated with
               hospitalization and factors associated with clinical severity
               (eg, admission to inpatient floor, admission to intensive care
               unit [ICU], admission to ICU with mechanical ventilation, shock,
               death) among those hospitalized. RESULTS: Among 19,976 COVID-19
               encounters, 15,913 (79.7\%) patients were discharged from the
               emergency department (ED) and 4063 (20.3\%) were hospitalized.
               The clinical severity distribution among those hospitalized was
               moderate (3222, 79.3\%), severe (431, 11.3\%), and very severe
               (380, 9.4\%). Factors associated with hospitalization vs
               discharge from the ED included private payor insurance (adjusted
               odds ratio [aOR],1.16; 95\% CI, 1.1-1.3), obesity/type 2
               diabetes mellitus (type 2 DM) (aOR, 10.4; 95\% CI, 8.9-13.3),
               asthma (aOR, 1.4; 95\% CI, 1.3-1.6), cardiovascular disease,
               (aOR, 5.0; 95\% CI, 4.3- 5.8), immunocompromised condition (aOR,
               5.9; 95\% CI, 5.0-6.7), pulmonary disease (aOR, 5.3; 95\% CI,
               3.4-8.2), and neurologic disease (aOR, 3.2; 95\% CI, 2.7-5.8).
               Among children and adolescents hospitalized with COVID-19,
               greater disease severity was associated with Black or other
               non-White race; age greater than 4 years; and obesity/type 2 DM,
               cardiovascular, neuromuscular, and pulmonary conditions.
               CONCLUSIONS: Among children and adolescents presenting to US
               children's hospital EDs with COVID-19, 20\% were hospitalized;
               of these, 21\% received care in the ICU. Older children and
               adolescents had a lower risk for hospitalization but more severe
               illness when hospitalized. There were differences in disease
               severity by race and ethnicity and the presence of selected
               comorbidities. These factors should be taken into consideration
               when prioritizing mitigation and vaccination strategies.",
  journal   = "J. Hosp. Med.",
  publisher = "Frontline Medical Communications, Inc.",
  volume    =  16,
  number    =  10,
  pages     = "603--610",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Milota2021-bv,
  title     = "An immunologist's perspective on {anti-COVID-19} vaccines",
  author    = "Milota, Tomas and Strizova, Zuzana and Smetanova, Jitka and
               Sediva, Anna",
  abstract  = "PURPOSE OF REVIEW: Antisevere acute respiratory syndrome-corona
               virus 2 (SARS-CoV-2) vaccines may provide prompt, effective, and
               safe solution for the COVID-19 pandemic. Several vaccine
               candidates have been evaluated in randomized clinical trials
               (RCTs). Furthermore, data from observational studies mimicking
               real-life practice and studies on specific groups, such as
               pregnant women or immunocompromised patients who were excluded
               from RCTs, are currently available. The main aim of the review
               is to summarize and provide an immunologist's view on mechanism
               of action, efficacy and safety, and future challenges in
               vaccination against SARS-CoV-2. RECENT FINDINGS: mRNA and
               recombinant viral vector-based vaccines have been approved for
               conditional use in Europe and the USA. They show robust humoral
               and cellular responses, high with efficacy in prevention of
               COVID-19 infection (66.9 95\%) and favorable safety profile in
               RCTs. High efficacy of 80-92\% was observed in real-life
               practice. A pilot study also confirmed good safety profile of
               the mRNA vaccines in pregnant women. Unlike in those with
               secondary immunodeficiencies where postvaccination responses did
               not occur, encouraging results were obtained in patients with
               inborn errors of immunity. SUMMARY: Although both RCTs and
               observational studies suggest good efficacy and safety profiles
               of the vaccines, their long-term efficacy and safety are still
               being discussed. Despite the promising results, clinical
               evidence for specific groups such as children, pregnant and
               breastfeeding women, and immunocompromised patients, and for
               novel virus variants are lacking. VIDEO ABSTRACT:
               http://links.lww.com/COAI/A21.",
  journal   = "Curr. Opin. Allergy Clin. Immunol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  21,
  number    =  6,
  pages     = "545--552",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Xie2020-px,
  title     = "{COVID-19}: Imbalanced immune responses and potential
               immunotherapies",
  author    = "Xie, Bing and Zhang, Jiancheng and Li, Yuwen and Yuan, Shiying
               and Shang, You",
  abstract  = "The ongoing pandemic coronavirus disease 2019 (COVID-19) caused
               by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               is rapidly spreading and has resulted in grievous morbidity and
               mortality worldwide. Despite the high infectiousness of
               SARS-CoV-2, the majority of infected individuals are
               asymptomatic or have mild symptoms and could eventually recover
               as a result of their balanced immune function. On the contrary,
               immuno-compromised patients are prone to progress into severe or
               critical types underpinned by the entanglement of an
               overexuberant proinflammatory response and injured immune
               function. Therefore, well-coordinated innate and adaptive immune
               systems are pivotal to viral eradication and tissue repair. An
               in-depth understanding of the immunological processes underlying
               COVID-19 could facilitate rapidly identifying and choosing
               optimal immunotherapy for patients with severe SARS-CoV-2
               infection. In this review, based on current immunological
               evidence, we describe potential immune mechanisms and discuss
               promising immunotherapies for COVID-19, including IL-6R
               blockades, convalescent plasma, intravenous gamma globulin,
               thymosin alpha1, corticosteroids, and type-I interferon, and
               recent advances in the development of COVID-19 vaccines.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  11,
  pages     = "607583",
  year      =  2020,
  keywords  = "IL-6R blockade; convalescent plasma; coronavirus disease 2019;
               immunomodulation; intravenous gamma globulin; pathogenesis;
               severe acute respiratory syndrome coronavirus 2; thymosin alpha1",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Govender2021-dh,
  title     = "The {COVID-19} pandemic: An appraisal of its impact on human
               immunodeficiency virus infection and pre-eclampsia",
  author    = "Govender, Rowen and Moodley, Jagidesa and Naicker, Thajasvarie",
  abstract  = "PURPOSE OF REVIEW: The impact of the coronavirus disease 2019
               (COVID-19) pandemic is profound, with distressing consequences
               on many individuals, especially those with co-morbidities.
               Pregnant women are one such group of individuals who are at in
               increased risk of contracting COVID-19, due to their
               immunocompromised state. In South Africa, HIV infection and
               pre-eclampsia are the leading causes of maternal morbidity and
               mortality, with South Africa being the HIV epicentre of the
               world. The relationship between COVID-19 superimposed on HIV
               infection and preeclampsia is complex and uncertain due to their
               different immune responses, and therefore requires further
               research. RECENT FINDINGS: Notably evidence suggests that
               pregnant women with chronic comorbidities (HIV and
               pre-eclampsia) may be at a greater risk of contracting or
               encountering complications from COVID-19. Maternal stress,
               during a pandemic, as well as home delivery have become
               potential options for pregnant woman. Nonetheless there is
               currently a paucity of information on the combined effect of
               COVID-19 in HIV-associated preeclampsia. Understanding the
               pathogenesis of COVID-19 could potentially aid in developing
               effective treatment strategies for COVID-19 in HIV associated
               preeclampsia. This review article presents a comprehensive
               analysis of the current data in relation to COVID-19 and its
               effect on pregnant women, including symptoms, pathogenesis and
               the possible risk of vertical transmission. This paper also
               reviews its' interactions and effects on preeclamptic and HIV
               positive pregnant women with suspected or confirmed COVID-19.",
  journal   = "Curr. Hypertens. Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  23,
  number    =  2,
  pages     = "9",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; HIV; Pre-eclampsia; Pregnancy",
  language  = "en"
}

@ARTICLE{Candon2021-ge,
  title     = "{T} cell and antibody responses to {SARS-CoV-2}: Experience from
               a French transplantation and hemodialysis center during the
               {COVID-19} pandemic",
  author    = "Candon, Sophie and Guerrot, Dominique and Drouot, Laurent and
               Lemoine, Mathilde and Lebourg, Ludivine and Hanoy, M{\'e}lanie
               and Boyer, Olivier and Bertrand, Dominique",
  abstract  = "Immunosuppressed organ-transplanted patients are considered at
               risk for severe forms of COVID-19. Moreover, exaggerated innate
               and adaptive immune responses might be involved in severe
               progression of the disease. However, no data on the immune
               response to SARS-CoV-2 in transplanted patients are currently
               available. Here, we report the first assessment of antibody and
               T cell responses to SARS-CoV-2 in 11 kidney-transplanted
               patients recovered from RT-PCR-confirmed (n = 5) or initially
               suspected (n = 6) COVID-19. After reduction of immunosuppressive
               therapy, RT-PCR-confirmed COVID-19 transplant patients were able
               to mount vigorous antiviral T cell and antibody responses, as
               efficiently as two nontherapeutically immunosuppressed COVID-19
               patients on hemodialysis. By contrast, six RT-PCR-negative
               patients displayed no antibody response. Among them, three
               showed very low numbers of SARS-CoV-2-reactive T cells, whereas
               no T cell response was detected in the other three, potentially
               ruling out COVID-19 diagnosis. Low levels of T cell reactivity
               to SARS-CoV-2 were also detected in seronegative healthy
               controls without known exposure to the virus. These results
               suggest that during COVID-19, monitoring both T cell and
               serological immunity might be helpful for the differential
               diagnosis of COVID-19 but are also needed to evaluate a
               potential role of antiviral T cells in the development of severe
               forms of the disease.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  2,
  pages     = "854--863",
  month     =  feb,
  year      =  2021,
  keywords  = "immunobiology; infection and infectious agents - viral; kidney
               transplantation / nephrology; monitoring: immune; translational
               research / science",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Embi2021-iz,
  title     = "Effectiveness of 2-dose vaccination with {mRNA} {COVID-19}
               vaccines against {COVID-19-associated} hospitalizations among
               immunocompromised adults - nine states, {January-September} 2021",
  author    = "Embi, Peter J and Levy, Matthew E and Naleway, Allison L and
               Patel, Palak and Gaglani, Manjusha and Natarajan, Karthik and
               Dascomb, Kristin and Ong, Toan C and Klein, Nicola P and Liao,
               I-Chia and Grannis, Shaun J and Han, Jungmi and Stenehjem,
               Edward and Dunne, Margaret M and Lewis, Ned and Irving,
               Stephanie A and Rao, Suchitra and McEvoy, Charlene and Bozio,
               Catherine H and Murthy, Kempapura and Dixon, Brian E and Grisel,
               Nancy and Yang, Duck-Hye and Goddard, Kristin and Kharbanda,
               Anupam B and Reynolds, Sue and Raiyani, Chandni and Fadel,
               William F and Arndorfer, Julie and Rowley, Elizabeth A and
               Fireman, Bruce and Ferdinands, Jill and Valvi, Nimish R and
               Ball, Sarah W and Zerbo, Ousseny and Griggs, Eric P and
               Mitchell, Patrick K and Porter, Rachael M and Kiduko, Salome A
               and Blanton, Lenee and Zhuang, Yan and Steffens, Andrea and
               Reese, Sarah E and Olson, Natalie and Williams, Jeremiah and
               Dickerson, Monica and McMorrow, Meredith and Schrag, Stephanie J
               and Verani, Jennifer R and Fry, Alicia M and Azziz-Baumgartner,
               Eduardo and Barron, Michelle A and Thompson, Mark G and DeSilva,
               Malini B",
  abstract  = "Immunocompromised persons, defined as those with suppressed
               humoral or cellular immunity resulting from health conditions or
               medications, account for approximately 3\% of the U.S. adult
               population (1). Immunocompromised adults are at increased risk
               for severe COVID-19 outcomes (2) and might not acquire the same
               level of protection from COVID-19 mRNA vaccines as do
               immunocompetent adults (3,4). To evaluate vaccine effectiveness
               (VE) among immunocompromised adults, data from the VISION
               Network* on hospitalizations among persons aged $\geq$18 years
               with COVID-19-like illness from 187 hospitals in nine states
               during January 17-September 5, 2021 were analyzed. Using
               selected discharge diagnoses, VE against COVID-19-associated
               hospitalization conferred by completing a 2-dose series of an
               mRNA COVID-19 vaccine $\geq$14 days before the index
               hospitalization date (i.e., being fully vaccinated) was
               evaluated using a test-negative design comparing 20,101
               immunocompromised adults (10,564 [53\%] of whom were fully
               vaccinated) and 69,116 immunocompetent adults (29,456 [43\%] of
               whom were fully vaccinated). VE of 2 doses of mRNA COVID-19
               vaccine against COVID-19-associated hospitalization was lower
               among immunocompromised patients (77\%; 95\% confidence interval
               [CI] = 74\%-80\%) than among immunocompetent patients (90\%;
               95\% CI = 89\%-91\%). This difference persisted irrespective of
               mRNA vaccine product, age group, and timing of hospitalization
               relative to SARS-CoV-2 (the virus that causes COVID-19)
               B.1.617.2 (Delta) variant predominance in the state of
               hospitalization. VE varied across immunocompromising condition
               subgroups, ranging from 59\% (organ or stem cell transplant
               recipients) to 81\% (persons with a rheumatologic or
               inflammatory disorder). Immunocompromised persons benefit from
               mRNA COVID-19 vaccination but are less protected from severe
               COVID-19 outcomes than are immunocompetent persons, and VE
               varies among immunocompromised subgroups. Immunocompromised
               persons receiving mRNA COVID-19 vaccines should receive 3 doses
               and a booster, consistent with CDC recommendations (5), practice
               nonpharmaceutical interventions, and, if infected, be monitored
               closely and considered early for proven therapies that can
               prevent severe outcomes.",
  journal   = "MMWR Morb. Mortal. Wkly. Rep.",
  publisher = "Centers for Disease Control MMWR Office",
  volume    =  70,
  number    =  44,
  pages     = "1553--1559",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Rubin2021-bv,
  title    = "Audio interview: Advice for clinicians on covid-19 vaccines and
              social restrictions",
  author   = "Rubin, Eric J and Baden, Lindsey R and Morrissey, Stephen",
  journal  = "N. Engl. J. Med.",
  volume   =  384,
  number   =  17,
  pages    = "e77",
  month    =  apr,
  year     =  2021,
  language = "en"
}

@ARTICLE{Alshukairi2021-ug,
  title     = "Test-based de-isolation in {COVID-19} immunocompromised
               patients: Cycle threshold value versus {SARS-CoV-2} viral
               culture",
  author    = "Alshukairi, Abeer N and Tolah, Ahmed M and Dada, Ashraf and
               Al-Tawfiq, Jaffar A and Almagharbi, Reem S and Saeedi, Mohammed
               F and Al-Hamzi, Mohammed A and El-Kafrawy, Sherif A and
               Bahaudden, Husam A and El-Saed, Aiman and Al-Mozaini, Maha A and
               Khalid, Imran and Hefni, Lama K and Hassan, Ahmed M and
               Alandijany, Thamir A and Bajrai, Leena H and Bayumi, Daniyah T
               and Albishi, Ghadeer E and Althawadi, Sahar I and Zabani, Najla
               A and Perlman, Stanley and Azhar, Esam I",
  abstract  = "BACKGROUND: Immunocompromised patients with coronavirus disease
               2019 (COVID-19) have prolonged infectious viral shedding for
               more than 20 days. A test-based approach is suggested for
               de-isolation of these patients. METHODS: The strategy was
               evaluated by comparing severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) viral load (cycle threshold (Ct)
               values) and viral culture at the time of hospital discharge in a
               series of 13 COVID-19 patients: six immunocompetent and seven
               immunocompromised (five solid organ transplant patients, one
               lymphoma patient, and one hepatocellular carcinoma patient).
               RESULTS: Three of the 13 (23\%) patients had positive viral
               cultures: one patient with lymphoma (on day 16) and two
               immunocompetent patients (on day 7 and day 11). Eighty percent
               of the patients had negative viral cultures and had a mean Ct
               value of 20.5. None of the solid organ transplant recipients had
               positive viral cultures. CONCLUSIONS: The mean Ct value for
               negative viral cultures was 20.5 in this case series of
               immunocompromised patients. Unlike those with hematological
               malignancies, none of the solid organ transplant patients had
               positive viral cultures. Adopting the test-based approach for
               all immunocompromised patients may lead to prolonged quarantine.
               Large-scale studies in disease-specific populations are needed
               to determine whether a test-based approach versus a
               symptom-based approach or a combination is applicable for the
               de-isolation of various immunocompromised patients.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  108,
  pages     = "112--115",
  month     =  jul,
  year      =  2021,
  keywords  = "Immunocompromised patients; Isolation; SARS-CoV-2; Viral culture",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Di_Fusco2021-om,
  title     = "Evaluation of {COVID-19} vaccine breakthrough infections among
               immunocompromised patients fully vaccinated with {BNT162b2}",
  author    = "Di Fusco, Manuela and Moran, Mary M and Cane, Alejandro and
               Curcio, Daniel and Khan, Farid and Malhotra, Deepa and Surinach,
               Andy and Miles, Amanda and Swerdlow, David and McLaughlin, John
               M and Nguyen, Jennifer L",
  abstract  = "OBJECTIVE: To evaluate COVID-19 vaccine breakthrough infections
               among immunocompromised (IC) individuals. METHODS: Individuals
               vaccinated with BNT162b2 were selected from the US HealthVerity
               database (10 December 2020 to 8 July 2021). COVID-19 vaccine
               breakthrough infections were examined in fully vaccinated
               ($\geq$14 days after 2nd dose) IC individuals (IC cohort), 12
               mutually exclusive IC condition groups, and a non-IC cohort. IC
               conditions were identified using an algorithm based on diagnosis
               codes and immunosuppressive (IS) medication usage. RESULTS: Of
               1,277,747 individuals $\geq$16 years of age who received 2
               BNT162b2 doses, 225,796 (17.7\%) were identified as IC (median
               age: 58 years; 56.3\% female). The most prevalent IC conditions
               were solid malignancy (32.0\%), kidney disease (19.5\%), and
               rheumatologic/inflammatory conditions (16.7\%). Among the fully
               vaccinated IC and non-IC cohorts, a total of 978 breakthrough
               infections were observed during the study period; 124 (12.7\%)
               resulted in hospitalization and 2 (0.2\%) were inpatient deaths.
               IC individuals accounted for 38.2\% (N = 374) of all
               breakthrough infections, 59.7\% (N = 74) of all
               hospitalizations, and 100\% (N = 2) of inpatient deaths. The
               proportion with breakthrough infections was 3 times higher in
               the IC cohort compared to the non-IC cohort (N = 374 [0.18\%]
               vs. N = 604 [0.06\%]; unadjusted incidence rates were 0.89 and
               0.34 per 100 person-years, respectively. Organ transplant
               recipients had the highest incidence rate; those with >1 IC
               condition, antimetabolite usage, primary immunodeficiencies, and
               hematologic malignancies also had higher incidence rates
               compared to the overall IC cohort. Incidence rates in older
               ($\geq$65 years old) IC individuals were generally higher versus
               younger IC individuals (<65). LIMITATIONS: This retrospective
               analysis relied on coding accuracy and had limited capture of
               COVID-19 vaccine receipt. CONCLUSIONS: COVID-19 vaccine
               breakthrough infections are rare but are more common and severe
               in IC individuals. The findings from this large study support
               the FDA authorization and CDC recommendations to offer a 3rd
               vaccine dose to increase protection among IC individuals.",
  journal   = "J. Med. Econ.",
  publisher = "Informa UK Limited",
  volume    =  24,
  number    =  1,
  pages     = "1248--1260",
  month     =  jan,
  year      =  2021,
  keywords  = "BNT162b2 vaccine; COVID-19; I; I1; I10; I19; SARS-CoV-2;
               breakthrough infections; immunocompromised; tozinameran",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Beran2021-qx,
  title     = "Transmissibility and viral replication of {SARS-COV-2} in
               immunocompromised patients",
  author    = "Beran, Azizullah and Zink, Evan and Mhanna, Mohammed and
               Abugharbyeh, Aya and Hanrahan, Jennifer and Duggan, Joan and
               Assaly, Ragheb",
  abstract  = "Most of the available data are for the immunocompetent
               population, and the duration of live-virus shedding and
               transmissibility is well-understood in this population. However,
               the date regarding infectiousness and shedding of SARS-CoV-2 in
               the immunocompromised patients is scarce, with no specific
               guidelines regarding the isolation precautions of these
               patients. We summarized the findings of all the available
               studies published until now regarding transmissibility and
               replication of SARS-CoV-2 in immunosuppressed patients. Studies
               that reported data regarding viral shedding and replication from
               respiratory samples (oropharynx or nasopharynx) in
               immunosuppressed adults with COVID-19 were included. A total of
               21 studies, including 69 patients (mean age 52.2 years, and
               62.3\% males) were included. All patients had persistently
               positive RT-PCR for > 3 weeks, with median duration of 50.5 days
               (Interquartile range [IQR] 35-74 days. Five studies[3-7]
               (including nine patients) reported positive viral cultures with
               median time of 26 days (IQR 19-94.5). Two studies[7, 8]
               (including eight patients) reported detecting sub-genomic RNA
               (sg-RNA) with median duration of 59 days (IQR 29-78). Our review
               emphasizes the prolonged RT-PCR positivity and viral replication
               of SAR-CoV-2 in the immunosuppressed population. Our review
               highlights the importance of close follow-up and prolonged
               isolation precautions in immunosuppressed patients with
               persistently positive SARS-CoV-2 RT-PCR. Since viral culture may
               not be readily available, it may be reasonable to employ sg-RNA
               as an additional tool for detecting the infectious virus.
               Further studies with larger sample sizes are needed to evaluate
               the SARS-CoV-2 shedding and sg-RNA correlation to viral cultures
               in immunocompromised patients. This article is protected by
               copyright. All rights reserved.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  7,
  pages     = "4156--4160",
  month     =  jul,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{De_Greef2021-ys,
  title     = "Determinants of {IgG} antibodies kinetics after severe and
               critical {COVID-19}",
  author    = "De Greef, Julien and Scohy, Ana{\"\i}s and Zech, Francis and
               Aboubakar, Frank and Pilette, Charles and Gerard, Ludovic and
               Pothen, Lucie and Yildiz, Halil and Belkhir, Le{\"\i}la and
               Yombi, Jean Cyr",
  abstract  = "The kinetics of IgG antibodies after coronavirus disease 2019
               (COVID-19) remain poorly understood. We investigated factors
               influencing severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) IgG antibody levels and time to seronegativation
               during the follow-up of severe and critically ill patients. We
               retrospectively reviewed serological evaluations drawn during
               the follow-up of severe or critical laboratory-proven COVID-19
               patients hospitalized at a large academic hospital. Specific IgG
               titers were measured using a chemiluminescent assay targeting
               anti-spike and anti-nucleocapsid protein IgG. The influence of
               time, demographic factors, clinical and paraclinical
               characteristics, and COVID-19 therapeutics on IgG levels were
               assessed through linear regression using a mixed-effect model,
               and delay until IgG negativation through a Weibull regression
               model. The cohort included 116 patients with a total of 154 IgG
               measurements drawn at a median of 79 days after diagnosis. IgG
               antibodies were increased with age (p = 0.005) and decreased
               significantly over time (p = 0.0002). Using elapsed time and age
               as covariates, we demonstrated higher IgG levels in patients
               with a higher body mass index (BMI) (p = 0.0026) and lower IgG
               levels in immunocompromised patients (p = 0.032). A high BMI was
               further found to delay and immunodeficiency to hasten
               significantly seronegativation, whereas no significant effect
               was observed with corticosteroids. These data highlight the
               waning over time of IgG antibodies after severe or critical
               COVID-19. Age, BMI, and immunosuppression also appear to
               influence the IgG kinetics, while short-term corticotherapy does
               not. Those data improve the understanding of SARS-CoV-2 serology
               while further research should determine the determinants of
               long-term seroprotection.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  9,
  pages     = "5416--5424",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; IgG; SARS-CoV-2; corticosteroids; kinetics; serology",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Wang2021-yj,
  title     = "{COVID-19} reinfection: a rapid systematic review of case
               reports and case series",
  author    = "Wang, Jingzhou and Kaperak, Christopher and Sato, Toshiro and
               Sakuraba, Atsushi",
  abstract  = "The COVID-19 pandemic has infected millions of people worldwide
               and many countries have been suffering from a large number of
               deaths. Acknowledging the ability of SARS-CoV-2 to mutate into
               distinct strains as an RNA virus and investigating its potential
               to cause reinfection is important for future health policy
               guidelines. It was thought that individuals who recovered from
               COVID-19 generate a robust immune response and develop
               protective immunity; however, since the first case of documented
               reinfection of COVID-19 in August 2020, there have been a number
               of cases with reinfection. Many cases are lacking genomic data
               of the two infections, and it remains unclear whether they were
               caused by different strains. In the present study, we undertook
               a rapid systematic review to identify cases infected with
               different genetic strains of SARS-CoV-2 confirmed by PCR and
               viral genome sequencing. A total of 17 cases of genetically
               confirmed COVID-19 reinfection were found. One immunocompromised
               patient had mild symptoms with the first infection but developed
               severe symptoms resulting in death with the second infection.
               Overall, 68.8\% (11/16) had similar severity; 18.8\% (3/16) had
               worse symptoms; and 12.5\% (2/16) had milder symptoms with the
               second episode. Our case series shows that reinfection with
               different strains is possible, and some cases may experience
               more severe infections with the second episode. The findings
               also suggest that COVID-19 may continue to circulate even after
               achieving herd immunity through natural infection or
               vaccination, suggesting the need for longer-term transmission
               mitigation efforts.",
  journal   = "J. Investig. Med.",
  publisher = "BMJ",
  volume    =  69,
  number    =  6,
  pages     = "1253--1255",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19",
  language  = "en"
}

@ARTICLE{Yuksel2021-ro,
  title     = "A single-center report of {COVID-19} disease course and
               management in liver transplanted pediatric patients",
  author    = "Yuksel, Muhammed and Akturk, Hacer and Mizikoglu, Ozlem and
               Toroslu, Ertug and Arikan, Cigdem",
  abstract  = "BACKGROUND: In 2019, SARS-CoV-2 causing COVID-19 emerged. Severe
               COVID-19 symptoms may evolve by virtue of hyperactivation of the
               immune system. Equally, immunocompromised patients may be at
               increased risk to develop COVID-19. However, treatment
               guidelines for children following liver transplantation are
               elusive. METHODS: As a liver transplantation center, we
               diagnosed and followed up 10 children (male/female: 8/2) with a
               median age of 8.5 years (IQR: 5.2-11.0), with COVID-19
               post-liver transplant between March 2019 and December 2020.
               COVID-19 diagnosis was based on PCR test and or florid X-ray
               findings compatible with COVID-19 in the absence of other cause.
               We retrospectively collected clinical and laboratory data from
               electronic patient records following written consent from
               patients/parents. RESULTS: Nine patients were diagnosed as
               definitive (PCR positive) with one patient being diagnosed as
               probable COVID-19. Seven patients recovered without any support
               whereas three were admitted for non-invasive oxygenation.
               Lymphopenia and/or high levels of serum IL-6 were detected in
               four patients. Six patients mounted anti-SARS-CoV-2 antibodies
               at median 30 days (IQR: 26.5-119.0) following COVID-19
               diagnosis. Antibiotic therapy, favipiravir, anakinra, and IVIG
               were used as treatment in 4,1,1 and 2 patients, respectively.
               Furthermore, we kept the tacrolimus with or without everolimus
               but stopped MMF in 2 patients. Importantly, liver allograft
               function was retained in all patients. CONCLUSIONS: We found
               that being immunocompromised did not affect disease severity nor
               survival. Stopping MMF yet continuing with tacrolimus was an apt
               treatment modality in these patients.",
  journal   = "Pediatr. Transplant.",
  publisher = "Wiley",
  volume    =  25,
  number    =  7,
  pages     = "e14061",
  month     =  nov,
  year      =  2021,
  keywords  = "IL-6; SARS-CoV-2; antibody; children; immunosuppression;
               lymphopenia; solid organ; tacrolimus",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Mehta2020-qb,
  title     = "Coronavirus disease ({COVID-19)}: Comprehensive review of
               clinical presentation",
  author    = "Mehta, Om Prakash and Bhandari, Parshal and Raut, Akshay and
               Kacimi, Salah Eddine Oussama and Huy, Nguyen Tien",
  abstract  = "COVID-19 is a rapidly growing pandemic with its first case
               identified during December 2019 in Wuhan, Hubei Province, China.
               Due to the rampant rise in the number of cases in China and
               globally, WHO declared COVID-19 as a pandemic on 11th March
               2020. The disease is transmitted via respiratory droplets of
               infected patients during coughing or sneezing and affects
               primarily the lung parenchyma. The spectrum of clinical
               manifestations can be seen in COVID-19 patients ranging from
               asymptomatic infections to severe disease resulting in
               mortality. Although respiratory involvement is most common in
               COVID-19 patients, the virus can affect other organ systems as
               well. The systemic inflammation induced by the disease along
               with multisystem expression of Angiotensin Converting Enzyme 2
               (ACE2), a receptor which allows viral entry into cells, explains
               the manifestation of extra-pulmonary symptoms affecting the
               gastrointestinal, cardiovascular, hematological, renal,
               musculoskeletal, and endocrine system. Here, we have reviewed
               the extensive literature available on COVID-19 about various
               clinical presentations based on the organ system involved as
               well as clinical presentation in specific population including
               children, pregnant women, and immunocompromised patients. We
               have also briefly discussed about the Multisystemic Inflammatory
               Syndrome occurring in children and adults with COVID-19.
               Understanding the various clinical presentations can help
               clinicians diagnose COVID-19 in an early stage and ensure
               appropriate measures to be undertaken in order to prevent
               further spread of the disease.",
  journal   = "Front. Public Health",
  publisher = "Frontiers Media SA",
  volume    =  8,
  pages     = "582932",
  year      =  2020,
  keywords  = "Covid-19; SARS-CoV-2; clinical features; clinical presentation;
               coronavirus; signs and symptoms; symptomatology",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Waldman2021-il,
  title     = "Dermatology patients on biologics and certain other systemic
               therapies should receive a ``booster'' messenger {RNA}
               {COVID-19} vaccine dose: A critical appraisal of recent Food and
               Drug Administration and Advisory Committee on Immunization
               Practices recommendations",
  author    = "Waldman, Reid Alexander and Grant-Kels, Jane M",
  journal   = "J. Am. Acad. Dermatol.",
  publisher = "Elsevier BV",
  volume    =  85,
  number    =  5,
  pages     = "1113--1116",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; COVID-19 vaccine; SARS-CoV-2; adalimumab; brodalumab;
               certolizumab; dermatology; etanercept; glucocorticoid;
               golimumab; guselkumab; infliximab; ixekizumab; janus kinase
               inhibitor; mRNA vaccine; methotrexate; mycophenolate;
               prednisone; risankizumab; rituximab; secukinumab; tildrakizumab;
               vaccine",
  language  = "en"
}

@ARTICLE{Martynowicz2021-ny,
  title     = "Demographic, clinical, laboratory, and genetic risk factors
               associated with {COVID-19} severity in adults: A narrative
               review",
  author    = "Martynowicz, Helena and Jodkowska, Anna and Por{\k e}ba,
               Rafa{\l} and Mazur, Grzegorz and Wi{\k e}ckiewicz, Mieszko",
  abstract  = "Since the first report on it in December 2019 in Wuhan, China,
               the novel coronavirus disease 2019 (COVID-19) has rapidly spread
               throughout the world. Due to the lack of effective therapy
               available for COVID-19 patients, the identification of risk
               factors for the severe course of the disease is a matter of
               urgency. Therefore, the aim of this review was to report on
               evidence-based risk factors affecting the severity and prognosis
               of COVID-19. We searched the PubMed database for current
               literature to identify relevant publications concerning risk
               factors for COVID-19 severity. Demographic and social factors
               (age, gender, race, in-center communities/nursing homes),
               clinical factors (smoking, hypertension, obesity, diabetes,
               chronic lung diseases, cardiovascular diseases - CVD, chronic
               kidney disease - CKD, malignancies, dementia, cardiomyopathies,
               immunocompromised state), laboratory markers (C-reactive protein
               - CRP, leukocytosis, ferritin, interleukin (IL)-6, D-dimer,
               lactate dehydrogenase - LDH, aspartate aminotransferase - AST,
               procalcitonin, creatinine, lymphopenia, IL-2, IL-7, IL-10,
               granulocyte colony-stimulating factor - G-CSF, also known as
               colony-stimulating factor 3 - CSF 3, interferon gamma-inducible
               protein-10 - IP-10, monocyte chemoattractant protein-1 - MCP-1,
               macrophage inflammatory protein-1alpha - MIP1A, tumor necrosis
               factor alpha - TNF-$\alpha$), and genetic factors related to
               both the virus and the host were discussed. The identification
               of the potential risk factors affecting the severity and
               prognosis of COVID-19 may provide a chance for earlier and more
               effective management of COVID-19.",
  journal   = "Dent. Med. Probl.",
  publisher = "Wroclaw Medical University",
  volume    =  58,
  number    =  1,
  pages     = "115--121",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; demographics; risk factors; severity",
  copyright = "https://creativecommons.org/licenses/by/3.0/",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Fast2021-hl,
  title     = "Booster and additional primary dose {COVID-19} vaccinations
               among adults aged $\geq$65 years - United States, August 13,
               2021-November 19, 2021",
  author    = "Fast, Hannah E and Zell, Elizabeth and Murthy, Bhavini Patel and
               Murthy, Neil and Meng, Lu and Scharf, Lynn Gibbs and Black,
               Carla L and Shaw, Lauren and Chorba, Terence and Harris,
               Latreace Q",
  abstract  = "Vaccination against SARS-CoV-2 (the virus that causes COVID-19)
               is highly effective at preventing hospitalization due to
               SARS-CoV-2 infection and booster and additional primary dose
               COVID-19 vaccinations increase protection (1-3). During
               August-November 2021, a series of Emergency Use Authorizations
               and recommendations, including those for an additional primary
               dose for immunocompromised persons and a booster dose for
               persons aged $\geq$18 years, were approved because of reduced
               immunogenicity in immunocompromised persons, waning vaccine
               effectiveness over time, and the introduction of the highly
               transmissible B.1.617.2 (Delta) variant (4,5). Adults aged
               $\geq$65 years are at increased risk for COVID-19-associated
               hospitalization and death and were one of the populations first
               recommended a booster dose in the U.S. (5,6). Data on COVID-19
               vaccinations reported to CDC from 50 states, the District of
               Columbia (DC), and eight territories and freely associated
               states were analyzed to ascertain coverage with booster or
               additional primary doses among adults aged $\geq$65 years.
               During August 13-November 19, 2021, 18.7 million persons aged
               $\geq$65 years received a booster or additional primary dose of
               COVID-19 vaccine, constituting 44.1\% of 42.5 million eligible*
               persons in this age group who previously completed a primary
               vaccination series. Coverage was similar by sex and age group,
               but varied by primary series vaccine product and race and
               ethnicity, ranging from 30.3\% among non-Hispanic American
               Indian or Alaska Native persons to 50.5\% among non-Hispanic
               multiple/other race persons. Strategic efforts are needed to
               encourage eligible persons aged $\geq$18 years, especially those
               aged $\geq$65 years and those who are immunocompromised, to
               receive a booster and/or additional primary dose to ensure
               maximal protection against COVID-19.",
  journal   = "MMWR Morb. Mortal. Wkly. Rep.",
  publisher = "Centers for Disease Control MMWR Office",
  volume    =  70,
  number    =  50,
  pages     = "1735--1739",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ryan2021-ke,
  title    = "Predicting severe outcomes in Covid-19 related illness using only
              patient demographics, comorbidities and symptoms",
  author   = "Ryan, Charles and Minc, Alexa and Caceres, Juan and Balsalobre,
              Alexandra and Dixit, Achal and Ng, Becky Kapik and Schmitzberger,
              Florian and Syed-Abdul, Shabbir and Fung, Christopher",
  abstract = "OBJECTIVE: Development of a risk-stratification model to predict
              severe Covid-19 related illness, using only presenting symptoms,
              comorbidities and demographic data. MATERIALS AND METHODS: We
              performed a case-control study with cases being those with severe
              disease, defined as ICU admission, mechanical ventilation, death
              or discharge to hospice, and controls being those with non-severe
              disease. Predictor variables included patient demographics,
              symptoms and past medical history. Participants were 556 patients
              with laboratory confirmed Covid-19 and were included
              consecutively after presenting to the emergency department at a
              tertiary care center from March 1, 2020 to April 21, 2020
              RESULTS: Most common symptoms included cough (82\%), dyspnea
              (75\%), and fever/chills (77\%), with 96\% reporting at least one
              of these. Multivariable logistic regression analysis found that
              increasing age (adjusted odds ratio [OR], 1.05; 95\% confidence
              interval [CI], 1.03-1.06), dyspnea (OR, 2.56; 95\% CI:
              1.51-4.33), male sex (OR, 1.70; 95\% CI: 1.10-2.64),
              immunocompromised status (OR, 2.22; 95\% CI: 1.17-4.16) and CKD
              (OR, 1.76; 95\% CI: 1.01-3.06) were significant predictors of
              severe Covid-19 infection. Hyperlipidemia was found to be
              negatively associated with severe disease (OR, 0.54; 95\% CI:
              0.33-0.90). A predictive equation based on these variables
              demonstrated fair ability to discriminate severe vs non-severe
              outcomes using only this historical information (AUC: 0.76).
              CONCLUSIONS: Severe Covid-19 illness can be predicted using data
              that could be obtained from a remote screening. With validation,
              this model could possibly be used for remote triage to prioritize
              evaluation based on susceptibility to severe disease while
              avoiding unnecessary waiting room exposure.",
  journal  = "Am. J. Emerg. Med.",
  volume   =  45,
  pages    = "378--384",
  month    =  jul,
  year     =  2021,
  keywords = "Covid-19; Remote triage; Severe; Symptoms",
  language = "en"
}

@ARTICLE{Hersby2021-cp,
  title     = "{COVID-19-associated} pancytopenia can be self-limiting and does
               not necessarily warrant bone marrow biopsy for the purposes of
               {SARS-CoV-2} diagnostics",
  author    = "Hersby, D S and Do, T H and Gang, A O and Nielsen, T H",
  journal   = "Ann. Oncol.",
  publisher = "Elsevier BV",
  volume    =  32,
  number    =  1,
  pages     = "121--123",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Benotmane2021-sj,
  title     = "Biomarkers of cytokine release syndrome predict disease severity
               and mortality from {COVID-19} in kidney transplant recipients",
  author    = "Benotmane, Ilies and Perrin, Peggy and Vargas, Gabriela Gautier
               and Bassand, Xavier and Keller, Nicolas and Lavaux, Thomas and
               Ohana, Mickael and Bedo, Dimitri and Baldacini, Cl{\'e}ment and
               Sagnard, Mylene and Bozman, Dogan-Firat and Chiesa, Margaux
               Della and Cognard, No{\"e}lle and Olagne, J{\'e}r{\^o}me and
               Delagreverie, H{\'e}lo{\"\i}se and Marx, David and Heibel,
               Fran{\c c}oise and Braun, Laura and Moulin, Bruno and
               Fafi-Kremer, Samira and Caillard, Sophie",
  abstract  = "BACKGROUND: Data on coronavirus disease 2019 (COVID-19) in
               immunocompromised kidney transplant recipients (KTR) remain
               scanty. Although markers of inflammation, cardiac injury, and
               coagulopathy have been previously associated with mortality in
               the general population of patients with COVID-19, their
               prognostic impact amongst KTR with severe acute respiratory
               syndrome coronavirus-2 (SARS-CoV-2) infection has not been
               specifically investigated. METHODS: We conducted a cohort study
               of 49 KTR who presented with COVID-19. Clinical and laboratory
               risk factors for severe disease and mortality were prospectively
               collected and analyzed with respect to outcomes. The study
               participants were divided into 3 groups: (1) mild disease
               manageable in an outpatient setting (n = 8), (2) nonsevere
               disease requiring hospitalization (n = 21), and (3) severe
               disease (n = 20). RESULTS: Gastrointestinal manifestations were
               common at diagnosis. The 30-day mortality rate in hospitalized
               patients was 19.5\%. Early elevations of C-reactive protein
               (>100 mg/L) and interleukin-6 (>65 ng/L) followed by increases
               in high-sensitivity troponin I (>30 ng/L) and D-dimer (>960
               ng/mL) were significantly associated with severe disease and
               mortality. Viral load did not have prognostic significance in
               our sample, suggesting that outcomes were chiefly driven by a
               cytokine release syndrome (CRS). CONCLUSIONS: Regular monitoring
               of CRS biomarkers in KTR with COVID-19 is paramount to improve
               clinical outcomes.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  1,
  pages     = "158--169",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Wack2021-yg,
  title     = "{COVID-19} vaccine safety and efficacy in patients with
               immune-mediated inflammatory disease: Review of available
               evidence",
  author    = "Wack, Sarah and Patton, Timothy and Ferris, Laura K",
  abstract  = "Dermatologists diagnose and treat many immune-mediated
               inflammatory diseases (IMID). Understanding the inherent immune
               dysregulation of these diseases as well as the additional
               disruption that comes as a result of IMID treatments has been
               important during the COVID-19 pandemic. With vaccines becoming
               widely available, dermatologists need to be familiar with the
               risks and benefits of vaccination in these patients,
               particularly those taking biologics, in order to have informed
               discussions with their patients. In this review, we present the
               current evidence related to COVID-19 vaccine safety and efficacy
               in patients with IMID and review existing recommendations for
               vaccination against SARS-CoV-2. Given the current evidence,
               there is minimal concern that these patients are at any greater
               risk of harm from COVID-19 vaccination compared to healthy
               controls. For most, the benefit of avoiding severe COVID-19
               through vaccination will outweigh the theoretical risk of these
               vaccines. A question that is still outstanding is whether
               patients on biologics will generate a sufficient immune response
               to the vaccine, which may be dependent on the specific biologic
               therapy and indication being treated. This underscores the
               importance of following patients with IMID after vaccination to
               determine the safety, efficacy, and duration of the vaccine in
               this population.",
  journal   = "J. Am. Acad. Dermatol.",
  publisher = "Elsevier BV",
  volume    =  85,
  number    =  5,
  pages     = "1274--1284",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; IMID; MCTD; SARS-CoV-2; Systemic Lupus Erythematosus;
               atopic dermatitis; autoimmune disease; autoimmunity; biologics;
               dermatomyositis; hidradenitis suppurativa; myositis; pemphigoid;
               pemphigus; psoriasis; sarcoid; sclerosis; vaccines; vasculitis",
  language  = "en"
}

@ARTICLE{Plummer2021-iy,
  title     = "{COVID-19} vaccines for {HIV-infected} patients",
  author    = "Plummer, Maria M and Pavia, Charles S",
  abstract  = "Nearly 40 years have passed since the initial cases of infection
               with the human mmunodeficiency virus (HIV) were identified as a
               new disease entity and the cause of acquired immunodeficiency
               disease (AIDS). This virus, unlike any other, is capable of
               causing severe suppression of our adaptive immune defense
               mechanisms by directly infecting and destroying helper T cells
               leading to increased susceptibility to a wide variety of
               microbial pathogens, especially those considered to be
               intracellular or opportunistic. After T cells are infected, HIV
               reproduces itself via a somewhat unique mechanism involving
               various metabolic steps, which includes the use of a reverse
               transcriptase enzyme that enables the viral RNA to produce
               copies of its complementary DNA. Subsequent physiologic steps
               lead to the production of new virus progeny and the eventual
               death of the invaded T cell. Fortunately, both serologic and
               molecular tests (such as PCR) can be used to confirm the
               diagnosis of an HIV infection. In the wake of the current
               COVID-19 pandemic, it appears that people living with HIV/AIDS
               are equally or slightly more susceptible to the etiologic agent,
               SARS-CoV-2, than the general population having intact immune
               systems, but they may have more serious outcomes. Limited
               clinical trials have also shown that the currently available
               COVID-19 vaccines are both safe and effective in affording
               protection to HIV/AIDS patients. In this review, we further
               explore the unique dynamic of HIV/AIDS in the context of the
               worldwide COVID-19 pandemic and the implementation of vaccines
               as a protective measure against COVID-19, as well as what immune
               parameters and safeguards should be monitored in this
               immunocompromised group following vaccination.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  10,
  pages     = "1890",
  month     =  sep,
  year      =  2021,
  keywords  = "AIDS; COVID-19; HIV; SARS-Cov-2; SARS-Cov-2 vaccines; mRNA",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Chia2021-rr,
  title     = "Managing cancer in context of pandemic: a qualitative study to
               explore the emotional and behavioural responses of patients with
               cancer and their caregivers to {COVID-19}",
  author    = "Chia, Jace Ming Xuan and Goh, Zack Zhong Sheng and Chua, Zi Yang
               and Ng, Kennedy Yao Yi and Ishak, Diana and Fung, Si Ming and
               Ngeow, Joanne Yuen Yie and Griva, Konstadina",
  abstract  = "OBJECTIVES: Having to access life-sustaining treatment during
               the emerging COVID-19 outbreak has placed patients with cancer
               at an especially vulnerable position notwithstanding their
               immunocompromised condition. The present study aimed to
               elucidate cancer patients' and their caregivers' experiences
               during this outbreak. DESIGN: Face-to-face semistructured
               interviews were conducted. SETTING: A tertiary cancer care
               facility. PARTICIPANTS: 16 patients with cancer and 14
               caregivers. Inclusions criteria were: (A) diagnosed with cancer,
               (B) receiving active treatment or follow-ups, (C) aged 21 years
               and above and (D) fluent in English or Mandarin. RESULTS:
               Thematic analysis was conducted. Five themes were identified:
               heightened sense of threat, impact on healthcare experience,
               responsibility falls on oneself, striving for normalcy and sense
               of safety and trust. Heightened threat of COVID-19 was more
               pronounced in patients and linked to vulnerability and fear,
               uncertainty and actions of socially irresponsible others.
               Dominant in their healthcare experience was prioritising cancer
               and treatment amidst heightened threat and anticipatory worry
               about treatment disruptions. Both noted on the importance of
               taking responsibility for one's health, with caregivers
               reporting a reinforced sense of duty towards patients. They
               strived to maintain normalcy by viewing COVID-19 as beyond
               personal control, downplaying and living life as usual. Their
               resolve was supported by a sense of safety from the actions of
               authorities, hospitals and trust towards healthcare providers.
               CONCLUSIONS: Cancer intensifies threat and the emotional impact
               of COVID-19 and may trigger specific concerns related to
               treatment. Psychoeducation interventions led by healthcare
               providers over digital platforms could help address
               cancer-specific concerns and support patients and caregivers
               during the pandemic.",
  journal   = "BMJ Open",
  publisher = "BMJ",
  volume    =  11,
  number    =  1,
  pages     = "e041070",
  month     =  jan,
  year      =  2021,
  keywords  = "infectious diseases; oncology; qualitative research",
  language  = "en"
}

@ARTICLE{Eberhardt2021-io,
  title    = "Coronavirus disease 2019 vaccination in transplant recipients",
  author   = "Eberhardt, Christiane S and Balletto, Elisa and Cornberg, Markus
              and Mikulska, Malgorzata",
  abstract = "PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19)
              vaccination is considered one of the most promising and
              socioeconomically sustainable strategy to help control the
              pandemic and several vaccines are currently being distributed in
              nationwide mass immunization campaigns. Very limited data are
              available on benefits and risks of COVID-19 vaccination in
              immunocompromised patients and in particular in solid organ or
              hematopoietic stem cell transplant recipients as they were
              excluded from phase III trials. This review summarizes current
              knowledge, international guidelines and controversies regarding
              COVID-19 vaccination in these vulnerable populations. RECENT
              FINDINGS: Various COVID-19 vaccine platforms showed good efficacy
              in phase III trials in the immunocompetent and there are data
              arising on the safety and immunogenicity of these vaccines in the
              immunocompromised population. SUMMARY: Transplant recipients
              could benefit significantly from COVID-19 vaccination, both
              through active immunization provided they elicit protective
              vaccine responses, and probably through cocooning by immunization
              of caregivers and healthcare personnel and thus reducing the risk
              of SARS-coronavirus-2 exposure. Although awaiting more data on
              the safety and efficacy of COVID-19 vaccines to inform potential
              adaptations of vaccine regimens, we strongly recommend
              prioritizing COVID-19 vaccination of solid and hematopoietic stem
              cell transplant recipients to decrease COVID-19-related morbidity
              and mortality.",
  journal  = "Curr. Opin. Infect. Dis.",
  volume   =  34,
  number   =  4,
  pages    = "275--287",
  month    =  aug,
  year     =  2021,
  language = "en"
}

@ARTICLE{Norgard2021-vl,
  title     = "Hospitalization for {COVID-19} in patients treated with selected
               immunosuppressant and immunomodulating agents, compared to the
               general population: A Danish cohort study",
  author    = "N{\o}rg{\aa}rd, Bente Mertz and Nielsen, Jan and Knudsen, Torben
               and Nielsen, Rasmus Gaardskaer and Larsen, Michael Due and
               J{\o}lving, Line Riis and Kjeldsen, Jens",
  abstract  = "AIMS: In the Danish population, we examined whether patients
               treated with thiopurines, methotrexate, systemic
               corticosteroids, anti-tumour necrosis factor (TNF)-$\alpha$
               agents, anti-interleukin therapeutic agents, selective
               immunosuppressive agents and cyclosporine/tacrolimus had an
               increased risk of hospitalization for COVID- 19, compared to the
               background population. METHODS: A nationwide cohort study
               including all people alive in Denmark on 1 March 2020. Exposed
               patients constituted those exposed to thiopurines (n = 5484),
               methotrexate (n = 17 977), systemic corticosteroids (n = 55
               868), anti-TNF-$\alpha$ agents (n = 17 857), anti-interleukin
               therapeutic agents (n = 3744), selective immunosuppressive
               agents (n = 3026) and cyclosporine/tacrolimus (n = 1143) in a
               period of 12 months prior to 1 March 2020 (estimated time of
               outbreak in Denmark). We estimated the adjusted risk of
               hospitalization for COVID-19 for patients treated with the
               above-mentioned categories of medications, compared to the rest
               of the population. RESULTS: The adjusted odds ratios of
               hospitalization in patients treated with corticosteroids and
               cyclosporine/tacrolimus were 1.64 (95\% confidence interval [CI]
               1.35 to 2.00) and 4.75 (95\% CI 1.96 to 11.49), respectively.
               The risks of hospitalization in patients treated with
               thiopurines, methotrexate, and anti-TNF-$\alpha$ agents, were
               1.93 (95\% CI 0.91 to 4.08), 0.74 (95\% CI 0.43 to 1.28), 1.00
               (95\% CI 0.52 to 1.94), respectively. The number of outcomes in
               patients treated with anti-interleukin therapeutic agents and
               selective immunosuppressive agents was too small for analysis.
               CONCLUSION: Patients treated with systemic corticosteroids and
               cyclosporine/tacrolimus had a significantly increased risk of
               being hospitalized for COVID-19. Our study does not uncover
               whether the increased risk is related to the drug itself, the
               underlying condition for which the patient is treated or other
               factors.",
  journal   = "Br. J. Clin. Pharmacol.",
  publisher = "Wiley",
  volume    =  87,
  number    =  4,
  pages     = "2111--2120",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; biologics; clinical epidemiology; hospitalization;
               immunosuppressive; pharmacoepidemiology; thiopurines",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Condom2021-oj,
  title     = "The direct and indirect effects of {COVID-19} pandemic in a
               real-life hematological setting",
  author    = "Condom, Maria and Mussetti, Alberto and Maluquer, Clara and
               Parody, Roc{\'\i}o and Gonz{\'a}lez-Barca, Eva and Arnan,
               Montserrat and Albasanz-Puig, Adaia and Pomares, Helena and
               Salas, Maria Queralt and Carro, Itziar and Pe{\~n}a, Marta and
               Clapes, Vict{\`o}ria and Baca Cano, Cristina and Oliveira Ramos,
               Ana Carla and Sanz-Linares, Gabriela and Moreno-Gonz{\'a}lez,
               Gabriel and Mercadal, Santiago and Boqu{\'e}, Concepcion and
               Gudiol, Carlota and Domingo-Dom{\`e}nech, Eva and Sureda, Anna",
  abstract  = "BACKGROUND: Clinical outcomes of novel coronavirus 2019 disease
               (COVID-19) in onco-hematological patients are unknown. When
               compared to non-immunocompromised patients, onco-hematological
               patients seem to have higher mortality rates. AIMS: We describe
               the characteristics and outcomes of a consecutive cohort of 24
               onco-hematological patients with COVID-19 during the first month
               of the pandemic. We also describe variations in healthcare
               resource utilization within our hematology department. METHODS
               AND RESULTS: Data from patients between the first month of the
               pandemic were retrospectively collected. Clinical and logistic
               data were also collected and compared with the average values
               from the prior 3 months of activity. Prevalence of COVID-19 in
               our hematological population was 0.4\%. Baseline characteristics
               were as follows: male sex: 83\%, lymphoid diseases: 46\%, median
               age: 69 (22-82) years. Median follow-up in survivors was 14
               (9-28) days and inpatient mortality rate was 46\%. Average time
               to moderate/severe respiratory insufficiency and death were 3
               (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12
               patients who developed moderate to severe respiratory
               insufficiency recovered. Upon univariate analysis, the following
               factors were associated with higher mortality: age $\geq$ 70
               years (P = .01) and D-dimer $\geq$900 mcg/L (P = .04). With
               respect to indirect effects during the COVID-19 pandemic, and
               when compared with the prior 3 months of activity, inpatient
               mortality (excluding patients with COVID-19 included in the
               study) increased by 56\%. This was associated with a more
               frequent use of vasoactive drugs (+300\%) and advanced
               respiratory support (+133\%) in the hematology ward. In the
               outpatient setting, there was a reduction in initial visits
               (-55\%) and chemotherapy sessions (-19\%). A significant
               increase in phone visits was reported (+581\%). CONCLUSION:
               COVID-19 pandemic is associated with elevated mortality in
               hematological patients. Negative indirect effects are also
               evident within this setting.",
  journal   = "Cancer rep.",
  publisher = "Wiley",
  volume    =  4,
  number    =  4,
  pages     = "e1358",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; hematology; leukemia; lymphoma;
               telemedicine",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Buscemi2021-yi,
  title    = "Does interval time between liver transplant and {COVID-19}
              infection make the difference?",
  author   = "Buscemi, Vincenzo and De Carlis, Riccardo and Lauterio, Andrea
              and Merli, Marco and Puoti, Massimo and De Carlis, Luciano",
  journal  = "Dig. Liver Dis.",
  volume   =  53,
  number   =  2,
  pages    = "169--170",
  month    =  feb,
  year     =  2021,
  keywords = "Antiviral drugs; Immunosuppression; Pneumonia",
  language = "en"
}

@ARTICLE{Sarzi-Puttini2021-le,
  title     = "Prevalence of {COVID} infections in a population of rheumatic
               patients from Lombardy and Marche treated with biological drugs
               or small molecules: A multicentre retrospective study",
  author    = "Sarzi-Puttini, Piercarlo and Marotto, Daniela and Caporali,
               Roberto and Montecucco, Carlo Maurizio and Favalli, Ennio Giulio
               and Franceschini, Franco and Fredi, Michela and Balduzzi, Silvia
               and Bazzani, Chiara and Bongiovanni, Sara and Giorgi, Valeria
               and Batticciotto, Alberto and Cappelli, Antonella and Balzarini,
               Patrizia and Dagna, Lorenzo and Sartorelli, Silvia and
               Ravagnani, Viviana and Tamanini, Silvia and Farah, Sonia and
               Faggioli, Paola and Castelnovo, Laura and Lurati, Alfredo Maria
               and Galli, Massimo and Salaffi, Fausto",
  abstract  = "OBJECTIVE: The COVID-19 pandemic has raised questions about the
               management of systemic immunosuppressive treatments for
               rheumatic conditions. It is well known that rheumatic patients
               are at risk of developing infections because of their
               immunocompromised state. Moreover, drugs such as
               hydroxychloroquine or tocilizumab that are widely used to treat
               rheumatic diseases are now being used to treat COVID-19. The aim
               of this multicentre retrospective study of rheumatic patients in
               the Italian regions of Lombardy and Marche was to determine
               whether patients receiving biological or small molecules
               treatment are more susceptible to the development of COVID-19
               than the general population. METHODS: The local registry data of
               10,260 rheumatic patients being treated with bDMARDs or small
               molecules were evaluated from 15 March to 23 April 2020. The
               final analysis was based on the registry data relating to 7.204,
               telephone contacts and/or outpatient visits. RESULTS:
               Forty-seven of the 7.204 patients were diagnosed with COVID-19,
               seven of whom died; the patients who had symptoms resembling
               those of COVID-19 but had negative swabs were considered
               negative for the disease. The overall infection rate was 0.65,
               and the crude case fatality risk (CFR) in the patients with
               COVID-19 was 14.9\%. There was no difference in the mortality
               rate among the patients receiving the different individual
               biological drugs or small molecules. CONCLUSIONS: Our findings
               suggest that the susceptibility of rheumatic patients to
               COVID-19 is the same as that of the general population, but
               confirm that age, disease duration, and the number of
               co-morbidities are associated with an increased risk of a severe
               form of the disease. It seems that immunosuppressants drugs do
               not effectively represent a risk factor for COVID- 19.",
  journal   = "J. Autoimmun.",
  publisher = "Elsevier BV",
  volume    =  116,
  number    =  102545,
  pages     = "102545",
  month     =  jan,
  year      =  2021,
  keywords  = "Biologics; COVID 19; Dmards; Infections; Registries; Rheumatic
               disease; Small molecules",
  language  = "en"
}

@ARTICLE{Ponsford2021-oj,
  title     = "A systematic review and meta-analysis of inpatient mortality
               associated with nosocomial and community {COVID-19} exposes the
               vulnerability of immunosuppressed adults",
  author    = "Ponsford, Mark J and Ward, Tom J C and Stoneham, Simon M and
               Dallimore, Clare M and Sham, Davina and Osman, Khalid and Barry,
               Simon M and Jolles, Stephen and Humphreys, Ian R and Farewell,
               Daniel",
  abstract  = "Background: Little is known about the mortality of
               hospital-acquired (nosocomial) COVID-19 infection globally. We
               investigated the risk of mortality and critical care admission
               in hospitalised adults with nosocomial COVID-19, relative to
               adults requiring hospitalisation due to community-acquired
               infection. Methods: We systematically reviewed the peer-reviewed
               and pre-print literature from 1/1/2020 to 9/2/2021 without
               language restriction for studies reporting outcomes of
               nosocomial and community-acquired COVID-19. We performed a
               random effects meta-analysis (MA) to estimate the 1) relative
               risk of death and 2) critical care admission, stratifying
               studies by patient cohort characteristics and nosocomial case
               definition. Results: 21 studies were included in the primary MA,
               describing 8,251 admissions across 8 countries during the first
               wave, comprising 1513 probable or definite nosocomial COVID-19,
               and 6738 community-acquired cases. Across all studies, the risk
               of mortality was 1.3 times greater in patients with nosocomial
               infection, compared to community-acquired (95\% CI: 1.005 to
               1.683). Rates of critical care admission were similar between
               groups (Relative Risk, RR=0.74, 95\% CI: 0.50 to 1.08).
               Immunosuppressed patients diagnosed with nosocomial COVID-19
               were twice as likely to die in hospital as those admitted with
               community-acquired infection (RR=2.14, 95\% CI: 1.76 to 2.61).
               Conclusions: Adults who acquire SARS-CoV-2 whilst already
               hospitalised are at greater risk of mortality compared to
               patients admitted following community-acquired infection; this
               finding is largely driven by a substantially increased risk of
               death in individuals with malignancy or who had undergone
               transplantation. These findings inform public health and
               infection control policy and argue for individualised clinical
               interventions to combat the threat of nosocomial COVID-19,
               particularly for immunosuppressed groups. Systematic Review
               Registration: PROSPERO CRD42021249023.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "744696",
  month     =  oct,
  year      =  2021,
  keywords  = "covid-19; hospital-acquired; immunodeficiency; infection
               control; nosocomial transmission",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Bakasis2021-lw,
  title     = "{COVID-19} infection among autoimmune rheumatic disease
               patients: Data from an observational study and literature review",
  author    = "Bakasis, Athanasios-Dimitrios and Mavragani, Clio P and Boki,
               Kyriaki A and Tzioufas, Athanasios G and Vlachoyiannopoulos,
               Panayiotis G and Stergiou, Ioanna E and Skopouli, Fotini N and
               Moutsopoulos, Haralampos M",
  abstract  = "The impact of SARS-CoV-2 infection in patients with
               autoimmune/auto-inflammatory rheumatic diseases (AARD) under
               immunomodulatory treatment has been a focus of interest during
               the COVID-19 pandemic. In this observational study, demographic
               data, disease related features and comorbidities, COVID-19
               manifestations and outcome as well as antibody responses to
               SARS-CoV-2 were recorded among 77 consecutive patients with
               underlying AARD infected by SARS-CoV-2. Analysis of data was
               performed using univariate and multivariate models. Most
               patients (68.8\%) had a mild COVID-19 course. The predominant
               clinical manifestations were fatigue (58.4\%), low grade fever
               (45.4\%) and upper respiratory tract symptoms (68.8\%). About a
               quarter of patients required hospitalization (23.3\%) and the
               mortality rate was 1.3\%. Regarding COVID-19 severity, prior
               treatment with corticosteroids, mycophenolate mofetil or
               rituximab was more common in patients who developed a more
               serious disease course (60.0 vs 29.9\%, p = 0.003, 40.0 vs
               7.5\%, p = 0.003, 10.0 vs 0.0\%, p = 0.009, respectively). When
               disease related features and comorbidities were considered in
               multivariate models, older age and lung disease in the context
               of the AARD were found to be independent predictive factors for
               hospitalization (OR [95\%]: 1.09 [1.03-1.15] and 6.43
               [1.11-37.19]). Among COVID-19 related features, patients with
               shortness of breath and high-grade fever were more likely to get
               hospitalized (OR [95\%]: 7.06 [1.36-36.57], 12.04 [2.96-48.86]),
               while anosmia was independently associated with lower
               hospitalization risk (OR [95\%]: 0.09 [0.01-0.99]). Though the
               majority of AARD patients displayed a mild COVID-19 course,
               certain underlying disease features and COVID-19 related
               manifestations should prompt alertness for the physician to
               identify patients with AARD at high risk for severe COVID-19 and
               need for hospitalization.",
  journal   = "J. Autoimmun.",
  publisher = "Elsevier BV",
  volume    =  123,
  number    =  102687,
  pages     = "102687",
  month     =  sep,
  year      =  2021,
  keywords  = "Autoimmunity; COVID-19; Immunosuppression; Rheumatic disease;
               SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Loubet2021-dh,
  title     = "Covid-19 pandemic: an opportunity to seize to increase awareness
               and vaccine coverage in at-risk populations",
  author    = "Loubet, Paul and Sotto, Albert and {AVNIR group}",
  abstract  = "We aimed to assess the impact of the Covid-19 pandemic on the
               risk perception and attitudes concerning influenza and
               pneumococcal vaccination in an at-risk population. We performed
               an online survey between July 29th and October 12th 2020 in
               patients at risk of severe influenza and/or pneumococcal disease
               recruited from Ipsos internal panel or through AVNIR
               (Associations VacciNation Immunod{\'e}prim{\'e}es
               R{\'e}alit{\'e}), a group of patient associations. Among the
               2177 respondents, 1350 were female (62\%), median age was 58
               years (IQR 47-69), 62\% were immunocompromised. In total, 86\%
               of respondents declared being favorable to vaccination in
               general and felt at high-risk of more severe forms of Covid-19
               (81\%), pneumococcal disease (76\%) and influenza (74\%). More
               than half (52\%, 388/746) of patients were eager to be
               vaccinated annually against influenza for the next 2020/2021
               season and pneumococcal disease in the future: 62\% (376/606).
               In this sample of patients at-risk of severe forms of influenza,
               pneumococcal diseases and Covid-19, the self-perception of risk
               for these three diseases and positive opinion on vaccination in
               general were high. It is very likely that the pandemic will lead
               to an increase in influenza and pneumococcal vaccine coverage in
               this at-risk population.",
  journal   = "Hum. Vaccin. Immunother.",
  publisher = "Informa UK Limited",
  volume    =  17,
  number    =  10,
  pages     = "3472--3473",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Cadena2021-al,
  title     = "Aspergillosis: Epidemiology, diagnosis, and treatment",
  author    = "Cadena, Jose and Thompson, 3rd, George R and Patterson, Thomas F",
  abstract  = "The spectrum of disease produced by Aspergillus species ranges
               from allergic syndromes to chronic pulmonary conditions and
               invasive infections. Invasive aspergillosis is a major cause of
               morbidity and mortality in immunocompromised patients. Risk
               factors continue to evolve and include newer biological agents
               that target the immune system and postinfluenza infection; and
               it has been observed following COVID-19 infection. Diagnosis
               remains a challenge but non-culture-based methods are available.
               Antifungal resistance has emerged. Voriconazole remains the
               treatment of choice but isavuconazole and posaconazole have
               similar efficacy with less toxicity. Combination therapy is used
               with extensive infection and in severe immunosuppression.",
  journal   = "Infect. Dis. Clin. North Am.",
  publisher = "Elsevier BV",
  volume    =  35,
  number    =  2,
  pages     = "415--434",
  month     =  jun,
  year      =  2021,
  keywords  = "Aspergilloma; Aspergillosis; Chronic cavitary aspergillosis;
               Invasive pulmonary aspergillosis; Resistance",
  language  = "en"
}

@ARTICLE{Lerner2021-lc,
  title     = "Comparison of {COVID-19} outcomes in organ transplant recipients
               ({OTr}) and non-transplant patients: a study protocol for rapid
               review",
  author    = "Lerner, Alexis H and Klein, Elizabeth J and Hardesty, Anna and
               Panagiotou, Orestis A and Misquith, Chelsea and Farmakiotis,
               Dimitrios",
  abstract  = "BACKGROUND: The COVID-19 pandemic has devastated the global
               community with nearly 4.9 million deaths as of October 2021.
               While organ transplant (OT) recipients (OTr) may be at increased
               risk for severe COVID-19 due to their chronic immunocompromised
               state, outcomes for OTr with COVID-19 remain disputed in the
               literature. This review will examine whether OTr with COVID-19
               are at higher risk for severe illness and death than
               non-immunocompromised individuals. METHODS: MEDLINE (via Ovid
               and PubMed) and EMBASE (via Embase.com ) will be searched from
               December 2019 to October 2021 for observational studies
               (including cohort and case-control) that compare COVID-19
               clinical outcomes in OTr to those in individuals without history
               of OT. The primary outcome of interest will be mortality as
               defined in each study, with possible further analyses of
               in-hospital mortality, 28 or 30-day mortality, and all-cause
               mortality versus mortality attributable to COVID-19. The
               secondary outcome of interest will be the severity of COVID-19
               disease, most frequently defined as requiring intensive care
               unit admission or mechanical ventilation. Two reviewers will
               independently screen all abstracts and full-text articles.
               Potential conflicts will be resolved by a third reviewer and
               potentially discussion among all investigators. Methodological
               quality will be appraised using the Newcastle-Ottawa Scale. If
               data permit, we will perform random-effects meta-analysis with
               the Sidik-Jonkman estimator and the Hartung-Knapp adjustment for
               confidence intervals to estimate a summary measure of
               association between histories of transplant with each outcome.
               Potential sources of heterogeneity will be explored using
               meta-regression. Additional analyses will be conducted to
               explore the potential sources of heterogeneity (e.g., subgroup
               analysis) considering least minimal adjustment for confounders.
               DISCUSSION: This rapid review will assess the available evidence
               on whether OTr diagnosed with COVID-19 are at higher risk for
               severe illness and death compared to non-immunocompromised
               individuals. Such knowledge is clinically relevant and may
               impact risk stratification, allocation of organs and healthcare
               resources, and organ transplantation protocols during this, and
               future, pandemics. SYSTEMATIC REVIEW REGISTRATION: Open Science
               Framework (OSF) registration DOI:
               https://doi.org/10.17605/osf.io/4n9d7 .",
  journal   = "Syst. Rev.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  10,
  number    =  1,
  pages     = "299",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; Organ transplant",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Tchana-Sato2021-cb,
  title     = "Clinical course and challenging management of early {COVID-19}
               infection after heart transplantation: case report of two
               patients",
  author    = "Tchana-Sato, Vincent and Ancion, Arnaud and Tridetti, Julien and
               Sakalihasan, Natzi and Hayette, Marie Pierre and Detry, Olivier
               and Delvenne, Philippe and Amabili, Philippe and Senard, Marc
               and Hougrand, Olivier and Szecel, Delphine and Lavigne,
               Jean-Paul and Minga Lowampa, Elie and Ponte, Charlotte and
               Maquoi, Isabelle and Morimont, Philippe and Van Den Bulck,
               Melissa and Delbouille, Marie Helene and Defraigne, Jean Olivier
               and Lancellotti, Patrizio",
  abstract  = "BACKGROUND: There are limited data on Coronavirus disease 2019
               (COVID-19) in solid organ transplant patients, especially in
               heart transplant recipients, with only a few case reports and
               case series described so far. Heart transplant recipients may be
               at particular high risk due to their comorbidities and
               immunosuppressed state. CASE PRESENTATION: This report describes
               the clinical course and the challenging management of early
               COVID-19 infection in two heart transplant recipients who tested
               positive for the SARS-CoV-2 virus in the perioperative period of
               the transplant procedure. The two patients developed a severe
               form of the disease and ultimately died despite the initiation
               of an antiviral monotherapy with hydroxychloroquine coupled with
               the interruption of mycophenolate mofetil. CONCLUSIONS: These
               two cases illustrate the severity and poor prognosis of COVID-19
               in the perioperative period of a heart transplant. Thorough
               screening of donors and recipients is mandatory, and the issue
               of asymptomatic carriers needs to be addressed.",
  journal   = "BMC Infect. Dis.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  21,
  number    =  1,
  pages     = "89",
  month     =  jan,
  year      =  2021,
  keywords  = "Asymptomatic carrier; Case report; Coronavirus disease 2019
               (COVID-19); Heart transplantation; Severe acute respiratory
               syndrome coronavirus 2 (SARS-Cov-2)",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Manansala2021-ig,
  title     = "Management of immunosuppressants in the era of coronavirus
               disease-2019",
  author    = "Manansala, Michael and Baughman, Robert and Novak, Richard and
               Judson, Marc and Sweiss, Nadera",
  abstract  = "PURPOSE OF REVIEW: Patients on chronic immunosuppressive
               treatments at baseline are at increased risk of opportunistic
               infections. These patients are at especially increased risk of
               morbidity and mortality during the coronavirus-19 (COVID-19)
               pandemic. This review will focus on patients with diseases in
               which immunosuppression is a vital part of the treatment
               regimen, including those with solid organ transplants,
               rheumatologic disorders, sarcoidosis, and inflammatory bowel
               disease (IBD). We will summarize the current knowledge of
               immunosuppression in these diseases and the risk of contracting
               COVID-19. Furthermore, we will discuss if immunosuppression
               increases severity of COVID-19 presentation. RECENT FINDINGS:
               Since the start of the COVID-19 pandemic, a large number
               patients receiving chronic immunosuppression have been infected
               with SARS-CoV-2. Moreover, our understanding of the immunology
               of SARS-CoV-2 is advancing at a rapid pace. Currently, a number
               of clinical trials are underway to investigate the role of
               immunosuppressive treatments in the management of this disease.
               SUMMARY: Currently, there is no conclusive evidence to suggest
               that solid organ transplant recipients on chronic
               immunosuppression are at increased risk of contracting COVID-19.
               Solid organ transplant recipients may be at increased risk for
               worse COVID-19 outcomes but the data are not consistent. There
               is evidence to suggest that patients with rheumatologic
               disorders or IBDs are not at increased risk of contracting
               COVID-19 and do not necessarily experience worse clinical
               outcomes. Patients with sarcoidosis are not necessarily at
               increased risk of COVID-19, although there is limited data
               available to determine if immunosuppression worsens outcomes in
               this population.",
  journal   = "Curr. Opin. Pulm. Med.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  27,
  number    =  3,
  pages     = "176--183",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Kapriniotis2021-hw,
  title     = "Heart and lung transplantation in the era of {COVID-19}: Early
               recommendations and outcomes",
  author    = "Kapriniotis, Konstantinos and Giannis, Dimitrios and Geropoulos,
               Georgios and Evangeliou, Alexandros P and Ziogas, Ioannis A and
               Panagiotopoulos, Nikolaos",
  abstract  = "The severe acute respiratory syndrome coronavirus 2 pandemic has
               dramatically changed medical practices worldwide. These changes
               have been aimed both to reallocate resources toward fighting the
               novel coronavirus and to prevent its transmission during
               nonurgent medical and surgical interventions. Heart and lung
               transplantation could not be an exception, as most transplant
               centers have either restricted their activity to only urgent,
               lifesaving procedures or stopped these surgical procedures for
               various periods of time depending on the local virus
               epidemiology. The effect of this infection on the
               immunosuppressed heart and lung transplant recipient is still
               questionable; however, there are limited reports suggesting that
               there is no increased risk of transmission or more severe
               disease course compared with that shown in the general
               population. Transplant organizations have disseminated early
               recommendations as a guidance in a yet evolving situation.
               Finally, data suggest that lung transplant could potentially
               serve as an ultimate, lifesaving procedure for COVID-19-related
               end-stage respiratory failure in carefully selected patients.",
  journal   = "Exp. Clin. Transplant.",
  publisher = "Baskent University",
  volume    =  19,
  number    =  11,
  pages     = "1117--1123",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Luk2021-le,
  title     = "Impact of diabetes on {COVID-19} and other infection: Report
               from the 22nd Hong Kong Diabetes and Cardiovascular Risk
               {Factors-East} Meets West Symposium",
  author    = "Luk, Andrea O Y and Ng, Susanna S S and Holt, Richard I G",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has posed
               enormous challenges to healthcare systems worldwide. The
               negative impact of COVID-19 is widespread and includes not only
               people who contracted the disease but also those with chronic
               morbidities such as diabetes whose care is compromised due to
               diversion of medical resources. People with diabetes are
               generally more susceptible to infection as a result of altered
               immunity. People with diabetes have a worse prognosis from
               COVID-19 and there is evidence to suggest that severe acute
               respiratory syndrome coronavirus 2 may directly affect
               pancreatic function precipitating hyperglycaemic crises. In the
               United Kingdom, one of the most heavily affected countries,
               guidelines are in place to unify the management of people with
               diabetes hospitalized for COVID-19. Diabetes services are
               re-organized to ensure that medical care of people with diabetes
               is maintained despite resource and other practical constraints.
               Public health measures including social distancing, hand hygiene
               and the use of face masks are crucial in containing community
               transmission of the virus. Hong Kong, one of the most densely
               populated city in the world, is particularly vulnerable and has
               in place a stringent containment policy and aggressive contact
               tracing to ensure public safety during this pandemic.",
  journal   = "Diabet. Med.",
  publisher = "Wiley",
  volume    =  38,
  number    =  5,
  pages     = "e14547",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; diabetes; infection",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Subedi2021-dl,
  title     = "Adjunctive nutraceutical therapies for {COVID-19}",
  author    = "Subedi, Lalita and Tchen, Stephanie and Gaire, Bhakta Prasad and
               Hu, Bingren and Hu, Kurt",
  abstract  = "The novel coronavirus, severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2/COVID-19), is a worldwide pandemic, as
               declared by the World Health Organization (WHO). It is a
               respiratory virus that infects people of all ages. Although it
               may present with mild to no symptoms in most patients, those who
               are older, immunocompromised, or with multiple comorbidities may
               present with severe and life-threatening infections. Throughout
               history, nutraceuticals, such as a variety of phytochemicals
               from medicinal plants and dietary supplements, have been used as
               adjunct therapies for many disease conditions, including viral
               infections. Appropriate use of these adjunct therapies with
               antiviral proprieties may be beneficial in the treatment and/or
               prophylaxis of COVID-19. In this review, we provide a
               comprehensive summary of nutraceuticals, such as vitamins C, D,
               E, zinc, melatonin, and other phytochemicals and function foods.
               These nutraceuticals may have potential therapeutic efficacies
               in fighting the threat of the SARS-CoV-2/COVID-19 pandemic.",
  journal   = "Int. J. Mol. Sci.",
  publisher = "MDPI AG",
  volume    =  22,
  number    =  4,
  pages     = "1963",
  month     =  feb,
  year      =  2021,
  keywords  = "antiviral therapy; novel coronavirus; nutraceuticals; pandemic;
               viral infection",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Saade2021-bx,
  title     = "Herpesvirus reactivation during severe {COVID-19} and high rate
               of immune defect",
  author    = "Saade, A and Moratelli, G and Azoulay, E and Darmon, M",
  abstract  = "OBJECTIVE: We assessed herpesvirus reactivation in severe
               SARS-CoV-2 infection. METHODS: Retrospective study including
               consecutive patients admitted to an onco-hematology intensive
               care unit (ICU) for severe COVID-19. Replication of EBV, CMV,
               and HSV was evaluated. Competing risk analyses were used to
               assess the cumulative risk of viral reactivation, and
               time-dependent Cox and Fine and Gray models to assess risk
               factors for viral reactivation. RESULTS: Among 100 patients, 38
               were immunocompromised. Sixty-three patients presented viral
               reactivation (12\% for HSV, 58\% EBV and 19\% CMV). Symptomatic
               patients received treatment. Overall cumulative incidence of
               viral reactivation was 56.1\% [55.9-56.4] at 10 days. After
               adjustment, a preexisting hematological malignancy (sHR
               [95\%CI]=0.31 [0.11-0.85]) and solid organ transplantation (sHR
               [95\% CI]=2.09 [1.13-3.87]) remained independently associated
               with viral reactivation. Viral reactivation (P=0.34) was not
               associated with mortality. CONCLUSIONS: Incidence of herpesvirus
               reactivation in patients admitted to the ICU for severe COVID-19
               was high, but rarely required antiviral treatment.",
  journal   = "Infect Dis Now",
  publisher = "Elsevier BV",
  volume    =  51,
  number    =  8,
  pages     = "676--679",
  month     =  nov,
  year      =  2021,
  keywords  = "CMV; COVID-19; SARS-CoV-2; Viral reactivation",
  language  = "en"
}

@ARTICLE{El_Fakih2021-ut,
  title     = "Clinical course and outcomes of {COVID-19} in hematopoietic cell
               transplant patients, a regional report from the Middle East",
  author    = "El Fakih, Riad and Haroon, Alfadil and Alfraih, Feras and
               Al-Khabori, Murtadha K and Alzahrani, Mohsen and Alhuraiji,
               Ahmad and Hamadah, Abdulaziz and AlJohani, Naif I and Alahmari,
               Bader and Essa, Mohammed F and Motabi, Ibraheem H and Tailor,
               Imran K and Almaghrabi, Reem S and Al-Farsi, Khalil and
               Abosoudah, Ibraheem and Ayas, Mouhab and Elhassan, Tusneem A and
               Suhebeh, Ashraf M and Ahmed, Syed Osman and Alhayli, Saud and
               Kaloyannidis, Panayotis and Alsaeed, Ahmad and Anezi, Khalid Al
               and Alamoudi, Sameer and Damlaj, Moussab and Hashmi, Hani Al and
               Aljurf, Mahmoud",
  abstract  = "The coronavirus disease-2019 (COVID-19) caused by SARS
               Coronavirus 2 (SARS-CoV-2) is a potentially lethal infection.
               Cancer patients, and specifically hematopoietic cell transplant
               (HCT) recipients are severely immunocompromised and may be at a
               higher risk of a complicated course with this infection. We
               aimed to study the COVID-19 outcomes and severity in post HCT
               patients. We retrospectively reviewed post-HCT patients
               diagnosed with COVID-19 between March 15, 2020, and December 1,
               2020 at 10 transplant centers across the Middle East. We
               identified 91 patients with confirmed SARS-CoV-2 infection
               across 10 transplant centers. The median age upon presentation
               with COVID-19 was 35. Fifty two patients were post allo-HCT
               while the remaining 39 patients were post auto-HCT. The median
               time from transplant was 14.9 months. Mortality rate was 4.4\%.
               Hospital admission rate was 53\%. ICU admission rate was 14\%.
               Mechanical ventilation rate was 10\%. Oxygen supplementation
               rate was 18\%. Time from HCT to COVID-19 >6 months was
               associated with lower admission rates and lower rates of the
               ``severity'' composite endpoint. Antibody responses was seen
               67\% of evaluable patients. In this series of HCT recipients, we
               report overall favorable clinical outcomes for patients with
               COVID-19 and provide preliminary insights into the clinical
               course of this disease in this specific population.",
  journal   = "Bone Marrow Transplant.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  56,
  number    =  9,
  pages     = "2144--2151",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Finsterer2021-gp,
  title     = "{SARS-CoV-2} and myasthenia",
  author    = "Finsterer, Josef and Scorza, Fulvio A and Scorza, Carla A and
               Fiorini, Ana C",
  abstract  = "The COVID-19 pandemic due to infection with SARS-CoV-2 not only
               affects political, economic, social, and cultural life, but also
               has a significant impact on medicine. This article is protected
               by copyright. All rights reserved.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  7,
  pages     = "4133--4135",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID\_19; SARS-CoV-2; acetyl-choline receptor; exacerbation;
               myasthenia",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Politis2021-vi,
  title     = "Post-donation information and haemovigilance reporting for
               {COVID-19} in Greece: Information supporting the absence of
               {SARS-CoV-2} possible transmission through blood components",
  author    = "Politis, C and Papadaki, M and Politi, L and Kourti, G and
               Richardson, C and Asariotou, M and Tsakris, A and Mentis, A",
  abstract  = "BACKGROUND: Although the SARS-CoV-2 virus is transmitted mainly
               through the respiratory tract, possible transmission by
               transfusion from asymptomatic carriers should be explored. As
               yet there are no reports of transfusion transmission of
               COVID-19. Haemovigilance findings within a three-month
               surveillance period during the new coronavirus pandemic are
               presented. MATERIALS AND METHODS: Due to great demand and
               shortage, blood sessions in outpatient facilities were organized
               during the high prevalence period of COVID-19, alongside a
               national plan to monitor the evolving public health situation by
               random molecular screening of high-risk groups of the
               population. Haemovigilance protocols were implemented as well as
               surveillance for any COVID-19 case reported post-transfusion. A
               14-day quarantine and follow-up molecular and antibody testing
               of any COVID-19 positive case was obligatory. RESULTS:
               Post-donation, post-transfusion information and molecular
               testing of swab samples collected from three asymptomatic donors
               at risk for COVID-19, revealed the case of an immunosupressed
               patient who had been transfused with whole blood derived
               platelets from a donor subsequently diagnosed with COVID-19. The
               recipient exhibited no symptoms of the disease. Molecular and
               antibody testing results were negative. CONCLUSION:
               Haemovigilance provided information supporting the absence of
               transfusion transmission of COVID-19, thus strengthening the
               hypothesis that, even if it cannot yet be definitively ruled
               out, COVID-19 is not transmitted through blood transfusion. As
               of early June 2020, a perfect test does not exist, therefore
               haemovigilance along with the implementation of strict proactive
               measures is crucial to identify eluding asymptomatic individuals
               and ensure blood safety during the pandemic.",
  journal   = "Transfus. Clin. Biol.",
  publisher = "Elsevier BV",
  volume    =  28,
  number    =  1,
  pages     = "55--59",
  month     =  feb,
  year      =  2021,
  keywords  = "Haemovigilance; SARS-CoV-2; Transfusion transmission",
  language  = "en"
}

@ARTICLE{Chavda2021-ze,
  title     = "Mucormycosis - An opportunistic infection in the aged
               immunocompromised individual: A reason for concern in {COVID-19}",
  author    = "Chavda, Vivek P and Apostolopoulos, Vasso",
  journal   = "Maturitas",
  publisher = "Elsevier BV",
  volume    =  154,
  pages     = "58--61",
  month     =  dec,
  year      =  2021,
  keywords  = "Aged; Aging people; COVID-19; Immunocompromised; Infection;
               Mucormycosis; SARS-CoV-2; Yeast infection",
  language  = "en"
}

@ARTICLE{Miranda2021-ud,
  title     = "{Post-COVID-19} neurocandidiasis",
  author    = "Miranda, Miguel A and Sousa, Sandra C and Montes, Vera L",
  abstract  = "Associated with a significant morbidity and mortality,
               neurocandidiasis affects severely immunocompromised patients,
               especially if recently treated with antibiotics or
               corticosteroids. We present the case of a 70-year-old man
               admitted to an intensive care unit due to a Sars-Cov-2
               pneumonia, with fever, coma, and multifocal neurological
               deficits reported 13 days after extubation. After isolation of
               Candida albicans in both urine and blood cultures and a brain
               MRI with multiple gadolinium-enhanced ring lesions, a diagnosis
               of neurocandidiasis was assumed and aggressive antifungal
               therapy started. During treatment, the patient developed a
               hospital-acquired pneumonia with fatal outcome.",
  journal   = "Neurol. Sci.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  42,
  number    =  11,
  pages     = "4419--4420",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Helito2021-kg,
  title    = "Poor Sleep quality and health-related quality of life impact in
              adolescents with and without chronic immunosuppressive conditions
              during {COVID-19} quarantine",
  author   = "Helito, Alberto C and Lindoso, Livia and Sieczkowska, Sofia M and
              Astley, Camilla and Queiroz, Ligia B and Rose, Natalia and
              Santos, Claudia Renata P and Bolzan, Thalis and Peralta, Rita
              Mar{\'\i}a I A and Franco, Ruth R and Cominato, Louise and
              Pereira, Rosa Maria R and Tannuri, Uenis and Campos, Lucia Maria
              A and Louren{\c c}o, Benito and Toma, Ricardo K and Medeiros,
              Karina and Watanabe, Andr{\'e}ia and Grangeiro, Patricia Moreno
              and Farhat, Sylvia C and Casella, Caio B and Polanczyk, Guilherme
              V and Gualano, Bruno and Silva, Clovis A and {HC-FMUSP Adolescent
              COVID-19 Study Group} and Sallum, Adriana M E and Iraha, Amanda Y
              and Ihara, Bianca P and Mazzolani, Bruna C and Martinez, Claudia
              A and Strabelli, Claudia A A and Fonseca, Claudia B and Lima,
              Dandara C C and Setoue, Debora N D and Roz, Deborah F P and
              Smaira, Fabiana I and Roschel, Hamilton and Miyatani, Helena T
              and Marques, Isabela G and Oba, Jane and Ferreira, Juliana C O
              and Simon, Juliana R and Kozu, Katia and Saccani, Ligia P and
              Martiniano, Lorena V M and Miranda, Luana C A and Silva, Luiz E V
              and Laurentino, Mois{\'e}s F and Aikawa, Nadia E and Sakita,
              Neusa K and Tanigava, Nicolas Y and Pereira, Paulo R A and
              Palmeira, Patr{\'\i}cia and Angelo, Simone S and Lavorato, Sofia
              S M and Bernardes, Tamires M and Franco, Tathiane C and Viana,
              Vivianne S L and Barros, Vera P M F R and Zheng, Yingying",
  abstract = "OBJECTIVE: To assess the possible factors that influence sleep
              quality in adolescents with and without chronic immunosuppressive
              conditions quarantined during the coronavirus disease 2019
              (COVID-19) pandemic. METHODS: This cross-sectional study included
              305 adolescents with chronic immunocompromised conditions and 82
              healthy adolescents. Online surveys were completed, which
              included questions on socio-demographic data and self-rated
              healthcare routine during COVID-19 quarantine and the following
              validated questionnaires: the Pittsburgh Sleep Quality Index
              (PSQI), Pediatric Quality of Life Inventory 4.0 (PedsQL4.0), and
              Pediatric Outcome Data Collection Instrument (PODCI). RESULTS:
              The median current age [14 (10-18) vs. 15 (10-18) years, p=0.847]
              and frequency of female sex (62\% vs. 58\%, p=0.571) were similar
              in adolescents with chronic conditions compared with healthy
              adolescents. The frequency of poor sleep quality was similar in
              both groups (38\% vs. 48\%, p=0.118). Logistic regression
              analysis, including both healthy adolescents and adolescents with
              chronic conditions (n=387), demonstrated that self-reported
              increase in screen time (odds ratio [OR] 3.0; 95\% confidence
              interval [CI] 1.3-6.8; p=0.008) and intrafamilial violence report
              (OR 2.1; 95\% CI 1.2-3.5; p=0.008) were independently associated
              with poor sleep quality in these adolescents. However, the PODCI
              global function score was associated with a lower OR for poor
              sleep quality (OR 0.97; 95\% CI 0.94-0.99; p=0.001). Further
              logistic regression, including only adolescents with chronic
              conditions (n=305), demonstrated that self-reported increase in
              screen time (OR 3.1; 95\% CI 1.4-6.8; p=0.006) and intrafamilial
              violence report (OR 2.0; 95\% CI 1.2-3.4; p=0.011) remained
              independently associated with poor quality of sleep, whereas a
              lower PODCI global function score was associated with a lower OR
              for sleep quality (OR 0.96; 95\% CI 0.94-0.98; p<0.001).
              CONCLUSION: Self-reported increases in screen time and
              intrafamilial violence report impacted sleep quality in both
              healthy adolescents and those with chronic conditions. Decreased
              health-related quality of life was observed in adolescents with
              poor sleep quality.",
  journal  = "Clinics (Sao Paulo)",
  volume   =  76,
  pages    = "e3501",
  month    =  nov,
  year     =  2021,
  language = "en"
}

@ARTICLE{Chaudhari2021-gz,
  title     = "Comorbidities and inflammation associated with ovarian cancer
               and its influence on {SARS-CoV-2} infection",
  author    = "Chaudhari, Sima and Dey Pereira, Satyajit and Asare-Warehene,
               Meshach and Naha, Ritam and Kabekkodu, Shama Prasada and Tsang,
               Benjamin K and Satyamoorthy, Kapaettu",
  abstract  = "Coronavirus disease 2019 (COVID-19) caused by the novel severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide
               is a major public health concern. Cancer patients are considered
               a vulnerable population to SARS-CoV-2 infection and may develop
               several COVID-19 symptoms. The heightened immunocompromised
               state, prolonged chronic pro-inflammatory milieu coupled with
               comorbid conditions are shared in both disease conditions and
               may influence patient outcome. Although ovarian cancer (OC) and
               COVID-19 are diseases of entirely different primary organs, both
               diseases share similar molecular and cellular characteristics in
               their microenvironment suggesting a potential cooperativity
               leading to poor outcome. In COVID-19 related cases,
               hospitalizations and deaths worldwide are lower in women than in
               males; however, comorbidities associated with OC may increase
               the COVID-19 risk in women. The women at the age of 50-60 years
               are at greater risk of developing OC as well as SARS-CoV-2
               infection. Increased levels of gonadotropin and androgen,
               dysregulated renin-angiotensin-aldosterone system (RAAS),
               hyper-coagulation and chronic inflammation are common conditions
               observed among OC and severe cases of COVID-19. The upregulation
               of common inflammatory cytokines and chemokines such as tumor
               necrosis factor $\alpha$ (TNF-$\alpha$), interleukin
               (IL)-1$\beta$, IL-2, IL-6, IL-10, interferon-$\gamma$-inducible
               protein 10 (IP-10), granulocyte colony-stimulating factor
               (G-CSF), monocyte chemoattractant protein-1 (MCP-1), macrophage
               colony-stimulating factor (M-CSF), among others in the sera of
               COVID-19 and OC subjects suggests potentially similar
               mechanism(s) involved in the hyper-inflammatory condition
               observed in both disease states. Thus, it is conceivable that
               the pathogenesis of OC may significantly contribute to the
               potential infection by SARS-CoV-2. Our understanding of the
               influence and mechanisms of SARS-CoV-2 infection on OC is at an
               early stage and in this article, we review the underlying
               pathogenesis presented by various comorbidities of OC and
               correlate their influence on SARS-CoV-2 infection.",
  journal   = "J. Ovarian Res.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  14,
  number    =  1,
  pages     = "39",
  month     =  feb,
  year      =  2021,
  keywords  = "Hormones; Inflammation; Ovarian cancer; SARS-CoV-2; risk factor",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Stefan2021-pz,
  title    = "Vaccination against {COVID-19}",
  author   = "{\v S}tefan, Marek and Dlouh{\'y}, Pavel and Bezd{\'\i}{\v
              c}kov{\'a}, Lenka",
  abstract = "Vaccination is essential to manage the COVID-19 pandemic.
              Vaccination significantly protects against severe COVID-19,
              hospitalization and death; it also protects against symptomatic
              infection and reduces the risk of transmission to other people.
              Protection against the new SARS-CoV-2 variants may be lower, but
              protection against severe course and death remains high. Two mRNA
              vaccines (BNT162b2 and mRNA-1273) and two vector vaccines
              (AZD1222 and Ad26.COV2.S) are currently available in the Czech
              Republic. Vaccination of persons over 60 years of age and
              immunocompromised persons, who are demonstrably at the highest
              risk of a serious course of the disease, is of the utmost
              importance. In order to achieve adequate vaccination coverage, it
              is necessary to motivate other groups of people to be vaccinated,
              including children over 12 years of age and young adults.
              Vaccination is also recommended in pregnant women in the 2nd and
              3rd trimesters and in breastfeeding women. For selected groups of
              vaccines, a third dose of vaccination is recommended (additional
              third dose 4 weeks after the second dose or a booster dose 8 to
              12 months after the second dose). The side effects are usually
              mild, with serious complications (including anaphylaxis,
              thrombocytopenia with thrombosis syndrome, myocarditis,
              Guillain-Barr{\'e} syndrome and capillary leak syndrome) being
              rare.",
  journal  = "Klin. Mikrobiol. Infekc. Lek.",
  volume   =  27,
  number   =  2,
  pages    = "49--60",
  month    =  jun,
  year     =  2021,
  language = "cs"
}

@ARTICLE{Li2021-xv,
  title     = "Systematically comparing {COVID-19} with the 2009 influenza
               pandemic for hospitalized patients",
  author    = "Li, Pengfei and Wang, Yining and Peppelenbosch, Maikel P and Ma,
               Zhongren and Pan, Qiuwei",
  abstract  = "OBJECTIVES: This study aimed to comprehensively compare the
               clinical features of hospitalized COVID-19 patients with
               hospitalized 2009 influenza pandemic patients. METHODS: Medline,
               Embase, Web of Science, Cochrane CENTRAL, and Google scholar
               were systematically searched to identify studies related to
               COVID-19 and the 2009 influenza pandemic. The pooled incidence
               rates of clinical features were estimated using the
               DerSimonian-Laird random-effects model with the Freeman-Tukey
               double arcsine transformation method. RESULTS: The incidence
               rates of fever, cough, shortness of breath, sore throat,
               rhinorrhea, myalgia/muscle pain, or vomiting were found to be
               significantly higher in influenza patients when compared with
               COVID-19 patients. The incidence rates of comorbidities,
               including cardiovascular disease/hypertension and diabetes, were
               significantly higher in COVID-19 compared with influenza
               patients. In contrast, comorbidities such as asthma, chronic
               obstructive pulmonary disease, and immunocompromised conditions
               were significantly more common in influenza compared with
               COVID-19 patients. Unexpectedly, the estimated rates of
               intensive care unit admission, treatment with extracorporeal
               membrane oxygenation, treatment with antibiotics, and fatality
               were comparable between hospitalized COVID-19 and 2009 influenza
               pandemic patients. CONCLUSIONS: This study comprehensively
               estimated the differences and similarities of the clinical
               features and burdens of hospitalized COVID-19 and 2009 influenza
               pandemic patients. This information will be important to better
               understand the current COVID-19 pandemic.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  102,
  pages     = "375--380",
  month     =  jan,
  year      =  2021,
  keywords  = "2009 influenza pandemic; COVID-19; Clinical features;
               Comorbidities; Meta-analysis; Symptoms",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Malsy2021-jb,
  title     = "Sustained response after remdesivir and convalescent plasma
               therapy in a B-cell-depleted patient with protracted Coronavirus
               disease 2019 ({COVID-19})",
  author    = "Malsy, Jakob and Veletzky, Luzia and Heide, Janna and Hennigs,
               Annette and Gil-Ibanez, Ines and Stein, Alexander and
               L{\"u}tgehetmann, Marc and Rosien, Ulrich and Jasper, Dorothea
               and Peine, Sven and Hiller, Jens and Haag, Friedrich and
               Schmiedel, Stefan and Huber, Samuel and Jordan, Sabine and Addo,
               Marylyn M and Schulze Zur Wiesch, Julian",
  abstract  = "We provide detailed clinical, virological, and immunological
               data of a B-cell-depleted patient treated with obinutuzumab for
               follicular lymphoma with protracted coronavirus disease 2019
               (COVID-19) and viremia. A sustained response was achieved after
               2 courses of remdesivir and subsequent convalescent plasma
               therapy. Immunocompromised patients might require combined and
               prolonged antiviral treatment regimens.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  73,
  number    =  11,
  pages     = "e4020--e4024",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; convalescent plasma; follicular lymphoma;
               obinutuzumab; remdesivir",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Kennedy2021-vg,
  title     = "An overview of viral infections of the nervous system in the
               immunosuppressed",
  author    = "Kennedy, Peter G E",
  abstract  = "Several viruses have the capacity to cause serious infections of
               the nervous system in patients who are immunosuppressed.
               Individuals may be immunosuppressed because of primary inherited
               immunodeficiency, secondary immunodeficiency due to particular
               diseases such as malignancy, administration of immunosuppressant
               drugs or organ or bone marrow transplantation. The viruses
               capable of such opportunistic infection of the nervous system
               include herpes simplex virus (HSV), Varicella-Zoster virus
               (VZV), Cytomegalovirus (CMV), Epstein -Barr virus (EBV), Human
               Herpes virus type 6 (HHV-6), JC virus (JCV), enterovirus,
               measles virus and Covid-19. In most cases it seems likely that
               immunological defence mechanisms in the immunosuppressed are
               deficient which creates a suitable environment for certain
               viruses to become opportunistic in the nervous and other
               systems. Further research is required both to understand these
               opportunistic mechanisms in more detail and also to determine
               how many virus infections are modified by specific inborn errors
               of immunological responses.",
  journal   = "J. Neurol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  268,
  number    =  8,
  pages     = "3026--3030",
  month     =  aug,
  year      =  2021,
  keywords  = "Immunodeficiency; Immunosuppression; Infection; Nervous system;
               PCR; Virus",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Moris2021-zd,
  title     = "{COVID-19} among liver transplant recipients",
  author    = "Moris, Dimitrios",
  journal   = "Gastroenterology",
  publisher = "Elsevier BV",
  volume    =  161,
  number    =  3,
  pages     = "1068",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Cimolai2021-ix,
  title     = "Complicating infections associated with common endemic human
               respiratory coronaviruses",
  author    = "Cimolai, Nevio",
  abstract  = "Coronaviruses OC43, 229E, NL63, and HKU1 are endemic human
               respiratory coronaviruses that typically cause mild to moderate
               upper respiratory infections, similar to the common cold. They
               also may cause simple and complicated lower respiratory
               infections, otitis media, asthma exacerbations, gastroenteritis,
               and a few systemic complications. These viruses are usually
               seasonal (with winter dominance) and affect nearly all age
               groups. The seasonal and annual variation in virus prevalence
               has implications for understanding the concept of acquired
               immunity and its persistence or diminution. Coronaviruses
               generally have outbreak potential in susceptible populations of
               any age, particularly in patients with comorbidities, who tend
               to have increased clinical disease. These 4 coronaviruses are
               often found in the context of what appears to be coinfection
               with other pathogens, but especially other viruses. If
               coronaviruses are not specifically tested for, the sole
               detection of a viral copathogen would suggest the pathogen is
               the causative agent, when a coronavirus may be culpable, or
               both. The detection of these viruses in circumstances where
               respiratory viruses are generally sought in clinical samples is,
               therefore, justified. These pathogens can be chronically shed
               from the respiratory tract, which is more likely to occur among
               immunocompromised and complicated patients. These viruses share
               the potential for genetic drift. The genome is among the largest
               of RNA viruses, and the capability of these viruses to further
               change is likely underestimated. Given the potential disease
               among humans, it is justified to search for effective antiviral
               chemotherapy for these viruses and to consider uses in niche
               situations should effective therapy be defined. Whereas
               SARS-CoV-2 may follow the epidemiological pattern of SARS-CoV
               and extinguish slowly over time, there is yet concern that
               SARS-CoV-2 may establish itself as an endemic human respiratory
               coronavirus similar to OC43, 2299E, NL63, and HKU1. Until
               sufficient data are acquired to better understand the potential
               of SARS-CoV-2, continued work on antiviral therapy and
               vaccination is imperative.",
  journal   = "Health Secur.",
  publisher = "Mary Ann Liebert Inc",
  volume    =  19,
  number    =  2,
  pages     = "195--208",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus; Epidemiology; Infectious diseases;
               Pneumonia; SARS",
  language  = "en"
}

@ARTICLE{Kliger2021-io,
  title     = "{COVID-19} and dialysis patients: Unsolved problems in early
               2021",
  author    = "Kliger, Alan S and Silberzweig, Jeffrey",
  journal   = "J. Am. Soc. Nephrol.",
  publisher = "American Society of Nephrology (ASN)",
  volume    =  32,
  number    =  5,
  pages     = "1018--1020",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; chronic dialysis",
  language  = "en"
}

@ARTICLE{Hammad2021-xy,
  title     = "Management and outcome of Coronavirus disease 2019 ({COVID-19})
               in pediatric cancer patients: A single centre experience from a
               developing country",
  author    = "Hammad, Mahmoud and Shalaby, Lobna and Sidhom, Iman and Sherief,
               Nancy and Abdo, Ibrahim and Soliman, Sonia and Madeny, Youssef
               and Hassan, Reem and Elmeniawy, Shaimaa and Khamis, Nagwa and
               Zaki, Iman and Mansour, Tarek and El-Ansary, Mohamed Gamal and
               Al-Halfawy, Ahmed and Abouelnaga, Sherif and Elhaddad, Alaa",
  abstract  = "INTRODUCTION: Sufficient data pertaining to the impact of the
               Coronavirus disease 2019 (COVID-19) on pediatric cancer patients
               is still lacking. The aim of this prospective study was to
               describe clinical management and outcomes of COVID-19 in
               pediatric oncology patients. PATIENTS AND METHODS: Conducted
               between May 1, 2020 and November 30, 2020, this study included
               76 pediatric oncology patients with confirmed COVID-19.
               Remdesivir (RDV) was the antiviral therapy used. RESULTS: The
               median age of patients was 9 years. Sixty patients were on first
               line treatment. Hematological malignancies constituted 86.8\% of
               patients. Severe to critical infections were 35.4\% of patients.
               The commonest symptom was fever (93.4\%). Chemotherapy was
               delayed in 59.2\% of patients and doses were modified in 30.2\%.
               The 60-day overall survival (OS) stood at 86.8\%, with
               mortalities occurring only among critical patients. Of sixteen
               acute leukemia patients in the first induction therapy, 13
               survived and 10 achieved complete remission. A negative RT-PCR
               within 2 weeks and improvement of radiological findings were
               statistically related to disease severity (P = .008 and .002,
               respectively). Better OS was associated with regression of
               radiological findings after 30 days from infection (P = .002).
               Forty-five patients received RDV, 42.1\% had severe and critical
               forms of infection compared to 25.7\% in the No-RDV group and
               yet OS was comparable in both groups. CONCLUSION: Most pediatric
               cancer patients with COVID-19 should have good clinical outcomes
               except for patients with critical infections. Cancer patients
               can tolerate chemotherapy including induction phase, alongside
               COVID-19 treatment. In severe and critical COVID-19, RDV might
               have a potential benefit.",
  journal   = "Clin. Lymphoma Myeloma Leuk.",
  publisher = "Elsevier BV",
  volume    =  21,
  number    =  11,
  pages     = "e853--e864",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunocompromised patients; pediatric
               cancer; remdesivir",
  language  = "en"
}

@ARTICLE{Mallah2021-ea,
  title     = "{COVID-19}: breaking down a global health crisis",
  author    = "Mallah, Saad I and Ghorab, Omar K and Al-Salmi, Sabrina and
               Abdellatif, Omar S and Tharmaratnam, Tharmegan and Iskandar,
               Mina Amin and Sefen, Jessica Atef Nassef and Sidhu, Pardeep and
               Atallah, Bassam and El-Lababidi, Rania and Al-Qahtani, Manaf",
  abstract  = "Coronavirus disease 2019 (COVID-19) is the second pandemic of
               the twenty-first century, with over one-hundred million
               infections and over two million deaths to date. It is a novel
               strain from the Coronaviridae family, named Severe Acute
               Respiratory Distress Syndrome Coronavirus-2 (SARS-CoV-2); the
               7th known member of the coronavirus family to cause disease in
               humans, notably following the Middle East Respiratory syndrome
               (MERS), and Severe Acute Respiratory Distress Syndrome (SARS).
               The most characteristic feature of this single-stranded RNA
               molecule includes the spike glycoprotein on its surface. Most
               patients with COVID-19, of which the elderly and
               immunocompromised are most at risk, complain of flu-like
               symptoms, including dry cough and headache. The most common
               complications include pneumonia, acute respiratory distress
               syndrome, septic shock, and cardiovascular manifestations.
               Transmission of SARS-CoV-2 is mainly via respiratory droplets,
               either directly from the air when an infected patient coughs or
               sneezes, or in the form of fomites on surfaces. Maintaining
               hand-hygiene, social distancing, and personal protective
               equipment (i.e., masks) remain the most effective precautions.
               Patient management includes supportive care and anticoagulative
               measures, with a focus on maintaining respiratory function.
               Therapy with dexamethasone, remdesivir, and tocilizumab appear
               to be most promising to date, with hydroxychloroquine,
               lopinavir, ritonavir, and interferons falling out of favour.
               Additionally, accelerated vaccination efforts have taken place
               internationally, with several promising vaccinations being mass
               deployed. In response to the COVID-19 pandemic, countries and
               stakeholders have taken varying precautions to combat and
               contain the spread of the virus and dampen its collateral
               economic damage. This review paper aims to synthesize the impact
               of the virus on a global, micro to macro scale.",
  journal   = "Ann. Clin. Microbiol. Antimicrob.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  20,
  number    =  1,
  pages     = "35",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus; Global \& Public Health; Infectious
               Diseases; Pandemic",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Zhang2021-vi,
  title     = "The influence of corticosteroids, immunosuppressants and
               biologics on patients with inflammatory bowel diseases,
               psoriasis and rheumatic diseases in the era of {COVID-19}: A
               review of current evidence",
  author    = "Zhang, Mengyuan and Bai, Xiaoyin and Cao, Wei and Ji, Junyi and
               Wang, Luo and Yang, Yang and Yang, Hong",
  abstract  = "Patients with inflammatory bowel disease, psoriasis or other
               rheumatic diseases treated with corticosteroids,
               immunomodulators and biologics might face additional risk during
               COVID-19 epidemic due to their immunocompromised status.
               However, there was still no unanimous opinion on the use of
               these therapy during COVID-19 epidemic. Current studies
               suggested that systemic corticosteroids might increase the risk
               of hospitalization, as well as risks of ventilation, ICU, and
               death among patients with immune-mediated inflammatory diseases.
               Anti-TNF agent was associated with lower rate of
               hospitalization, as well as lower risks of ventilation, ICU, and
               death. No significant changes in rates of hospitalization,
               ventilation, ICU and mortality were observed in patients treated
               with immunomodulators or biologics apart from anti-TNF agents.
               The underlying mechanism of these results might be related to
               pathway of antiviral immune response and cytokine storm induced
               by SARS-COV-2 infection. Decision on the use of corticosteroids,
               immunomodulators and biologics should be made after weighing the
               benefits and potential risks based on individual patients.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "677957",
  month     =  jul,
  year      =  2021,
  keywords  = "2019-nCoV; COVID-19; SARS-CoV-2; autoimmune; biologics;
               corticosteroids; immunomodulators",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Schmidt2021-kg,
  title     = "Cellular immunity predominates over humoral immunity after
               homologous and heterologous {mRNA} and vector-based {COVID-19}
               vaccine regimens in solid organ transplant recipients",
  author    = "Schmidt, Tina and Klemis, Verena and Schub, David and
               Schneitler, Sophie and Reichert, Matthias C and Wilkens,
               Heinrike and Sester, Urban and Sester, Martina and Mihm, Janine",
  abstract  = "Knowledge on the immunogenicity of vector-based and
               mRNA-vaccines in solid organ transplant recipients is limited.
               Therefore, SARS-CoV-2-specific T cells and antibodies were
               analyzed in 40 transplant recipients and 70 controls after
               homologous or heterologous vaccine-regimens. Plasmablasts and
               SARS-CoV-2-specific CD4 and CD8 T cells were quantified using
               flow cytometry. Specific antibodies were analyzed by ELISA and
               neutralization assay. The two vaccine types differed after the
               first vaccination, as IgG and neutralizing activity were more
               pronounced after mRNA priming (p = .0001 each), whereas CD4 and
               CD8 T cell levels were higher after vector priming (p = .009; p
               = .0001). All regimens were well tolerated, and
               SARS-CoV-2-specific antibodies and/or T cells after second
               vaccination were induced in 100\% of controls and 70.6\% of
               transplant recipients. Although antibody and T cell levels were
               lower in patients, heterologous vaccination led to the most
               pronounced induction of antibodies and CD4 T cells. Plasmablast
               numbers were significantly higher in controls and correlated
               with SARS-CoV-2-specific IgG- and T cell levels. While
               antibodies were only detected in 35.3\% of patients, cellular
               immunity was more frequently found (64.7\%) indicating that
               assessment of antibodies is insufficient to identify
               COVID-19-vaccine responders. In conclusion, heterologous
               vaccination seems promising in transplant recipients, and
               combined analysis of humoral and cellular immunity improves the
               identification of responders among immunocompromised
               individuals.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  12,
  pages     = "3990--4002",
  month     =  dec,
  year      =  2021,
  keywords  = "T cell biology; clinical research/practice; flow cytometry;
               infection and infectious agents - viral; infectious disease;
               vaccine",
  copyright = "http://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Sieminska2021-ji,
  title     = "Mild and asymptomatic {COVID-19} convalescents present long-term
               endotype of immunosuppression associated with neutrophil subsets
               possessing regulatory functions",
  author    = "Siemi{\'n}ska, Izabela and W{\k e}glarczyk, Kazimierz and
               Surmiak, Marcin and Kurowska-Baran, Dorota and Sanak, Marek and
               Siedlar, Maciej and Baran, Jarek",
  abstract  = "The SARS-CoV-2 infection [coronavirus disease 2019 (COVID-19)]
               is associated with severe lymphopenia and impaired immune
               response, including expansion of myeloid cells with regulatory
               functions, e.g., so-called low-density neutrophils, containing
               granulocytic myeloid-derived suppressor cells (LDNs/PMN-MDSCs).
               These cells have been described in both infections and cancer
               and are known for their immunosuppressive activity. In the case
               of COVID-19, long-term complications have been frequently
               observed (long-COVID). In this context, we aimed to investigate
               the immune response of COVID-19 convalescents after a mild or
               asymptomatic course of disease. We enrolled 13 convalescents who
               underwent a mild or asymptomatic infection with SARS-CoV-2,
               confirmed by a positive result of the PCR test, and 13 healthy
               donors without SARS-CoV-2 infection in the past. Whole blood was
               used for T-cell subpopulation and LDNs/PMN-MDSCs analysis.
               LDNs/PMN-MDSCs and normal density neutrophils (NDNs) were sorted
               out by FACS and used for T-cell proliferation assay with
               autologous T cells activated with anti-CD3 mAb. Serum samples
               were used for the detection of anti-SARS-CoV-2 neutralizing IgG
               and GM-CSF concentration. Our results showed that in
               convalescents, even 3 months after infection, an elevated level
               of LDNs/PMN-MDSCs is still maintained in the blood, which
               correlates negatively with the level of CD8+ and double-negative
               T cells. Moreover, LDNs/PMN-MDSCs and NDNs showed a tendency for
               affecting the production of anti-SARS-CoV-2 S1 neutralizing
               antibodies. Surprisingly, our data showed that in addition to
               LDNs/PMN-MDSCs, NDNs from convalescents also inhibit
               proliferation of autologous T cells. Additionally, in the
               convalescent sera, we detected significantly higher
               concentrations of GM-CSF, indicating the role of emergency
               granulopoiesis. We conclude that in mild or asymptomatic
               COVID-19 convalescents, the neutrophil dysfunction, including
               propagation of PD-L1-positive LDNs/PMN-MDSCs and NDNs, is
               responsible for long-term endotype of immunosuppression.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "748097",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 convalescents; granulocyte-macrophage colony
               stimulating factor (GM-CSF); granulocytic myeloid-derived
               suppressor cells (PMN-MDSCs); immunosuppression; low-density
               neutrophils (LDNs); normal density neutrophils",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Chaudhary2021-xu,
  title     = "Insights into {COVID-19} vaccine development based on
               immunogenic structural proteins of {SARS-CoV-2}, host immune
               responses, and herd immunity",
  author    = "Chaudhary, Jitendra Kumar and Yadav, Rohitash and Chaudhary,
               Pankaj Kumar and Maurya, Anurag and Kant, Nimita and Rugaie,
               Osamah Al and Haokip, Hoineiting Rebecca and Yadav, Deepika and
               Roshan, Rakesh and Prasad, Ramasare and Chatrath, Apurva and
               Singh, Dharmendra and Jain, Neeraj and Dhamija, Puneet",
  abstract  = "The first quarter of the 21st century has remarkably been
               characterized by a multitude of challenges confronting human
               society as a whole in terms of several outbreaks of infectious
               viral diseases, such as the 2003 severe acute respiratory
               syndrome (SARS), China; the 2009 influenza H1N1, Mexico; the
               2012 Middle East respiratory syndrome (MERS), Saudi Arabia; and
               the ongoing coronavirus disease 19 (COVID-19), China. COVID-19,
               caused by SARS-CoV-2, reportedly broke out in December 2019,
               Wuhan, the capital of China's Hubei province, and continues
               unabated, leading to considerable devastation and death
               worldwide. The most common target organ of SARS-CoV-2 is the
               lungs, especially the bronchial and alveolar epithelial cells,
               culminating in acute respiratory distress syndrome (ARDS) in
               severe patients. Nevertheless, other tissues and organs are also
               known to be critically affected following infection, thereby
               complicating the overall aetiology and prognosis. Excluding
               H1N1, the SARS-CoV (also referred as SARS-CoV-1), MERS, and
               SARS-CoV-2 are collectively referred to as coronaviruses, and
               taxonomically placed under the realm Riboviria, order
               Nidovirales, suborder Cornidovirineae, family Coronaviridae,
               subfamily Orthocoronavirinae, genus Betacoronavirus, and
               subgenus Sarbecovirus. As of 23 September 2021, the ongoing
               SARS-CoV-2 pandemic has globally resulted in around 229 million
               and 4.7 million reported infections and deaths, respectively,
               apart from causing huge psychosomatic debilitation, academic
               loss, and deep economic recession. Such an unprecedented
               pandemic has compelled researchers, especially epidemiologists
               and immunologists, to search for SARS-CoV-2-associated potential
               immunogenic molecules to develop a vaccine as an immediate
               prophylactic measure. Amongst multiple structural and
               non-structural proteins, the homotrimeric spike (S) glycoprotein
               has been empirically found as the most suitable candidate for
               vaccine development owing to its immense immunogenic potential,
               which makes it capable of eliciting both humoral and
               cell-mediated immune responses. As a consequence, it has become
               possible to design appropriate, safe, and effective vaccines,
               apart from related therapeutic agents, to reduce both morbidity
               and mortality. As of 23 September 2021, four vaccines, namely,
               Comirnaty, COVID-19 vaccine Janssen, Spikevax, and Vaxzevria,
               have received the European Medicines Agency's (EMA) approval,
               and around thirty are under the phase three clinical trial with
               emergency authorization by the vaccine-developing
               country-specific National Regulatory Authority (NRA). In
               addition, 100-150 vaccines are under various phases of
               pre-clinical and clinical trials. The mainstay of global
               vaccination is to introduce herd immunity, which would protect
               the majority of the population, including immunocompromised
               individuals, from infection and disease. Here, we primarily
               discuss category-wise vaccine development, their respective
               advantages and disadvantages, associated efficiency and
               potential safety aspects, antigenicity of SARS-CoV-2 structural
               proteins and immune responses to them along with the emergence
               of SARS-CoV-2 VOC, and the urgent need of achieving herd
               immunity to contain the pandemic.",
  journal   = "Cells",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  11,
  pages     = "2949",
  month     =  oct,
  year      =  2021,
  keywords  = "SARS-CoV-2; coronavirus disease 19; herd immunity; immune
               response; infectious disease; pandemic; vaccination",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Lobelo2021-rd,
  title     = "Clinical, behavioural and social factors associated with racial
               disparities in {COVID-19} patients from an integrated healthcare
               system in Georgia: a retrospective cohort study",
  author    = "Lobelo, Felipe and Bienvenida, Alan and Leung, Serena and
               Mbanya, Armand and Leslie, Elizabeth and Koplan, Kate and Shin,
               Sangmin Ryan",
  abstract  = "OBJECTIVES: To identify sociodemographic, clinical and
               behavioural drivers of racial disparities and their association
               with clinical outcomes among Kaiser Permanente Georgia (KPGA)
               members with COVID-19. DESIGN: Retrospective cohort of patients
               with COVID-19 seen from 3 March to 29 October 2020. We described
               the distribution of underlying comorbidities, quality of care
               metrics, demographic and social determinants of health (SDOH)
               indicators across race groups. We also described clinical
               outcomes in hospitalised patients including length of stay,
               intensive care unit (ICU) admission, readmission and mortality.
               We performed multivariable analyses for hospitalisation risk
               among all patients with COVID-19 and stratifyied by race and
               sex. SETTING: KPGA, an integrated healthcare system.
               PARTICIPANTS: 5712 patients who all had laboratory-confirmed
               COVID-19. Of them, 57.8\% were female, 58.4\% black, 29.5\%
               white, 8.5\% Hispanic and 3.6\% Asian. RESULTS: Black patients
               had the highest proportions of living in neighborhoods under the
               federal poverty line (12.4\%) and in more deprived locations
               (neighbourhood deprivation index=0.4). Overall, 14.4\% (n=827)
               of this cohort was hospitalised. Asian patients had the highest
               rates of ICU admission (53.1\%) and mechanical ventilation
               (21.9\%). Among all patients, Hispanics (adjusted 1.60, 95\% CI
               (1.08, 2.37)), blacks (1.43 (1.13, 1.83)), age in years (1.03
               (1.02, 1.04)) and living in a zip code with high unemployment
               (1.08 (1.03, 1.13)) were associated with higher odds of
               hospitalisation. COVID-19 patients with chronic obstructive
               pulmonary disease (2.59 (1.67, 4.02)), chronic heart failure
               (1.79 (1.31, 2.45)), immunocompromised (1.77 (1.16, 2.70)), with
               glycated haemoglobin >8\% (1.68 (1.19, 2.38)), depression (1.60
               (1.24, 2.06)), hypertension (1.5 (1.21, 1.87)) and physical
               inactivity (1.25 (1.03, 1.51)) had higher odds of
               hospitalisation. CONCLUSIONS: Black and Hispanic KPGA patients
               were at higher odds of hospitalisation, but not mortality,
               compared with other race groups. Beyond previously reported
               sociodemographics and comorbidities, factors such as quality of
               care, lifestyle behaviours and SDOH indicators should be
               considered when designing and implementing interventions to
               reduce COVID-19 racial disparities.",
  journal   = "BMJ Open",
  publisher = "BMJ",
  volume    =  11,
  number    =  5,
  pages     = "e044052",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; epidemiology; public health; quality in health care",
  language  = "en"
}

@ARTICLE{Giorgakis2021-nb,
  title     = "{COVID-19} in solid organ transplant recipients",
  author    = "Giorgakis, Emmanouil and Zehtaban, Shannon P and Stevens, Amanda
               E and Bhusal, Sushma and Burdine, Lyle",
  abstract  = "First identified in December 2019, the novel severe acute
               respiratory syndrome coronavirus-2 has spread widely.
               Coronavirus disease 2019 (COVID-19) was declared a pandemic in
               March 2020. Post-transplant patients appear to be particularly
               vulnerable. University of Arkansas for Medical Sciences (UAMS)
               is the only abdominal transplant institution in the state of
               Arkansas. Between March 25 to April 20, four transplant
               recipients with functioning grafts tested positive for COVID-19.
               Three were African American; one was Hispanic. Median age was
               62.5 years (range 49-65). Three patients had received kidney
               transplant (KT). One had received a simultaneous liver-kidney
               (SLK).",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  1,
  pages     = "e13419",
  month     =  feb,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Leibbrand2021-zj,
  title    = "Oncological rehabilitation and development of strategies in
              crisis situations using the example of the Covid 19 pandemic in
              2020 by using a patient and staff survey results of pandemic care",
  author   = "Leibbrand, Birgit and Seifart, Ulf",
  abstract = "INTRODUCTION: Cancer is a life-threatening disease often with
              curative therapy approaches, high risk of relapse and distressing
              symptoms, which require immediate, quality-assured care
              throughout the entire therapy process including rehabilitation,
              even in a pandemie. METHODS: We started to develop a pandemic
              plan to maintain oncological rehabilitation in February 2020.
              With the involvement of the whole clinic staff we developed
              protection scenarios with the aim of achieving Covid-19-free
              clinics. Schedules were developed and implemented based on the
              epidemiological bulletins of the RKI (Robert Koch Institute,
              Germany) of 2017 (influenza infection) and 2020 (Covid-19). The
              effects of these measures were evaluated by means of a patient
              and employee survey. RESULTS: The challenges of the pandemic have
              been successfully implemented. Both the patient and employee
              surveys showed a high level of acceptance of the measures. For
              example, 98.5\% of patients stated that the continuation of
              rehabilitation was important for their health, even in the
              pandemic situation. At the same time, 87\% felt safe. 88\% of all
              employees (MA) and 93\% of MA in the risk group stated that the
              protective measures were introduced at the right time. At the
              same time, 76\% of all employees and 84\% of the employees in the
              risk group agreed with the additional burden. In spite of the
              high risk potential in the clinics (immunocompromised patients,
              patients from different districts with different levels of
              exposure), an outbreak of SARS-CoV-2 could be avoided in the
              clinics. CONCLUSION: The timely roll-out of adapted pandemic
              rules in rehabilitation clinics enables the continuation of
              high-quality oncological rehabilitation even in pandemic times
              and thus contributes to a stabilisation of the supply chain for
              cancer diseases. A high level of acceptance of the measures among
              patients and hospital staff was evaluated.",
  journal  = "Rehabilitation (Stuttg.)",
  volume   =  60,
  number   =  2,
  pages    = "142--151",
  month    =  apr,
  year     =  2021,
  language = "de"
}

@ARTICLE{Soni2022-mk,
  title     = "A systematic review on {SARS-CoV-2-associated} fungal
               coinfections",
  author    = "Soni, Shringika and Namdeo Pudake, Ramesh and Jain, Utkarsh and
               Chauhan, Nidhi",
  abstract  = "A severe pandemic of Coronavirus Disease (COVID-19) has been
               sweeping the globe since 2019, and this time, it did not stop,
               with frequent mutations transforming into virulent strains, for
               instance, B.1.1.7, B.1.351, and B.1.427. In recent months, a
               fungal infection, mucormycosis has emerged with more fatal
               responses and significantly increased mortality rate. To measure
               the severity and potential alternative approaches against black
               fungus coinfection in COVID-19 patients, PubMed, Google Scholar,
               World Health Organization (WHO) newsletters, and other online
               resources, based on the cases reported and retrospective
               observational analysis were searched from the years 2015-2021.
               The studies reporting mucormycosis with Severe Acute Respiratory
               Syndrome Coronavirus 2 (SARS-CoV-2) coinfection and/or
               demonstrating potential risk factors, such as a history of
               diabetes mellitus or suppressed immune system were included, and
               reports published in non-English language were excluded. More
               than 20 case reports and observational studies on black fungus
               coinfection in COVID-19 patients were eligible for inclusion.
               The results indicated that diabetes mellitus, hyperglycemic, and
               immunocompromised COVID-19 patients with mucormycosis were at a
               higher risk. We found that it was prudent to assess the
               potential risk factors and severity of invasive mycosis via
               standardized diagnostic and clinical settings. Large-scale
               studies need to be conducted to identify early biomarkers and
               optimization of diagnostic methods has to be established per
               population and geographical variation. This will not only help
               clinicians around the world to detect the coinfection in time
               but also will prepare them for future outbreaks of other
               potential pandemics.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  94,
  number    =  1,
  pages     = "99--109",
  month     =  jan,
  year      =  2022,
  keywords  = "COVID-19; black fungus; diagnosis; fungal infection;
               mucormycosis",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Guetl2021-od,
  title     = "{SARS-CoV-2} positive virus culture 7 weeks after onset of
               {COVID-19} in an immunocompromised patient suffering from {X}
               chromosome-linked agammaglobulinemia",
  author    = "Guetl, Katharina and Moazedi-Fuerst, Florentine and Rosskopf,
               Konrad and Brodmann, Marianne and Krause, Robert and Eller,
               Philipp and Wilhelmer, Patricia and Eisner, Florian and Sareban,
               Nazanin and Schlenke, Peter and Kessler, Harald H and Steinmetz,
               Ivo and Redlberger-Fritz, Monika and Stiasny, Karin and
               Stradner, Martin",
  journal   = "J. Infect.",
  publisher = "Elsevier BV",
  volume    =  82,
  number    =  3,
  pages     = "414--451",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Chang2021-iw,
  title     = "Cancer telerehabilitation",
  author    = "Chang, Philip and Asher, Arash",
  abstract  = "Telemedicine has clear benefits to the cancer population,
               including reducing the risk of contracting communicable disease,
               reaching remote populations, and added convenience. With
               adequate preparation, cancer rehabilitation telemedicine can
               serve as a suitable substitute for in-person encounters in
               several situations. There are limits with technologic deficits,
               reimbursement questions, and the inability to conduct hands-on
               physical examinations. It is important to appropriately triage
               patients to the most suitable visit type, whether telemedicine
               or in person, with aims of reducing unnecessary risks,
               monitoring for potential complications, and having productive
               encounters.",
  journal   = "Phys. Med. Rehabil. Clin. N. Am.",
  publisher = "Elsevier BV",
  volume    =  32,
  number    =  2,
  pages     = "277--289",
  month     =  may,
  year      =  2021,
  keywords  = "Cancer rehabilitation; Oncology rehabilitation; Telemedicine;
               Telerehabilitation",
  language  = "en"
}

@ARTICLE{Roedl2021-uu,
  title     = "Viral dynamics of {SARS-CoV-2} in critically ill allogeneic
               hematopoietic stem cell transplant recipients and
               immunocompetent patients with {COVID-19}",
  author    = "Roedl, Kevin and Heidenreich, Silke and Pfefferle, Susanne and
               Jarczak, Dominik and Urbanowicz, Tatiana Theresa and N{\"o}rz,
               Dominik and Aepfelbacher, Martin and Kr{\"o}ger, Nicolaus and
               Kluge, Stefan and L{\"u}tgehetmann, Marc and Christopeit,
               Maximilian and Wichmann, Dominic",
  journal   = "Am. J. Respir. Crit. Care Med.",
  publisher = "American Thoracic Society",
  volume    =  203,
  number    =  2,
  pages     = "242--245",
  month     =  jan,
  year      =  2021,
  keywords  = "CAR-T cells; COVID-19; HSCT; SARS-CoV-2; allogeneic
               hematopoietic stem cell transplantation",
  language  = "en"
}

@ARTICLE{Krasnow2021-vq,
  title     = "Cancer, transplant, and immunocompromising conditions were not
               significantly associated with severe illness or death in
               hospitalized {COVID-19} patients",
  author    = "Krasnow, Maya R and Litt, Henry K and Lehmann, Christopher J and
               Lio, Jonathan and Zhu, Mengqi and Sherer, Renslow",
  abstract  = "OBJECTIVE: Patients with cancer, transplant, and other
               immunocompromising conditions are at uncertain risk of severe
               COVID-19 illness. This study aimed to clarify whether patients
               with immunocompromising conditions were more likely to develop
               severe COVID-19 illness in a single urban academic medical
               center. METHODS: A retrospective chart review and electronic
               data extraction of the first 401 patients at the University of
               Chicago Hospitals with SARS-CoV-2 infection was performed.
               Patients met criteria for severe COVID-19 illness if they
               required ICU level care, high flow oxygen, positive pressure
               support, helmet non-invasive ventilation, mechanical
               ventilation, or ECMO, developed ARDS, or died. RESULTS: The mean
               age was 60 years, 52\% were women, 90\% were African American,
               and mortality at 30 days post discharge was 13\%. Severe
               COVID-19 illness was found in 168 (40\%) patients. Of the 56
               patients with past or current cancer, 25 (45\%) had severe
               illness (p=0.76). Of the 55 patients with other
               immunocompromised conditions, 24 (44\%) had severe illness
               (p=0.89) After controlling for age, sex, and race, neither
               cancer (p=0.73) nor immunocompromised conditions (p=0.64) were
               associated with severe illness. CONCLUSION: No association was
               found between severe COVID-19 illness and cancer, transplant,
               and other immunocompromising conditions in a cohort of mostly
               African American patients.",
  journal   = "J. Clin. Virol.",
  publisher = "Elsevier BV",
  volume    =  140,
  number    =  104850,
  pages     = "104850",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Cancer; Immunocompromised; SARS-CoV-2; Severe acute
               respiratory syndrome coronavirus-2; Transplant",
  language  = "en"
}

@ARTICLE{Yasuda2021-gx,
  title     = "Resolution of one-year persisting {COVID-19} pneumonia and
               development of immune thrombocytopenia in a follicular lymphoma
               patient with preceding rituximab maintenance therapy: A
               follow-up report and literature review of cases with prolonged
               infections",
  author    = "Yasuda, Hajime and Mori, Yosuke and Chiba, Asako and Bai, Jie
               and Murayama, Goh and Matsushita, Yasushi and Miyake, Sachiko
               and Komatsu, Norio",
  abstract  = "BACKGROUND: We previously reported elsewhere of a follicular
               lymphoma patient suffering from persistent COVID-19 pneumonia
               that was still ongoing at 2 months after onset. MATERIALS AND
               METHODS: We provide a follow-up report of the case along with a
               literature review of immunocompromised lymphoma patients
               experiencing prolonged COVID-19 infections. RESULTS: Although
               requiring a full 1 year, the presented case eventually achieved
               spontaneous resolution of COVID-19 pneumonia. Anti-SARS-CoV-2
               antibodies could not be detected throughout the disease course,
               but COVID-19-directed T-cell response was found to be intact.
               The patient also developed secondary immune thrombocytopenia
               subsequent to COVID-19 pneumonia. We found 19 case reports of
               immunocompromised lymphoma patients with prolonged COVID-19
               infections in the literature. All 5 patients who died did not
               receive convalescent plasma therapy, whereas resolution of
               COVID-19 infection was achieved in 8 out of 9 patients who
               received convalescent plasma therapy. CONCLUSIONS: We
               demonstrate through the presented case that while
               time-consuming, resolution of COVID-19 infections may be
               achieved without aid from humoral immunity if cellular immunity
               is intact. Immunocompromised lymphoma patients are at risk of a
               prolonged disease course of COVID-19, and convalescent plasma
               therapy may be a promising approach in such patients.",
  journal   = "Clin. Lymphoma Myeloma Leuk.",
  publisher = "Elsevier BV",
  volume    =  21,
  number    =  10,
  pages     = "e810--e816",
  month     =  oct,
  year      =  2021,
  keywords  = "Anti-sars-cov-2 antibodies; Chemotherapy; Convalescent plasma;
               Coronavirus; Itp",
  language  = "en"
}

@ARTICLE{Amodio2021-ik,
  title     = "Humoral and cellular response following vaccination with the
               {BNT162b2} {mRNA} {COVID-19} vaccine in patients affected by
               primary immunodeficiencies",
  author    = "Amodio, Donato and Ruggiero, Alessandra and Sgrulletti, Mayla
               and Pighi, Chiara and Cotugno, Nicola and Medri, Chiara and
               Morrocchi, Elena and Colagrossi, Luna and Russo, Cristina and
               Zaffina, Salvatore and Di Matteo, Gigliola and Cifaldi, Cristina
               and Di Cesare, Silvia and Rivalta, Beatrice and Pacillo, Lucia
               and Santilli, Veronica and Giancotta, Carmela and Manno, Emma
               Concetta and Ciofi Degli Atti, Marta and Raponi, Massimiliano
               and Rossi, Paolo and Finocchi, Andrea and Cancrini, Caterina and
               Perno, Carlo Federico and Moschese, Viviana and Palma, Paolo",
  abstract  = "Mass SARS-Cov-2 vaccination campaign represents the only
               strategy to defeat the global pandemic we are facing.
               Immunocompromised patients represent a vulnerable population at
               high risk of developing severe COVID-19 and thus should be
               prioritized in the vaccination programs and in the study of the
               vaccine efficacy. Nevertheless, most data on efficacy and safety
               of the available vaccines derive from trials conducted on
               healthy individuals; hence, studies on immunogenicity of
               SARS-CoV2 vaccines in such populations are deeply needed. Here,
               we perform an observational longitudinal study analyzing the
               humoral and cellular response following the BNT162b2 mRNA
               COVID-19 vaccine in a cohort of patients affected by inborn
               errors of immunity (IEI) compared to healthy controls (HC). We
               show that both IEI and HC groups experienced a significant
               increase in anti-SARS-CoV-2 Abs 1 week after the second
               scheduled dose as well as an overall statistically significant
               expansion of the Ag-specific CD4+CD40L+ T cells in both HC and
               IEI. Five IEI patients did not develop any specific CD4+CD40L+ T
               cellular response, with one of these patients unable to also
               mount any humoral response. These data raise immunologic
               concerns about using Ab response as a sole metric of protective
               immunity following vaccination for SARS-CoV-2. Taken together,
               these findings suggest that evaluation of vaccine-induced
               immunity in this subpopulation should also include
               quantification of Ag-specific T cells.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "727850",
  month     =  oct,
  year      =  2021,
  keywords  = "BNT162b2 mRNA COVID-19 vaccine; COVID-19; Comirnaty; SARS-CoV-2;
               SARS-CoV-2 antibody; antigen-specific T cell; inborn errors of
               immunity; vaccine efficacy",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Kuchi_Bhotla2021-sj,
  title     = "Opportunistic mycoses in {COVID-19} patients/survivors: Epidemic
               inside a pandemic",
  author    = "Kuchi Bhotla, Haripriya and Balasubramanian, Balamuralikrishnan
               and Meyyazhagan, Arun and Pushparaj, Karthika and Easwaran,
               Murugesh and Pappusamy, Manikantan and Alwin Robert, Asirvatham
               and Arumugam, Vijaya Anand and Tsibizova, Valentina and Msaad
               Alfalih, Abdullah and Aljowaie, Reem M and Saravanan,
               Muthupandian and Di Renzo, Gian Carlo",
  abstract  = "Being considered minor vexations, fungal infections hinder the
               life of about 15\% of the world population superficially, with
               rare threats to life in case of invasive sepsis. A significant
               rise in the intrusive mycoses due to machiavellian fungal
               species is observed over the years due to increased pathology
               and fatality in people battling life-threatening diseases.
               Individuals undergoing therapy with immune suppressive drugs
               plus recovering from viral infections have shown to develop
               fungal sepsis as secondary infections while recovering or after.
               Currently, the whole world is fighting against the fright of
               Coronavirus disease (COVID-19), and corticosteroids being the
               primitive therapeutic to combat the COVID-19 inflammation, leads
               to an immune-compromised state, thereby allowing the not so
               harmful fungi to violate the immune barrier and flourish in the
               host. A wide range of fungal co-infection is observed in the
               survivors and patients of COVID-19. Fungal species of Candida,
               Aspergillus and Mucorales, are burdening the lives of COVID-19
               patients/survivors in the form of Yellow/Green, White and Black
               fungus. This is the first article of its kind to assemble note
               on fungal infections seen in the current human health scenario
               till date and provides a strong message to the clinicians,
               researchers and physicians around the world ``non-pathological
               fungus should not be dismissed as contaminants, they can quell
               immunocompromised hosts''.",
  journal   = "J. Infect. Public Health",
  publisher = "Elsevier BV",
  volume    =  14,
  number    =  11,
  pages     = "1720--1726",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Corticosteroids; Immunosuppressed; Intrusive fungus;
               Sepsis",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Caillard2021-sr,
  title     = "{SARS-CoV-2} viral dynamics in immunocompromised patients",
  author    = "Caillard, Sophie and Benotmane, Ilies and Gautier Vargas,
               Gabriela and Perrin, Peggy and Fafi-Kremer, Samira",
  abstract  = "While the median duration of SARS-CoV-2 viral RNA detection in
               nasopharyngeal swabs collected from immunocompetent subjects is
               approximately 18 days,1 data for immunocompromised patients are
               not yet available. Here, we prospectively monitored the dynamic
               changes of SARS-CoV-2 RNA viral loads in serial nasopharyngeal
               swab, saliva, and respiratory specimens collected from kidney
               transplant recipients (KTR) hospitalized with a confirmed
               diagnosis of Covid-19.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  4,
  pages     = "1667--1669",
  month     =  apr,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Oviedo-Joekes2021-ps,
  title    = "Take home injectable opioids for opioid use disorder during and
              after the {COVID-19} Pandemic is in urgent need: a case study",
  author   = "Oviedo-Joekes, Eugenia and MacDonald, Scott and Boissonneault,
              Charles and Harper, Kelli",
  abstract = "BACKGROUND: In North America the opioid poisoning crisis
              currently faces the unprecedented challenges brought by the
              COVID-19 pandemic, further straining people and communities
              already facing structural and individual vulnerabilities. People
              with opioid use disorder (OUD) are facing unique challenges in
              response to COVID-19, such as not being able to adopt best
              practices (e.g., physical distancing) if they're financially
              insecure or living in shelters (or homeless). They also have
              other medical conditions that make them more likely to be
              immunocompromised and at risk of developing COVID-19. In response
              to the COVID-19 public health emergency, national and provincial
              regulatory bodies introduced guidance and exemptions to mitigate
              the spread of the virus. Among them, clinical guidance for
              prescribers were issued to allow take home opioid medications for
              opioid agonist treatment (OAT). Take Home for injectable opioid
              agonist treatment (iOAT) is only considered within a restrictive
              regulatory structure, specific to the pandemic. Nevertheless,
              this risk mitigation guidance allowed carries, mostly daily
              dispensed, to a population that would not have access to it prior
              to the pandemic. In this case it is presented and discussed that
              if a carry was possible during the pandemic, then the carry could
              continue post COVID-19 to address a gap in our approach to
              individualize care for people with OUD receiving iOAT. CASE
              PRESENTATION: Here we present the first case of a patient in
              Canada with long-term OUD that received take home injectable
              diacetylmorphine to self-isolate in an approved site after being
              diagnosed with COVID-19 during a visit to the emergency room
              where he was diagnosed with cellulitis and admitted to receive
              antibiotics. CONCLUSION: In the present case we demonstrated that
              it is feasible to provide iOAT outside the community clinic with
              no apparent negative consequences. Improving upon and making
              permanent these recently introduced risk mitigating guidance
              during COVID-19, have the potential not just to protect during
              the pandemic, but also to address long-overdue barriers to access
              evidence-based care in addiction treatment.",
  journal  = "Subst. Abuse Treat. Prev. Policy",
  volume   =  16,
  number   =  1,
  pages    = "22",
  month    =  mar,
  year     =  2021,
  keywords = "Diacetylmorphine; Direct observed treatment; Injectable opioid
              agonist treatment; Opioid use disorder; Patient centered care;
              Take home doses",
  language = "en"
}

@ARTICLE{Mendes_Pedro2021-lc,
  title     = "{SARS-CoV-2} and cancer: Beyond immunosuppression",
  author    = "Mendes Pedro, Diogo and Mendes Pedro, Marta Maria and Valadas,
               Em{\'\i}lia and Hanscheid, Thomas",
  abstract  = "N/a.",
  journal   = "Acta Med. Port.",
  publisher = "Ordem dos Medicos",
  volume    =  34,
  number    =  3,
  pages     = "237",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; Neoplasms; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Furer2021-es,
  title     = "Immunogenicity and safety of the {BNT162b2} {mRNA} {COVID-19}
               vaccine in adult patients with autoimmune inflammatory rheumatic
               diseases and in the general population: a multicentre study",
  author    = "Furer, Victoria and Eviatar, Tali and Zisman, Devy and Peleg,
               Hagit and Paran, Daphna and Levartovsky, David and Zisapel,
               Michael and Elalouf, Ofir and Kaufman, Ilana and Meidan, Roni
               and Broyde, Adi and Polachek, Ari and Wollman, Jonathan and
               Litinsky, Ira and Meridor, Katya and Nochomovitz, Hila and
               Silberman, Adi and Rosenberg, Dana and Feld, Joy and Haddad,
               Amir and Gazzit, Tal and Elias, Muna and Higazi, Nizar and
               Kharouf, Fadi and Shefer, Gabi and Sharon, Orly and Pel, Sara
               and Nevo, Sharon and Elkayam, Ori",
  abstract  = "INTRODUCTION: Vaccination represents a cornerstone in mastering
               the COVID-19 pandemic. Data on immunogenicity and safety of
               messenger RNA (mRNA) vaccines in patients with autoimmune
               inflammatory rheumatic diseases (AIIRD) are limited. METHODS: A
               multicentre observational study evaluated the immunogenicity and
               safety of the two-dose regimen BNT162b2 mRNA vaccine in adult
               patients with AIIRD (n=686) compared with the general population
               (n=121). Serum IgG antibody levels against SARS-CoV-2 spike
               S1/S2 proteins were measured 2-6 weeks after the second vaccine
               dose. Seropositivity was defined as IgG $\geq$15 binding
               antibody units (BAU)/mL. Vaccination efficacy, safety, and
               disease activity were assessed within 6 weeks after the second
               vaccine dose. RESULTS: Following vaccination, the seropositivity
               rate and S1/S2 IgG levels were significantly lower among
               patients with AIIRD versus controls (86\% (n=590) vs 100\%,
               p<0.0001 and 132.9$\pm$91.7 vs 218.6$\pm$82.06 BAU/mL, p<0.0001,
               respectively). Risk factors for reduced immunogenicity included
               older age and treatment with glucocorticoids, rituximab,
               mycophenolate mofetil (MMF), and abatacept. Rituximab was the
               main cause of a seronegative response (39\% seropositivity).
               There were no postvaccination symptomatic cases of COVID-19
               among patients with AIIRD and one mild case in the control
               group. Major adverse events in patients with AIIRD included
               death (n=2) several weeks after the second vaccine dose,
               non-disseminated herpes zoster (n=6), uveitis (n=2), and
               pericarditis (n=1). Postvaccination disease activity remained
               stable in the majority of patients. CONCLUSION: mRNA BNTb262
               vaccine was immunogenic in the majority of patients with AIIRD,
               with an acceptable safety profile. Treatment with
               glucocorticoids, rituximab, MMF, and abatacept was associated
               with a significantly reduced BNT162b2-induced immunogenicity.",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1330--1338",
  month     =  oct,
  year      =  2021,
  keywords  = "Covid-19; biological therapy; methotrexate; rituximab;
               vaccination",
  language  = "en"
}

@ARTICLE{Gergen2021-oh,
  title     = "Coronavirus disease 2019 in lung transplant recipients",
  author    = "Gergen, Anna K and Madsen, Helen J and Tilva, Keval R and Smith,
               Joshua B and Weyant, Michael J",
  abstract  = "We report risk factors, clinical manifestations, and treatment
               course of 2 lung transplant recipients diagnosed with
               coronavirus disease 2019 (COVID-19) pneumonia. Both patients
               underwent an initial hospitalization and discharged home,
               followed by readmission several days later with significant
               worsening of respiratory status and infectious symptoms. The
               first patient underwent prolonged hospitalization requiring
               tracheostomy and feeding tube placement. The second patient
               declined intubation and expired. The early documented
               experiences of COVID-19 pneumonia in lung transplant recipients
               suggest that although recovery is achievable, the high rate of
               comorbid conditions and immunocompromised state may place these
               patients at higher risk for poor outcomes.",
  journal   = "Ann. Thorac. Surg.",
  publisher = "Elsevier BV",
  volume    =  111,
  number    =  5,
  pages     = "e343--e345",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Thuluvath2021-xh,
  title     = "Analysis of antibody responses after {COVID-19} vaccination in
               liver transplant recipients and those with chronic liver
               diseases",
  author    = "Thuluvath, Paul J and Robarts, Polly and Chauhan, Mahak",
  abstract  = "BACKGROUND \& AIMS: Liver transplant (LT) recipients or other
               immunocompromised patients were not included in the registration
               trials studying the efficacy of vaccines against SARS-CoV-2.
               Although the clinical efficacy of COVID-19 vaccines in
               immunocompromised patients is unknown, many societies have
               recommended vaccination of this highly vulnerable patient
               population. METHODS: In this prospective study, we determined
               antibody responses to spike protein, 4 weeks after the 2nd dose
               of mRNA vaccines or after the single dose of Johnson \& Johnson
               vaccine, in LT recipients and those with chronic liver disease
               (CLD) with and without cirrhosis. RESULTS: Of the 233 patients
               enrolled so far, 62 were LT recipients, 79 had cirrhosis (10
               decompensated) and 92 had CLD without cirrhosis. Antibody titers
               were defined as undetectable (250 U/ml). Of the 62 patients who
               had LT, antibody levels were undetectable in 11 patients and
               suboptimal (median titer 17.6, range 0.47-212 U/ml) in 27
               patients. Among 79 patients with cirrhosis, 3 had undetectable
               antibody levels and 15 had suboptimal (median titer 41.3, range
               0.49-221 U/L) antibody responses. Of the 92 patients without
               cirrhosis, 4 had undetectable antibody levels and 19 had
               suboptimal (median titer 95.5, range 4.9-234 U/L) antibody
               responses. Liver transplantation, use of 2 or more
               immunosuppression medications and vaccination with a single dose
               of the Johnson \& Johnson vaccine were associated with poor
               immune response on multivariable analysis. No patient had any
               serious adverse events. CONCLUSIONS: Poor antibody responses
               after SARS-CoV-2 vaccination were seen in 61\% of LT recipients
               and 24\% of those with CLD. LAY SUMMARY: The clinical efficacy
               of COVID-19 vaccines in immunocompromised patients is unknown.
               We performed a prospective study to evaluate immune responses to
               COVID-19 vaccines (Moderna, Pfizer or Johnson \& Johnson) in 62
               liver transplant recipients, 79 patients with cirrhosis and 92
               with chronic liver diseases without cirrhosis. We found that
               17.8\% of liver transplant recipients, 3.8\% of those with
               cirrhosis and 4.3\% of those with chronic liver diseases without
               cirrhosis had undetectable antibody levels. In total, 61.3\% of
               liver transplant recipients and 24\% of those with chronic liver
               diseases (with or without cirrhosis) had poor antibody responses
               (undetectable or suboptimal). Liver transplantation, use of
               immunosuppressive medications and vaccination with a single dose
               of Johnson \& Johnson vaccine were associated with poor antibody
               responses when adjusted for other factors.",
  journal   = "J. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  75,
  number    =  6,
  pages     = "1434--1439",
  month     =  dec,
  year      =  2021,
  keywords  = "SARS-CoV-2; cirrhosis; immunocompromised; liver transplant; mRNA
               vaccine",
  language  = "en"
}

@ARTICLE{Cohen2021-ny,
  title     = "Continuation and discontinuation rates of biologics in
               dermatology patients during {COVID-19} pandemic",
  author    = "Cohen, Stephanie R and Kahn, Jared S and Gao, David X and
               Fiumara, Kristin and Lam, Anh and Dumont, Nicole and Rosmarin,
               David",
  journal   = "J. Cutan. Med. Surg.",
  publisher = "SAGE Publications",
  volume    =  25,
  number    =  6,
  pages     = "646--647",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; biologics; systemic medications",
  language  = "en"
}

@ARTICLE{Ahmadian2021-qp,
  title     = "Immunosuppressant management in renal transplant patients with
               {COVID-19}",
  author    = "Ahmadian, Elham and Zununi Vahed, Sepideh and Mammadova, Shakar
               and Abediazar, Sima",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic poses a special
               risk for both immunosuppressed patients, especially transplant
               recipients. Although the knowledge about this infection is
               growing, many uncertainties remain, particularly regarding the
               kidney. Kidney transplant recipients (KDRs) should be considered
               immunocompromised hosts since a potential risk for infection,
               comorbidity, and immunosuppression exposure exists.
               Additionally, the management of immunosuppressive agents in KDRs
               remains challenging. Potential drug interactions with
               immunosuppressive treatment escalated the risk of unwanted side
               effects. In this review, we aimed to attain an augmented
               awareness and improved management immunosuppressant for COVID-19
               KDRs.",
  journal   = "Biomed Res. Int.",
  publisher = "Hindawi Limited",
  volume    =  2021,
  pages     = "9318725",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Abbasi2021-hi,
  title     = "Researchers tie severe immunosuppression to chronic {COVID-19}
               and virus variants",
  author    = "Abbasi, Jennifer",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  325,
  number    =  20,
  pages     = "2033--2035",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Buehrle2021-ho,
  title     = "A review of treatment and prevention of Coronavirus disease 2019
               among solid organ transplant recipients",
  author    = "Buehrle, Deanna J and Sutton, Robert R and McCann, Erin L and
               Lucas, Aaron E",
  abstract  = "Therapeutic management of solid organ transplant (SOT)
               recipients infected with severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease
               2019 (COVID-19), may challenge healthcare providers given a
               paucity of clinical data specific to this cohort. Herein, we
               summarize and review the studies that have formed the framework
               for current COVID-19 consensus management guidelines. Our review
               focuses on COVID-19 treatment options including monoclonal
               antibody products, antiviral agents such as remdesivir, and
               immunomodulatory agents such as corticosteroids, interleukin
               inhibitors, and kinase inhibitors. We highlight the presence or
               absence of clinical data of these therapeutics related to the
               SOT recipient with COVID-19. We also describe data surrounding
               COVID-19 vaccination of the SOT recipient. Understanding the
               extent and limitations of observational and clinical trial data
               for the prevention and treatment of COVID-19 specific to the SOT
               population is crucial for optimal management. Although minimal
               data exist on clinical outcomes among SOT recipients treated
               with varying COVID-19 therapeutics, reviewing these agents and
               the studies that have led to their inclusion or exclusion in
               clinical management of COVID-19 highlights the need for further
               studies of these therapeutics in SOT patients with COVID-19.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  9,
  pages     = "1706",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunosuppressed; solid organ transplant;
               vaccine",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Havlin2021-fk,
  title     = "Immunogenicity of {BNT162b2} {mRNA} {COVID-19} vaccine and
               {SARS-CoV-2} infection in lung transplant recipients",
  author    = "Havlin, Jan and Svorcova, Monika and Dvorackova, Eliska and
               Lastovicka, Jan and Lischke, Robert and Kalina, Tomas and
               Hubacek, Petr",
  abstract  = "The immunogenicity of the novel mRNA COVID-19 vaccine in
               immunocompromised lung transplant recipients is still unknown.
               We compared the antibody response after the first and second
               doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech)
               with the response after natural SARS-CoV-2 infection in lung
               transplant recipients. None of the vaccinees tested after two
               doses of the mRNA BNT162b2 vaccine developed anti-SARS-CoV-2
               IgG, while 85\% patients presented an antibody response after
               SARS-CoV-2 infection. The absence of antibody response to
               vaccination led us to investigate the cellular response in a
               subset of patients. We detected SARS-CoV-2 specific T-cells in 4
               out of 12 tested patients. Some patients therefore might have
               clinical benefit from the vaccine despite an absent antibody
               response. These results contrast with the excellent antibody
               response in immunocompetent individuals observed in mRNA
               BNT162b2 trials and indicate an urgent need to identify the best
               vaccine type and scheme for immunocompromised transplanted
               patients.",
  journal   = "J. Heart Lung Transplant.",
  publisher = "Elsevier BV",
  volume    =  40,
  number    =  8,
  pages     = "754--758",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; antibody response; immunogenicity; lung
               transplantation; mRNA vaccine",
  language  = "en"
}

@ARTICLE{Chikowe2021-fu,
  title     = "Potential of Malawi's medicinal plants in Covid-19 disease
               management: A review",
  author    = "Chikowe, Ibrahim and Mtewa, Andrew G and Tembo, David and Smith,
               Dallas and Ibrahim, Edna and Mwamatope, Bonface and Nkhungulu,
               Justin and Kumpalume, Peter and Maroyi, Alfred",
  abstract  = "The Coronavirus Disease 2019 (COVID-19) caused by severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered an
               international pandemic that has led to significant public health
               problems. To date, limited evidence exists to suggest that drugs
               are effective against the disease. As possible treatments are
               being investigated, herbal medicines have shown potential for
               producing novel antiviral agents for the COVID-19 disease. Aim:
               This review explored the potential of Malawi's traditional
               medicinal plants for the management of COVID-19. Methods: The
               authors searched on PubMed and Google scholar for medicinal
               plants that are used in Malawi and published in openly available
               peer reviewed journals. Plants linked with antiviral treatment,
               anti-COVID-19 activity or COVID-19 symptoms management were
               targeted. These included activity against pneumonia,
               inflammation, cough, difficulty in breathing, pain/aches, fever,
               diarrhoea, rheumatism, fatigue, asthma, immunocompromised and
               cardiovascular diseases. Results: 11 studies were found with 306
               plant species. 127 plant species had at least one COVID-19
               related pharmacological activity. Of these plant species, the
               number of herbal entities used for each indication was:
               pain/aches (87), fever (2), pneumonia (9), breathing/asthma
               problems (5), coughing (11), diarrhoea (1), immunosuppression
               (8), blood issues (10), fatigue (2), heart problems (11),
               inflammation (8), rheumatism (10) and viral diseases (12).
               Thirty (30) species were used for more than one disease and
               Azedarachta indica topped the list (6 of the 13 COVID-19 related
               diseases). The majority of the species had phytochemicals known
               to have antiviral activity or mechanisms of actions linked to
               COVID-19 and consequent diseases' treatment pathways.
               Conclusion: Medicinal plants are a promising source of compounds
               that can be used for drug development of COVID-19 related
               diseases. This review highlights potential targets for the World
               Health Organization and other research entities to explore in
               order to assist in controlling the pandemic.",
  journal   = "Malawi Med. J.",
  publisher = "African Journals Online (AJOL)",
  volume    =  33,
  number    =  2,
  pages     = "85--107",
  month     =  jun,
  year      =  2021,
  keywords  = "corona virus; drug development; herbal products; screening;
               traditional medicine",
  language  = "en"
}

@ARTICLE{Bhogireddy2021-sm,
  title     = "Is Mucormycosis an inevitable complication of Covid-19 in India?",
  author    = "Bhogireddy, Ramadevi and Krishnamurthy, Venkataraman and Jabaris
               S, Sugin Lal and Pullaiah, Chitikela P and Manohar, Swetha",
  abstract  = "Mucormycosis or black fungus infection is a less common disease
               but highly fatal infection, infecting the immunocompromised
               individuals. The site of predilection of the fungus is found to
               be lungs and brain in addition to its sequestration in
               sinusoidal spaces. Presently with the ongoing COVID 19 pandemic,
               the prevalence of this infection is found to be high in the
               Indian population. The fungus establishes itself by affecting
               the compromised immune system of an individual and thereby
               making the individual susceptible to other diseases/infection.
               The reasons attributed to the sudden upsurge are steroidal
               therapeutics abuse, tocilizumab therapy and diabetes mellitus.To
               avert the cytokine storm, the medical health workers are
               necessitated to include steroid drugs in COVID 19 treatment
               protocol however inclusion of these drugs in patients who do
               essentially require steroids can have their immune system
               debilitated and permit the invasion of this fungus. According to
               International Diabetes Federation (IDF), 77 million Indians are
               known to be diabetic, cautioning the physicians to be vigilante
               of the impending black fungus infection in the event of COVID19
               affliction in such individuals. There is causal relationship
               between anti-hyperglycemic drugs and weakened immune system and
               opportunity for the fungus invasion. This review attempts to
               explain the inter-relatedness of COVID19 infection, its
               treatment and eventual black fungus infection risk.",
  journal   = "Braz. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  25,
  number    =  3,
  pages     = "101597",
  month     =  may,
  year      =  2021,
  keywords  = "Covid-19; Diabetes mellitus; Immunity; Mucormycosis; Steroidal
               drugs",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Langerbeins2021-jt,
  title     = "Immune dysfunction in patients with chronic Lymphocytic leukemia
               and challenges during {COVID-19} pandemic",
  author    = "Langerbeins, Petra and Eichhorst, Barbara",
  abstract  = "The novel severe acute respiratory syndrome coronavirus
               (SARS-CoV-2) has been first described in December 2019 in Wuhan,
               China, and has led to a worldwide pandemic ever since. Initial
               clinical data imply that cancer patients are particularly at
               risk for a severe course of SARS-CoV-2. In patients with chronic
               lymphocytic leukemia (CLL), infections are a main contributor to
               morbidity and mortality driven by an impaired immune system.
               Treatment initiation is likely to induce immune modulation that
               further increases the risk for severe infections. This article
               aims to give an overview on pathogenesis and risk of infectious
               complications in patients with CLL. In this context, we discuss
               current data of SARS-CoV-2 infections in patients with CLL and
               how the pandemic impacts their management.",
  journal   = "Acta Haematol.",
  publisher = "S. Karger AG",
  volume    =  144,
  number    =  5,
  pages     = "508--518",
  month     =  feb,
  year      =  2021,
  keywords  = "Chronic lymphocytic leukemia; Coronavirus disease 2019;
               Immunodeficiency; Infections",
  copyright = "https://www.karger.com/Services/SiteLicenses",
  language  = "en"
}

@ARTICLE{Devilliers2021-hl,
  title     = "Ocular manifestations of viral diseases",
  author    = "Devilliers, M-J and Ben Hadj Salah, W and Barreau, E and Da
               Cunha, E and M'Garrech, M and B{\'e}nichou, J and Labetoulle, M
               and Rousseau, A",
  abstract  = "Viral infections may involve all ocular tissues and may have
               short and long-term sight-threatening consequences. Among them,
               ocular infections caused by herpesviruses are the most frequent.
               HSV-1 keratitis and kerato-uveitis affect approximately are the
               leading cause of infectious blindness in the Western world,
               mainly because of corneal opacification caused by recurrences.
               For this reason, they may warrant long-term antiviral
               prophylaxis. Herpes zoster ophthalmicus, accounts for 10 to 20\%
               of all shingles locations and can be associated with severe
               ocular involvement (keratitis, kerato-uveitis) of which a
               quarter becomes chronic/recurrent. Post herpetic neuralgias in
               the trigeminal territory can be particularly debilitating.
               Necrotizing retinitis caused by herpesviruses (HSV, VZV, CMV)
               are seldom, but must be considered as absolute visual
               emergencies, requiring urgent intravenous and intravitreal
               antiviral treatment. Clinical pictures depend on the immune
               status of the host. Adenovirus are the most frequent cause of
               infectious conjunctivitis. These most often benign infections
               are highly contagious and may be complicated by visually
               disabling corneal lesions that may last over months or years.
               Some arboviruses may be associated with inflammatory ocular
               manifestations. Among them, congenital Zika infections may cause
               macular or optic atrophy. Conjunctivitis is frequent during the
               acute phase of Ebola virus disease. Up to 15\% of survivors
               present with severe chronic inflammatory ocular conditions
               caused by viral persistence in uveal tissues. Finally,
               COVID-19-associated conjunctivitis can precede systemic disease,
               or even be the unique manifestation of the disease. Utmost
               caution must be taken because of viral shedding in tears.",
  journal   = "Rev. Med. Interne",
  publisher = "Elsevier BV",
  volume    =  42,
  number    =  6,
  pages     = "401--410",
  month     =  jun,
  year      =  2021,
  keywords  = "Arbovirose; Arboviruses; CMV; COVID-19; Ebola; Herpes;
               Keratitis; K{\'e}ratite; Retinitis; Rubella; Rub{\'e}ole;
               R{\'e}tinite; Uveitis; Uv{\'e}ite; Zona; Zoster",
  language  = "fr"
}

@ARTICLE{Suleyman2021-ir,
  title     = "Nosocomial fungal infections: Epidemiology, infection control,
               and prevention",
  author    = "Suleyman, Geehan and Alangaden, George J",
  abstract  = "Invasive fungal infections are an important cause of morbidity
               and mortality in hospitalized patients and in the
               immunocompromised population. This article reviews the current
               epidemiology of nosocomial fungal infections in adult patients,
               with an emphasis on invasive candidiasis (IC) and invasive
               aspergillosis (IA). Included are descriptions of nosocomial
               infections caused by Candida auris, an emerging pathogen, and
               IC- and IA-associated with coronavirus disease 2019. The
               characteristics and availability of newer nonculture-based tests
               for identification of nosocomial fungal pathogens are discussed.
               Recently published recommendations and guidelines for the
               control and prevention of these nosocomial fungal infections are
               summarized.",
  journal   = "Infect. Dis. Clin. North Am.",
  publisher = "Elsevier BV",
  volume    =  35,
  number    =  4,
  pages     = "1027--1053",
  month     =  dec,
  year      =  2021,
  keywords  = "Aspergillus; Candida; Fungal infection; Nosocomial",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Christie2021-co,
  title     = "Guidance for implementing {COVID-19} prevention strategies in
               the context of varying community transmission levels and
               vaccination coverage",
  author    = "Christie, Athalia and Brooks, John T and Hicks, Lauri A and
               Sauber-Schatz, Erin K and Yoder, Jonathan S and Honein, Margaret
               A and {CDC COVID-19 Response Team}",
  abstract  = "COVID-19 vaccination remains the most effective means to achieve
               control of the pandemic. In the United States, COVID-19 cases
               and deaths have markedly declined since their peak in early
               January 2021, due in part to increased vaccination coverage (1).
               However, during June 19-July 23, 2021, COVID-19 cases increased
               approximately 300\% nationally, followed by increases in
               hospitalizations and deaths, driven by the highly transmissible
               B.1.617.2 (Delta) variant* of SARS-CoV-2, the virus that causes
               COVID-19. Available data indicate that the vaccines authorized
               in the United States (Pfizer-BioNTech, Moderna, and Janssen
               [Johnson \& Johnson]) offer high levels of protection against
               severe illness and death from infection with the Delta variant
               and other currently circulating variants of the virus (2).
               Despite widespread availability, vaccine uptake has slowed
               nationally with wide variation in coverage by state (range =
               33.9\%-67.2\%) and by county (range = 8.8\%-89.0\%).
               Unvaccinated persons, as well as persons with certain
               immunocompromising conditions (3), remain at substantial risk
               for infection, severe illness, and death, especially in areas
               where the level of SARS-CoV-2 community transmission is high.
               The Delta variant is more than two times as transmissible as the
               original strains circulating at the start of the pandemic and is
               causing large, rapid increases in infections, which could
               compromise the capacity of some local and regional health care
               systems to provide medical care for the communities they serve.
               Until vaccination coverage is high and community transmission is
               low, public health practitioners, as well as schools,
               businesses, and institutions (organizations) need to regularly
               assess the need for prevention strategies to avoid stressing
               health care capacity and imperiling adequate care for both
               COVID-19 and other non-COVID-19 conditions. CDC recommends five
               critical factors be considered to inform local decision-making:
               1) level of SARS-CoV-2 community transmission; 2) health system
               capacity; 3) COVID-19 vaccination coverage; 4) capacity for
               early detection of increases in COVID-19 cases; and 5)
               populations at increased risk for severe outcomes from COVID-19.
               Among strategies to prevent COVID-19, CDC recommends all
               unvaccinated persons wear masks in public indoor settings. Based
               on emerging evidence on the Delta variant (2), CDC also
               recommends that fully vaccinated persons wear masks in public
               indoor settings in areas of substantial or high transmission.
               Fully vaccinated persons might consider wearing a mask in public
               indoor settings, regardless of transmission level, if they or
               someone in their household is immunocompromised or is at
               increased risk for severe disease, or if someone in their
               household is unvaccinated (including children aged <12 years who
               are currently ineligible for vaccination).",
  journal   = "MMWR Morb. Mortal. Wkly. Rep.",
  publisher = "Centers for Disease Control MMWR Office",
  volume    =  70,
  number    =  30,
  pages     = "1044--1047",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ramakrishnan2021-cd,
  title     = "Unraveling the mystery surrounding post-acute sequelae of
               {COVID-19}",
  author    = "Ramakrishnan, Rakhee K and Kashour, Tarek and Hamid, Qutayba and
               Halwani, Rabih and Tleyjeh, Imad M",
  abstract  = "More than one year since its emergence, corona virus disease
               2019 (COVID-19) is still looming large with a paucity of
               treatment options. To add to this burden, a sizeable subset of
               patients who have recovered from acute COVID-19 infection have
               reported lingering symptoms, leading to significant disability
               and impairment of their daily life activities. These patients
               are considered to suffer from what has been termed as
               ``chronic'' or ``long'' COVID-19 or a form of post-acute
               sequelae of COVID-19, and patients experiencing this syndrome
               have been termed COVID-19 long-haulers. Despite recovery from
               infection, the persistence of atypical chronic symptoms,
               including extreme fatigue, shortness of breath, joint pains,
               brain fogs, anxiety and depression, that could last for months
               implies an underlying disease pathology that persist beyond the
               acute presentation of the disease. As opposed to the direct
               effects of the virus itself, the immune response to severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) is believed to
               be largely responsible for the appearance of these lasting
               symptoms, possibly through facilitating an ongoing inflammatory
               process. In this review, we hypothesize potential immunological
               mechanisms underlying these persistent and prolonged effects,
               and describe the multi-organ long-term manifestations of
               COVID-19.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "686029",
  month     =  jun,
  year      =  2021,
  keywords  = "SARS-CoV-2; chronic COVID-19; clinical manifestations;
               immunopathology; long COVID-19; long-haulers; post-acute
               COVID-19 syndrome; post-acute sequelae of COVID-19",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Shahab2021-iy,
  title     = "A unique triad of invasive sinusitis, brain abscess with focal
               cerebritis, and {COVID-19}",
  author    = "Shahab, Ahmed and Arora, Alok and Chhina, Sultan S and Dhillon,
               Saud and Nazir, Umair",
  abstract  = "BACKGROUND We present a case of invasive sinusitis with
               rhinocerebral infection in a patient who had mild symptoms of
               COVID-19 infection and did not receive any immunosuppressive
               therapies. CASE REPORT A 49-year-old man with a history of
               uncontrolled diabetes presented to the hospital with multiple
               generalized tonic clonic seizures. He had recently been
               diagnosed with mild COVID-19 and was treated at home with
               supportive care only. He was found to have cerebritis in the
               right frontal lobe along with right fronto-ethmoid sinusitis. He
               underwent extensive testing with nasal endoscopy with gram stain
               and culture, cryptococcal studies, 1-3-Beta-D glucan, blood
               cultures, fungal CSF studies, Lyme disease, HIV, Fungitell
               assay, and galactomannan studies, which were all negative. He
               was started on i.v. antibacterial therapy with cefepime,
               vancomycin, and metronidazole along with amphotericin B. After 2
               weeks, his repeat imaging revealed progression of cerebritis
               along with new early abscess. Given these findings, his
               antibiotics were changed to meropenem and the amphotericin B
               dose was increased. He was recommended debridement and sinus
               surgery but refused. During the course of treatment, he
               developed acute kidney injury and was switched to Posaconazole.
               Unfortunately, the patient decided to leave against medical
               advice 6 weeks into admission. He was advised to continue
               Posaconazole and levofloxacin but he could only afford
               levofloxacin. He was then recommended long-term levofloxacin. He
               has since recovered, with resolution of cerebritis noted in
               follow-up imaging 1 year later. CONCLUSIONS Our patient had mild
               COVID-19 infection and presented with secondary infective
               complications, which are usually associated with an
               immunocompromised state, despite receiving no
               immunosuppressives. It is imperative that all clinicians
               treating COVID-19 be watchful for fungal or bacterial
               co-infections in patients with active SARS-CoV-2 infection, even
               if the presenting symptoms are mild, particularly if other risk
               factors are present.",
  journal   = "Am. J. Case Rep.",
  publisher = "International Scientific Information, Inc.",
  volume    =  22,
  pages     = "e933177",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Perez-Martinez2021-qp,
  title     = "Clinical outcome of {SARS-CoV-2} infection in immunosuppressed
               children in Spain",
  author    = "P{\'e}rez-Martinez, Antonio and Guerra-Garc{\'\i}a, Pilar and
               Melgosa, Marta and Frauca, Esteban and Fernandez-Camblor,
               Carlota and Remesal, Agustin and Calvo, Cristina",
  abstract  = "Limited information is available regarding SARS-CoV-2 infections
               in children with underlying diseases. A retrospective study of
               children less than 15 years old with primary or secondary
               immunosuppression infected with SARS-CoV-2 during March 2020 was
               performed. In this series, 8 immunocompromised patients with
               COVID-19 disease are reported, accounting for 15\% of the
               positive cases detected in children in a reference hospital. The
               severity of the symptoms was mild-moderate in the majority with
               a predominance of febrile syndrome, with mild radiological
               involvement and in some cases with mild respiratory distress
               that required oxygen therapy. The rational and prudent
               management of these patients is discussed, evaluating possible
               treatments and options for hospitalization or outpatient
               follow-up.Conclusion: In our experience, monitoring of children
               with immunosuppression and COVID-19 disease can be performed as
               outpatients if close monitoring is possible. Hospitalization
               should be assessed when high fever, radiological involvement,
               and/or respiratory distress are present. What is Known: 
               SARS-CoV-2 infection is usually mild in children. What is New: 
               Outcome of immunosuppressed children with COVID-19 is generally
               good, with a mild-moderate course.",
  journal   = "Eur. J. Pediatr.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  180,
  number    =  3,
  pages     = "967--971",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Cancer; Immunosuppression; Transplant",
  language  = "en"
}

@ARTICLE{Haidar2021-sr,
  title     = "Improving the outcomes of immunocompromised patients with
               Coronavirus disease 2019",
  author    = "Haidar, Ghady and Mellors, John W",
  abstract  = "Recent case studies have highlighted the fact that certain
               immunocompromised individuals are at risk for prolonged
               SARS-CoV-2 replication, intrahost viral evolution of
               multiply-mutated variants, and poor clinical outcomes. The
               immunologic determinants of this risk, the duration of
               infectiousness, and optimal treatment and prevention strategies
               in immunocompromised hosts are ill defined. Of additional
               concern is the widespread use of immunosuppressive medications
               to treat COVID-19, which may enhance and prolong viral
               replication in the context of immunodeficiency. We outline the
               rationale for 4 interrelated approaches to usher in an era of
               evidence-based medicine for optimal management of
               immunocompromised patients with COVID-19: multicenter
               pathogenesis and outcomes studies to relate the risk of severe
               disease to the type and degree of immunodeficiency, studies to
               evaluate immunologic responses to SARS-CoV-2 vaccines, studies
               to evaluate the efficacy of monoclonal antibodies for primary
               prophylaxis, and clinical trials of novel antiviral agents for
               the treatment of COVID-19.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  73,
  number    =  6,
  pages     = "e1397--e1401",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunocompromised; monoclonal antibody;
               vaccine",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Molhave2022-wp,
  title     = "Clinical management of {COVID-19} patients - an update",
  author    = "M{\o}lhave, Martin and Agergaard, Jane and Wejse, Christian",
  abstract  = "SARS-CoV-2 virus may cause COVID-19 disease, which causes
               mild-to-moderate disease in 80\% of laboratory-confirmed cases
               which may be community-managed. A considerable age-dependent
               mortality is seen among elderly and other at-risk populations
               but among young and healthy individuals it is < 0.5\%. Long-term
               health issues have been reported following severe COVID-19
               requiring hospitalization as well as after cases of mild
               COVID-19 without hospitalization. Upon receiving COVID-19
               suspected patients at hospitals, patients should be isolated and
               PPE should be worn by all health staff when in contact with the
               patients. Additionally, patients are tested for the presence of
               SARS-CoV-2 RNA by PCR, and blood samples are drawn. Imaging is
               not pivotal for the diagnosis, but chest X-ray is a relevant
               examination for all and is used to determine severity and
               treatment need Abnormal findings on CT scans are found in most
               patients, most frequently peripheral ground-glass opacity and
               bilateral patchy shadowing are present. Patients are, according
               to their needs and risks, treated with oxygen therapy,
               anticoagulation therapy, steroids, antivirals, or
               immunosupressive drugs on special indications. Convalescent
               plasma therapy and monoclonal antibodies have a limited role in
               the treatment, mostly in severely immunocompromised patients.
               Patients with long-term sequelae should be evaluated in a
               post-COVID outpatient clinic. The most frequent reported
               symptoms include cognitive impairment, dyspnea, loss of smell
               and taste, and mental and physical fatigue although a wide
               spectrum of symptoms from other organ systems are also reported.
               The current treatment is based on symptom relief and
               rehabilitation as there is no documented specific medical
               treatment.",
  journal   = "Semin. Nucl. Med.",
  publisher = "Elsevier BV",
  volume    =  52,
  number    =  1,
  pages     = "4--10",
  month     =  jan,
  year      =  2022,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Dolan2021-ta,
  title     = "{SARS-CoV-2} persistence in immunocompromised children",
  author    = "Dolan, Susan A and Mulcahy Levy, Jean and Moss, Angela and
               Pearce, Kelly and Butler, Molly and Jung, Sarah and Dominguez,
               Samuel R and Mwangi, Eric and Maloney, Kelly and Rao, Suchitra",
  abstract  = "OBJECTIVES: We evaluated the length of time immunocompromised
               children (ICC) remain positive for severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2), identified factors
               associated with viral persistence, and determined cycle
               threshold (CT ) values of children with viral persistence as a
               surrogate of viral load. METHODS: We conducted a retrospective
               cohort study of ICC at a pediatric hospital from March 2020 to
               March 2021. Immunocompromised status was defined as primary,
               secondary, or acquired due to medical
               comorbidities/immunosuppressive treatment. The primary outcome
               was time to first of two consecutive negative SARS-CoV-2
               polymerase chain reaction (PCR) tests at least 24 hours apart.
               Testing of sequential clinical specimens from the same subject
               was conducted using the Centers for Disease Control (CDC)
               2019-nCoV real-time reverse transcriptase (RT)-PCR Diagnostic
               Panel assay. Descriptive statistics, Kaplan-Meier curve median
               event times and log-rank tests were used to compare outcomes
               between groups. RESULTS: Ninety-one children met inclusion
               criteria. Median age was 15.5 years (interquartile range [IQR]
               8-18), 64\% were male, 58\% were White, and 43\% were
               Hispanic/Latinx. Most (67\%) were tested in outpatient settings
               and 58\% were asymptomatic. The median time to two negative
               tests was 42 days (IQR 25.0-55.0), with no differences in median
               time by illness presentation or level of immunosuppression.
               Seven children had more than one sample available for repeat
               testing, and five of seven (71\%) children had initial CT values
               of 6 weeks and moderate to high viral load.",
  journal   = "Pediatr. Blood Cancer",
  publisher = "Wiley",
  volume    =  68,
  number    =  12,
  pages     = "e29277",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; SARS CoV-2; immunocompromised; pediatrics; shedding;
               viral persistence",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Stanoeva2021-er,
  title     = "Towards a sensitive and accurate interpretation of molecular
               testing for {SARS-CoV-2}: a rapid review of 264 studies",
  author    = "Stanoeva, Kamelia R and van der Eijk, Annemiek A and Meijer,
               Adam and Kortbeek, Laetitia M and Koopmans, Marion P G and
               Reusken, Chantal B E M",
  abstract  = "BackgroundSensitive molecular diagnostics and correct test
               interpretation are crucial for accurate COVID-19 diagnosis and
               thereby essential for good clinical practice. Furthermore, they
               are a key factor in outbreak control where active case finding
               in combination with isolation and contact tracing are
               crucial.AimWith the objective to inform the public health and
               laboratory responses to the pandemic, we reviewed current
               published knowledge on the kinetics of SARS-CoV-2 infection as
               assessed by RNA molecular detection in a wide range of clinical
               samples.MethodsWe performed an extensive search on studies
               published between 1 December 2019 and 15 May 2020, reporting on
               molecular detection and/or isolation of SARS-CoV-2 in any human
               laboratory specimen.ResultsWe compiled a dataset of 264 studies
               including 32,515 COVID-19 cases, and additionally aggregated
               data points (n = 2,777) from sampling of 217 adults with known
               infection timeline. We summarised data on SARS-CoV-2 detection
               in the respiratory and gastrointestinal tract, blood, oral
               fluid, tears, cerebrospinal fluid, peritoneal fluid, semen,
               vaginal fluid; where provided, we also summarised specific
               observations on SARS-CoV-2 detection in pregnancy, infancy,
               children, adolescents and immunocompromised
               individuals.ConclusionOptimal SARS-CoV-2 molecular testing
               relies on choosing the most appropriate sample type, collected
               with adequate sampling technique, and with the infection
               timeline in mind. We outlined knowledge gaps and directions for
               future well-documented systematic studies.",
  journal   = "Euro Surveill.",
  publisher = "European Centre for Disease Control and Prevention (ECDC)",
  volume    =  26,
  number    =  10,
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Laboratory Diagnosis; Polymerase Chain Reaction;
               SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Brogna2021-lb,
  title     = "{COVID-19} pneumonia in vaccinated population: A six clinical
               and radiological case series",
  author    = "Brogna, Barbara and Bignardi, Elio and Brogna, Claudia and
               Capasso, Chiara and Gagliardi, Giuliano and Martino, Alberigo
               and Musto, Lanfranco Aquilino",
  abstract  = "Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and
               its related disease (COVID-19) continue to represent a challenge
               for humans. To date, vaccination programs have represented an
               opportunity to navigate the pandemic. However, the advent of new
               genetic COVID-19 variants has increased more attention
               representing a worrying threat not only for not vaccinated but
               also for vaccinated people as virus infections have been shown
               also in the last ones. Herein, we report different clinical
               cases and radiological findings of COVID-19 pneumonia in six
               fully vaccinated patients. Two patients had a history of
               Rituximab therapy for follicular lymphoma and with persistent
               positivity for SARS-CoV-2 on nasopharyngeal/oropharyngeal
               (NP/OP) swabs and with moderate pneumonia on the chest computed
               tomography (CT). One patient who resulted to be positive to
               delta variant 8 days after the second vaccination dose, died
               shortly after. Two patients were hospitalized due to the
               worsening of fever and dyspnea in presence of mild pneumonia on
               CT. In one patient mild pneumonia was found on the chest-CT
               performed after a lipothymic episode associated with chest pain
               and positive NP/OP swab tested for SARS-CoV-2. These data
               suggested that in fully vaccinated people, caution should be
               preserved, and the use of masks and social distancing should be
               continued in all closed environments. However, further clinical
               trials should be done to better understand how various factors
               can influence vaccine immunogenicity as the presence of virus
               mutations, age factors, and the presence of an immunocompromised
               state.",
  journal   = "Medicina (Kaunas)",
  publisher = "MDPI AG",
  volume    =  57,
  number    =  9,
  pages     = "891",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19 pneumonia; COVID-19 vaccines; SARS-CoV-2; case reports;
               immunocompromised state",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Saeed2021-zc,
  title     = "Impact of {COVID-19} pandemic on management of pediatric kidney
               transplant recipients",
  author    = "Saeed, Bassam",
  abstract  = "Children appear to be less commonly and less severely affected
               by COVID-19 than adults, accounting for 1\% to 5\% of all
               COVID-19 cases. The COVID-19 pande mic has challenged pediatric
               kidney transplant programs to provide safe and consistent care
               during this difficult and unprecedented time. So far during this
               pandemic, best practices being delivered to pediatric kidney
               transplant patients are based on available information from
               published literature and expert opinions. The key areas of
               pediatric kidney transplant care that may be affected by the
               COVID-19 pandemic include transplant activity, outpatient clinic
               activity, monitoring, multidisciplinary care, medications
               (immunosuppression and others), patient/family
               education/support, school and employment, and care of pediatric
               kidney transplant patients who are COVID-19 positive. It has
               been presumed that children with chronic kidney disease and/or
               those who take immunosuppressants may be at increased risk for
               complications from COVID-19 infection; however, available
               evidence has now suggested that immunosuppressed children with
               kidney transplant are not at increased risk of severe COVID-19
               disease. Clinicians should remain aware that transplant
               recipients may present with atypical symptoms. In addition,
               because evidence-based reports to support specific adjustments
               to immunosuppressive medications in relation to COVID-19 are not
               yet available, decisions on reduction or discontinuation of
               immunosuppression should be on a case-by-case basis for kidney
               transplant recipients who are COVID-19 positive. Reports to
               support evidence-based management of pediatric kidney transplant
               patients during the COVID-19 pandemic are lacking; therefore,
               expert opinion and available knowledge and experience remain
               subject to biases.",
  journal   = "Exp. Clin. Transplant.",
  publisher = "Baskent University",
  volume    =  19,
  number    =  9,
  pages     = "894--898",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Rubin2021-lv,
  title     = "Audio interview: Monoclonal antibodies and booster shots",
  author    = "Rubin, Eric J and Baden, Lindsey R and Morrissey, Stephen",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  385,
  number    =  7,
  pages     = "e29",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Nayak2021-es,
  title     = "Host response to {SARS-CoV2} and emerging variants in
               pre-existing liver and gastrointestinal diseases",
  author    = "Nayak, Baibaswata and Lal, Geetanjali and Kumar, Sonu and Das,
               Chandan J and Saraya, Anoop and {Shalimar}",
  abstract  = "Background: Novel coronavirus SARS-CoV2 is evolving continuously
               with emergence of several variants of increasing transmission
               capabilities and pandemic potential. Generation of variants
               occurs through accumulation of mutations due to the RNA nature
               of viral genome, which is further enhanced by variable selection
               pressures of this ongoing pandemic. COVID-19 presentations of
               SARS-CoV2 are mainly pulmonary manifestations with or without
               mild gastrointestinal (GI) and hepatic symptoms. However, the
               virus has evolved beyond pulmonary manifestations to multisystem
               disorder due to systemic inflammation and cytokine storm.
               Definitive cause of acute or late onset of inflammation,
               infection in various organs, and host response to emerging
               variants lacks clarity and needs elucidation. Several studies
               have reported underlying diseases including diabetes,
               hypertension, obesity, cardio- and cerebrovascular disorders,
               and immunocompromised conditions as significant risk factors for
               severe form of COVID-19. Pre-existing liver and GI diseases are
               also highly predominant in the population, which can alter
               COVID-19 outcome due to altered immune status and host response.
               We aim to review the emerging variants of SARS-CoV2 and host
               response in patients with pre-existing liver and GI diseases.
               Methods: In this review, we have elucidated the emergence and
               characteristic features of new SARS-CoV2 variants, mechanisms of
               infection and host immune response, GI and hepatic manifestation
               with radiologic features of COVID-19, and outcomes in
               pre-existing liver and GI diseases. Key Findings: Emerging
               variants of concern (VOC) have shown increased transmissibility
               and virulence with severe COVID-19 presentation and mortality.
               There is a drastic swift of variants from the first wave to the
               next wave of infections with predominated major VOC including
               alpha (B.1.1.7, UK), beta (B.1.351, South Africa), gamma
               (B.1.1.28.1, Brazil), and delta (B1.1.617, India) variants. The
               mutations in the spike protein of VOC are implicated for
               increased receptor binding (N501Y, P681R) and immune escape
               (L452R, E484K/Q, T478K/R) to host response. Pre-existing liver
               and GI diseases not only have altered tissue expression and
               distribution of viral entry ACE2 receptor but also host protease
               TMPRSS2, which is required for both spike protein binding and
               cleavage to initiate infection. Altered immune status due to
               pre-existing conditions results in delayed virus clearance or
               prolonged viremia. Even though GI and hepatic manifestations of
               SARS-CoV2 are less severe, the detection of virus in patient's
               stool indicates GI tropism, replication, and shedding from the
               GI tract. COVID-19-induced liver injury, acute hepatic
               decompensation, and incidences of acute-on-chronic liver failure
               may change the disease outcomes. Conclusions: The changes in the
               spike protein of emerging variants, immunomodulation by viral
               proteins, and altered expression of host viral entry receptor in
               pre-existing diseases are the key determinants of host response
               to SARS-CoV2 and its disease outcome.",
  journal   = "Front. Cell. Infect. Microbiol.",
  publisher = "Frontiers Media SA",
  volume    =  11,
  pages     = "753249",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV2; emerging variants; gastrointestinal
               disease; liver; manifestations; variants of concern",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Scribano2021-jh,
  title     = "Why do immunosuppressed patients with inflammatory bowel disease
               not seem to be at a higher risk of {COVID-19}?",
  author    = "Scribano, Maria Lia",
  abstract  = "The COVID-19 pandemic has created a public health emergency. In
               this context, there are major concerns for patients with
               inflammatory bowel disease (IBD), particularly for those treated
               with immunomodulators, biologics, and Janus Kinase inhibitors.
               Infection susceptibility is, in fact, one of the reported risks
               for immunotherapy drugs. This review provides the existing
               evidence from worldwide case series describing: (a) the risk for
               the SARS-CoV-2 infection and (b) the risk of a severe infection
               outcome in patients with IBD treated with immunotherapy.
               Further, the review discusses the potential mechanisms
               underlying why this group of patients with IBD might be
               protected from contracting the infection and from a worse
               disease. From the available data, it appears that these patients
               should have an enhanced adherence to the recommended preventive
               measures, suggesting a role in reducing their risk of infection.
               Furthermore, the immunotherapy may dampen the cytokine storm and
               inflammation associated with COVID-19. The results of this
               review seem to confirm that patients with IBD receiving
               immunomodulators, biologics, or Janus Kinase inhibitors do not
               have an increased risk of contracting SARS-CoV-2 infection or
               develop a more severe COVID-19. According to the current
               evidence, it is advisable to maintain immunotherapy, apart from
               corticosteroids, in patients with IBD in order to avoid relapse.
               This review reports only on the cases of patients who tested
               positive for SARS-CoV-2 by RT-PCR of a nasopharyngeal swab
               sample. This is a limitation and a more accurate epidemiological
               picture of the infection will be obtained only via the expanded
               use of antibody tests.",
  journal   = "Dig. Dis. Sci.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  66,
  number    =  9,
  pages     = "2855--2864",
  month     =  sep,
  year      =  2021,
  keywords  = "Adherence; COVID-19; Containment measures; Immunotherapies;
               Inflammatory bowel disease; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Garcia-Guillen2021-vb,
  title     = "{COVID-19}: Overview of rheumatology fellows",
  author    = "Garcia-Guill{\'e}n, Andrea and Jeria, Sicylle and Lobo-Prat,
               David and Sainz, Lu{\'\i}s",
  abstract  = "SARS-COV-2 infection has spread worldwide since it originated in
               December 2019, in Wuhan, China. The pandemic has largely
               demonstrated the resilience of the world's health systems and is
               the greatest health emergency since World War II. There is no
               single therapeutic approach to the treatment of COVID-19 and the
               associated immune disorder. The lack of randomised clinical
               trials (RCTs) has led different countries to tackle the disease
               based on case series, or from results of observational studies
               with off-label drugs. We as rheumatologists in general, and
               specifically rheumatology fellows, have been on the front line
               of the pandemic, modifying our activities and altering our
               training itinerary. We have attended patients, we have learned
               about the management of the disease and from our previous
               experience with drugs for arthritis and giant cell arteritis, we
               have used these drugs to treat COVID-19.",
  journal   = "Reumatol. Cl{\'\i}n. (Engl. Ed.)",
  publisher = "Elsevier BV",
  volume    =  17,
  number    =  9,
  pages     = "491--493",
  month     =  nov,
  year      =  2021,
  keywords  = "Biological agents; Biol{\'o}gicos; COVID-19; Coronavirus;
               Pandemia; Pandemic; Resident; Residente; Reumat{\'o}logos;
               Rheumatologists",
  language  = "en"
}

@ARTICLE{Olive-Cirera2022-qd,
  title     = "Impact of {COVID-19} in immunosuppressed children with
               neuroimmunologic disorders",
  author    = "Oliv{\'e}-Cirera, Gemma and Fonseca, Elianet and
               Cantar{\'\i}n-Extremera, Ver{\'o}nica and V{\'a}zquez-L{\'o}pez,
               Mar{\'\i}a and Jim{\'e}nez-Legido, Mar{\'\i}a and
               Gonz{\'a}lez-{\'A}lvarez, Ver{\'o}nica and Ribeiro-Constante,
               Juliana and Camacho-Salas, Ana and Mart{\'\i}, Itxaso and
               Cancho-Candela, Ramon and Mart{\'\i}nez-Gonz{\'a}lez, Mar{\'\i}a
               Jes{\'u}s and Saiz, Albert and Armangu{\'e}, Tha{\'\i}s and
               {Spanish Study Group NeuroimmunoPed-Covid}",
  abstract  = "BACKGROUND AND OBJECTIVES: To investigate whether children
               receiving immunosuppressive therapies for neuroimmunologic
               disorders had (1) increased susceptibility to SARS-CoV2
               infection or to develop more severe forms of COVID-19; (2)
               increased relapses or autoimmune complications if infected; and
               (3) changes in health care delivery during the pandemic.
               METHODS: Patients with and without immunosuppressive treatment
               were recruited to participate in a retrospective survey
               evaluating the period from March 14, 2020, to March 30, 2021.
               Demographics, clinical features, type of immunosuppressive
               treatment, suspected or confirmed COVID-19 in the patients or
               cohabitants, and changes in care delivery were recorded.
               RESULTS: One hundred fifty-three children were included: 84
               (55\%) female, median age 13 years (interquartile range [8-16]
               years), 79 (52\%) on immunosuppressive treatment. COVID-19 was
               suspected or confirmed in 17 (11\%) (all mild), with a frequency
               similar in patients with and without immunosuppressive treatment
               (11/79 [14\%] vs 6/74 [8\%], p = 0.3085). The frequency of
               neurologic relapses was similar in patients with (18\%) and
               without (21\%) COVID-19. Factors associated with COVID-19
               included having cohabitants with COVID-19 (p < 0.001) and lower
               blood levels of vitamin D (p = 0.039). Return to face-to-face
               schooling or mask type did not influence the risk of infection,
               although 43(28\%) children had contact with a classmate with
               COVID-19. Clinic visits changed from face to face to remote for
               120 (79\%) patients; 110 (92\%) were satisfied with the change.
               DISCUSSION: In this cohort of children with neuroimmunologic
               disorders, the frequency of COVID-19 was low and not affected by
               immunosuppressive therapies. The main risk factors for
               developing COVID-19 were having cohabitants with COVID-19 and
               low vitamin D levels.",
  journal   = "Neurol. Neuroimmunol. Neuroinflamm.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  9,
  number    =  1,
  pages     = "e1101",
  month     =  jan,
  year      =  2022,
  language  = "en"
}

@ARTICLE{Sharma2021-ie,
  title     = "Clinical experience of coronavirus disease 2019 in hematopoietic
               cell transplant and chimeric antigen receptor T-cell recipients",
  author    = "Sharma, Akshay and Bhatt, Neel S and Hijano, Diego R",
  abstract  = "PURPOSE OF REVIEW: To discuss the clinical experience of
               coronavirus disease 2019 (COVID-19) in hematopoietic cell
               transplant and chimeric antigen receptor T-cell therapy
               recipients over the past year and to identify key knowledge gaps
               for future research. RECENT FINDINGS: Immunocompromised
               individuals and those with chronic health conditions are
               especially susceptible to infections, which have had a
               disproportionate impact on health outcomes during the COVID-19
               pandemic. Several studies have evaluated the clinical
               characteristics and outcomes of transplant and cellular therapy
               (TCT) recipients who developed COVID-19. Age, sex, comorbid
               conditions, and social determinants of health are important
               predictors of the risk of severe acute respiratory syndrome
               coronavirus 2 infection and of the eventual severity of the
               disease. Various treatment approaches have been investigated
               over the last year. The paradigm of management strategies
               continues to evolve as more experience is accumulated. SUMMARY:
               In this review, we summarize some important findings as they
               relate to the clinical characteristics of TCT recipients who
               develop COVID-19. We also discuss some treatment approaches that
               are currently recommended and opine on vaccination in this
               population.",
  journal   = "Curr. Opin. Hematol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  28,
  number    =  6,
  pages     = "394--400",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Brackin2021-sk,
  title     = "Fungal genomics in respiratory medicine: What, how and when?",
  author    = "Brackin, Amelie P and Hemmings, Sam J and Fisher, Matthew C and
               Rhodes, Johanna",
  abstract  = "Respiratory infections caused by fungal pathogens present a
               growing global health concern and are a major cause of death in
               immunocompromised patients. Worryingly, coronavirus disease-19
               (COVID-19) resulting in acute respiratory distress syndrome has
               been shown to predispose some patients to airborne fungal
               co-infections. These include secondary pulmonary aspergillosis
               and mucormycosis. Aspergillosis is most commonly caused by the
               fungal pathogen Aspergillus fumigatus and primarily treated
               using the triazole drug group, however in recent years, this
               fungus has been rapidly gaining resistance against these
               antifungals. This is of serious clinical concern as multi-azole
               resistant forms of aspergillosis have a higher risk of mortality
               when compared against azole-susceptible infections. With the
               increasing numbers of COVID-19 and other classes of
               immunocompromised patients, early diagnosis of fungal infections
               is critical to ensuring patient survival. However, time-limited
               diagnosis is difficult to achieve with current culture-based
               methods. Advances within fungal genomics have enabled molecular
               diagnostic methods to become a fast, reproducible, and
               cost-effective alternative for diagnosis of respiratory fungal
               pathogens and detection of antifungal resistance. Here, we
               describe what techniques are currently available within
               molecular diagnostics, how they work and when they have been
               used.",
  journal   = "Mycopathologia",
  publisher = "Springer Science and Business Media LLC",
  volume    =  186,
  number    =  5,
  pages     = "589--608",
  month     =  oct,
  year      =  2021,
  keywords  = "Aspergillus fumigatus; Genomics; Mycoses; Respiratory diseases",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Talgam-Horshi2021-fi,
  title     = "Clinical outcomes and antibody response in {COVID-19-positive}
               pediatric solid organ transplant recipients",
  author    = "Talgam-Horshi, Efrat and Mozer-Glassberg, Yael and
               Waisbourd-Zinman, Orit and Ashkenazi-Hoffnung, Liat and Haskin,
               Orly and Levi, Shelly and Hamdani, Gilad and Landau, Daniel and
               Alfandary, Hadas",
  abstract  = "We describe the clinical and laboratory manifestations and
               outcomes of 25 pediatric solid organ transplant recipients who
               tested positive for severe acute respiratory coronavirus-2.
               Twenty-one (84\%) developed a mild disease; 22 of 23 (96\%) had
               a positive serologic response. Two patients (8\%), both kidney
               transplant recipients with additional comorbidities, developed a
               severe disease. The findings emphasize the need for close
               monitoring of this population.",
  journal   = "Pediatr. Infect. Dis. J.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  40,
  number    =  12,
  pages     = "e514--e516",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Cornberg2021-ag,
  title     = "{EASL} position paper on the use of {COVID-19} vaccines in
               patients with chronic liver diseases, hepatobiliary cancer and
               liver transplant recipients",
  author    = "Cornberg, Markus and Buti, Maria and Eberhardt, Christiane S and
               Grossi, Paolo Antonio and Shouval, Daniel",
  abstract  = "According to a recent World Health Organization estimate, the
               severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               pandemic, which originated in China in 2019, has spread
               globally, infecting nearly 100 million people worldwide by
               January 2021. Patients with chronic liver diseases (CLD),
               particularly cirrhosis, hepatobiliary malignancies, candidates
               for liver transplantation, and immunosuppressed individuals
               after liver transplantation appear to be at increased risk of
               infections in general, which in turn translates into increased
               mortality. This is also the case for SARS-CoV-2 infection, where
               patients with cirrhosis, in particular, are at high risk of a
               severe COVID-19 course. Therefore, vaccination against various
               pathogens including SARS-CoV-2, administered as early as
               possible in patients with CLD, is an important protective
               measure. However, due to impaired immune responses in these
               patients, the immediate and long-term protective response
               through immunisation may be incomplete. The current SARS-CoV-2
               pandemic has led to the exceptionally fast development of
               several vaccine candidates. A small number of these SARS-CoV-2
               vaccine candidates have already undergone phase III,
               placebo-controlled, clinical trials in healthy individuals with
               proof of short-term safety, immunogenicity and efficacy.
               However, although regulatory agencies in the US and Europe have
               already approved some of these vaccines for clinical use,
               information on immunogenicity, duration of protection and
               long-term safety in patients with CLD, cirrhosis, hepatobiliary
               cancer and liver transplant recipients has yet to be generated.
               This review summarises the data on vaccine safety,
               immunogenicity, and efficacy in this patient population in
               general and discusses the implications of this knowledge on the
               introduction of the new SARS-CoV-2 vaccines.",
  journal   = "J. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  74,
  number    =  4,
  pages     = "944--951",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Cirrhosis; Influenza; Liver transplantation;
               SARS-CoV-2; Vaccine",
  language  = "en"
}

@ARTICLE{noauthor_2021-gx,
  title    = "In brief: Third dose of {mRNA-based} {COVID-19} vaccines for
              immunocompromised persons",
  journal  = "Med. Lett. Drugs Ther.",
  volume   =  63,
  number   =  1633,
  pages    = "145--146",
  month    =  sep,
  year     =  2021,
  keywords = "COVID-19; Comirnaty; Spikevax; vaccines",
  language = "en"
}

@ARTICLE{Hasbal2021-ot,
  title     = "Effect of calcineurin inhibitors and mammalian target of
               rapamycin inhibitors on the course of {COVID-19} in kidney
               transplant recipients",
  author    = "Hasbal, Nuri Baris and Turgut, Didem and Gok Oguz, Ebru and Ulu,
               Sena and Gungor, Ozkan",
  abstract  = "Coronavirus disease 19 (COVID-19) has been an ongoing pandemic
               since December 2019. Unfortunately, kidney transplant recipients
               are a high-risk group during the disease course, and scientific
               data are still limited in this patient group. Beyond the dosage
               of immunosuppressive drugs, pharmacological immunosuppression
               may also alter the infection response in the COVID-19 course.
               The effects of immunosuppressive agents on the development and
               process of infection should not be decided only by determining
               how potent they are and how much they suppress the immune
               system; it is also thought that the direct effect of the virus,
               increased oxidative stress, and cytokine storm play a role in
               the pathogenesis of COVID-19 disease. There are data about
               immunosuppressive drugs like calcineurin inhibitors (CNI) or
               mammalian target of rapamycin inhibitors (mTORi) therapy related
               to their beneficial effects during any infection course. Limited
               data suggest that the use of CNI or mTORi may have beneficial
               effects on the process. In this hypothetical review, the
               probable impacts of CNI and mTORi on the pathogenesis of the
               COVID-19 were investigated.",
  journal   = "Ann. Transplant.",
  publisher = "International Scientific Information, Inc.",
  volume    =  26,
  pages     = "e929279",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Lee2021-aq,
  title     = "{COVID-19} severity potentially modulated by
               cardiovascular-disease-associated immune dysregulation",
  author    = "Lee, Abby C and Castaneda, Grant and Li, Wei Tse and Chen,
               Chengyu and Shende, Neil and Chakladar, Jaideep and Taub, Pam R
               and Chang, Eric Y and Ongkeko, Weg M",
  abstract  = "Patients with underlying cardiovascular conditions are
               particularly vulnerable to severe COVID-19. In this project, we
               aimed to characterize similarities in dysregulated immune
               pathways between COVID-19 patients and patients with
               cardiomyopathy, venous thromboembolism (VTE), or coronary artery
               disease (CAD). We hypothesized that these similarly dysregulated
               pathways may be critical to how cardiovascular diseases (CVDs)
               exacerbate COVID-19. To evaluate immune dysregulation in
               different diseases, we used four separate datasets, including
               RNA-sequencing data from human left ventricular cardiac muscle
               samples of patients with dilated or ischemic cardiomyopathy and
               healthy controls; RNA-sequencing data of whole blood samples
               from patients with single or recurrent event VTE and healthy
               controls; RNA-sequencing data of human peripheral blood
               mononuclear cells (PBMCs) from patients with and without
               obstructive CAD; and RNA-sequencing data of platelets from
               COVID-19 subjects and healthy controls. We found similar immune
               dysregulation profiles between patients with CVDs and COVID-19
               patients. Interestingly, cardiomyopathy patients display the
               most similar immune landscape to COVID-19 patients.
               Additionally, COVID-19 patients experience greater upregulation
               of cytokine- and inflammasome-related genes than patients with
               CVDs. In all, patients with CVDs have a significant overlap of
               cytokine- and inflammasome-related gene expression profiles with
               that of COVID-19 patients, possibly explaining their greater
               vulnerability to severe COVID-19.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  6,
  pages     = "1018",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; cardiomyopathy; coronary artery disease; inflammation;
               venous thromboembolism event",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Van_Ouwerkerk2021-en,
  title     = "Prospective study into {COVID-19-like} symptoms in patients with
               and without immune-mediated inflammatory diseases or
               immunomodulating drugs",
  author    = "van Ouwerkerk, Lotte and van der Meulen-de Jong, Andrea E and
               Ninaber, Maarten K and Teng, Y K Onno and Huizinga, Tom Wj and
               Allaart, Cornelia F",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1364--1365",
  month     =  oct,
  year      =  2021,
  keywords  = "Covid-19; antirheumatic agents; autoimmune diseases",
  language  = "en"
}

@ARTICLE{Haskin2021-bj,
  title     = "Serological response to the {BNT162b2} {COVID-19} {mRNA} vaccine
               in adolescent and young adult kidney transplant recipients",
  author    = "Haskin, Orly and Ashkenazi-Hoffnung, Liat and Ziv, Noa and
               Borovitz, Yael and Dagan, Amit and Levi, Shelly and Koren, Gili
               and Hamdani, Gilad and Levi-Erez, Daniella and Landau, Daniel
               and Alfandary, Hadas",
  abstract  = "BACKGROUND: Initial reports in adult kidney transplant
               recipients (KTR) indicate low immunogenicity after 2 doses of
               the BNT162b2 COVID-19 mRNA vaccine. We describe the
               immunogenicity of this vaccine compared to the serologic
               response in naturally infected COVID-19 positive adolescent and
               young adult KTR. METHODS: For this prospective observational
               study, the study group included 38 KTR who received 2 doses of
               the tested vaccine, and the control group included 14 KTR who
               had a previous polymerase chain reaction-confirmed COVID-19
               infection. RESULTS: The mean age was 18 $\pm$ 3 y. Positive
               serologic responses were observed in 63\% and 100\% of the study
               and control groups, respectively (P = 0.01). Antibody titers
               were almost 30-fold higher in the control than the study group
               (median [interquartile range (IQR)]: 2782 [1908-11 000] versus
               100.3 [4.7-1744] AU/mL, P < 0.001), despite the longer time from
               the COVID-19 infection to serologic testing compared to time
               from vaccination (median [IQR]: 157.5 [60-216] versus 37
               [20.5-53] d, P = 0.011). Among vaccinated patients, higher
               proportions of those seronegative than seropositive were
               previously treated with rituximab (50\% versus 8\%, P = 0.01).
               Time from the second vaccine dose to serologic testing was
               longer in seropositive than seronegative patients (median [IQR]:
               24.5 [15-40] versus 46 [27-56] d, P = 0.05). No patient
               developed symptomatic COVID-19 disease postvaccination.
               CONCLUSIONS: The BNT162b2 COVID-19 mRNA vaccine yielded higher
               positive antibody response in adolescent and young adult KTR
               than previously reported for adult KTR. Antibody titers after
               vaccination were significantly lower than following COVID-19
               infection. Longer time may be required to mount appropriate
               humoral immunity to vaccination in KTR.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  11,
  pages     = "e226--e233",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Maricic2020-wi,
  title     = "A direct {RT-qPCR} approach to test large numbers of individuals
               for {SARS-CoV-2}",
  author    = "Maricic, Tomislav and Nickel, Olaf and Aximu-Petri, Ayinuer and
               Essel, Elena and Gansauge, Marie and Kanis, Philipp and Macak,
               Dominik and Richter, Julia and Riesenberg, Stephan and
               Bokelmann, Lukas and Zeberg, Hugo and Meyer, Matthias and Borte,
               Stephan and P{\"a}{\"a}bo, Svante",
  abstract  = "SARS-CoV-2 causes substantial morbidity and mortality in elderly
               and immunocompromised individuals, particularly in retirement
               homes, where transmission from asymptomatic staff and visitors
               may introduce the infection. Here we present a cheap and fast
               screening method based on direct RT-qPCR to detect SARS-CoV-2 in
               single or pooled gargle lavages (``mouthwashes''). This method
               detects individuals with large viral loads (Ct$\leq$29) and we
               use it to test all staff at a nursing home daily over a period
               of three weeks in order to reduce the risk that the infection
               penetrates the facility. This or similar approaches can be
               implemented to protect hospitals, nursing homes and other
               institutions in this and future viral epidemics.",
  journal   = "PLoS One",
  publisher = "Public Library of Science (PLoS)",
  volume    =  15,
  number    =  12,
  pages     = "e0244824",
  month     =  dec,
  year      =  2020,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Bulbuloglu2021-jf,
  title     = "The effect of immunosuppressive therapy after liver
               transplantation on activities of daily living and fear of death
               during the {COVID-19} pandemic",
  author    = "Bulbuloglu, Semra and Kapikiran, Gurkan",
  abstract  = "BACKGROUND: In our study, we aimed to investigate the effect of
               immunosuppressive therapy after liver transplantation on
               activities of daily living and fear of death during the COVID-19
               pandemic. METHODS: This study was conducted as a cross-sectional
               study with the participation of 213 liver transplant patients
               hospitalized in the liver transplant center of a university
               hospital. The data analysis was performed with IBM SPSS
               (Statistical Package for the Social Sciences) Statistics 25.
               RESULTS: Katz's Activities of Daily Living (ADL) were
               semi-independent and the total score was 11.07 $\pm$ 1.59, and
               the Death Attitude Profile-Revised (DAP-R) total score was
               152.23 $\pm$ 5.34. It was determined that the DAP-R score was
               around 150 points in the minimum and maximum score ranges of
               Katz ADL after liver transplantation. CONCLUSIONS: High fear of
               death threatens resilience and can make patients feel lonely,
               helpless, sad, abandoned and stressed. Clinicians should spend
               more time with their patients.",
  journal   = "Transpl. Immunol.",
  publisher = "Elsevier BV",
  volume    =  69,
  number    =  101470,
  pages     = "101470",
  month     =  dec,
  year      =  2021,
  keywords  = "Activities of daily living; Attitude to death; COVID-19;
               Immunosuppressive therapy; Liver transplantation",
  language  = "en"
}

@ARTICLE{Diebold2021-no,
  title     = "Temporal trends of {COVID-19} related in-hospital mortality and
               demographics in Switzerland - a retrospective single centre
               cohort study",
  author    = "Diebold, Matthias and Martinez, Aur{\'e}lien Emmanuel and Adam,
               Kai-Manuel and Bassetti, Stefano and Osthoff, Michael and Kassi,
               Elianne and Steiger, J{\"u}rg and Pargger, Hans and Siegemund,
               Martin and Battegay, Manuel and Khanna, Nina and Schaub, Stefan
               and Wesch, Conrad and Dickenmann, Michael and Weisser, Maja",
  abstract  = "AIMS: The aim of this study was to analyse the demographics,
               risk factors and in-hospital mortality rates of patients
               admitted with coronavirus disease 2019 (COVID-19) to a tertiary
               care hospital in Switzerland. METHODS: In this single-centre
               retrospective cohort study at the University Hospital Basel, we
               included all patients with confirmed severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2) infection hospitalised from
               27 February 2020 to 10 May 2021. Patients' characteristics were
               extracted from the electronic medical record system. The primary
               outcome of this study was temporal trends of COVID-19-related
               in-hospital mortality. Secondary outcomes were COVID-19-related
               mortality in patients hospitalised on the intensive care unit
               (ICU), admission to ICU, renal replacement therapy and length of
               hospital stay, as well as a descriptive analysis of risk factors
               for in-hospital mortality. RESULTS: During the study period we
               included 943 hospitalisations of 930 patients. The median age
               was 65 years (interquartile range [IQR] 53--76) and 63\% were
               men. The numbers of elderly patients, patients with multiple
               comorbidities and need for renal replacement therapy decreased
               from the first and second to the third wave. The median length
               of stay and need for ICU admission were similar in all waves.
               Throughout the study period 88 patients (9.3\%) died during the
               hospital stay. Crude in-hospital mortality was similar over the
               course of the first two waves (9.5\% and 10.2\%, respectively),
               whereas it decreased in the third wave (5.4\%). Overall
               mortality in patients without comorbidities was low at 1.6\%,
               but it increased in patients with any comorbidity to 12.6\%.
               Predictors of all-cause mortality over the whole period were age
               (adjusted odds ratio [aOR] per 10-year increase 1.81, 95\%
               confidence interval [CI] 1.45--2.26; p <0.001), male sex (aOR
               1.68, 95\% CI 1.00--2.82; p = 0.048), immunocompromising
               condition (aOR 2.09, 95\% CI 1.01--4.33; p = 0.048) and chronic
               kidney disease (aOR 2.25, 95\% CI 1.35--3.76; p = 0.002).
               CONCLUSION: In our study in-hospital mortality was 9.5\%, 10.2\%
               and 5.4\% in the first, second and third waves, respectively.
               Age, immunocompromising condition, male sex and chronic kidney
               disease were factors associated with in-hospital mortality.
               Importantly, patients without any comorbidity had a very low
               in-hospital mortality regardless of age.",
  journal   = "Swiss Med. Wkly",
  publisher = "EMH Swiss Medical Publishers, Ltd.",
  volume    =  151,
  pages     = "w20572",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Laracy2021-wb,
  title     = "The solid organ transplant recipient with {SARS-CoV-2} infection",
  author    = "Laracy, Justin C and Miko, Benjamin A and Pereira, Marcus R",
  abstract  = "PURPOSE OF REVIEW: The COVID-19 pandemic is a major challenge to
               global health, particularly among vulnerable populations. Here,
               we describe the emerging epidemiology and relevant data on
               treatment options for COVID-19. We discuss the implications of
               current knowledge for solid organ transplant (SOT) recipients.
               RECENT FINDINGS: Risk factors and outcomes of COVID-19 among SOT
               recipients remain uncertain, but recent data suggest similar
               outcomes to the general population. Case reports of
               donor-derived SARS-CoV-2 infection are emerging. Few studies on
               treatment of COVID-19 among SOT recipients are available, and
               therefore, general recommendations are similar to the general
               population. Vaccine efficacy in the SOT population is uncertain.
               SUMMARY: COVID-19 remains a significant threat to SOT recipients
               and studies on treatment and prevention specific to this
               population are urgently needed. Although vaccines represent the
               greatest hope to control this pandemic, their efficacy in this
               immunocompromised population is uncertain.",
  journal   = "Curr. Opin. Organ Transplant.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  26,
  number    =  4,
  pages     = "412--418",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Zafari2021-fu,
  title     = "{$B$-thalassemia} major and Coronavirus-19, mortality and
               morbidity: A systematic review study",
  author    = "Zafari, Mandana and Rad, Mohammad T S and Mohseni, Fatemeh and
               Nikbakht, Nasimeh",
  abstract  = "$\beta$-Thalassemia ($\beta$-thal) is one of the most common
               inherited diseases all over the world. These patients are very
               susceptible to infection disease, and the mortality and
               morbidity of infected patients will increase. The object of this
               systematic review study was to determine mortality and morbidity
               of infected $\beta$-thal patients with coronavirus disease 2019
               (COVID-19). We searched PubMed, Elsevier, and Scholar Google to
               obtain related papers. The time of search was 21 June until 17
               July 2020. All original and review articles and case reports
               were searched with key words: COVID 19, beta or
               $\beta$-thalassemia ($\beta$-thal), mortality and morbidity.
               Data were extracted after quality assessment of all articles. We
               obtained seven, 21 and six articles from PubMed, Scholar Google
               and Science Direct, respectively. Finally, seven articles were
               discussed in our study. The total number of enrolled patients
               was 34. Twenty-six patients carried transfusion-dependent
               $\beta$-thal major ($\beta$-TM). The most common symptoms were
               fever, cough, pain and dyspnea. Nine patients died. The result
               of this study has shown that the mortality and morbidity of
               infected $\beta$-thal patients will escalate.",
  journal   = "Hemoglobin",
  publisher = "Informa UK Limited",
  volume    =  45,
  number    =  1,
  pages     = "1--4",
  month     =  jan,
  year      =  2021,
  keywords  = "coronavirus-19 (COVID-19); morbidity; mortality;
               $\beta$-Thalassemia major ($\beta$-TM)",
  language  = "en"
}

@ARTICLE{Cajamarca-Baron2021-de,
  title     = "{SARS-CoV-2} ({COVID-19}) in patients with some degree of
               immunosuppression",
  author    = "Cajamarca-Baron, Jairo and Guavita-Navarro, Diana and
               Buitrago-Bohorquez, Jhon and Gallego-Cardona, Laura and Navas,
               Angela and Cubides, Hector and Arredondo, Ana Mar{\'\i}a and
               Escobar, Alejandro and Rojas-Villarraga, Adriana",
  abstract  = "BACKGROUND: It is not clear whether patients with some degree of
               immunosuppression have worse outcomes in SARS-CoV-2 infection,
               compared to healthy people. OBJECTIVE: To carry out a narrative
               review of the information available on infection by SARS-CoV-2
               in immunosuppressed patients, especially patients with cancer,
               transplanted, neurological diseases, primary and secondary
               immunodeficiencies. RESULTS: Patients with cancer and recent
               cancer treatment (chemotherapy or surgery) and SARS-CoV-2
               infection have a higher risk of worse outcomes. In transplant
               patients (renal, cardiac and hepatic), with neurological
               pathologies (multiple sclerosis (MS), neuromyelitis optica
               (NMODS), myasthenia gravis (MG)), primary immunodeficiencies and
               infection with human immunodeficiency virus (HIV) in association
               with immunosuppressants, studies have shown no tendency for
               worse outcomes. CONCLUSION: Given the little evidence we have so
               far, the behaviour of SARS-CoV-2 infection in immunosuppressed
               patients is unclear, but current studies have not shown worse
               outcomes, except for patients with cancer.",
  journal   = "Reumatol. Cl{\'\i}n. (Engl. Ed.)",
  publisher = "Elsevier BV",
  volume    =  17,
  number    =  7,
  pages     = "408--419",
  month     =  aug,
  year      =  2021,
  keywords  = "Cancer; Coronavirus; C{\'a}ncer; Diseases of the nervous system;
               Enfermedades del sistema nervioso; Enfermedades reum{\'a}ticas;
               Human immunodeficiency virus; Immunosuppression;
               Inmunosupresi{\'o}n; Rheumatic diseases; Transplantation;
               Trasplante; Virus de la inmunodeficiencia humana",
  language  = "en"
}

@ARTICLE{Gundavda2021-ds,
  title     = "Cancer or {COVID-19}? A review of recommendations for {COVID-19}
               vaccination in cancer patients",
  author    = "Gundavda, Manit K and Gundavda, Kaival K",
  abstract  = "OPINION STATEMENT: While emergency use is authorized for
               numerous COVID-19 vaccines and the high-risk population
               including cancer patients or those with immunosuppression due to
               disease or therapy is prioritized, data on this group's specific
               safety and efficacy of these vaccines remains limited. Safety
               data from clinical trials and population data may be
               extrapolated, and these vaccines may be used for cancer
               patients. However, concerns of efficacy due to the variable
               immune response in patients with active cancers undergoing
               active therapy and cancer survivors with chronic
               immunosuppression remain. The authors aim to discuss the current
               recommendations for use of COVID-19 vaccination in patients with
               cancer.",
  journal   = "Curr. Treat. Options Oncol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  22,
  number    =  10,
  pages     = "95",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 vaccination; Cancer care; Expert recommendations;
               Medical oncology treatments; Prevention of SARS-CoV-2 infection;
               Safety and efficacy",
  language  = "en"
}

@ARTICLE{Ebeid2021-xp,
  title     = "{COVID-19} in children with cancer: A single low-middle income
               center experience",
  author    = "Ebeid, Fatma S E and Ragab, Iman A and Elsherif, Nayera H K and
               Makkeyah, Sara and Mostafa, Salwa and Eltonbary, Khadiga and
               Matbouly, Safa and Mostafa, Aya and Goma, Heba and Agwa, Sara H
               and Hafez, Hala M and Girgis, Samia and El Gendy, Yasmin G and
               El-Sayed, Manal H",
  abstract  = "BACKGROUND: Coronavirus disease-2019 (COVID-19) could be
               associated with morbidity and mortality in immunocompromised
               children. OBJECTIVE: The objective of this study was to measure
               the frequency of severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) infection among hospitalized children with cancer
               and to detect the associated clinical manifestations and
               outcomes. METHODOLOGY: A prospective noninterventional study
               including all hospitalized children with cancer conducted
               between mid-April and mid-June 2020 in Ain Shams University
               Hospital, Egypt. Clinical, laboratory, and radiologic data were
               collected. SARS-CoV-2 infection was diagnosed by reverse
               transcription polymerase chain reaction tests in nasopharyngeal
               swabs. RESULTS: Fifteen of 61 hospitalized children with cancer
               were diagnosed with SARS-CoV-2. Their mean age was 8.3$\pm$3.5
               years. Initially, 10 (66.7\%) were asymptomatic and 5 (33.3\%)
               were symptomatic with fever and/or cough. Baseline laboratory
               tests other than SARS-CoV-2 reverse transcription polymerase
               chain reaction were not diagnostic; the mean absolute lymphocyte
               count was 8.7$\pm$2.4$\times$109/L. C-reactive protein was
               mildly elevated in most of the patients. Imaging was performed
               in 10 (66.7\%) patients with significant radiologic findings
               detected in 4 (40\%) patients. Treatment was mainly supportive
               with antibiotics as per the febrile neutropenia protocol and
               local Children Hospital guidance for management of COVID-19 in
               children. CONCLUSIONS: Pediatric cancer patients with COVID-19
               were mainly asymptomatic or with mild symptoms. A high index of
               suspicion and regular screening with nasopharyngeal swab in
               asymptomatic hospitalized cancer patients is recommended.",
  journal   = "J. Pediatr. Hematol. Oncol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  43,
  number    =  8,
  pages     = "e1077--e1081",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Perez-Gonzalez2021-bu,
  title    = "Hepatic transplant during {SARS-CoV-2} ({COVID-19}) pandemic. A
              literature review",
  author   = "P{\'e}rez-Gonz{\'a}lez, Bernardo and Thomas-Lora, Freyris C and
              Hoyo, Irma and Flores-Garc{\'\i}a, Nayelli C and
              Rodr{\'\i}guez-Aguilar, Erika F and P{\'a}ez-Zayas, V{\'\i}ctor M
              and M{\'a}rquez-Guill{\'e}n, Ernesto and Visag-Castillo,
              V{\'\i}ctor and Garc{\'\i}a-Ju{\'a}rez, Ignacio and Contreras,
              Alan G",
  abstract = "ANTECEDENTES: En diciembre de 2019 se identific{\'o} en la ciudad
              de Wuhan, China, un nuevo beta coronavirus, el SARS-CoV-2, como
              agente causal de neumon{\'\i}a grave, conocida como COVID-19, lo
              cual ha provocado medidas estrictas de aislamiento, cierre de
              programas de trasplante hep{\'a}tico y la necesidad de modificar
              los protocolos de tratamiento. OBJETIVO: Documentar la
              informaci{\'o}n publicada sobre el impacto de la COVID-19 en la
              poblaci{\'o}n con antecedente de trasplante hep{\'a}tico y
              establecer un protocolo de tratamiento. M{\'E}TODO: Se buscaron
              en PubMed los t{\'e}rminos MeSH ``SARS-CoV-2'', ``COVID-19'',
              ``trasplante hep{\'a}tico'' y ``tratamiento''. RESULTADOS: Hasta
              el momento se ha demostrado en la poblaci{\'o}n con trasplante
              hep{\'a}tico una mayor facilidad para adquirir el virus, sin una
              diferencia en la mortalidad al compararla con la poblaci{\'o}n
              general. La inmunosupresi{\'o}n debe continuar, sin suspender los
              inhibidores de la calcineurina. Del tratamiento espec{\'\i}fico,
              los esteroides son los que han demostrado el mayor beneficio
              cl{\'\i}nico y una disminuci{\'o}n de la mortalidad.
              CONCLUSI{\'O}N: El trasplante hep{\'a}tico no se asocia de manera
              independiente a una mayor mortalidad. Otros factores, adem{\'a}s
              del trasplante, deben tomarse en cuenta al momento de establecer
              la gravedad. BACKGROUND: In December 2019, a new beta
              coronavirus, SARS-CoV-2, was identified in the city of Wuhan,
              China, as a causative agent of severe pneumonia, known as
              COVID-19, which has led to strict isolation measures, closure of
              liver transplantation programs and the need to modify treatment
              protocols. OBJECTIVE: Document the information published so far
              on the impact of COVID-19 in the population with a history of
              liver transplantation and establish a treatment protocol. METHOD:
              MeSH terms were searched for ``SARS-CoV-2'', ``COVID-19'',
              ``liver transplantation'' and ``treatment''. RESULTS: Up to now,
              a greater ease in acquiring the virus has been shown in the liver
              transplant population, without a difference in mortality when
              compared to the general population. Immunosuppression should
              continue at the minimum tolerated levels, without suspending
              calcineurin inhibitors. Of the specific treatment, steroids are
              those that have shown the greatest clinical benefit and decreased
              mortality. CONCLUSION: Liver transplantation is not independently
              associated with higher mortality. Factors other than
              transplantation must be taken into account when considering the
              risk of severity.",
  journal  = "Cir. Cir.",
  volume   =  89,
  number   =  2,
  pages    = "269--274",
  year     =  2021,
  keywords = "COVID-19; Liver transplant; Trasplante hep{\'a}tico; Tratamiento;
              Treatment",
  language = "en"
}

@ARTICLE{Deborska-Materkowska2021-ui,
  title     = "The immunology of {SARS-CoV-2} infection and vaccines in solid
               organ transplant recipients",
  author    = "D{\k e}borska-Materkowska, Dominika and Kami{\'n}ska, Dorota",
  abstract  = "Since its outbreak in December 2019, the coronavirus disease
               2019 (COVID-19) pandemic, caused by severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2), led to an enormous rise in
               scientific response with an excess of COVID-19-related studies
               on the pathogenesis and potential therapeutic approaches. Solid
               organ transplant (SOT) recipients are a heterogeneous population
               with long-lasting immunosuppression as a joining element.
               Immunocompromised patients are a vulnerable population with a
               high risk of severe infections and an increased
               infection-related mortality rate. It was postulated that the
               hyperinflammatory state due to cytokine release syndrome during
               severe COVID-19 could be alleviated by immunosuppressive therapy
               in SOT patients. On the other hand, it was previously
               established that T cell-mediated immunity, which is
               significantly weakened in SOT recipients, is the main component
               of antiviral immune responses. In this paper, we present the
               current state of science on COVID-19 immunology in relation to
               solid organ transplantation with prospective therapeutic and
               vaccination strategies in this population.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  9,
  pages     = "1879",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; cellular immunity; humoral immunity; solid organ
               transplant recipients; vaccination",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Connors2021-ym,
  title     = "The impact of immuno-aging on {SARS-CoV-2} vaccine development",
  author    = "Connors, Jennifer and Bell, Matthew R and Marcy, Jennifer and
               Kutzler, Michele and Haddad, Elias K",
  abstract  = "The SARS-CoV-2 pandemic has almost 56 million confirmed cases
               resulting in over 1.3 million deaths as of November 2020. This
               infection has proved more deadly to older adults (those >65
               years of age) and those with immunocompromising conditions. The
               worldwide population aged 65 years and older is increasing, and
               the total number of aged individuals will outnumber those
               younger than 65 years by the year 2050. Aging is associated with
               a decline in immune function and chronic activation of
               inflammation that contributes to enhanced viral susceptibility
               and reduced responses to vaccination. Here we briefly review the
               pathogenicity of the virus, epidemiology and clinical response,
               and the underlying mechanisms of human aging in improving
               vaccination. We review current methods to improve vaccination in
               the older adults using novel vaccine platforms and adjuvant
               systems. We conclude by summarizing the existing clinical trials
               for a SARS-CoV-2 vaccine and discussing how to address the
               unique challenges for vaccine development presented with an
               aging immune system.",
  journal   = "GeroScience",
  publisher = "Springer Science and Business Media LLC",
  volume    =  43,
  number    =  1,
  pages     = "31--51",
  month     =  feb,
  year      =  2021,
  keywords  = "(4-6): SARS-CoV-2; Adjuvants; Aging; Vaccine delivery platforms;
               Vaccines",
  language  = "en"
}

@ARTICLE{Thoo2021-ir,
  title     = "Highly specific and reliable in vitro diagnostic analysis of
               memory {T} and {B} lymphocytes in a Swiss cohort of {COVID-19}
               patients",
  author    = "Thoo, Lester and Gumowski, Pierre I and Kammermann, Kevin and
               Nussli, Swelia and Grabscheid, Benno and Hausmann, Oliver and
               Axius, Ulrika and Pichler, Werner J and Yerly, Daniel",
  abstract  = "The SARS-CoV-2 pandemic has claimed many lives and disrupted the
               quality of life of most individuals. Diagnostic tests not only
               serve to confirm past exposure but can provide information
               crucial for guiding healthcare options for patients. Current
               diagnostic tests for the presence of the SARS-CoV-2 virus or
               anti-spike protein antibodies do not address the question
               whether longer lasting cellular immunity is mounted in most
               individuals. Using an activation marker flow cytometric
               immunoassay (SARS-CoV-2 lymphocytes analysis), we showed that
               both CD4+/CD8+ T cell and B cell activation differ between
               na{\"\i}ve and infected individuals up to 11 months after
               infection. On the basis of the specificity of this diagnostic
               tool for detecting both SARS-CoV-2-experienced T and B cells, we
               propose that this assay could benefit immunocompromised
               individuals who are unable to mount sustained antibody
               responses, by determining cellular immunity as possible partial
               protection, and for studying immune correlates of protection -
               thereby increasing knowledge of COVID-19 in a wider range of
               patient groups.",
  journal   = "Swiss Med. Wkly",
  publisher = "EMH Swiss Medical Publishers, Ltd.",
  volume    =  151,
  number    = "37-38",
  pages     = "w30005",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Dayco2021-uj,
  title     = "Perpetually positive: {Post-COVID} Interstitial Lung Disease in
               an immunocompromised patient with diffuse large B-cell lymphoma",
  author    = "Dayco, John S and El-Reda, Zeinab and Sumbal, Nabeel and
               Alhusain, Rashid and Raheem, Shaheena",
  abstract  = "As more patients recover from COVID-19 infection, long-term
               complications are beginning to arise. Our case report will
               explore a debilitating long-term complication, Post-COVID
               Interstitial Lung Disease (PC-ILD). We will introduce a patient
               who developed PC-ILD in the setting of diffuse large B-cell
               lymphoma, outlining a difficult hospital course, including a
               positive COVID-19 polymerase chain reaction (PCR) for more than
               3 months. We will then discuss the human body's physiological
               response to the virus and how our patient was not able to
               adequately mount an immune response. Finally, the
               pathophysiology of PC-ILD will be explored and correlated with
               the patient's subsequent computed tomographic images obtained
               over a 3-month period. The difficult hospital course and complex
               medical decision-making outlined in this case report serve as a
               reminder for health care providers to maintain vigilance in
               protecting our most vulnerable patient population from such a
               devastating disease process.",
  journal   = "J. Investig. Med. High Impact Case Rep.",
  publisher = "SAGE Publications",
  volume    =  9,
  pages     = "23247096211041207",
  month     =  jan,
  year      =  2021,
  keywords  = "geriatrics; hematology; immunology; infectious disease;
               oncology; radiology/imaging",
  language  = "en"
}

@ARTICLE{Wargo2021-iw,
  title    = "Coronavirus ({COVID-19}) infection-induced chilblains: A brisk
              perieccrine inflammatory response",
  author   = "Wargo, Jeffrey J and Weir, Nathan M and Shamma, H Nicholas",
  abstract = "ABSTRACT: The varying cutaneous and pathological manifestations
              of coronavirus 2 (SARS-CoV-2 or COVID-19) may have prognostic
              implications. Acral ischemic findings present with a
              hypercoagulable state in critically ill COVID-19 patients.
              Pathologically confirmed varicella-like exanthem and perniosis
              COVID-19 cases have correlated with paucisymptomatic and
              asymptomatic patients in previous reports. We present the second
              case of biopsy-proven COVID-19 infection-induced chilblains
              (pernio) in a paucisymptomatic patient with a brisk perieccrine
              lymphocytic response. Based on an antecedent pathological study,
              we know coronavirus particles have been seen in the eccrine gland
              associated with a brisk peri-inflammatory response. The prominent
              perieccrine inflammation is helpful in the diagnosis of COVID-19
              infections. Currently, nonischemic pathological findings
              correlate with a good prognosis based on the paucisymptomatic or
              asymptomatic nature of their disease courses. Patients presenting
              with suspected COVID-19 infection-induced chilblains who are
              paucisymptomatic or asymptomatic should be isolated and
              immediately tested with polymerase chain reaction (PCR) testing
              (as there is a delay in diagnosis based on the poor sensitivity
              of the current rapid test). We continue to stress the importance
              of early diagnosis and quarantining to prevent spread to the
              older and immunocompromised patients.",
  journal  = "Am. J. Dermatopathol.",
  volume   =  43,
  number   =  2,
  pages    = "144--145",
  month    =  feb,
  year     =  2021,
  language = "en"
}

@ARTICLE{Rubin2021-kf,
  title     = "Audio interview: Protecting the immunosuppressed against
               covid-19",
  author    = "Rubin, Eric J and Baden, Lindsey R and Morrissey, Stephen",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  384,
  number    =  21,
  pages     = "e88",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Pani2021-zr,
  title     = "Results of the {RENAISSANCE} Study: {REsponse} to {BNT162b2}
               {COVID-19} vacciNe-short- And long-term Immune {reSponSe}
               {evAluatioN} in health Care workErs",
  author    = "Pani, Arianna and Cento, Valeria and Vismara, Chiara and
               Campisi, Daniela and Di Ruscio, Federica and Romandini,
               Alessandra and Senatore, Michele and Schenardi, Paolo Andrea and
               Gagliardi, Oscar Matteo and Giroldi, Simona and Zoppini, Laura
               and Moreno, Mauro and Corradin, Matteo and Epis, Oscar
               Massimiliano and Ughi, Nicola and Cuppari, Irene and Crocchiolo,
               Roberto and Merli, Marco and Bosio, Marco and Rossini, Silvano
               and Puoti, Massimo and Scaglione, Francesco",
  abstract  = "OBJECTIVE: To evaluate the severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) anti-spike (S) IgG antibody
               production after vaccination with BNT162b2 and the protection
               from symptomatic breakthrough infections in health care workers.
               METHODS: This prospective observational study (RENAISSANCE) had
               as a primary end point the evaluation of serologic response to
               BNT162b2 14 days after a second dose. SARS-CoV-2 anti-S IgG
               antibodies were evaluated with LIAISON SARS-CoV-2 TrimericS IgG
               assay (DiaSorin S.p.A.), which is able to detect the presence of
               both binding and neutralizing antibodies for trimeric spike
               glycoprotein. Participants were recruited from February 1, 2021,
               to February 22, 2021. Occurrence of vaccine breakthrough
               infections was assessed by reverse transcription-polymerase
               chain reaction on symptomatic and contact cases up to June 6,
               2021. RESULTS: Of 2569 staff evaluated, only 4 were
               nonresponders (0.16\%; 95\% CI, 0.04\% to 0.41\%). All 4
               nonresponders were severely immunosuppressed and receiving
               treatment with mycophenolate mofetil or mycophenolic acid. At 14
               days after the second dose, 67.5\% (1733) of staff had anti-S
               IgG titers of 2000 BAU/mL or higher; 19.2\% (494), between 1500
               and 2000 BAU/mL; 9.8\% (251), between 1000 and 1500 BAU/mL; and
               3.4\% (87), 1000 BAU/mL or lower. Women had a higher probability
               of having higher titers than men (64.5\% [1044/1618] vs 58.3\%
               [410/703]; P=.005). This was confirmed after adjustment for age
               group (odds ratio, 1.275; 95\% CI, 1.062 to 1.531; P=.009). Four
               months after the end of the vaccination program, only 13
               participants (0.26\%) had experienced a breakthrough SARS-CoV-2
               infection, including 1 nonresponder. This was the only
               participant requiring hospitalization for severe COVID-19.
               CONCLUSION: The vaccination campaign among health care workers
               at the ASST GOM Niguarda has resulted in a marked serologic
               response and reduction of incident COVID-19 cases. Yet, the lack
               of protection should not be overlooked in immunocompromised
               individuals.",
  journal   = "Mayo Clin. Proc.",
  publisher = "Elsevier BV",
  volume    =  96,
  number    =  12,
  pages     = "2966--2979",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Weinstock-Guttman2021-ne,
  title     = "Late-onset cutaneous reaction to {BNT162b2} {mRNA} {COVID-19}
               vaccine in an immunocompromised patient",
  author    = "Weinstock-Guttman, Bianca and Jakimovski, Dejan",
  journal   = "Mult. Scler.",
  publisher = "SAGE Publications",
  volume    =  27,
  number    =  14,
  pages     = "2291--2292",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Elcioglu2021-xa,
  title     = "{COV{\.I}D-19} infection in a membranous nephropathy patient
               treated with rituximab",
  author    = "Elcioglu, Omer Celal and Artan, Ayse Serra and Mirioglu, Safak
               and Gursu, Meltem and Durdu, Bulent and Meric Koc, Meliha and
               Okyaltirik, Fatmanur and Gultekin, Mehmet Ali and Kazancioglu,
               Rumeyza",
  abstract  = "While COVID-19 pandemic continues to affect our country and most
               countries in the world, we have to make some changes both in our
               social life and our approach to healthcare. We have to struggle
               with the pandemic on one hand and also try to follow up and
               treat our patients with chronic diseases in the most appropriate
               way. In this period, one of our group of patients who are
               challenging us for follow-up and treatment are those who should
               start or continue to use immunosuppressive therapy. In order to
               contribute to the accumulation of knowledge in this area, we
               wanted to report a patient who was followed up with the
               diagnosis of COVID-19 and had been administered rituximab very
               recently due to a nephrotic syndrome caused by membranous
               nephropathy.",
  journal   = "CEN Case Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  10,
  number    =  1,
  pages     = "83--87",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus; Immunosuppression; Membranous
               nephropathy; Rituximab",
  language  = "en"
}

@ARTICLE{Park2021-xc,
  title     = "{COVID-19} vaccination in patients with autoimmune inflammatory
               rheumatic diseases: Clinical guidance of the Korean College of
               Rheumatology",
  author    = "Park, Jin Kyun and Lee, Eun Bong and Shin, Kichul and Sung, Yoon
               Kyoung and Kim, Tae Hwan and Kwon, Seong Ryul and Lee, Myeung Su
               and Hong, Seung Jae and Choi, Byoong Yong and Lee, Shin Seok and
               Back, Han Joo and {Korean College of Rheumatology Task Force for
               COVID-19 Vaccine Guidance for Patients with Autoimmune
               Inflammatory Rheumatic Diseases}",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has caused more
               than 100 million infections and 2 million deaths worldwide. In
               up to 20\% of cases, COVID-19 infection can take a severe,
               life-threatening course. Therefore, preventive measures such as
               mask-wearing, hand hygiene, and social distancing are important.
               COVID-19 vaccines that use novel vaccine technology can prevent
               up to 95\% of infections. However, the uncertainty regarding the
               efficacy and safety of vaccination in patients with autoimmune
               inflammatory rheumatic disease (AIIRD), who are
               immunocompromised due to underlying immune dysfunction and
               concomitant immunosuppressive treatment, warrants clear
               guidance. A task force of the Korean College of Rheumatology
               formulated a set of vaccination guidance based on the currently
               available data and expert consensus. The currently available
               COVID-19 vaccines are considered to be safe and effective. Every
               patient with AIIRD should receive one of the available COVID-19
               vaccines unless contraindicated for medical reasons such as
               prior allergy/anaphylaxis to the COVID-19 vaccine or its
               components. Patients should continue immunosuppressive treatment
               for their underlying AIIRD, including biological and targeted
               synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs).
               Corticosteroids should be reduced to the lowest dose possible
               without aggravating the AIIRD. To improve the vaccine response,
               methotrexate can be withheld for 1-2 weeks after each
               vaccination, and the timing of rituximab and abatacept infusion
               should be adjusted if clinically acceptable. Rheumatologists
               should play a leading role in educating and vaccinating patients
               with AIIRD.",
  journal   = "J. Korean Med. Sci.",
  publisher = "Korean Academy of Medical Sciences",
  volume    =  36,
  number    =  12,
  pages     = "e95",
  month     =  mar,
  year      =  2021,
  keywords  = "Autoimmune Inflammatory Rheumatic Diseases; COVID-19;
               Immunosuppression; Vaccines",
  language  = "en"
}

@ARTICLE{Dheir2021-dl,
  title     = "Clinical course of {COVID-19} disease in immunosuppressed renal
               transplant patients",
  author    = "Dheir, Hamad and Sipahi, Sava{\c s} and Yaylac{\i}, Sel{\c c}uk
               and {\c C}etin, Esma Seda and Gen{\c c}, Ahmed Bilal and
               F{\i}rat, Necattin and K{\"o}ro{\u g}lu, Mehmet and Muratda{\u
               g}{\i}, G{\"u}rkan and Tomak, Yakup and {\"O}zmen, Kezban and
               Ate{\c s}, {\"O}mer Faruk and Karabay, O{\u g}uz",
  abstract  = "Background/aim: We aimed to identify clinical settings of renal
               transplant patients with COVID-19. Materials and methods: In
               this retrospective study, we included kidney transplant
               inpatients with laboratory confirmed COVID-19 who had been
               discharged or had died by October 1st, 2020. Characteristics of
               the patients, including basal and last outpatient biochemical
               parameters were recorded. Discontinuation or dosage reduction of
               immunosuppressives and other treatment information was
               documented. Results: Twenty patients were included in this
               study, of whom 18 were discharged and 2 died in hospital. The
               mean duration of hospitalization and follow-up were 9.7 $\pm$
               6.4 days and 4.5 $\pm$ 2.0 months, respectively. Fourteen
               patients (70\%) were male and mean age was 48.0 $\pm$ 10.3
               years. At admission, all had immunosuppression withdrawn and
               were started on methylprednisolone 16 mg/ day (50\%) or
               dexamethasone (50\%). Tacrolimus/m-TOR inhibitors were reduced
               by 50\% and all antimetabolites were discontinued. Hemodialysis
               was needed for 10\% of patients. Acute kidney injury was
               detected in 25\% of the patients. With respect to
               hospitalization time and complications, there was no significant
               difference between patients who used dexamethasone and those who
               did not (P > 0.05). The discontinued immunosuppressives were
               resumed within 2 to 4 weeks after discharge according to the
               severity of disease. No rehospitalization or acute rejection was
               detected during the follow-up of the patients. Conclusion: Renal
               transplant patients are considered a high risk group for
               COVID-19. It can be said that discontinuation or reducing
               dosages of immunosuppressives may be effective and safe in
               kidney transplant patients.",
  journal   = "Turk. J. Med. Sci.",
  publisher = "The Scientific and Technological Research Council of Turkey
               (TUBITAK-ULAKBIM)",
  volume    =  51,
  number    =  2,
  pages     = "428--434",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; acute rejection; immunosuppression; kidney
               transplantation; mortality",
  language  = "en"
}

@ARTICLE{Fernandez-Ruiz2021-si,
  title     = "Severe acute respiratory syndrome coronavirus 2 infection in the
               stem cell transplant recipient - clinical spectrum and outcome",
  author    = "Fern{\'a}ndez-Ruiz, Mario and Aguado, Jos{\'e} Mar{\'\i}a",
  abstract  = "PURPOSE OF REVIEW: Focusing on large multicenter cohorts
               reported over the last months, this review aims at summarizing
               the available evidence by July 2021 on the impact of coronavirus
               disease 2019 (COVID-19) on hematopoietic stem cell transplant
               (HSCT) recipients in terms of epidemiology, clinical features,
               and outcome. RECENT FINDINGS: The incidence of COVID-19 in
               institutional cohorts varied according to different regions and
               study periods from 0.4\% to 8.3\%. Clinical presentation was
               overall comparable to other immunocompromised hosts and the
               general population. Microbiologically confirmed superinfection
               occurred in 13-25\% of recipients, with most episodes due to
               hospital-acquired bacteria and few reported cases of
               COVID-19-associated aspergillosis. Prolonged nasopharyngeal
               severe acute respiratory syndrome coronavirus 2 shedding has
               been demonstrated for as long as 210 days. Mortality rates were
               similar across studies (14.8-28.4\%) and did not markedly differ
               from those observed in nontransplant hematological patients
               during the first wave. Older age and shorter time from
               transplantation were associated with mortality, as well as
               underlying disease status and amount of immunosuppression. No
               outcome differences were found in most studies between
               allogeneic and autologous procedures. SUMMARY: Considerable
               advances have been achieved in the characterization of COVID-19
               in the HSCT population, although uncertainties remain in the
               optimal therapeutic management.",
  journal   = "Curr. Opin. Infect. Dis.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  34,
  number    =  6,
  pages     = "654--662",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Lombardi2021-lk,
  title     = "Mini review immunological consequences of immunization with
               {COVID-19} {mRNA} vaccines: Preliminary results",
  author    = "Lombardi, Andrea and Bozzi, Giorgio and Ungaro, Riccardo and
               Villa, Simone and Castelli, Valeria and Mangioni, Davide and
               Muscatello, Antonio and Gori, Andrea and Bandera, Alessandra",
  abstract  = "Background: BNT162b2 and mRNA-1273 are the two recently approved
               mRNA-based vaccines against COVID-19 which has shown excellent
               safety and efficacy. Preliminary data about specific and
               neutralizing antibodies is available covering the first 100 days
               after vaccination. Methods: We reviewed all the publications
               regarding the immunologic consequences of BNT162b2 and mRNA-1273
               vaccination. A summary of specific antibodies concentration and
               neutralizing antibodies titers elicited by each vaccine is
               provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring
               safety and efficacy profile, with the latter above 94\%. They
               can elicit specific antibodies titers and neutralizing
               antibodies concentrations that are far superior from those
               observed among COVID-19 human convalescent serum, across a wide
               span of age, for at least 100 days after vaccination. Moreover,
               the vaccine-induced T cellular response is oriented toward a TH1
               response and no evidence of vaccine-enhanced disease have been
               reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific
               antibodies titers and neutralizing antibodies concentrations
               above those observed among COVID-19 human convalescent serum in
               the first 100 days after vaccination. Data about vaccine
               efficacy in those with previous COVID-19 or immunocompromised is
               still limited.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "657711",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; CTL; RNA vaccine; SARS-CoV-2; antibodies;
               neutralization test",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Marko2021-sp,
  title     = "Can we safely use systemic treatment in atopic dermatitis during
               the {COVID-19} pandemic? Overview of selected conventional and
               biologic systemic therapies",
  author    = "Marko, Monika and Pawliczak, Rafa{\l}",
  abstract  = "Introduction: Since the onset of the coronavirus disease 2019
               (COVID-19) pandemic, the medical community has faced major
               challenges that affect disease management in all areas.
               Dermatologists and immunologists have to choose appropriate
               treatment strategy taking into consideration the risk of
               infection and possible exacerbation of the course of the disease
               in patients with confirmed infection. Management of atopic
               dermatitis (AD) in moderate to severe cases is based on systemic
               therapy such as cyclosporine, azathioprine, methotrexate and
               dupilumab.Areas covered: A literature search in PubMed database
               was performed until 6 March 2021. In this review, the authors
               discuss non-biologic and biologic systemic medications for AD
               and provide an overview of therapeutic recommendations during
               COVID-19 pandemic.Expert opinion: In case of an active COVID-19
               infection, conventional systemic treatment and biological
               treatment needs to be stopped until clinical recovery.
               Noninfected patients with systemic treatment of AD should
               continue their therapy via self-application. The authors can
               conclude that understanding of dupilumab therapy is better
               recognized in context AD treatment during COVID-19 pandemic in
               comparison to cyclosporine, azathioprine and methotrexate.
               However, this systemic immunosuppressants still require further
               investigation and literature complementation.",
  journal   = "Expert Rev. Clin. Immunol.",
  publisher = "Informa UK Limited",
  volume    =  17,
  number    =  6,
  pages     = "619--627",
  month     =  jun,
  year      =  2021,
  keywords  = "Atopic dermatitis; Covid-19; azathioprine; cyclosporine;
               dupilumab; methotrexate; systemic treatment",
  language  = "en"
}

@ARTICLE{Wozniak2021-dp,
  title     = "Telemedicine health disparities in oncology care",
  author    = "Wozniak, Anna Maria and Rallis, Kathrine S and Elkaddoum,
               Ronaldo",
  journal   = "Future Oncol.",
  publisher = "Future Medicine Ltd",
  volume    =  17,
  number    =  14,
  pages     = "1695--1698",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; cancer care; coronavirus disease 2019; e-health;
               health inequalities; oncology; social disparities;
               teleconsultation; telemedicine; teleoncology",
  language  = "en"
}

@ARTICLE{Ismaiel2021-gr,
  title     = "The impact of {COVID-19} outbreak on the incidence of acute
               invasive fungal rhinosinusitis",
  author    = "Ismaiel, Wael F and Abdelazim, Mohamed H and Eldsoky, Ibrahim
               and Ibrahim, Ahmed A and Alsobky, Mahmoud E and Zafan, Ebtesam
               and Hasan, Abdulkarim",
  abstract  = "BACKGROUND: Acute invasive fungal rhinosinusitis (AIFRS) is
               aggressive morbidity affecting immunocompromised patients.
               Coronavirus disease 2019 (COVID-19) may allow secondary fungal
               disease through a propensity to cause respiratory infection by
               affecting the immune system leading to dysregulation and reduced
               numbers of T lymphocytes, CD4+T, and CD8+T cells, altering the
               innate immunity. The aim of this study is to evaluate the
               incidence of acute invasive fungal rhinosinusitis (AIFRS) in
               COVID-19 patients. METHODOLOGY: Data for acute invasive
               rhinosinusitis was obtained from the Otorhinolaryngology
               departments at our tertiary hospital at the period from January
               2017 to December 2020. Then the risk factors of comorbid
               diseases and fungal types between post-COVID-19 and non-COVID-19
               groups regarding the incidence of AIFRS are compared. RESULTS:
               Consequently, the incidence of AIFRS showed a more significant
               difference (P < 0.05) in post-COVID-19 patients than in
               non-COVID-19 especially in immunocompromised patients, diabetic,
               renal, and liver dysfunction patients as well as patients with
               risk factors of AIFRS. The most common organisms affecting
               patients with AIFRS are Rhizopus oryzae, Aspergillus fumigatus,
               and Absidia mucor. CONCLUSIONS: The incidence of AIFRS is
               markedly prominent in post-COVID-19 patients than in those of
               non-COVID-19, especially in immunocompromised, diabetic, renal,
               and liver dysfunction patients and patients with risk factors
               for rhinosinusitis.",
  journal   = "Am. J. Otolaryngol.",
  publisher = "Elsevier BV",
  volume    =  42,
  number    =  6,
  pages     = "103080",
  month     =  nov,
  year      =  2021,
  keywords  = "Coronavirus; Fungal; Immunocompromised; Rhinosinusitis",
  language  = "en"
}

@ARTICLE{Papautsky2021-lt,
  title     = "Emotional response of {US} breast cancer survivors during the
               {COVID-19} pandemic",
  author    = "Papautsky, Elizabeth Lerner and Hamlish, Tamara",
  abstract  = "In a sample of 633 US adult breast cancer survivors, we examined
               health-related worry as a function vulnerability as influenced
               by communication, trust, and planning with their cancer care
               team during the COVID-19 pandemic. We found significant positive
               correlations between communication and trust, communication and
               planning, and trust and planning. ANCOVAs with treatment status,
               immunocompromised status, and delays (separately) as IVs, trust
               as a covariate, and cancer-related worry as a DV, yielded
               significant models. A noteworthy finding is the presence of
               trust as a significant covariate in models of vulnerability and
               worry.",
  journal   = "Cancer Invest.",
  publisher = "Informa UK Limited",
  volume    =  39,
  number    =  1,
  pages     = "3--8",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; breast cancer; survey research; trust; worry",
  language  = "en"
}

@ARTICLE{Agrati2021-hs,
  title     = "{COVID-19} vaccination in fragile patients: Current evidence and
               an harmonized transdisease trial",
  author    = "Agrati, Chiara and Di Cosimo, Serena and Fenoglio, Daniela and
               Apolone, Giovanni and Ciceri, Fabio and Ciliberto, Gennaro and
               Baldanti, Fausto and Costantini, Massimo and Giannarelli, Diana
               and Ippolito, Giuseppe and Locatelli, Franco and Mantovani,
               Alberto and Morrone, Aldo and Tagliavini, Fabrizio and Uccelli,
               Antonio and Zinzani, Pier Luigi and Silvestris, Nicola and
               Rescigno, Maria",
  abstract  = "Patients diagnosed with malignancy, neurological and
               immunological disorders, i.e., fragile patients, have been
               excluded from COVID-19 vaccine trials. However, this population
               may present immune response abnormalities, and relative reduced
               vaccine responsiveness. Here we review the limited current
               evidence on the immune responses to vaccination of patients with
               different underlying diseases. To address open questions we
               present the VAX4FRAIL study aimed at assessing immune responses
               to vaccination in a large transdisease cohort of patients with
               cancer, neurological and rheumatological diseases.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "704110",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; cancer; immunocompromised; myasthenia;
               vaccine",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Solomon2021-ty,
  title     = "An early experience of {COVID-19} disease in pediatric and young
               adult renal transplant recipients",
  author    = "Solomon, Sonia and Pereira, Tanya and Samsonov, Dmitry",
  abstract  = "BACKGROUND: COVID-19 is caused by a novel form of coronavirus
               known as SARS-CoV-2. Patients can present with a wide variety of
               symptoms from fever to severe respiratory distress.
               Immunocompromised patients, including solid organ transplant
               recipients, may present with atypical symptoms, making the
               diagnosis of COVID-19 more difficult to make. New reports have
               been emerging about the management of COVID-19 disease in adult
               renal transplant recipients. However, very little is known in
               pediatric renal transplant recipients. METHODS: Here, we
               describe a case report of four pediatric renal transplant
               recipients who presented with mild-to-moderate COVID-19 disease.
               RESULTS: All patients presented with upper respiratory infection
               symptoms, with one requiring hospitalization for hypoxia.
               Patients were treated mostly with supportive care. Two of the
               patients developed AKI which resolved four to eight weeks after
               illness. All four patients developed COVID IgG antibodies one to
               two months after becoming infected. CONCLUSION: This case series
               demonstrates that immunocompromised renal transplant recipients
               have comparable outcomes compared with immunocompetent children.",
  journal   = "Pediatr. Transplant.",
  publisher = "Wiley",
  volume    =  25,
  number    =  5,
  pages     = "e13972",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; pediatrics; renal transplant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Chela2021-lv,
  title     = "A review on medical management of inflammatory bowel disease
               during the coronavirus disease 2019 pandemic",
  author    = "Chela, Harleen and Pasha, Syed Bilal and Wan, Xiu-Feng and
               Ghouri, Yezaz A",
  abstract  = "The coronavirus disease 2019 pandemic has engulfed the world and
               is the highlight of medical community at this time. As humanity
               fights the battle against this virus, questions are arising
               regarding the appropriate management of at risk patient
               populations. The immunocompromised cohort is particularly
               susceptible to this infection, and we have tried to explore the
               medical management of one such group, which is composed of
               individuals with inflammatory bowel disease (IBD). There is
               limited data on the management of IBD during the ongoing
               pandemic. Several medical societies have put forth suggestions
               on how to manage immunocompromised patients in order to minimize
               risk of developing coronavirus disease 2019. This review aims to
               present available recommendations from experts and provides an
               insight on preventive and therapeutic strategies that can be
               implemented for the medical management of patients with IBD. We
               anticipate that as more information arises, new guidelines will
               emerge.",
  journal   = "J. Gastroenterol. Hepatol.",
  publisher = "Wiley",
  volume    =  36,
  number    =  4,
  pages     = "918--926",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Corona virus; Crohn's disease; Immunosuppressant;
               Inflammatory bowel diseases; SARS-CoV-2; Ulcerative colitis",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Chavarot2021-it,
  title     = "{COVID-19} severity in kidney transplant recipients is similar
               to nontransplant patients with similar comorbidities",
  author    = "Chavarot, Nathalie and Gueguen, Juliette and Bonnet, Guillaume
               and Jdidou, Mariam and Trimaille, Antonin and Burger, Carole and
               Amrouche, Lucile and Weizman, Orianne and Pommier, Thibaut and
               Aubert, Olivier and Celier, Joffrey and Sberro-Soussan, Rebecca
               and Geneste, Laura and Panagides, Vassili and Delahousse, Michel
               and Marsou, Wassima and Aguilar, Claire and Deney, Antoine and
               Zuber, Julien and Fauvel, Charles and Legendre, Christophe and
               Mika, Delphine and Pezel, Theo and Anglicheau, Dany and Sutter,
               Willy and Zaidan, Mohamad and Snanoudj, Renaud and Cohen, Ariel
               and Scemla, Anne and {Critical COVID-19 France Investigators}",
  abstract  = "Higher rates of severe COVID-19 have been reported in kidney
               transplant recipients (KTRs) compared to nontransplant patients.
               We aimed to determine if poorer outcomes were specifically
               related to chronic immunosuppression or underlying
               comorbidities. We used a 1:1 propensity score-matching method to
               compare survival and severe disease-free survival (defined as
               death and/or need for intensive care unit [ICU]) incidence in
               hospitalized KTRs and nontransplant control patients between
               February 26 and May 22, 2020. Patients were matched for risk
               factors of severe COVID-19: age, sex, body mass index, diabetes
               mellitus, preexisting cardiopathy, chronic lung disease, and
               basal renal function. We included 100 KTRs (median age
               [interquartile range (IQR)]) 64.7 years (55.3-73.1) in three
               French transplant centers. After a median follow-up of 13 days
               (7-30), transfer to ICU was required for 34 patients (34\%) and
               death occurred in 26 patients (26\%). Overall, 43 patients
               (43\%) developed a severe disease during a median follow-up of
               8.5 days (2-14). Propensity score matching to a large French
               cohort of 2017 patients hospitalized in 24 centers, revealed
               that survival was similar between KTRs and matched nontransplant
               patients with respective 30-day survival of 62.9\% and 71\% (p =
               .38) and severe disease-free 30-day survival of 50.6\% and
               47.5\% (p = .91). These findings suggest that severity of
               COVID-19 in KTRs is related to their associated comorbidities
               and not to chronic immunosuppression.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  3,
  pages     = "1285--1294",
  month     =  mar,
  year      =  2021,
  keywords  = "clinical research / practice; infection and infectious agents;
               infection and infectious agents - viral; kidney transplantation
               / nephrology",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Gupta2021-vq,
  title    = "Clinical spectrum of {COVID-19} cases and their correlation with
              S.ldh levels- an observational study from southeast Rajasthan",
  author   = "Gupta, Deepak and Sharma, Ramavtar and Patwardhan, Bhalachandra
              and Mathur, Rajendra Dutt",
  abstract = "INTRODUCTION AND BACKGROUND: The novel coronavirus or commonly
              referred to as the covid-19, has been a threat to the global
              health as well as the world economy. It all started from the
              Wuhan city of china in December 2019, when a cluster of pneumonia
              cases with severe acute respiratory symptoms were reported with
              unknown etiology, majority of cases linked to the exposure to
              wholesale seafood market in Hunan. On January 7th, after the
              nomenclature of this causative agent was done as Corona Virus
              Disease 2019, COVID19, the struggles to combat and try to control
              this illness have only so far been less helpful as more and more
              countries have exponential proportion of cases. On the other side
              of the illness are the efforts being done constantly to study the
              characteristics of the virus, newer treatment agents, expanding
              testing facilities and finally to find a vaccine as soon as
              possible. Although most human coronavirus infections are mild,
              the epidemics of the two beta corona viruses, severe acute
              respiratory syndrome coronavirus (SARS-CoV) and Middle East
              respiratory syndrome coronavirus (MERS-CoV)20-24 have caused more
              than 10 000 cumulative cases in the past two decades, with
              mortality rates of 10\% for SARS-CoV and 37\% for MERS-CoV. The
              2019-nCoV has features typical of the coronavirus family and was
              classified in the beta coronavirus. Four viruses - (HCoV 229E,
              NL63, OC43, and HKU1) are endemic globally and account for 10\%
              to 30\% of upper respiratory tract infections in adults and
              typically cause common cold symptoms in immunocompetent
              individuals. Currently, the patients infected by the novel
              coronavirus are the main source of infection. Although
              asymptomatic infected can also be a source. Transmission of the
              virus happens mainly through respiratory droplets and close
              contact (defined as that within 1m distance and lasting for
              several minutes). A possibility of aerosol transmission in a
              relatively closed environment for a long-time exposure to high
              concentrations has also not been denied as of yet. Since the
              information regarding the illness, the treatment principles have
              been in constant scrutiny and have been changed dynamically as we
              get to know more about the virus, studies of covid19 cases would
              be a major stepping stone in acquiring maximum if not hundred
              percent knowledge about covid19. MATERIALS AND METHODS: An
              observational retrospective case study was done for a fixed
              duration of a month i.e from 23/05/2020 to 23/06/2020. Patients
              satisfying the inclusion and exclusion criteria were included
              under the study. INCLUSION CRITERIA: Age >40yrs with symptoms of
              severe acute respiratory Illness (screened as per the symptom
              suggestive of acute respiratory illness, mohfw.gov.in)
              Asymptomatic aged >40yrs with comorbidities and in direct contact
              with confirmed cases of covid19. EXCLUSION CRITERIA:
              Immunocompromised patients. Pregnant patients. Autoimmune disease
              patients History of psychiatric illness The patients were
              isolated in different wards based on the presence or absence and
              severity of symptoms. Detailed history, general and systemic
              examination and investigations were done. Samples of throat and
              nasal swab were sent for RT-PCR assay of covid19 testing done by
              Real time reverse transcriptase based PCR. Regular monitoring of
              patients was done. Treatment given based on the most recent
              guidelines update by the ICMR and made available by the Ministry
              of Health and Family Welfare. STATISTICAL ANALYSIS: Data was
              analysed by using SPSS 22.0 (trial version) software and T test,
              Chi-square Pierson's correlation and other appropriate
              statistical test will be used to analyse the data. Aims
              Objectives: To understand the symptomatology, disease course and
              complications of covid19. To study the changes in laboratory
              parameters in association with severity of illness. To study the
              effect of presence of comorbidities with respect to the outcome
              of covid19 Ethical Considerations: Since it being a retrospective
              observational study, complete patient confidentiality was being
              maintained while collecting and analysing the data as well as
              during the tabulation of the results.",
  journal  = "J. Assoc. Physicians India",
  volume   =  69,
  number   =  9,
  pages    = "11--12",
  month    =  sep,
  year     =  2021,
  language = "en"
}

@ARTICLE{Hernandez-Garduno2021-wu,
  title     = "Comorbidities that predict acute respiratory syndrome
               coronavirus 2 test positivity in Mexican Children: A
               case-control study",
  author    = "Hern{\'a}ndez-Gardu{\~n}o, Eduardo",
  abstract  = "Some comorbidities are risk factors for severe coronavirus
               disease (Covid-19) but it is unknown whether some increase
               susceptibility to Covid-19 in children. In this Mexican
               case-control study, contact with patients with Covid-19, or
               having obesity, or having diabetes, or hypertension or been
               immunosuppressed independently increased the risk for Covid-19
               in the whole sample analysis. However, only contact history and
               obesity remained statistically significant in the separated
               analysis of girls and boys. The results suggest that obesity is
               not only associated with severe disease but also increases risk
               for Covid-19. Contrary to findings in adults, no difference
               between cases and controls was found for gender, presence of
               pneumonia or surrogates of severe disease including admission to
               intensive care unit, tracheal intubation or whether patient had
               died. This indicates that Covid-19 is less severe in children
               than adults. Future research is needed to establish the
               mechanisms involved in obesity and Covid-19 in children.",
  journal   = "Pediatr. Obes.",
  publisher = "Wiley",
  volume    =  16,
  number    =  5,
  pages     = "e12740",
  month     =  may,
  year      =  2021,
  keywords  = "Covid-19; SARS-CoV-2; comorbidities; obesity; risk factor",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Van_Dam2021-ji,
  title     = "Herpes zoster after {COVID} vaccination",
  author    = "van Dam, C S and Lede, I and Schaar, J and Al-Dulaimy, M and
               R{\"o}sken, R and Smits, M",
  abstract  = "COVID-19 presents in various ways, but mainly as a pulmonary
               disease (Marzano, 2020). Skin manifestations have been reported,
               including reactivation of the varicella-zoster virus (Marzano,
               2020). Our case report describes two adults developing herpes
               zoster after vaccination with tozinameran (the Pfizer-BioNTech
               COVID-19 mRNA vaccine). A possible cause for this reaction is a
               transient lymphocytopenia that occurs after the vaccination -
               similar to that in COVID-19 disease (Mulligan, 2020; Wang, 2020;
               Qin, 2020; Brabilla, 2020; Wang, 2020; Wei, 2017). In the
               context of vaccinating older and/or immunocompromised adults,
               our observations can be the starting point for further
               evaluation of a possible relationship between COVID-19, COVID
               vaccines, and herpes zoster.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  111,
  pages     = "169--171",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Herpes Zoster; vaccine",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Ningombam2021-vx,
  title     = "Mutant strains of {SARS-CoV-2} are more prone to infect obese
               patient: a review",
  author    = "Ningombam, Somorjit Singh and Kumar, Rakesh and Tanwar, Pranay",
  abstract  = "The current review critically analyzes obesity as an important
               risk factor for increased predisposition towards coronavirus
               disease 2019 (COVID-19), its severity and causal death in
               current pandemic. Countries with higher prevalence of exposed
               obese individuals experienced the highest number of mortalities.
               The analysis also proved that individuals having more adipose
               tissue in body have a higher level of angiotensin-converting
               enzyme 2 (ACE2), which is identified as functional receptor for
               COVID-19. Therefore, obese individuals are worse in condition
               because of a higher presence of adiposity increases the number
               of ACE2 expressing cells. Furthermore, in silico interactions of
               ACE2 and different variants of coronavirus 2 (CoV-2) spike S1
               protein suggest that mutant strains are more infectious than
               wildtype as they bind to host ACE2 protein with high binding
               affinities. Certain specific cancers including cervical cancer,
               pancreatic and rectal adenocarcinomas have more expression of
               such receptors and pose additional risk to already
               immunocompromised cancer patients. This review emphasizes
               obesity, as the covert risk factor of COVID-19 infection and
               sensitizes about of calorie restrictions, immunity building and
               preventive measures.",
  journal   = "Wien. Klin. Wochenschr.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  133,
  number    = "7-8",
  pages     = "383--392",
  month     =  apr,
  year      =  2021,
  keywords  = "Angiotensin-converting enzyme 2; COVID-19; Comorbidities;
               Protein-protein interaction; Spike protein",
  language  = "en"
}

@ARTICLE{Nadeem2021-uu,
  title     = "{Epstein-Barr} virus coinfection in {COVID-19}",
  author    = "Nadeem, Asim and Suresh, Krithika and Awais, Hassan and Waseem,
               Saba",
  abstract  = "Epstein-Barr virus (EBV), a member of the herpes virus family,
               is a causative agent for infectious mononucleosis in young
               adults. It has an asymptomatic and subclinical distribution in
               about 90\% to 95\% of the world population based on
               seropositivity. EBV is associated with various lymphomas,
               nasopharyngeal carcinoma, and in immunocompromised states can
               give rise to aggressive lymphoproliferative disorders.
               Symptomatic patients mostly present with mild hepatitis, rash,
               oral symptoms, lymphadenopathy, and generalized malaise.
               Recently with the COVID-19 (coronavirus disease-2019) pandemic,
               hepatitis has been found to be related to acute EBV and
               cytomegalovirus reactivation versus acute infection in the
               absence of other major causes. We describe a case of EBV
               coinfection in a patient with resolving mild COVID-19 infection.",
  journal   = "J. Investig. Med. High Impact Case Rep.",
  publisher = "SAGE Publications",
  volume    =  9,
  pages     = "23247096211040626",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; EBV; hepatitis",
  language  = "en"
}

@ARTICLE{Varley2021-fq,
  title     = "Long-term safety of rituximab (risks of viral and opportunistic
               infections)",
  author    = "Varley, Cara D and Winthrop, Kevin L",
  abstract  = "PURPOSE OF REVIEW: We reviewed the current data on infections
               associated with rituximab use published over the last 5 years.
               RECENT FINDINGS: New literature was available on rates of
               serious infections, Hepatitis B reactivation and screening, and
               infection with Severe Acute Respiratory Syndrome Coronavirus 2.
               Rates of infection varied by study and population, however,
               higher risk of infection in patients with underlying
               rheumatologic diseases was seen in those who required a therapy
               switch, had a smoking history, and those undergoing retreatment
               who had a serious infection with their first course of therapy.
               With regards to HBV, the proportion of patients screened
               continues to be inadequate. Despite the upfront cost, HBV
               screening and prophylaxis were found to be cost effective. There
               is still limited data regarding COVID-19 severity in the setting
               of rituximab, however, rituximab, especially in combination with
               steroids, may lead to more severe disease and higher mortality.",
  journal   = "Curr. Rheumatol. Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  23,
  number    =  9,
  pages     = "74",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Hepatitis B; Infection; Rituximab; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Braxton2021-gv,
  title     = "Hamsters as a model of severe acute respiratory syndrome
               Coronavirus-2",
  author    = "Braxton, Alicia M and Creisher, Patrick S and Ruiz-Bedoya,
               Camilo A and Mulka, Katie R and Dhakal, Santosh and Ordonez,
               Alvaro A and Beck, Sarah E and Jain, Sanjay K and Villano, Jason
               S",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
               the cause of coronavirus disease 2019 (COVID-19), rapidly spread
               across the world in late 2019, leading to a pandemic. While
               SARS-CoV-2 infections predominately affect the respiratory
               system, severe infections can lead to renal and cardiac injury
               and even death. Due to its highly transmissible nature and
               severe health implications, animal models of SARS-CoV-2 are
               critical to developing novel therapeutics and preventatives.
               Syrian hamsters (Mesocricetus auratus) are an ideal animal model
               of SARS-CoV-2 infections because they recapitulate many aspects
               of human infections. After inoculation with SARS-CoV-2, hamsters
               become moribund, lose weight, and show varying degrees of
               respiratory disease, lethargy, and ruffled fur.
               Histopathologically, their pulmonary lesions are consistent with
               human infections including interstitial to broncho-interstitial
               pneumonia, alveolar hemorrhage and edema, and granulocyte
               infiltration. Similar to humans, the duration of clinical signs
               and pulmonary pathology are short lived with rapid recovery by
               14 d after infection. Immunocompromised hamsters develop more
               severe infections and mortality. Preclinical studies in hamsters
               have shown efficacy of therapeutics, including convalescent
               serum treatment, and preventatives, including vaccination, in
               limiting or preventing clinical disease. Although hamster
               studies have contributed greatly to our understanding of the
               pathogenesis and progression of disease after SARS-CoV-2
               infection, additional studies are required to better
               characterize the effects of age, sex, and virus variants on
               clinical outcomes in hamsters. This review aims to describe key
               findings from studies of hamsters infected with SARS-CoV-2 and
               to highlight areas that need further investigation.",
  journal   = "Comp. Med.",
  publisher = "American Association for Laboratory Animal Science",
  volume    =  71,
  number    =  5,
  pages     = "398--410",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Picchianti_Diamanti2021-ht,
  title     = "Severe acute respiratory syndrome Coronavirus-2 infection and
               autoimmunity 1 year later: The era of vaccines",
  author    = "Picchianti Diamanti, Andrea and Rosado, Maria Manuela and
               Nicastri, Emanuele and Sesti, Giorgio and Pioli, Claudio and
               Lagan{\`a}, Bruno",
  abstract  = "Impressive efforts have been made by researchers worldwide in
               the development of target vaccines against the novel severe
               acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and in
               improving the management of immunomodulating agents. Currently,
               different vaccine formulations, such as viral vector, mRNA, and
               protein-based, almost all directed toward the spike protein that
               includes the domain for receptor binding, have been approved.
               Although data are not conclusive, patients affected by
               autoimmune rheumatic diseases (ARDs) seem to have a slightly
               higher disease prevalence, risk of hospitalization, and death
               from coronavirus disease-2019 (COVID-19) than the general
               population. Therefore, ARD patients, under immunosuppressive
               agents, have been included among the priority target groups for
               vaccine administration. However, specific cautions are needed to
               optimize vaccine safety and effectiveness in these patients,
               such as modification in some of the ongoing immunosuppressive
               therapies and the preferential use of mRNA other than
               vector-based vaccines. Immunomodulating agents can be a
               therapeutic opportunity for the management of COVID-19 patients;
               however, their clinical impact depends on how they are handled.
               To place in therapy immunomodulating agents in the correct
               window of opportunity throughout the identification of surrogate
               markers of disease progression and host immune response is
               mandatory to optimize patient's outcome.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "708848",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; autoimmune rheumatic disease (ARD);
               infections; vaccines",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Merad2021-uk,
  title     = "An aberrant inflammatory response in severe {COVID-19}",
  author    = "Merad, Miriam and Subramanian, Aruna and Wang, Taia T",
  abstract  = "Severe COVID-19 arises from the convergence of inadequate
               pre-existing immunity and a host response that damages, rather
               than repairs, tissues. We outline clinical presentations of
               COVID-19 that are likely driven by dysregulated host immunity,
               discuss potential mechanisms underlying pathological responses,
               and highlight important areas for basic research on this topic.",
  journal   = "Cell Host Microbe",
  publisher = "Elsevier BV",
  volume    =  29,
  number    =  7,
  pages     = "1043--1047",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Orner2021-vu,
  title     = "Comparison of {SARS-CoV-2} {IgM} and {IgG} seroconversion
               profiles among hospitalized patients in two {US} cities",
  author    = "Orner, Erika P and Rodgers, Mary A and Hock, Karl and Tang, Mei
               San and Taylor, Russell and Gardiner, Mary and Olivo, Ana and
               Fox, Amy and Prostko, John and Cloherty, Gavin and Farnsworth,
               Christopher W",
  abstract  = "The clinical and public health utility of severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic
               testing requires a better understanding of the dynamics of the
               humoral response to infection. To track seroconversion of IgG
               and IgM antibodies in patients with SARS-CoV-2 infection and its
               association with patient and clinical factors and outcomes.
               Residual patient specimens were analyzed on the Abbott ARCHITECT
               i2000 instrument using the Abbott SARS-CoV-2 IgG assay and
               prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom
               onset date, mortality, and specimen collection date were
               obtained from electronic medical records. Three hundred
               fifty-nine longitudinal samples were collected from 89
               hospitalized patients 0 to 82 days postsymptom onset. Of all,
               51.7\% of the patients developed IgG and IgM antibodies
               simultaneously; 32.8\% seroconverted for IgM before IgG. On
               average, patients seroconverted for IgG by 8 days and for IgM by
               7 days postsymptom onset. All patients achieved IgG
               seropositivity by 19 days and IgM seropositivity by 17 days.
               Median time to IgG and IgM seroconversion was prolonged and
               initial levels of IgG were lower in immunocompromised patients
               and patients <65 years of age compared to immune competent
               patients and those $\geq$65 years of age. Immunocompromised
               patients also had persistently lower levels of IgM that peaked
               on day 17.6 and decreased thereafter compared to immune
               competent patients. IgM seroconversion in patients who died
               reached significantly higher levels later after symptom onset
               than in those who recovered. SARS-CoV-2 infected patients have
               similar time to seroconversion for IgG and IgM. However,
               differences in immune status and age alter time to
               seroconversion. These results may help guide serologic testing
               application in COVID-19 management.",
  journal   = "Diagn. Microbiol. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  99,
  number    =  4,
  pages     = "115300",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Humoral immune response; SARS-CoV-2 serology;
               Seroconversion; Serologic assay",
  language  = "en"
}

@ARTICLE{Sran2021-nq,
  title     = "{COVID-19} in kidney transplant patients from a large {UK}
               transplant center: Exploring risk factors for disease severity",
  author    = "Sran, K and Olsburgh, J and Kasimatis, T and Clark, K and
               G{\"o}kmen, R and Hilton, R and Shah, S and Shaw, C and Farmer,
               C and Kilbride, H and Asgari, E",
  abstract  = "BACKGROUND: The novel severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) pandemic has raised concern for the
               health of immunocompromised individuals, who are potentially at
               higher risk of more severe infection and poorer outcomes. As a
               large London transplant center serving a diverse patient
               population, we report the outcomes of SARS-CoV-2 infection in
               our cohort of 2848 kidney and/or pancreas transplant patients.
               METHODS: Data were obtained retrospectively for all transplant
               patients who attended hospital during the peak of the pandemic
               and had a positive nasopharyngeal SARS-CoV-2 test. RESULTS:
               Sixty-six patients were found to be positive for SARS-CoV-2.
               Twenty percent were treated as outpatients, 59\% were admitted
               to the general ward, and 21\% required intensive care. Treatment
               consisted of reduced immunosuppression, antibiotics for
               pneumonia or sepsis, and other supportive treatments. Within our
               cohort, 12 patients died (18\%), with an overall mortality of
               0.4\%. Predictive risk factors for COVID-19 severity were
               explored. CONCLUSIONS: Severe disease was associated with lower
               hemoglobin prior to COVID-19 diagnosis and lower lymphocyte
               count at the time of diagnosis but not age, sex, ethnicity, or
               preexisting comorbidities. Lower glomerular filtration rate and
               higher C-reactive protein were associated with more severe
               disease. Despite no use of hydroxychloroquine, azithromycin,
               antiviral, or immunomodulatory medications, our mortality rate
               (kidney and pancreas transplant patients) is similar to current
               international rates.",
  journal   = "Transplant. Proc.",
  publisher = "Elsevier BV",
  volume    =  53,
  number    =  4,
  pages     = "1160--1168",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Julian2021-kn,
  title     = "Utility of Ct values in differentiating {COVID-19} reinfection
               versus prolonged viral shedding in an immunocompromised patient",
  author    = "Julian, Katherine and Shah, Neal and Banjade, Rashmi and Bhatt,
               Dhirisha",
  abstract  = "We describe the case of a 26-year-old man who presented to an
               outside hospital with concerns of blurred vision. He
               subsequently tested positive for COVID-19 and his lab work
               suggested acute leukaemia. The patient was admitted to our
               hospital and completed a course of remdesivir. He eventually
               tested negative for COVID-19 before initiating chemotherapy. Two
               days after starting chemotherapy, he developed a neutropenic
               fever and tested positive for COVID-19. Through this case, we
               aim to bring attention to patients who recurrently test positive
               with COVID-19 PCR testing, thereby causing a dilemma of
               differentiating between reinfections and prolonged shedding of
               the virus, as well as understand and use cycle threshold values
               to discern these aetiologies.",
  journal   = "BMJ Case Rep.",
  publisher = "BMJ",
  volume    =  14,
  number    =  7,
  pages     = "e243692",
  month     =  jul,
  year      =  2021,
  keywords  = "haematology (incl blood transfusion); infectious diseases",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Vivarelli2021-kf,
  title     = "Immune-checkpoint inhibitors from cancer to {COVID19}: A
               promising avenue for the treatment of patients with {COVID19}
               (Review)",
  author    = "Vivarelli, Silvia and Falzone, Luca and Torino, Francesco and
               Scandurra, Giuseppa and Russo, Giulia and Bordonaro, Roberto and
               Pappalardo, Francesco and Spandidos, Demetrios A and Raciti,
               Giuseppina and Libra, Massimo",
  abstract  = "The severe acute respiratory syndrome associated coronavirus2
               (SARSCoV2) poses a threat to human life worldwide. Since early
               March, 2020, coronavirus disease 2019 (COVID19), characterized
               by an acute and often severe form of pneumonia, has been
               declared a pandemic. This has led to a boom in biomedical
               research studies at all stages of the pipeline, from the in
               vitro to the clinical phase. In line with this global effort,
               known drugs, currently used for the treatment of other
               pathologies, including antivirals, immunomodulating compounds
               and antibodies, are currently used offlabel for the treatment
               of COVID19, in association with the supportive standard care.
               Yet, no effective treatments have been identified. A new hope
               stems from medical oncology and relies on the use of
               immunecheckpoint inhibitors (ICIs). In particular, amongst the
               ICIs, antibodies able to block the programmed death1 (PD1)/PD
               ligand-1 (PDL1) pathway have revealed a hidden potential. In
               fact, patients with severe and critical COVID19, even prior to
               the appearance of acute respiratory distress syndrome, exhibit
               lymphocytopenia and suffer from Tcell exhaustion, which may
               lead to viral sepsis and an increased mortality rate. It has
               been observed that cancer patients, who usually are
               immunocompromised, may restore their antitumoral immune
               response when treated with ICIs. Moreover, viral-infected mice
               and humans, exhibit a Tcell exhaustion, which is also observed
               following SARSCoV2 infection. Importantly, when treated with
               antiPD1 and antiPDL1 antibodies, they restore their Tcell
               competence and efficiently counteract the viral infection. Based
               on these observations, four clinical trials are currently open,
               to examine the efficacy of antiPD1 antibody administration to
               both cancer and noncancer individuals affected by COVID19. The
               results may prove the hypothesis that restoring exhausted
               Tcells may be a winning strategy to beat SARSCoV2 infection.",
  journal   = "Int. J. Oncol.",
  publisher = "Spandidos Publications",
  volume    =  58,
  number    =  2,
  pages     = "145--157",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; cancer; immune-checkpoint inhibitors;
               immunotherapy; anti-PD-1 monoclonal antibody",
  language  = "en"
}

@ARTICLE{Hubbard2021-dw,
  title    = "Comparison of two automated immunoassays for the detection of
              {SARS-CoV-2} nucleocapsid antibodies",
  author   = "Hubbard, Jacqueline A and Geno, K Aaron and Khan, Jenna and
              Szczepiorkowski, Zbigniew M and de Gijsel, David and Ovalle,
              Anais A and AlSalman, Ahmad S and Gallagher, Torrey L and
              Johnston, Abigail A and Tibbetts, Amanda R and Vital, Sarah E and
              Cervinski, Mark A and Nerenz, Robert D",
  abstract = "BACKGROUND: Severe acute respiratory syndrome coronavirus 2
              (SARS-CoV-2) is a novel member of the coronavirus family that
              caused the global coronavirus 2019 (COVID-19) pandemic. The
              prevalence remains largely unknown because of early testing
              supply shortages. Although it cannot currently be used to
              determine level of immunity, antibody testing can contribute to
              epidemiological studies, identify convalescent plasma donors, or
              satisfy curiosity about previous exposure to the virus. METHODS:
              407 samples collected from hospitalized inpatients with and
              without a confirmed SARS-CoV-2 infection, 170 remnant clinical
              specimens collected and frozen prior to the COVID-19 outbreak,
              and paired serum and plasma samples from 23 convalescent plasma
              donors were used to determine performance characteristics of the
              Abbott SARS-CoV-2 IgG and Roche Elecsys Anti-SARS-CoV-2 assays.
              The sensitivity, specificity, imprecision, interferences, and
              sample stability were determined. These assays were then used to
              characterize the antibody response in serial samples from 20
              SARS-CoV-2 positive inpatients. RESULTS: Both assays exhibited
              100\% specificity (95\% CI; 99.05-100.00), giving no positive
              results in 170 specimens collected before July 2019 and 215
              specimens from patients without a confirmed SARS-CoV-2 infection.
              Differences between platforms were most notable in SARS-CoV-2
              positive samples. Roche offered higher sensitivity in
              convalescent plasma donors at 95.7\% (95\% CI; 78.1-99.9) versus
              91.3\% (95\% CI; 72.0-98.9) but Abbott detected antibodies in 2
              immunocompromised patients whereas Roche did not. The Roche and
              Abbott platforms also exhibited different trends in antibody
              signal for a subset of patients. CONCLUSIONS: Both the Abbott and
              Roche platforms offer excellent specificity but different trends
              in antibody signal may reflect qualitative differences in the
              types of antibodies recognized by the 2 assays. Negative
              serologic results do not exclude previous SARS-CoV-2 infection.",
  journal  = "J. Appl. Lab. Med.",
  volume   =  6,
  number   =  2,
  pages    = "429--440",
  month    =  mar,
  year     =  2021,
  keywords = "COVID-19; IgG; SARS-CoV-2; antibody; convalescent; coronavirus",
  language = "en"
}

@ARTICLE{Wang2021-pu,
  title     = "Summary report of seven cases of {COVID-19} infection in renal
               transplant recipients",
  author    = "Wang, Tianyu and Qiu, Tao and Yuan, Yan and Chen, Zhongbao and
               Ma, Xiaoxiong and Zhang, Long and Jin, Zeya and Zou, Jilin and
               Zhang, Yalong and Zhou, Jiangqiao",
  abstract  = "The coronavirus disease 2019 (COVID-19) has swept the world,
               posing a serious threat to people's lives and health. Several
               cases of COVID-19 infection in renal transplant recipients
               (RTRs) have been reported, but the treatment and prognosis have
               not been fully elucidated. We followed-up with RTRs infected
               with SARS-CoV2 in our center and classified them as five
               clinical types-asymptomatic, mild, moderate, severe, and
               critical. The immunosuppressive agents were not adjusted in
               asymptomatic carriers and mild patients, the former was mainly
               treated by isolation, and the latter was treated by low-dose
               intravenous immunoglobulin (IVIG) to enhance immunity. For
               moderate or severe patients, the immunosuppressive agents were
               largely reduced or even interrupted, low-dose IVIG was adopted,
               and low-dose methylprednisolone (MP) was used to inhibit
               inflammation and rejection. Immunosuppressants were discontinued
               early in critical patients; IVIG, high-dose MP, and antibiotics
               were used. Meanwhile, all patients received at least one
               antiviral drugs. After aggressive treatment, three patients
               developed acute kidney injury, and two showed reversal, while
               the remaining one lost the allograft kidney; one patient died,
               while other patients were discharged. For different clinical
               types of RTRs infected with COVID-19, personalized therapies
               were essential, Meanwhile, patients with COVID-19 infection may
               have different outcomes due to their different clinical
               manifestations.",
  journal   = "Transpl. Immunol.",
  publisher = "Elsevier BV",
  volume    =  69,
  number    =  101445,
  pages     = "101445",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; Management; Renal transplant; SARS-CoV-2; Treatment",
  language  = "en"
}

@ARTICLE{Ganesh2021-wt,
  title     = "Real-world clinical outcomes of bamlanivimab and
               casirivimab-imdevimab among high-risk patients with mild to
               moderate Coronavirus disease 2019",
  author    = "Ganesh, Ravindra and Philpot, Lindsey M and Bierle, Dennis M and
               Anderson, Ryan J and Arndt, Lori L and Arndt, Richard F and
               Culbertson, Tracy L and Destro Borgen, Molly J and Hanson, Sara
               N and Kennedy, Brian D and Kottke, Brian B and Larsen, Jennifer
               J and Ramar, Priya and Rosedahl, Jordan K and Seville, Maria
               Teresa and Speicher, Leigh L and Tulledge-Scheitel, Sidna M and
               Wilker, Caroline G and Razonable, Raymund R",
  abstract  = "BACKGROUND: Bamlanivimab and casirivimab-imdevimab are
               authorized for treatment of mild to moderate coronavirus disease
               2019 (COVID-19) in high-risk patients. We compared the outcomes
               of patients who received these therapies to identify factors
               associated with hospitalization and other clinical outcomes.
               METHODS: Adult patients who received monoclonal antibody from 19
               November 2020 to 11 February 2021 were selected and divided into
               those who received bamlanivimab (n = 2747) and
               casirivimab-imdevimab (n = 849). The 28-day all-cause and
               COVID-19-related hospitalizations were compared between the
               groups. RESULTS: The population included 3596 patients; the
               median age was 62 years, and 50\% were female. All had $\geq$1
               medical comorbidity; 55\% had multiple comorbidities. All-cause
               and COVID-19-related hospitalization rates at 28 days were
               3.98\% and 2.56\%, respectively. After adjusting for medical
               comorbidities, there was no significant difference in all-cause
               and COVID-19-related hospitalization rates between bamlanivimab
               and casirivimab-imdevimab (adjusted hazard ratios [95\%
               confidence interval], 1.4 [.9-2.2] and 1.6 [.8-2.7],
               respectively). Chronic kidney, respiratory and cardiovascular
               diseases, and immunocompromised status were associated with
               higher likelihood of hospitalization. CONCLUSIONS: This
               observational study on the use of bamlanivimab and
               casirivimab-imdevimab in high-risk patients showed similarly low
               rates of hospitalization. The number and type of medical
               comorbidities are associated with hospitalizations after
               monoclonal antibody treatment.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  224,
  number    =  8,
  pages     = "1278--1286",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; bamlanivimab; casirivimab; hospitalization; outcomes",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Rubin2021-aj,
  title     = "Audio interview: A new {mRNA} vaccine",
  author    = "Rubin, Eric J and Baden, Lindsey R and Morrissey, Stephen",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  384,
  number    =  25,
  pages     = "e109",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Self2021-oo,
  title     = "Comparative effectiveness of Moderna, {Pfizer-BioNTech}, and
               Janssen (Johnson \& Johnson) vaccines in preventing {COVID-19}
               hospitalizations among adults without immunocompromising
               conditions - United States, {March-August} 2021",
  author    = "Self, Wesley H and Tenforde, Mark W and Rhoads, Jillian P and
               Gaglani, Manjusha and Ginde, Adit A and Douin, David J and
               Olson, Samantha M and Talbot, H Keipp and Casey, Jonathan D and
               Mohr, Nicholas M and Zepeski, Anne and McNeal, Tresa and
               Ghamande, Shekhar and Gibbs, Kevin W and Files, D Clark and
               Hager, David N and Shehu, Arber and Prekker, Matthew E and
               Erickson, Heidi L and Gong, Michelle N and Mohamed, Amira and
               Henning, Daniel J and Steingrub, Jay S and Peltan, Ithan D and
               Brown, Samuel M and Martin, Emily T and Monto, Arnold S and
               Khan, Akram and Hough, Catherine L and Busse, Laurence W and Ten
               Lohuis, Caitlin C and Duggal, Abhijit and Wilson, Jennifer G and
               Gordon, Alexandra June and Qadir, Nida and Chang, Steven Y and
               Mallow, Christopher and Rivas, Carolina and Babcock, Hilary M
               and Kwon, Jennie H and Exline, Matthew C and Halasa, Natasha and
               Chappell, James D and Lauring, Adam S and Grijalva, Carlos G and
               Rice, Todd W and Jones, Ian D and Stubblefield, William B and
               Baughman, Adrienne and Womack, Kelsey N and Lindsell,
               Christopher J and Hart, Kimberly W and Zhu, Yuwei and Mills,
               Lisa and Lester, Sandra N and Stumpf, Megan M and Naioti, Eric A
               and Kobayashi, Miwako and Verani, Jennifer R and Thornburg,
               Natalie J and Patel, Manish M and {IVY Network}",
  abstract  = "Three COVID-19 vaccines are authorized or approved for use among
               adults in the United States (1,2). Two 2-dose mRNA vaccines,
               mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech,
               received Emergency Use Authorization (EUA) by the Food and Drug
               Administration (FDA) in December 2020 for persons aged $\geq$18
               years and aged $\geq$16 years, respectively. A 1-dose viral
               vector vaccine (Ad26.COV2 from Janssen [Johnson \& Johnson])
               received EUA in February 2021 for persons aged $\geq$18 years
               (3). The Pfizer-BioNTech vaccine received FDA approval for
               persons aged $\geq$16 years on August 23, 2021 (4). Current
               guidelines from FDA and CDC recommend vaccination of eligible
               persons with one of these three products, without preference for
               any specific vaccine (4,5). To assess vaccine effectiveness (VE)
               of these three products in preventing COVID-19 hospitalization,
               CDC and collaborators conducted a case-control analysis among
               3,689 adults aged $\geq$18 years who were hospitalized at 21
               U.S. hospitals across 18 states during March 11-August 15, 2021.
               An additional analysis compared serum antibody levels
               (anti-spike immunoglobulin G [IgG] and anti-receptor binding
               domain [RBD] IgG) to SARS-CoV-2, the virus that causes COVID-19,
               among 100 healthy volunteers enrolled at three hospitals 2-6
               weeks after full vaccination with the Moderna, Pfizer-BioNTech,
               or Janssen COVID-19 vaccine. Patients with immunocompromising
               conditions were excluded. VE against COVID-19 hospitalizations
               was higher for the Moderna vaccine (93\%; 95\% confidence
               interval [CI] = 91\%-95\%) than for the Pfizer-BioNTech vaccine
               (88\%; 95\% CI = 85\%-91\%) (p = 0.011); VE for both mRNA
               vaccines was higher than that for the Janssen vaccine (71\%;
               95\% CI = 56\%-81\%) (all p<0.001). Protection for the
               Pfizer-BioNTech vaccine declined 4 months after vaccination.
               Postvaccination anti-spike IgG and anti-RBD IgG levels were
               significantly lower in persons vaccinated with the Janssen
               vaccine than the Moderna or Pfizer-BioNTech vaccines. Although
               these real-world data suggest some variation in levels of
               protection by vaccine, all FDA-approved or authorized COVID-19
               vaccines provide substantial protection against COVID-19
               hospitalization.",
  journal   = "MMWR Morb. Mortal. Wkly. Rep.",
  publisher = "Centers for Disease Control MMWR Office",
  volume    =  70,
  number    =  38,
  pages     = "1337--1343",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Kupferschmidt2021-ad,
  title     = "Where did 'weird' Omicron come from?",
  author    = "Kupferschmidt, Kai",
  journal   = "Science",
  publisher = "American Association for the Advancement of Science (AAAS)",
  volume    =  374,
  number    =  6572,
  pages     = "1179",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Qiu2021-uw,
  title     = "Long-term clinical and immunological impact of severe {COVID-19}
               on a living kidney transplant recipient - A case report",
  author    = "Qiu, Liru and Zhang, Ji and Huang, Yafei and Chen, Gen and Chen,
               Zhishui and Ming, Changsheng and Lu, Xia and Gong, Nianqiao",
  abstract  = "The long-term impact of COVID-19 on transplant recipients
               remains unknown. We describe the case of a 30-year-old male
               kidney transplant recipient from Wuhan, China that was treated
               for severe COVID-19 in February 2020. He suffered an acute lung
               and renal injury and required systemic treatment including
               adjustment of his immunosuppressant regime. He was followed up
               to 1-year after discharge. No chronic lung fibrosis or
               deterioration of his pulmonary function was observed. Despite
               COVID-19 mediated damage to his renal tubular cells, no
               transplant rejection occurred. His immunological profile
               demonstrated both cellular anti-SARS-CoV-2 reactivity and
               specific humoral immunity, indicating that it is beneficial for
               the transplanted patients to be immunized with SARS-CoV-2 virus
               vaccine. This case will help guide clinical decision making for
               immunocompromised individuals that become infected with
               SARS-CoV-2.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "741765",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; immunity; living kidney transplant; lung injury; renal
               tubular injury",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Raiano2021-gj,
  title    = "Home mobile radiography service in the {COVID-19} era",
  author   = "Raiano, N and Raiano, C and Mazio, F and Rossi, I and Bordino, U
              and De Simone, G and Fusco, R and Granata, V and Cerciello, V and
              Setola, S V and Petrillo, A",
  abstract = "Demographic changes in the Western world linked to the increase
              in the elderly population, life expectancy and above all cancer
              patients and chronically ill patients, often entrusted to home
              care or in healthcare residences, highlight an exponential
              increase in requests for diagnostic tests at home. Conventional
              radiographic examinations, such as thoracic, musculoskeletal and
              abdominal images are the most requested and are important first
              level diagnostic tests. To date and, in particular, in times of
              COVID-19 emergency, these patients need to be transferred to the
              hospital to perform radiological examinations which involve an
              increase in costs for the health system and an increased risk for
              the health of these patients, already often debilitated and
              immunocompromised. This article discussed the benefits of taking
              conventional chest x-rays directly at the patient's home.",
  journal  = "Eur. Rev. Med. Pharmacol. Sci.",
  volume   =  25,
  number   =  8,
  pages    = "3338--3341",
  month    =  apr,
  year     =  2021,
  language = "en"
}

@ARTICLE{Arrambide2021-mu,
  title    = "{SARS-CoV-2} infection in multiple sclerosis: Results of the
              Spanish neurology society registry",
  author   = "Arrambide, Georgina and Llaneza-Gonz{\'a}lez, Miguel {\'A}ngel
              and Costa-Frossard Fran{\c c}a, Lucienne and Meca-Lallana,
              Virginia and D{\'\i}az, Eva Fern{\'a}ndez- and Moreno-Torres,
              Irene and Garc{\'\i}a-Dom{\'\i}nguez, Jose Manuel and
              Ortega-Suero, Gloria and Ayuso-Peralta, Luc{\'\i}a and
              G{\'o}mez-Moreno, Mayra and Sotoca-Fern{\'a}ndez, Javier J and
              Caminero-Rodr{\'\i}guez, Ana Bel{\'e}n and Rodr{\'\i}guez de
              Antonio, Luis A and Corujo-Su{\'a}rez, Marcial and
              Otano-Mart{\'\i}nez, Mar{\'\i}a A and P{\'e}rez-Miralles,
              Francisco Carlos and Reyes-Garrido, Virginia and Ayuso-Blanco,
              Teresa and Balseiro-G{\'o}mez, Jos{\'e} Jes{\'u}s and
              Mu{\~n}oz-Pasadas, Mercedes and P{\'e}rez-Molina, Inmaculada and
              Arnal-Garc{\'\i}a, Carmen and Domingo-Santos, {\'A}ngela and
              Guijarro-Castro, Cristina and {\'I}{\~n}iguez-Mart{\'\i}nez,
              Cristina and T{\'e}llez Lara, Nieves and Castellanos-Pinedo,
              Fernando and Castillo-Trivi{\~n}o, Tamara and
              Cerd{\'a}n-Santacruz, Debora Mar{\'\i}a and P{\'e}rez-Sempere,
              {\'A}ngel and Torres, Berta Sebasti{\'a}n and {\'A}lvarez de
              Arcaya, Amaya and Costa-Arp{\'\i}n, Eva and Dur{\'a}n-Ferreras,
              Eduardo and Fragoso-Mart{\'\i}nez, Marta and Gonz{\'a}lez-Platas,
              Montserrat and Landete Pascual, Lamberto and Mill{\'a}n-Pascual,
              Jorge and Oreja-Guevara, Celia and Meca-Lallana, Jos{\'e} E",
  abstract = "OBJECTIVE: To understand COVID-19 characteristics in people with
              multiple sclerosis (MS) and identify high-risk individuals due to
              their immunocompromised state resulting from the use of
              disease-modifying treatments. METHODS: Retrospective and
              multicenter registry in patients with MS with suspected or
              confirmed COVID-19 diagnosis and available disease course (mild =
              ambulatory; severe = hospitalization; and critical = intensive
              care unit/death). Cases were analyzed for associations between MS
              characteristics and COVID-19 course and for identifying risk
              factors for a fatal outcome. RESULTS: Of the 326 patients
              analyzed, 120 were cases confirmed by real-time PCR, 34 by a
              serologic test, and 205 were suspected. Sixty-nine patients
              (21.3\%) developed severe infection, 10 (3\%) critical, and 7
              (2.1\%) died. Ambulatory patients were higher in relapsing MS
              forms, treated with injectables and oral first-line agents,
              whereas more severe cases were observed in patients on pulsed
              immunosuppressors and critical cases among patients with no
              therapy. Severe and critical infections were more likely to
              affect older males with comorbidities, with progressive MS forms,
              a longer disease course, and higher disability. Fifteen of 33
              patients treated with rituximab were hospitalized. Four deceased
              patients have progressive MS, 5 were not receiving MS therapy,
              and 2 were treated (natalizumab and rituximab). Multivariate
              analysis showed age (OR 1.09, 95\% CI, 1.04-1.17) as the only
              independent risk factor for a fatal outcome. CONCLUSIONS: This
              study has not demonstrated the presumed critical role of MS
              therapy in the course of COVID-19 but evidenced that people with
              MS with advanced age and disease, in progressive course, and
              those who are more disabled have a higher probability of severe
              and even fatal disease.",
  journal  = "Neurol. Neuroimmunol. Neuroinflamm.",
  volume   =  8,
  number   =  5,
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Winthrop2021-lu,
  title     = "{SARS-CoV-2} and the rheumatology patient: the last 12 months
               and a boost in the future",
  author    = "Winthrop, Kevin L and Whitley, Richard J and Aletaha, Daniel",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1249--1251",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; autoimmune diseases; vaccination",
  language  = "en"
}

@ARTICLE{Eliseeva2021-of,
  title     = "Monoclonal antibody therapies for rapidly progressive and highly
               active multiple sclerosis in the era of the {COVID-19} pandemic",
  author    = "Eliseeva, D D and Vasiliev, A V and Abramova, A A and Kochergin,
               I A and Zakharova, M N",
  abstract  = "As the COVID-19 pandemic continues, reducing the risk of
               infection for immunocompromised patients remains an important
               issue. Patients with aggressive multiple sclerosis (MS) require
               immunosuppressive therapy in order to control the overactive
               autoimmune response. Preliminary international and national
               trials demonstrate that older age, higher disability status and
               progressive MS are generally associated with a more severe
               clinical course of COVID-19. However, uncertainty remains about
               the effect of disease-modifying therapies on the COVID-19
               clinical presentation. In this article, we pay special attention
               to monoclonal antibodies used for immune reconstitution therapy,
               which results in significant changes to the T-cell and/or B-cell
               repertoire. Based on the published data from registries in
               different countries, we attempted to estimate the benefits and
               risks of these therapies in a complicated epidemiological
               setting.",
  journal   = "Zh. Nevrol. Psikhiatr. Im. S S Korsakova",
  publisher = "Media Sphere Publishing Group",
  volume    =  121,
  number    = "7. Vyp. 2",
  pages     = "31--36",
  year      =  2021,
  keywords  = "COVID-19; alemtuzumab; highly active multiple sclerosis;
               immunosuppressive therapy; natalizumab; ocrelizumab",
  language  = "ru"
}

@ARTICLE{Wu2021-jr,
  title     = "The {COVID-19} vaccination hesitancy among the people with
               inflammatory bowel disease in China: A questionnaire study",
  author    = "Wu, Xia and Lin, Jue and Buch, Heena and Ding, Quchen and Zhang,
               Faming and Cui, Bota and Ji, Guozhong",
  abstract  = "Objective: To explore the attitudes and views of patients with
               inflammatory bowel disease (IBD) on COVID-19 vaccination.
               Methods: An online interview questionnaire concerning the
               acceptance or hesitancy toward vaccination for COVID-19 was
               designed and 543 patients with IBD in China were invited to
               complete the structured self-administered anonymous
               questionnaire. Results: Of all the participants, 50.7\% were
               indecisive about the vaccination and only 16.0\% opted for it.
               Vaccination hesitancy was significantly associated with women
               and those without medical or biomedical backgrounds. The
               acceptance of COVID-19 vaccination was higher in participants
               with no history of immune-modifying therapies, especially in
               those without immunosuppressants. Participants who considered
               vaccination critically important to self-health or the health of
               others were more likely to choose immediately or later
               vaccination. Safety and potential adverse reactions, personal
               hypoimmunity, efficacy, and reliability of COVID-19 vaccines
               were the top three concerns of the participants that were
               independent of their willingness for vaccination. Conclusions:
               This study discloses the presence of hesitancy for COVID-19
               vaccination in patients with IBD. Further studies are warranted
               to evaluate the efficacy and safety of COVID-19 vaccines in IBD
               individuals, with a specific focus on the impact of
               immune-modifying therapies. Health education and recommendation
               from authoritative sources may facilitate COVID-19 vaccination
               efforts.",
  journal   = "Front. Public Health",
  publisher = "Frontiers Media SA",
  volume    =  9,
  pages     = "731578",
  month     =  oct,
  year      =  2021,
  keywords  = "SARS-CoV-2 vaccination; immunocompromised population;
               inflammatory bowel disease; perspective; willingness",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Kenig2021-an,
  title     = "Treatment of B-cell depleted {COVID-19} patients with
               convalescent plasma and plasma-based products",
  author    = "Kenig, Ariel and Ishay, Yuval and Kharouf, Fadi and Rubin, Limor",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 infected
               patients, receiving background anti-CD20 therapy, were treated
               with convalescent plasma or plasma-based products. Eight
               patients were included in the study, presenting with prolonged
               disease course and delayed viral clearance. CP/plasma-based
               products were offered as an add-on therapy to standard medical
               treatment. All patients showed remarkable clinical and
               laboratory improvement. In addition, polymerase chain reaction
               from nasopharyngeal swabs rapidly converted to negative
               following plasma administration. This study emphasizes the
               therapeutic efficacy of convalescent plasma and plasma-based
               products in a subgroup of immunocompromised patients with
               iatrogenic B-cell depletion.",
  journal   = "Clin. Immunol.",
  publisher = "Elsevier BV",
  volume    =  227,
  number    =  108723,
  pages     = "108723",
  month     =  jun,
  year      =  2021,
  keywords  = "B-cells; COVID-19; Convalescent plasma; Rituximab; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Abid2021-kr,
  title     = "Bronchoalveolar lavage-based {COVID-19} testing in patients with
               cancer",
  author    = "Abid, Muhammad Bilal and Chhabra, Saurabh and Buchan, Blake and
               Graham, Mary Beth and Abedin, Sameem and Thapa, Bicky and
               D'Souza, Anita and George, Ben and Hamadani, Mehdi",
  abstract  = "OBJECTIVE/BACKGROUND: A few case reports in the setting of
               coronavirus disease 2019 (COVID-19) and multiplex polymerase
               chain reaction (PCR)-based assays for common respiratory
               pathogens have shown a higher yield of bronchoalveolar lavage
               (BAL) samples than upper airway specimens in immunocompromised
               patients. METHODS: A retrospective study was conducted reviewing
               patients diagnosed with COVID-19 at the Medical College of
               Wisconsin (Milwaukee, WI, USA) between March 13, 2020 and June
               11, 2020. All patients tested positive for SARS-CoV-2 via
               real-time reverse transcriptase PCR (RT-PCR), through a
               nasopharyngeal or a bronchoscopy specimen. RESULTS: During the
               study period, 53 bronchoscopy procedures were performed at the
               institution, of which five patients tested positive for
               COVID-19. Of the five patients, three underwent BAL testing
               based on high clinical suspicion for COVID-19 after the
               nasopharyngeal (NP) swab(s) was negative. All three patients had
               underlying cancers and had lymphopenia for a considerable
               duration prior to being diagnosed with COVID-19. Two patients
               had better outcomes that could be attributed to earlier BAL
               specimen testing resulting in timely medical intervention.
               CONCLUSION: This study underscores the need for early lower
               respiratory tract sampling, whenever possible, in patients with
               cancer and prolonged lymphopenia. High clinical suspicion ought
               to supersede false-negative NP reverse transcriptase-PCR as
               early bronchoscopic evaluation in cancer patients, who are
               either receiving active treatment or are immunosuppressed, can
               allow timely institution of efficacious treatment, enrollment
               into clinical trials, as well as effective infection control. In
               the apt clinical setting in patients with cancer, presumptive
               treatment may also be considered to minimize exposure to
               healthcare providers and proceduralists.",
  journal   = "Hematol. Oncol. Stem Cell Ther.",
  publisher = "Elsevier BV",
  volume    =  14,
  number    =  1,
  pages     = "65--70",
  month     =  mar,
  year      =  2021,
  keywords  = "Bronchoalveolar lavage; Cancer; Coronavirus Disease 2019
               (COVID-19); Corticosteroids; Hematological malignancy;
               Immunocompromised; SARS-CoV-2; lymphopenia",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Ganjei2021-xn,
  title     = "Methotrexate as a safe immunosuppressive agent during the
               {COVID-19} pandemic",
  author    = "Ganjei, Zakiye and Faraji Dana, Hoorvash and Ebrahimi-Dehkordi,
               Sepehr and Alidoust, Fereshte and Bahmani, Kiumars",
  abstract  = "BACKGROUND: During the ongoing COVID-19 pandemic,
               immunocompromised patients are at a higher risk of severe
               infection, since the immune system has an important role in
               defeating this disease. This study compares the severity of
               COVID-19 in patients taking methotrexate with the severity of
               their family members' illness as patients with normal immune
               system function. METHODS: A total of 35 participants, including
               14 patients taking methotrexate and 21 patients with normal
               immune function, entered this study, and the indicators of
               COVID-19 severity were compared between these two groups.
               RESULTS: The case group, who were on methotrexate therapy, had
               significantly less severe COVID-19 based on their symptoms,
               including fever (p = 0.000) and cough and dyspnea (p = 0.01) as
               well as in terms of COVID-19 severity indicators such as
               pulmonary involvement (p = 0.001), ferritin level (p = 0.001),
               white blood cell count (p = 0.008) and CRP level (p = 0.006),
               compared to the control group. There was a significant
               correlation between taking methotrexate and lower severity in
               COVID-19 disease. CONCLUSION: The present findings demonstrated
               that methotrexate does not predispose patients to severe
               COVID-19; on the contrary, patients taking methotrexate may
               experience a milder disease, possibly due to their reduced
               severe inflammatory reactions as a result of inhibited
               TNF$\alpha$, lowered IL6, and increased T regulatory cells.
               According to these findings, methotrexate appears to be a
               suitable treatment option for patients who need
               immunosuppressive medications during the COVID-19 pandemic.",
  journal   = "Int. Immunopharmacol.",
  publisher = "Elsevier BV",
  volume    =  101,
  number    = "Pt B",
  pages     = "108324",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; Immunocompromised; Methotrexate",
  language  = "en"
}

@ARTICLE{Graff2021-yf,
  title     = "Risk factors for severe {COVID-19} in children",
  author    = "Graff, Kelly and Smith, Christiana and Silveira, Lori and Jung,
               Sarah and Curran-Hays, Shane and Jarjour, Jane and Carpenter,
               Lauren and Pickard, Kasey and Mattiucci, Michael and Fresia,
               Joellen and McFarland, Elizabeth J and Dominguez, Samuel R and
               Abuogi, Lisa",
  abstract  = "BACKGROUND: There are limited pediatric data regarding severe
               COVID-19 disease. Our study aims to describe the epidemiology
               and identify risk factors for severe COVID-19 disease in
               children. METHODS: This is a retrospective cohort study among
               children with positive SARS-CoV-2 PCR from March to July 2020 at
               Children's Hospital Colorado. Risk factors for severe disease
               were analyzed as defined by hospital admission, respiratory
               support, or critical care. Univariable and multivariable
               analyses were conducted. RESULTS: Among 454 patients identified
               with SARS-CoV-2, 191 (42.1\%) were females, median age 11 years.
               Fifty-five percent of all patients identified as Hispanic
               compared with 29\% among all hospital visits in 2019 (P 20 years
               [adjusted odds ratio (aOR), 7.85; P 20 years, asthma,
               gastrointestinal condition, and similar symptoms at presentation
               were also predictors for respiratory support. Elevated
               C-reactive protein was associated with the need for critical
               care with median of 17.7 mg/dL (IQR, 5.3-22.9) versus 1.95 mg/dL
               (IQR, 0.7-5.5) among patients requiring critical versus no
               critical care (OR, 1.2; P = 0.02). CONCLUSIONS: Extremes of age,
               comorbid conditions, and elevated CRP are predictors of severe
               disease in children. Findings from this study can inform
               pediatric providers and public health officials to tailor
               clinical management, pandemic planning, and resource allocation.",
  journal   = "Pediatr. Infect. Dis. J.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  40,
  number    =  4,
  pages     = "e137--e145",
  month     =  apr,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Lee2021-lt,
  title     = "{SARS-CoV-2} vaccination for adult patients with inflammatory
               bowel disease: Expert consensus statements by {KASID}",
  author    = "Lee, Yoo Jin and Kim, Seong-Eun and Park, Yong Eun and Chang, Ji
               Young and Song, Hyun Joo and Kim, Duk Hwan and Yang, Young Joo
               and Kim, Byung Chang and Lee, Jae Gon and Yang, Hee Chan and
               Choi, Miyoung and Myung, Seung-Jae and {Clinical Practice
               Guideline Committee of the Korean Association for the Study of
               the Intestinal Diseases}",
  abstract  = "Coronavirus disease 2019 (COVID-19), caused by the novel
               coronavirus, is threatening global health worldwide with
               unprecedented contagiousness and severity. The best strategy to
               overcome COVID-19 is a vaccine. Various vaccines are currently
               being developed, and mass vaccination is in progress. Despite
               the very encouraging clinical trial results of these vaccines,
               there is insufficient information on the safety and efficacy of
               vaccines for inflammatory bowel disease (IBD) patients facing
               various issues. After reviewing current evidence and
               international guidelines, the Korean Association for the Study
               of Intestinal Diseases (KASID) developed an expert consensus
               statement on COVID-19 vaccination issues for Korean IBD
               patients. This expert consensus statement emphasizes that severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               vaccination be strongly recommended for IBD patients, and it is
               safe for IBD patients receiving immunomodulatory therapy.",
  journal   = "Korean J. Gastroenterol.",
  publisher = "The Korean Society of Gastroenterology",
  volume    =  78,
  number    =  2,
  pages     = "117--128",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; COVID-19 vaccines; Inflammatory bowel diseases;
               SARS-CoV-2",
  language  = "ko"
}

@ARTICLE{Kim2021-ge,
  title    = "{RSV} genomic diversity and the development of a globally
              effective {RSV} intervention",
  author   = "Kim, Sonnie and Williams, Thomas C and Viboud, Cecile and
              Campbell, Harry and Chen, Jiani and Spiro, David J",
  abstract = "Respiratory syncytial virus (RSV) is the most common cause of
              serious lower respiratory tract illness in infants and children
              and causes significant disease in the elderly and
              immunocompromised. Recently there has been an acceleration in the
              development of candidate RSV vaccines, monoclonal antibodies and
              therapeutics. However, the effects of RSV genomic variability on
              the implementation of vaccines and therapeutics remain poorly
              understood. To address this knowledge gap, the National Institute
              of Allergy and Infectious Diseases and the Fogarty International
              Center held a workshop to summarize what is known about the
              global burden and transmission of RSV disease, the
              phylogeographic dynamics and genomics of the virus, and the
              networks that exist to improve the understanding of RSV disease.
              Discussion at the workshop focused on the implications of viral
              evolution and genomic variability for vaccine and therapeutics
              development in the context of various immunization strategies.
              This paper summarizes the meeting, highlights research gaps and
              future priorities, and outlines what has been achieved since the
              meeting took place. It concludes with an examination of what the
              RSV community can learn from our understanding of SARS-CoV-2
              genomics and what insights over sixty years of RSV research can
              offer the rapidly evolving field of COVID-19 vaccines.",
  journal  = "Vaccine",
  volume   =  39,
  number   =  21,
  pages    = "2811--2820",
  month    =  may,
  year     =  2021,
  keywords = "Epidemiology; Evolution; Genomics; Global health; Respiratory
              syncytial virus; Therapeutics; Transmission; Vaccines",
  language = "en"
}

@ARTICLE{Sahu2021-mx,
  title    = "Challenges of cellular therapy during the {COVID-19} pandemic",
  author   = "Sahu, Kamal Kant and Ailawadhi, Sikander and Malvik, Natalie and
              Cerny, Jan",
  abstract = "Currently, coronavirus disease 2019 (COVID-19) has spread
              worldwide and continues to rise. There remains a significant
              unmet need for patients with hematological malignancies requiring
              specialized procedures and treatments, like cellular therapy to
              treat or cure their disease. For instance, chimeric antigen
              receptor T (CAR-T) cell therapy is approved for
              relapsed/refractory (after two or more lines of therapy) diffuse
              large B cell lymphoma and B cell acute lymphoblastic leukemia
              that is refractory or in the second relapse in patients younger
              than 25 years of age. Similarly, hematopoietic stem cell
              transplantation (HSCT) can be a lifesaving procedure for many
              patients, such as those with acute myeloid leukemia with
              high-risk cytogenetics. Unfortunately, the COVID-19 pandemic has
              thrust upon the hematologists and transplant specialists' unique
              challenges with the implementation and management of cellular
              therapy. One of the significant concerns regarding this
              immunocompromised patient population is the significant risk of
              acquiring SARS-CoV-2 infection due to its highly contagious
              nature. Experts have recommended that if medically indicated,
              especially in high-risk disease (where chemotherapy is unlikely
              to work), these lifesaving procedures should not be delayed even
              during the COVID-19 pandemic. However, proceeding with CAR-T cell
              therapy and HSCT during the pandemic is a considerable task and
              requires dedication from the transplant team and buy-in from the
              patients and their family or support system. Open conversations
              should be held with the patients about the risks involved in
              undergoing cellular therapies during current times and the
              associated future uncertainties.",
  journal  = "Adv. Exp. Med. Biol.",
  volume   =  1318,
  pages    = "657--672",
  year     =  2021,
  keywords = "COVID-19; Cellular therapy; Chimeric antigen receptor;
              Coronavirus; Pandemic; Stem cells; T cells",
  language = "en"
}

@ARTICLE{Dhand2021-vi,
  title     = "Successful liver transplantation in a patient recovered from
               {COVID-19}",
  author    = "Dhand, Abhay and Bodin, Roxana and Wolf, David C and Schluger,
               Aaron and Nabors, Christopher and Nog, Rajat and Diflo, Thomas
               and Nishida, Seigo",
  abstract  = "Transplantation in potential candidates who have recently
               recovered from COVID-19 is a challenge with uncertainties
               regarding the diagnosis, multi-organ systemic involvement,
               prolonged viral shedding in immunocompromised patients, and
               optimal immunosuppression. A 42 year male with alcoholic
               hepatitis underwent a successful deceased donor liver
               transplantation 71 days after the initial diagnosis of COVID-19.
               At the time of transplant, he was SARS-CoV-2 PCR negative for 24
               days and had a MELD score of 33. His post-operative course was
               complicated by acute rejection which responded to intense
               immune-suppression using T-cell depletion and steroids. He was
               discharged with normal end-organ function and no evidence of any
               active infection including COVID-19. Prospective organ
               transplant recipients who have recovered from COVID-19 can be
               considered for transplantation after careful pre-transplant
               evaluation, donor selection, and individualized risk-benefit
               analysis.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  2,
  pages     = "e13492",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; coronavirus; liver transplantation",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Cordova-Martinez2021-gn,
  title     = "{$B$-glucans} could be adjuvants for {SARS-CoV-2} virus vaccines
               ({COVID-19})",
  author    = "C{\'o}rdova-Mart{\'\i}nez, Alfredo and Caballero-Garc{\'\i}a,
               Alberto and Roche, Enrique and Noriega, David C",
  abstract  = "Waiting for an effective treatment against the SARS-CoV-2 virus
               (the cause of COVID-19), the current alternatives include
               prevention and the use of vaccines. At the moment, vaccination
               is the most effective strategy in the fight against pandemic.
               Vaccines can be administered with different natural biological
               products (adjuvants) with immunomodulating properties. Adjuvants
               can be taken orally, complementing vaccine action. Adjuvant
               compounds could play a key role in alleviating the symptoms of
               the disease, as well as in enhancing vaccine action. Adjuvants
               also contribute to an effective immune response and can enhance
               the protective effect of vaccines in immunocompromised
               individuals such as the elderly. Adjuvants must not produce
               adverse effects, toxicity, or any other symptoms that could
               alter immune system function. Vaccine adjuvants are substances
               of wide varying chemical structure that are used to boost the
               immune response against a simultaneously administered antigen.
               Glucans could work as adjuvants due to their immunomodulatory
               biological activity. In this respect, $\beta$-(1,3)-(1,6)
               glucans are considered the most effective and safe according to
               the list issued by the European Commission. Only glucans with a
               $\beta$-(1,3) bond linked to a $\beta$-(1,6) are considered
               modulators of certain biological responses. The aim of this
               review is to present the possible effects of $\beta$-glucans as
               adjuvants in the efficacy of vaccines against SARS-CoV-2 virus.",
  journal   = "Int. J. Environ. Res. Public Health",
  publisher = "MDPI AG",
  volume    =  18,
  number    =  23,
  pages     = "12636",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunomodulators; vaccination;
               $\beta$-glucans",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Hadi2021-qs,
  title     = "{COVID-19} vaccination is safe and effective in patients with
               inflammatory bowel disease: Analysis of a large
               multi-institutional research network in the United States",
  author    = "Hadi, Yousaf Bashir and Thakkar, Shyam and Shah-Khan, Sardar
               Momin and Hutson, William and Sarwari, Arif and Singh,
               Shailendra",
  journal   = "Gastroenterology",
  publisher = "Elsevier BV",
  volume    =  161,
  number    =  4,
  pages     = "1336--1339.e3",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Crohn's Disease; Inflammatory Bowel Disease;
               Ulcerative Colitis; Vaccination",
  language  = "en"
}

@ARTICLE{Moreno-Noguez2021-mx,
  title     = "Risk factors associated with {SARS-CoV-2} pneumonia in the
               pediatric population",
  author    = "Moreno-Noguez, Mois{\'e}s and Rivas-Ruiz, Rodolfo and
               Roy-Garc{\'\i}a, Ivonne A and Pacheco-Rosas, Daniel O and
               Moreno-Espinosa, Sarbelio and Flores-Pulido, Andrey A",
  abstract  = "INTRODUCCI{\'O}N: Hasta ahora existen pocos estudios sobre las
               caracter{\'\i}sticas cl{\'\i}nicas de la poblaci{\'o}n
               pedi{\'a}trica con neumon{\'\i}a por COVID-19. El objetivo de
               este estudio fue analizar los datos que se asocian con el
               desarrollo de neumon{\'\i}a en ni{\~n}os y adolescentes con
               infecci{\'o}n por SARS-CoV-2 en M{\'e}xico. M{\'E}TODOS: Se
               llev{\'o} a cabo un an{\'a}lisis secundario de la base de datos
               de la Direcci{\'o}n General de Epidemiolog{\'\i}a del Gobierno
               Mexicano. Se incluyeron menores de 19 a{\~n}os con infecci{\'o}n
               por SARS-CoV-2 confirmada mediante la prueba de
               retrotranscripci{\'o}n acoplada a la reacci{\'o}n en cadena de
               la polimerasa (RT-PCR). La variable dependiente fue el
               diagn{\'o}stico de neumon{\'\i}a. Se calcularon las razones de
               momios (RM) y los intervalos de confianza del 95\% (IC95\%). Se
               realizaron modelos de regresi{\'o}n log{\'\i}stica m{\'u}ltiple
               para ajustar los factores asociados a neumon{\'\i}a. RESULTADOS:
               Se incluyeron 1443 ni{\~n}os con diagn{\'o}stico de COVID-19. La
               mediana de edad de los participantes fue de 12 a{\~n}os (rango
               intercuartilar 25-75: 5-16). La neumon{\'\i}a se present{\'o} en
               141 ni{\~n}os (9.8\%). Los principales factores de riesgo fueron
               edad < 3 a{\~n}os (RM: 3.5; IC95\%: 2.45-5.03), diabetes u
               obesidad (RM: 12.6; IC95\%: 4.62-34.91) e inmunocompromiso (RM:
               7.03; IC95\%: 3.97-13.61). CONCLUSIONES: Los ni{\~n}os con
               COVID-19 menores de 3 a{\~n}os y con comorbilidad, especialmente
               diabetes u obesidad, y los inmunocomprometidos presentan mayor
               riesgo de desarrollar neumon{\'\i}a. BACKGROUND: Currently,
               there are a few studies on the clinical characteristics of the
               pediatric population with COVID-19 and pneumonia. This study
               aimed to analyze data associated with the development of
               pneumonia in children and adolescents with SARS-CoV-2 infection
               throughout Mexico. METHODS: We conducted a secondary analysis of
               the database of the Direcci{\'o}n General de Epidemiolog{\'\i}a
               of the Mexican Government. We included children under the age of
               19 who were confirmed with SARS-CoV-2 infection by reverse
               transcription-polymerase chain reaction (RT-PCR) test. The
               dependent variable was the diagnosis of pneumonia. Odds ratios
               (OR) and 95\% confidence intervals (95\% CI) were calculated.
               Multiple logistic regression models were performed to adjust
               factors associated with pneumonia. RESULTS: A total of 1443
               children with a COVID-19 diagnosis were included. The median age
               of the participants was 12 years (interquartile range 25, 75: 5,
               16). Pneumonia occurred in 141 children (9.8\%). The main risk
               factors were age < 3 years (OR, 3.5; 95\%CI, 2.45-5.03);
               diabetes or obesity (OR, 12.6; 95\%CI, 4.62-34.91); and
               immunocompromise (OR, 7.03; 95\%CI, 3.97-13.61). CONCLUSIONS:
               Children < 3 years with COVID-19 and comorbidities, especially
               diabetes or obesity, and immunocompromised patients have a
               higher risk of developing pneumonia.",
  journal   = "Bol. Med. Hosp. Infant. Mex.",
  publisher = "Publicidad Permanyer, SLU",
  volume    =  78,
  number    =  4,
  pages     = "251--258",
  year      =  2021,
  keywords  = "COVID-19; Factores de riesgo; Neumon{\'\i}a; Pediatrics;
               Pediatr{\'\i}a; Pneumonia; Risk-factors",
  language  = "en"
}

@ARTICLE{Hayashi2021-ma,
  title     = "A retrospective analysis of perioperative chemotherapy and
               Coronavirus disease in patients with breast cancer",
  author    = "Hayashi, Kazumi and Tamura, Miho and Nagasaki, Eijiro and
               Yoshii, Yukiko and Ishigaki, Takayuki and Kazama, Takashi and
               Kamio, Makiko and Nogi, Hiroko and Toriumi, Yasuo and Takeyama,
               Hiroshi and Yano, Shingo",
  abstract  = "BACKGROUND/AIM: Since January 2020, coronavirus disease
               (COVID-19) cases have been confirmed in Japan, and the number of
               patients with COVID-19 has been increasing. Two emergency
               declarations have been made previously and one is currently in
               effect. Based on our experience of a situation that could affect
               cancer treatment, this study retrospectively examined the
               correlation between perioperative anticancer therapy and
               COVID-19 incidence in patients with breast cancer. PATIENTS AND
               METHODS: Patients who underwent perioperative anticancer therapy
               for breast cancer at our hospital from February 2020 to February
               2021 were included in this study. The presence or absence of
               COVID-19, timing of anticancer drug initiation, and clinical
               data were collected. RESULTS: No cases of COVID-19 were
               diagnosed in patients receiving perioperative anticancer therapy
               at our hospital. CONCLUSION: Regimen modification, active use of
               supportive care, and patient lifestyle were factors reducing the
               incidence of COVID-19.",
  journal   = "Anticancer Res.",
  publisher = "Anticancer Research USA Inc.",
  volume    =  41,
  number    =  4,
  pages     = "2193--2195",
  month     =  apr,
  year      =  2021,
  keywords  = "Covid-19; breast cancer; chemotherapy",
  language  = "en"
}

@ARTICLE{Haddad2021-zq,
  title     = "Cancer patients in the era of Coronavirus: What to fear most?",
  author    = "Haddad, Fady Gh and Kourie, Hampig Raphael and Gebara, Nicole
               and Matta, Christian and Eid, Roland and El Karak, Fady and
               Nasr, Fadi and Chahine, Georges and Ghosn, Marwan and Kattan,
               Joseph",
  abstract  = "BACKGROUND: The severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) pandemic led to a worldwide medical crisis,
               affecting mostly immunocompromised patients, such as cancer
               patients. Various cancer societies have issued recommendations
               regarding patients care, but few studies addressed the
               perception of cancer patients regarding this pandemic.
               OBJECTIVE: The aim of the study was to assess the perception of
               cancer patients regarding their health risks during this
               pandemic and the preventive measures taken. MATERIALS AND
               METHODS: An anonymous survey was conducted among cancer patients
               presenting for their treatment, during 10 consecutive working
               days, at the one-day clinic of Hotel-Dieu de France University
               hospital in Beirut. We evaluated their state of disease,
               comorbidities, precautions taken, and their concerns regarding
               the virus spread. RESULTS: A total of 216 patients responded
               with a mean age of 60 years. The majority had a good performance
               status (performance status = 0-1 in 79.6\%), 51.4\% had
               metastatic disease, and chemotherapy was the main therapy used
               (65.7\%). A total of 52.3\% of patients considered themselves to
               be at increased risk of contracting the virus. A total of 55.1\%
               were more worried about the coronavirus rather than their
               disease. The priority was for the treatment of their cancer in
               47.7\% of the total patients studied. Of note, only 2.8\% of
               planned one-day clinic reservations were canceled or postponed
               to avoid COVID-19 exposure. CONCLUSIONS: Although cancer is a
               disease with a high mortality rate, many patients are more
               concerned about the actual pandemic rather than their disease.
               Nevertheless, the absenteeism from their treatment sessions
               during the COVID-19 atmosphere was minimal.",
  journal   = "J. Patient Saf.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  17,
  number    =  1,
  pages     = "e35--e38",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Tavakolpour2021-ut,
  title     = "A systematic review on efficacy, safety, and
               treatment-durability of low-dose rituximab for the treatment of
               Pemphigus: special focus on {COVID-19} pandemic concerns",
  author    = "Tavakolpour, Soheil and Aryanian, Zeinab and Seirafianpour,
               Farnoosh and Dodangeh, Milad and Etesami, Ifa and Daneshpazhooh,
               Maryam and Balighi, Kamran and Mahmoudi, Hamidreza and Goodarzi,
               Azadeh",
  abstract  = "BACKGROUND: Rituximab is a FDA-approved monoclonal antibody for
               adults with moderate to severe potentially life-threatening
               pemphigus vulgaris. Recent studies have focused on assessments
               of efficacy and safety of low-dose rituximab (<2 gram in each
               cycle). METHOD: Databases were searched from 2010 to 2020 (last
               update: 1 June 2020). RESULT: Nine studies were entered;
               including180 cases (92: women, 88: men, age range: 9-83 years).
               The dosages of each Rituximab cycle varied between
               ultra-low-dose ($\leq$500 mg for a cycle, either multiple
               infusions or a single infusion), low-dose (2 $\times$ 375 mg/m2
               or 2 $\times$ 500 mg) and modified-dose (3 $\times$ 375 mg/m2 or
               3 $\times$ 500 mg). The efficacy and safety of Rituximab in the
               studies are known by the recovery time, relapse time, and side
               events. According to the studies, 2 $\times$ 500 can lead to
               complete remission in a broad range, from 35 to 82\%. These
               differences might be explained by different end-points and
               variable cumulative corticosteroid dosage after RTX
               administration. Although the studies showed that low dose RTX is
               efficient, there are some controversies regarding the choosing
               low-dose for severe patients. CONCLUSION: Considering the
               effectiveness of low-dose, intermediate dose, and ultra-low-dose
               protocols of Rituximab in inducing remission in pemphigus
               disease and considering factors such as cost of therapy, and the
               need to induce a minimum of immunosuppression for a minimum
               duration in the COVID-19 pandemic, suggested to use low-dose
               Rituximab protocol (2 infusions of 500 mg Rituximab: interval of
               2 weeks) to induce the remission in mild-to-moderate pemphigus
               patients.",
  journal   = "Immunopharmacol. Immunotoxicol.",
  publisher = "Informa UK Limited",
  volume    =  43,
  number    =  5,
  pages     = "507--518",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Pemphigus; autoimmune bullous skin disorder; low-dose;
               rituximab; systematic review; ultra-low-dose; under-standard
               dose",
  language  = "en"
}

@ARTICLE{Borges2021-zu,
  title     = "Long-term evolution of {SARS-CoV-2} in an immunocompromised
               patient with non-Hodgkin lymphoma",
  author    = "Borges, V{\'\i}tor and Isidro, Joana and Cunha, M{\'a}rio and
               Cochicho, Daniela and Martins, Lu{\'\i}s and Banha, Lu{\'\i}s
               and Figueiredo, Margarida and Rebelo, Leonor and Trindade, Maria
               C{\'e}u and Duarte, S{\'\i}lvia and Vieira, Lu{\'\i}s and Alves,
               Maria Jo{\~a}o and Costa, In{\^e}s and Guiomar, Raquel and
               Santos, Madalena and Cort{\^e}-Real, Rita and Dias, Andr{\'e}
               and P{\'o}voas, Diana and Cabo, Jo{\~a}o and Figueiredo, Carlos
               and Manata, Maria Jos{\'e} and Maltez, Fernando and Gomes da
               Silva, Maria and Gomes, Jo{\~a}o Paulo",
  abstract  = "Recent studies have shown that persistent SARS-CoV-2 infections
               in immunocompromised patients can trigger the accumulation of an
               unusual high number of mutations with potential relevance at
               both biological and epidemiological levels. Here, we report a
               case of an immunocompromised patient (non-Hodgkin lymphoma
               patient under immunosuppressive therapy) with a persistent
               SARS-CoV-2 infection (marked by intermittent positivity) over at
               least 6 months. Viral genome sequencing was performed at days 1,
               164, and 171 to evaluate SARS-CoV-2 evolution. Among the 15
               single-nucleotide polymorphisms (SNPs) (11 leading to amino acid
               alterations) and 3 deletions accumulated during this long-term
               infection, four amino acid changes (V3G, S50L, N87S, and A222V)
               and two deletions (18-30del and 141-144del) occurred in the
               virus Spike protein. Although no convalescent plasma therapy was
               administered, some of the detected mutations have been
               independently reported in other chronically infected
               individuals, which supports a scenario of convergent adaptive
               evolution. This study shows that it is of the utmost relevance
               to monitor the SARS-CoV-2 evolution in immunocompromised
               individuals, not only to identify novel potentially adaptive
               mutations, but also to mitigate the risk of introducing
               ``hyper-evolved'' variants in the community. IMPORTANCE Tracking
               the within-patient evolution of SARS-CoV-2 is key to
               understanding how this pandemic virus shapes its genome toward
               immune evasion and survival. In the present study, by monitoring
               a long-term COVID-19 immunocompromised patient, we observed the
               concurrent emergence of mutations potentially associated with
               immune evasion and/or enhanced transmission, mostly targeting
               the SARS-CoV-2 key host-interacting protein and antigen. These
               findings show that the frequent oscillation in the immune status
               in immunocompromised individuals can trigger an accelerated
               virus evolution, thus consolidating this study model as an
               accelerated pathway to better understand SARS-CoV-2 adaptive
               traits and anticipate the emergence of variants of concern.",
  journal   = "mSphere",
  publisher = "American Society for Microbiology",
  volume    =  6,
  number    =  4,
  pages     = "e0024421",
  month     =  aug,
  year      =  2021,
  keywords  = "SARS-CoV-2; convergent evolution; genome sequencing;
               immunocompromised host; long-term infection",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Mrzljak2021-vf,
  title     = "Seroprevalence of {SARS-CoV-2} in Croatian solid-organ
               transplant recipients",
  author    = "Mrzljak, Anna and Jurekovi{\'c}, {\v Z}eljka and Pavi{\v
               c}i{\'c}-{\v S}ari{\'c}, Jadranka and Stevanovi{\'c}, Vladimir
               and Tabain, Irena and Hru{\v s}kar, {\v Z}eljka and Mikuli{\'c},
               Danko and Barbi{\'c}, Ljubo and Vilibi{\'c}-{\v C}avlek, Tatjana",
  abstract  = "Introduction: The data on the coronavirus disease (COVID-19) in
               solid-organ transplant recipients (SOTRs) in Croatia is unknown.
               The aim of this study was to analyze the seroprevalence of
               severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
               Croatian SOTRs. Materials and methods: From 7 September to 27
               November 2020 (beginning of the second COVID-19 pandemic wave),
               a cross-sectional screening for COVID-19 was performed in the
               adult outpatient liver (LTRs; N = 280) and kidney transplant
               recipients (KTRs; N = 232). Serum samples were initially tested
               for SARS-CoV-2 IgG antibodies using a commercial enzyme-linked
               immunosorbent assay (ELISA; Vircell Microbiologists, Granada,
               Spain). All positive samples were confirmed using a virus
               neutralization test (VNT). Data on risk exposure and COVID-19
               related symptoms were collected using a questionnaire. Results:
               The transplanted cohort's seroprevalence detected by ELISA and
               VNT was 20.1\% and 3.1\%, respectively. Neutralizing (NT)
               antibodies developed in 15.6\% of anti-SARS-CoV-2 ELISA IgG
               positive SOTRs. The difference in seropositivity rates between
               LTRs and KTRs was not statistically significant (ELISA 21.1\%
               vs. 19.0\%, P = 0.554; VNT 3.6\% vs. 2.6\%, P = 0.082). Overall
               VNT positivity rates were higher in patients who reported
               participation in large community events (5.9\% vs. 1.0\%; P =
               0.027) as well as in patients who reported COVID-19 related
               symptoms in the past six months. In addition, symptomatic VNT
               positive patients showed significantly higher (P = 0.031) NT
               antibody titers (median 128, interquartile range (IQR) = 32-128)
               compared to asymptomatic patients (median 16, IQR = 16-48).
               Conclusions: This study showed that 15.6\% of anti-SARS-CoV-2
               ELISA positive Croatian SOTRs developed NT antibodies indicating
               protective immunity. Further studies are needed to determine the
               dynamic of NT antibodies and COVID-19 immunity duration in
               immunocompromised populations such as LTRs and KTRs.",
  journal   = "Biochem. Med. (Zagreb)",
  publisher = "Croatian Society for Medical Biochemistry and Laboratory
               Medicine",
  volume    =  31,
  number    =  3,
  pages     = "030901",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2 antibodies; seroprevalence; solid-organ
               transplant recipients",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Ghazizadeh_Esslami2021-zk,
  title    = "{COVID-19} in transplant recipient children: An Iranian referral
              hospital-based study",
  author   = "Ghazizadeh Esslami, Golnaz and Mamishi, Setareh and Mahmoudi,
              Shima and Navaeian, Amene and Behfar, Maryam and Hamidieh, Amir
              Ali and Alimadadi, Hosein and Mahmoudieh, Yasmine",
  abstract = "To our knowledge, there is still very limited information on the
              severity, mortality, laboratory, and radiologic findings of
              COVID-19 infection in transplant patients, particularly children.
              In this study, we report and analyze 7 transplant recipients with
              laboratory-confirmed COVID-19 infection. The median age was 7.5
              years (IQR: 31month-10 years), and 71\% of the patients were
              male. All cases presented with a fever. The median duration of
              fever before admission was 2 days (IQR:1-8 days). Five patients
              (71\%) experienced cough and dyspnea. Lymphocytopenia (Median of
              0.6 (IQR: 0.14-2.0$\times$ 10 cells per L) and thrombocytopenia
              (Median of 65 (IQR: 49-201$\times$ 10 cells per L) were the most
              common CBC findings (both seen in 5 out of the 7 patients. Among
              4 of the patients who underwent CT scans, 2 had ground glass
              opacity and consolidations. The mean number of lobe involvement
              in our patients was 3(0-5), and 75\% of the cases showed
              bilateral lung involvement in the imaging. In 4 patients (51\%)
              the disease course manifested severely, and 2 patients are now
              deceased (28.6\%). In conclusion, immunocompromised pediatric
              subgroups may experience higher rates of disease severity and
              mortality in comparison with the immunocompetent pediatric
              population.",
  journal  = "Acta Biomed.",
  volume   =  92,
  number   =  2,
  pages    = "e2021095",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Keuchel2021-ns,
  title     = "Infectious diseases affecting the small bowel - what not to miss",
  author    = "Keuchel, Martin and Bota, Marc and Baltes, Peter",
  abstract  = "PURPOSE OF REVIEW: This review summarizes infectious diseases
               involving the small bowel (SB) with a focus on recent literature
               related to diagnosis and pathophysiology. RECENT FINDINGS:
               Typical symptom for SB infections is diarrhea, mostly
               self-limiting. Pathogens include bacteria, viruses, fungi,
               protozoan parasites, and helminths. Host-pathogen interaction is
               of special interest in infections with potentially severe or
               prolonged course. Research uses increasingly enterocyte cell
               culture systems. SARS-CoV2 can also infect enterocytes via
               angiotensin converting enzyme 2 (ACE2) receptor and causes
               gastrointestinal complaints in some patients. Chronic SB
               infections as tuberculosis, Cytomegalovirus, or Epstein-Barr
               virus have to be differentiated from Crohn's and other diseases.
               Severe rare fungal and protozoan parasitic infections can cause
               relevant morbidity in immunocompromised patients.
               Soil-transmitted helminthic infections are a special issue in
               endemic areas. SUMMARY: Many infections involve the SB,
               typically causing mild and self-limiting diarrhea. Symptomatic
               therapy, hygiene, and isolation are the mainstay of management.
               However, some patients develop severe or chronic disease.
               Immunosuppression is a major cause for severe, but also for rare
               opportunistic systemic infections that can also affect the SB.",
  journal   = "Curr. Opin. Gastroenterol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  37,
  number    =  3,
  pages     = "255--266",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Rodriguez-Pla2021-pc,
  title     = "{COVID-19} pneumonia in a patient with granulomatosis with
               polyangiitis on rituximab: case-based review",
  author    = "Rodriguez-Pla, Alicia and Vikram, Holenarasipur R and Khalid,
               Vanood and Wesselius, Lewis J",
  abstract  = "A 77-year-old man with past medical history of granulomatosis
               with polyangiitis (GPA) on rituximab and prednisone, presented
               to the hospital with worsening cough and shortness of breath. He
               had tested positive for severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) infection by nasal swab polymerase
               chain reaction (PCR) while asymptomatic, 6 weeks earlier. He
               started with cough and shortness of breath 2 weeks after his
               initial positive test. After developing symptoms, he tested
               negative twice by nasal swab PCR, but the PCR of his
               bronchioloalveolar lavage was positive for SARS-CoV-2. He did
               not develop antibodies against coronavirus. Prednisone 15 mg
               daily was continued, and he received remdesivir, and
               convalescent plasma with quick recovery. We reviewed the
               literature to search for similar cases. Our case suggests that
               SARS-CoV-2 infection in patients on rituximab may have an
               atypical presentation and the diagnosis may be delayed due to
               negative PCR testing in the nasal swab. Patients may benefit
               from treatment with convalescent plasma.",
  journal   = "Rheumatol. Int.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  8,
  pages     = "1509--1514",
  month     =  aug,
  year      =  2021,
  keywords  = "Autoimmune rheumatic disease; B cell depletion; COVID-19; GPA;
               Granulomatosis with polyangiitis; Immunosuppression;
               Immunosuppressive treatment; Rituximab; SARS-CoV-2; Vasculitis",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Izurieta2021-ac,
  title     = "Natural history of Coronavirus disease 2019: Risk factors for
               hospitalizations and deaths among >26 million {US} Medicare
               beneficiaries",
  author    = "Izurieta, Hector S and Graham, David J and Jiao, Yixin and Hu,
               Mao and Lu, Yun and Wu, Yue and Chillarige, Yoganand and
               Wernecke, Michael and Menis, Mikhail and Pratt, Douglas and
               Kelman, Jeffrey and Forshee, Richard",
  abstract  = "BACKGROUND: The current study was performed to evaluate risk
               factors for severe coronavirus disease 2019 (COVID-19) outcomes
               among Medicare beneficiaries during the pandemic's early phase.
               METHODS: In a retrospective cohort study covering Medicare
               fee-for-service beneficiaries, we separated out elderly
               residents in nursing homes (NHs) and those with end-stage renal
               disease (ESRD) from the primary study population of individuals
               age $\geq$65 years. Outcomes included COVID-19 hospital
               encounters and COVID-19-associated deaths. We estimated adjusted
               odds ratios (ORs) using logistic regression. RESULTS: We
               analyzed 25 333 329 elderly non-NH beneficiaries without ESRD,
               653 966 elderly NH residents, and 292 302 patients with ESRD.
               COVID-related death rates (per 10 000) were much higher among
               elderly NH residents (275.7) and patients with ESRD (60.8) than
               in the primary study population (5.0). Regression-adjusted
               clinical predictors of death among the primary population
               included immunocompromised status (OR, 1.43), frailty index
               conditions such as cognitive impairment (3.16), and other
               comorbid conditions, including congestive heart failure (1.30).
               Demographic-related risk factors included male sex (OR, 1.77),
               older age (3.09 for 80- vs 65-year-olds), Medicaid
               dual-eligibility status (2.17), and racial/ethnic minority.
               Compared with whites, ORs were higher for blacks (2.47),
               Hispanics (3.11), and Native Americans (5.82). Results for
               COVID-19 hospital encounters were consistent. CONCLUSIONS:
               Frailty, comorbid conditions, and race/ethnicity were strong
               risk factors for COVID-19 hospitalization and death among the US
               elderly.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  223,
  number    =  6,
  pages     = "945--956",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; disease severity; epidemics; risk factors",
  language  = "en"
}

@ARTICLE{Kapila2021-xh,
  title     = "Oral health's inextricable connection to systemic health:
               Special populations bring to bear multimodal relationships and
               factors connecting periodontal disease to systemic diseases and
               conditions",
  author    = "Kapila, Yvonne L",
  abstract  = "The landscape in dentistry is changing as emerging studies
               continue to reveal that periodontal health impacts systemic
               health, and vice versa. Population studies, clinical studies,
               and in vitro animal studies underscore the critical importance
               of oral health to systemic health. These inextricable
               relationships come to the forefront as oral diseases, such as
               periodontal disease, take root. Special populations bring to
               bear the multimodal relationships between oral and systemic
               health. Specifically, periodontal disease has been associated
               with diabetes, metabolic syndrome, obesity, eating disorders,
               liver disease, cardiovascular disease, Alzheimer disease,
               rheumatoid arthritis, adverse pregnancy outcomes, and cancer.
               Although bidirectional relationships are recognized, the
               potential for multiple comorbidities, relationships, and
               connections (multimodal relationships) also exists. Proposed
               mechanisms that mediate this connection between oral and
               systemic health include predisposing and precipitating factors,
               such as genetic factors (gene polymorphisms), environmental
               factors (stress, habits-such as smoking and high-fat
               diets/consumption of highly processed foods), medications,
               microbial dysbiosis and bacteremias/viremias/microbemias, and an
               altered host immune response. Thus, in a susceptible host, these
               predisposing and precipitating factors trigger the onset of
               periodontal disease and systemic disease/conditions. Further,
               high-throughput sequencing technologies are shedding light on
               the dark matter that comprises the oral microbiome. This has
               resulted in better characterization of the oral microbial
               dysbiosis, including putative bacterial periodontopathogens and
               shifts in oral virome composition during disease. Multiple
               laboratory and clinical studies have illustrated that both
               eukaryotic and prokaryotic viruses within subgingival plaque and
               periodontal tissues affect periodontal inflammation, putative
               periodontopathogens, and the host immune response. Although the
               association between herpesviruses and periodontitis and the
               degree to which these viruses directly aggravate periodontal
               tissue damage remain unclear, the benefits to periodontal health
               found from prolonged administration of antivirals in
               immunocompromised or immunodeficient individuals demonstrates
               that specific populations are possibly more susceptible to viral
               periodontopathogens. Thus, it may be important to further
               examine the implications of viral pathogen involvement in
               periodontitis and perhaps it is time to embrace the viral dark
               matter within the periodontal environment to fully comprehend
               the pathogenesis and systemic implications of periodontitis.
               Emerging data from the coronavirus disease 2019 pandemic further
               underscores the inextricable connection between oral and
               systemic health, with high levels of the severe acute
               respiratory syndrome coronavirus 2 angiotensin-converting enzyme
               2 receptor noted on oral tissues (tongue) and an allostatic load
               or overload paradigm of chronic stress likely contributing to
               rapid breakdown of oral/dental, periodontal, and peri-implant
               tissues. These associations exist within a framework of
               viremias/bacteremias/microbemias, systemic inflammation, and/or
               disturbances of the immune system in a susceptible host. A
               thorough review of systemic and oral diseases and conditions and
               their mechanistic, predisposing, and precipitating factors are
               paramount to better addressing the oral and systemic health and
               needs of our patients.",
  journal   = "Periodontol. 2000",
  publisher = "Wiley",
  volume    =  87,
  number    =  1,
  pages     = "11--16",
  month     =  oct,
  year      =  2021,
  keywords  = "microbemias; oral health; periodontal disease; susceptible host;
               systemic disease; systemic inflammation",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Blasi2021-rb,
  title     = "{SARS-CoV-2} vaccines: A critical perspective through efficacy
               data and barriers to herd immunity",
  author    = "Blasi, Francesco and Gramegna, Andrea and Sotgiu, Giovanni and
               Saderi, Laura and Voza, Antonio and Aliberti, Stefano and Amati,
               Francesco",
  abstract  = "Non-pharmacological interventions and tracing-testing strategy
               proved insufficient to reduce SARS-CoV-2 spreading worldwide.
               Several vaccines with different mechanisms of action are
               currently under development. This review describes the potential
               target antigens evaluated for SARS-CoV-2 vaccine in the context
               of both conventional and next-generation platforms. We reported
               experimental data from phase-3 trials with a focus on different
               definitions of efficacy as well as factors affecting real-life
               effectiveness of SARS-CoV-2 vaccination, including logistical
               issues associated to vaccine availability, delivery, and
               immunization strategies. On this background, new variants of
               SARS-CoV-2 are discussed. We also provided a critical view on
               vaccination in special populations at higher risk of infection
               or severe disease as elderly people, pregnant women and
               immunocompromised patients. A final paragraph addresses safety
               on the light of the unprecedented reduction of length of the
               vaccine development process and faster authorization.",
  journal   = "Respir. Med.",
  publisher = "Elsevier BV",
  volume    =  180,
  number    =  106355,
  pages     = "106355",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Primary prevention; SARS-CoV-2; Vaccination",
  language  = "en"
}

@ARTICLE{Perez2021-yb,
  title     = "Liver involvement in children with {SARS-COV-2} infection: Two
               distinct clinical phenotypes caused by the same virus",
  author    = "Perez, Adriana and Cantor, Amanda and Rudolph, Bryan and Miller,
               Jonathan and Kogan-Liberman, Debora and Gao, Qi and Da Silva,
               Bernardo and Margolis, Kara G and Ovchinsky, Nadia and Martinez,
               Mercedes",
  abstract  = "BACKGROUND AND AIMS: Severe Acute Respiratory Syndrome
               Coronavirus-2 (SARS-CoV-2) associated acute liver injury (ALI)
               has been linked to poor outcomes in adults. Here we compare
               characteristics in children with elevated ALT (E-ALT) in two
               distinct manifestations of the infection, multisystem
               inflammatory syndrome-children (MIS-C) and coronavirus disease
               2019 (COVID-19). METHODS: This is a retrospective study of
               patients $\leq$21 years of age with positive for SARS-CoV-2 PCR.
               E-ALT was defined as alanine aminotransferase (ALT) > 40 U/L.
               Bivariate analysis and multivariable logistic regression were
               obtained to describe differences in children with and without
               E-ALT in COVID-19 and MIS-C. RESULTS: E-ALT was detected in 36\%
               of the 291 patients; 31\% with COVID-19, and 51\% with MIS-C.
               E-ALT in COVID-19 was associated with obesity (P < .001),
               immunocompromised status (P = .04), and chronic liver disease (P
               = .01). In the regression models, E-ALT in COVID-19 was
               associated with higher c-reactive protein (OR 1.08, P = .01)
               after adjusting for common independent predictors. Children with
               E-ALT and MIS-C were more often boys (P = .001), Hispanic (P =
               .04), or Black (P < .001). In MIS-C, male gender (OR 5.3, P =
               .02) and Black race (OR 4.4, P = .04) were associated with
               increased odds of E-ALT. Children with E-ALT in both cohorts had
               significantly higher multiorgan dysfunction, longer
               hospitalization, and ICU stay. Children with MIS-C had 2.3-fold
               increased risk of E-ALT compared to COVID-19. No association was
               found between E-ALT and mortality. CONCLUSION: E-ALT with
               SARS-CoV-2 presents as elevated transaminases without hepatic
               synthetic dysfunction. Patients with either manifestation of
               SARS-CoV-2 infection and E-ALT experienced more severe disease.",
  journal   = "Liver Int.",
  publisher = "Wiley",
  volume    =  41,
  number    =  9,
  pages     = "2068--2075",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 ALI in children; acute liver failure; acute liver
               injury and MISC; elevated ALT; liver involvement in SARS-CoV2",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Moelling2021-ul,
  title    = "Within-host and between-host evolution in {SARS-CoV-2-new}
              variant's source",
  author   = "Moelling, Karin",
  abstract = "Some of the newly emerging corona viral variants show high
              numbers of mutations. This is unexpected for a virus with a low
              mutation rate due to an inherent proof-reading system. Could such
              a variant arise under very special conditions occurring in a host
              where the virus replicates and mutates in a rather unlimited
              fashion, such as in immune compromised patients? The virus was
              shown to replicate in an immunosuppressed cancer patient for more
              than 105 days and might be a source of new variants. These
              patients are asymptomatic and the virus may therefore escape
              detection and attention and be high-risk. Similarly, HIV-infected
              individuals may be immunocompromised and support coronavirus
              replication with increased mutation rates. The patients may
              promote ``within-host evolution''. Some of the viruses present in
              such a highly mutagenic swarm or quasispecies within one patient
              may become founders and cause a pandemic by further
              ``between-host evolution''. B.1.1.7 with 23 mutations may be such
              a case. Immunosuppressed patients can be identified and treated
              by the synthetic antibody cocktails as passive immunization and
              kept under control. Immunosuppressed patients can be easily
              identified and supervised by healthcare workers-once they become
              aware of the risk-to avoid new variants with pandemic potential.",
  journal  = "Viruses",
  volume   =  13,
  number   =  5,
  month    =  apr,
  year     =  2021,
  keywords = "corona; emerging variants; immunosuppression; origin; pandemic;
              prevention; risk",
  language = "en"
}

@ARTICLE{Jackson2021-ge,
  title     = "Predictors at admission of mechanical ventilation and death in
               an observational cohort of adults hospitalized with Coronavirus
               disease 2019",
  author    = "Jackson, Brendan R and Gold, Jeremy A W and Natarajan, Pavithra
               and Rossow, John and Neblett Fanfair, Robyn and da Silva,
               Juliana and Wong, Karen K and Browning, Sean D and Bamrah
               Morris, Sapna and Rogers-Brown, Jessica and Hernandez-Romieu,
               Alfonso C and Szablewski, Christine M and Oosmanally, Nadine and
               Tobin-D'Angelo, Melissa and Drenzek, Cherie and Murphy, David J
               and Hollberg, Julie and Blum, James M and Jansen, Robert and
               Wright, David W and Sewell, William M and Owens, Jack D and
               Lefkove, Benjamin and Brown, Frank W and Burton, Deron C and
               Uyeki, Timothy M and Bialek, Stephanie R and Patel, Priti R and
               Bruce, Beau B",
  abstract  = "BACKGROUND: Coronavirus disease (COVID-19) can cause severe
               illness and death. Predictors of poor outcome collected on
               hospital admission may inform clinical and public health
               decisions. METHODS: We conducted a retrospective observational
               cohort investigation of 297 adults admitted to 8 academic and
               community hospitals in Georgia, United States, during March
               2020. Using standardized medical record abstraction, we
               collected data on predictors including admission demographics,
               underlying medical conditions, outpatient antihypertensive
               medications, recorded symptoms, vital signs, radiographic
               findings, and laboratory values. We used random forest models to
               calculate adjusted odds ratios (aORs) and 95\% confidence
               intervals (CIs) for predictors of invasive mechanical
               ventilation (IMV) and death. RESULTS: Compared with age <45
               years, ages 65-74 years and $\geq$75 years were predictors of
               IMV (aORs, 3.12 [95\% CI, 1.47-6.60] and 2.79 [95\% CI,
               1.23-6.33], respectively) and the strongest predictors for death
               (aORs, 12.92 [95\% CI, 3.26-51.25] and 18.06 [95\% CI,
               4.43-73.63], respectively). Comorbidities associated with death
               (aORs, 2.4-3.8; P < .05) included end-stage renal disease,
               coronary artery disease, and neurologic disorders, but not
               pulmonary disease, immunocompromise, or hypertension.
               Prehospital use vs nonuse of angiotensin receptor blockers (aOR,
               2.02 [95\% CI, 1.03-3.96]) and dihydropyridine calcium channel
               blockers (aOR, 1.91 [95\% CI, 1.03-3.55]) were associated with
               death. CONCLUSIONS: After adjustment for patient and clinical
               characteristics, older age was the strongest predictor of death,
               exceeding comorbidities, abnormal vital signs, and laboratory
               test abnormalities. That coronary artery disease, but not
               chronic lung disease, was associated with death among
               hospitalized patients warrants further investigation, as do
               associations between certain antihypertensive medications and
               death.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  73,
  number    =  11,
  pages     = "e4141--e4151",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; angiotensin receptor antagonists;
               hospitalization; mortality",
  language  = "en"
}

@ARTICLE{Zilla2021-nd,
  title     = "{SARS-CoV-2} serologic immune response in exogenously
               immunosuppressed patients",
  author    = "Zilla, Megan L and Keetch, Christian and Mitchell, Gretchen and
               McBreen, Jeffery and Shurin, Michael R and Wheeler, Sarah E",
  abstract  = "BACKGROUND: While it is presumed that immunosuppressed patients,
               such as solid organ transplant recipients on immunosuppression,
               are at greater risk from SARS-CoV-2 infection than the general
               population, the antibody response to infection in this patient
               population has not been studied. METHODS: In this report, we
               follow the anti-SARS-CoV-2 antibody levels in patients with
               COVID-19 who are undergoing exogenous immunosuppression.
               Specifically, we studied the antibody response of 3 solid organ
               transplant recipient patients, 3 patients who take daily inhaled
               fluticasone, and a patient on etanercept and daily inhaled
               fluticasone, and compared them to 5 patients not on exogenous
               immunosuppression. RESULTS: We found that the solid organ
               transplant patients on full immunosuppression are at risk of
               having a delayed antibody response and poor outcome. We did not
               find evidence that inhaled steroids or etanercept predispose
               patients to delayed immune response to SARS-CoV-2. CONCLUSION:
               The data presented here suggest that solid organ transplant
               recipients may be good candidates for early targeted
               intervention against SARS-CoV-2.",
  journal   = "J. Appl. Lab. Med.",
  publisher = "Oxford University Press (OUP)",
  volume    =  6,
  number    =  2,
  pages     = "486--490",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Yilmaz2021-yg,
  title     = "Assessment of clinical outcomes in renal transplant recipients
               with {COVID-19}",
  author    = "Yilmaz, Gulay and Ebru, Ozdemir and Ibrahim, Berber and Ulkem,
               Cakir",
  abstract  = "The coronavirus disease 2019 (COVID-19) has affected more than a
               hundred million individuals and caused more than three million
               deaths worldwide. Specific risk groups were defined for
               increased risk of mortality and morbidity in COVID-19, and renal
               transplant recipients are at a significantly increased risk
               regarding outcomes due to their immunosuppressed conditions.
               This study evaluated the general characteristics of kidney
               transplant recipients with COVID-19 infection. Among 1257
               transplant cases, 56 had COVID-19 infection, and 23 (41\%) were
               hospitalized during the 9-month study period. Among all COVID-19
               cases, 58\% were male with a mean age of 45.5 ($\pm$13.2, 19-71)
               years, and the most frequent comorbidities were hypertension
               (70.9\%) and diabetes (23.6\%). Hospitalized patients were older
               (p = 0.03) and had higher rates of hypertension (p = 0.008),
               diabetes (p = 0.002), and ischemic heart disease (p = 0.03).
               Therapeutic management included antimetabolite withdrawal and
               prednisolone increase in 71\%, calcineurin inhibitor withdrawal
               in 8\% and decrease in 58\%, hydroxychloroquine in 17\%,
               tocilizumab in 3\%, and antivirals in 67\% of patients. Acute
               kidney injury and respiratory failure developed in 34\% and
               85\%, respectively. The mortality rate was 23\%. These results
               emphasized that the COVID-19 infection in renal transplant
               recipients significantly increases the risk of morbidity and
               mortality. Therefore, these patients should be intervened
               earlier and monitored closely to prevent poor outcomes.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  12,
  pages     = "6760--6764",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; mortality; patient outcomes; renal transplant;
               transplant recipients",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Gonzalez-Candelas2021-pd,
  title     = "One year into the pandemic: Short-term evolution of {SARS-CoV-2}
               and emergence of new lineages",
  author    = "Gonz{\'a}lez-Candelas, Fernando and Shaw, Marie-Anne and Phan,
               Tung and Kulkarni-Kale, Urmila and Paraskevis, Dimitrios and
               Luciani, Fabio and Kimura, Hirokazu and Sironi, Manuela",
  abstract  = "The COVID-19 pandemic was officially declared on March 11th,
               2020. Since the very beginning, the spread of the virus has been
               tracked nearly in real-time by worldwide genome sequencing
               efforts. As of March 2021, more than 830,000 SARS-CoV-2 genomes
               have been uploaded in GISAID and this wealth of data allowed
               researchers to study the evolution of SARS-CoV-2 during this
               first pandemic year. In parallel, nomenclatures systems, often
               with poor consistency among each other, have been developed to
               designate emerging viral lineages. Despite general fears that
               the virus might mutate to become more virulent or transmissible,
               SARS-CoV-2 genetic diversity has remained relatively low during
               the first ~ 8 months of sustained human-to-human transmission.
               At the end of 2020/beginning of 2021, though, some alarming
               events started to raise concerns of possible changes in the
               evolutionary trajectory of the virus. Specifically, three new
               viral variants associated with extensive transmission have been
               described as variants of concern (VOC). These variants were
               first reported in the UK (B.1.1.7), South Africa (B.1.351) and
               Brazil (P.1). Their designation as VOCs was determined by an
               increase of local cases and by the high number of amino acid
               substitutions harboured by these lineages. This latter feature
               is reminiscent of viral sequences isolated from
               immunocompromised patients with long-term infection, suggesting
               a possible causal link. Here we review the events that led to
               the identification of these lineages, as well as emerging data
               concerning their possible implications for viral phenotypes,
               reinfection risk, vaccine efficiency and epidemic potential.
               Most of the available evidence is, to date, provisional, but
               still represents a starting point to uncover the potential
               threat posed by the VOCs. We also stress that genomic
               surveillance must be strengthened, especially in the wake of the
               vaccination campaigns.",
  journal   = "Infect. Genet. Evol.",
  publisher = "Elsevier BV",
  volume    =  92,
  number    =  104869,
  pages     = "104869",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Diagnostic tests; Lineages; SARS-CoV-2; VACCINES;
               Variants",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Gaspar-Rodriguez2021-my,
  title     = "Coronavirus persistence in human respiratory tract and cell
               culture: An overview",
  author    = "Gaspar-Rodr{\'\i}guez, Adriana and Padilla-Gonz{\'a}lez, Ana and
               Rivera-Toledo, Evelyn",
  abstract  = "Emerging human coronaviruses, including the recently identified
               SARS-CoV-2, are relevant respiratory pathogens due to their
               potential to cause epidemics with high case fatality rates,
               although endemic coronaviruses are also important for
               immunocompromised patients. Long-term coronavirus infections had
               been described mainly in experimental models, but it is
               currently evident that SARS-CoV-2 genomic-RNA can persist for
               many weeks in the respiratory tract of some individuals
               clinically recovered from coronavirus infectious disease-19
               (COVID-19), despite a lack of isolation of infectious virus. It
               is still not clear whether persistence of such viral RNA may be
               pathogenic for the host and related to long-term sequelae. In
               this review, we summarize evidence of SARS-CoV-2 RNA persistence
               in respiratory samples besides results obtained from cell
               culture and histopathology describing long-term coronavirus
               infection. We also comment on potential mechanisms of
               coronavirus persistence and relevance for pathogenesis.",
  journal   = "Braz. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  25,
  number    =  5,
  pages     = "101632",
  month     =  sep,
  year      =  2021,
  keywords  = "Cell culture; Non-productive infection; Persistence of viral
               RNA; SARS-CoV-2; Viral pathogenesis",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Keating2021-bn,
  title     = "Early detection of {SARS-CoV-2} and other infections in solid
               organ transplant recipients and household members using wearable
               devices",
  author    = "Keating, Brendan J and Mukhtar, Eyas H and Elftmann, Eric D and
               Eweje, Feyisope R and Gao, Hui and Ibrahim, Lina I and
               Kathawate, Ranganath G and Lee, Alexander C and Li, Eric H and
               Moore, Krista A and Nair, Nikhil and Chaluvadi, Venkata and
               Reason, Janaiya and Zanoni, Francesca and Honkala, Alexander T
               and Al-Ali, Amein K and Abdullah Alrubaish, Fatima and Ahmad
               Al-Mozaini, Maha and Al-Muhanna, Fahad A and Al-Romaih, Khaldoun
               and Goldfarb, Samuel B and Kellogg, Ryan and Kiryluk, Krzysztof
               and Kizilbash, Sarah J and Kohut, Taisa J and Kumar, Juhi and
               O'Connor, Matthew J and Rand, Elizabeth B and Redfield, Robert R
               and Rolnik, Benjamin and Rossano, Joseph and Sanchez, Pablo G
               and Alavi, Arash and Bahmani, Amir and Bogu, Gireesh K and
               Brooks, Andrew W and Metwally, Ahmed A and Mishra, Tejas and
               Marks, Stephen D and Montgomery, Robert A and Fishman, Jay A and
               Amaral, Sandra and Jacobson, Pamala A and Wang, Meng and Snyder,
               Michael P",
  abstract  = "The increasing global prevalence of SARS-CoV-2 and the resulting
               COVID-19 disease pandemic pose significant concerns for clinical
               management of solid organ transplant recipients (SOTR). Wearable
               devices that can measure physiologic changes in biometrics
               including heart rate, heart rate variability, body temperature,
               respiratory, activity (such as steps taken per day) and sleep
               patterns, and blood oxygen saturation show utility for the early
               detection of infection before clinical presentation of symptoms.
               Recent algorithms developed using preliminary wearable datasets
               show that SARS-CoV-2 is detectable before clinical symptoms in
               >80\% of adults. Early detection of SARS-CoV-2, influenza, and
               other pathogens in SOTR, and their household members, could
               facilitate early interventions such as self-isolation and early
               clinical management of relevant infection(s). Ongoing studies
               testing the utility of wearable devices such as smartwatches for
               early detection of SARS-CoV-2 and other infections in the
               general population are reviewed here, along with the practical
               challenges to implementing these processes at scale in pediatric
               and adult SOTR, and their household members. The resources and
               logistics, including transplant-specific analyses pipelines to
               account for confounders such as polypharmacy and comorbidities,
               required in studies of pediatric and adult SOTR for the robust
               early detection of SARS-CoV-2, and other infections are also
               reviewed.",
  journal   = "Transpl. Int.",
  publisher = "Wiley",
  volume    =  34,
  number    =  6,
  pages     = "1019--1031",
  month     =  jun,
  year      =  2021,
  keywords  = "eHealth; mHealth; telemedicine; transplantation; wearables",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Woopen2021-hv,
  title     = "Approach to {SARS-CoV-2} vaccination in patients with multiple
               sclerosis",
  author    = "Woopen, Christina and Schleu{\ss}ner, Katharina and Akg{\"u}n,
               Katja and Ziemssen, Tjalf",
  abstract  = "For more than a year now, severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) has been causing the coronavirus
               disease (COVID-19) pandemic with high mortality and detrimental
               effects on society, economy, and individual lives. Great hopes
               are being placed on vaccination as one of the most potent escape
               strategies from the pandemic and multiple vaccines are already
               in clinical use. However, there is still a lot of insecurity
               about the safety and efficacy of vaccines in patients with
               autoimmune diseases like multiple sclerosis (MS), especially
               under treatment with immunomodulatory or immunosuppressive
               drugs. We propose strategic approaches to SARS-CoV-2 vaccination
               management in MS patients and encourage fellow physicians to
               measure the immune response in their patients. Notably, both
               humoral and cellular responses should be considered since the
               immunological equivalent for protection from SARS-CoV-2 after
               infection or vaccination still remains undefined and will most
               likely involve antiviral cellular immunity. It is important to
               gain insights into the vaccine response of immunocompromised
               patients in order to be able to deduce sensible strategies for
               vaccination in the future.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "701752",
  month     =  jun,
  year      =  2021,
  keywords  = "CD20; coronavirus disease (COVID-19); immune response;
               immunomodulation; immunotherapy; multiple sclerosis; severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2);
               vaccination",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Ferrari2021-tj,
  title     = "Convalescent hyperimmune plasma for chemo-immunotherapy induced
               immunodeficiency in {COVID-19} patients with hematological
               malignancies",
  author    = "Ferrari, Silvia and Caprioli, Chiara and Weber, Alessandra and
               Rambaldi, Alessandro and Lussana, Federico",
  abstract  = "During the severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) outbreak, patients with defective immunity after
               chemo-immunotherapy due to hematological disorders showed
               prolonged symptoms and worse prognosis of coronavirus
               disease-2019 (COVID-19) pneumonia, probably due to inadequate
               adaptive immune response and noneffective viral clearance. We
               describe a single-center series of hematological
               immunocompromised patients undergoing passive immunization with
               hyperimmune plasma for persistent COVID-19 symptoms. In all
               cases, such treatment was well tolerated and contributed to
               clinical and radiological improvement and recovery; viral
               clearance was also achieved in a patients' subset. Although
               requiring further investigation, these results suggest a
               specific role for hyperimmune plasma administration in
               hematological patients.",
  journal   = "Leuk. Lymphoma",
  publisher = "Informa UK Limited",
  volume    =  62,
  number    =  6,
  pages     = "1490--1496",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; hyperimmune plasma; immunodeficiency;
               onco-hematological patients",
  language  = "en"
}

@ARTICLE{Kamrul-Hasan2021-es,
  title    = "Mucormycosis, the deadly new worry to {COVID-19} pandemic",
  author   = "Kamrul-Hasan, A B and Selim, S",
  abstract = "Recently, mucormycosis, extremely rare fungal infections are
              emerging as a matter of concern in COVID-19. The saprophytic
              fungi of Mucorales species cause the disease, Mucormycosis, only
              in immunocompromised hosts. Clinical presentation of mucormycosis
              is related to the underlying conditions; rhino-cerebral disease
              is the most common form, especially in patients with diabetes
              mellitus; pulmonary, cutaneous, or gastrointestinal infections
              can also occur. Severe COVID-19 itself is a life-threatening
              disease and various factors, including diabetes, especially when
              complicated by ketoacidosis, previous respiratory pathology,
              immunosuppressive therapy, nosocomial infection sources and
              systemic immune alterations of COVID-19 itself predispose to
              mucormycosis. No specific biomarkers are available to diagnose
              mucormycosis; imaging of the involved area and histopathological
              examination of the biopsied tissue are most important in
              diagnosis. The underlying medical conditions must be corrected;
              these include good glycemic control, tapering of steroids, and
              reducing or stopping immunosuppressive medications. Systemic
              antifungal therapy with liposomal Amphotericin B is the medical
              treatment of choice though drug resistance is not uncommon.
              Surgical debridement of devitalized tissue is often required.
              Severe COVID-19 patients with secondary co-infections require
              longer hospitalization and had higher risks of death. The
              mortality rate is almost 50\% despite timely adequate treatment.
              The judicious use of systemic glucocorticoids and
              immunosuppressive agents for treating severe disease and
              hyperglycemia control seems vital for preventing and managing
              mucormycosis.",
  journal  = "Mymensingh Med. J.",
  volume   =  30,
  number   =  3,
  pages    = "874--880",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Chen2021-ks,
  title     = "Emergence of multiple {SARS-CoV-2} antibody escape variants in
               an immunocompromised host undergoing convalescent plasma
               treatment",
  author    = "Chen, Liang and Zody, Michael C and Di Germanio, Clara and
               Martinelli, Rachel and Mediavilla, Jose R and Cunningham, Marcus
               H and Composto, Kaelea and Chow, Kar Fai and Kordalewska, Milena
               and Corvelo, Andr{\'e} and Oschwald, Dayna M and Fennessey,
               Samantha and Zetkulic, Marygrace and Dar, Sophia and Kramer,
               Yael and Mathema, Barun and Germer, Soren and Stone, Mars and
               Simmons, Graham and Busch, Michael P and Maniatis, Tom and
               Perlin, David S and Kreiswirth, Barry N",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               variants of concern (VOCs), harboring spike protein N-terminal
               domain (NTD) or receptor-binding domain (RBD) mutations, exhibit
               reduced in vitro susceptibility to convalescent-phase serum,
               commercial antibody cocktails, and vaccine neutralization and
               have been associated with reinfections. The accumulation of
               these mutations could be the consequence of intrahost viral
               evolution due to prolonged infection in immunocompromised hosts.
               In this study, we document the microevolution of SARS-CoV-2
               recovered from sequential tracheal aspirates from an
               immunosuppressed patient on steroids and convalescent plasma
               therapy and identify the emergence of multiple NTD and RBD
               mutations. SARS-CoV-2 genomes from the first swab (day 0) and
               from three tracheal aspirates (days 7, 21, and 27) were compared
               at the sequence level. We identified a mixed viral population
               with five different S protein mutations (141 to 144 deletion,
               243 to 244 deletion, E484K, Q493K, and Q493R) at the NTD or RBD
               region from the second tracheal aspirate sample (day 21) and a
               predominance of the S protein 141 to 144 LGVY deletion and E484K
               mutant on day 27. The neutralizing antibodies against various S
               protein lentiviral pseudovirus mutants, as well as the
               anti-SARS-CoV-2 total Ig and IgG, showed ``U'' shape dynamics,
               in support of the endogenous development of neutralizing
               antibodies. The patient's compromised immune status, the
               antirejection regiment, convalescent plasma treatment, and the
               development of neutralizing antibodies may have resulted in
               unique selective pressures on the intrahost genomic evolution,
               and this observation supports the hypotheses that VOCs can
               independently arise and that immunocompromised patients on
               convalescent plasma therapy are potential breeding grounds for
               immune escape mutants. IMPORTANCE Over a year of the COVID-19
               pandemic, distinct severe acute respiratory syndrome coronavirus
               2 (SARS-CoV-2) lineages have arisen in multiple geographic areas
               around the world. SARS-CoV-2 variants of concern (VOCs), i.e.,
               B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2
               (delta), harboring mutations and/or deletions in spike protein
               N-terminal domain (NTD) or receptor-binding domain (RBD) regions
               showed evidence of increased transmissibility and disease
               severity and possible reduced vaccine efficacy. In this study,
               we report the emergence of five different NTD and RBD mutations
               in an uncommon SARS-CoV-2 B.1.369 lineage from an
               immunosuppressed patient undergoing steroid and convalescent
               plasma therapy. The observation highlighted that VOCs can
               independently arise in immunocompromised populations undergoing
               anti-SARS-CoV-2 therapy, and enhanced measures will be required
               to reduce the transmission.",
  journal   = "mSphere",
  publisher = "American Society for Microbiology",
  volume    =  6,
  number    =  4,
  pages     = "e0048021",
  month     =  aug,
  year      =  2021,
  keywords  = "SARS-CoV-2; convalescent plasma; immunosuppression; spike
               protein; variants of concern",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Corey2021-ih,
  title     = "{SARS-CoV-2} variants in patients with immunosuppression",
  author    = "Corey, Lawrence and Beyrer, Chris and Cohen, Myron S and
               Michael, Nelson L and Bedford, Trevor and Rolland, Morgane",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  385,
  number    =  6,
  pages     = "562--566",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Peter2021-vv,
  title     = "{COVID-19} vaccination: Recommendations for management of
               patients with allergy or immune-based diseases",
  author    = "Peter, J",
  abstract  = "As South Africa continues to battle the second wave of
               SARS-CoV-2 infections, the imminent arrival of vaccines against
               COVID-19 offers hope. Vaccine roll-out has been accompanied by
               heightened media coverage that has created both excitement and
               anxiety, reporting on the shortened timeline of vaccine trials
               and approvals, as well as the recent series of anaphylaxis cases
               associated with the two approved mRNA COVID-19 vaccines.
               Patients with allergic and other immune-based diseases are
               subgroups especially concerned about vaccine safety and
               efficacy. This practice guideline offers broad recommendations
               for COVID-19 vaccination in various subgroups of allergic and
               immunebased disease, highlighting risk/benefit evaluation, and
               where and how routine vaccination should be altered.",
  journal   = "S. Afr. Med. J.",
  publisher = "South African Medical Association NPC",
  volume    =  111,
  number    =  4,
  pages     = "291--294",
  month     =  feb,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Friedman2021-vc,
  title     = "Impact of disease-modifying antirheumatic drugs on vaccine
               immunogenicity in patients with inflammatory rheumatic and
               musculoskeletal diseases",
  author    = "Friedman, Marcia A and Curtis, Jeffrey R and Winthrop, Kevin L",
  abstract  = "Patients with rheumatic diseases are at increased risk of
               infectious complications; vaccinations are a critical component
               of their care. Disease-modifying antirheumatic drugs may reduce
               the immunogenicity of common vaccines. We will review here
               available data regarding the effect of these medications on
               influenza, pneumococcal, herpes zoster, SARS-CoV-2, hepatitis B,
               human papilloma virus and yellow fever vaccines. Rituximab has
               the most substantial impact on vaccine immunogenicity, which is
               most profound when vaccinations are given at shorter intervals
               after rituximab dosing. Methotrexate has less substantial effect
               but appears to adversely impact most vaccine immunogenicity.
               Abatacept likely decrease vaccine immunogenicity, although these
               studies are limited by the lack of adequate control groups.
               Janus kinase and tumour necrosis factor inhibitors decrease
               absolute antibody titres for many vaccines, but do not seem to
               significantly impact the proportions of patients achieving
               seroprotection. Other biologics (interleukin-6R (IL-6R),
               IL-12/IL-23 and IL-17 inhibitors) have little observed impact on
               vaccine immunogenicity. Data regarding the effect of these
               medications on the SARS-CoV-2 vaccine immunogenicity are just
               now emerging, and early glimpses appear similar to our
               experience with other vaccines. In this review, we summarise the
               most recent data regarding vaccine response and efficacy in this
               setting, particularly in light of current vaccination
               recommendations for immunocompromised patients.",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1255--1265",
  month     =  oct,
  year      =  2021,
  keywords  = "antirheumatic agents; methotrexate; rituximab; tumour necrosis
               factor inhibitors; vaccination",
  language  = "en"
}

@ARTICLE{Abdel-Aziz2021-rd,
  title     = "Acute invasive fungal rhinosinusitis and Coronavirus disease
               2019",
  author    = "Abdel-Aziz, Mosaad and Azab, Noha",
  abstract  = "ABSTRACT: Acute invasive fungal rhinosinusitis (mucormycosis) is
               a rare, highly fatal disease. This opportunistic fungal
               infection causes angioinvasion and ischemic tissue necrosis. It
               mainly affects immunocompromised patients. Since the coronavirus
               disease 2019 (COVID-19) outbreak, many case reports have
               described the rhino-orbital-cerebral mucormycosis associated
               with COVID-19. However, the underlying predisposing factors are
               unknown. Several factors, other than diabetes, which is the most
               well-known contributing factor, may be involved in causing this
               severe fungal infection in COVID-19 patients. These factors may
               include steroid therapy, which is being used in severely
               dyspneic patients, the use of broad-spectrum antibiotics that
               may cause fungal flare-ups, and hospitalization with possible
               nosocomial infections. In addition, increased serum ferritin
               levels, possible endothelial damage, and pancreatic islets
               affection among COVID-19 patients may be implicated. Head and
               neck surgeons should be aware of the increasing prevalence of
               craniofacial mucormycosis among COVID-19 patients, as early
               diagnosis and prompt treatment are essential to improve the
               outcomes.",
  journal   = "J. Craniofac. Surg.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  32,
  number    =  8,
  pages     = "e827--e830",
  year      =  2021,
  language  = "en"
}

@ARTICLE{Selvan2021-fd,
  title     = "Geotrichum infection in an immunocompetent host with
               {SARS-CoV-2} infection",
  author    = "Selvan, Kavitha and Mutlu, G{\"o}khan",
  abstract  = "There has been increasing reports of secondary bacterial and
               fungal infections associated with COVID-19. Following the
               initial reports of infection with Aspergillus spp., and Candida
               spp. there has been a significant rise in infections with
               Mucorales spp. In this case report, we present a case of
               Geotrichum spp. infection in an immunocompetent host with
               COVID-19. To our knowledge, this is the first case of Geotrichum
               infection in COVID-19. Geotrichum is a rare emerging pathogen
               that causes invasive disease, termed geotrichosis, which occurs
               in immunocompromised adult hosts with neutropenia. The
               development of invasive fungal infection such as Geotrichum in
               patients with SARS-CoV-2 infection requires a high degree of
               clinical suspicion and should be considered particularly in
               those who have an underlying immunocompromised state and those
               receiving corticosteroids or other immunosuppressive agents.",
  journal   = "Tuberk. Toraks",
  publisher = "Bilimsel Tip Publishing House",
  volume    =  69,
  number    =  3,
  pages     = "421--424",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Eissa2021-hu,
  title     = "Voltammetric-based immunosensor for the detection of
               {SARS-CoV-2} nucleocapsid antigen",
  author    = "Eissa, Shimaa and Alhadrami, Hani A and Al-Mozaini, Maha and
               Hassan, Ahmed M and Zourob, Mohammed",
  abstract  = "Since the COVID-19 disease caused by the novel severe acute
               respiratory syndrome coronavirus 2 (SARS- CoV-2) was declared a
               pandemic, it has spread rapidly, causing one of the most serious
               outbreaks in the last century. Reliable and rapid diagnostic
               tests for COVID-19 are crucial to control and manage the
               outbreak. Here, a label-free square wave voltammetry-based
               biosensing platform for the detection of SARS-CoV-2 in
               nasopharyngeal samples is reported. The sensor was constructed
               on screen-printed carbon electrodes coated with gold
               nanoparticles. The electrodes were functionalized using
               11-mercaptoundecanoic acid (MUA) which was used for the
               immobilization of an antibody against SARS-CoV-2 nucleocapsid
               protein (N protein). The binding of the immunosensor with the N
               protein caused a change in the electrochemical signal. The
               detection was realised by measuring the change in reduction peak
               current of a redox couple using square wave voltammetry at 0.04
               V versus Ag ref. electrode on the immunosensor upon binding with
               the N protein. The electrochemical immunosensor showed high
               sensitivity with a linear range from 1.0 pg.mL-1 to 100 ng.mL-1
               and a limit of detection of 0.4 pg.mL-1 for the N protein in PBS
               buffer pH 7.4. Moreover, the immunosensor did not exhibit
               significant response with other viruses such as HCoV, MERS-CoV,
               Flu A and Flu B, indicating the high selectivity of the sensor
               for SARS-CoV-2. However, cross reactivity of the biosensor with
               SARS-CoV is indicated, which gives ability of the sensor to
               detect both SARS-CoV and SARS-CoV-2. The biosensor was
               successfully applied to detect the SARS-CoV-2 virus in clinical
               samples showing good correlation between the biosensor response
               and the RT-PCR cycle threshold values. We believe that the
               capability of miniaturization, low-cost and fast response of the
               proposed label-free electrochemical immunosensor will facilitate
               the point-of-care diagnosis of COVID 19 and help prevent further
               spread of infection.",
  journal   = "Mikrochim. Acta",
  publisher = "Springer Science and Business Media LLC",
  volume    =  188,
  number    =  6,
  pages     = "199",
  month     =  may,
  year      =  2021,
  keywords  = "Antibody; Biosensor; Electrochemical detection; Immunosensor;
               Nucleocapsid protein; Voltammetry",
  language  = "en"
}

@ARTICLE{Bhat2021-ky,
  title     = "Dynamics of viral {RNA} load, virus culture, seroconversion \&
               infectivity in {COVID-19} patients: Implications on isolation
               policy",
  author    = "Bhat, Vivek and Chavan, Preeti and Khattry, Navin and Gupta,
               Sudeep",
  abstract  = "The ongoing SARS-CoV-2 pandemic has spread all over the world
               due to rapid person-to-person transmission. More information
               about viral load dynamics and replication is needed for clarity
               on duration of infectiousness of an individual, along with its
               implications on transmission. This is important to healthcare
               facilities and public health authorities in formulating guidance
               on the duration of isolation for patients and return to work
               criteria for healthcare workers. The duration of detection of
               viral RNA by molecular methods in the upper respiratory tract
               has ranged from 2 to 12 wk. Viral RNA detection by reverse
               transcription polymerase chain reaction (RT-PCR) does not
               necessarily mean that the individual is infectious to others, as
               the detected virus may not be replication competent. Infectious
               virus is generally not shed beyond 20 days of the onset of
               symptoms in most patients, including severely ill and
               immunocompromised, as indicated by failure to isolate
               replication-competent virus beyond this timeline in available
               studies. Further, detection of neutralizing antibodies in the
               serum, although associated with positive RT-PCR, is generally
               not associated with infectious virus shedding as indicated by
               negative viral cultures beyond this period. In this review, we
               analyze the current literature on the dynamics of viral load,
               culture, seroconversion and their implications on infectivity
               and the duration of isolation precautions for COVID-19 patients.",
  journal   = "Indian J. Med. Res.",
  publisher = "Medknow",
  volume    =  153,
  number    = "5\&6",
  pages     = "585--590",
  year      =  2021,
  keywords  = "Antibody; COVID-19; culture; infectivity; seroconversion; viral
               load",
  language  = "en"
}

@ARTICLE{Strengert2021-jj,
  title     = "Cellular and humoral immunogenicity of a {SARS-CoV-2} {mRNA}
               vaccine in patients on haemodialysis",
  author    = "Strengert, Monika and Becker, Matthias and Ramos, Gema Morillas
               and Dulovic, Alex and Gruber, Jens and Juengling, Jennifer and
               L{\"u}rken, Karsten and Beigel, Andrea and Wrenger, Eike and
               Lonnemann, Gerhard and Cossmann, Anne and Stankov, Metodi V and
               Dopfer-Jablonka, Alexandra and Kaiser, Philipp D and Traenkle,
               Bjoern and Rothbauer, Ulrich and Krause, G{\'e}rard and
               Schneiderhan-Marra, Nicole and Behrens, Georg M N",
  abstract  = "BACKGROUND: Patients with chronic renal insufficiency on
               maintenance haemodialysis face an increased risk of COVID-19
               induced mortality and impaired vaccine responses. To date, only
               a few studies have addressed SARS-CoV-2 vaccine elicited
               immunity in this immunocompromised population. METHODS: We
               assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk
               dialysis patients and characterised systemic cellular and
               humoral immune responses in serum and saliva using interferon
               $\gamma$ release assay and multiplex-based cytokine and
               immunoglobulin measurements. We further compared binding
               capacity and neutralization efficacy of vaccination-induced
               immunoglobulins against emerging SARS-CoV-2 variants Alpha,
               Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay.
               FINDINGS: Patients on maintenance haemodialysis exhibit
               detectable but variable cellular and humoral immune responses
               against SARS-CoV-2 and variants of concern after a two-dose
               regimen of BNT162b2. Although vaccination-induced
               immunoglobulins were detectable in saliva and plasma, both
               anti-SARS-CoV-2 IgG and neutralization efficacy was reduced
               compared to a vaccinated non-dialysed control population.
               Similarly, T-cell mediated interferon $\gamma$ release after
               stimulation with SARS-CoV-2 spike peptides was significantly
               diminished. INTERPRETATION: Quantifiable humoral and cellular
               immune responses after BNT162b2 vaccination in individuals on
               maintenance haemodialysis are encouraging, but urge for
               longitudinal follow-up to assess longevity of immunity.
               Diminished virus neutralization and interferon $\gamma$
               responses in the face of emerging variants of concern may favour
               this at-risk population for re-vaccination using modified
               vaccines at the earliest opportunity. FUNDING: Initiative and
               Networking Fund of the Helmholtz Association of German Research
               Centres, EU Horizon 2020 research and innovation program, State
               Ministry of Baden-W{\"u}rttemberg for Economic Affairs, Labour
               and Tourism.",
  journal   = "EBioMedicine",
  publisher = "Elsevier BV",
  volume    =  70,
  number    =  103524,
  pages     = "103524",
  month     =  aug,
  year      =  2021,
  keywords  = "Dialysis; Immunocompromised; Protective immunity; SARS-CoV-2;
               Variants of concern; mRNA vaccination",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Singh2021-ia,
  title     = "Mitigation of in-hospital risk of coronavirus disease 2019:
               Experience from a haematology-oncology and stem cell transplant
               setting",
  author    = "Singh, Suvir and Paul, Davinder and Jain, Kunal and Singh,
               Jagdeep",
  abstract  = "Background: . Coronavirus disease 2019 (Covid-19) was first
               described in December 2019 and has evolved into an ongoing
               global pandemic. Cancer patients on chemotherapy are
               immunocompromised and are at the highest risk of
               Covid-19-related complications. We describe our experience with
               the management of haematology-oncology and stem cell transplant
               (SCT) patients receiving curative chemotherapy in a hospital
               with a high influx of Covid-19 patients. Methods: . We did a
               prospective observational study at a 99-bedded cancer centre of
               a tertiary care teaching hospital from April 2020 to September
               2020. Preventive measures taken were categorized as follows: (i)
               staff: screening, mandatory use of personal protective equipment
               (PPE), risk stratification of potential exposure and testing and
               isolation as needed; (ii) patients: mandatory viral polymerase
               chain reaction testing, segregation of positive and untested
               patients and testing of family members; and (iii) environment:
               mandatory regular cleaning, visitor restriction, telemedicine
               services and reassignment of priority to clinic visits.
               Treatment of the underlying conditions was continued with added
               precautions. Results: . A total of 54 patients were included in
               the analysis, including 48 with haematological malignancies and
               6 for stem cell therapy. Preventive measures were universally
               applied, and chemotherapy with a curative intent was initiated
               as per protocol. Three patients were detected to have Covid-19
               infection before admission and one after the institution of
               chemotherapy. Nine patients died after the first cycle of
               chemotherapy, 2 due to severe Covid-19-related illness and 7 due
               to complications of chemotherapy or disease progression.
               Conclusions: . In the wake of the Covid-19 pandemic, treatment
               for haematological malignancies must continue while balancing
               the risk of Covid-19 infections. Our report emphasizes the
               effectiveness of measures such as hand hygiene, social
               isolation, patient segregation, use of masks and PPE and
               universal pre-treatment testing for Covid-19 in reducing the
               risk of infection in a high-risk clinical setting.",
  journal   = "Natl. Med. J. India",
  publisher = "Scientific Scholar",
  volume    =  34,
  number    =  1,
  pages     = "10--14",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Patone2021-du,
  title     = "Mortality and critical care unit admission associated with the
               {SARS-CoV-2} lineage B.1.1.7 in England: an observational cohort
               study",
  author    = "Patone, Martina and Thomas, Karen and Hatch, Rob and Tan, Pui
               San and Coupland, Carol and Liao, Weiqi and Mouncey, Paul and
               Harrison, David and Rowan, Kathryn and Horby, Peter and
               Watkinson, Peter and Hippisley-Cox, Julia",
  abstract  = "BACKGROUND: A more transmissible variant of SARS-CoV-2, the
               variant of concern 202012/01 or lineage B.1.1.7, has emerged in
               the UK. We aimed to estimate the risk of critical care
               admission, mortality in patients who are critically ill, and
               overall mortality associated with lineage B.1.1.7 compared with
               non-B.1.1.7. We also compared clinical outcomes between these
               two groups. METHODS: For this observational cohort study, we
               linked large primary care (QResearch), national critical care
               (Intensive Care National Audit \& Research Centre Case Mix
               Programme), and national COVID-19 testing (Public Health
               England) databases. We used SARS-CoV-2 positive samples with
               S-gene molecular diagnostic assay failure (SGTF) as a proxy for
               the presence of lineage B.1.1.7. We extracted two cohorts from
               the data: the primary care cohort, comprising patients in
               primary care with a positive community COVID-19 test reported
               between Nov 1, 2020, and Jan 26, 2021, and known SGTF status;
               and the critical care cohort, comprising patients admitted for
               critical care with a positive community COVID-19 test reported
               between Nov 1, 2020, and Jan 27, 2021, and known SGTF status. We
               explored the associations between SARS-CoV-2 infection with and
               without lineage B.1.1.7 and admission to a critical care unit
               (CCU), 28-day mortality, and 28-day mortality following CCU
               admission. We used Royston-Parmar models adjusted for age, sex,
               geographical region, other sociodemographic factors (deprivation
               index, ethnicity, household housing category, and smoking status
               for the primary care cohort; and ethnicity, body-mass index,
               deprivation index, and dependency before admission to acute
               hospital for the CCU cohort), and comorbidities (asthma, chronic
               obstructive pulmonary disease, type 1 and 2 diabetes, and
               hypertension for the primary care cohort; and cardiovascular
               disease, respiratory disease, metastatic disease, and
               immunocompromised conditions for the CCU cohort). We reported
               information on types and duration of organ support for the
               B.1.1.7 and non-B.1.1.7 groups. FINDINGS: The primary care
               cohort included 198 420 patients with SARS-CoV-2 infection. Of
               these, 117 926 (594\%) had lineage B.1.1.7, 836 (04\%) were
               admitted to CCU, and 899 (04\%) died within 28 days. The
               critical care cohort included 4272 patients admitted to CCU. Of
               these, 2685 (628\%) had lineage B.1.1.7 and 662 (155\%) died
               at the end of critical care. In the primary care cohort, we
               estimated adjusted hazard ratios (HRs) of 215 (95\% CI
               175-265) for CCU admission and 165 (136-201) for 28-day
               mortality for patients with lineage B.1.1.7 compared with the
               non-B.1.1.7 group. The adjusted HR for mortality in critical
               care, estimated with the critical care cohort, was 091
               (076-109) for patients with lineage B.1.1.7 compared with
               those with non-B.1.1.7 infection. INTERPRETATION: Patients with
               lineage B.1.1.7 were at increased risk of CCU admission and
               28-day mortality compared with patients with non-B.1.1.7
               SARS-CoV-2. For patients receiving critical care, mortality
               appeared to be independent of virus strain. Our findings
               emphasise the importance of measures to control exposure to and
               infection with COVID-19. FUNDING: Wellcome Trust, National
               Institute for Health Research Oxford Biomedical Research Centre,
               and the Medical Sciences Division of the University of Oxford.",
  journal   = "Lancet Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  21,
  number    =  11,
  pages     = "1518--1528",
  month     =  nov,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Blumberg2021-bn,
  title     = "The future of {SARS-CoV-2} vaccines in transplant recipients: To
               be determined",
  author    = "Blumberg, Emily A and Manuel, Oriol and Sester, Martina and
               Ison, Michael G",
  abstract  = "The increasing availability of SARS-CoV-2 vaccines has been
               heralded as the intervention that will finally stem the COVID-19
               pandemic. However, it is unclear how immunosuppressed patients,
               including solid organ transplant recipients will respond to
               vaccination. Given the smaller numbers of affected patients,
               compared with vaccine trials in the general population, the
               changing epidemiology of the pandemic with the emergence of
               concerning viral variants, and greater precautionary measure
               adherence, it may be difficult to determine efficacy in this
               population. Consequently, assessment of immunogenicity,
               including measurement of antibodies to the spike
               receptor-binding domain and evaluation of cellular responses,
               provides important information to define the host response to
               this vaccine.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  8,
  pages     = "2629--2630",
  month     =  aug,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Long2021-an,
  title     = "High flow nasal cannula for adult acute hypoxemic respiratory
               failure in the {ED} setting",
  author    = "Long, Brit and Liang, Stephen Y and Lentz, Skyler",
  abstract  = "INTRODUCTION: High flow nasal cannula (HFNC) is a noninvasive
               ventilation (NIV) system that has demonstrated promise in the
               emergency department (ED) setting. OBJECTIVE: This narrative
               review evaluates the utility of HFNC in adult patients with
               acute hypoxemic respiratory failure in the ED setting.
               DISCUSSION: HFNC provides warm (37 C), humidified (100\%
               relative humidity) oxygen at high flows with a reliable fraction
               of inspired oxygen (FiO2). HFNC can improve oxygenation, reduce
               airway resistance, provide humidified flow that can flush
               anatomical dead space, and provide a low amount of positive end
               expiratory pressure. Recent literature has demonstrated efficacy
               in acute hypoxemic respiratory failure, including pneumonia,
               acute respiratory distress syndrome (ARDS), coronavirus disease
               2019 (COVID-19), interstitial lung disease, immunocompromised
               states, the peri-intubation state, and palliative care, with
               reduced need for intubation, length of stay, and mortality in
               some of these conditions. Individual patient factors play an
               important role in infection control risks with respect to the
               use of HFNC in patients with COVID-19. Appropriate personal
               protective equipment, adherence to hand hygiene, surgical mask
               placement over the HFNC device, and environmental controls
               promoting adequate room ventilation are the foundation for
               protecting healthcare personnel. Frequent reassessment of the
               patient placed on HFNC is necessary; those with severe end organ
               dysfunction, thoracoabdominal asynchrony, significantly
               increased respiratory rate, poor oxygenation despite HFNC, and
               tachycardia are at increased risk of HFNC failure and need for
               further intervention. CONCLUSIONS: HFNC demonstrates promise in
               several conditions requiring respiratory support. Further
               randomized trials are needed in the ED setting.",
  journal   = "Am. J. Emerg. Med.",
  publisher = "Elsevier BV",
  volume    =  49,
  pages     = "352--359",
  month     =  nov,
  year      =  2021,
  keywords  = "Acute hypoxemic respiratory failure; COVID-19; High-flow nasal
               cannula; Noninvasive ventilation",
  language  = "en"
}

@ARTICLE{Loman2021-ic,
  title     = "``How to'' operate a pediatric neuropsychology practice during
               the {COVID-19} pandemic: Real tips from one practice's
               experience",
  author    = "Loman, Michelle and Vogt, Elisabeth and Miller, Lauren and
               Landsman, Rachel and Duong, Priscilla and Kasten, Jessica and
               DeFrancisco, Danielle and Koop, Jennifer and Heffelfinger, Amy",
  abstract  = "This paper aims to provide pediatric neuropsychologists with
               suggested processes and procedures to continue to provide
               neuropsychology services during the COVID-19 global pandemic.
               Our practice is located within an academic medical
               center/children's hospital, and setting-specific recommendations
               may not extend to all practices, though our hope is that others
               find guidance from our approach to providing pediatric
               neuropsychology evaluations when physical distancing is
               required. With consideration of ethics, equity, and assessment
               validity, we provide suggestions for a) modifying practices
               around seeing patients during COVID-19, b) tele-health for the
               pediatric neuropsychologist, c) safety standards and
               requirements, and d) working with special populations (e.g.,
               Autism Spectrum Disorder, bilingual populations,
               immunocompromised patients, and acute inpatient assessment).",
  journal   = "Child Neuropsychol.",
  publisher = "Informa UK Limited",
  volume    =  27,
  number    =  2,
  pages     = "251--279",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; Practice guidelines; ethics; pandemic; pediatric
               neuropsychology; telehealth; teleneuropsychology",
  language  = "en"
}

@ARTICLE{Tassone2021-dm,
  title     = "Immunosuppression as a risk factor for {COVID-19}: a
               meta-analysis",
  author    = "Tassone, Daniel and Thompson, Alexander and Connell, William and
               Lee, Tanya and Ungaro, Ryan and An, Ping and Ding, Yijuan and
               Ding, Nik S",
  abstract  = "BACKGROUND: While immunosuppression poses a theoretical increase
               in the risk of COVID-19, the nature of this relationship is yet
               to be ascertained. AIMS: To determine whether immunosuppressed
               patients are at higher risk of COVID-19 to help inform the
               management of patients receiving immunosuppressant therapies
               during the pandemic. METHODS: We performed a random-effects
               meta-analysis of data from studies that reported on the
               prevalence of immunosuppression among patient cohorts with
               COVID-19. RESULTS: Sixty full-text publications were identified.
               In total, six individual studies were included in the final
               analysis, contributing a total of 10 049 patients with COVID-19
               disease. The prevalence of immunosuppressed patients among the
               study cohorts with COVID-19 ranged from 0.126\% to 1.357\%. In
               the pooled cohort a total of 64/10 049 (0.637\%) patients with
               COVID-19 disease was immunosuppressed. Observed to expected
               ratios were used to compare the prevalence of immunosuppression
               in cohorts with confirmed COVID-19 disease to the background
               prevalence of immunosuppression in the general community. The
               observed to expected ratio of immunosuppression among patients
               with COVID-19 illness, relative to the general community, was
               0.12 (95\% confidence interval: 0.05-0.27). CONCLUSIONS:
               Compared to the general population, immunosuppressed patients
               were not at significantly increased risk of COVID-19 infection.
               This finding provides support for current expert consensus
               statements, which have recommended the continuation of
               immunosuppressant therapy in the absence of COVID-19.",
  journal   = "Intern. Med. J.",
  publisher = "Wiley",
  volume    =  51,
  number    =  2,
  pages     = "199--205",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; immunocompromised host; immunosuppression; infection;
               risk",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Elhamamsy2021-mf,
  title    = "Rhino-orbital Cerebral Mucormycosis in non-diabetic patients with
              {COVID-19}",
  author   = "Elhamamsy, Salaheldin and Bayer, Tom and Al-Kaffas, Mai and
              Hatahet, Sarah and Grover, Mohnish and Samdhani, Sunil and Nanda,
              Aman and Gravenstein, Stefan",
  abstract = "Rhino-orbital Cerebral Mucormycosis (ROCM), a rare invasive
              fungal infection, affects diabetic and immunocompromised
              individuals. Recent reports have raised the alarm for invasive
              ROCM associated with SARS-CoV-2 infection. SARS-CoV-2 infection
              causes immune cell dysregulation, cytokine dysregulation, and is
              associated with invasive fungal infections. Immunosuppressive
              treatment of COVID-19 with corticosteroids increases the risk of
              opportunistic infection. We present a series of 3 cases of
              invasive ROCM with different outcomes in immunocompetent
              nondiabetic patients who all received corticosteroids at doses
              higher than those recommended by the World Health Organization,
              and who received oxygen during their SARS-CoV-2 treatment course.
              Immune dysregulatory effects of COVID-19 and high-dose
              corticosteroids may both have caused predisposition to ROCM in
              these cases. Additionally, health system stress caused by
              responding to COVID-19 surges may have predisposed patients to
              exposure to mucormycosis-causing fungi through use of
              non-sterilized water for oxygen humidification. In light of these
              cases, we encourage guideline-based corticosteroid dosing in the
              management of COVID-19 as well as vigilance for invasive
              mucormycosis and prompt treatment in corticosteroid-treated
              patients.",
  journal  = "R. I. Med. J. (2013)",
  volume   =  104,
  number   =  8,
  pages    = "19--21",
  month    =  oct,
  year     =  2021,
  keywords = "COVID-19; ROCM; SARS-CoV-2; mucormycosis",
  language = "en"
}

@ARTICLE{Simpson2021-bo,
  title     = "Research priorities for control of zoonoses in South Africa",
  author    = "Simpson, Greg and Quesada, Fabiola and Chatterjee, Pranab and
               Kakkar, Manish and Chersich, Matthew F and Thys, S{\'e}verine",
  abstract  = "BACKGROUND: Zoonoses pose major threats to the health of humans,
               domestic animals and wildlife, as seen in the COVID-19 pandemic.
               Zoonoses are the commonest source of emerging human infections
               and inter-species transmission is facilitated by anthropogenic
               factors such as encroachment and destruction of wilderness
               areas, wildlife trafficking and climate change. South Africa was
               selected for a 'One Health' study to identify research
               priorities for control of zoonoses due to its complex disease
               burden and an overstretched health system. METHODS: A
               multidisciplinary group of 18 experts identified priority
               zoonotic diseases, knowledge gaps and proposed research
               priorities for the next 5 y. Each priority was scored using
               predefined criteria by another group of five experts and then
               weighted by a reference group (n=28) and the 18 experts.
               RESULTS: Seventeen diseases were mentioned with the top five
               being rabies (14/18), TB (13/18), brucellosis (11/18), Rift
               Valley fever (9/11) and cysticercosis (6/18). In total, 97
               specific research priorities were listed, with the majority on
               basic epidemiological research (n=57), such as measuring the
               burden of various zoonoses (n=24), followed by 20 on development
               of new interventions. The highest research priority score was
               for improving existing interventions (0.77/1.0), followed by
               health policy and systems research (0.72/1.0). CONCLUSION:
               Future zoonotic research should improve understanding of
               zoonotic burden and risk factors and new interventions in public
               health. People with limited rural services, immunocompromised,
               in informal settlements and high-risk occupations, should be the
               highest research priority.",
  journal   = "Trans. R. Soc. Trop. Med. Hyg.",
  publisher = "Oxford University Press (OUP)",
  volume    =  115,
  number    =  5,
  pages     = "538--550",
  month     =  may,
  year      =  2021,
  keywords  = "South Africa; disease burden; one health; research priorities;
               zoonoses",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Mastrangelo2021-vg,
  title     = "Impact of {COVID-19} pandemic in children with {CKD} or
               immunosuppression",
  author    = "Mastrangelo, Antonio and Morello, William and Vidal, Enrico and
               Guzzo, Isabella and Annicchiarico Petruzzelli, Luigi and
               Benetti, Elisa and Materassi, Marco and Giordano, Mario and
               Pasini, Andrea and Corrado, Ciro and Puccio, Giuseppe and
               Chimenz, Roberto and Pecoraro, Carmine and Massella, Laura and
               Peruzzi, Licia and Montini, Giovanni and {COVID-19 Task Force of
               the Italian Society of Pediatric Nephrology} and {COVID-19 TASK
               FORCE of the Italian Society of Pediatric Nephrology}",
  journal   = "Clin. J. Am. Soc. Nephrol.",
  publisher = "American Society of Nephrology (ASN)",
  volume    =  16,
  number    =  3,
  pages     = "449--451",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; children; chronic kidney disease; glomerular disease;
               immunosuppression; kidney transplantation",
  language  = "en"
}

@ARTICLE{Kinoshita2021-fv,
  title     = "Robust antibody and {T} cell responses to {SARS-CoV-2} in
               patients with antibody deficiency",
  author    = "Kinoshita, Hannah and Durkee-Shock, Jessica and
               Jensen-Wachspress, Mariah and Kankate, Vaishnavi V and Lang,
               Haili and Lazarski, Christopher A and Keswani, Anjeni and
               Webber, Kathleen C and Montgomery-Recht, Kimberly and
               Walkiewicz, Magdalena and Notarangelo, Luigi D and Burbelo,
               Peter D and Fuss, Ivan and Cohen, Jeffrey I and Bollard,
               Catherine M and Keller, Michael D",
  abstract  = "Immunocompromised patients, including those with inborn errors
               of immunity (IEI), may be at increased risk for severe or
               prolonged infections with SARS-CoV-2 (Zhu et al. N Engl J Med.
               382:727-33, 2020; Guan et al. 2020; Minotti et al. J Infect.
               81:e61-6, 2020). While antibody and T cell responses to
               SARS-CoV-2 structural proteins are well described in healthy
               convalescent donors, adaptive humoral and cellular immunity has
               not yet been characterized in patients with antibody deficiency
               (Grifoni et al. Cell. 181:1489-1501 e1415, 2020; Burbelo et al.
               2020; Long et al. Nat Med. 26:845-8, 2020; Braun et al. 2020).
               Herein, we describe the clinical course, antibody, and T cell
               responses to SARS-CoV-2 structural proteins in a cohort of adult
               and pediatric patients with antibody deficiencies (n = 5) and
               controls (related and unrelated) infected with SARS-CoV-2. Five
               patients within the same family (3 with antibody deficiency, 2
               immunocompetent controls) showed antibody responses to
               nucleocapsid and spike proteins, as well as SARS-CoV-2 specific
               T cell immunity at days 65-84 from onset of symptoms. No
               significant difference was identified between immunocompromised
               patients and controls. Two additional unrelated, adult patients
               with common variable immune deficiency were assessed. One did
               not show antibody response, but both demonstrated
               SARS-CoV-2-specific T cell immunity when evaluated 33 and 76
               days, respectively, following SARS-CoV-2 diagnosis. This report
               is the first to show robust T cell activity and humoral immunity
               against SARS-CoV-2 structural proteins in some patients with
               antibody deficiency. Given the reliance on spike protein in most
               candidate vaccines (Folegatti et al. Lancet. 396:467-78, 2020;
               Jackson et al. N Engl J Med. 383:1920-31, 2020), the responses
               are encouraging. Additional studies will be needed to further
               define the timing of onset of immunity, longevity of the immune
               response, and variability of response in immunocompromised
               patients.",
  journal   = "J. Clin. Immunol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  6,
  pages     = "1146--1153",
  month     =  aug,
  year      =  2021,
  keywords  = "Antibody deficiency; COVID-19; SARS-CoV-2; T cell response;
               adaptive immune response; common variable immunodeficiency",
  language  = "en"
}

@ARTICLE{Axelrad2021-rt,
  title     = "From the American epicenter: Coronavirus disease 2019 in
               patients with inflammatory bowel disease in the New York city
               metropolitan area",
  author    = "Axelrad, Jordan E and Malter, Lisa and Hong, Simon and Chang,
               Shannon and Bosworth, Brian and Hudesman, David",
  abstract  = "BACKGROUND: We aimed to characterize patients with inflammatory
               bowel disease (IBD) and novel coronavirus disease 2019
               (COVID-19). METHODS: We performed a case series of patients with
               IBD and confirmed or highly suspected COVID-19 to assess rates
               of severe outcomes. RESULTS: We identified 83 patients with IBD
               with confirmed (54\%) or highly suspected (46\%) COVID-19. The
               overall hospitalization rate was 6\%, generally comprising
               patients with active Crohn's disease or older men with
               comorbidities, and 1 patient expired. DISCUSSION: In this series
               of patients with IBD, severe outcomes of COVID-19 were rare and
               comparable to similarly aged individuals in the general
               population.",
  journal   = "Inflamm. Bowel Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  27,
  number    =  5,
  pages     = "662--666",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus; SARS-CoV-2; inflammatory bowel disease",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Al-Makki2021-zo,
  title     = "Neutropenic fever in {COVID-19} in kidney transplant patient",
  author    = "Al-Makki, Akram and Taber, Tim",
  journal   = "Rev. Med. Virol.",
  publisher = "Wiley",
  volume    =  31,
  number    =  1,
  pages     = "1--2",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; kidney transplant; neutropenic fever",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Qu2021-bs,
  title     = "Persistent bacterial coinfection of a {COVID-19} patient caused
               by a genetically adapted Pseudomonas aeruginosa chronic
               colonizer",
  author    = "Qu, Jiuxin and Cai, Zhao and Liu, Yumei and Duan, Xiangke and
               Han, Shuhong and Liu, Jihong and Zhu, Yuao and Jiang, Zhaofang
               and Zhang, Yingdan and Zhuo, Chao and Liu, Yang and Liu, Yingxia
               and Liu, Lei and Yang, Liang",
  abstract  = "Pseudomonas aeruginosa is a biofilm-forming opportunistic
               pathogen which causes chronic infections in immunocompromised
               patients and leads to high mortality rate. It is identified as a
               common coinfecting pathogen in COVID-19 patients causing
               exacerbation of illness. In our hospital, P. aeruginosa is one
               of the top coinfecting bacteria identified among COVID-19
               patients. We collected a strong biofilm-forming P. aeruginosa
               strain displaying small colony variant morphology from a severe
               COVID-19 patient. Genomic and transcriptomic sequencing analyses
               were performed with phenotypic validation to investigate its
               adaptation in SARS-CoV-2 infected environment. Genomic
               characterization predicted specific genomic islands highly
               associated with virulence, transcriptional regulation, and DNA
               restriction-modification systems. Epigenetic analysis revealed a
               specific N6-methyl adenine (m6A) methylating pattern including
               methylation of alginate, flagellar and quorum sensing associated
               genes. Differential gene expression analysis indicated that this
               isolate formed excessive biofilm by reducing flagellar formation
               (7.4 to 1,624.1 folds) and overproducing extracellular matrix
               components including CdrA (4.4 folds), alginate (5.2 to 29.1
               folds) and Pel (4.8-5.5 folds). In summary, we demonstrated that
               P. aeuginosa clinical isolates with novel epigenetic markers
               could form excessive biofilm, which might enhance its antibiotic
               resistance and in vivo colonization in COVID-19 patients.",
  journal   = "Front. Cell. Infect. Microbiol.",
  publisher = "Frontiers Media SA",
  volume    =  11,
  pages     = "641920",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; DNA methylation; Pseudomonas aeruginosa; biofilm;
               coinfection",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Gentile2021-dq,
  title     = "Pneumocystis jirovecii pneumonia in {non-HIV} patients
               recovering from {COVID-19}: A single-center experience",
  author    = "Gentile, Ivan and Viceconte, Giulio and Lanzardo, Amedeo and
               Zotta, Irene and Zappulo, Emanuela and Pinchera, Biagio and
               Scotto, Riccardo and Schiano Moriello, Nicola and Foggia, Maria
               and Giaccone, Agnese and Messina, Gaetana and Salvatore, Paola
               and Buonomo, Antonio Riccardo and {Federico Ii Covid-Team}",
  abstract  = "OBJECTIVE: to describe a single-center experience of
               Pneumocystis jirovecii pneumonia (PJP) in non-HIV patients
               recovering from COVID-19. METHODS: We report the cases of five
               non-HIV patients with COVID-19 who also developed PJP at a
               University Hospital. RESULTS: With the exception of one subject,
               who experienced an atypical and prolonged course of COVID-19,
               all the patients developed PJP after the clinical resolution of
               COVID-19 pneumonia. All but one patient had no pre-existing
               immunosuppressive conditions or other risk factors for PJP
               development at COVID-19 diagnosis. Nonetheless, following the
               course of COVID-19 infection, all the patients fulfilled at
               least one host factor for PJP; indeed, all the patients had
               received at least 2 weeks of high-dose steroids and three out of
               five had a CD4+ cell count <200/mm3. CONCLUSIONS: The use of
               corticosteroids for COVID-19 respiratory impairment seems to be
               the most common risk factor for PJP, together with viral-induced
               and iatrogenic lymphopenia. The worsening in respiratory
               function and the characteristic radiological picture during or
               after COVID-19 pneumonia should raise the suspicion of PJP, even
               in immunocompetent patients. PJP primary chemoprophylaxis can be
               considered in selected high-risk COVID-19 patients, but further
               studies are needed.",
  journal   = "Int. J. Environ. Res. Public Health",
  publisher = "MDPI AG",
  volume    =  18,
  number    =  21,
  pages     = "11399",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Pneumocystis jirovecii; corticosteroids; invasive
               fungal infections; lymphopenia",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Meir2021-cb,
  title     = "State of the {CAR-T}: Risk of infections with chimeric antigen
               receptor T-cell therapy and determinants of {SARS-CoV-2} vaccine
               responses",
  author    = "Meir, Juliet and Abid, Muhammad Abbas and Abid, Muhammad Bilal",
  abstract  = "Chimeric antigen receptor T cell (CAR-T) therapy has shown
               unprecedented response rates in patients with
               relapsed/refractory (R/R) hematologic malignancies. Although
               CAR-T therapy gives hope to heavily pretreated patients, the
               rapid commercialization and cumulative immunosuppression of this
               therapy predispose patients to infections for a prolonged
               period. CAR-T therapy poses distinctive short- and long-term
               toxicities and infection risks among patients who receive CAR
               T-cells after multiple prior treatments, often including
               hematopoietic cell transplantation. The acute toxicities include
               cytokine release syndrome and immune effector cell-associated
               neurotoxicity syndrome. The long-term B cell depletion,
               hypogammaglobulinemia, and cytopenia further predispose patients
               to severe infections and abrogate the remission success achieved
               by the living drug. These on-target-off-tumor toxicities deplete
               B-cells across the entire lineage and further diminish immune
               responses to vaccines. Early observational data suggest that
               patients with hematologic malignancies may not mount adequate
               humoral and cellular responses to SARS-CoV-2 vaccines. In this
               review, we summarize the immune compromising factors indigenous
               to CAR-T recipients. We discuss the immunogenic potential of
               different SARS-CoV-2 vaccines for CAR-T recipients based on the
               differences in vaccine manufacturing platforms. Given the lack
               of data related to the safety and efficacy of SARS-CoV-2
               vaccines in this distinctively immunosuppressed cohort, we
               summarize the infection risks associated with Food and Drug
               Administration-approved CAR-T constructs and the potential
               determinants of vaccine responses. The review further highlights
               the potential need for booster vaccine dosing and the promise
               for heterologous prime-boosting and other novel vaccine
               strategies in CAR-T recipients. \copyright{} 2021 American
               Society for Transplantation and Cellular Therapy. Published by
               Elsevier Inc.",
  journal   = "Transplant Cell Ther",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  12,
  pages     = "973--987",
  month     =  dec,
  year      =  2021,
  keywords  = "CAR-T therapy; COVID-19; Cellular immunity; Hematopoietic cell
               transplantation; Humoral immunity; Immunocompromised;
               Neutralizing antibodies; SARS-CoV-2; Vaccine response; mRNA
               vaccine",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Ma2021-ue,
  title     = "{CAR-NK} cells effectively target {SARS-CoV-2-spike-expressing}
               cell lines in vitro",
  author    = "Ma, Minh Tuyet and Badeti, Saiaditya and Chen, Chih-Hsiung and
               Kim, James and Choudhary, Alok and Honnen, Bill and Reichman,
               Charles and Calianese, David and Pinter, Abraham and Jiang,
               Qingkui and Shi, Lanbo and Zhou, Renping and Xu, Huanbin and Li,
               Qingsheng and Gause, William and Liu, Dongfang",
  abstract  = "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is
               highly contagious and presents a significant public health
               issue. Current therapies used to treat coronavirus disease 2019
               (COVID-19) include monoclonal antibody cocktail, convalescent
               plasma, antivirals, immunomodulators, and anticoagulants. The
               vaccines from Pfizer and Moderna have recently been authorized
               for emergency use, which are invaluable for the prevention of
               SARS-CoV-2 infection. However, their long-term side effects are
               not yet documented, and populations with immunocompromised
               conditions (e.g., organ-transplantation and immunodeficient
               patients) may not be able to mount an effective immune response.
               In addition, there are concerns that wide-scale immunity to
               SARS-CoV-2 may introduce immune pressure that could select for
               escape mutants to the existing vaccines and monoclonal antibody
               therapies. Emerging evidence has shown that chimeric antigen
               receptor (CAR)- natural killer (NK) immunotherapy has potent
               antitumor response in hematologic cancers with minimal adverse
               effects in recent studies, however, the potentials of CAR-NK
               cells in treating COVID-19 has not yet been fully exploited.
               Here, we improve upon a novel approach for the generation of
               CAR-NK cells for targeting SARS-CoV-2 and its various mutants.
               CAR-NK cells were generated using the scFv domain of S309
               (henceforward, S309-CAR-NK), a SARS-CoV and SARS-CoV-2
               neutralizing antibody (NAbs) that targets the highly conserved
               region of SARS-CoV-2 spike (S) glycoprotein and is therefore
               more likely to recognize different variants of SARS-CoV-2
               isolates. S309-CAR-NK cells can specifically bind to pseudotyped
               SARS-CoV-2 virus and its D614G, N501Y, and E484K mutants.
               Furthermore, S309-CAR-NK cells can specifically kill target
               cells expressing SARS-CoV-2 S protein in vitro and show superior
               killing activity and cytokine production, compared to that of
               the recently reported CR3022-CAR-NK cells. Thus, these results
               pave the way for generating 'off-the-shelf' S309-CAR-NK cells
               for treatment in high-risk individuals as well as provide an
               alternative strategy for patients unresponsive to current
               vaccines.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "652223",
  month     =  jul,
  year      =  2021,
  keywords  = "CAR (chimeric antigen receptor); COVID-19; E484K variant; N501Y
               variant; NK cells; SARS-CoV-2; off-the-shelf",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tian2021-pi,
  title     = "An {HIV-infected} patient with coronavirus disease 2019 has a
               favourable prognosis: a case report",
  author    = "Tian, Chong and Tang, Lei and Wu, Jiahong and Li, Wuchao and
               Ming, Xing and Zhou, Hourong and Wu, Weidong and Zeng, Xianchun",
  abstract  = "The coronavirus disease 2019 (COVID-19), caused by severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread
               rapidly, which now has turned into a pandemic. The new emerging
               infectious disease has raised many challenges and uncertainties
               regarding disease management and prognosis in immunocompromised
               patient populations. The risk of COVID-19 among people living
               with human immunodeficiency virus (HIV) has different opinions.
               Some scholars speculated that patients with HIV may be at
               decreased risk for complications of COVID-19 because HIV
               antiretroviral medications may have activity against
               coronaviruses such as SARS-CoV-2. But others have the opposite
               because of the immunosuppression for HIV patients. Here we
               reported a case of HIV-infected patient confirmed with COVID-19
               and had a favourable prognosis. The patient was a 24-year-old
               male who was diagnosed with HIV infection 2 years ago and then
               followed a regular antiretroviral therapy (ART). After infected
               with COVID-19, the patient had no other clinical symptoms and
               laboratory abnormalities throughout the course of the disease
               except presented with fever for a short-term (2 days), and no
               secondary infection or exacerbation occurred after admission in
               hospital. Follow-up chest CT showed that the lung lesions
               disappeared within a short period of time. After standard
               treatment by 9 days, the patient was cured and discharged. This
               report highlights the importance of ART for HIV-infected
               persons, and with regular ART for HIV patients may reduce
               adverse consequences after infection with COVID-19.",
  journal   = "Ann. Palliat. Med.",
  publisher = "AME Publishing Company",
  volume    =  10,
  number    =  5,
  pages     = "5808--5812",
  month     =  may,
  year      =  2021,
  keywords  = "Coronavirus disease 2019 (COVID-19); case report; human
               immunodeficiency virus (HIV); severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2)",
  language  = "en"
}

@ARTICLE{Anantharaman2021-xb,
  title     = "{SARS-CoV-2} clinical outcomes in patients with cancer in a
               large integrated health care system in Northern California",
  author    = "Anantharaman, Archana and Dusendang, Jennifer R and Schmittdiel,
               Julie A and Harzstark, Andrea L",
  abstract  = "The SARS-CoV-2 (COVID-19) pandemic continues to affect many
               lives globally. Patients with cancer undergoing potentially
               immunosuppressive therapies appear to be at particular risk for
               the disease and its complications. Here, we describe the
               experience of patients with cancer within Kaiser Permanente, a
               large, integrated health system in Northern California. Between
               February 25, 2020, and June 8, 2020, 4,627 patients were
               diagnosed with COVID-19, of whom 33 had active cancer treatment
               within 180 days and 214 had a history of cancer. Patients with
               active cancer treatment had a statistically higher risk of
               requiring noninvasive ventilation (odds ratio [OR], 2.57;
               confidence interval [CI], 1.10-6.01), and there was a
               nonsignificant trend toward higher risk of death (OR, 2.78; CI,
               0.92-8.43). Those with a history of cancer had comparable
               outcomes to those without cancer. These data demonstrate an
               increased risk of complications from COVID-19 for patients with
               active cancer treatment.",
  journal   = "Oncologist",
  publisher = "Oxford University Press (OUP)",
  volume    =  26,
  number    =  3,
  pages     = "e500--e504",
  month     =  mar,
  year      =  2021,
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Chowdary2021-vk,
  title     = "Experience of {SARS-CoV-2} infection in two kidney transplant
               recipients living with {HIV-1} infection",
  author    = "Chowdary, Prashanth and Shetty, Shraddha and Booth, John and
               Khurram, Muhammad Arslan and Yaqoob, Magdi and Mohamed, Ismail
               Heyder",
  abstract  = "There is still no consensus on the optimal management of
               COVID-19 within the general population due to the emerging
               evidence base. High-risk groups, including kidney transplant
               recipients living with HIV present unique additional challenges.
               Here we discuss two kidney transplant recipients living with HIV
               with SARS-CoV-2 infection and their clinical course, and review
               the existing literature for this subset of challenging patients.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  2,
  pages     = "e13500",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; HIV; SARS-CoV-2; calcineurin inhibitor; renal
               transplant; transplantation",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Couzin-Frankel2021-ud,
  title     = "Relief and worry for immune-suppressed people",
  author    = "Couzin-Frankel, Jennifer",
  journal   = "Science",
  publisher = "American Association for the Advancement of Science (AAAS)",
  volume    =  372,
  number    =  6541,
  pages     = "443--444",
  month     =  apr,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Vyas2021-am,
  title    = "The role and delicate balance of Host Immunity in Coronavirus
              Disease-19",
  author   = "Vyas, Ashish Kumar and Varma, Vishwanath and Garg, Garima and
              Gupta, Priyal and Trehanpati, Nirupma",
  abstract = "Severe Acute Respiratory Syndrome (SARS) associated with
              SARS-CoV-2, causes a severe form of the respiratory illness known
              as Coronavirus Disease-19 (COVID-19). COVID-19 has emerged as a
              worldwide pandemic with a high number of fatalities.
              Approximately 112,654,202 people have been infected so far with
              this disease which has led to the death of more than one point
              seven million (2,496,749) till 24th Feb, 2021. Measures to
              counter this disease have led to a global economic slowdown.
              Multiple drug trials are ongoing and several putative candidates
              for vaccination against the virus have been approved and are in
              the pipeline. Many studies have also characterized the
              immunological profile of patients infected with COVID-19. Some
              studies suggest that the severity of the COVID-19 infection is
              directly associated with the cytokine storm. In this review, we
              aim to compile the available knowledge and describe the nature of
              immune responses in patients infected with COVID-19 in different
              age groups, comorbidity, and immune-compromised state and their
              association with disease severity.",
  journal  = "Iran. J. Immunol.",
  volume   =  18,
  number   =  1,
  pages    = "1--12",
  month    =  mar,
  year     =  2021,
  language = "en"
}

@ARTICLE{Melmed2021-ir,
  title     = "Winter is coming! Clinical, immunologic, and practical
               considerations for vaccinating patients with inflammatory bowel
               disease during the Coronavirus disease-2019 pandemic",
  author    = "Melmed, Gil Y and Rubin, David T and McGovern, Dermot P B",
  journal   = "Gastroenterology",
  publisher = "Elsevier BV",
  volume    =  160,
  number    =  3,
  pages     = "639--644",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; Ethics; Inflammatory Bowel Disease; Justice;
               SARS-CoV-2; Vaccine",
  language  = "en"
}

@ARTICLE{Zhao2021-ok,
  title     = "In the shadow of {COVID-19}: {HIV-infected} individuals need
               more attention",
  author    = "Zhao, Tianming and Xuan, Kun and Uy, John Patrick and Sun,
               Chenyu",
  abstract  = "COVID-19 pandemic has made the medical situation of HIV-infected
               individuals more complicated in low-income countries especially
               those with high incidence of acquired immunodeficiency syndrome
               (AIDS). Besides, the COVID-19 pandemic may also have an impact
               on acquired immunodeficiency syndrome (AIDS) patients' access to
               medical services. Although the difference between COVID-19
               prevalence in HIV-infected individuals and general population is
               still unclear, the physical and mental health status of HIV
               infected people are needed to pay more attention on account of
               their growing concern of health status during COVID-19 pandemic.
               In this paper, we suggested that future studies should explore
               the prevalence, clinical characteristics, and health outcomes of
               HIV/SARS-CoV-2 co-infection patients. Besides, rapid
               identification of SARS-CoV-2 co-infection among HIV population
               through the high-risk population screening and the international
               assistance for low-income countries could be warranted. This
               article is protected by copyright. All rights reserved.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  2,
  pages     = "611",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; HIV; medical services; screening",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Hu2021-yx,
  title     = "Management of immunosuppression in kidney transplant recipients
               with {COVID-19} pneumonia: A summary of 41 confirmed cases
               reported worldwide",
  author    = "Hu, Qianchao and Zhong, Zibiao and Xiong, Yan and Ye, Shaojun
               and Wang, Yanfeng and Ye, Qifa",
  abstract  = "There is no consensus on immunosuppression management for kidney
               transplant recipients (KTRs) with SARS-CoV-2 pneumonia.
               Therefore, we conducted a search in English database from
               October 2019 to July 2020 and extracted data from cases with
               treatment details worldwide, and total of 41 recipients with a
               median age of 50 years were enrolled in this study. Most of them
               were males (75.8\%). The most common presenting symptoms were
               fever (80.5\%), cough (63.4\%), and fatigue (41.5\%). Patients
               were classified into three catalogs according to severity of
               pneumonia: 17 (41.5\%) were mild, 15 (36.6\%) severe, and 9
               (21.9\%) critical disease. Laboratory tests revealed that serum
               creatinine of critical patients was significantly higher than
               that of mild or severe patients. 68.3\% received oxygen support;
               all patients received antiviral therapy, and 15 (36.6\%)
               recipients were additionally treated with intravenous
               immunoglobulin and interferon-$\alpha$. 19.5\% of patients
               maintained immunosuppressive therapy; 36.6\% suspended
               antimetabolite; and 43.9\% only treated with corticosteroid. Six
               (14.6\%) patients died (severe: 2, critical: 4); high creatinine
               with low lymphocyte count was the biggest challenge of
               immunosuppression management. In all, it is necessary to pay
               close attention to renal function and lymphocyte count in KTRs
               infected with COVID-19 and choose appropriate medication
               programs according to the specific situations.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  1,
  pages     = "e13425",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; immunosuppression management; kidney transplant
               recipient",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Hadi2021-ez,
  title    = "Outcomes of {COVID-19} in solid organ transplant recipients: A
              propensity-matched analysis of a large research network",
  author   = "Hadi, Yousaf B and Naqvi, Syeda F Z and Kupec, Justin T and
              Sofka, Sarah and Sarwari, Arif",
  abstract = "BACKGROUND: Organ transplant recipients comprise an
              immunocompromised and vulnerable cohort. Outcomes of coronavirus
              disease 2019 (COVID-19) in solid organ transplant (SOT)
              recipients remain understudied. METHODS: We used a multicenter
              federated research network to compare clinical outcomes of
              COVID-19 in patients with SOT to a propensity--matched cohort of
              patients without SOT. RESULTS: We identified 2307 SOT recipients
              and 231 047 nontransplant patients with COVID-19. Transplant
              patients were more likely to be male individuals, older, have a
              body mass index >30 kg/m2, and have comorbid hypertension,
              diabetes, nicotine dependence, heart failure, and ischemic heart
              disease compared with the nontransplant group (P < 0.05).
              One-to-one matching was performed for diabetes, hypertension,
              chronic lung diseases, race, nicotine dependence, heart failure,
              ischemic heart disease, and gender. There was no difference in
              the composite outcome of intubation or mechanical ventilation at
              30 days (risk ratio [RR], 1.04; 95\% confidence interval [CI],
              0.86-1.26) or 60 days (RR, 1.03; 95\% CI, 0.86-1.24) between the
              2 groups. Hospitalization rate was higher in the transplant
              cohort (30.97\% versus 25.47\%; RR, 1.22; 95\% CI, 1.11-1.34).
              There was no difference in mortality at 30 days (6.45\% versus
              5.29\%; RR, 1.22; 95\% CI, 0.88-1.68) or 60 days postdiagnosis
              (RR, 1.05; 95\% CI, 0.83-1.32). More patients in the SOT group
              developed acute renal injury compared with non-SOT cohort
              (24.73\% versus 14.29\%; RR, 1.73; 95\% CI, 1.53-1.96).
              CONCLUSIONS: Patients with SOT have high COVID-19-related
              mortality; however, propensity-matched analyses reveal that this
              increased risk is secondary to higher burden of comorbidities.
              SOT status independently increases risk of hospital admission and
              acute kidney injury.",
  journal  = "Transplantation",
  volume   =  105,
  number   =  6,
  pages    = "1365--1371",
  month    =  jun,
  year     =  2021,
  language = "en"
}

@ARTICLE{Smith2021-xu,
  title     = "St Andrew's {COVID-19} surgery safety ({StACS}) study: The Burns
               Centre experience",
  author    = "Smith, A C D and Miranda, B H and Strong, B and Jica, R C I and
               Pinto-Lopes, R and Khan, W and Martin, N A and El-Muttardi, N
               and Barnes, D and Shelley, O P",
  abstract  = "BACKGROUND: The COVID-19 pandemic caused by the Severe Acute
               Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has the
               potential to significantly impact burns patients both directly
               through infective complications of an immunocompromised cohort,
               and indirectly through disruption of care pathways and resource
               limitations. The pandemic presents new challenges that must be
               overcome to maintain patient safety; in particular, the
               potential increased risks of surgical intervention, anaesthesia
               and ventilation. This study comprehensively reviews the measures
               implemented to adapt referral pathways and mitigate the risk
               posed by COVID-19 during the height of the pandemic, within a
               large Burns Centre. METHODS: A prospective cohort study was
               designed to assess patients treated at the Burns Centre during
               the UK COVID-19 pandemic peak (April-May 2020), following
               implementation of new safety measures. All patients were
               analysed for 30-day mortality. In addition, a prospective
               controlled cohort study was undertaken on all inpatients and a
               random sample of outpatients with telephone follow-up at 30
               days. These patients were divided into three groups (operative
               inpatients, non-operative inpatients, outpatients). COVID-19
               related data collected included test results, contact with
               proven cases, isolation status and symptoms. The implemented
               departmental service COVID-19 safety adaptations are described.
               RESULTS: Of 323 patients treated at the Burns Centre during the
               study period, no 30-day COVID-19 related deaths occurred
               (0/323). Of the 80 patients analysed in the prospective
               controlled cohort section of the study, 51 underwent COVID-19
               testing, 3.9\% (2/51) were positive. Both cases were in the
               operative group, however in comparison to the non-operative and
               outpatient groups, there was no significant increase in COVID-19
               incidence in operative patients. CONCLUSIONS: We found no
               COVID-19 related mortality during the study period. With
               appropriate precautions, burns patients were not exposed to an
               increased COVID-19 risk. Similarly, burns patients undergoing
               operative management were not at a significantly increased risk
               of contracting COVID-19 in comparison to non-operative groups.",
  journal   = "Burns",
  publisher = "Elsevier BV",
  volume    =  47,
  number    =  7,
  pages     = "1547--1555",
  month     =  nov,
  year      =  2021,
  keywords  = "Burn; Burns; COVID-19; Coronavirus; Surgery",
  language  = "en"
}

@ARTICLE{Alexander2021-sn,
  title     = "{SARS-CoV-2} vaccination for patients with inflammatory bowel
               disease: a British Society of Gastroenterology Inflammatory
               Bowel Disease section and {IBD} Clinical Research Group position
               statement",
  author    = "Alexander, James L and Moran, Gordon W and Gaya, Daniel R and
               Raine, Tim and Hart, Ailsa and Kennedy, Nicholas A and Lindsay,
               James O and MacDonald, Jonathan and Segal, Jonathan P and
               Sebastian, Shaji and Selinger, Christian P and Parkes, Miles and
               Smith, Philip J and Dhar, Anjan and Subramanian, Sreedhar and
               Arasaradnam, Ramesh and Lamb, Christopher A and Ahmad, Tariq and
               Lees, Charlie W and Dobson, Liz and Wakeman, Ruth and Iqbal,
               Tariq H and Arnott, Ian and Powell, Nick and {Inflammatory Bowel
               Disease section of the British Society of Gastroenterology and
               the the Inflammatory Bowel Disease Clinical Research Group}",
  abstract  = "SARS-CoV-2 has caused a global health crisis and mass
               vaccination programmes provide the best opportunity for
               controlling transmission and protecting populations. Despite the
               impressive clinical trial results of the BNT162b2
               (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and
               mRNA-1273 (Moderna) vaccines, important unanswered questions
               remain, especially in patients with pre-existing conditions. In
               this position statement endorsed by the British Society of
               Gastroenterology Inflammatory Bowel Disease (IBD) section and
               IBD Clinical Research Group, we consider SARS-CoV-2 vaccination
               strategy in patients with IBD. The risks of SARS-CoV-2
               vaccination are anticipated to be very low, and we strongly
               support SARS-CoV-2 vaccination in patients with IBD. Based on
               data from previous studies with other vaccines, there are
               conceptual concerns that protective immune responses to
               SARS-CoV-2 vaccination may be diminished in some patients with
               IBD, such as those taking anti-TNF drugs. However, the benefits
               of vaccination, even in patients treated with anti-TNF drugs,
               are likely to outweigh these theoretical concerns. Key areas for
               further research are discussed, including vaccine hesitancy and
               its effect in the IBD community, the effect of immunosuppression
               on vaccine efficacy, and the search for predictive biomarkers of
               vaccine success.",
  journal   = "Lancet Gastroenterol. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  6,
  number    =  3,
  pages     = "218--224",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Rosano2021-xt,
  title     = "{COVID-19} vaccination in patients with heart failure: a
               position paper of the Heart Failure Association of the European
               Society of Cardiology",
  author    = "Rosano, Giuseppe and Jankowska, Ewa A and Ray, Robin and Metra,
               Marco and Abdelhamid, Magdy and Adamopoulos, Stamatis and Anker,
               Stefan D and Bayes-Genis, Antoni and Belenkov, Yury and Gal,
               Tuvia B and B{\"o}hm, Michael and Chioncel, Ovidiu and
               Cohen-Solal, Alain and Farmakis, Dimitrios and Filippatos,
               Gerasimos and Gonz{\'a}lez, Arantxa and Gustafsson, Finn and
               Hill, Loreena and Jaarsma, Tiny and Jouhra, Fadi and Lainscak,
               Mitja and Lambrinou, Ekaterini and Lopatin, Yury and Lund, Lars
               H and Milicic, Davor and Moura, Brenda and Mullens, Wilfried and
               Piepoli, Massimo F and Ponikowski, Piotr and Rakisheva, Amina
               and Ristic, Arsen and Savarese, Gianluigi and Seferovic, Petar
               and Senni, Michele and Thum, Thomas and Tocchetti, Carlo G and
               Van Linthout, Sophie and Volterrani, Maurizio and Coats, Andrew
               J S",
  abstract  = "Patients with heart failure (HF) who contract SARS-CoV-2
               infection are at a higher risk of cardiovascular and
               non-cardiovascular morbidity and mortality. Regardless of
               therapeutic attempts in COVID-19, vaccination remains the most
               promising global approach at present for controlling this
               disease. There are several concerns and misconceptions regarding
               the clinical indications, optimal mode of delivery, safety and
               efficacy of COVID-19 vaccines for patients with HF. This
               document provides guidance to all healthcare professionals
               regarding the implementation of a COVID-19 vaccination scheme in
               patients with HF. COVID-19 vaccination is indicated in all
               patients with HF, including those who are immunocompromised
               (e.g. after heart transplantation receiving immunosuppressive
               therapy) and with frailty syndrome. It is preferable to
               vaccinate against COVID-19 patients with HF in an optimal
               clinical state, which would include clinical stability, adequate
               hydration and nutrition, optimized treatment of HF and other
               comorbidities (including iron deficiency), but corrective
               measures should not be allowed to delay vaccination. Patients
               with HF who have been vaccinated against COVID-19 need to
               continue precautionary measures, including the use of facemasks,
               hand hygiene and social distancing. Knowledge on strategies
               preventing SARS-CoV-2 infection (including the COVID-19
               vaccination) should be included in the comprehensive educational
               programmes delivered to patients with HF.",
  journal   = "Eur. J. Heart Fail.",
  publisher = "Wiley",
  volume    =  23,
  number    =  11,
  pages     = "1806--1818",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Heart failure; SARS-CoV-2; Vaccination",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Millen2021-eg,
  title     = "Severity of {COVID-19} in children with cancer: Report from the
               United Kingdom Paediatric Coronavirus Cancer Monitoring Project",
  author    = "Millen, Gerard C and Arnold, Roland and Cazier, Jean-Baptiste
               and Curley, Helen and Feltbower, Richard G and Gamble, Ashley
               and Glaser, Adam W and Grundy, Richard G and Lee, Lennard Y W
               and McCabe, Martin G and Phillips, Robert S and Stiller, Charles
               A and V{\'a}rnai, Csilla and Kearns, Pamela R",
  abstract  = "BACKGROUND: Children with cancer are frequently
               immunocompromised. While children are generally thought to be at
               less risk of severe SARS-CoV-2 infection than adults,
               comprehensive population-based evidence for the risk in children
               with cancer is unavailable. We aimed to produce evidence of the
               incidence and outcomes from SARS-CoV-2 in children with cancer
               attending all hospitals treating this population across the UK.
               METHODS: Retrospective and prospective observational study of
               all children in the UK under 16 diagnosed with cancer through
               data collection from all hospitals providing cancer care to this
               population. Eligible patients tested positive for SARS-CoV-2 on
               reverse transcription polymerase chain reaction (RT-PCR). The
               primary end-point was death, discharge or end of active care for
               COVID-19 for those remaining in hospital. RESULTS: Between 12
               March 2020 and 31 July 2020, 54 cases were identified: 15 (28\%)
               were asymptomatic, 34 (63\%) had mild infections and 5 (10\%)
               moderate, severe or critical infections. No patients died and
               only three patients required intensive care support due to
               COVID-19. Estimated incidence of hospital identified SARS-CoV-2
               infection in children with cancer under 16 was 3\%. CONCLUSIONS:
               Children with cancer with SARS-CoV-2 infection do not appear at
               increased risk of severe infection compared to the general
               paediatric population. This is reassuring and supports the
               continued delivery of standard treatment.",
  journal   = "Br. J. Cancer",
  publisher = "Springer Science and Business Media LLC",
  volume    =  124,
  number    =  4,
  pages     = "754--759",
  month     =  feb,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Devi2021-mj,
  title    = "Febrile neutropenia due to {COVID-19} in an immunocompetent
              patient",
  author   = "Devi, Yumkham Monica and Sehrawat, Amit and Panda, Prasan Kumar
              and Nath, Uttam Kumar",
  abstract = "While lymphopenia has been a common finding in COVID-19
              infection, particularly in severe cases, febrile neutropenia has
              been very rarely reported in immunocompetent patients with
              COVID-19. Herein, we report the case of a 76-year-old
              hypertensive and diabetic man who was hospitalised with severe
              COVID-19 infection and developed delayed-onset severe neutropenia
              with neutropenic fever, which responded to treatment with
              antibiotics and granulocyte colony-stimulating factor. This case
              highlights the importance of identifying a rare complication
              (febrile neutropenia on the fifth week) of COVID-19 infection in
              hospitalised patients by intensive monitoring and aggressive
              management for favourable outcomes.",
  journal  = "BMJ Case Rep.",
  volume   =  14,
  number   =  4,
  month    =  apr,
  year     =  2021,
  keywords = "COVID-19; adult intensive care; haematology (drugs and
              medicines); infectious diseases",
  language = "en"
}

@ARTICLE{Rnjak2021-uc,
  title     = "{COVID-19} convalescent plasma as long-term therapy in
               immunodeficient patients?",
  author    = "Rnjak, D and Ravli{\'c}, S and {\v S}ola, A-M and Halassy, B and
               {\v S}emni{\v c}ki, J and {\v S}uperba, M and He{\'c}imovi{\'c},
               A and Kurolt, I-C and Kurtovi{\'c}, T and Ma{\v c}ak {\v
               S}afranko, {\v Z} and Polan{\v c}ec, D and Bendelja, K and Mu{\v
               s}lin, T and Juki{\'c}, I and Vuk, T and Zeni{\'c}, L and
               Artukovi{\'c}, M",
  abstract  = "OBJECTIVES: The patients with hematological malignancies are a
               vulnerable group to COVID-19, due to the immunodeficiency
               resulting from the underlying disease and oncological treatment
               that significantly impair cellular and humoral immunity. Here we
               report on a beneficial impact of a passive immunotherapy with
               convalescent plasma to treat a prolonged, active COVID-19
               infection in a patient with a history of nasopharyngeal diffuse
               large B-cell lymphoma treated with the therapy inducing
               substantial impairment of particularly humoral arm of immune
               system. The specific aim was to quantify SARS-CoV2 neutralizing
               antibodies in a patient plasma during the course of therapy.
               MATERIALS AND METHODS: Besides the standard of care treatment
               and monitoring, neutralizing antibody titers in patient's serum
               samples, calibrated according to the First WHO International
               Standard for anti-SARS-CoV-2 immunoglobulin (human), were
               quantified in a time-dependent manner. During the immunotherapy
               period peripheral blood flow cytometry immunophenotyping was
               conducted to characterize lymphocyte subpopulations. RESULTS:
               The waves of clinical improvements and worsening coincided with
               transfused neutralizing antibodies rises and drops in the
               patient's systemic circulation, proving their contribution in
               controlling the disease progress. Besides the patient's lack of
               own humoral immune system, immunophenotyping analysis revealed
               also the reduced level of helper T-lymphocytes and immune
               exhaustion of monocytes. CONCLUSION: Therapeutic approach based
               on convalescent plasma transfusion transformed a prolonged,
               active COVID-19 infection into a manageable chronic disease.",
  journal   = "Transfus. Clin. Biol.",
  publisher = "Elsevier BV",
  volume    =  28,
  number    =  3,
  pages     = "264--270",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Convalescent plasma; Immunodeficiency; Infective
               virus-neutralization assay; Neutralizing antibody; SARS-CoV-2",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Donato2021-qs,
  title     = "Clinical and laboratory evaluation of patients with {SARS-CoV-2}
               pneumonia treated with high-titer convalescent plasma",
  author    = "Donato, Michele L and Park, Steven and Baker, Melissa and
               Korngold, Robert and Morawski, Alison and Geng, Xue and Tan,
               Ming and Ip, Andrew and Goldberg, Stuart and Rowley, Scott and
               Chow, Kar and Brown, Emily and Zenreich, Joshua and McKiernan,
               Phyllis and Buttner, Kathryn and Ullrich, Anna and Long, Laura
               and Feinman, Rena and Ricourt, Andrea and Kemp, Marlo and
               Vendivil, Mariefel and Suh, Hyung and Balani, Bindu and Cicogna,
               Cristina and Sebti, Rani and Al-Khan, Abdulla and Sperber,
               Steven and Desai, Samit and Fanning, Stacey and Arad, Danit and
               Go, Ronaldo and Tam, Elizabeth and Rose, Keith and Sadikot, Sean
               and Siegel, David and Gutierrez, Martin and Feldman, Tatyana and
               Goy, Andre and Pecora, Andrew and Biran, Noa and Leslie, Lori
               and Gillio, Alfred and Timmapuri, Sarah and Boonstra, Michele
               and Singer, Sam and Kaur, Sukhdeep and Richards, Ernest and
               Perlin, David S",
  abstract  = "Here, we report on a phase IIa study to determine the intubation
               rate, survival, viral clearance, and development of endogenous
               Abs in patients with COVID-19 pneumonia treated with
               convalescent plasma (CCP) containing high levels of neutralizing
               anti-SARS-CoV-2 Abs. Radiographic and laboratory evaluation
               confirmed all 51 treated patients had COVID-19 pneumonia. Fresh
               or frozen CCP from donors with high titers of neutralizing Abs
               was administered. The nonmechanically ventilated patients (n =
               36) had an intubation rate of 13.9\% and a 30-day survival rate
               of 88.9\%, and the overall survival rate for a comparative group
               based on network data was 72.5\% (1625/2241). Patients had
               negative nasopharyngeal swab rates of 43.8\% and 73.0\% on days
               10 and 30, respectively. Patients mechanically ventilated had a
               day-30 mortality rate of 46.7\%; the mortality rate for a
               comparative group based on network data was 71.0\% (369/520).
               All evaluable patients were found to have neutralizing Abs on
               day 3 (n = 47), and all but 1 patient had Abs on days 30 and 60.
               The only adverse event was a mild rash. In this study on
               patients with COVID-19 disease, we show therapeutic use of CCP
               was safe and conferred transfer of Abs, while preserving
               endogenous immune response.",
  journal   = "JCI Insight",
  publisher = "American Society for Clinical Investigation",
  volume    =  6,
  number    =  6,
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Immunotherapy",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Mohamed2021-xd,
  title     = "Outcomes of renal transplant recipients with {SARS-CoV-2}
               infection in the eye of the storm: A comparative study with
               waitlisted patients",
  author    = "Mohamed, Ismail H and Chowdary, Prashanth B and Shetty, Shraddha
               and Sammartino, Cinzia and Sivaprakasam, Rajesh and Lindsey, Ben
               and Thuraisingham, Raj and Yaqoob, Muhammad M and Khurram,
               Muhammad A",
  abstract  = "BACKGROUND: Patients with chronic kidney disease stage 5 and
               those on immunosuppression are particularly vulnerable and are
               shielded as per public health strategy. We present our
               experience of coronavirus disease 2019 (COVID-19) transplant
               patients in one of the most affected parts of the UK with direct
               comparison to waitlisted patients. METHODS: A single-center
               prospective study of symptomatic severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2) positive waitlisted and
               transplant patients was undertaken to compare these groups and
               assess clinical outcomes. RESULTS: A total of 60 consecutive
               symptomatic SARS-CoV-2 positive patients were identified with 32
               active waitlisted patients and 28 functioning renal transplants.
               Demographics were similar. The incidence of symptomatic COVID-19
               in the waitlisted group was 9.9\% compared to 1.9\% in renal
               transplant patients (P < 0.001). Immunosuppression did not
               influence initial symptomology. Fifteen percent of patients in
               the waitlisted and 32\% in the transplant groups died (P =
               0.726). Mortality as proportion of total waitlisted (321
               patients) and transplant population (1434 patients) of our
               centre was 1.5\% and 0.6\% (P < 0.001), respectively. C-reactive
               protein (CRP) at 48 h and peak CRP were associated with
               mortality in both groups while quick sequential organ failure
               assessment score at 48 h (P = 0.036) was associated with
               mortality for transplant patients. CONCLUSIONS: Incidence of
               COVID-19 is higher in the waitlisted population but transplant
               patients have more severe disease, reflected by higher
               mortality. CRP at 48 h can be used as a predictive tool. In the
               absence of effective treatments, the current strategy of
               shielding is arguably the most important factor in protecting
               patients while resuming transplantation.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  1,
  pages     = "115--120",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Broseta2021-vf,
  title     = "{SARS-CoV-2} infection in a Spanish cohort of {CKD-5D} patients:
               Prevalence, clinical presentation, outcomes, and {DE-isolation}
               results",
  author    = "Broseta, Jos{\'e} Jes{\'u}s and Rodr{\'\i}guez-Espinosa, Diana
               and Cuadrado, Elena and Guill{\'e}n-Olmos, Elena and Hermida,
               Evelyn and Montagud-Marrahi, Enrique and Rodas, Lida and Vera,
               Manel and Fontser{\'e}, N{\'e}stor and Arias, Marta and Cases,
               Aleix and Maduell, Francisco",
  abstract  = "INTRODUCTION: COVID-19 is a highly contagious disease that has
               easily spread worldwide. Outpatient maintenance hemodialysis
               seems to entail an increased risk of contagion, and previous
               reports inform of increased mortality among this population.
               METHODS: We retrospectively analyzed clinical and laboratory
               parameters, outcomes, and management once discharged of CKD-5D
               patients infected with SARS-CoV-2 from our health area. RESULTS:
               Out of the 429 CKD-5D population, 36 were diagnosed with
               SARS-CoV-2 infection (8\%): 34 on in-center hemodialysis and 2
               on peritoneal dialysis. Five were asymptomatic. The most common
               symptom was fever (70\%), followed by dyspnea and cough. History
               of cardiovascular disease and elevation of LDH and C-reactive
               protein during admission were associated with higher mortality.
               Thirteen patients died (36\%), 8 patients were admitted to an
               ICU, and survival was low (38\%) among the latter. The mean time
               to death was 12 days. Most discharged patients got negative
               rRT-PCR in nasopharyngeal swabs within 26 days of diagnosis.
               However, there is a portion of cured patients that continue to
               have positive results even more than 2 months after the initial
               presentation. CONCLUSIONS: Patients on dialysis have an
               increased mortality risk if infected with SARS-CoV-2. Preventive
               measures have proven useful. Thus, proper ones, such as
               universal screening of the population and isolation when
               required, need to be generalized. Better de-isolation criteria
               are necessary to ensure an appropriate use of public health
               resources.",
  journal   = "Blood Purif.",
  publisher = "S. Karger AG",
  volume    =  50,
  number    = "4-5",
  pages     = "531--538",
  year      =  2021,
  keywords  = "COVID-19; De-isolation; Hemodialysis; Peritoneal dialysis;
               SARS-CoV-2",
  copyright = "https://www.karger.com/Services/SiteLicenses",
  language  = "en"
}

@ARTICLE{Hernandez-Coronado2021-fn,
  title     = "Successful second outpatient autologous hematopoietic cell
               transplant for relapsed {POEMS} syndrome in a patient with
               coexisting {HIV}, {HBV} and syphilis infections during the
               {COVID-19} pandemic",
  author    = "Hern{\'a}ndez-Coronado, Marcela and Jaime-P{\'e}rez, Jos{\'e}
               Carlos and Villarreal-Mart{\'\i}nez, Alejandra and
               Ocampo-Candiani, Jorge and G{\'o}mez-Almaguer, David",
  abstract  = "Polyneuropathy, organomegaly, endocrinopathy, monoclonal
               gammopathy, and skin changes (POEMS) syndrome is a multisystem
               autoinflammatory disease due to an underlying plasma cell
               disorder that lacks a standard treatment strategy because of its
               rarity. We report a case of relapsed POEMS syndrome successfully
               treated with a second ambulatory autologous hematopoietic-cell
               transplantation (AHCT) after a daratumumab desensitization
               protocol performed during the coronavirus disease (COVID-19)
               pandemic in a patient with coexisting human immunodeficiency
               virus (HIV), hepatitis B virus (HBV) and syphilis infections. He
               is a 37-year old Latin-American male who had been treated with
               radiation, CyBorD regimen, AHCT and bortezomib therapy before
               being referred to our service. It was decided to administer
               daratumumab therapy and subsequently perform the transplant.
               Placement of central venous access, fluid infusion, conditioning
               regimen with melphalan and previously cryopreserved autograft
               infusion were carried out in an outpatient basis. Following
               second AHCT, the patient demonstrated clinical, VEGF,
               hematological response and remains SARS-CoV-2 infection-free and
               in POEMS remission with excellent quality-of-life at last follow
               up (6 months). We evidenced that thanks to an outpatient
               transplant program, the best therapeutic modalities can be
               offered to patients with hematologic malignancies in the context
               of present or future pandemics. Finally, high-complexity
               patients with HIV infection should have access to the same
               treatment strategies as non-infected patients. A second AHCT in
               the outpatient setting is feasible, safe and highly effective to
               treat patients with relapsed POEMS syndrome.",
  journal   = "Transpl. Immunol.",
  publisher = "Elsevier BV",
  volume    =  67,
  number    =  101412,
  pages     = "101412",
  month     =  aug,
  year      =  2021,
  keywords  = "Autologous transplant; Daratumumab; HIV; Hematopoietic cell
               transplantation; Outpatient HCT; POEMS syndrome",
  language  = "en"
}

@ARTICLE{Sopirala2021-eg,
  title    = "Predisposition of {COVID-19} patients to secondary infections:
              set in stone or subject to change?",
  author   = "Sopirala, Madhuri M",
  abstract = "PURPOSE OF REVIEW: There likely are several predisposing factors
              to secondary infections in patients with Coronavirus disease 2019
              (COVID-19), some of which may be preventable. The aim of this
              review is to explore the literature, summarize potential
              predisposing factors to secondary infections and their incidence.
              It also summarizes a variety of healthcare scenarios in which
              different kinds of secondary infections occur. RECENT FINDINGS:
              Apart from immune dysregulation, severe resource limitations in
              healthcare settings have made COVID-19 units conducive to a
              variety of secondary infections. Long-term effect of excess
              antibiotic use in COVID-19 patients is yet to be studied. Very
              few studies have assessed secondary infections as the primary
              outcome measure making it difficult to know the true incidence.
              Mortality attributable to secondary infections in COVID-19
              patients is also unclear. SUMMARY: Incidence of secondary
              infections in COVID-19 patients is likely higher than what is
              reported in the literature. Well designed studies are needed to
              understand the incidence and impact of secondary infections in
              this patient population. Many of these may be preventable
              especially now, as personal protective equipment and other
              healthcare resources are recovering. Infection prevention and
              control (IPC) and antimicrobial stewardship programmes (ASP) must
              reassess current situation to correct any breaches that could
              potentially cause more harm in these already vulnerable patients
              as we brace for a future surge with another pandemic wave.",
  journal  = "Curr. Opin. Infect. Dis.",
  volume   =  34,
  number   =  4,
  pages    = "357--364",
  month    =  aug,
  year     =  2021,
  language = "en"
}

@ARTICLE{Sarno2021-pi,
  title     = "{COVID-19} infection in kidney transplant recipients in Italy:
               Management issues in a kidney transplant center",
  author    = "Sarno, Gerardo and Russo, Enrico and Ferrara, Aristide and
               Cerbone, Vincenzo and Villa, Rachele and De Rosa, Paride",
  journal   = "Exp. Clin. Transplant.",
  publisher = "Baskent University",
  volume    =  19,
  number    =  3,
  pages     = "284--286",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{SeyedAlinaghi2021-at,
  title    = "Predictors of the prolonged recovery period in {COVID-19}
              patients: a cross-sectional study",
  author   = "SeyedAlinaghi, Seyedahmad and Abbasian, Ladan and Solduzian,
              Mohammad and Ayoobi Yazdi, Niloofar and Jafari, Fatemeh and
              Adibimehr, Alireza and Farahani, Aazam and Salami Khaneshan,
              Arezoo and Ebrahimi Alavijeh, Parvaneh and Jahani, Zahra and
              Karimian, Elnaz and Ahmadinejad, Zahra and Khalili, Hossein and
              Seifi, Arash and Ghiasvand, Fereshteh and Ghaderkhani, Sara and
              Rasoolinejad, Mehrnaz",
  abstract = "BACKGROUND: The clinical course of COVID-19 may vary
              significantly. The presence of comorbidities prolongs the
              recovery time. The recovery in patients with mild-to-moderate
              symptoms might take 10 days, while in those with a critical
              illness or immunocompromised status could take 15 days.
              Considering the lack of data about predictors that could affect
              the recovery time, we conducted this study to identify them.
              METHODS: This cross-sectional study was implemented in the
              COVID-19 clinic of a teaching and referral university hospital in
              Tehran. Patients with the highly suggestive symptoms who had
              computed tomography (CT) imaging results with typical findings of
              COVID-19 or positive results of reverse transcriptase-polymerase
              chain reaction (RT-PCR) were enrolled in the study. Inpatient and
              outpatient COVID-19 participants were followed up by regular
              visits or phone calls, and the recovery period was recorded.
              RESULTS: A total of 478 patients were enrolled. The mean age of
              patients was 54.11 $\pm$ 5.65 years, and 44.2\% were female. The
              median time to recovery was 13.5 days (IQR: 9). Although in the
              bivariate analysis, multiple factors, including hypertension,
              fever, diabetes mellitus, gender, and admission location,
              significantly contributed to prolonging the recovery period, in
              multivariate analysis, only dyspnea had a significant association
              with this variable (p = 0.02, the adjusted OR of 2.05; 95\% CI
              1.12-3.75). CONCLUSION: This study supports that dyspnea is a
              predictor of recovery time. It seems like optimal management of
              the comorbidities plays the most crucial role in recovery from
              COVID-19.",
  journal  = "Eur. J. Med. Res.",
  volume   =  26,
  number   =  1,
  pages    = "41",
  month    =  may,
  year     =  2021,
  keywords = "COVID-19; Comorbidities; Dyspnea; Predictors; Recovery; Time",
  language = "en"
}

@ARTICLE{Louapre2021-wm,
  title     = "Outcomes of coronavirus disease 2019 in patients with
               neuromyelitis optica and associated disorders",
  author    = "Louapre, C{\'e}line and Maillart, Elisabeth and Papeix, Caroline
               and Zeidan, Sinead and Biotti, Damien and Lepine, Zo{\'e} and
               Wahab, Abir and Zedet, Mickael and Labauge, Pierre and Tilikete,
               Caroline and Pique, Julie and Tourbah, Ayman and Mathey,
               Guillaume and Dimitri Boulos, Dalia and Branger, Pierre and
               Kremer, Laurent Daniel and Marignier, Romain and Collongues,
               Nicolas and De Seze, J{\'e}r{\^o}me",
  abstract  = "BACKGROUND: Outcomes of coronavirus disease 2019 (COVID-19) in
               patients with neuromyelitis optica spectrum disorders (NMOSD) or
               myelin oligodendrocyte glycoprotein antibody-associated disease
               (MOGAD), often treated with immunosuppressive therapies, are
               still unknown. METHODS: We conducted a multicenter,
               retrospective, observational cohort study among all French
               expert centers for neuromyelitis optica and related disorders.
               Patients with NMOSD or MOGAD included in the study received a
               confirmed or highly suspected diagnosis of COVID-19 between 1
               March 2020 and 30 June 2020. Main outcome was COVID-19 severity
               score assessed on a seven-point ordinal scale ranging from 1
               (not hospitalized with no limitations on activities) to 7
               (death). RESULTS: Fifteen cases (mean [SD] age: 39.3 [14.3]
               years, 11 female) were included. Five patients (33.3\%) were
               hospitalized, all receiving rituximab. A 24-year-old patient
               with positive aquaporine-4 antibody, with obesity as
               comorbidity, needed mechanical ventilation. Outpatients were
               receiving anti-CD20 (5), mycophenolate mofetil (3) or
               azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4]
               years), with a longer disease duration (mean [SD]: 8.3 [6.3]
               years) and had a lower expanded disability severity score (EDSS)
               score (median [range] EDSS: 2.5 [0-4]) relative to patients
               requiring hospitalization (mean [SD] age: 44.0 [16.4] years,
               mean [SD] disease duration: 5.8 [5.5] years, median [range]
               EDSS: 4 [0-6.5]). CONCLUSIONS: COVID-19 outcome was overall
               favorable in this cohort. Larger international studies are
               needed to identify risk factors of severe COVID-19; however, we
               recommend personal protective measures to reduce risk of
               SARS-CoV-2 infection in this immunocompromised population.",
  journal   = "Eur. J. Neurol.",
  publisher = "Wiley",
  volume    =  28,
  number    =  10,
  pages     = "3461--3466",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; MOGAD; NMOSD; immunosuppressant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Russo2021-rx,
  title    = "Evaluation of the {anti-COVID-19} vaccination campaign in the
              Metropolitan Area of Milan (Lombardy Region, Northern Italy)",
  author   = "Russo, Antonio Giampiero and Tunesi, Sara and Consolazio, David
              and Decarli, Adriano and Bergamaschi, Walter",
  abstract = "OBJECTIVES: to present an evaluation of the campaign for
              vaccination against COVID-19 in the territory covered by the
              Agency for Health Protection of the Metropolitan Area of Milan
              from 01.01.2021 to 30.09.2021. DESIGN: descriptive study of
              vaccine adherence; predictive study of the factors associated
              with vaccine adherence, efficacy of vaccination in terms of
              hospitalization and mortality, and factors that increase the risk
              of hospital admission following full vaccination. SETTING AND
              PARTICIPANTS: population-based study with subjects aged >18 years
              eligible for vaccination (N. 2,981,997). An information system
              obtained by integrating various administrative healthcare sources
              made it possible to analyse socioeconomic characteristics,
              COVID-19 related hospitalizations, and general mortality in
              subjects eligible for vaccination. MAIN OUTCOME MEASURES: full
              vaccination (2 doses); COVID-19-related hospitalizations,
              COVID-19-related hospitalizations occurring more than 15 days
              after the second dose, general mortality. RESULTS: in the first
              nine months of the vaccination campaign, 74.7\% of the subjects
              (N. 2,228,915) was fully vaccinated, whereas 15.6\% (N. 465,829)
              did not even receive one dose. Women have a lower probability of
              getting vaccinated than men; the 50-59 years and 70+ years age
              groups emerge as the most problematic to reach, while the younger
              one (<40) is the most adherent. A social gradient emerged, with
              residents of more disadvantaged areas progressively less incline
              to get vaccinated than those living in more affluent areas.
              Adherence is greater in Italian citizenship and is likely to
              increase with an increase in the number of chronic conditions.
              Hospitalizations amounted to 1.22\% (N. 5,672) in the
              unvaccinated population compared to 0.05\% (N. 1,013) in the
              vaccinated population; general mortality was 4.51\% (N. 15,198)
              in the unvaccinated population against 0.32\% (N. 8.733) in the
              vaccinated population. Sociodemographic factors and the presence
              of previous health conditions are important predictors of
              hospitalization outcomes even within the fully vaccinated
              population. Specifically, the highest hazard ratios are found in
              subjects with heart failure (HR 2.15; 95\%CI 1.83-2.53), in
              immunocompromised patients (HR 2.02; 95\%CI 1.52-2.69), and in
              transplant recipients (HR 1.92; 95\%CI 1.10-3.33). CONCLUSIONS:
              vaccination campaign adherence is affected by the
              sociodemographic characteristics of the population and is a
              determining factor in preventing hospitalizations for COVID-19
              and death. The persistent higher risk of hospitalization in
              chronic subjects following the second dose emphasizes the need to
              direct booster doses to the more vulnerable. Information systems
              proved to be effective monitoring tools in the absence of
              specific trials.",
  journal  = "Epidemiol. Prev.",
  volume   =  45,
  pages    = "In press",
  year     =  2021,
  keywords = "COVID-19; hospitalizations; informative systems ; mortality;
              sociodemographic factors; vaccination",
  language = "en"
}

@ARTICLE{Dong2021-qu,
  title     = "Comprehensive characterization of {COVID-19} patients with
               repeatedly positive {SARS-CoV-2} tests using a large U.s.
               electronic health record database",
  author    = "Dong, Xiao and Zhou, Yujia and Shu, Xiao-Ou and Bernstam, Elmer
               V and Stern, Rebecca and Aronoff, David M and Xu, Hua and
               Lipworth, Loren",
  abstract  = "In the absence of genome sequencing, two positive molecular
               tests for severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) separated by negative tests, prolonged time, and
               symptom resolution remain the best surrogate measure of possible
               reinfection. Using a large electronic health record database, we
               characterized clinical and testing data for 23 patients with
               repeatedly positive SARS-CoV-2 PCR test results $\geq$60 days
               apart, separated by $\geq$2 consecutive negative test results.
               The prevalence of chronic medical conditions, symptoms, and
               severe outcomes related to coronavirus disease 19 (COVID-19)
               illness were ascertained. The median age of patients was 64.5
               years, 40\% were Black, and 39\% were female. A total of 83\%
               smoked within the prior year, 61\% were overweight/obese, 83\%
               had immunocompromising conditions, and 96\% had $\geq$2
               comorbidities. The median interval between the two positive
               tests was 77 days. Among the 19 patients with 60 to 89 days
               between positive tests, 17 (89\%) exhibited symptoms or clinical
               manifestations consistent with COVID-19 at the time of the
               second positive test and 14 (74\%) were hospitalized at the
               second positive test. Of the four patients with $\geq$90 days
               between two positive tests (patient 2 [PT2], PT8, PT14, and
               PT19), two had mild or no symptoms at the second positive test
               and one, an immunocompromised patient, had a brief
               hospitalization at the first diagnosis, followed by intensive
               care unit (ICU) admission at the second diagnosis 3 months
               later. Our study demonstrated a high prevalence of compromised
               immune systems, comorbidities, obesity, and smoking among
               patients with repeatedly positive SARS-CoV-2 tests. Despite
               limitations, including a lack of semiquantitative estimates of
               viral load, these data may help prioritize suspected cases of
               reinfection for investigation and continued surveillance.
               IMPORTANCE The comprehensive characterization of severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and
               clinical data for patients with repeatedly positive SARS-CoV-2
               tests can help prioritize suspected cases of reinfection for
               investigation in the absence of genome sequencing data and for
               continued surveillance of the potential long-term health
               consequences of SARS-CoV-2 infection.",
  journal   = "Microbiol. Spectr.",
  publisher = "American Society for Microbiology",
  volume    =  9,
  number    =  1,
  pages     = "e0032721",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; EHR; reinfection",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Prendecki2021-py,
  title     = "Humoral and T-cell responses to {SARS-CoV-2} vaccination in
               patients receiving immunosuppression",
  author    = "Prendecki, Maria and Clarke, Candice and Edwards, Helena and
               McIntyre, Stacey and Mortimer, Paige and Gleeson, Sarah and
               Martin, Paul and Thomson, Tina and Randell, Paul and Shah, Anand
               and Singanayagam, Aran and Lightstone, Liz and Cox, Alison and
               Kelleher, Peter and Willicombe, Michelle and McAdoo, Stephen P",
  abstract  = "ObjectiveThere is an urgent need to assess the impact of
               immunosuppressive therapies on the immunogenicity and efficacy
               of SARS-CoV-2 vaccination.MethodsSerological and T-cell ELISpot
               assays were used to assess the response to first-dose and
               second-dose SARS-CoV-2 vaccine (with either BNT162b2 mRNA or
               ChAdOx1 nCoV-19 vaccines) in 140 participants receiving
               immunosuppression for autoimmune rheumatic and glomerular
               diseases.ResultsFollowing first-dose vaccine, 28.6\% (34/119) of
               infection-na{\"\i}ve participants seroconverted and 26.0\%
               (13/50) had detectable T-cell responses to SARS-CoV-2. Immune
               responses were augmented by second-dose vaccine, increasing
               seroconversion and T-cell response rates to 59.3\% (54/91) and
               82.6\% (38/46), respectively. B-cell depletion at the time of
               vaccination was associated with failure to seroconvert, and
               tacrolimus therapy was associated with diminished T-cell
               responses. Reassuringly, only 8.7\% of infection-na{\"\i}ve
               patients had neither antibody nor T-cell responses detected
               following second-dose vaccine. In patients with evidence of
               prior SARS-CoV-2 infection (19/140), all mounted high-titre
               antibody responses after first-dose vaccine, regardless of
               immunosuppressive therapy.ConclusionSARS-CoV-2 vaccines are
               immunogenic in patients receiving immunosuppression, when
               assessed by a combination of serology and cell-based assays,
               although the response is impaired compared with healthy
               individuals. B-cell depletion following rituximab impairs
               serological responses, but T-cell responses are preserved in
               this group. We suggest that repeat vaccine doses for serological
               non-responders should be investigated as means to induce more
               robust immunological response.",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1322--1329",
  month     =  oct,
  year      =  2021,
  keywords  = "B-lymphocytes; COVID-19; autoimmune diseases; rituximab;
               vaccination",
  language  = "en"
}

@ARTICLE{Goss2021-du,
  title     = "The pediatric solid organ transplant experience with {COVID-19}:
               An initial multi-center, multi-organ case series",
  author    = "Goss, Matthew B and Galv{\'a}n, N Thao N and Ruan, Wenly and
               Munoz, Flor M and Brewer, Eileen D and O'Mahony, Christine A and
               Melicoff-Portillo, Ernestina and Dreyer, William J and Miloh,
               Tamir A and Cigarroa, Francisco G and Ranch, Daniel and Yoeli,
               Dor and Adams, Megan A and Koohmaraie, Sarah and Harter, Diana M
               and Rana, Abbas and Cotton, Ronald T and Carter, Beth and Patel,
               Shreena and Moreno, Nicolas F and Leung, Daniel H and Goss, John
               A",
  abstract  = "The clinical course of COVID-19 in pediatric solid organ
               transplant recipients remains ambiguous. Though preliminary
               experiences with adult transplant recipients have been
               published, literature centered on the pediatric population is
               limited. We herein report a multi-center, multi-organ cohort
               analysis of COVID-19-positive transplant recipients $\leq$ 18
               years at time of transplant. Data were collected via
               institutions' respective electronic medical record systems.
               Local review boards approved this cross-institutional study.
               Among 5 transplant centers, 26 patients (62\% male) were
               reviewed with a median age of 8 years. Six were heart
               recipients, 8 kidney, 10 liver, and 2 lung. Presenting symptoms
               included cough (n = 12 (46\%)), fever (n = 9 (35\%)), dry/sore
               throat (n = 3 (12\%)), rhinorrhea (n = 3 (12\%)), anosmia (n = 2
               (8\%)), chest pain (n = 2 (8\%)), diarrhea (n = 2 (8\%)),
               dyspnea (n = 1 (4\%)), and headache (n = 1 (4\%)). Six patients
               (23\%) were asymptomatic. No patient required supplemental
               oxygen, intubation, or ECMO. Eight patients (31\%) were
               hospitalized at time of diagnosis, 3 of whom were already
               admitted for unrelated problems. Post-transplant
               immunosuppression was reduced for only 2 patients (8\%). All
               symptomatic patients recovered within 7 days. Our
               multi-institutional experience suggests the prognoses of
               pediatric transplant recipients infected with COVID-19 may
               mirror those of immunocompetent children, with infrequent
               hospitalization and minimal treatment, if any, required.",
  journal   = "Pediatr. Transplant.",
  publisher = "Wiley",
  volume    =  25,
  number    =  3,
  pages     = "e13868",
  month     =  may,
  year      =  2021,
  keywords  = "pediatric transplantation; viral infection",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Tougeron2021-qc,
  title     = "Severe acute respiratory syndrome coronavirus 2 vaccination for
               patients with solid cancer: Review and point of view of a French
               oncology intergroup ({GCO}, {TNCD}, {UNICANCER})",
  author    = "Tougeron, David and Hentzien, Maxime and Seitz-Polski, Barbara
               and Bani-Sadr, Firouze and Bourhis, Jean and Ducreux, Michel and
               Gaujoux, S{\'e}bastien and Gorphe, Philippe and Guiu, Boris and
               Hoang-Xuan, Kh{\^e} and Huguet, Florence and Lecomte, Thierry
               and Li{\`e}vre, Astrid and Louvet, Christophe and Maggiori,
               L{\'e}on and Mansi, Laura and Mariani, Pascale and Michel,
               Pierre and Servettaz, Am{\'e}lie and Thariat, Juliette and
               Westeel, Virgine and Aparicio, Thomas and Blay, Jean-Yves and
               Bouch{\'e}, Olivier and {for Th{\'e}saurus National de
               Canc{\'e}rologie Digestive (TNCD)} and {r{\'e}seau de Groupes
               Coop{\'e}rateurs en Oncologie (GCO)} and {F{\'e}d{\'e}ration
               Nationale des Centres de Lutte Contre le Cancer (UNICANCER)} and
               {Association de Chirurgie H{\'e}pato-Bilio-Pancr{\'e}atique et
               Transplantation (ACHBT)} and {Association de Recherche sur les
               Cancers Gyn{\'e}cologiques-Groupes d'Investigateurs Nationaux
               pour l'{\'e}tude des Cancers Ovariens et du Sein
               (ARCAGY-GINECO)} and {F{\'e}d{\'e}ration Francophone de
               Canc{\'e}rologie Digestive (FFCD)} and {Groupe Coop{\'e}rateur
               multidisciplinaire en Oncologie (GERCOR)} and {Groupe
               d'Oncologie Radioth{\'e}rapie T{\^e}te et Cou-Intergroupe ORL
               (GORTEC-Intergroupe ORL)} and {Intergroupe Francophone de
               Canc{\'e}rologie Thoracique (IFCT)} and {InterGroupe
               Coop{\'e}rateur de Neuro-Oncologie/Association des
               Neuro-Oncologues d'Expression Fran{\c c}aise (IGCNO-ANOCEF)} and
               {Soci{\'e}t{\'e} Fran{\c c}aise de Chirurgie Digestive (SFCD)}
               and {Soci{\'e}t{\'e} Fran{\c c}aise d'Endoscopie Digestive
               (SFED)} and {Soci{\'e}t{\'e} Fran{\c c}aise de Radioth{\'e}rapie
               Oncologique (SFRO)} and {Soci{\'e}t{\'e} Fran{\c c}aise de
               Radiologie (SFR)} and {Soci{\'e}t{\'e} Nationale Fran{\c c}aise
               de Colo-Proctologie (SNFCP)} and {Soci{\'e}t{\'e} Nationale
               Fran{\c c}aise de Gastroent{\'e}rologie (SNFGE)}",
  abstract  = "The impacts of the severe acute respiratory syndrome coronavirus
               2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a
               high risk of death from coronavirus disease 2019 (COVID-19) in
               patients with cancer treated by chemotherapy. SARS-CoV-2
               vaccines represent an opportunity to decrease the rate of severe
               COVID-19 cases in patients with cancer and also to restore
               normal cancer care. Patients with cancer to be targeted for
               vaccination are difficult to define owing to the limited
               contribution of these patients in the phase III trials testing
               the different vaccines. It seems appropriate to vaccinate not
               only patients with cancer with ongoing treatment or with a
               treatment having been completed less than 3 years ago but also
               household and close contacts. High-risk patients with cancer who
               are candidates for priority access to vaccination are those
               treated by chemotherapy. The very high-priority population
               includes patients with curative treatment and palliative first-
               or second-line chemotherapy, as well as patients requiring
               surgery or radiotherapy involving a large volume of lung, lymph
               node and/or haematopoietic tissue. When possible, vaccination
               should be carried out before cancer treatment begins. SARS-CoV-2
               vaccination can be performed during chemotherapy while avoiding
               periods of neutropenia and lymphopenia. For organisational
               reasons, vaccination should be performed in cancer care centres
               with messenger RNA vaccines (or non-replicating adenoviral
               vaccines in non-immunocompromised patients). Considering the
               current state of knowledge, the benefit-risk ratio strongly
               favours SARS-CoV-2 vaccination of all patients with cancer. To
               obtain more data concerning the safety and effectiveness of
               vaccines, it is necessary to implement cohorts of vaccinated
               patients with cancer.",
  journal   = "Eur. J. Cancer",
  publisher = "Elsevier BV",
  volume    =  150,
  pages     = "232--239",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; Chemotherapy; Coronavirus; Radiotherapy; SARS-CoV-2;
               Solid cancers; Vaccination",
  language  = "en"
}

@ARTICLE{Fernandez-Ruiz2021-on,
  title     = "{SARS-CoV-2-specific} cell-mediated immunity in kidney
               transplant recipients recovered from {COVID-19}",
  author    = "Fern{\'a}ndez-Ruiz, Mario and Olea, Beatriz and Gim{\'e}nez,
               Estela and Laguna-Goya, Roc{\'\i}o and Trujillo, Hernando and
               Caravaca-Font{\'a}n, Fernando and Guti{\'e}rrez, Eduardo and
               L{\'o}pez-Medrano, Francisco and Remigia, Mar{\'\i}a Jos{\'e}
               and Almendro-Vazquez, Patricia and Polanco, Natalia and
               Gonz{\'a}lez, Esther and Ruiz-Merlo, Tamara and Parra, Patricia
               and San Juan, Rafael and Andr{\'e}s, Amado and Navarro, David
               and Aguado, Jos{\'e} Mar{\'\i}a",
  abstract  = "BACKGROUND: The magnitude and kinetics of severe acute
               respiratory syndrome coronavirus 2-specific cell-mediated
               immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients
               remain largely unknown. METHODS: We enumerated
               SARS-CoV-2-specific interferon-$\gamma$-producing CD69+ CD4+ and
               CD8+ T cells at months 4 and 6 from the diagnosis of coronavirus
               disease 2019 (COVID-19) in 21 KT recipients by intracellular
               cytokine staining. Overlapping peptides encompassing the
               SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino
               acid sequence and the membrane protein were used as stimulus.
               SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed
               by ELISA at month 6. RESULTS: Detectable ($\geq$0.1\%)
               SARS-CoV-2-specific CD4+ T-cell response was found in 57.1\% and
               47.4\% of patients at months 4 and 6. Corresponding rates for
               CD8+ T cells were 19.0\% and 42.1\%, respectively. Absolute
               SARS-CoV-2-specific T-cell counts increased from month 4 to
               month 6 in CD8+ (P = 0.086) but not CD4+ subsets (P = 0.349).
               Four of 10 patients with any detectable response at month 4 had
               lost SARS-CoV-2-CMI by month 6, whereas 5 of 9 patients mounted
               SARS-CoV-2-CMI within this period. All but 2 patients (89.5\%)
               tested positive for SARS-CoV-2 IgG. Patients lacking detectable
               SARS-CoV-2-specific CD4+ response by month 6 were more likely to
               be under tacrolimus (100.0\% versus 66.7\%; P = 0.087) and to
               have received tocilizumab for the previous COVID-19 episode
               (40.0\% versus 0.0\%; P = 0.087). CONCLUSIONS: Although still
               exploratory and limited by small sample size, the present study
               suggests that a substantial proportion of KT recipients
               exhibited detectable SARS-CoV-2-CMI after 6 months from COVID-19
               diagnosis.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  6,
  pages     = "1372--1380",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Vuille-Lessard2021-wm,
  title     = "Autoimmune hepatitis triggered by {SARS-CoV-2} vaccination",
  author    = "Vuille-Lessard, {\'E}lise and Montani, Matteo and Bosch, Jaume
               and Semmo, Nasser",
  abstract  = "The development of autoimmune diseases has been reported after
               SARS-CoV-2 infection. Vaccination against SARS-CoV-2 could also
               trigger auto-immunity, as it has been described with other
               vaccines. An aberrant immune response induced by molecular
               mimicry and bystander activation, especially in predisposed
               individuals, is a potential mechanism. We report the case of a
               76-year-old woman with Hashimoto thyroiditis and prior COVID-19
               infection who developed severe autoimmune hepatitis (with
               typical features including strongly positive anti-smooth muscle
               antibody and markedly elevated immunoglobulins G, as well as
               typical histological findings) following SARS-CoV-2 vaccination
               (mRNA-1273 SARS-CoV-2 vaccine, Moderna\textregistered{}). The
               link between SARS-CoV-2 vaccination and the development of
               autoimmune diseases needs to be further investigated. Although a
               causality relationship cannot be proven, caution may be
               warranted when vaccinating individuals with known autoimmune
               diseases.",
  journal   = "J. Autoimmun.",
  publisher = "Elsevier BV",
  volume    =  123,
  number    =  102710,
  pages     = "102710",
  month     =  sep,
  year      =  2021,
  keywords  = "Autoimmune hepatitis; COVID-19; SARS-CoV-2; Vaccination",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Van_Ballegooie2021-ua,
  title     = "Health services: A mixed methods assessment of Canadian cancer
               patient education materials related to the 2019 novel
               Coronavirus",
  author    = "van Ballegooie, Courtney and Hoang, Peter",
  abstract  = "The 2019 novel coronavirus (COVID-19) pandemic has prompted the
               reorganization in the scheduling and method of care for many
               patients, including patients diagnosed with cancer. Cancer
               patients, who have an immunocompromised status, may be at a
               higher risk of severe symptoms from infection with COVID-19.
               While information is rapidly evolving regarding COVID-19,
               Canada, both nationally and provincially, has been conveying new
               information to patients online. We assessed the content and
               readability of COVID-19-related online Canadian patient
               education material (PEM) for cancer patients to determine if the
               content of the material was written at a grade reading level
               that the majority of Canadians can understand. PEMs were
               extracted from provincial cancer agencies and the national
               Canadian Cancer Society, evaluated using 10 readability scales,
               qualitatively analyzed to identify their themes and difficult
               word content. Thirty-eight PEMs from both national and
               provincial cancers associations were, on average, written above
               the recommended 7th grade level. Each of the associations'
               average grade levels were: BC Cancer (11.00 95\% confidence
               interval [CI] 8.27-13.38), CancerControl Alberta (10.46 95\% CI
               8.29-12.62), Saskatchewan Cancer Agency (11.08 95\% CI
               9.37-12.80), Cancer Care Manitoba (9.55 95\% CI 6.02-13.01),
               Cancer Care Ontario (9.35 95\% CI 6.80-11.90), Cancer Care Nova
               Scotia (10.95 95\% CI 9.86-12.04), Cancer Care Eastern Health
               Newfoundland and Labrador (10.14 95\% CI 6.87-13.41), and the
               Canadian Cancer Society (10.06 95\% CI 8.07-12.05). Thematic
               analysis identified 4 themes: public health strategy,
               information about COVID-19, patient instructions during
               COVID-19, and resources. Fifty-three percent of the complex
               words identified were medical jargon. This represents an
               opportunity to improve PEM readability, to allow for greater
               comprehension amongst a wider target audience.",
  journal   = "Cancer Control",
  publisher = "SAGE Publications",
  volume    =  28,
  pages     = "1073274821989709",
  month     =  jan,
  year      =  2021,
  keywords  = "cancer; coronavirus; health literacy; patient education
               material; readability",
  language  = "en"
}

@ARTICLE{Patel2021-wh,
  title     = "Evaluation of post-introduction {COVID-19} vaccine
               effectiveness: Summary of interim guidance of the World Health
               Organization",
  author    = "Patel, Minal K and Bergeri, Isabel and Bresee, Joseph S and
               Cowling, Benjamin J and Crowcroft, Natasha S and Fahmy, Kamal
               and Hirve, Siddhivinayak and Kang, Gagandeep and Katz, Mark A
               and Lanata, Claudio F and L'Azou Jackson, Ma{\"\i}na and Joshi,
               Sudhir and Lipsitch, Marc and Mwenda, Jason M and Nogareda,
               Francisco and Orenstein, Walter A and Ortiz, Justin R and
               Pebody, Richard and Schrag, Stephanie J and Smith, Peter G and
               Srikantiah, Padmini and Subissi, Lorenzo and Valenciano, Marta
               and Vaughn, David W and Verani, Jennifer R and Wilder-Smith,
               Annelies and Feikin, Daniel R",
  abstract  = "Phase 3 randomized-controlled trials have provided promising
               results of COVID-19 vaccine efficacy, ranging from 50 to 95\%
               against symptomatic disease as the primary endpoints, resulting
               in emergency use authorization/listing for several vaccines.
               However, given the short duration of follow-up during the
               clinical trials, strict eligibility criteria, emerging variants
               of concern, and the changing epidemiology of the pandemic, many
               questions still remain unanswered regarding vaccine performance.
               Post-introduction vaccine effectiveness evaluations can help us
               to understand the vaccine's effect on reducing infection and
               disease when used in real-world conditions. They can also
               address important questions that were either not studied or were
               incompletely studied in the trials and that will inform evolving
               vaccine policy, including assessment of the duration of
               effectiveness; effectiveness in key subpopulations, such as the
               very old or immunocompromised; against severe disease and death
               due to COVID-19; against emerging SARS-CoV-2 variants of
               concern; and with different vaccination schedules, such as
               number of doses and varying dosing intervals. WHO convened an
               expert panel to develop interim best practice guidance for
               COVID-19 vaccine effectiveness evaluations. We present a summary
               of the interim guidance, including discussion of different study
               designs, priority outcomes to evaluate, potential biases,
               existing surveillance platforms that can be used, and
               recommendations for reporting results.",
  journal   = "Vaccine",
  publisher = "Elsevier BV",
  volume    =  39,
  number    =  30,
  pages     = "4013--4024",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Vaccination; Vaccine effectiveness",
  language  = "en"
}

@ARTICLE{Golbets2022-xa,
  title     = "Secondary organizing pneumonia after recovery of mild {COVID-19}
               infection",
  author    = "Golbets, Evgeny and Kaplan, Alon and Shafat, Tali and Yagel,
               Yael and Jotkowitz, Alan and Awesat, Jenan and Barski, Leonid",
  abstract  = "A 36-year-old male with diffuse large B-cell lymphoma on
               maintenance rituximab therapy presented to the emergency
               department with high fever and fatigue. A chest X-ray showed a
               lobar infiltrate, 40 days before admission the patient suffered
               from a mild coronavirus disease 2019 (COVID-19) infection and
               fully recovered. PCR nasopharyngeal swab was negative for
               COVID-19. Comprehensive biochemical, radiological, and
               pathological evaluation including 18-fluorodeoxyglucose positron
               emission tomography with computed tomography and transbronchial
               lung biopsy found no pathogen or lymphoma recurrence. Treatment
               for pneumonia with antibiotic and antifungal agents was
               nonbeneficial. A diagnosis of secondary organizing pneumonia
               (OP) was made after pneumonia migration and a rapid response to
               corticosteroids. OP secondary to a viral respiratory infection
               has been well described. Raising awareness for post-COVID-19 OP
               has therapeutic and prognostic importance because those patients
               benefit from steroid therapy. We believe the condition described
               here is underdiagnosed and undertreated by doctors worldwide.
               Because of the ongoing global pandemic we are now encountering a
               new kind of patient, patients that have recovered from COVID-19.
               We hope that this case may contribute to gaining more knowledge
               about this growing patient population.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  94,
  number    =  1,
  pages     = "417--423",
  month     =  jan,
  year      =  2022,
  keywords  = "SARS coronavirus; coronavirus; organizing pneumonia; post
               COVID-19",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Costa_Frossard-Franca2021-oq,
  title    = "Vaccination against {SARS-CoV-2} in patients with multiple
              sclerosis",
  author   = "Costa Frossard-Fran{\c c}a, L and Garc{\'\i}a-Dom{\'\i}nguez, J M
              and Moreno-Torres, I and Fort{\'u}n, J and Villar, L M and
              Meca-Lallana, V",
  abstract = "INTRODUCTION: The recent availability of SARS-CoV-2 vaccines has
              raised concerns in certain patient groups, such as those with
              multiple sclerosis. However, there are currently few publications
              that provide information on this issue. We pooled the information
              available on the safety and efficacy of vaccination against
              SARS-CoV-2 in patients with multiple sclerosis, with and without
              disease-modifying therapy. DEVELOPMENT: The study consisted in a
              literature search focused on the types of SARS-CoV-2 vaccines,
              the current status of their approval, and the data available on
              the safety and efficacy of vaccines in patients with multiple
              sclerosis, including the new COVID-19 vaccines. Based on this
              search, the document has been designed taking into account
              current evidence and expert recommendations. There are no data on
              the safety and efficacy of SARS-CoV-2 vaccines in patients with
              multiple sclerosis. However, evidence does exist to suggest that
              messenger RNA (mRNA) vaccines against SARS-CoV-2 are as safe in
              these patients as in other individuals. Some therapies with
              immunosuppressants might reduce the effectiveness of these
              vaccines and require the scheduling of their administration,
              preferably before the start of treatment if possible. CONCLUSION:
              The data available make it possible to recommend mRNA vaccines
              against SARS-CoV-2 in patients with multiple sclerosis. In
              patients on fingolimod, cladribine, alemtuzumab, ocrelizumab and
              rituximab, vaccination prior to the initiation of medication
              administration would be recommendable whenever possible.",
  journal  = "Rev. Neurol.",
  volume   =  72,
  number   =  7,
  pages    = "250--260",
  month    =  apr,
  year     =  2021,
  language = "es"
}

@ARTICLE{Truffot2021-gi,
  title     = "{SARS-CoV-2} variants in immunocompromised patient given
               antibody monotherapy",
  author    = "Truffot, Aur{\'e}lie and Andr{\'e}ani, Julien and Le
               Mar{\'e}chal, Marion and Caporossi, Alban and Epaulard, Olivier
               and Germi, Raphaele and Poignard, Pascal and Larrat, Sylvie",
  abstract  = "A 72-year-old immunocompromised man infected with severe acute
               respiratory syndrome coronavirus 2 received bamlanivimab
               monotherapy. Viral evolution was monitored in nasopharyngeal and
               blood samples by melting curve analysis of single-nucleotide
               polymorphisms and whole-genome sequencing. Rapid emergence of
               spike receptor binding domain mutations was found, associated
               with a compartmentalization of viral populations.",
  journal   = "Emerg. Infect. Dis.",
  publisher = "Centers for Disease Control and Prevention (CDC)",
  volume    =  27,
  number    =  10,
  pages     = "2725--2728",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; bamlanivimab; compartmentalization;
               coronavirus disease; coronaviruses; immunotherapy; monoclonal
               antibody; monotherapy; respiratory infections; selection; severe
               acute respiratory syndrome coronavirus 2; variants; viruses;
               whole-genome sequencing; zoonoses",
  language  = "en"
}

@ARTICLE{Zervou2021-ku,
  title     = "{SARS-CoV-2} antibody responses in solid organ transplant
               recipients",
  author    = "Zervou, Fainareti N and Ali, Nicole M and Neumann, Henry J and
               Madan, Rebecca Pellett and Mehta, Sapna A",
  abstract  = "Antibody responses among immunocompromised solid organ
               transplant recipients (SOT) infected with Severe Acute
               Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) may be
               diminished compared to the general population and have not been
               fully characterized. We conducted a cohort study at our
               transplant center to investigate the rate of seroconversion for
               SARS-CoV-2 IgG antibodies among SOT recipients who were
               diagnosed with Coronavirus disease 2019 (COVID-19) and underwent
               serum SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA)
               testing. The 61 patients who were included in the final analysis
               underwent initial SARS-CoV-2 IgG testing at a median of 62 days
               (Interquartile range 55.0-75.0) from symptom onset. Note that,
               51 of 61 patients (83.6\%) had positive SARS-CoV-2 IgG results,
               whereas 10 (16.4\%) had negative IgG results. Six (60\%) out of
               10 seronegative patients underwent serial IgG testing and
               remained seronegative up to 17 weeks post-diagnosis. Use of
               belatacept in maintenance immunosuppression was significantly
               associated with negative IgG antibodies to SARS-CoV-2 both in
               univariate and multivariate analyses (Odds ratio 0.04, p = .01).
               In conclusion, the majority of organ transplant recipients with
               COVID-19 in our study developed SARS-CoV-2 antibodies. Further
               longitudinal studies of the durability and immunologic role of
               these IgG responses and the factors associated with lack of
               seroconversion are needed.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  5,
  pages     = "e13728",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; antibody response; transplant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Riella2021-sv,
  title     = "Preventing Coronavirus disease 2019 in kidney transplant
               recipients: Where should we begin?",
  author    = "Riella, Leonardo V and Azzi, Jamil R and Cravedi, Paolo",
  abstract  = "CONTEXT: Chronic immunosuppression is associated with an
               increased risk of opportunistic infections. Although kidney
               transplant recipients with coronavirus disease 2019 (COVID-19)
               have higher mortality than the general population, data on their
               risk of infection with severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) are unknown. Subject of Review: A
               recent single-center screening study from the UK
               (Transplantation. 2021 Jan 1;105(1):151-7) showed that 89
               (10.4\%) of 855 consecutive kidney transplant recipients tested
               positive for SARS-CoV-2 antibodies. Risk factors for infection
               included a nonwhite background, diabetes, and a history of
               allograft rejection. Risk factors for mortality in individuals
               who developed COVID-19 were older age and receiving steroids.
               Second Opinion: This study shows that the rate of SARS-CoV-2
               infection in kidney transplant recipients is similar to the one
               observed in the general population in the same area (13\%),
               indicating that transplant recipients are not at increased risk
               of COVID-19. However, the investigators raise the interesting
               point that since transplant individuals were advised to shelter
               earlier than the general population, they may be in fact more
               susceptible. This statement is hard to substantiate, but the
               identification of specific risk factors for infection and poor
               outcomes is crucial to tailor strategies to prevent spread of
               the infection. This is particularly important, considering that
               kidney transplant recipients may be at increased risk of
               prolonged viral spread and in-host viral mutations, making them
               not just a particularly fragile population for COVID-19 but also
               a potentially major source of further contagions.",
  journal   = "Nephron",
  publisher = "S. Karger AG",
  volume    =  145,
  number    =  3,
  pages     = "280--284",
  month     =  mar,
  year      =  2021,
  keywords  = "Acute rejection; Immunology; Renal transplantation; SARS-CoV2;
               Vaccine",
  copyright = "https://www.karger.com/Services/SiteLicenses",
  language  = "en"
}

@ARTICLE{Suarez-Garcia2021-kh,
  title     = "In-hospital mortality among immunosuppressed patients with
               {COVID-19}: Analysis from a national cohort in Spain",
  author    = "Su{\'a}rez-Garc{\'\i}a, In{\'e}s and Perales-Fraile, Isabel and
               Gonz{\'a}lez-Garc{\'\i}a, Andr{\'e}s and Mu{\~n}oz-Blanco,
               Arturo and Manzano, Luis and Fabregate, Mart{\'\i}n and
               D{\'\i}ez-Manglano, Jes{\'u}s and Aizpuru, Eva Fonseca and
               Fern{\'a}ndez, Francisco Arnalich and Garc{\'\i}a, Alejandra
               Garc{\'\i}a and G{\'o}mez-Huelgas, Ricardo and Ramos-Rinc{\'o}n,
               Jos{\'e}-Manuel and {SEMI-COVID-19 Network}",
  abstract  = "BACKGROUND: Whether immunosuppressed (IS) patients have a worse
               prognosis of COVID-19 compared to non-IS patients is not known.
               The aim of this study was to evaluate the clinical
               characteristics and outcome of IS patients hospitalized with
               COVID-19 compared to non-IS patients. METHODS: We designed a
               retrospective cohort study. We included all patients
               hospitalized with laboratory-confirmed COVID-19 from the
               SEMI-COVID-19 Registry, a large multicentre national cohort in
               Spain, from March 27th until June 19th, 2020. We used
               multivariable logistic regression to assess the adjusted odds
               ratios (aOR) of in-hospital death among IS compared to non-IS
               patients. RESULTS: Among 13 206 included patients, 2 111
               (16.0\%) were IS. A total of 166 (1.3\%) patients had solid
               organ (SO) transplant, 1081 (8.2\%) had SO neoplasia, 332
               (2.5\%) had hematologic neoplasia, and 570 (4.3\%), 183 (1.4\%)
               and 394 (3.0\%) were receiving systemic steroids, biological
               treatments, and immunosuppressors, respectively. Compared to
               non-IS patients, the aOR (95\% CI) for in-hospital death was
               1.60 (1.43-1.79) for all IS patients, 1.39 (1.18-1.63) for
               patients with SO cancer, 2.31 (1.76-3.03) for patients with
               haematological cancer and 3.12 (2.23-4.36) for patients with SO
               transplant. The aOR (95\% CI) for death for patients who were
               receiving systemic steroids, biological treatments and
               immunosuppressors compared to non-IS patients were 2.16
               (1.80-2.61), 1.97 (1.33-2.91) and 2.06 (1.64-2.60),
               respectively. IS patients had a higher odds than non-IS patients
               of in-hospital acute respiratory distress syndrome, heart
               failure, myocarditis, thromboembolic disease and multiorgan
               failure. CONCLUSIONS: IS patients hospitalized with COVID-19
               have a higher odds of in-hospital complications and death
               compared to non-IS patients.",
  journal   = "PLoS One",
  publisher = "Public Library of Science (PLoS)",
  volume    =  16,
  number    =  8,
  pages     = "e0255524",
  month     =  aug,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Coll2021-vo,
  title     = "{COVID-19} in solid organ transplant recipients in Spain
               throughout 2020: Catching the wave?",
  author    = "Coll, Elisabeth and Fern{\'a}ndez-Ruiz, Mario and Padilla,
               Mar{\'\i}a and Moreso, Francesc and Hern{\'a}ndez-Vicente, Ana
               and Ya{\~n}ez, I{\~n}igo and Molina, Mar{\'\i}a and
               V{\'a}zquez-S{\'a}nchez, Teresa and Crespo, Marta and Facundo,
               Carme and Rodr{\'\i}guez-Ferrero, Mar{\'\i}a Luisa and Ruiz
               Fuentes, Mar{\'\i}a Carmen and Loinaz, Carmelo and Bernal,
               Gabriel and Melilli, Edoardo and Bravo, Carlos and Diekmann,
               Fritz and Llad{\'o}, Laura and Garc{\'\i}a-{\'A}lvarez, Teresa M
               and Salcedo, Magdalena and Beneyto, Isabel and Castells, Lluis
               and Alonso, Rodrigo and Rodr{\'\i}guez-Benot, Alberto and
               D{\'\i}az-Corte, Carmen and Graus, Javier and Ortiz-Bautista,
               Carlos and Garc{\'\i}a-Cos{\'\i}o, Mar{\'\i}a Dolores and
               Hinojal, Rosa and Pe{\~n}a, Luc{\'\i}a and Dom{\'\i}nguez-Gil,
               Beatriz and {Spanish Group for the Study of COVID-19 in
               Transplant Recipients.}",
  abstract  = "BACKGROUND: Few studies have analyzed differences in clinical
               presentation and outcomes in solid organ transplant (SOT)
               recipients with coronavirus disease 2019 (COVID-19) across
               different pandemic waves. METHODS: In this multicenter,
               nationwide, prospective study, we compared demographics and
               clinical features, therapeutic management, and outcomes in SOT
               recipients diagnosed with COVID-19 in Spain before (first wave)
               or after (second wave) 13 July 2020. RESULTS: Of 1634 SOT
               recipients, 690 (42.2\%) and 944 (57.8\%) were diagnosed during
               the first and second periods, respectively. Compared with the
               first wave, recipients in the second were younger (median: 63 y
               [interquartile range, IQR: 53-71] versus 59 y [IQR: 49-68]; P <
               0.001) and less likely to receive anti-severe acute respiratory
               syndrome coronavirus 2 drugs (81.8\% versus 8.1\%; P < 0.001),
               with no differences in immunomodulatory therapies (46.8\% versus
               47.0\%; P = 0.931). Adjustment of immunosuppression was less
               common during the second period (76.4\% versus 53.6\%; P <
               0.001). Hospital admission (86.7\% versus 58.1\%; P < 0.001),
               occurrence of acute respiratory distress syndrome (34.1\% versus
               21.0\%; P < 0.001), and case-fatality rate (25.8\% versus
               16.7\%; P < 0.001) were lower in the second period. In
               multivariate analysis, acquiring COVID-19 during the first wave
               was associated with an increased risk of death (OR: 1.47; 95\%
               confidence interval [CI], 1.12-1.93; P = 0.005), although this
               impact was lost in the subgroup of patients requiring hospital
               (OR: 0.97; 95\% CI, 0.73-1.29; P = 0.873) or intensive care unit
               admission (OR: 0.65; 95\% CI, 0.35-1.18; P = 0.157).
               CONCLUSIONS: We observed meaningful changes in demographics,
               therapeutic approaches, level of care, and outcomes between the
               first and second pandemic waves. However, outcomes have not
               improved in the more severe cases of posttransplant COVID-19.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  10,
  pages     = "2146--2155",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ali2021-iy,
  title     = "Hepatic manifestations of nonhepatotropic infectious agents
               including severe acute respiratory syndrome Coronavirus-2,
               Adenovirus, herpes simplex virus, and Coxiella burnetii",
  author    = "Ali, Saeed and Prakash, Sameer and Murali, Arvind R",
  abstract  = "Nonhepatotropic viruses such as adenovirus, herpes simplex
               virus, flaviviruses, filoviruses, and human herpes virus, and
               bacteria such as Coxiella burnetii, can cause liver injury
               mimicking acute hepatitis. Most of these organisms cause a
               self-limited infection. However, in immunocompromised patients,
               they can cause severe hepatitis or in some cases fulminant
               hepatic failure requiring an urgent liver transplant. Hepatic
               dysfunction is also commonly seen in patients with severe acute
               respiratory syndrome coronavirus-2 infection. Patients with
               preexisting liver diseases are likely at risk for severe
               coronavirus disease 2019 (COVID-19) and may be associated with
               poor outcomes.",
  journal   = "Gastroenterol. Clin. North Am.",
  publisher = "Elsevier BV",
  volume    =  50,
  number    =  2,
  pages     = "383--402",
  month     =  jun,
  year      =  2021,
  keywords  = "Adenovirus hepatitis; COVID-19; Coxiella burnetii; HSV
               hepatitis; Hepatitis",
  language  = "en"
}

@ARTICLE{Perreault2021-yv,
  title     = "Mitigating the risk of {COVID-19} exposure by transitioning from
               clinic-based to home-based immune globulin infusion",
  author    = "Perreault, Sarah and Schiffer, Molly and Clinchy-Jarmoszko,
               Virginia and Bocchetta, Nicole and Barbarotta, Lisa and
               Abdelghany, Osama and Foss, Francine and Huntington, Scott and
               Seropian, Stuart and Isufi, Iris",
  abstract  = "PURPOSE: Intravenous immune globulin (IVIG) therapy is used in
               patients with hypogammaglobulinemia to lower the risk of
               infections. IVIG and subcutaneous IVIG (SCIG) therapy have been
               to shown to be safe and effective when administered as
               clinic-based infusions. Concern from both patients and providers
               for increased transmission of the coronavirus disease 2019
               (COVID-19) virus to immunosuppressed patients with scheduled
               medical visits and procedures made it necessary for us to
               reassess our process of how we manage patient care in general
               and chronic clinic infusions in particular. Here we describe our
               experience of transitioning patients from clinic-based to home
               based IVIG and/or SCIG infusions to decrease the risk of
               COVID-19 exposure. METHODS: Criteria were developed to identify
               high-risk immunosuppressed patients who would be appropriate
               candidates for potential conversion to home based IVIG
               infusions. Data were collected via chart review, and cost
               analysis was performed using Medicare Part B reimbursement data.
               A patient outcome questionnaire was developed for administration
               through follow-up phone calls. RESULTS: From March to May 2020,
               45 patients met criteria for home-based infusion, with 27
               patients (60\%) agreeing to home-based infusion. Posttransition
               patient outcomes assessment, conducted in 26 patients (96\%),
               demonstrated good patient understanding of the home-based
               infusion process. No infusion-related complications were
               reported, and 24 patients (92\%) had no concerns about receiving
               future IVIG and/or SCIG doses at home. No patient tested
               positive for COVID-19 during the study period. Clinic infusion
               visits decreased by 26.6 visits per month, resulting in a total
               of 106 hours of additional available infusion chair time per
               month and associated cost savings of \$12,877. CONCLUSION:
               Transition of clinic based to home based IVIG/SCIG infusion can
               be successfully done to decrease potential exposure during a
               pandemic in a high-risk immunosuppressed population, with no
               impact on patient satisfaction, adherence, or efficacy. The
               home-based infusion initiative was associated with a reduction
               in costs to patients and an increase in available chair time in
               the infusion clinic.",
  journal   = "Am. J. Health. Syst. Pharm.",
  publisher = "Oxford University Press (OUP)",
  volume    =  78,
  number    =  12,
  pages     = "1112--1117",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; immunosuppressed population; intravenous immune
               globulin; subcutaneous immune globulin",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Cleto-Yamane2021-di,
  title     = "Screening of {COVID-19} in outpatient children with cancer or
               solid organ transplantation: preliminary report",
  author    = "Cleto-Yamane, Tha{\'\i}s Lira and Rodrigues-Santos, Gustavo and
               de Magalh{\~a}es-Barbosa, Maria Clara and Moura, Patr{\'\i}cia
               Gomes and Vasconcelos, Rafael Dias and Gouveia, Jaqueline Leal
               Santos and de Oliveira, Anne Louise and Ferreira, Fernanda Couto
               and Shalders, Ana Let{\'\i}cia and de Oliveira, Mariana Barros
               Genu{\'\i}no and Lima-Setta, Fernanda and da Cunha, Antonio
               Jos{\'e} Ledo Alves and Prata-Barbosa, Arnaldo",
  abstract  = "Clinical presentation of severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) infection in pediatric
               immunosuppressed patients is unknown. Emerging data describe a
               milder or asymptomatic course in children compared with adults
               in this scenario. We present the seroprevalence and clinical
               features of coronavirus disease 2019 in a prospective cohort of
               114 immunosuppressed children and adolescents from three groups:
               kidney transplantation, liver transplantation, and cancer
               patients. Among the thirty-five (30.7\%) patients who had a
               positive serological test for SARS-CoV-2, 77\% did not report
               previous symptoms and none of them developed any complications
               of coronavirus disease 2019 (COVID-19) after 30 or more days of
               follow-up. Among those who were symptomatic, diarrhea, fever,
               and cough were the most common findings.Conclusion:
               Seroprevalence of SARS-CoV-2 infection is high among
               immunosuppressed children and adolescents. COVID-19 has a mild
               or asymptomatic course in most of these patients. What is Known:
                The number of immunosuppressed patients with coronavirus
               disease 2019 is increasing.  Viral infections have the
               potential for greater severity in immunocompromised children.
               What is New:  Seroprevalence for severe acute respiratory
               syndrome coronavirus 2 in immunocompromised pediatric patients
               was 31\%.  A quarter of the serology-positive patients reported
               mild symptoms and none of them developed multisystem
               inflammatory syndrome in children associated with coronavirus
               disease 2019.",
  journal   = "Eur. J. Pediatr.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  180,
  number    =  10,
  pages     = "3237--3241",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Kidney transplantation; Leukemia; Liver
               transplantation; Oncology; Pediatrics; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Niyonkuru2021-dg,
  title     = "Prolonged viral shedding of {SARS-CoV-2} in two
               immunocompromised patients, a case report",
  author    = "Niyonkuru, Melissa and Pedersen, Rune Micha and Assing, Kristian
               and Andersen, Thomas Emil and Skov, Marianne Nielsine and
               Johansen, Isik Somuncu and Madsen, Lone Wulff",
  abstract  = "BACKGROUND: The duration of viable Severe Acute Respiratory
               Syndrome Coronavirus 2 (SARS-CoV-2) shedding in
               immunocompromised patients is still unknown. This case report
               describes the duration of viable SARS-CoV-2 in two
               immunocompromised patients with completely different clinical
               courses and further addresses the immunological aspects. CASE
               PRESENTATIONS: Oropharyngeal swaps were collected continuously
               during hospitalization for two immunocompromised patients
               infected with SARS-CoV-2 and sent for analysis to real time
               reverse transcription polymerase chain reaction (RT-PCR), viral
               culture assessed by plaque assay and full genome sequencing.
               Blood samples for flow cytometry and further immunological
               analysis were taken once during admission. One patient was
               without symptoms of Coronavirus disease 2019 (COVID-19) whereas
               the other had severe respiratory symptoms requiring a stay at an
               intensive care unit (ICU) and treatment with remdesivir and
               dexamethasone. Despite their difference in clinical courses,
               they both continuously shed SARS-CoV-2 with high viral loads in
               culture. Both patients had undetectable anti SARS-CoV-2 IgG
               levels about 2 weeks after the first positive real time RT-PCR
               test of SARS-CoV-2, marked expansions of virus reactive CD8+ T
               cells but cellular markers indicative of attenuated humoral
               immunity. CONCLUSIONS: Our case illustrates the importance of
               distinguishing isolation guidelines for patients infected with
               SARS-CoV-2 according to their immunological status. Furthermore,
               it demonstrates the need for immune markers relating to viral
               shedding in immunocompromised patients.",
  journal   = "BMC Infect. Dis.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  21,
  number    =  1,
  pages     = "743",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Immunocompromised host; SARS-CoV-2; Virus shedding",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Shafer2021-cf,
  title     = "Leveraging interdisciplinary teams for pre-visit planning to
               improve pneumococcal immunization rates among internal medicine
               subspecialty practices",
  author    = "Shafer, Rebecca and Kearns, Christina and Carney, Maria and
               Sagar, Ankita",
  abstract  = "BACKGROUND: Despite the ready availability of pneumococcal
               vaccines and recommendation of vaccination by Center for Disease
               Control and Prevention (CDC), the immunization rates among
               adults less than 65 years of age with chronic and
               immunocompromised conditions remain low. METHODS: This
               interventional (cohort) study aimed to improve the pneumococcal
               vaccination rate for patients with an increased risk of
               pneumococcal disease by utilizing a three-pronged approach. This
               included: (1) clinician education webinar, (2) pre-visit
               counseling performed by registered nurses, targeted toward
               patients with upcoming appointments, to address vaccination
               status, and (3) modified pre-visit interdisciplinary team huddle
               with clinicians and registered nurses to review which patients
               are amenable to vaccination at the time of visit and those who
               may benefit from re-engagement and further motivational
               interviewing. After the completion of the 10-week intervention,
               study organizers reviewed the percent of patients with completed
               pneumococcal vaccinations. RESULTS: In this 10-week rapid cycle
               initiative, a total of 482 patients were eligible for
               vaccination. During the intervention phase, 370 patients were
               contacted and of these 38\% of patients were amenable to
               receiving a vaccine during the pre-visit counseling, 5\% were
               previously vaccinated, 18\% were not amenable, and 38\% were
               unreachable prior to visit. This initiative resulted in a 43\%
               increase in the vaccination rate in this cohort. CONCLUSIONS:
               The significant increase in vaccination rate supports the
               utilization of a framework in the multidisciplinary approach to
               pre-visit planning in non-primary care specialties and other
               vaccination efforts, especially emerging diseases such as
               COVID-19. Future directions of study include the efficacy of
               telemedicine counseling with a same-day appointment for
               vaccination, co-location of registered nurses within the
               practice sites, as well as the use of other ancillary staff
               (such as medical office assistants) to engage patients in
               pre-visit planning.",
  journal   = "J. Prim. Care Community Health",
  publisher = "SAGE Publications",
  volume    =  12,
  pages     = "21501319211060986",
  month     =  jan,
  year      =  2021,
  keywords  = "interdisciplinary team; internal medicine; pneumococcal
               vaccination",
  language  = "en"
}

@ARTICLE{Isac2021-hz,
  title     = "Prevention of {VAP}: Endless evolving evidences-systematic
               literature review",
  author    = "Isac, Chandrani and Samson, Hema Roslin and John, Anitha",
  abstract  = "INTRODUCTION: Prevention of ventilator associated pneumonia
               (VAP) is the focus in critical care units. Immunocompromised
               patients, older adults, and postoperative patients are at
               greater risk for VAP. With the dynamic changes in the empirical
               world, updated evidence must be used to guide the standard of
               practice. This literature review assimilates the recent evidence
               for VAP prevention. METHOD: The Preferred Reporting Items for
               Systematic Reviews and Meta-analysis framework guided the
               selection of the included research articles. Medline, EBSCO
               host, CINAHL, UpToDate and Google Scholar databases explored,
               for relevant publications between 2010 and 2020. The quality of
               evidence for the 14 studies selected were rated using the
               hierarchy of quantitative research designs. RESULTS:
               Evidence-based VAP preventive strategies are prevention of
               aspiration, minimizing ventilator days, reducing the pathogen
               load, safe endotracheal suction practices, and pharmaceutical
               preventive measures. The mandates for VAP preventive measures
               among coronavirus disease 2019 (COVID-19) patients is included.
               CONCLUSION: Though some of these themes identify with the past,
               the nuances in their implementation are highlights of this
               review. The review reiterates the need to revisit ambiguous
               practices implemented for VAP prevention. Adherence to
               evidence-based practices, by education, training, and reduction
               of workload is the key to VAP prevention.",
  journal   = "Nurs. Forum",
  publisher = "Wiley",
  volume    =  56,
  number    =  4,
  pages     = "905--915",
  month     =  oct,
  year      =  2021,
  keywords  = "critical care unit; evidence-based practices; mechanical
               ventilation; ventilator associated pneumonia",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Lynch2021-vr,
  title    = "Genomic evolution of {SARS-CoV-2} virus in immunocompromised
              patient, Ireland",
  author   = "Lynch, Maureen and Macori, Guerrino and Fanning, S{\'e}amus and
              O'Regan, Edel and Hunt, Eoin and O'Callaghan, Dermot and
              McCullagh, Brian and Jennings, Cormac and Fortune, Anne",
  abstract = "We examined virus genomic evolution in an immunocompromised
              patient with prolonged severe acute respiratory syndrome
              coronavirus 2 infection. Genomic sequencing revealed genetic
              variation during infection: 3 intrahost mutations and possible
              superinfection with a second strain of the virus. Prolonged
              infection in immunocompromised patients may lead to emergence of
              new virus variants.",
  journal  = "Emerg. Infect. Dis.",
  volume   =  27,
  number   =  9,
  pages    = "2499--2501",
  month    =  sep,
  year     =  2021,
  keywords = "2019 novel coronavirus disease; B-cell therapy; COVID-19;
              SARS-CoV-2; coronavirus disease; immunocompromised; respiratory
              infections; severe acute respiratory syndrome coronavirus 2;
              superinfection; virus evolution; viruses; zoonoses",
  language = "en"
}

@ARTICLE{Atsuta2021-hk,
  title    = "Hematopoietic stem cell transplantation during the {COVID-19}
              pandemic with reference to {EBMT} recommendation",
  author   = "Atsuta, Yuya and Doki, Noriko",
  abstract = "Coronavirus disease 2019 (COVID-19), caused by the severe acute
              respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread
              worldwide and was classified as a pandemic by the World Health
              Organization in March 2020. However, its clinical manifestations
              and optimal management in immunosuppressed patients, including
              recipients of hematopoietic stem cell transplantation (HSCT), are
              unknown. There have been some international guidelines for the
              management of COVID-19 in HSCT recipients. In this issue, we
              describe the Japanese real-world clinical condition and careful
              points, explaining those international guidelines.",
  journal  = "Rinsho Ketsueki",
  volume   =  62,
  number   =  2,
  pages    = "106--114",
  year     =  2021,
  keywords = "Allogeneic hematopoietic stem cell transplantation; Coronavirus
              disease 2019 (COVID-19); Severe acute respiratory syndrome
              coronavirus 2 (SARS-CoV-2)",
  language = "ja"
}

@ARTICLE{Clark2021-xq,
  title     = "{SARS-CoV-2} evolution in an immunocompromised host reveals
               shared neutralization escape mechanisms",
  author    = "Clark, Sarah A and Clark, Lars E and Pan, Junhua and Coscia,
               Adrian and McKay, Lindsay G A and Shankar, Sundaresh and
               Johnson, Rebecca I and Brusic, Vesna and Choudhary, Manish C and
               Regan, James and Li, Jonathan Z and Griffiths, Anthony and
               Abraham, Jonathan",
  abstract  = "Many individuals mount nearly identical antibody responses to
               SARS-CoV-2. To gain insight into how the viral spike (S) protein
               receptor-binding domain (RBD) might evolve in response to common
               antibody responses, we studied mutations occurring during virus
               evolution in a persistently infected immunocompromised
               individual. We use antibody Fab/RBD structures to predict, and
               pseudotypes to confirm, that mutations found in late-stage
               evolved S variants confer resistance to a common class of
               SARS-CoV-2 neutralizing antibodies we isolated from a healthy
               COVID-19 convalescent donor. Resistance extends to the
               polyclonal serum immunoglobulins of four out of four healthy
               convalescent donors we tested and to monoclonal antibodies in
               clinical use. We further show that affinity maturation is
               unimportant for wild-type virus neutralization but is critical
               to neutralization breadth. Because the mutations we studied
               foreshadowed emerging variants that are now circulating across
               the globe, our results have implications to the long-term
               efficacy of S-directed countermeasures.",
  journal   = "Cell",
  publisher = "Elsevier BV",
  volume    =  184,
  number    =  10,
  pages     = "2605--2617.e18",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; affinity maturation; antibody
               neutralization; immunocompromised host; neutralization escape;
               variants of concern",
  language  = "en"
}

@ARTICLE{Scharrer2021-lm,
  title     = "Humoral response to {COVID-19} infection in immunosuppressed
               patients with inflammatory bowel disease",
  author    = "Scharrer, Susanna and Kutschera, Maximilian and Weseslindtner,
               Lukas and Primas, Christian and Vogelsang, Harald",
  abstract  = "The course of coronavirus 19 (COVID-19) might be determined by
               certain comorbidities (e.g. diabetes, hypertension and other
               cardiovascular diseases) and advanced age. Because the impact of
               immunosuppression on disease severity is not entirely clear,
               management of patients under immunosuppressive treatment remains
               controversial. Six cases of inflammatory bowel disease (IBD)
               patients with COVID-19 on immunosuppressive medication are
               presented. The aim of this study was to describe patients'
               clinical manifestation and chronologic development of
               virus-specific antibodies of severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) infection before and after restart
               with immunosuppressive/biological therapy as an indicator for a
               specific immune response. All patients were tested for the
               presence of SARS-CoV-2-RNA with PCR, were in clinical remission
               prior to COVID-19 and only one patient continued his
               immunosuppressive treatment during the COVID-19 infection.
               Initial symptoms of COVID-19 were pyrexia, diarrhea, cephalea,
               and dysgeusia and anosmia. No patient needed admission to
               hospital or ICU. The SARS-CoV-2 antibody development was
               described to be late in three of the six patients. Late antibody
               development seems to be more frequent in older patients and in
               patients with combined immunosuppressive treatment. In this
               scenario, SARS-CoV-2 antibody testing could be useful prior to
               restarting immunosuppressive therapy.",
  journal   = "Eur. J. Gastroenterol. Hepatol.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  33,
  number    =  3,
  pages     = "443--447",
  month     =  mar,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Wang2021-ox,
  title     = "Retropharyngeal abscess in an adult with pneumonia during
               {COVID-19} outbreak",
  author    = "Wang, Tianyu and Liu, Haibin and Liang, Caiquan and Zhang, Hang
               and Liao, Jianchun and Liu, Huanhai",
  abstract  = "BACKGROUND: Retropharyngeal abscesses are rarely reported in
               adults and occur mostly in patients with immunocompromised or as
               a foreign body complication. Admittedly, the treatment of
               retropharyngeal abscesses frequently involves surgical drainage
               to achieve the best results. However, when retropharyngeal
               abscesses occurred in a highly suspected patient with COVID-19,
               the managements and treatments should be caution to prevent the
               spread of the virus. CLINICAL PRESENTATION: On February 13, a
               40-year-old male with retropharyngeal abscesses turned to our
               department complaining dyspnea and dysphagia. In addition, his
               chest CT scan shows a suspected COVID-19 infection, thus making
               out Multiple Disciplinary Team determine to perform percutaneous
               drainage and catheterization through left anterior cervical
               approach under the guidance of B-ultrasound. Finally, the
               patient recovered and was discharged from the hospital on
               February 27 after 14 days of isolation. There was no recurrence
               after half a year follow-up. CONCLUSIONS: By presenting this
               case, we aim at raising awareness of different surgical drainage
               methods and summarizing our experience in the management of
               retropharyngeal abscesses during the outbreak of COVID-19.",
  journal   = "J. Craniofac. Surg.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  32,
  number    =  2,
  pages     = "691--693",
  year      =  2021,
  language  = "en"
}

@ARTICLE{Nozato2021-jf,
  title     = "Successful treatment of {COVID-19} with colchicine in a kidney
               transplant recipient",
  author    = "Nozato, S and Ito, A and Terashima, K and Nozato, Y and Yoshii,
               Y and Seki, K and Yoshimoto, R and Morishima, A and Sakaguchi, K
               and Kitano, M",
  journal   = "QJM",
  publisher = "Oxford University Press (OUP)",
  volume    =  114,
  number    =  3,
  pages     = "197--199",
  month     =  may,
  year      =  2021,
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Stockdill2021-kl,
  title     = "Telehealth in palliative care: Communication strategies from the
               {COVID-19} pandemic",
  author    = "Stockdill, Macy L and Barnett, Michael D and Taylor, Richard and
               Dionne-Odom, J Nicholas and Bakitas, Marie",
  abstract  = "Palliative care was once believed to be too high-touch to be
               delivered via telehealth. However, numerous studies have
               demonstrated the positive effects of palliative care delivered
               through telehealth. Because the COVID-19 pandemic has quickly
               shifted how health care is delivered to patients with cancer,
               particularly because of their immunocompromised status and the
               risks associated with unnecessary exposures in the clinic,
               previous lessons from palliative care research studies can be
               used to inform practice. This article presents a case study that
               illustrates evidence and best practices for continuing to
               deliver palliative care via telehealth after COVID-19
               restrictions are lifted.",
  journal   = "Clin. J. Oncol. Nurs.",
  publisher = "Oncology Nursing Society (ONS)",
  volume    =  25,
  number    =  1,
  pages     = "17--22",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; communication; end-of-life care; palliative care;
               telehealth",
  language  = "en"
}

@ARTICLE{LHuillier2021-bt,
  title     = "{SARS-CoV-2} and pediatric solid organ transplantation: Current
               knowns and unknowns",
  author    = "L'Huillier, Arnaud G and Danziger-Isakov, Lara and Chaudhuri,
               Abanti and Green, Michael and Michaels, Marian G and M
               Posfay-Barbe, Klara and van der Linden, Dimitri and Verma, Anita
               and McCulloch, Mignon and Ardura, Monica I",
  abstract  = "The COVID-19 pandemic has proven to be a challenge in regard to
               the clinical presentation, prevention, diagnosis, and management
               of SARS-CoV-2 infection among children who are candidates for
               and recipients of SOT. By providing scenarios and frequently
               asked questions encountered in routine clinical practice, this
               document provides expert opinion and summarizes the available
               data regarding the prevention, diagnosis, and management of
               SARS-CoV-2 infection among pediatric SOT candidates and
               recipients and highlights ongoing knowledge gaps requiring
               further study. Currently available data are still lacking in the
               pediatric SOT population, but data have emerged in both the
               adult SOT and general pediatric population regarding the
               approach to COVID-19. The document provides expert opinion
               regarding prevention, diagnosis, and management of SARS-CoV-2
               infection among pediatric SOT candidates and recipients.",
  journal   = "Pediatr. Transplant.",
  publisher = "Wiley",
  volume    =  25,
  number    =  5,
  pages     = "e13986",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; SOT; children; pediatrics",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Mancuso2021-fr,
  title     = "Modifications in systemic rheumatic disease medications:
               Patients' perspectives during the height of the {COVID-19}
               pandemic in New York city",
  author    = "Mancuso, Carol A and Duculan, Roland and Jannat-Khah, Deanna and
               Barbhaiya, Medha and Bass, Anne R and Mandl, Lisa A and Mehta,
               Bella",
  abstract  = "OBJECTIVE: Concerns about severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) infection may have led to changes or
               discontinuation of immunosuppressive medications among patients
               with systemic rheumatic disease. Our goal was to assess
               patients' perspectives regarding medication modifications and
               deviations from planned uses during the height of the pandemic.
               METHODS: Adult patients of 13 rheumatologists at an academic
               center with physician-diagnosed rheumatic disease and prescribed
               disease-modifying medications were interviewed by telephone and
               asked open-ended questions about the impact of SARS-CoV-2 on
               their medications. Responses were analyzed using content and
               thematic analyses to generate categories that described patterns
               of medication modification. RESULTS: A total of 112 patients
               (mean age 50 years, 86\% women, 34\% non-White race or Latino
               ethnicity) with diverse diagnoses (30\% lupus, 26\% rheumatoid
               arthritis, 44\% other) who were taking various medications were
               enrolled. Patients reported clinically relevant issues that were
               iteratively reviewed to generate unique categories of medication
               modification: medications and increased or decreased risk of
               SARS-CoV-2 infection; role of hydroxychloroquine; maintaining
               medication status quo; role of glucocorticoids; increasing or
               decreasing existing medications in relation to clinical disease
               activity; postponing infusions; and medication plan if infected
               by SARS-CoV-2. Some modifications were suboptimal for disease
               control but were made to mitigate infection risk and to minimize
               potential harm when patients were unable to obtain laboratory
               tests and physical examinations due to cessation of in-person
               office visits. CONCLUSION: During the height of the pandemic,
               substantial medication modifications were made that, in some
               cases, were temporizing measures and deviations from planned
               regimens. Future studies will assess short- and long-term
               sequelae of these medication modifications.",
  journal   = "Arthritis Care Res. (Hoboken)",
  publisher = "Wiley",
  volume    =  73,
  number    =  6,
  pages     = "909--917",
  month     =  jun,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Kirchner2021-wt,
  title     = "{SARS-CoV-2-specific} immunity in immunosuppressed {COVID-19}
               convalescents with autoimmune hepatitis",
  author    = "Kirchner, Theresa and Jaeckel, Elmar and Falk, Christine S and
               Eiz-Vesper, Britta and Taubert, Richard",
  journal   = "J. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  75,
  number    =  6,
  pages     = "1506--1509",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Goudsmit2021-ea,
  title     = "Factors associated with {SARS-CoV-2} infection and outcome in
               patients with solid tumors or hematological malignancies: a
               single-center study",
  author    = "Goudsmit, Anouk and Cubilier, Edouard and Meert, Anne-Pascale
               and Aftimos, Philippe and Stathopoulos, Konstantinos and
               Spilleboudt, Chloe and Loizidou, Angela",
  abstract  = "BACKGROUND: Immunocompromised cancer patients are presumed to be
               at high risk of developing COVID-19 infection. Predisposing
               factors to contracting COVID-19 and to severe outcomes have been
               described in registries but were not compared between solid
               tumors and hematological malignancies. METHOD: This
               retrospective single oncologic center study included adults with
               solid tumors or hematological malignancies referred to testing
               by naso-pharyngeal swab for a SARS-CoV-2 RT-PCR from March 10 to
               May 18, 2020. RESULTS: A total of 212 patients were included in
               the study. Forty-five (21\%) were tested positive with
               SARS-CoV-2. The univariate analysis with positive SARS-CoV-2 PCR
               as a dependent variable reveals significant odds ratios (ORs)
               for age-with a mean of 62.5 years-(OR: 1.05, 95\% CI:
               1.02-1.08), performance status $\geq$2 (OR: 2.38, 95\% CI:
               1.22-4.70), inpatient status (OR: 2.36, 95\%CI: 1.11-4.91), and
               hematological malignancies (OR: 2.48, 95\% CI: 1.23-4.96). In
               contrast, OR for solid tumors reveals a negative association
               (OR: 0.40, 95\% CI: 0.20-0.81). When integrating severe outcome
               (ICU admission or COVID-19-related death) as a dependent
               variable, the univariate logistic regression model shows
               significant ORs for pre-existing lymphopenia (OR: 4.0, 95\% CI:
               1.17-15.04), hematological malignancies (OR: 3.73, 95\% CI:
               1.09-13.80), and a negative association for solid tumors (OR:
               0.27; 95\% CI: 0.07-0.92). CONCLUSION: In patients referred for
               SARS-CoV-2 testing, hematological malignancies were associated
               with a higher risk of COVID-19 infection and severe outcomes.
               Other factors were age and inpatient status.",
  journal   = "Support. Care Cancer",
  publisher = "Springer Science and Business Media LLC",
  volume    =  29,
  number    =  11,
  pages     = "6271--6278",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Hematological malignancies; SARS-CoV-2; Solid tumor",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Balashov2021-yh,
  title     = "{SARS-CoV-2} convalescent plasma therapy in pediatric patient
               after hematopoietic stem cell transplantation",
  author    = "Balashov, Dmitry and Trakhtman, Pavel and Livshits, Anna and
               Kovalenko, Irina and Tereshenko, Galina and Solopova, Galina and
               Petraikina, Elena and Maschan, Alexei and Novichkova, Galina",
  abstract  = "Immunocompromised patients, including HSCT recipients, may have
               a poor prognosis after contracting COVID-19 due to the absence
               of a pathogen-specific adaptive immune response. One of the
               possible options for severe COVID-19 treatment may be the
               transfusion of hyperimmune SARS-CoV-2 convalescent plasma. A
               9-month-old girl with juvenile myelomonocytic leukemia received
               an HSCT from a haploidentical donor. On day +99, during routine
               virologic monitoring, SARS-CoV-2 was detected without any
               clinical symptoms. On day +144, the child developed a
               polysegmental bilateral viral pneumonia with 60 \% damage to the
               lung tissue and confirm a positive SARS-Cov-2 results in throat
               swab. The patient was treated with tocilizumab and three doses
               of fresh frozen plasma obtained from a SARS-CoV-2 convalescent
               patient. Therapy with tocilizumab and three doses of fresh
               frozen plasma was well tolerated. In spite of full resolution of
               the lung lesions, complete elimination of SARS-CoV-2 has not
               been achieved 4 months after the first detection, which is due
               to persistence of secondary immunodeficiency after HSCT and the
               lack of reconstitution of the adaptive immune response. This
               case represents a demonstration of an atypical course of
               COVID-19 and the delayed development of lung lesions, which was
               most likely associated with the features of the patient's immune
               status after HSCT. SARS-CoV-2 convalescent plasma in combination
               with other therapeutic approaches is one of the possible
               curative options for this clinical situation.",
  journal   = "Transfus. Apher. Sci.",
  publisher = "Elsevier BV",
  volume    =  60,
  number    =  1,
  pages     = "102983",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; Convalescent plasma; Immunocompromised patients;
               Pediatric; Stem cell transplantation",
  language  = "en"
}

@ARTICLE{Papa-Gobbi2021-gi,
  title     = "Novel coronavirus ({SARS-CoV-2}) infection in a patient with
               multivisceral transplant",
  author    = "Papa-Gobbi, Rodrigo and Bueno, Alba and Serradilla, Javier and
               Talayero, Paloma and Stringa, Pablo and Pascual-Miguel,
               B{\'a}rbara and Alcolea-S{\'a}nchez, Alida and
               Gonz{\'a}lez-Sacristan, Roc{\'\i}o and Andr{\'e}s, Ane M and
               L{\'o}pez-Santamar{\'\i}a, Manuel and Rumbo, Mart{\'\i}n and
               Ramos-Boluda, Esther and Hern{\'a}ndez-Oliveros, Francisco",
  abstract  = "Coronavirus disease 2019 (COVID-19) pandemic has become one of
               the most challenging episodes in the history of modern public
               health, with particular emphasis in high risk population.
               However, the evidence regarding their response to the Severe
               Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2), the agent
               responsible for COVID-19 is scant 2 . Herein we present the
               clinical and therapeutic course of a SARS-CoV-2 infection in a
               patient with multivisceral transplant and a recent tuberculosis
               infection.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  1,
  pages     = "e13430",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-19; clinical research/practice; coronavirus;
               immunosuppression; infection and infectious agents-viral;
               multivisceral transplant; small bowel; visceral transplant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Duong2021-ea,
  title     = "What's important to know about the new {COVID-19} variants?",
  author    = "Duong, Diana",
  journal   = "CMAJ",
  publisher = "CMA Joule Inc.",
  volume    =  193,
  number    =  4,
  pages     = "E141--E142",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Komec2021-xo,
  title     = "Three candida auris case reports from Istanbul, turkey",
  author    = "K{\"o}me{\c c}, Selda and Karab{\i}{\c c}ak, Nilg{\"u}n and
               Ceylan, Ay{\c s}e Nur and G{\"u}lmez, Abdurrahman and {\"O}zalp,
               Onur",
  abstract  = "Candida auris is a fungal pathogen that was first identified in
               2009. Since its definition, it has spread globally and has
               caused life-threatening nosocomial infections. Increases in the
               number of immunocompromised individuals, empirical use of
               broad-spectrum antimicrobials and widespread use of
               catheterizations are the predisposing factors in the development
               of infection. There are problems for the identification of
               C.auris with the routine methods. In this case report,
               infections with C.auris, isolated for the first time from three
               patients in our hospital's intensive care units (ICU) between
               November 2020-January 2021, were presented. The first case was a
               46-year-old male patient with laryngeal carcinoma who developed
               cardiopulmonary arrest during anesthesia induction in the tumor
               operation, and was followed up in the ICU. C.auris growth was
               detected in the blood and intravenous (IV) catheter tip cultures
               on the 66th day of admittance. Cure achieved on the 24th day
               under caspofungin treatment as no growth was determined. Second
               case was a 71-year-old female patient admitted to the emergency
               department with shortness of breath and general condition
               disorder that developed after COVID-19 infection and
               hospitalized in ICU with the diagnosis of pneumonia and acute
               renal failure. In the 16th day of admittance C.auris growth was
               detected in blood and from catheter tip cultures and the patient
               died in the 18th day. The third case was a 49-year-old male
               patient, followed up in ICU with the diagnosis of subarachnoid
               hemorrhage after he admitted to the emergency department with
               confusion. In the 35th day of admittance, 100000 CFU/ mL C auris
               growth was detected in urine culture. The patient was accepted
               as asymptomatic fungiuria and followed up in the ICU. It was
               determined that the three patients were intubated, had urinary
               and femoral venous catheters and were being followed under wide
               spectrum antibiotherapy when the growth of C.auris was detected.
               Isolates identified as C.auris by MALDI-TOF Microflex LT/SH
               Smart MS in the Medical Microbiology Laboratory were then
               confirmed by conventional methods and DNA sequencing in the
               National Mycology Reference Laboratory. Antifungal
               susceptibility tests were performed by broth microdilution
               method. Fluconazole MIC values were >256 mg/ml for all cases.
               Long-term survival in hospital environments, colonization on
               skin, resistance to disinfectants of C.auris, facilitate the
               spread of the fungi and resistance to antifungals lead to
               treatment failures. In this case report, it was aimed to draw
               attention to the infections with C.auris, its diagnosis and risk
               factors.",
  journal   = "Mikrobiyol. Bul.",
  publisher = "Bilimsel Tip Publishing House",
  volume    =  55,
  number    =  3,
  pages     = "452--460",
  month     =  jul,
  year      =  2021,
  language  = "tr"
}

@ARTICLE{Bird2021-up,
  title     = "Severe acute respiratory syndrome coronavirus 2 ({SARS-CoV-2})
               seroconversion in hematology-oncology patients",
  author    = "Bird, Paul W and Badhwar, Vinay and Kennedy, Ben and Ladani,
               Sapna and Tang, Julian W-T",
  abstract  = "Since the emergence of severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) in China at the end of 2019, the
               virus has spread rapidly across the globe leading to millions of
               infections and subsequent deaths. Although the virus infects
               those exposed indiscriminately, there are groups in society at
               an increased risk of severe infection, leading to increased
               morbidity. Patients suffering from hematological cancers,
               particularly leukemia, lymphoma, and myeloma, may be one such
               group and previous studies have suggested that they may be at a
               three to four times greater risk of severe COVID-19 after
               SARS-CoV-2 infection, leading to admissions to ICU, mechanical
               ventilation, and death compared to those without such
               malignancies. Serological testing for IgG seroconversion has
               been extensively studied in the immunocompetent, but fewer
               publications have characterized this process in large series of
               immunocompromised patients. This study described 20 patients
               with hematological cancers who tested positive for SARS-CoV-2
               via PCR with 12 of the patients receiving further serological
               testing. We found that of the 12 patients screened for
               SARS-CoV-2 IgG antibodies, only 2 (16.6\%) were able to generate
               an immune response to the infection. Yet despite this low
               seroconversion rate in this cohort, none of these patients died
               or became particularly unwell with COVID-19 or its related
               complications.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  7,
  pages     = "4585--4591",
  month     =  jul,
  year      =  2021,
  keywords  = "SARS coronavirus; immune responses; immunoglobulin; virus
               classification",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Rincon-Arevalo2021-es,
  title     = "Impaired humoral immunity to {SARS-CoV-2} {BNT162b2} vaccine in
               kidney transplant recipients and dialysis patients",
  author    = "Rincon-Arevalo, Hector and Choi, Mira and Stefanski, Ana-Luisa
               and Halleck, Fabian and Weber, Ulrike and Szelinski, Franziska
               and Jahrsd{\"o}rfer, Bernd and Schrezenmeier, Hubert and Ludwig,
               Carolin and Sattler, Arne and Kotsch, Katja and Potekhin,
               Alexander and Chen, Yidan and Burmester, Gerd R and Eckardt,
               Kai-Uwe and Guerra, Gabriela Maria and Durek, Pawel and
               Heinrich, Frederik and Ferreira-Gomes, Marta and Radbruch,
               Andreas and Budde, Klemens and Lino, Andreia C and Mashreghi,
               Mir-Farzin and Schrezenmeier, Eva and D{\"o}rner, Thomas",
  abstract  = "Patients with kidney failure are at increased risk of SARS-CoV-2
               infection, making effective vaccinations a critical need. It is
               not known how well mRNA vaccines induce B and plasma cell
               responses in dialysis patients (DPs) or kidney transplant
               recipients (KTRs) compared with healthy controls (HCs). We
               studied humoral and B cell responses of 35 HCs, 44 DPs, and 40
               KTRs. Markedly impaired anti-BNT162b2 responses were identified
               among KTRs and DPs compared with HCs. In DPs, the response was
               delayed (3 to 4 weeks after boost) and reduced with anti-S1 IgG
               and IgA positivity in 70.5 and 68.2\%, respectively. In
               contrast, KTRs did not develop IgG responses except for one
               patient who had a previous unrecognized infection and developed
               anti-S1 IgG. Most antigen-specific B cells (RBD+) were
               identified in the plasmablast or post-switch memory B cell
               compartments in HCs, whereas RBD+ B cells were enriched among
               pre-switch and na{\"\i}ve B cells from DPs and KTRs. The
               frequency and absolute number of antigen-specific circulating
               plasmablasts in the cohort correlated with the Ig response, a
               characteristic not reported for other vaccinations. In
               conclusion, these data indicated that immunosuppression resulted
               in impaired protective immunity after mRNA vaccination,
               including Ig induction with corresponding generation of
               plasmablasts and memory B cells. Thus, there is an urgent need
               to improve vaccination protocols in patients after kidney
               transplantation or on chronic dialysis.",
  journal   = "Sci. Immunol.",
  publisher = "American Association for the Advancement of Science (AAAS)",
  volume    =  6,
  number    =  60,
  pages     = "eabj1031",
  month     =  jun,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Barriere2021-ea,
  title     = "Nous devons respecter le sch{\'e}ma vaccinal {anti-SARS-CoV-2}
               sans d{\'e}calage chez les patients atteints de cancer sous
               traitement",
  author    = "Barri{\`e}re, J{\'e}r{\^o}me and Audigier-Valette, Clarisse and
               Borchiellini, Delphine and Hoch, Benjamin and Castelnau, Olivier
               and Francois, Eric and Gastaud, Lauris and Skaf, Richard and
               Berdah, Jean-Fran{\c c}ois and Marie, Wislez and Lescaut, Willy
               and Peyrade, Fr{\'e}d{\'e}ric and Cluzeau, Thomas and Cassuto,
               Oph{\'e}lie and Carles, Michel",
  journal   = "Bull. Cancer",
  publisher = "Elsevier BV",
  volume    =  108,
  number    =  4,
  pages     = "341--342",
  month     =  apr,
  year      =  2021,
  language  = "fr"
}

@ARTICLE{Gomez-Mayordomo2021-ci,
  title     = "Clinical exacerbation of {SARS-CoV2} infection after fingolimod
               withdrawal",
  author    = "Gomez-Mayordomo, Victor and Montero-Escribano, Paloma and
               Mat{\'\i}as-Guiu, Jordi A and Gonz{\'a}lez-Garc{\'\i}a, Nuria
               and Porta-Etessam, Jes{\'u}s and Mat{\'\i}as-Guiu, Jorge",
  abstract  = "The role of disease-modifying therapies in patients with
               autoimmune disorders during severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV2) infection is controversial.
               Immunocompromised patients could have a more severe coronavirus
               disease-2019 (COVID-19) due to the absence of an adequate immune
               response against the SARS-CoV-2. However, therapies that act on
               immune response could play a protective role by dampening the
               cytokine-release syndrome. Fingolimod is a drug used for immune
               therapy in patients with multiple sclerosis (MS) through the
               sequestration of activated lymphocytes in the lymph nodes. We
               report the case of a 57-year-old man with relapsing-remitting MS
               treated with fingolimod that showed a reactivation of COVID-19
               with signs of hyperinflammation syndrome after fingolimod
               withdrawal. Our case suggests that discontinuation of fingolimod
               during COVID-19 could imply a worsening of SARS-CoV2 infection.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  volume    =  93,
  number    =  1,
  pages     = "546--549",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; coronavirus; exacerbation; fingolimod;
               multiple sclerosis",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Frampton2021-lj,
  title     = "Genomic characteristics and clinical effect of the emergent
               {SARS-CoV-2} B.1.1.7 lineage in London, {UK}: a whole-genome
               sequencing and hospital-based cohort study",
  author    = "Frampton, Dan and Rampling, Tommy and Cross, Aidan and Bailey,
               Heather and Heaney, Judith and Byott, Matthew and Scott, Rebecca
               and Sconza, Rebecca and Price, Joseph and Margaritis, Marios and
               Bergstrom, Malin and Spyer, Moira J and Miralhes, Patricia B and
               Grant, Paul and Kirk, Stuart and Valerio, Chris and Mangera,
               Zaheer and Prabhahar, Thaventhran and Moreno-Cuesta, Jeronimo
               and Arulkumaran, Nish and Singer, Mervyn and Shin, Gee Yen and
               Sanchez, Emilie and Paraskevopoulou, Stavroula M and Pillay,
               Deenan and McKendry, Rachel A and Mirfenderesky, Mariyam and
               Houlihan, Catherine F and Nastouli, Eleni",
  abstract  = "BACKGROUND: Emergence of variants with specific mutations in key
               epitopes in the spike protein of SARS-CoV-2 raises concerns
               pertinent to mass vaccination campaigns and use of monoclonal
               antibodies. We aimed to describe the emergence of the B.1.1.7
               variant of concern (VOC), including virological characteristics
               and clinical severity in contemporaneous patients with and
               without the variant. METHODS: In this cohort study, samples
               positive for SARS-CoV-2 on PCR that were collected from Nov 9,
               2020, for patients acutely admitted to one of two hospitals on
               or before Dec 20, 2020, in London, UK, were sequenced and
               analysed for the presence of VOC-defining mutations. We fitted
               Poisson regression models to investigate the association between
               B.1.1.7 infection and severe disease (defined as point 6 or
               higher on the WHO ordinal scale within 14 days of symptoms or
               positive test) and death within 28 days of a positive test and
               did supplementary genomic analyses in a cohort of chronically
               shedding patients and in a cohort of remdesivir-treated
               patients. Viral load was compared by proxy, using PCR cycle
               threshold values and sequencing read depths. FINDINGS: Of 496
               patients with samples positive for SARS-CoV-2 on PCR and who met
               inclusion criteria, 341 had samples that could be sequenced. 198
               (58\%) of 341 had B.1.1.7 infection and 143 (42\%) had
               non-B.1.1.7 infection. We found no evidence of an association
               between severe disease and death and lineage (B.1.1.7 vs
               non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 097
               [95\% CI 072-131]), or in analyses adjusted for hospital, sex,
               age, comorbidities, and ethnicity (adjusted PR 102
               [076-138]). We detected no B.1.1.7 VOC-defining mutations in
               123 chronically shedding immunocompromised patients or in 32
               remdesivir-treated patients. Viral load by proxy was higher in
               B.1.1.7 samples than in non-B.1.1.7 samples, as measured by
               cycle threshold value (mean 288 [SD 47] vs 320 [48];
               p=00085) and genomic read depth (1280 [1004] vs 831 [682];
               p=00011). INTERPRETATION: Emerging evidence exists of increased
               transmissibility of B.1.1.7, and we found increased virus load
               by proxy for B.1.1.7 in our data. We did not identify an
               association of the variant with severe disease in this
               hospitalised cohort. FUNDING: University College London
               Hospitals NHS Trust, University College London/University
               College London Hospitals NIHR Biomedical Research Centre,
               Engineering and Physical Sciences Research Council.",
  journal   = "Lancet Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  21,
  number    =  9,
  pages     = "1246--1256",
  month     =  sep,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Tarris2021-mu,
  title     = "Chronic kidney disease linked to {SARS-CoV-2} infection: a case
               report",
  author    = "Tarris, Georges and de Rougemont, Alexis and Estienney,
               Marie-Ana{\"\i}s and Journet, Julien and Lariotte,
               Anne-C{\'e}cile and Aubignat, Damien and Rebibou, Jean-Michel
               and De La Vega, Mathilde Funes and Legendre, Mathieu and
               Belliot, Gael and Martin, Laurent",
  abstract  = "BACKGROUND: The recent COVID-19 pandemic has raised concerns
               about patient diagnosis and follow-up of chronically ill
               patients. Patients suffering from chronic illnesses,
               concomitantly infected by SARS-CoV-2, globally tend to have a
               worse prognosis and poor outcomes. Renal tropism and acute
               kidney injury following SARS-CoV-2 infection has recently been
               described in the literature, with elevated mortality rates.
               Furthermore, patients with pre-existing chronic kidney disease,
               infected by SARS-CoV-2, should be monitored carefully. Here, we
               report the case of a 69-year-old patient with splenic marginal
               zone lymphoma, suffering from longstanding chronic kidney
               disease following SARS-CoV-2 infection. CASE PRESENTATION: A
               69-year-old male patient previously diagnosed with pulmonary
               embolism and splenic marginal zone lymphoma (Splenomegaly,
               Matutes 2/5, CD5 negative and CD23 positive), was admitted to
               the hospital with shortness of breath, fever and asthenia. A
               nasopharyngeal swab test was performed in addition to a CT-scan,
               which confirmed SARS-CoV-2 infection. Blood creatinine increased
               following SARS-CoV-2 infection at 130 $\mu$mol/l, with usual
               values at 95 $\mu$mol/l. The patient was discharged at home with
               rest and symptomatic medical treatment (paracetamol and
               hydration), then readmitted to the hospital in August 2020. A
               kidney biopsy was therefore conducted as blood creatinine levels
               were abnormally elevated. Immunodetection performed in a renal
               biopsy specimen confirmed co-localization of SARS-CoV2
               nucleocapsid and protease 3C proteins with ACE2, Lewis x and
               sialyl-Lewis x antigens in proximal convoluted tubules and
               podocytes. Co-localization of structural and non-structural
               viral proteins clearly demonstrated viral replication in
               proximal convoluted tubules in this chronically ill patient.
               Additionally, we observed the co-localization of sialyl-Lewis x
               and ACE2 receptors in the same proximal convoluted tubules.
               Reverse Transcriptase-Polymerase Chain Reaction test performed
               on the kidney biopsy was negative, with very low Ct levels
               (above 40). The patient was finally readmitted to the
               haematology department for initiation of chemotherapy, including
               CHOP protocol and Rituximab. CONCLUSIONS: Our case emphasizes on
               the importance of monitoring kidney function in immunosuppressed
               patients and patients suffering from cancer following SARS-CoV-2
               infection, through histological screening. Further studies will
               be required to decipher the mechanisms underlying chronic kidney
               disease and the putative role of sialyl-Lewis x and HBGA during
               SARS-CoV-2 infection.",
  journal   = "BMC Nephrol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  22,
  number    =  1,
  pages     = "278",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Case report; Chronic kidney disease; Chronic viral
               replication; Coronavirus; HBGA; Immunocompromised; Lewis
               antigens; SARS-CoV-2",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Cekic2021-oo,
  title     = "The impact of the {SARS-CoV-2} pandemic in {PID} patients
               receiving ig replacement therapy",
  author    = "Cekic, Sukru and Cicek, Fatih and Kilic, Sara Sebnem",
  journal   = "J. Clin. Immunol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  4,
  pages     = "733--737",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Parkinson2021-uy,
  title     = "'They're getting a taste of our world': A qualitative study of
               people with multiple sclerosis' experiences of accessing health
               care during the {COVID-19} pandemic in the Australian Capital
               Territory",
  author    = "Parkinson, Anne and Drew, Janet and Hall Dykgraaf, Sally and
               Fanning, Vanessa and Chisholm, Katrina and Elisha, Mark and
               Lueck, Christian and Phillips, Christine and Desborough, Jane",
  abstract  = "BACKGROUND: People with multiple sclerosis (MS), who are often
               immunocompromised, require complex care and engage with a
               variety of health-care providers to manage their health.
               OBJECTIVE: To elucidate people with MS' experiences of accessing
               health care during the COVID-19 pandemic in Australia. DESIGN: A
               qualitative study involving semi-structured interviews and
               thematic analysis. SETTINGS AND PARTICIPANTS: Eight adults with
               a clinical diagnosis of MS participated in telephone or video
               call interviews between June and July 2020. RESULTS:
               Participants were aware that having MS made them more vulnerable
               to contracting COVID-19. In some cases, usual care was postponed
               or not sought. Some circumstances warranted the risk of a
               face-to-face consultation. Benefits of telehealth consultations
               included improved access, convenience and being contact-free. In
               comparison with video consultations, those via telephone were
               considered less personal and limited capacity to read body
               language, and for physical examination. Most participants hoped
               to incorporate telehealth into their future health-care
               routines. DISCUSSION AND CONCLUSION: Personal risk assessment
               and trust in health-care professionals are determinants of the
               mode through which people with MS accessed health care during
               the COVID-19 pandemic. Telehealth has been a valuable tool to
               mitigate COVID-19 transmission through enabling contact-free
               consultations. People with MS may find specific value in video
               consultations, which enable visualization of physical function.
               There is a need for training and support for all clinicians to
               conduct remote consultations. PATIENT OR PUBLIC CONTRIBUTION:
               This study was conducted by a team comprised of four people with
               MS, a neurologist and four health services researchers.",
  journal   = "Health Expect.",
  publisher = "Wiley",
  volume    =  24,
  number    =  5,
  pages     = "1607--1617",
  month     =  oct,
  year      =  2021,
  keywords  = "multiple sclerosis; pandemic; patient experience; qualitative;
               risk assessment; telehealth",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Kolonko2021-hn,
  title     = "{COVID-19} infection in solid organ transplant recipients: A
               single-center experience with patients immediately after
               transplantation",
  author    = "Kolonko, Aureliusz and Dudzicz, Sylwia and Wiecek, Andrzej and
               Kr{\'o}l, Robert",
  abstract  = "In our transplant center, infection with SARS-CoV-2 virus was
               confirmed in 4 organ transplant recipients (3 kidney and 1 liver
               transplant recipients) during their early post-transplant
               hospital stay. In this paper, we report the basic
               characteristics, management, clinical course, and outcomes of
               these patients.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  1,
  pages     = "e13381",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; infectious complications; kidney transplantation;
               liver transplantation; outcomes",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Kaila2021-fw,
  title     = "{SARS-CoV-2} late shedding may be infectious between
               immunocompromised hosts",
  author    = "Kaila, Ville and Sirkeoja, Simo and Blomqvist, Soile and
               Rannikko, Juha and Viskari, Hanna and Lyly-Yrj{\"a}n{\"a}inen,
               Tiina and Syrj{\"a}nen, Jaana",
  abstract  = "BACKGROUND: Immunocompromised patients shed SARS-CoV-2 for
               extended periods, but to our knowledge person-to-person
               transmission from late shedding has not been reported. THE CASE:
               We present a case in which a COVID-19 patient infected another
               over 28 days after the patient's initial symptoms, past current
               guideline recommendations of 20 days for length of isolation in
               immunocompromised patients. Whole genome sequencing of their
               viruses was performed to ascertain the transmission. DISCUSSION:
               Severely immunocompromised patients, whose clearance of the
               virus is impaired, may remain infectious for extended periods.
               Caution should be taken particularly in hospital settings where
               lapses in isolation procedures might pose increased risk,
               especially to other immunocompromised patients.",
  journal   = "Infect. Dis. (Lond.)",
  publisher = "Informa UK Limited",
  volume    =  53,
  number    =  11,
  pages     = "880--882",
  month     =  nov,
  year      =  2021,
  keywords  = "Covid; SARS-CoV-2; immunosuppression; late shedding;
               transmission",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Camprubi2021-js,
  title     = "Persistent replication of {SARS-CoV-2} in a severely
               immunocompromised patient treated with several courses of
               remdesivir",
  author    = "Camprub{\'\i}, Daniel and Gaya, Anna and Marcos, Maria Angeles
               and Mart{\'\i}-Soler, Helena and Soriano, Alex and Mosquera,
               Maria Del Mar and Oliver, Aina and Santos, Marta and Mu{\~n}oz,
               Jose and Garc{\'\i}a-Vidal, Carol",
  abstract  = "Microbiological response of SARS-CoV-2 to remdesivir in
               immunocompromised patients has not been evaluated. We present
               the case of a severely immunocompromised patient with persistent
               replication of SARS-CoV-2, who required different courses of
               remdesivir. Short courses of remdesivir might be insufficient in
               immunocompromised patients due to prolonged viral clearance.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  104,
  pages     = "379--381",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; Lymphoma; Remdesivir; SARS-CoV-2",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Cusi2021-nt,
  title    = "Hyperimmune plasma in three immuno-deficient patients affected by
              non-severe, prolonged {COVID-19}: a single-center experience",
  author   = "Cusi, Maria Grazia and Conticini, Edoardo and Gandolfo, Claudia
              and Anichini, Gabriele and Savellini, Gianni Gori and Valente,
              Serafina and Franchi, Federico and Scolletta, Sabino and
              Percivalle, Elena and Frediani, Bruno",
  abstract = "BACKGROUND: Convalescent plasma (CP) and hyperimmune plasma (HP)
              are passive immunotherapies consisting in the infusion of plasma
              from recovered people into infected patients. Following
              pre-existing evidence in many other viral diseases, such as SARS,
              MERS and Ebola, CP and HP have also been proposed for the
              treatment of COVID-19. Nevertheless, due to the lack of large,
              well-designed, clinical trials, no clear-cut guidelines exist
              about what subtype of patient CP and HP should be administered
              to. CASE PRESENTATION: We have reported the cases of 3 patients,
              all immunosuppressed and affected by non-severe, prolonged
              COVID-19. They were treated with HP, whose neutralizing titer was
              higher than 1/80. The first patient was a 55-year-old male, who
              had undergone lung transplant. He was under therapy with
              Tacrolimus and developed non-neutralizing antibodies against
              SARS-CoV2. The second patient was a 77-year-old female, affected
              by follicular lymphoma. She had tested positive for SARS-CoV2
              after 6 months. The third was a 60-year-old patient, affected by
              chronic leukemia. He did not develop antibodies after 2-month
              disease. All 3 patients received HP and had tested negative for
              SARS-CoV2 within 2 weeks. CONCLUSION: Despite encouraging initial
              data, no strong evidence exist in support of CP and HP to treat
              COVID-19. In our experience, although limited due to the reduced
              number of patients, we found a good safety and efficacy of HP in
              3 immuno-deficient subjects. Further data are needed in order to
              assess whether this subtype of patients may particularly benefit
              from passive immunization.",
  journal  = "BMC Infect. Dis.",
  volume   =  21,
  number   =  1,
  pages    = "630",
  month    =  jul,
  year     =  2021,
  keywords = "COVID-19; Convalescent plasma; Hyperimmune plasma;
              Immunodeficiency; SARS-CoV2",
  language = "en"
}

@ARTICLE{Lim2021-rk,
  title     = "Unilateral frosted branch angiitis in an human immunodeficiency
               virus-infected patient with concurrent {COVID-19} infection: a
               case report",
  author    = "Lim, Tsu Hong and Wai, Yong Zheng and Chong, Jia Cherng",
  abstract  = "BACKGROUND: Frosted branch angiitis (FBA) is an uncommon ocular
               sign with multiple causes. With the recent outbreak of
               coronavirus disease 2019 (COVID-19), many cases of ocular
               manifestation in association with this disease have been
               reported. However, as yet we have no complete understanding of
               this condition. We report here the first case of FBA in a human
               immunodeficiency virus-infected patient with coexisting
               cytomegalovirus (CMV) and COVID-19 infection. CASE PRESENTATION:
               A 33-year-old Malay man with underlying acquired
               immunodeficiency syndrome receiving highly active antiretroviral
               therapy was referred to the Opthalmology Department with
               complaints of blurry vision for the past 2 months. He had tested
               positive for and been diagnosed with COVID-19 1 month
               previously. Clinical examination of the fundus revealed
               extensive perivascular sheathing of both the artery and vein
               suggestive of FBA in the right eye. Laboratory testing of nasal
               swabs for COVID-19 polymerase chain reaction (PCR) and serum CMV
               antibody were positive. The patient was then admitted to the
               COVID-19 ward and treated with intravenous ganciclovir.
               CONCLUSION: Clinicians should be aware of and take the necessary
               standard precautions for possible coexistence of COVID-19 in an
               immunocompromised patient presenting with blurred vision, eye
               redness, dry eye and foreign body sensation despite the absence
               of clinical features suggestive of COVID-19. Whether FBA is one
               of the ocular signs of co-infection of COVID-19 and CMV remains
               unknown. Further studies are needed to provide more information
               on ocular signs presented in patients with concurrent COVID-19
               and CMV infections.",
  journal   = "J. Med. Case Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  15,
  number    =  1,
  pages     = "267",
  month     =  may,
  year      =  2021,
  keywords  = "Coronavirus disease 2019; Cytomegalovirus; Frosted branch
               angiitis",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Roeker2021-kx,
  title     = "{COVID-19} vaccine efficacy in patients with chronic lymphocytic
               leukemia",
  author    = "Roeker, Lindsey E and Knorr, David A and Thompson, Meghan C and
               Nivar, Mariely and Lebowitz, Sonia and Peters, Nicole and
               Deonarine, Jr, Isaac and Momotaj, Saddia and Sharan, Saumya and
               Chanlatte, Vanessa and Hampton, Bianca and Butala, Liana and
               Amato, Lindsay and Richford, Angela and Lunkenheimer, Jessica
               and Battiato, Kristen and Laudati, Carissa and Mato, Anthony R",
  journal   = "Leukemia",
  publisher = "Springer Science and Business Media LLC",
  volume    =  35,
  number    =  9,
  pages     = "2703--2705",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Schramm2021-az,
  title     = "Poor humoral and T-cell response to two-dose {SARS-CoV-2}
               messenger {RNA} vaccine {BNT162b2} in cardiothoracic transplant
               recipients",
  author    = "Schramm, Ren{\'e} and Costard-J{\"a}ckle, Angelika and Rivinius,
               Rasmus and Fischer, Bastian and M{\"u}ller, Benjamin and Boeken,
               Udo and Haneya, Assad and Provaznik, Zdenek and Knabbe,
               Cornelius and Gummert, Jan",
  abstract  = "AIMS: Immunocompromised patients have been excluded from studies
               of SARS-CoV-2 messenger RNA vaccines. The immune response to
               vaccines against other infectious agents has been shown to be
               blunted in such patients. We aimed to analyse the humoral and
               cellular response to prime-boost vaccination with the BNT162b2
               vaccine (Pfizer-BioNTech) in cardiothoracic transplant
               recipients. METHODS AND RESULTS: A total of 50 transplant
               patients [1-3 years post heart (42), lung (7), or heart-lung (1)
               transplant, mean age 55 $\pm$ 10 years] and a control group of
               50 healthy staff members were included. Blood samples were
               analysed 21 days after the prime and the boosting dose,
               respectively, to quantify anti-SARS-CoV-2 spike protein (S)
               immunoglobulin titres (tested by Abbott, Euroimmun and
               RocheElecsys Immunoassays, each) and the functional inhibitory
               capacity of neutralizing antibodies (Genscript). To test for a
               specific T-cell response, heparinized whole blood was stimulated
               with SARS-CoV-2 specific peptides, covering domains of the viral
               spike, nucleocapsid and membrane protein, and the
               interferon-$\gamma$ release was measured (QuantiFERON Monitor
               ELISA, Qiagen). The vast majority of transplant patients (90\%)
               showed neither a detectable humoral nor a T-cell response three
               weeks after the completed two-dose BNT162b2 vaccination; these
               results are in sharp contrast to the robust immunogenicity seen
               in the control group: 98\% exhibited seroconversion after the
               prime dose already, with a further significant increase of IgG
               titres after the booster dose (average > tenfold increase), a
               more than 90\% inhibition capability of neutralizing antibodies
               as well as evidence of a T-cell responsiveness. CONCLUSIONS: The
               findings of poor immune responses to a two-dose BNT162b2
               vaccination in cardiothoracic transplant patients have a
               significant impact for organ transplant recipients specifically
               and possibly for immunocompromised patients in general. It urges
               for a review of future vaccine strategies in these patients.",
  journal   = "Clin. Res. Cardiol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  110,
  number    =  8,
  pages     = "1142--1149",
  month     =  aug,
  year      =  2021,
  keywords  = "BioNTech/Pfizer (BNT162b2) vaccine; Covid-19 infection;
               Immunocompromised patients; Immunogenicity; Transplant
               recipients",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Patel2021-ok,
  title     = "Human immunodeficiency virus and severe acute respiratory
               syndrome Coronavirus 2 coinfection: A systematic review of the
               literature and challenges",
  author    = "Patel, Raj H and Acharya, Arpan and Chand, Hitendra S and Mohan,
               Mahesh and Byrareddy, Siddappa N",
  abstract  = "The concurrence of infection with human immunodeficiency virus
               (HIV) and severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2), the causative agent of coronavirus disease 2019
               (COVID-19), presents an intriguing problem with many
               uncertainties underlying their pathogenesis. Despite over 96.2
               million cases of COVID-19 worldwide as of January 22, 2021,
               reports of patients coinfected with HIV and SARS-CoV-2 are
               scarce. It remains unknown whether HIV patients are at a greater
               risk of infection from SARS-CoV-2, despite their
               immunocompromised status. We present a systematic review of the
               literature reporting cases of HIV and SARS-CoV-2 coinfection,
               and examine trends of clinical outcomes among coinfected
               patients. We systematically compiled 63 reports of HIV-1 and
               SARS-CoV-2 coinfection, published as of January 22, 2021. These
               studies were retrieved through targeted search terms applied to
               PubMed/Medline and manual search. Despite scattered evidence,
               reports indicate a favorable prognosis for HIV patients with
               strict adherence to combined antiretroviral therapy (cART).
               However, the presence of comorbidities was associated with a
               poorer prognosis in HIV/SARS-CoV-2 patients, despite cART and
               viral suppression. Studies were limited by geographic coverage,
               small sample size, lack of patient details, and short follow-up
               durations. Although some anti-HIV drugs have shown promising in
               vitro activity against SARS-CoV-2, there is no conclusive
               evidence of the clinical efficacy of any anti-HIV drug in the
               treatment of COVID-19. Further research is needed to explain the
               under-representation of severe COVID-19 cases among the HIV
               patient population and to explore the possible protective
               mechanisms of cART in this vulnerable population.",
  journal   = "AIDS Res. Hum. Retroviruses",
  publisher = "Mary Ann Liebert Inc",
  volume    =  37,
  number    =  4,
  pages     = "266--282",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; HIV; SARS-CoV-2; antiviral; cART; coinfection",
  language  = "en"
}

@ARTICLE{Ryan2021-ez,
  title     = "Vaccinated but not protected-living immunocompromised during the
               pandemic",
  author    = "Ryan, Lindsay",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  325,
  number    =  24,
  pages     = "2443--2444",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Suvvari2021-hk,
  title     = "Mucormycosis: A killer in the shadow of {COVID-19}",
  author    = "Suvvari, Tarun Kumar and Arigapudi, Nithya and Kandi, Venkata
               Ramana and Kutikuppala, Lv Simhachalam",
  journal   = "J. Mycol. Med.",
  publisher = "Elsevier BV",
  volume    =  31,
  number    =  3,
  pages     = "101161",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Poore2021-kj,
  title     = "A comparison of {SARS-CoV-2} nucleocapsid and spike antibody
               detection using three commercially available automated
               immunoassays",
  author    = "Poore, Brad and Nerenz, Robert D and Brodis, Dina and Brown,
               Charles I and Cervinski, Mark A and Hubbard, Jacqueline A",
  abstract  = "INTRODUCTION: Commercially available serological assays for
               SARS-CoV-2 detect antibodies to either the nucleocapsid or spike
               protein. Here we compare the performance of the Beckman-Coulter
               SARS-CoV-2 spike IgG assay to that of the Abbott SARS-CoV-2
               nucleocapsid IgG and Roche Anti-SARS-CoV-2 nucleocapsid total
               antibody assays. In addition, we document the trend in
               nucleocapsid and spike antibodies in sequential samples
               collected from convalescent plasma donors. METHODS: Plasma or
               serum samples from 20 individual SARS-CoV-2 RT-PCR-positive
               inpatients (n = 172), 20 individual convalescent donors with a
               previous RT-PCR-confirmed SARS-CoV-2 infection (n = 20), were
               deemed positive SARS-CoV-2 samples. RT-PCR-negative inpatients
               (n = 24), and 109 pre-SARS-CoV-2 samples were determined to be
               SARS-CoV-2 negative. Samples were assayed by the Abbott, Roche,
               and Beckman assays. RESULTS: All three assays demonstrated 100\%
               specificity. Abbott, Beckman, and Roche platforms had
               sensitivities of 98\%, 93\%, and 90\% respectively, with the
               difference in sensitivity attributed primarily to samples from
               immunocompromised patients. After the exclusion of samples
               immunocompromised patients, all assays exhibited $\geq$ 95\%
               sensitivity. In sequential samples collected from the same
               individuals, the Roche nucleocapsid antibody assay demonstrated
               continually increasing signal intensity, with maximal values
               observed at the last time point examined. In contrast, the
               Beckman spike IgG antibody signal peaked between 14 and 28 days
               post positive SARS-CoV-2 PCR and steadily declined in subsequent
               samples. Subsequent collections 51-200 days (median of 139 days)
               post positive SARS-CoV-2 RT-PCR from five inpatients and five
               convalescent donors revealed that spike and nucleocapsid
               antibodies remained detectable for several months after
               confirmed infection. CONCLUSIONS: The three assays are sensitive
               and specific for SARS-CoV-2 antibodies. Nucleocapsid and spike
               antibodies were detectable for up to 200 days post-positive
               SARS-CoV-2 PCR but demonstrated markedly different trends in
               signal intensity.",
  journal   = "Clin. Biochem.",
  publisher = "Elsevier BV",
  volume    =  95,
  pages     = "77--80",
  month     =  sep,
  year      =  2021,
  keywords  = "Antibody test; COVID-19; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Zimmerli2021-rb,
  title    = "Case report: Stepwise anti-inflammatory and {anti-SARS-CoV-2}
              effects following convalescent plasma therapy with full clinical
              recovery",
  author   = "Zimmerli, Aurelia and Monti, Matteo and Fenwick, Craig and
              Eckerle, Isabella and Beigelman-Aubry, Catherine and Pellaton,
              C{\'e}line and Jaton, Katia and Dumas, Dominique and Stamm,
              Gian-Marco and Infanti, Laura and Andreu-Ullrich, Heidrun and
              Germann, Daphn{\'e} and Mean, Marie and Vollenweider, Peter and
              Stadelmann, Raphael and Prella, Maura and Comte, Denis and Guery,
              Benoit and Gachoud, David and Rufer, Nathalie",
  abstract = "In these times of COVID-19 pandemic, concern has been raised
              about the potential effects of SARS-CoV-2 infection on
              immunocompromised patients, particularly on those receiving
              B-cell depleting agents and having therefore a severely depressed
              humoral response. Convalescent plasma can be a therapeutic option
              for these patients. Understanding the underlying mechanisms of
              convalescent plasma is crucial to optimize such therapeutic
              approach. Here, we describe a COVID-19 patient who was deeply
              immunosuppressed following rituximab (anti-CD20 monoclonal
              antibody) and concomitant chemotherapy for chronic lymphoid
              leukemia. His long-term severe T and B cell lymphopenia allowed
              to evaluate the treatment effects of convalescent plasma.
              Therapeutic outcome was monitored at the clinical, biological and
              radiological level. Moreover, anti-SARS-CoV-2 antibody titers
              (IgM, IgG and IgA) and neutralizing activity were assessed over
              time before and after plasma transfusions, alongside to
              SARS-CoV-2 RNA quantification and virus isolation from the upper
              respiratory tract. Already after the first cycle of plasma
              transfusion, the patient experienced rapid improvement of
              pneumonia, inflammation and blood cell counts, which may be
              related to the immunomodulatory properties of plasma.
              Subsequently, the cumulative increase in anti-SARS-CoV-2
              neutralizing antibodies due to the three additional plasma
              transfusions was associated with progressive and finally complete
              viral clearance, resulting in full clinical recovery. In this
              case-report, administration of convalescent plasma revealed a
              stepwise effect with an initial and rapid anti-inflammatory
              activity followed by the progressive SARS-CoV-2 clearance. These
              data have potential implications for a more extended use of
              convalescent plasma and future monoclonal antibodies in the
              treatment of immunosuppressed COVID-19 patients.",
  journal  = "Front. Immunol.",
  volume   =  12,
  pages    = "613502",
  month    =  apr,
  year     =  2021,
  keywords = "B-cell depletion; chronic SARS-CoV-2 infection; convalescent
              plasma therapy; neutralizing antibodies; severe
              immunosuppression; viral clearance",
  language = "en"
}

@ARTICLE{Sandino_Perez2021-bc,
  title    = "Pericarditis secondary to {COVID-19} infection in a kidney
              transplant recipient",
  author   = "Sandino P{\'e}rez, Justo and Aubert Girbal, Lucia and
              Caravaca-Font{\'a}n, Fernando and Polanco, Natalia and Sevillano
              Prieto, {\'A}ngel and Andr{\'e}s, Amado",
  journal  = "Nefrol. (Engl. Ed.)",
  volume   =  41,
  number   =  3,
  pages    = "349--352",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Fenwick2021-sh,
  title     = "A highly potent antibody effective against {SARS-CoV-2} variants
               of concern",
  author    = "Fenwick, Craig and Turelli, Priscilla and Perez, Laurent and
               Pellaton, C{\'e}line and Esteves-Leuenberger, Line and Farina,
               Alex and Campos, J{\'e}r{\'e}my and Lana, Erica and Fiscalini,
               Flurin and Raclot, Charl{\`e}ne and Pojer, Florence and Lau,
               Kelvin and Demurtas, Davide and Descatoire, Marc and Joo, Victor
               S and Foglierini, Mathilde and Noto, Alessandra and Abdelnabi,
               Rana and Foo, Caroline S and Vangeel, Laura and Neyts, Johan and
               Du, Wenjuan and Bosch, Berend-Jan and Veldman, Geertruida and
               Leyssen, Pieter and Thiel, Volker and LeGrand, Roger and
               L{\'e}vy, Yves and Trono, Didier and Pantaleo, Giuseppe",
  abstract  = "Control of the ongoing SARS-CoV-2 pandemic is endangered by the
               emergence of viral variants with increased transmission
               efficiency, resistance to marketed therapeutic antibodies, and
               reduced sensitivity to vaccine-induced immunity. Here, we screen
               B cells from COVID-19 donors and identify P5C3, a highly potent
               and broadly neutralizing monoclonal antibody with picomolar
               neutralizing activity against all SARS-CoV-2 variants of concern
               (VOCs) identified to date. Structural characterization of P5C3
               Fab in complex with the spike demonstrates a neutralizing
               activity defined by a large buried surface area, highly
               overlapping with the receptor-binding domain (RBD) surface
               necessary for ACE2 interaction. We further demonstrate that P5C3
               shows complete prophylactic protection in the
               SARS-CoV-2-infected hamster challenge model. These results
               indicate that P5C3 opens exciting perspectives either as a
               prophylactic agent in immunocompromised individuals with poor
               response to vaccination or as combination therapy in
               SARS-CoV-2-infected individuals.",
  journal   = "Cell Rep.",
  publisher = "Elsevier BV",
  volume    =  37,
  number    =  2,
  pages     = "109814",
  month     =  oct,
  year      =  2021,
  keywords  = "SARS-CoV-2; neutralizing antibodies; variants of concern",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Tomkins-Tinch2021-kt,
  title     = "{SARS-CoV-2} reinfection in a liver transplant recipient",
  author    = "Tomkins-Tinch, Christopher H and Daly, Jennifer S and
               Gladden-Young, Adrianne and Theodoropoulos, Nicole M and Madaio,
               Michael P and Yu, Neng and Vanguri, Vijay K and Siddle,
               Katherine J and Adams, Gordon and Krasilnikova, Lydia A and
               Movahedi, Babak and Bozorgzadeh, Adel and Simin, Karl and
               Lemieux, Jacob E and Luban, Jeremy and Park, Daniel J and
               MacInnis, Bronwyn L and Sabeti, Pardis C and Levitz, Stuart M",
  journal   = "Ann. Intern. Med.",
  publisher = "American College of Physicians",
  volume    =  174,
  number    =  8,
  pages     = "1178--1180",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Danthu2021-zh,
  title    = "Humoral response after {SARS-CoV-2} {mRNA} vaccination in a
              cohort of hemodialysis patients and kidney transplant recipients",
  author   = "Danthu, Cl{\'e}ment and Hantz, S{\'e}bastien and Dahlem, Arthur
              and Duval, Marion and Ba, Bacary and Guibbert, Manon and El
              Ouafi, Zhour and Ponsard, S{\'e}verine and Berrahal, Insaf and
              Achard, Jean-Michel and Bocquentin, Fr{\'e}d{\'e}rique and Allot,
              Vincent and Rerolle, Jean-Philippe and Alain, Sophie and
              Tour{\'e}, Fatouma",
  abstract = "BACKGROUND: Kidney transplant recipients and patients receiving
              hemodialysis are immunocompromised populations that are
              prioritized for COVID-19 vaccination but were excluded from
              clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and
              rates of seroconversion after vaccination are lower among
              patients with CKD and those taking immunosuppressants compared
              with controls. Data are lacking regarding their humoral response
              to vaccination to prevent COVID-19. METHODS: This investigation
              of early serological response after COVID-19 vaccination with the
              Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients
              undergoing hemodialysis, 74 kidney transplant recipients, and
              seven healthy controls. We recorded data from the medical file
              for various clinical parameters, including response to hepatitis
              B vaccination, and measured antibody titers against SARS-CoV-2 at
              0, 14, 28, 36, and 58 days after the first injection. RESULTS: In
              controls, we detected antibodies at a positive level (>13
              arbitrary units per ml; AU/ml) at day 14 postinjection, which
              increased progressively to peak at day 36 (1082 AU/ml;
              interquartile range [IQR], 735.0-1662.0). Patients undergoing
              hemodialysis had lower titers that peaked at day 58 (276 AU/ml;
              IQR, 83.4-526.0). We detected a positive antibody level in only
              three transplant recipients at day 36. In patients on
              hemodialysis, those aged 75 years, and serum albumin and Kt/V
              were positively correlated with serological response (P<0.04 and
              P<0.0, respectively); nonresponders to HBV vaccine had the lowest
              anti-SARS-CoV-2 antibody titers. CONCLUSIONS: Our results suggest
              that the postvaccination humoral response is strongly inhibited
              by immunosuppressant therapy in kidney transplant recipients, and
              is reduced by the uremic condition in patients undergoing
              hemodialysis.",
  journal  = "J. Am. Soc. Nephrol.",
  volume   =  32,
  number   =  9,
  pages    = "2153--2158",
  month    =  sep,
  year     =  2021,
  keywords = "COVID-19; hemodialyzed; humoral response; kidney transplant
              recipients; kinetic; vaccine",
  language = "en"
}

@ARTICLE{Bestilleiro2021-hk,
  title     = "Nosocomial infection outbreak due to {SARS-COV-2} in a hospital
               unit of particularly vulnerable patients",
  author    = "Bestilleiro, Roc{\'\i}o Seijo and Se{\~n}aris, Diana Martinez
               and Rodr{\'\i}guez, Mar{\'\i}a Jos{\'e} Pereira and V{\'a}zquez,
               Rita Galeiras and Rodr{\'\i}guez, Raquel Garc{\'\i}a and
               Rodriguez, Mar{\'\i}a Teresa Garc{\'\i}a and Mart{\'\i}n,
               Cristina Gonz{\'a}lez and Pillado, Mar{\'\i}a Teresa Seoane and
               Barreiro, Vanesa Balboa and Vali{\~n}a, Valent{\'\i}n Vald{\'e}s
               and D{\'\i}az, Sonia P{\'e}rtega",
  abstract  = "Objectives: To report a COVID-19 outbreak among workers and
               inpatients at a medical ward for especially vulnerable patients.
               Methods: Descriptive study of a nosocomial COVID-19 outbreak
               registered in March-April 2020 at medical ward of
               onco-hematological patients in an Spanish hospital. Confirmed
               cases were hospitalized patients, healthcare and non-healthcare
               workers who tested positive by PCR on a nasopharyngeal swab.
               Results: Twenty-two COVID-19 cases (12 workers and 10
               inpatients) were laboratory-confirmed. Initial cases were a
               healthcare provider and a visitor who tested positive. The
               median patients age was 73 years (range 62-88). The main reason
               of admission was haematological in 8 patients and oncologic in
               2. All patients followed an immunosuppressive treatment, 5/10
               with high-flow oxygen nebulizations. Five patients presented a
               moderate/serious evolution, and 5 patients died. The mean
               workers age was 42.1$\pm$10.9. One healthworker required
               Intensive Care Unit admission, and all of them recovered
               completely. Conclusions: In the hospital setting, close patients
               surveillance for SARS-CoV-2 is essential, especially in
               immunosuppressed patients. Replacing nebulizations or high-flow
               oxygen therapies, when other equivalent options were available,
               to reduce dispersion, and controlling ventilation ducts,
               together with hygiene measures and an active follow-up on
               inpatients, visitors and workers appear to be important in
               preventing nosocomial outbreaks.",
  journal   = "Int. J. Med. Sci.",
  publisher = "Ivyspring International Publisher",
  volume    =  18,
  number    =  10,
  pages     = "2146--2154",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus Infections; Disease outbreaks; Health
               personnel; Infectious Disease Transmission,
               Professional-to-Patient.; Infectious Disesase Transmission,
               Patient-to-Professional",
  language  = "en"
}

@ARTICLE{Felten2021-tc,
  title     = "Cluster analysis reveals three main patterns of beliefs and
               intention with respect to {SARS-CoV-2} vaccination in patients
               with autoimmune and inflammatory diseases",
  author    = "Felten, Renaud and Dubois, Maxime and Ugarte-Gil, Manuel F and
               Chaudier, Aurore and Kawka, Lou and Bergier, Hugo and
               Costecalde, Charlotte and Pijnenburg, Luc and Fort,
               J{\'e}r{\'e}my and Chatelus, Emmanuel and Sordet, Christelle and
               Javier, Rose-Marie and Gottenberg, Jacques-Eric and Sibilia,
               Jean and Fuentes-Silva, Yurilis J and Arnaud, Laurent",
  abstract  = "INTRODUCTION: Given the COVID-19 pandemic, it is crucial to
               understand the underlying behavioural determinants of SARS-CoV-2
               vaccine hesitancy in patients with autoimmune or inflammatory
               rheumatic diseases (AIIRDs). We aimed to analyse patterns of
               beliefs and intention regarding SARS-CoV-2 vaccination in AIIRD
               patients, as a mean of identifying pragmatic actions that could
               be taken to increase vaccine coverage in this population.
               METHODS: Data relating to 1258 AIIRD patients were analysed
               using univariate and multivariate logistic regression models, to
               identify variables associated independently with willingness to
               get vaccinated against SARS-CoV-2. Subsets of patients showing
               similar beliefs and intention about SARS-CoV-2 vaccination were
               characterized using cluster analysis. RESULTS: Hierarchical
               cluster analysis identified three distinct clusters of AIIRD
               patients. Three predominant patient attitudes to SARS-COV-2
               vaccination were identified: voluntary, hesitant and suspicious.
               While vaccine willingness differed significantly across the
               three clusters (P < 0.0001), there was no significant difference
               regarding fear of getting COVID-19 (P = 0.11), the presence of
               comorbidities (P = 0.23), the use of glucocorticoids (P = 0.21),
               or immunocompromised status (P = 0.63). However, patients from
               cluster \#2 (hesitant) and \#3 (suspicious) were significantly
               more concerned about vaccination, the use of a new vaccine
               technology, lack of long-term data in relation to COVID-19
               vaccination, and potential financial links with pharmaceutical
               companies (P < 0.0001 in all) than patients from cluster \#1
               (voluntary). DISCUSSION: Importantly, the differences between
               clusters in terms of patient beliefs and intention was not
               related to the fear of getting COVID-19 or to any state of
               frailty, but was related to specific concerns about vaccination.
               This study may serve as a basis for improved communication and
               thus help increase COVID-19 vaccine coverage among AIIRD
               patients.",
  journal   = "Rheumatology (Oxford)",
  publisher = "Oxford University Press (OUP)",
  volume    =  60,
  number    = "SI",
  pages     = "SI68--SI76",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; autoimmune diseases; behaviour; cluster analysis;
               inflammatory rheumatic diseases; vaccination",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Del_Rio2021-jb,
  title     = "Confronting the delta variant of {SARS-CoV-2}, summer 2021",
  author    = "Del Rio, Carlos and Malani, Preeti N and Omer, Saad B",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  326,
  number    =  11,
  pages     = "1001--1002",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Gupta2021-gi,
  title     = "Feasibility of convalescent plasma therapy in kidney transplant
               recipients with severe {COVID-19}: A single-center prospective
               cohort study",
  author    = "Gupta, Akash and Kute, Vivek B and Patel, Himanshu V and
               Engineer, Divyesh P and Banerjee, Subho and Modi, Pranjal R and
               Rizvi, Syed J and Mishra, Vineet V and Patel, Ansy H and
               Navadiya, Vijay",
  abstract  = "OBJECTIVES: There are limited clinical data on feasibility and
               safety of convalescent plasma therapy in kidney transplant
               recipients with severe COVID-19. The present study was conducted
               to explore the feasibility of convalescent plasma treatment in
               10 kidney transplant recipients with severe COVID-19. MATERIALS
               AND METHODS: The prospective observational cohort study was
               conducted at the Institute of Kidney Disease and Research
               Centre, Ahmedabad, India. All patients were admitted to the
               intensive care unit and received antiviral therapy,
               glucocorticoids, and other supportive care. Two doses of 200 mL
               each of convalescent plasma with neutralization activity of
               >1:640 were transfused into patients 24 hours apart following
               the World Health Organization blood transfusion protocol. The
               endpoints were the improvement of clinical symptoms and
               laboratory parameters within 1 day and 7 days after convalescent
               plasma transfusion. RESULTS: The patients showed resolution of
               clinical symptoms, and there was a significant decrease in
               inflammatory markers (P < .05) within 7 days of convalescent
               plasma transfusion. Of the 10 patients, 9 patients had full
               recovery and 1 patient died. CONCLUSIONS: Convalescent plasma
               therapy is highly safe and clinically feasible and reduces
               mortality in kidney transplant recipients with severe COVID-19.
               Larger clinical registries and randomized clinical trials should
               be conducted to further explore the clinical outcomes associated
               with convalescent plasma use in kidney transplant recipients
               with severe COVID-19.",
  journal   = "Exp. Clin. Transplant.",
  publisher = "Baskent University",
  volume    =  19,
  number    =  4,
  pages     = "304--309",
  month     =  apr,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Versyck2021-xi,
  title     = "Invasive pulmonary aspergillosis in {COVID-19} critically ill
               patients: Results of a French monocentric cohort",
  author    = "Versyck, Maaike and Zarrougui, Wafa and Lambiotte, Fabien and
               Elbeki, Nabil and Saint-Leger, Piehr",
  abstract  = "INTRODUCTION: Coronavirus disease 2019 or COVID-19 is a new
               infectious disease responsible for potentially severe
               respiratory impairment associated with initial
               immunosuppression. Similarly to influenza, several authors have
               described a higher risk of fungal infection after COVID-19, in
               particular for invasive pulmonary aspergillosis. The main
               objective here is to define the prevalence of invasive pulmonary
               aspergillosis (IPA) in a cohort of COVID-19 patients with
               moderate to severe acute respiratory disease syndrome (ARDS).
               MATERIAL AND METHODS: We conducted a large monocentric
               retrospective study investigating all the ventilated COVID-19
               patients with ARDS hospitalized at Valenciennes' general
               hospital, France, between March 15, 2020 and April 30, 2020. In
               the center a systematic IPA screening strategy was carried out
               for all ARDS patients, with weekly tests of serum galactomannan
               and beta-D-glucan. Bronchoalveolar lavage with culture and chest
               CT scan were performed when the serum assays were positives.
               RESULTS: A total of 54 patients were studied. Their median age
               was 65 years, and 37 of the patients (71\%) were male. Two
               patients had chronic immunosuppression and among all the
               patients, only 2 non-immunocompromised presented a putative IPA
               during their stay. CONCLUSION: The prevalence of IPA in this
               cohort of COVID-19 patients (3.7\%) is not higher than what is
               described in the other ARDS populations in the literature. These
               results are however different from the previous publications on
               COVID-19 patients and must therefore be confirmed by larger and
               multicentric studies.",
  journal   = "J. Mycol. Med.",
  publisher = "Elsevier BV",
  volume    =  31,
  number    =  2,
  pages     = "101122",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; Intensive care unit; Invasive pulmonary aspergillosis;
               SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Cucurull-Canosa2021-ip,
  title     = "Descripci{\'o}n de 12 pacientes {VIH} positivos que han padecido
               la {COVID-19} en nuestra {\'a}rea",
  author    = "Cucurull-Canosa, Josep and Vega-Molpeceres, Sonia and
               Dami{\'a}n-Rodr{\'\i}guez, Jorge Alberto and Pons-Vi{\~n}as,
               Estel",
  journal   = "Enferm. infecc. microbiol. clin. (Engl. )",
  publisher = "Elsevier BV",
  volume    =  39,
  number    =  4,
  pages     = "208--210",
  month     =  apr,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Verhagen2021-ka,
  title     = "Human {CD4+} {T} cells specific for dominant epitopes of
               {SARS-CoV-2} Spike and Nucleocapsid proteins with therapeutic
               potential",
  author    = "Verhagen, Johan and van der Meijden, Edith D and Lang, Vanessa
               and Kremer, Andreas E and V{\"o}lkl, Simon and Mackensen,
               Andreas and Aigner, Michael and Kremer, Anita N",
  abstract  = "Since December 2019, Coronavirus disease-19 (COVID-19) has
               spread rapidly throughout the world, leading to a global effort
               to develop vaccines and treatments. Despite extensive progress,
               there remains a need for treatments to bolster the immune
               responses in infected immunocompromised individuals, such as
               cancer patients who recently underwent a haematopoietic stem
               cell transplantation. Immunological protection against COVID-19
               is mediated by both short-lived neutralizing antibodies and
               long-lasting virus-reactive T cells. Therefore, we propose that
               T cell therapy may augment efficacy of current treatments. For
               the greatest efficacy with minimal adverse effects, it is
               important that any cellular therapy is designed to be as
               specific and directed as possible. Here, we identify T cells
               from COVID-19 patients with a potentially protective response to
               two major antigens of the SARS-CoV-2 virus, Spike and
               Nucleocapsid protein. By generating clones of highly
               virus-reactive CD4+ T cells, we were able to confirm a set of
               nine immunodominant epitopes and characterize T cell responses
               against these. Accordingly, the sensitivity of T cell clones for
               their specific epitope, as well as the extent and focus of their
               cytokine response was examined. Moreover, using an advanced T
               cell receptor (TCR) sequencing approach, we determined the
               paired TCR-$\alpha$$\beta$ sequences of clones of interest.
               While these data on a limited population require further
               expansion for universal application, the results presented here
               form a crucial first step towards TCR-transgenic CD4+ T cell
               therapy of COVID-19.",
  journal   = "Clin. Exp. Immunol.",
  publisher = "Wiley",
  volume    =  205,
  number    =  3,
  pages     = "363--378",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; T cell; T cell receptor; epitope",
  copyright = "https://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Bertrand2021-wn,
  title     = "Antibody and {T} cell response to {SARS-CoV-2} messenger {RNA}
               {BNT162b2} vaccine in kidney transplant recipients and
               hemodialysis patients",
  author    = "Bertrand, Dominique and Hamzaoui, Mouad and Lem{\'e}e, Veronique
               and Lamulle, Julie and Hanoy, M{\'e}lanie and Laurent, Charlotte
               and Lebourg, Ludivine and Etienne, Isabelle and Lemoine,
               Mathilde and Le Roy, Frank and Nezam, Dorian and Plantier,
               Jean-Christophe and Boyer, Olivier and Guerrot, Dominique and
               Candon, Sophie",
  abstract  = "BACKGROUND: Severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) is associated with a high rate of mortality in
               patients with ESKD, and vaccination is hoped to prevent
               infection. METHODS: Between January 18 and February 24, 2021,
               225 kidney transplant recipients (KTRs) and 45 patients on
               hemodialysis (HDPs) received two injections of mRNA BNT162b2
               vaccine. The postvaccinal humoral and cellular response was
               explored in the first 45 KTRs and ten HDPs. RESULTS: After the
               second dose, eight HDPs (88.9\%) and eight KTRs (17.8\%)
               developed antispike SARS-CoV-2 antibodies (P<0.001). Median
               titers of antibodies in responders were 1052 AU/ml (IQR,
               515-2689) in HDPs and 671 AU/ml (IQR, 172-1523) in KTRs
               (P=0.40). Nine HDPs (100\%) and 26 KTRs (57.8\%) showed a
               specific T cell response (P=0.06) after the second injection. In
               responders, median numbers of spike-reactive T cells were 305
               SFCs per 106 CD3+ T cells (IQR, 95-947) in HDPs and 212 SFCs per
               106 CD3+ T cells (IQR, 61-330) in KTRs (P=0.40). In KTRs, the
               immune response to BNT162b2 seemed influenced by the
               immunosuppressive regimen, particularly tacrolimus or
               belatacept. CONCLUSION: Immunization with BNT162b2 seems more
               efficient in HDPs, indicating that vaccination should be highly
               recommended in these patients awaiting a transplant. However,
               the current vaccinal strategy for KTRs may not provide effective
               protection against COVID-19 and will likely need to be improved.",
  journal   = "J. Am. Soc. Nephrol.",
  publisher = "American Society of Nephrology (ASN)",
  volume    =  32,
  number    =  9,
  pages     = "2147--2152",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; clinical immunology; hemodialysis; kidney
               transplantation",
  language  = "en"
}

@ARTICLE{Hunsinger2021-yf,
  title     = "{COVID-19} reinfection in an immunosuppressed patient without an
               antibody response",
  author    = "Hunsinger, Dr Hillary P and Kutti Sridharan, Dr Gurusaravanan
               and Rokkam, Dr Venkata R P and Fantry, Dr Lori E",
  journal   = "Am. J. Med. Sci.",
  publisher = "Elsevier BV",
  volume    =  362,
  number    =  1,
  pages     = "103",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Burack2021-pt,
  title     = "Prevalence and predictors of {SARS-CoV-2} antibodies among solid
               organ transplant recipients with confirmed infection",
  author    = "Burack, Daniel and Pereira, Marcus R and Tsapepas, Demetra S and
               Harren, Patricia and Farr, Maryjane A and Arcasoy, Selim and
               Cohen, David J and Mohan, Sumit and Emond, Jean C and Hod, Eldad
               A and Verna, Elizabeth C",
  abstract  = "It remains uncertain whether immunocompromised patients
               including solid organ transplant (SOT) recipients will have a
               robust antibody response to SARS-CoV-2 infection. We enrolled
               all adult SOT recipients at our center with confirmed SARS-CoV-2
               infection who underwent antibody testing with a single
               commercially available anti-nucleocapsid antibody test at least
               7 days after diagnosis in a retrospective cohort. Seventy SOT
               recipients were studied (56\% kidney, 19\% lung, 14\% liver
               $\pm$ kidney, and 11\% heart $\pm$ kidney recipients).
               Thirty-six (51\%) had positive anti-nucleocapsid antibody
               testing, and 34 (49\%) were negative. Recipients of a kidney
               allograft were less likely to have positive antibody testing
               compared to those who did not receive a kidney (p = .04). In the
               final multivariable model, the years from transplant to
               diagnosis (OR 1.26, p = .002) and baseline immunosuppression
               with more than two agents (OR 0.26, p = .03) were significantly
               associated with the antibody test result, controlling for kidney
               transplantation. In conclusion, among SOT recipients with
               confirmed infection, only 51\% of patients had detectable
               anti-nucleocapsid antibodies, and transplant-related variables
               including the level and nature of immunosuppression were
               important predictors. These findings raise the concern that SOT
               recipients with COVID-19 may be less likely to form SARS-CoV-2
               antibodies.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  volume    =  21,
  number    =  6,
  pages     = "2254--2261",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; antibodies; serology; transplant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Levy2021-pu,
  title    = "Monoclonal antibody-mediated neutralization of {SARS-CoV-2} in an
              {IRF9-deficient} child",
  author   = "L{\'e}vy, Romain and Zhang, Peng and Bastard, Paul and Dorgham,
              Karim and Melki, Isabelle and Hadchouel, Alice and Hartoularos,
              George C and Neven, B{\'e}n{\'e}dicte and Castelle, Martin and
              Roy, Charlotte and Toin, Tom and Berteloot, Laureline and Bizien,
              Lucy and Abid, Han{\`e}ne and Burgard, Marianne and
              Houhou-Fidouh, Nadhira and Rozenberg, Flore and Jouanguy,
              Emmanuelle and Ye, Chun Jimmie and Gorochov, Guy and Zhang, Qian
              and Casanova, Jean-Laurent",
  abstract = "We describe an unvaccinated child at risk for life-threatening
              COVID-19 due to an inherited deficiency of IRF9, which governs
              ISGF-3-dependent responses to type I and III interferons (IFN).
              She was admitted, with a high nasal SARS-CoV-2 load on day 1 of
              upper respiratory tract infection. She was viremic on day 2 and
              received casirivimab and imdevimab. Her clinical manifestations
              and viremia disappeared on days 3 and 4, respectively.
              Circulating SARS-CoV-2 virus induced the expression of
              IFN-stimulated genes in leukocytes on day 1, whereas the
              secretion of blood type I IFNs, which peaked on day 4, did not.
              Antibody-mediated SARS-CoV-2 neutralization is, therefore,
              sufficient to overcome a deficiency of antiviral IFNs.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  118,
  number   =  45,
  month    =  nov,
  year     =  2021,
  keywords = "COVID-19; RNA-seq; SARS-CoV-2; inherited primary
              immunodeficiency; interferon",
  language = "en"
}

@ARTICLE{Gavriatopoulou2021-nt,
  title     = "Poor neutralizing antibody responses in 106 patients with {WM}
               after vaccination against {SARS-CoV-2}: a prospective study",
  author    = "Gavriatopoulou, Maria and Terpos, Evangelos and
               Ntanasis-Stathopoulos, Ioannis and Briasoulis, Alexandros and
               Gumeni, Sentiljana and Malandrakis, Panagiotis and Fotiou,
               Despina and Migkou, Magdalini and Theodorakakou, Foteini and
               Eleutherakis-Papaiakovou, Evangelos and Kanellias, Nikolaos and
               Kastritis, Efstathios and Trougakos, Ioannis P and Dimopoulos,
               Meletios A",
  abstract  = "Immunocompromised patients with hematologic malignancies are
               more susceptible to COVID-19 and at higher risk of severe
               complications and worse outcomes compared with the general
               population. In this context, we evaluated the humoral response
               by determining the titers of neutralizing antibodies (NAbs)
               against SARS-CoV-2 in patients with Waldenstr{\"o}m
               macroglobulinemia (WM) after vaccination with the BNT162b2 or
               AZD1222 vaccine. A US Food and Drug Administration-approved
               enzyme-linked immunosorbent assay-based methodology was
               implemented to evaluate NAbs on the day of the first vaccine
               shot, as well as on days 22 and 50 afterward. A total of 106
               patients with WM (43\% men; median age, 73 years) and 212
               healthy controls (46\% men; median age, 66 years) who were
               vaccinated during the same period at the same center were
               enrolled in the study (which is registered at
               www.clinicaltrials.gov as \#NCT04743388). Our data indicate that
               vaccination with either 2 doses of the BNT162b2 or 1 dose of the
               AZD1222 vaccine leads to lower production of NAbs against
               SARS-CoV-2 in patients with WM compared with controls on days 22
               and 50 (P < .001 for all comparisons). Disease-related immune
               dysregulation and therapy-related immunosuppression are involved
               in the low humoral response. Importantly, active treatment with
               either rituximab or Bruton's tyrosine kinase inhibitors was
               proven as an independent prognostic factor for suboptimal
               antibody response after vaccination. In conclusion, patients
               with WM have low humoral response after COVID-19 vaccination,
               which underlines the need for timely vaccination ideally during
               a treatment-free period and for continuous vigilance on
               infection control measures.",
  journal   = "Blood Adv.",
  publisher = "American Society of Hematology",
  volume    =  5,
  number    =  21,
  pages     = "4398--4405",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Velayos2021-zm,
  title     = "Prior immunosuppressive therapy and severe illness among
               patients diagnosed with {SARS-CoV-2}: A community-based study",
  author    = "Velayos, Fernando S and Dusendang, Jennifer R and Schmittdiel,
               Julie A",
  abstract  = "BACKGROUND: An estimated 10 million people in the USA are
               immunocompromised, a risk factor for severe COVID-19. Data
               informing whether immune-mediated medications lead to more
               severe infection are sparse. OBJECTIVE: Determine whether
               outpatient immunosuppressive therapies that treat autoimmune
               inflammatory disease or prevent solid organ transplant rejection
               are associated with severe illness after diagnosis with
               SARS-CoV-2 DESIGN: Retrospective cohort study PARTICIPANTS:
               Adults with a positive PCR nasal swab for SARS-CoV-2 from
               February 25 to September 9, 2020, cared for within a large
               integrated health care organization MAIN MEASURES: Exposure was
               defined as an outpatient fill of prednisone, immunomodulator,
               small-molecule, or biologic therapy in the 105 days prior to a
               positive SARS-CoV-2 PCR test. The main outcome was either
               hospitalization, ICU admission, or death within 45 days after
               diagnosis of SARS-CoV-2. Multivariable logistic regression
               models were adjusted for age, race, gender, body mass index,
               comorbidities, and autoimmune disease. KEY RESULTS: A total of
               39,686 adults had a positive PCR test. In the primary analysis,
               prior prednisone use was associated with severe illness after
               diagnosis with SARS-CoV-2 (odds ratio (OR) 1.31; 95\% confidence
               interval (CI) 1.08-1.60); however, immunomodulator (OR 0.88;
               95\% CI 0.57-1.34) and biologic/small-molecule therapy (OR 1.26;
               95\% CI 0.79-2.00) were not. Secondary analyses showed variable
               risk among therapies: Janus-kinase inhibitors had an increased
               odds of severe illness (OR 3.35; 95\% CI 1.16-9.67),
               thiopurines/conventionaldisease-modifying antirheumatic drugs
               had a reduced odds (OR 0.53; 95\% CI 0.32-0.88), and tumor
               necrosis factor inhibitors were not associated (OR 0.45; 95\% CI
               0.18-1.08). CONCLUSIONS AND RELEVANCE: Outpatient use of
               prednisone is associated with severe illness after diagnosis of
               SARS-CoV-2. Immunomodulator and biologic/small-molecule therapy
               were not associated, but different risk subgroups were
               identified. Our findings can inform risk-benefit discussions in
               the clinic and risk-based recommendations for patients on these
               therapies.",
  journal   = "J. Gen. Intern. Med.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  36,
  number    =  12,
  pages     = "3794--3801",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Braun-Moscovici2021-ul,
  title     = "Disease activity and humoral response in patients with
               inflammatory rheumatic diseases after two doses of the Pfizer
               {mRNA} vaccine against {SARS-CoV-2}",
  author    = "Braun-Moscovici, Yolanda and Kaplan, Marielle and Braun, Maya
               and Markovits, Doron and Giryes, Samy and Toledano, Kohava and
               Tavor, Yonit and Dolnikov, Katya and Balbir-Gurman, Alexandra",
  abstract  = "BACKGROUND: The registration trials of messenger RNA (mRNA)
               vaccines against SARS-CoV-2 did not address patients with
               inflammatory rheumatic diseases (IRD). OBJECTIVE: To assess the
               humoral response after two doses of mRNA vaccine against
               SARS-CoV-2, in patients with IRD treated with immunomodulating
               drugs and the impact on IRD activity. METHODS: Consecutive
               patients treated at the rheumatology institute, who received
               their first SARS-CoV-2 (Pfizer) vaccine, were recruited to the
               study, at their routine visit. They were reassessed 4-6 weeks
               after receiving the second dose of vaccine, and blood samples
               were obtained for serology. IRD activity assessment and the
               vaccine side effects were documented during both visits. IgG
               antibodies (Abs) against SARS-CoV-2 were detected using the
               SARS-CoV-2 IgG II Quant (Abbott) assay. RESULTS: Two hundred and
               sixty-four patients with stable disease, (mean(SD) age 57.6
               (13.18) years, disease duration 11.06 (7.42) years), were
               recruited. The immunomodulatory therapy was not modified before
               or after the vaccination. After the second vaccination, 227
               patients (86\%) mounted IgG Ab against SARS-CoV-2 (mean (SD)
               5830.8 (8937) AU/mL) and 37 patients (14\%) did not, 22/37 were
               treated with B cell-depleting agents. The reported side effects
               of the vaccine were minor. The rheumatic disease remained stable
               in all patients. CONCLUSIONS: The vast majority of patients with
               IRD developed a significant humoral response following the
               administration of the second dose of the Pfizer mRNA vaccine
               against SARS-CoV-2 virus. Only minor side effects were reported
               and no apparent impact on IRD activity was noted.",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1317--1321",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; antirheumatic agents; autoimmune diseases; biological
               therapy; vaccination",
  language  = "en"
}

@ARTICLE{Mulder2021-kr,
  title     = "Reinfection of severe acute respiratory syndrome Coronavirus 2
               in an immunocompromised patient: A case report",
  author    = "Mulder, Marlies and van der Vegt, Dewi S J M and Oude Munnink,
               Bas B and GeurtsvanKessel, Corine H and van de Bovenkamp, Jeroen
               and Sikkema, Reina S and Jacobs, Esther M G and Koopmans, Marion
               P G and Wegdam-Blans, Marjolijn C A",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  73,
  number    =  9,
  pages     = "e2841--e2842",
  month     =  nov,
  year      =  2021,
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Rubin2021-qt,
  title     = "Monoclonal antibodies for {COVID-19} preexposure prophylaxis
               can't come fast enough for some people",
  author    = "Rubin, Rita",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  326,
  number    =  19,
  pages     = "1895--1897",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Almontasheri2021-fs,
  title     = "The clinical course of {COVID-19} pneumonia in a 19-year-old man
               on intravenous immunoglobulin replacement therapy for X-linked
               agammaglobulinemia",
  author    = "Almontasheri, Ali and Al-Husayni, Faisal and Alsuraihi, Anas K
               and Binyahib, Hanan and Albanna, Amr S",
  abstract  = "BACKGROUND Since the emergence of coronavirus disease 2019
               (COVID-19), patients with the illness have presented with
               considerable variation in severity. Some infected individuals
               present mild or no symptoms, while others present severe illness
               with some fatal outcomes. Multiple lines of management have been
               suggested for critically ill patients, such as intravenous
               immunoglobulin (IVIG) and steroids. IVIG is the main treatment
               for patients with X-linked agammaglobulinemia. Multiple studies
               have reported that these patients have excellent outcomes when
               they contract COVID-19. This report describes the clinical
               course of COVID-19 pneumonia due to severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2) infection in a 19-year-old
               man on IVIG replacement therapy for X-linked agammaglobulinemia
               (XLA). CASE REPORT A patient with XLA receiving a monthly dose
               of IVIG and having bronchiectasis managed by prophylactic
               azithromycin presented with fever, shortness of breath,
               productive cough, and diarrhea. He was admitted to our hospital
               with SARS-CoV-2 infection. His treatment course for COVID-19 was
               uncomplicated and had excellent results. He completed a 10-day
               course of piperacillin/tazobactam and his symptoms resolved 3
               days after admission, without complications, oxygen
               supplementation, or intensive care unit admission. CONCLUSIONS
               Patients with XLA have weakened immunity and therefore may
               present with an infection as a first symptom. This report
               describes the mild course of COVID-19 pneumonia in an
               immunologically vulnerable patient with XLA who presented with
               SARS-CoV-2 infection while undergoing IVIG replacement therapy.
               Currently, IVIG is one of many supportive immune therapies
               undergoing clinical evaluation in patients with severe COVID-19.",
  journal   = "Am. J. Case Rep.",
  publisher = "International Scientific Information, Inc.",
  volume    =  22,
  pages     = "e929447",
  month     =  feb,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Sakhi2021-wj,
  title     = "Kinetics of {anti-SARS-CoV-2} {IgG} antibodies in hemodialysis
               patients six months after infection",
  author    = "Sakhi, Hamza and Dahmane, Djamal and Attias, Philippe and
               Kofman, Thomas and Bouvier, Magali and Lapidus, Nathanael and
               Fourati, Slim and El Karoui, Khalil and {Mondor NephroCov Study
               Group}",
  abstract  = "BACKGROUND: The humoral response against severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) in the
               hemodialysis population, including its dynamics over time,
               remains poorly understood. METHODS: To analyze initial and
               long-term humoral responses against SARS-CoV-2 in a hemodialysis
               population, we retrospectively evaluated findings from
               SARS-CoV-2 IgG serologic assays targeting the nucleocapsid
               antigen or spike antigen up to 6 months of follow-up in patients
               on hemodialysis in the Paris, France, region who had recovered
               from coronavirus disease 2019 (COVID-19). RESULTS: Our analysis
               included 83 patients (median age 65 years); 59 (71\%) were male
               and 28 (34\%) had presented with severe COVID-19. We observed
               positive initial SARS-CoV-2 IgG antinucleocapsid serology in 74
               patients (89\%) at a median of 67 days postdiagnosis. By
               multivariable analysis, immunocompromised status was the only
               factor significantly associated with lack of an IgG
               antinucleocapsid antibody response. Follow-up data were
               available at 6 months postdiagnosis for 60 of 74 patients (81\%)
               with positive initial antinucleocapsid serology, and 15 (25\%)
               of them had negative antinucleocapsid serology at month 6. In
               total, 14 of 15 sera were tested for antispike antibodies, 3 of
               14 (21\%) of which were also negative. Overall, 97\% of
               antinucleocapsid-antibody-positive specimens were also
               antispike-antibody positive. Female sex, age >70 years, and
               nonsevere clinical presentation were independently associated
               with faster IgG antinucleocapsid titer decay in multivariable
               analysis. After adjustment for sex and age >70 years, nonsevere
               clinical presentation was the only factor associated with faster
               decay of IgG antispike antibodies. CONCLUSIONS: This study
               characterizes evolution of the SARS-CoV-2 antibody response in
               patients on hemodialysis and identifies factors that are
               associated with lack of seroconversion and with IgG titer decay.",
  journal   = "J. Am. Soc. Nephrol.",
  publisher = "American Society of Nephrology (ASN)",
  volume    =  32,
  number    =  5,
  pages     = "1033--1036",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; SARS-CoV-2 antibody; hemodialysis;
               serology",
  language  = "en"
}

@ARTICLE{Hoffman2021-hd,
  title    = "Organ transplantation in the era of the {COVID-19} global
              pandemic",
  author   = "Hoffman, Tomer and Mor, Eytan",
  journal  = "Isr. Med. Assoc. J.",
  volume   =  23,
  number   =  3,
  pages    = "145--146",
  month    =  mar,
  year     =  2021,
  language = "en"
}

@ARTICLE{Parashar2021-uf,
  title     = "Reckoning {$\gamma$-Glutamyl-S-allylcysteine} as a potential
               main protease (mpro) inhibitor of novel {SARS-CoV-2} virus
               identified using docking and molecular dynamics simulation",
  author    = "Parashar, Arun and Shukla, Arpit and Sharma, Ankush and Behl,
               Tapan and Goswami, Dweipayan and Mehta, Vineet",
  abstract  = "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or
               COVID-19), outbreak was first reported in December 2019 in the
               Wuhan, China. COVID-19 managed to spread worldwide and so far
               more than 9.1 million cases and more than 4.7 lakh death has
               been reported globally. Children, pregnant women, elderly
               population, immunocompromised patients, and patients with
               conditions like asthma, diabetes, etc. are highly vulnerable to
               COVID infection. Currently, there is no treatment available for
               COVID-19 infection. Traditional medicinal plants have provided
               bioactive molecules in the past that are efficiently used during
               conditions like cancer, malaria, microbial infections,
               immune-compromised states, etc. AYUSH India has recommended the
               use of Curcuma longa, Allium sativum, Ocimum tenuiflorum, and
               Withania somnifera for immune-boosting during SARS-CoV-2
               infection. In the present study, we investigated the potential
               of 63-major bioactive molecules of these plants against
               SARS-CoV-2 main protease (Mpro) through docking studies and
               compared the results with known inhibitor 11a. Our results
               proposed cuscohygrine, $\gamma$-Glutamyl-S-allylcysteine,
               anahygrine, and S-allylcystein as the potent inhibitors against
               Mpro identified using molecular docking and molecular simulation
               dynamics. Interestingly, these molecules are from A. sativum,
               and W. somnifera, which are known for their antimicrobial and
               immunomodulatory potential. None of the proposed molecules have
               earlier been reported as antiviral molecules. Our results
               predict very strong potential of these four-molecules against
               SARS-CoV-2 Mpro, especially $\gamma$-glutamyl-S-allylcysteine,
               as all four form hydrogen bonding with Glu166 that is a crucial
               residue for the formation of the biologically active dimeric
               form of Mpro. Therefore, we strongly recommend further research
               on these biomolecules against SARS-CoV-2.",
  journal   = "Drug Dev. Ind. Pharm.",
  publisher = "Informa UK Limited",
  volume    =  47,
  number    =  5,
  pages     = "699--710",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Molecular docking; SARS-CoV-2; allium sativum;
               coronavirus; withania somnifera",
  language  = "en"
}

@ARTICLE{Malipiero2021-es,
  title     = "Assessment of humoral and cellular immunity induced by the
               {BNT162b2} {SARS-CoV-2} vaccine in healthcare workers, elderly
               people, and immunosuppressed patients with autoimmune disease",
  author    = "Malipiero, Giacomo and Moratto, Anna and Infantino, Maria and
               D'Agaro, Pierlanfranco and Piscianz, Elisa and Manfredi,
               Mariangela and Grossi, Valentina and Benvenuti, Enrico and
               Bulgaresi, Matteo and Benucci, Maurizio and Villalta, Danilo",
  abstract  = "The development of vaccines to prevent SARS-CoV-2 infection has
               mainly relied on the induction of neutralizing antibodies (nAbs)
               to the Spike protein of SARS-CoV-2, but there is growing
               evidence that T cell immune response can contribute to
               protection as well. In this study, an anti-receptor binding
               domain (RBD) antibody assay and an INF$\gamma$-release assay
               (IGRA) were used to detect humoral and cellular responses to the
               Pfizer-BioNTech BNT162b2 vaccine in three separate cohorts of
               COVID-19-na{\"\i}ve patients: 108 healthcare workers (HCWs), 15
               elderly people, and 5 autoimmune patients treated with
               immunosuppressive agents. After the second dose of vaccine, the
               mean values of anti-RBD antibodies (Abs) and INF$\gamma$ were
               123.33 U/mL (range 27.55-464) and 1513 mIU/mL (range 145-2500)
               in HCWs and 210.7 U/mL (range 3-500) and 1167 mIU/mL (range
               83-2500) in elderly people. No correlations between age and
               immune status were observed. On the contrary, a weak but
               significant positive correlation was found between INF$\gamma$
               and anti-RBD Abs values (rho = 0.354, p = 0.003). As to the
               autoimmune cohort, anti-RBD Abs were not detected in the two
               patients with absent peripheral CD19+B cells, despite high
               INF$\gamma$ levels being observed in all 5 patients after
               vaccination. Even though the clinical relevance of T cell
               response has not yet been established as a correlate of
               vaccine-induced protection, IGRA testing has showed optimal
               sensitivity and specificity to define vaccine responders, even
               in patients lacking a cognate antibody response to the vaccine.",
  journal   = "Immunol. Res.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  69,
  number    =  6,
  pages     = "576--583",
  month     =  dec,
  year      =  2021,
  keywords  = "Antibodies; COVID-19; INF$\gamma$; Immunogenicity; SARS-CoV-2;
               Vaccine",
  language  = "en"
}

@ARTICLE{Hayashi2021-kv,
  title     = "The case of a liver-transplant recipient with severe acute
               respiratory syndrome coronavirus 2 infection who had a favorable
               outcome",
  author    = "Hayashi, Kazuhiko and Ito, Yuki and Yamane, Ryosuke and
               Yoshizaki, Michiyo and Matsushita, Komei and Kajikawa, Go and
               Kozawa, Takashi and Mizutani, Taro and Shimizu, Yuko and Nagano,
               Kenichi and Tachi, Kosuke and Yoshioka, Kentaro and Goto, Hidemi",
  abstract  = "The outbreak of coronavirus disease 2019 (COVID-19), caused by
               severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
               was identified in 2019; thereafter, the COVID-19 outbreak became
               a health emergency of international concern. The impact of
               COVID-19 on liver-transplant recipients is unclear. Thus, it is
               currently unknown whether liver-transplant recipients are at a
               higher risk of developing complications related to COVID-19.
               Here, we report the case of liver-transplant recipients who were
               infected with SARS-CoV-2. A 20-year-old man who had undergone
               living-donor liver transplantation from his father at 5 years of
               age because of congenital biliary atresia was referred to our
               hospital for SARS-CoV-2 infection. Chest computed tomography did
               not show any abnormalities; however, laboratory results revealed
               liver dysfunction. He received tacrolimus as maintenance therapy
               that was continued at the same dose. He has not developed severe
               pulmonary disease and was discharged after 10 days of
               hospitalization. Limited data are available on post-transplant
               patients with COVID-19, and this case of a young patient without
               metabolic comorbidities did not show any association of severe
               COVID-19 under tacrolimus treatment. The progression of COVID-19
               in liver-transplant recipients is complex, and COVID-19 risk
               should be evaluated in each patient until the establishment of
               optimal guidelines.",
  journal   = "Clin. J. Gastroenterol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  14,
  number    =  3,
  pages     = "842--845",
  month     =  jun,
  year      =  2021,
  keywords  = "Coronavirus disease 2019; Liver transplantation; Severe acute
               respiratory syndrome coronavirus 2",
  language  = "en"
}

@ARTICLE{Bakhsh2021-mo,
  title     = "Unusual source of recurrent Corynebacterium bacteraemia in an
               immunocompromised patient",
  author    = "Bakhsh, Abdul Rahim Ali and Lewis, Keir Edward",
  abstract  = "We describe a unique case of a patient with acute myeloid
               leukaemia (AML), with recurring infections during chemotherapy
               from chronic nasal carriage of non-diphtherial Corynebacterium,
               who was eventually diagnosed as she presented with neutropaenic
               sepsis. Identifying (often multiple) sources of infection in
               immunocompromised patients is crucial but deciding whether
               multiple organisms, which in health are considered as
               commensals, are actually pathogenic during vulnerable states-can
               be clinically difficult. Our case highlights the efforts to
               correctly identify the actual source of this rare organism and
               the recognition of its pathogenic potential when other illnesses
               present. We also review the literature of Corynebacteria in
               patients with haematological malignancies but believe this is
               the first case of AML to be infected with Corynebacterium
               presenting during the COVID-19 pandemic with a probable
               incidental positive swab for SARS-CoV-2.",
  journal   = "BMJ Case Rep.",
  publisher = "BMJ",
  volume    =  14,
  number    =  6,
  pages     = "e242560",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; haematology (incl blood transfusion); infectious
               diseases; oncology",
  language  = "en"
}

@ARTICLE{Rimar2021-hw,
  title     = "{SARS-COV-2} vaccination after stem cell transplantation for
               scleroderma",
  author    = "Rimar, Doron and Slobodin, Gleb and Paz, Alona and Henig, Israel
               and Zuckerman, Tsila",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1354--1355",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; systemic sclerosis; vaccination",
  language  = "en"
}

@ARTICLE{Huang2021-em,
  title     = "Prolonged {SARS-Cov-2} shedding with rapid {IgG} antibody decay
               in a {COVID-19} patient: A case report",
  author    = "Huang, Jinbao and Lan, Changqing and Wang, Xinhang and Huang,
               Mingxiang",
  abstract  = "BACKGROUND: The coronavirus disease 2019 (COVID-19) epidemic is
               still spreading rapidly around the world. Recent cases with
               prolonged severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) RNA detection have been successively reported, and
               the phenomenon of false-negative real-time polymerase chain
               reaction (RT-PCR) results of SARS-CoV-2 RNA or ``repositive''
               was also described in COVID-19 patients. METHODS: We report a
               69-year-old female patient with hypertension, suspected lung
               tumor, and previous history of total hysterectomy for
               hysteromyoma who presented with moderate COVID-19 symptoms and
               was positive for SARS-CoV-2 RNA by RT-PCR when she traveled from
               the USA to China. RESULTS: The patient required second and third
               re-hospitalizations due to ``repositive'' SARS-CoV-2 throat swab
               test results during post-charge solitary isolation and
               observation, and serum SARS-CoV-2-IgG decayed rapidly before
               disappearing on illness Day 139 when the throat swab was still
               positive. The virus shedding lasted for at least 146 days (the
               last positive throat swab test result was on illness Day 146,
               and the first true-negative test result was on illness Day 151)
               since her initial positive test. CONCLUSION: Prolonged
               SARS-CoV-2 RNA viral shedding is prone to occur in an
               immunocompromised host, wherein changes in the host immune
               status can lead to repeated positive SARS-CoV-2 detection.
               Moreover, the SARS-CoV-2-IgG may decrease rapidly and disappear
               before virus removal, indicating there may be certain
               limitations on the protective effect of the SARS-CoV-2 antibody,
               which deserves clinical attention.",
  journal   = "J. Clin. Lab. Anal.",
  publisher = "Wiley",
  volume    =  35,
  number    =  11,
  pages     = "e24002",
  month     =  nov,
  year      =  2021,
  keywords  = "SARS-Cov-2; antibodies; coronavirus disease 2019; false negative
               of RT-PCR; prolonged viral RNA shedding",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Chauhan2021-hj,
  title     = "Mucormycosis after {COVID-19} in a patient with diabetes",
  author    = "Chauhan, Khushboo and Soni, Deepak and Sarkar, Deepayan and
               Karuna, Tadepalli and Sharma, Bhavana and Singh, Sarman and
               Karkhur, Samendra",
  journal   = "Lancet",
  publisher = "Elsevier BV",
  volume    =  398,
  number    =  10301,
  pages     = "e10",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Varma2021-mj,
  title     = "Renal graft artery thrombosis following {COVID-19} infection",
  author    = "Varma, Prem P and Kute, Vivek B and Bajpai, Geet",
  journal   = "Nephrology (Carlton)",
  publisher = "Wiley",
  volume    =  26,
  number    =  11,
  pages     = "932--933",
  month     =  nov,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Wei2021-fb,
  title     = "Prolonged shedding of {SARS-CoV-2} in an elderly liver
               transplant patient infected by {COVID-19}: a case report",
  author    = "Wei, Lai and Liu, Bin and Zhao, Yuanyuan and Chen, Zhishui",
  abstract  = "Coronavirus disease 2019 (COVID-19) pandemic gripped the globe.
               SARS-CoV-2 is highly infectious and is susceptible to all
               populations. Immunosuppressed patients have greater risk for
               opportunistic infections. However, the understanding regarding
               the biological characteristics of SARS-CoV-2 in immunosuppressed
               patients remains unclear. Herein, we present a case of prolonged
               shedding of SARS-CoV-2 in a liver transplant patient with
               COVID-19. A 61-year-old male post liver transplant was confirmed
               COVID-19 infection on day 10 of illness onset. The patient has
               received immunosuppressive treatment for over 11 years and has a
               history of hypertension for 10 years. With antiviral treatment
               and temporary discontinuation of tacrolimus immunosuppression,
               he had complete clinical symptoms relieve on day 24. However,
               recurrently positive tests of SARS-CoV-2 RNA were presented on
               day 35 and on day 39 after two consecutive negative tests. IgG
               antibody test for SARS-CoV-2 was positive with IgM negative on
               day 41. The final shedding duration lasted 52 days. Prolonged
               shedding of SARS-CoV-2 should be a matter of concern and might
               attribute to long-term immunosuppression. Therefore, dynamic
               surveillance and prolonged quarantine are required for
               immunocompromised individuals. Further data should be collected
               to investigate if there is a universal prolonged shedding window
               of SARS-CoV-2 in immunosuppressed patients.",
  journal   = "Ann. Palliat. Med.",
  publisher = "AME Publishing Company",
  volume    =  10,
  number    =  6,
  pages     = "7003--7007",
  month     =  jun,
  year      =  2021,
  keywords  = "Coronavirus disease 2019 (COVID-19); case report; elder; liver;
               transplantation",
  language  = "en"
}

@ARTICLE{Truong2021-jv,
  title     = "Increased viral variants in children and young adults with
               impaired humoral immunity and persistent {SARS-CoV-2} infection:
               A consecutive case series",
  author    = "Truong, Thao T and Ryutov, Alex and Pandey, Utsav and Yee,
               Rebecca and Goldberg, Lior and Bhojwani, Deepa and
               Aguayo-Hiraldo, Paibel and Pinsky, Benjamin A and Pekosz, Andrew
               and Shen, Lishuang and Boyd, Scott D and Wirz, Oliver F and
               R{\"o}ltgen, Katharina and Bootwalla, Moiz and Maglinte, Dennis
               T and Ostrow, Dejerianne and Ruble, David and Han, Jennifer H
               and Biegel, Jaclyn A and Li, Maggie and Huang, Chunhong and
               Sahoo, Malaya K and Pannaraj, Pia S and O'Gorman, Maurice and
               Judkins, Alexander R and Gai, Xiaowu and Dien Bard, Jennifer",
  abstract  = "BACKGROUND: There is increasing concern that persistent
               infection of SARS-CoV-2 within immunocompromised hosts could
               serve as a reservoir for mutation accumulation and subsequent
               emergence of novel strains with the potential to evade immune
               responses. METHODS: We describe three patients with acute
               lymphoblastic leukemia who were persistently positive for
               SARS-CoV-2 by real-time polymerase chain reaction. Viral
               viability from longitudinally-collected specimens was assessed.
               Whole-genome sequencing and serological studies were performed
               to measure viral evolution and evidence of immune escape.
               FINDINGS: We found compelling evidence of ongoing replication
               and infectivity for up to 162 days from initial positive by
               subgenomic RNA, single-stranded RNA, and viral culture analysis.
               Our results reveal a broad spectrum of infectivity, host immune
               responses, and accumulation of mutations, some with the
               potential for immune escape. INTERPRETATION: Our results
               highlight the potential need to reassess infection control
               precautions in the management and care of immunocompromised
               patients. Routine surveillance of mutations and evaluation of
               their potential impact on viral transmission and immune escape
               should be considered.",
  journal   = "EBioMedicine",
  publisher = "Elsevier BV",
  volume    =  67,
  number    =  103355,
  pages     = "103355",
  month     =  may,
  year      =  2021,
  keywords  = "SARS-CoV-2; case report; immunocompromised; pediatric;
               persistent infection; variants",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Ciuffreda2021-st,
  title     = "Longitudinal study of a {SARS-CoV-2} infection in an
               immunocompromised patient with X-linked agammaglobulinemia",
  author    = "Ciuffreda, Laura and Lorenzo-Salazar, Jos{\'e} M and
               Alcoba-Florez, Julia and Rodriguez-P{\'e}rez, H{\'e}ctor and
               Gil-Campesino, Helena and {\'I}{\~n}igo-Campos, Antonio and
               Garc{\'\i}a-Mart{\'\i}nez de Artola, Diego and
               Valenzuela-Fern{\'a}ndez, Agust{\'\i}n and Hayek-Peraza,
               Marcelino and Rojo-Alba, Susana and Alvarez-Arg{\"u}elles, Marta
               Elena and D{\'\i}ez-Gil, Oscar and Gonz{\'a}lez-Montelongo,
               Rafaela and Flores, Carlos",
  journal   = "J. Infect.",
  publisher = "Elsevier BV",
  volume    =  83,
  number    =  5,
  pages     = "607--635",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{De_Bree2021-tp,
  title    = "{SARS-CoV-2} neutralizing monoclonal antibodies: a potential
              breakthrough in the early treatment of Covid-19 in high-risk
              patients",
  author   = "de Bree, Godelieve J and Wiersinga, W Joost",
  abstract = "Despite vaccination, a substantial proportion of
              immunocompromised patients have an increased risk for severe
              Covid-19. Treatment with SARS-CoV-2 neutralizing monoclonal
              antibodies has been shown to be safe and can prevent Covid-19
              associated hospitalization and death. Monoclonal antibodies
              neutralize the virus and promote the immune response against
              SARS-CoV-2. Treatment with monoclonal antibodies is a potential
              breakthrough for the treatment of patients who are at high risk
              for severe disease when given early after infection. The first
              encouraging clinical trial data and the imminent availability of
              combination antibody therapy create a ``momentum'' to address
              several essential questions that are necessary to address for the
              structural use of this treatment in routine clinical care. These
              concern the real-world effect and sustainability of treatment of
              vulnerable patients, the optimal logistics and the
              cost-effectiveness of these novel compounds.",
  journal  = "Ned. Tijdschr. Geneeskd.",
  volume   =  165,
  month    =  oct,
  year     =  2021,
  language = "nl"
}

@ARTICLE{Redjoul2021-rv,
  title     = "Antibody response after second {BNT162b2} dose in allogeneic
               {HSCT} recipients",
  author    = "Redjoul, Rabah and Le Bouter, Anne and Beckerich, Florence and
               Fourati, Slim and Maury, S{\'e}bastien",
  journal   = "Lancet",
  publisher = "Elsevier BV",
  volume    =  398,
  number    =  10297,
  pages     = "298--299",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Tuschen2021-yw,
  title     = "Renal transplantation after recovery from {COVID-19} - a case
               report with implications for transplant programs in the face of
               the ongoing corona-pandemic",
  author    = "Tuschen, Katharina and Anders, Johanna and Elfanish, Amin and
               Schildgen, Verena and Schildgen, Oliver and Becker, Jan Ulrich
               and Weidemann, Alexander",
  abstract  = "BACKGROUND: The ongoing coronavirus pandemic has major impacts
               on both patients and healthcare systems worldwide, thus creating
               new realities. Patients on maintenance dialysis listed for renal
               transplantation are a vulnerable subgroup with many
               comorbidities and recurring contacts with the healthcare system.
               Due to the COVID-19 pandemic transplant numbers have dropped
               considerably, further increasing waiting times in this high-risk
               population. On the other hand, knowledge of the severity of
               SARS-CoV-2 infection in immunocompromised patients, development
               and persistence of neutralising antibodies in such patients is
               just emerging. It is unclear how best to address the dilemma of
               postponing the life-saving transplantation. CASE PRESENTATION:
               We present a case report of a successful kidney transplantation
               only 65 days after the recipient was hospitalized for treatment
               of COVID-19 pneumonia. In a follow up of 9 months, we observed
               no signs of recurrent disease and transplant function is
               excellent. Monitoring SARS-CoV-2 antibody response demonstrates
               stable IgG levels. CONCLUSION: This reassuring case provides
               guidance to transplant centers how to proceed with kidney
               transplantation safely during the pandemic. Careful
               consideration of risks and benefits of the organ offer, full
               recovery from COVID-19 symptoms and the presence of a positive
               SARS-CoV-2 IgG antibody test, qualifies for kidney
               transplantation.",
  journal   = "BMC Nephrol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  22,
  number    =  1,
  pages     = "251",
  month     =  jul,
  year      =  2021,
  keywords  = "Antibody response; Immunosuppression; Kidney transplantation;
               Reactivation; SARS-CoV-2",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Van_Egeren2021-gt,
  title     = "Controlling long-term {SARS-CoV-2} infections can slow viral
               evolution and reduce the risk of treatment failure",
  author    = "Van Egeren, Debra and Novokhodko, Alexander and Stoddard,
               Madison and Tran, Uyen and Zetter, Bruce and Rogers, Michael S
               and Joseph-McCarthy, Diane and Chakravarty, Arijit",
  abstract  = "The rapid emergence and expansion of novel SARS-CoV-2 variants
               threatens our ability to achieve herd immunity for COVID-19.
               These novel SARS-CoV-2 variants often harbor multiple point
               mutations, conferring one or more evolutionarily advantageous
               traits, such as increased transmissibility, immune evasion and
               longer infection duration. In a number of cases, variant
               emergence has been linked to long-term infections in individuals
               who were either immunocompromised or treated with convalescent
               plasma. In this paper, we used a stochastic evolutionary
               modeling framework to explore the emergence of fitter variants
               of SARS-CoV-2 during long-term infections. We found that
               increased viral load and infection duration favor emergence of
               such variants. While the overall probability of emergence and
               subsequent transmission from any given infection is low, on a
               population level these events occur fairly frequently. Targeting
               these low-probability stochastic events that lead to the
               establishment of novel advantageous viral variants might allow
               us to slow the rate at which they emerge in the patient
               population, and prevent them from spreading deterministically
               due to natural selection. Our work thus suggests practical ways
               to achieve control of long-term SARS-CoV-2 infections, which
               will be critical for slowing the rate of viral evolution.",
  journal   = "Sci. Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  11,
  number    =  1,
  pages     = "22630",
  month     =  nov,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Toruner2021-ju,
  title     = "Turkish {IBD} organization's position statement on inflammatory
               bowel disease management recommendations during {COVID-19}
               pandemic",
  author    = "T{\"o}r{\"u}ner, Murat and Kalkan, {\.I}smail Hakk{\i} and
               Aky{\"u}z, Filiz and Tezel, Ahmet and {\c C}elik, Aykut Ferhat",
  abstract  = "The COVID-19 pandemic, caused by the novel severe acute
               respiratory syndrome coronavirus 2, has resulted in high
               mortality and morbidity worldwide and is still a growing
               problem. Inflammatory bowel disease (IBD) is a chronic
               inflammatory disease for which a substantial number of patients
               are treated with immunosuppressive medications, either
               occasionally or long-term. Despite the accumulating evidence,
               there is still a lack of knowledge about the impact of COVID-19
               on IBD patients, especially those who are under
               immunosuppressive treatment. Moreover, following the emergence
               of several COVID vaccines, there are concerns regarding vaccine
               effectiveness and possible side effects in such patients. In
               this context, we tried to briefly summarize the accumulating
               evidence and recommendations for the management of IBD in the
               context of the COVID-19 pandemic.",
  journal   = "Turk. J. Gastroenterol.",
  publisher = "AVES Publishing Co.",
  volume    =  32,
  number    =  6,
  pages     = "488--492",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Essa2021-st,
  title     = "Lack of transmission of {SARS-CoV-2} by platelet transfusion
               from a {COVID-19-positive} donor in a hematopoietic stem cell
               transplantation patient",
  author    = "Essa, Mohammed F and Elbashir, Enas and Batarfi, Khalid and
               Alharbi, Musaed",
  journal   = "Pediatr. Blood Cancer",
  publisher = "Wiley",
  volume    =  68,
  number    =  2,
  pages     = "e28658",
  month     =  feb,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Kasereka2021-ep,
  title     = "Neuroinvasive potential of human coronavirus {OC43}: case report
               of fatal encephalitis in an immunocompromised host",
  author    = "Kasereka, Masumbuko C and Hawkes, Michael T",
  abstract  = "Neurologic manifestations of COVID-19 include anosmia, ageusia,
               encephalopathy, agitation, confusion, ischemic strokes,
               Guillain-Barr{\'e} syndrome, seizures, and hemorrhagic
               encephalitis. Although mechanisms of central nervous system
               (CNS) injury are likely diverse, direct viral invasion of the
               CNS has been demonstrated in case reports. Neurotropism of human
               coronaviruses (HCoVs) is therefore of great interest in the
               context of the COVID-19 pandemic. Here we present an
               autopsy-proven case of fatal human coronavirus (HCoV)-OC43
               encephalitis in an infant with aplastic thymus and chronic
               T-cell lymphopenia. Clinicians should remain alert to the
               possibility of direct CNS invasion by human coronaviruses,
               including the novel pandemic SARS-CoV-2.",
  journal   = "J. Neurovirol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  27,
  number    =  2,
  pages     = "340--344",
  month     =  apr,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Carraway2021-ka,
  title     = "Preventing the spread: A comprehensive cancer center's journey
               to prevent the spread of Coronavirus Disease (covid-19) during
               the 2020 pandemic",
  author    = "Carraway, Stephanie and Martin, Stacy and Greene, John N",
  abstract  = "BACKGROUND: On March 11, 2020, the World Health Organization
               (WHO) declared Coronavirus Disease (COVID-19) a pandemic.
               Hospitals around the world began to implement infection
               prevention and control (IPC) measures to stop further spread and
               prevent infections within their facilities. Healthcare
               organizations were challenged to develop response plans, procure
               personal protective equipment (PPE) that was in limited supply
               while continuing to provide quality, safe care. METHODS: As a
               comprehensive cancer center with immunocompromised patients, our
               efforts began immediately. Preventative measures were
               established and, as of September 2020, over 14,000 patients have
               been tested within the facility. From March 2020 through
               September 2020, only one case of hospital acquired (HA) COVID-19
               was identified among our patients. Two cases of suspected
               community acquired (SCA) cases were also identified. Following
               the Centers for Disease Control (CDC) guidance, IPC measures
               were implemented within the facility as information science
               about the virus developed. This article addresses the IPC
               measures taken, such as enhancing isolation precautions,
               implementing screening protocols, disinfecting and reusing N95
               respirators, by the center throughout the pandemic as well as
               the challenges that arouse with a new and emerging infectious
               disease. CONCLUSIONS: The infection control measures implemented
               at our comprehensive cancer center during the COVID-19 pandemic
               allowed our center to continue to provide world class cancer
               care with minimal COVID-19 infection transmission among patients
               and team members.",
  journal   = "Cancer Control",
  publisher = "SAGE Publications",
  volume    =  28,
  pages     = "10732748211017166",
  month     =  jan,
  year      =  2021,
  keywords  = "Covid-19; comprehensive cancer center; infection; oncology;
               prevention",
  language  = "en"
}

@ARTICLE{Lenti2021-ba,
  title     = "Acute kidney injury caused by {COVID-19} in a patient with
               Crohn's disease treated with adalimumab",
  author    = "Lenti, Marco Vincenzo and Gregorini, Marilena and Borrelli de
               Andreis, Federica and Rampino, Teresa and D'Ambrosio, Gioacchino
               and Verga, Laura and Vanoli, Alessandro and Mengoli, Caterina
               and Ravetta, Valentina and Paulli, Marco and Di Sabatino,
               Antonio",
  journal   = "J. Clin. Pathol.",
  publisher = "BMJ",
  volume    =  74,
  number    =  8,
  pages     = "540--542",
  month     =  aug,
  year      =  2021,
  keywords  = "Crohn disease; kidney; tumour necrosis factors",
  language  = "en"
}

@ARTICLE{Nijman2021-wg,
  title     = "Risk factors for in-hospital mortality in laboratory-confirmed
               {COVID-19} patients in the Netherlands: A competing risk
               survival analysis",
  author    = "Nijman, Gerine and Wientjes, Maike and Ramjith, Jordache and
               Janssen, Nico and Hoogerwerf, Jacobien and Abbink, Evertine and
               Blaauw, Marc and Dofferhoff, Ton and van Apeldoorn, Marjan and
               Veerman, Karin and de Mast, Quirijn and Ten Oever, Jaap and
               Hoefsloot, Wouter and Reijers, Monique H and van Crevel, Reinout
               and van de Maat, Josephine S",
  abstract  = "BACKGROUND: To date, survival data on risk factors for COVID-19
               mortality in western Europe is limited, and none of the
               published survival studies have used a competing risk approach.
               This study aims to identify risk factors for in-hospital
               mortality in COVID-19 patients in the Netherlands, considering
               recovery as a competing risk. METHODS: In this observational
               multicenter cohort study we included adults with PCR-confirmed
               SARS-CoV-2 infection that were admitted to one of five hospitals
               in the Netherlands (March to May 2020). We performed a competing
               risk survival analysis, presenting cause-specific hazard ratios
               (HRCS) for the effect of preselected factors on the absolute
               risk of death and recovery. RESULTS: 1,006 patients were
               included (63.9\% male; median age 69 years, IQR: 58-77).
               Patients were hospitalized for a median duration of 6 days (IQR:
               3-13); 243 (24.6\%) of them died, 689 (69.9\%) recovered, and 74
               (7.4\%) were censored. Patients with higher age (HRCS 1.10, 95\%
               CI 1.08-1.12), immunocompromised state (HRCS 1.46, 95\% CI
               1.08-1.98), who used anticoagulants or antiplatelet medication
               (HRCS 1.38, 95\% CI 1.01-1.88), with higher modified early
               warning score (MEWS) (HRCS 1.09, 95\% CI 1.01-1.18), and higher
               blood LDH at time of admission (HRCS 6.68, 95\% CI 1.95-22.8)
               had increased risk of death, whereas fever (HRCS 0.70, 95\% CI
               0.52-0.95) decreased risk of death. We found no increased
               mortality risk in male patients, high BMI or diabetes.
               CONCLUSION: Our competing risk survival analysis confirms
               specific risk factors for COVID-19 mortality in a the
               Netherlands, which can be used for prediction research, more
               intense in-hospital monitoring or prioritizing particular
               patients for new treatments or vaccination.",
  journal   = "PLoS One",
  publisher = "Public Library of Science (PLoS)",
  volume    =  16,
  number    =  3,
  pages     = "e0249231",
  month     =  mar,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Smith2021-oi,
  title     = "Should older adult pneumococcal vaccination recommendations
               change due to decreased vaccination in children during the
               pandemic? A cost-effectiveness analysis",
  author    = "Smith, Kenneth J and Wateska, Angela R and Nowalk, Mary Patricia
               and Lin, Chyongchiou J and Harrison, Lee H and Schaffner,
               William and Zimmerman, Richard K",
  abstract  = "BACKGROUND: The COVID-19 pandemic is causing declines in
               childhood immunization rates. We examined potential
               COVID-19-related changes in pediatric 13-valent pneumococcal
               conjugate vaccine (PCV13) use, subsequent impact on childhood
               and adult pneumococcal disease rates, and how those changes
               might affect the favorability of PCV13 use in
               non-immunocompromised adults aged $\geq$65 years. METHODS: A
               Markov model estimated pediatric disease resulting from
               decreased PCV13 use in children aged 53\% increase in
               pneumococcal disease was required to favor PCV13 use in
               non-immunocompromised seniors at a \$200,000 per
               quality-adjusted life-year gained threshold, which corresponded
               to absolute decreases in pediatric PCV13 vaccination of >50\%
               over a 2-year period. In sensitivity analyses, senior PCV13
               vaccination was unfavorable if absolute decreases in pediatric
               PCV13 receipt were within plausible ranges, despite model
               assumptions favoring PCV13 use in seniors. CONCLUSION:
               COVID-19-related decreases in pediatric PCV13 use would need to
               be both substantial and prolonged to make heightened PCV13 use
               in non-immunocompromised seniors economically favorable.",
  journal   = "Vaccine",
  publisher = "Elsevier BV",
  volume    =  39,
  number    =  31,
  pages     = "4278--4282",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Cost-effectiveness analysis; Elderly; Pneumococcal
               vaccination",
  language  = "en"
}

@ARTICLE{Gandra2021-xh,
  title     = "The ``black fungus'' in India: The emerging syndemic of
               {COVID-19-associated} mucormycosis",
  author    = "Gandra, Sumanth and Ram, Sanjay and Levitz, Stuart M",
  journal   = "Ann. Intern. Med.",
  publisher = "American College of Physicians",
  volume    =  174,
  number    =  9,
  pages     = "1301--1302",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{De_la_Puerta2021-wc,
  title     = "Common seasonal respiratory virus infections in allogeneic stem
               cell transplant recipients during the {SARS-COV-2} pandemic",
  author    = "De la Puerta, Rosal{\'\i}a and Montoro, Juan and Aznar, Carla
               and Lorenzo, Ignacio and Gonz{\'a}lez-Barber{\'a}, Eva
               Mar{\'\i}a and Balaguer-Rosell{\'o}, Aitana and Guerreiro,
               Manuel and Dom{\'\i}nguez, Lara and Salavert, Miguel and
               Aguilar, Crist{\'o}bal and de la Rubia, Javier and Sanz, Jaime
               and G{\'o}mez, Mar{\'\i}a Dolores and Pi{\~n}ana, Jos{\'e} Luis",
  abstract  = "The SARS-COV-2 pandemic has led to strict and generalized
               transmission prevention measures that may have changed the
               epidemiological landscape of common seasonal respiratory virus
               (CSRV). Through a prospective CSRV survey program conducted from
               2016 onwards in allogeneic stem cell transplant (allo-HSCT)
               recipients with respiratory symptoms, we aimed to analyze and
               compare the epidemiology and characteristics of CSRV over three
               consecutive periods [from February 1 to September 30 of 2018
               (P1), 2019 (P2), and 2020 (P3)]. CSRV screening was performed
               through multiplex PCR assays during the study period. We
               identified 188 consecutive allo-HSCT recipients with 406
               episodes screened for CSRV during the study period, of which 147
               developed 300 CSRV. In P1 and P2 we diagnosed 115 (38.3\%) and
               145 (48.3\%) CSRV episodes, respectively, whereas in P3 only 40
               (13.3\%) episodes were detected (p < 0.001). During P3, we
               observed a reduction of 80.2\% in Ev/Rh, 93.3\% in RSV, 80\% in
               hIV, 96.3\% HPIV, 68.4\% in hMPV, 77.7\% in ADV, 100\% in HBoV,
               and 53.6\% in HCoV as compared to P1 and P2. Consequently, we
               also observed a decline in absolute numbers of lower respiratory
               tract disease (68.1\%), co-infections (91.7\%), and
               hospitalizations (72.6\%) during P3. We diagnosed SARS-COV-2 in
               nine allo-HSCT recipients, representing 23\% of all CSRV
               detections in that period. In conclusion, we provide evidence of
               a significant drop in CSRV circulation during the SARS-COV-2
               pandemic in our allo-HSCT recipients, indicating that prevention
               measures in the general population are highly effective in
               reducing CSRV prevalence and its complications in
               immunocompromised patients.",
  journal   = "Bone Marrow Transplant.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  56,
  number    =  9,
  pages     = "2212--2220",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Cozzani2021-ke,
  title     = "Considerations on {SARS-Cov-2} vaccines in patients with
               autoimmune blistering diseases",
  author    = "Cozzani, Emanuele and Gasparini, Giulia and Sticchi, Laura and
               Russo, Roberto and Icardi, Giancarlo and Parodi, Aurora",
  journal   = "Eur. J. Dermatol.",
  publisher = "John Libbey Eurotext",
  volume    =  31,
  number    =  3,
  pages     = "415--417",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Wang2021-lr,
  title     = "Influence of immunosuppression on seroconversion against
               {SARS-CoV-2} in two kidney transplant recipients",
  author    = "Wang, Aileen X and Quintero Cardona, Orlando and Ho, Dora Y and
               Busque, Stephan and Lenihan, Colin R",
  abstract  = "Solid organ transplant recipients are at risk for infectious
               complications due to chronic immunosuppression. The outbreak of
               coronavirus disease 2019 (COVID-19) in the United States has
               raised growing concerns for the transplant patient population.
               We seek to add to the current limited literature on COVID-19 in
               transplant recipients by describing the clinical course of two
               kidney transplant recipients with SARS-CoV-2 infection monitored
               by both RT-PCR and serology. Through careful adjustment of their
               immunosuppression regimen, both patients had excellent recovery
               with intact graft function and development of anti-SARS-CoV-2
               antibodies.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  1,
  pages     = "e13423",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; RT-PCR; SARS-CoV-2; antibodies; immunosuppression;
               seroconversion",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Tarhini2021-pv,
  title     = "Long-term severe acute respiratory syndrome Coronavirus 2
               ({SARS-CoV-2}) infectiousness among three immunocompromised
               patients: From prolonged viral shedding to {SARS-CoV-2}
               superinfection",
  author    = "Tarhini, Hassan and Recoing, Am{\'e}lie and Bridier-Nahmias,
               Antoine and Rahi, Mayda and Lambert, C{\'e}leste and Martres,
               Pascale and Lucet, Jean-Christophe and Rioux, Christophe and
               Bouzid, Donia and Lebourgeois, Samuel and Descamps, Diane and
               Yazdanpanah, Yazdan and Le Hingrat, Quentin and Lescure, Fran{\c
               c}ois-Xavier and Visseaux, Benoit",
  abstract  = "BACKGROUND: Guidelines for stopping coronavirus disease 2019
               patient isolation are mainly symptom-based, with isolation for
               10 to 20 days depending on their condition. METHODS: In this
               study, we describe 3 deeply immunocompromised patients, each
               with different clinical evolutions. We observed (1) the
               patients' epidemiological, clinical, and serological data, (2)
               infectiousness using viral culture, and (3) viral mutations
               accumulated over time. RESULTS: Asymptomatic carriage, symptom
               resolution, or superinfection with a second severe acute
               respiratory syndrome coronavirus 2 strain were observed, all
               leading to prolonged infectious viral shedding for several
               months. CONCLUSIONS: Understanding underlying mechanisms and
               frequency of prolonged infectiousness is crucial to adapt
               current guidelines and strengthen the use of systematic
               polymerase chain reaction testing before stopping isolation in
               immunocompromised populations.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  223,
  number    =  9,
  pages     = "1522--1527",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunocompromised patients; isolation;
               viral shedding",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Weigang2021-st,
  title     = "Within-host evolution of {SARS-CoV-2} in an immunosuppressed
               {COVID-19} patient as a source of immune escape variants",
  author    = "Weigang, Sebastian and Fuchs, Jonas and Zimmer, Gert and
               Schnepf, Daniel and Kern, Lisa and Beer, Julius and Luxenburger,
               Hendrik and Ankerhold, Jakob and Falcone, Valeria and Kemming,
               Janine and Hofmann, Maike and Thimme, Robert and
               Neumann-Haefelin, Christoph and Ulferts, Svenja and Grosse,
               Robert and Hornuss, Daniel and Tanriver, Yakup and Rieg,
               Siegbert and Wagner, Dirk and Huzly, Daniela and Schwemmle,
               Martin and Panning, Marcus and Kochs, Georg",
  abstract  = "The origin of SARS-CoV-2 variants of concern remains unclear.
               Here, we test whether intra-host virus evolution during
               persistent infections could be a contributing factor by
               characterizing the long-term SARS-CoV-2 infection dynamics in an
               immunosuppressed kidney transplant recipient. Applying RT-qPCR
               and next-generation sequencing (NGS) of sequential respiratory
               specimens, we identify several mutations in the viral genome
               late in infection. We demonstrate that a late viral isolate
               exhibiting genome mutations similar to those found in variants
               of concern first identified in UK, South Africa, and Brazil, can
               escape neutralization by COVID-19 antisera. Moreover, infection
               of susceptible mice with this patient's escape variant elicits
               protective immunity against re-infection with either the
               parental virus and the escape variant, as well as high
               neutralization titers against the alpha and beta SARS-CoV-2
               variants, B.1.1.7 and B.1.351, demonstrating a considerable
               immune control against such variants of concern. Upon lowering
               immunosuppressive treatment, the patient generated
               spike-specific neutralizing antibodies and resolved the
               infection. Our results suggest that immunocompromised patients
               could be a source for the emergence of potentially harmful
               SARS-CoV-2 variants.",
  journal   = "Nat. Commun.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  12,
  number    =  1,
  pages     = "6405",
  month     =  nov,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Catalano2021-kf,
  title     = "Preemptive antibody therapy for vaccine breakthrough
               {SARS-CoV-2} infection in immunocompromised patients",
  author    = "Catalano, Concetta and Servais, Sophie and Bonvoisin, Catherine
               and Couturier, Bruno and Hildebrand, Marc and Etienne, Isabelle
               and Meuris, Christelle and Goffard, Jean-Christophe and Wissing,
               Martin and Goldman, Michel and Le Moine, Alain",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  12,
  pages     = "e282",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Harris2021-zf,
  title     = "Management of Crohn's disease in an immunosuppressed
               {COVID-19-positive} patient: safety-driven prioritisation of
               nutritional therapy as a bridge to restarting immunosuppression",
  author    = "Harris, Clare and Harris, Richard James and Downey, Louise and
               Gwiggner, Markus",
  abstract  = "Active inflammatory bowel disease (IBD), combined
               immunosuppression and corticosteroid therapy have all been
               identified as risk factors for a poor outcome in COVID-19
               infection. The management of patients with both COVID-19
               infection and active IBD is therefore complex. We present the
               case of a 31-year-old patient with Crohn's disease, on dual
               immunosuppression with infliximab and mercaptopurine presenting
               with inflammatory small bowel obstruction and COVID-19
               infection. The case highlights the use of nutritional therapy,
               which remains underused in the management of adults with IBD, to
               manage his flare acutely. Following negative SARS-CoV-2 PCR
               testing and SARS-CoV-2 IgG testing confirming an antibody
               response, ustekinumab (anti-interleukin 12/23) was prescribed
               for long-term maintenance.",
  journal   = "BMJ Case Rep.",
  publisher = "BMJ",
  volume    =  14,
  number    =  3,
  pages     = "e239404",
  month     =  mar,
  year      =  2021,
  keywords  = "Crohn's disease; inflammatory bowel disease",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Malle2021-zq,
  title     = "Atypical inflammatory syndrome triggered by {SARS-CoV-2} in
               infants with Down syndrome",
  author    = "Malle, Louise and Bastard, Paul and Martin-Nalda, Andrea and
               Carpenter, Taya and Bush, Douglas and Patel, Roosheel and
               Colobran, Roger and Soler-Palacin, Pere and Casanova,
               Jean-Laurent and Gans, Melissa and Rivi{\`e}re, Jacques G and
               Bogunovic, Dusan",
  abstract  = "While adults with Down syndrome (DS) are at increased risk of
               severe COVID-19 pneumonia, little is known about COVID-19 in
               children with DS. In children without DS, SARS-CoV-2 can rarely
               cause severe COVID-19 pneumonia, or an even rarer and more
               typically pediatric condition, multisystem inflammatory syndrome
               in children (MIS-C). Although the underlying mechanisms are
               still unknown, MIS-C is thought to be primarily immune-mediated.
               Here, we describe an atypical, severe form of MIS-C in two
               infant girls with DS who were hospitalized for over 4 months.
               Immunological evaluation revealed pronounced neutrophilia, B
               cell depletion, increased circulating IL-6 and IL-8, and
               elevated markers of immune activation ICAM1 and FcRI.
               Importantly, uninfected children with DS presented with similar
               but less stark immune features at steady state, possibly
               explaining risk of further uncontrolled inflammation following
               SARS-CoV-2 infection. Overall, a severe, atypical form of MIS-C
               may occur in children with DS.",
  journal   = "J. Clin. Immunol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  7,
  pages     = "1457--1462",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Down syndrome; MIS-C; inborn errors of immunity",
  language  = "en"
}

@ARTICLE{Rodriguez-Espinosa2021-lo,
  title     = "Fatal {SARS-CoV-2} reinfection in an immunosuppressed patient on
               hemodialysis",
  author    = "Rodr{\'\i}guez-Espinosa, Diana and Broseta Monz{\'o}, Jos{\'e}
               Jes{\'u}s and Casals, Quim and Pi{\~n}eiro, Gast{\'o}n J and
               Rodas, Lida and Vera, Manel and Maduell, Francisco",
  journal   = "J. Nephrol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  34,
  number    =  4,
  pages     = "1041--1043",
  month     =  aug,
  year      =  2021,
  keywords  = "Hemodialysis; Immunosuppression; Kidney transplant; Reinfection",
  language  = "en"
}

@ARTICLE{Geisen2021-ya,
  title     = "Immunogenicity and safety of {anti-SARS-CoV-2} {mRNA} vaccines
               in patients with chronic inflammatory conditions and
               immunosuppressive therapy in a monocentric cohort",
  author    = "Geisen, Ulf M and Berner, Dennis K and Tran, Florian and
               S{\"u}mb{\"u}l, Melike and Vullriede, Lena and Ciripoi, Maria
               and Reid, Hayley M and Schaffarzyk, Annika and Longardt, Ann C
               and Franzenburg, Jeanette and Hoff, Paula and Schirmer, Jan H
               and Zeuner, Rainald and Friedrichs, Anette and Steinbach, Andrea
               and Knies, Christine and Markewitz, Robert Dh and Morrison,
               Peter J and Gerdes, Sascha and Schreiber, Stefan and Hoyer,
               Bimba F",
  abstract  = "INTRODUCTION: In light of the SARS-CoV-2 pandemic, protecting
               vulnerable groups has become a high priority. Persons at risk of
               severe disease, for example, those receiving immunosuppressive
               therapies for chronic inflammatory cdiseases (CIDs), are
               prioritised for vaccination. However, data concerning generation
               of protective antibody titres in immunosuppressed patients are
               scarce. Additionally, mRNA vaccines represent a new vaccine
               technology leading to increased insecurity especially in
               patients with CID. OBJECTIVE: Here we present for the first
               time, data on the efficacy and safety of anti-SARS-CoV-2 mRNA
               vaccines in a cohort of immunosuppressed patients as compared
               with healthy controls. METHODS: 42 healthy controls and 26
               patients with CID were included in this study (mean age 37.5 vs
               50.5 years). Immunisations were performed according to national
               guidelines with mRNA vaccines. Antibody titres were assessed by
               ELISA before initial vaccination and 7 days after secondary
               vaccination. Disease activity and side effects were assessed
               prior to and 7 days after both vaccinations. RESULTS:
               Anti-SARS-CoV-2 antibodies as well as neutralising activity
               could be detected in all study participants. IgG titres were
               significantly lower in patients as compared with controls (2053
               binding antibody units (BAU)/mL $\pm$1218 vs 2685$\pm$1102).
               Side effects were comparable in both groups. No severe adverse
               effects were observed, and no patients experienced a disease
               flare. CONCLUSION: We show that SARS-CoV-2 mRNA vaccines lead to
               development of antibodies in immunosuppressed patients without
               considerable side effects or induction of disease flares.
               Despite the small size of this cohort, we were able to
               demonstrate the efficiency and safety of mRNA vaccines in our
               cohort.",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1306--1311",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; arthritis; rheumatoid; tumor necrosis factor
               inhibitors; vaccination",
  language  = "en"
}

@ARTICLE{Moutinho-Pereira2021-wt,
  title     = "High-titre convalescent plasma therapy for an immunocompromised
               patient with systemic lupus erythematosus with protracted
               {SARS-CoV-2} infection",
  author    = "Moutinho-Pereira, Sara and Calisto, Raquel and Sabio, Federico
               and Guerreiro, Lu{\'\i}sa",
  abstract  = "A 39-year-old woman with systemic lupus erythematosus treated
               with anti-CD20 monoclonal antibody rituximab was admitted to our
               hospital with COVID-19 pneumonia. Despite receiving
               dexamethasone, she developed hypoxaemia and persistent lung
               opacities. As bronchoalveolar lavage was suggestive of
               cryptogenic organising pneumonia, high-dose corticosteroid was
               administered, and she received antimicrobial therapy for
               opportunistic infections without improvement. Reverse
               transcription PCR was repeatedly positive for SARS-CoV-2, and
               virus replication was confirmed in cell cultures. As no
               anti-SARS-CoV-2 antibodies were detected more than 100 days
               after symptom onset, she was treated with convalescent plasma
               with fast clinical improvement, returning home days later. Our
               case shows that persistent SARS-CoV-2 infection in an
               immunocompromised patient may be overturned with the appropriate
               treatment.",
  journal   = "BMJ Case Rep.",
  publisher = "BMJ",
  volume    =  14,
  number    =  8,
  pages     = "e244853",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; biological agents; respiratory system; systemic lupus
               erythematosus",
  language  = "en"
}

@ARTICLE{Alhumaid2021-lv,
  title     = "Extracorporeal membrane oxygenation support for {SARS-CoV-2}: a
               multi-centered, prospective, observational study in critically
               ill 92 patients in Saudi Arabia",
  author    = "Alhumaid, Saad and Al Mutair, Abbas and Alghazal, Header A and
               Alhaddad, Ali J and Al-Helal, Hassan and Al Salman, Sadiq A and
               Alali, Jalal and Almahmoud, Sana and Alhejy, Zulfa M and
               Albagshi, Ahmad A and Muhammad, Javed and Khan, Amjad and
               Sulaiman, Tarek and Al-Mozaini, Maha and Dhama, Kuldeep and
               Al-Tawfiq, Jaffar A and Rabaan, Ali A",
  abstract  = "BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has been
               used as a rescue strategy in patients with severe with acute
               respiratory distress syndrome (ARDS) due to SARS-CoV-2
               infection, but there has been little evidence of its efficacy.
               OBJECTIVES: To describe the effect of ECMO rescue therapy on
               patient-important outcomes in patients with severe SARS-CoV-2.
               METHODS: A case series study was conducted for the
               laboratory-confirmed SARS-CoV-2 patients who were admitted to
               the ICUs of 22 Saudi hospitals, between March 1, 2020, and
               October 30, 2020, by reviewing patient's medical records
               prospectively. RESULTS: ECMO use was associated with higher
               in-hospital mortality (40.2\% vs. 48.9\%; p = 0.000); lower
               COVID-19 virological cure (41.3\% vs 14.1\%, p = 0.000); and
               longer hospitalization (20.2 days vs 29.1 days; p = 0.000), ICU
               stay (12.6 vs 26 days; p = 0.000) and mechanical ventilation use
               (14.2 days vs 22.4 days; p = 0.000) compared to non-ECMO group.
               Also, there was a high number of patients with septic shock
               (19.6\%) and multiple organ failure (10.9\%); and more
               complications occurred at any time during hospitalization
               [pneumothorax (5\% vs 29.3\%, p = 0.000), bleeding requiring
               blood transfusion (7.1\% vs 38\%, p = 0.000), pulmonary embolism
               (6.4\% vs 15.2\%, p = 0.016), and gastrointestinal bleeding
               (3.3\% vs 8.7\%, p = 0.017)] in the ECMO group. However, PaO2
               was significantly higher in the 72-h post-ECMO initiation group
               and PCO2 was significantly lower in the 72-h post-ECMO start
               group than those in the 12-h pre-ECMO group (62.9 vs. 70 mmHg, p
               = 0.002 and 61.8 vs. 51 mmHg, p = 0.042, respectively).
               CONCLUSION: Following the use of ECMO, the mortality rate of
               patients and length of ICU and hospital stay were not improved.
               However, these findings need to be carefully interpreted, as
               most of our cohort patients were relatively old and had multiple
               severe comorbidities. Future randomized trials, although
               challenging to conduct, are highly needed to confirm or dispute
               reported observations.",
  journal   = "Eur. J. Med. Res.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  26,
  number    =  1,
  pages     = "141",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; Clinical; ECMO; Extracorporeal; Membrane; Mortality;
               Outcomes; Oxygenation; SARS-CoV-2; Saudi Arabia",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Wang2021-dg,
  title     = "A patient with end-stage renal disease who recovered from
               coronavirus disease 2019 then received a kidney transplant",
  author    = "Wang, Tianyu and Qiu, Tao and Wang, Ming and Yuan, Yan and Chen,
               Zhongbao and Ma, Xiaoxiong and Zhang, Long and Zou, Jilin and
               Jin, Zeya and Xu, Yu and Zhang, Yalong and Zhou, Jiangqiao",
  abstract  = "Since its emergence in December 2019 many end-stage renal
               disease (ESRD) patients have been infected with coronavirus
               disease 2019 (COVID-19). Herein, we describe the case of an ESRD
               patient who received a kidney transplant after recovering from
               COVID-19. We described the clinical course of COVID-19 and
               kidney transplant management, including the patient's symptoms,
               laboratory results, computed tomography, and antibody profiles.
               He recovered well, without complications. Chest computed
               tomography, PCR, and IgG results indicated no recurrence of
               COVID-19 during the subsequent two weeks. Therefore, kidney
               transplantation is feasible in an ESRD patient who has recovered
               from COVID-19, under a normal immunosuppressive regimen.",
  journal   = "Transpl. Immunol.",
  publisher = "Elsevier BV",
  volume    =  67,
  number    =  101395,
  pages     = "101395",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; End stage renal disease; IgG titer; Kidney
               transplantation",
  language  = "en"
}

@ARTICLE{Loubet2021-uz,
  title     = "A French cohort for assessing {COVID-19} vaccine responses in
               specific populations",
  author    = "Loubet, Paul and Wittkop, Linda and Tartour, Eric and Parfait,
               Beatrice and Barrou, Benoit and Blay, Jean-Yves and Hourmant,
               Maryvonne and Lach{\^a}tre, Marie and Laplaud, David-Axel and
               Laville, Martine and Laviolle, Bruno and Lelievre, Jean-Daniel
               and Morel, Jacques and Nguyen, St{\'e}phanie and Spano,
               Jean-Philippe and Terrier, Benjamin and Thiebaut, Anne and
               Viallard, Jean-Francois and Vrtovsnik, Fran{\c c}ois and de
               Lamballerie, Xavier and Launay, Odile",
  journal   = "Nat. Med.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  27,
  number    =  8,
  pages     = "1319--1321",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Watchmaker2022-gg,
  title     = "Brain death in a vaccinated patient with {COVID-19} infection",
  author    = "Watchmaker, Jennifer M and Belani, Puneet B",
  abstract  = "We present a case of brain death in a vaccinated,
               immunocompromised patient who presented with COVID-19 pneumonia.
               Imaging was characterized by diffuse cerebral edema,
               pseudo-subarachnoid hemorrhage, and no antegrade flow above the
               terminal internal carotid arteries. To our knowledge, this is
               the first case report with such findings in a vaccinated
               patient.",
  journal   = "Clin. Imaging",
  publisher = "Elsevier BV",
  volume    =  81,
  pages     = "92--95",
  month     =  jan,
  year      =  2022,
  keywords  = "Brain death; COVID-19; Immunocompromised; Neuroradiology;
               Systemic lupus erythematosus",
  language  = "en"
}

@ARTICLE{Mansoor2021-bu,
  title     = "Clinical characteristics, hospitalization, and mortality rates
               of Coronavirus disease 2019 among liver transplant patients in
               the United States: A multicenter research network study",
  author    = "Mansoor, Emad and Perez, Abe and Abou-Saleh, Mohannad and
               Sclair, Seth N and Cohen, Stanley and Cooper, Gregory S and
               Mills, Alexandra and Schlick, Kayla and Khan, Ahmad",
  journal   = "Gastroenterology",
  publisher = "Elsevier BV",
  volume    =  160,
  number    =  1,
  pages     = "459--462.e1",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; Liver Transplant; Mortality",
  language  = "en"
}

@ARTICLE{Liu2021-vd,
  title     = "Homecare encounters: An organizational response to innovative
               care for patients undergoing hematopoietic stem cell
               transplantation during {COVID-19}",
  author    = "Liu, Joann and Allen, Deborah Hutch and Lassiter, Martha and
               Cao, Felicia and Sung, Anthony D and Chao, Nelson J",
  abstract  = "BACKGROUND: Healthcare delivery has been significantly changed
               because of the COVID-19 pandemic. Patients undergoing
               hematopoietic stem cell transplantation (HSCT) are vulnerable to
               infections because of their immunocompromised status. The risk
               of nosocomial infection may be reduced by providing care to
               patients at home. OBJECTIVES: This article describes one cancer
               center's approach for delivering safe patient care through
               homecare encounters, the benefits of home care for HSCT, and
               future directions. METHODS: Patients received detailed
               information on home encounters. Advanced practice providers
               visited patients daily and then returned to the clinic to
               formulate a plan of care with the interprofessional care team.
               Transplantation RNs visited patients on the same day to provide
               the prescribed care. FINDINGS: Based on evaluations from 32
               patients and 12 providers, the results indicated that home care
               was safe, feasible, and beneficial for patient care post-HSCT
               during the COVID-19 pandemic.",
  journal   = "Clin. J. Oncol. Nurs.",
  publisher = "Oncology Nursing Society (ONS)",
  volume    =  25,
  number    =  4,
  pages     = "457--464",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; hematopoietic stem cell transplantation; home care;
               home encounters",
  language  = "en"
}

@ARTICLE{Ramirez-Sanchez2021-vc,
  title     = "A unique case of Miller {Fisher-Guillain-Barr{\'e}} overlap
               syndrome in a liver transplant recipient",
  author    = "Ramirez-Sanchez, Claudia and Syed, Rehan and Meier, Angela and
               LaBuzetta, Jamie Nicole and Hylton, Diana J and Taremi, Mahnaz",
  abstract  = "Guillain-Barr{\'e} syndrome (GBS) is an ascending demyelinating
               polyneuropathy often associated with recent infection. Miller
               Fisher syndrome represents a variant with predominant facial and
               cranial nerve involvement, although Miller Fisher and
               Guillain-Barr{\'e} overlap syndromes can occur.
               Guillain-Barr{\'e} spectrum syndromes have been thought to be
               rare among solid organ transplant recipients. We describe an
               immunocompromised patient with a liver transplant who presented
               with ophthalmoplegia and bulbar deficits. His symptoms rapidly
               progressed to a state of descending paralysis involving the
               diaphragm; he then developed acute respiratory failure and
               eventually developed quadriparesis. Electromyography and a nerve
               conduction study demonstrated a severe sensorimotor axonal
               polyneuropathy consistent with Miller Fisher variant
               Guillain-Barr{\'e} syndrome. Despite several negative
               nasopharyngeal swabs for COVID-19 polymerase chain reaction, a
               serology for SARS-CoV-2 IgG was positive. He was diagnosed with
               Miller Fisher-Guillain-Barr{\'e} overlap syndrome with rapid
               recovery following treatment with plasma exchange. Although
               Guillain-Barr{\'e} is a rare complication in solid organ
               transplant recipients, this case highlights the importance of
               rapid diagnosis and treatment of neurologic complications in
               transplant patients. Furthermore, it demonstrates a possible
               case of neurological complications from COVID-19 infection.",
  journal   = "J. Neurovirol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  27,
  number    =  5,
  pages     = "797--801",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Descending paralysis; Guillain-Barr{\'e} Syndrome;
               Liver transplantation; Miller Fisher syndrome",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Solanich2021-av,
  title     = "Pre-existing autoantibodies neutralizing high concentrations of
               type {I} interferons in almost 10\% of {COVID-19} patients
               admitted to intensive care in Barcelona",
  author    = "Solanich, Xavier and Rigo-Bonnin, Ra{\'u}l and Gumucio,
               Victor-David and Bastard, Paul and Rosain, J{\'e}r{\'e}mie and
               Philippot, Quentin and Perez-Fernandez, Xos{\'e}-Luis and
               Fuset-Cabanes, Maria-Paz and Gordillo-Benitez, Miguel-{\'A}ngel
               and Suarez-Cuartin, Guillermo and Boza-Hernandez, Enric and
               Riera-Mestre, Antoni and Parra-Mart{\'\i}nez, Alba and Colobran,
               Roger and Antol{\'\i}, Arnau and Navarro, Sergio and
               Rocamora-Blanch, Gemma and Framil, Mario and Calatayud, Laura
               and Corbella, Xavier and Casanova, Jean-Laurent and Morandeira,
               Francisco and Sabater-Riera, Joan",
  abstract  = "BACKGROUND: It is important to predict which patients infected
               by SARS-CoV-2 are at higher risk of life-threatening COVID-19.
               Several studies suggest that neutralizing auto-antibodies
               (auto-Abs) against type I interferons (IFNs) are predictive of
               critical COVID-19 pneumonia. OBJECTIVES: We aimed to test for
               auto-Abs to type I IFN and describe the main characteristics of
               COVID-19 patients admitted to intensive care depending on
               whether or not these auto-Abs are present. METHODS:
               Retrospective analysis of all COVID-19 patients admitted to an
               intensive care unit (ICU) in whom samples were available, from
               March 2020 to March 2021, in Barcelona, Spain. RESULTS: A total
               of 275 (70.5\%) out of 390 patients admitted to ICU were tested
               for type I IFNs auto-antibodies ($\alpha$2 and/or $\omega$) by
               ELISA, being positive in 49 (17.8\%) of them. Blocking activity
               of plasma diluted 1/10 for high concentrations (10 ng/mL) of
               IFNs was proven in 26 (9.5\%) patients. Almost all the patients
               with neutralizing auto-Abs were men (92.3\%). ICU patients with
               positive results for neutralizing IFNs auto-Abs did not show
               relevant differences in demographic, comorbidities, clinical
               features, and mortality, when compared with those with negative
               results. Nevertheless, some laboratory tests (leukocytosis,
               neutrophilia, thrombocytosis) related with COVID-19 severity, as
               well as acute kidney injury (17 [65.4\%] vs. 100 [40.2\%]; p =
               0.013) were significantly higher in patients with auto-Abs.
               CONCLUSION: Auto-Abs neutralizing high concentrations of type I
               IFNs were found in 9.5\% of patients admitted to the ICU for
               COVID-19 pneumonia in a hospital in Barcelona. These auto-Abs
               should be tested early upon diagnosis of SARS-CoV-2 infection,
               as they account for a significant proportion of life-threatening
               cases.",
  journal   = "J. Clin. Immunol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  8,
  pages     = "1733--1744",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; acute kidney injury; auto-antibodies; type
               I interferons",
  language  = "en"
}

@ARTICLE{Querido2021-hb,
  title     = "Kinetics of torquetenovirus {DNA} load in a recent kidney
               transplant recipient with mild {SARS-CoV-2} infection and a
               failed antibody response",
  author    = "Querido, Sara and Cal{\c c}a, Rita and Weigert, Andr{\'e} and
               Francisco, Diogo and Adrag{\~a}o, Teresa and Ana Pessanha, Maria
               and Gomes, Perp{\'e}tua and Rodrigues, Lu{\'\i}s and Figueira,
               Jo{\~a}o M and Cardoso, Concei{\c c}{\~a}o and Machado, Domingos",
  abstract  = "Kidney transplant (KT) recipients are at an increased risk for
               severe COVID-19 because of their immunosuppressed state. A
               42-year-old KT patient was diagnosed with COVID-19 three months
               after KT. Despite lymphopenia and several risk factors, he had a
               mild disease course. Nasopharyngeal real-time reverse
               transcriptase polymerase chain reaction for SARS-CoV-2 became
               negative 48 days after detection. SARS-CoV-2 IgG antibodies
               became negative after day 40. TTV DNA load increased with the
               onset COVID-19 and reduced after its resolution. This is the
               first report where TTV DNA load was measured during the course
               of COVID-19.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  2,
  pages     = "e13524",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; kidney transplant; torquetenovirus",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Bachelet2021-ry,
  title     = "Humoral response after {SARS-CoV-2} {mRNA} vaccines in dialysis
               patients: Integrating {anti-SARS-CoV-2} {Spike-Protein-RBD}
               antibody monitoring to manage dialysis centers in pandemic times",
  author    = "Bachelet, Thomas and Bourdenx, Jean-Philippe and Martinez,
               Charlie and Mucha, Simon and Martin-Dupont, Philippe and Perier,
               Valerie and Pommereau, Antoine",
  abstract  = "Dialysis patients are both the most likely to benefit from
               vaccine protection against SARS-CoV-2 and at the highest risk of
               not developing an immune response. Data from the medical field
               are thus mandatory. We report our experience with a
               BNT162b2-mRNA vaccine in a retrospective analysis of 241
               dialysis patients including 193 who underwent
               anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis.
               We show that a pro-active vaccine campaign is effective in
               convincing most patients to be vaccinated (95\%) and frequently
               elicits a specific antibody response (94.3\% after two doses and
               98.4\% after three doses). Only immunocompromised Status is
               associated with lack of seroconversion (OR 7.6 [1.5-38.2], p =
               0.02). We also identify factors associated with low response
               (last quartile; IgG7000AU/mL): age; previous SARS-CoV-2
               infection and active Cancer. From this experience, we propose a
               strategy integrating anti-spike IgG monitoring to guide
               revaccination and dialysis center management in pandemic times.",
  journal   = "PLoS One",
  publisher = "Public Library of Science (PLoS)",
  volume    =  16,
  number    =  10,
  pages     = "e0257646",
  month     =  oct,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Gupta2021-up,
  title     = "Robust and sustained antibody response to {SARS-CoV-2} in a
               child pre and post autologous hematopoietic stem cell transplant",
  author    = "Gupta, Aditya Kumar and Ramachandran, Mohanraj and Meena,
               Jagdish Prasad and Dwivedi, Tanima and Singh, Urvashi and Gupta,
               Ritu and Seth, Rachna",
  journal   = "Pediatr. Blood Cancer",
  publisher = "Wiley",
  volume    =  68,
  number    =  5,
  pages     = "e28848",
  month     =  may,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Pandrowala2021-rf,
  title     = "{SARS-CoV-2-related} multisystem inflammatory syndrome in an
               immunocompromised child with leukemia",
  author    = "Pandrowala, Ambreen and Panchal, Honey and Mudaliar, Sangeeta
               and Bodhanwala, Minnie and Prabhu, Shakuntala and Jain, Shreepal
               and Mishra, Jayashree and Hiwarkar, Prashant",
  journal   = "Pediatr. Blood Cancer",
  publisher = "Wiley",
  volume    =  68,
  number    =  7,
  pages     = "e28995",
  month     =  jul,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Mallett2021-ty,
  title     = "Peak moments - when kindergarten is high risk",
  author    = "Mallett, Sasha D",
  journal   = "N. Engl. J. Med.",
  publisher = "Massachusetts Medical Society",
  volume    =  385,
  number    =  17,
  pages     = "1543--1545",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Lucchini2021-xy,
  title     = "{COVID-19} infection in paediatric recipients of allogeneic stem
               cell transplantation: the {UK} experience",
  author    = "Lucchini, Giovanna and Furness, Caroline and Lawson, Sarah and
               Gibson, Brenda and Wynn, Robert and Slatter, Mary and Shillitoe,
               Ben and James, Beki and Carpenter, Ben and Hough, Rachael and
               Amrolia, Persis and de la Fuente, Josu and {UK and Ireland
               Paediatric BMT Group}",
  abstract  = "Data defining the clinical course of COVID19 infection in HSCT
               recipients are limited. We assessed the impact of COVID19 on
               paediatric HSCT recipients in the UK between February and June
               2020. Nine patients developed COVID 19 proven infection at a
               median time of 62 days post-transplant. Presenting symptoms were
               mostly fevers and cough. One case had a severe course, requiring
               non-invasive ventilation and receiving dexamethasone,
               tocilizumab, remdesivir. No patients died from COVID19. Two
               patients developed significant complications following COVID19
               disease. Our data describe a relative mild infection course in
               HSCT recipients but highlight potential infectious triggered
               complications.",
  journal   = "Br. J. Haematol.",
  publisher = "Wiley",
  volume    =  194,
  number    =  4,
  pages     = "e74--e77",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19 infection; COVID-19 outcomes; Immunosuppression;
               paediatric allogeneic stem cell transplantation",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Marion2021-xj,
  title    = "Safety and immunogenicity of {anti-SARS-CoV-2} messenger {RNA}
              vaccines in recipients of solid organ transplants",
  author   = "Marion, Olivier and Del Bello, Arnaud and Abravanel, Florence and
              Couat, Chlo{\'e} and Faguer, Stanislas and Esposito, Laure and
              Hebral, Anne Laure and Izopet, Jacques and Kamar, Nassim",
  journal  = "Ann. Intern. Med.",
  volume   =  174,
  number   =  9,
  pages    = "1336--1338",
  month    =  sep,
  year     =  2021,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Harrington2021-gi,
  title     = "Single dose of {BNT162b2} {mRNA} vaccine against severe acute
               respiratory syndrome coronavirus-2 ({SARS-CoV-2}) induces
               neutralising antibody and polyfunctional T-cell responses in
               patients with chronic myeloid leukaemia",
  author    = "Harrington, Patrick and Doores, Katie J and Radia, Deepti and
               O'Reilly, Amy and Lam, Ho Pui Jeff and Seow, Jeffrey and Graham,
               Carl and Lechmere, Thomas and McLornan, Donal and Dillon,
               Richard and Shanmugharaj, Yogita and Espehana, Andreas and
               Woodley, Claire and Saunders, Jamie and Curto-Garcia, Natalia
               and O'Sullivan, Jennifer and Raj, Kavita and Kordasti, Shahram
               and Malim, Michael H and Harrison, Claire and de Lavallade,
               Hugues",
  abstract  = "Patients receiving targeted cancer treatments such as tyrosine
               kinase inhibitors (TKIs) have been classified in the clinically
               extremely vulnerable group to develop severe acute respiratory
               syndrome coronavirus-2 (SARS-CoV-2), including patients with
               chronic myeloid leukaemia (CML) taking TKIs. In addition,
               concerns that immunocompromised individuals with solid and
               haematological malignancies may not mount an adequate immune
               response to a single dose of SARS-CoV-2 BNT162b2
               (Pfizer-BioNTech) vaccine have been raised. In the present
               study, we evaluated humoral and cellular immune responses after
               a first injection of BNT162b2 vaccine in 16 patients with CML.
               Seroconversion and cellular immune response before and after
               vaccination were assessed. By day 21 after vaccination,
               anti-Spike immunoglobulin G was detected in 14/16 (875\%) of
               the patients with CML and all developed a neutralising antibody
               response [serum dilution that inhibits 50\% infection (ID50 )
               >50], including medium (ID50 of 200-500) or high (ID50 of
               501-2000) neutralising antibodies titres in nine of the 16
               (5625\%) patients. T-cell response was seen in 14/15 (933\%)
               evaluable patients, with polyfunctional responses seen in 12/15
               (80\%) patients (polyfunctional CD4+ response nine of 15,
               polyfunctional CD8+ T-cell response nine of 15). These data
               demonstrate the immunogenicity of a single dose of SARS-CoV-2
               BNT162b2 vaccine in most patients with CML, with both
               neutralising antibodies and polyfunctional T-cell responses seen
               in contrast to patients with solid tumour or lymphoid
               haematological malignancies.",
  journal   = "Br. J. Haematol.",
  publisher = "Wiley",
  volume    =  194,
  number    =  6,
  pages     = "999--1006",
  month     =  sep,
  year      =  2021,
  keywords  = "BNT162b2 vaccine; SARS-CoV2 vaccine; chronic myeloid leukaemia;
               tyrosine kinase inhibitor",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Pb2021-us,
  title     = "Acute hypoxemia due to lung collapse in {COVID-19}: the role of
               therapeutic bronchoscopy",
  author    = "Pb, Sryma and Madan, Karan and Mohan, Anant and Hadda, Vijay and
               Tiwari, Pawan and Guleria, Randeep and Mittal, Saurabh",
  abstract  = "Bronchoscopy is an aerosol-generating procedure and involves a
               high risk of transmission of SARS-CoV-2 to health care workers.
               There are very few indications for performing bronchoscopy in a
               patient with confirmed COVID-19. These include atelectasis,
               foreign body aspiration, and suspected superinfection in
               immunocompromised patients. Proper use of standard personal
               protective equipment is mandatory to reduce the risk of
               transmission to health care workers. In this article, we
               describe a case of acute lung collapse in a 16-year-old boy with
               cerebral palsy who was infected with COVID-19. This patient
               responded to therapeutic bronchoscopy and had complete
               resolution of lung collapse within 24 hours of the procedure.",
  journal   = "Adv. Respir. Med.",
  publisher = "VM Media SP. zo.o VM Group SK",
  volume    =  89,
  number    =  4,
  pages     = "448--450",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; atelectasis; bronchoscopy",
  language  = "en"
}

@ARTICLE{Deng2021-ps,
  title     = "Breakthrough infections with multiple lineages of {SARS-CoV-2}
               variants reveals continued risk of severe disease in
               immunosuppressed patients",
  author    = "Deng, Xufang and Evdokimova, Monika and O'Brien, Amornrat and
               Rowe, Cynthia L and Clark, Nina M and Harrington, Amanda and
               Reid, Gail E and Uprichard, Susan L and Baker, Susan C",
  abstract  = "The pandemic of COVID-19 caused by SARS-CoV-2 infection
               continues to spread around the world. Vaccines that elicit
               protective immunity have reduced infection and mortality,
               however new viral variants are arising that may evade
               vaccine-induced immunity or cause disease in individuals who are
               unable to develop robust vaccine-induced responses.
               Investigating the role of viral variants in causing severe
               disease, evading vaccine-elicited immunity, and infecting
               vulnerable individuals is important for developing strategies to
               control the pandemic. Here, we report fourteen breakthrough
               infections of SARS-CoV-2 in vaccinated individuals with symptoms
               ranging from asymptomatic/mild (6/14) to severe disease (8/14).
               High viral loads with a median Ct value of 19.6 were detected in
               the nasopharyngeal specimens from subjects regardless of disease
               severity. Sequence analysis revealed four distinct virus
               lineages, including alpha and gamma variants of concern.
               Immunosuppressed individuals were more likely to be hospitalized
               after infection (p = 0.047), however no specific variant was
               associated with severe disease. Our results highlight the high
               viral load that can occur in asymptomatic breakthrough
               infections and the vulnerability of immunosuppressed individuals
               to post-vaccination infections by diverse variants of
               SARS-CoV-2.",
  journal   = "Viruses",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  9,
  pages     = "1743",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; breakthrough infections;
               immunosuppression; post-vaccination infections; variants of
               concern",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Nevermann2021-de,
  title     = "Transplantation programs facing lack of empirical evidence on
               {SARS-CoV-2} vaccination: A society recommendation consensus
               update",
  author    = "Nevermann, Nora and Wiering, Leke and Wu, Helen and Moroder,
               Philipp and Brandl, Andreas and Globke, Brigitta and Krenzien,
               Felix and Raschzok, Nathanael and Sch{\"o}ning, Wenzel and
               Lurje, Georg and {\"O}llinger, Robert and Schmelzle, Moritz and
               Pratschke, Johann and Ritschl, Paul Viktor",
  abstract  = "BACKGROUND: Since phase III trials for the most prominent
               vaccines excluded immunocompromised or immunosuppressed
               patients, data on safety and efficacy of SARS-CoV-2 vaccines for
               recipients of solid organ transplantations are scarce. AIMS: Our
               study offers a synthesis of expert opinions aligned with
               available data addressing key questions of the clinical
               management of SARS-CoV-2 vaccinations for transplant patients.
               METHOD: An online research was performed retrieving available
               recommendations by national and international transplantation
               organizations and state institutions on SARS-CoV2 vaccination
               management for transplant recipients. RESULTS: Eleven key
               statements were identified from recommendations by 18 national
               and international societies, and consensus for the individual
               statements was evaluated by means of the Society Recommendation
               Consensus score. The highest consensus level (SRC A) was found
               for prioritized access to vaccination for transplant patients
               despite anticipation of a weakened immune response. All
               currently authorized vaccines can be considered safe for
               transplant patients (SRC A). The handling of immunosuppressive
               medication, the timely management of vaccines, and other aspects
               were aligned with available expert opinions. CONCLUSION: Expert
               consensus can be determined for crucial aspects of the
               implementation of SARS-CoV-2 vaccination programs. We hereby
               offer a tool for immediate decision-making until empirical data
               becomes available.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  4,
  pages     = "e13696",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2 vaccination; solid organ transplantation",
  copyright = "http://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Naghashzadeh2021-oa,
  title     = "Coronavirus disease 2019 outcomes in heart transplant
               recipients: a single-center case series",
  author    = "Naghashzadeh, Farah and Shafaghi, Shadi and Sharif-Kashani,
               Babak and Tabarsi, Payam and Saliminejad, Leila and Noorali,
               Sima",
  abstract  = "BACKGROUND: With the rapidly expanding pandemic of severe acute
               respiratory syndrome coronavirus-2, a chronic immunosuppressed
               state in solid organ transplant recipients is a concern. We
               reported coronavirus disease 2019 in heart transplant recipients
               and described the patients' course from diagnosis to either
               hospital admission or improvement in symptoms. CASE
               PRESENTATION: This study retrospectively identified 13 white
               (Iranian) heart transplant patients with coronavirus disease
               2019 between December 2019 and October 2020. The mean age of
               patients was 43.7 years (19-65 years); seven (70\%) were men.
               Laboratory and treatment data were collected for those admitted
               or managed as outpatients. Outcomes were also recorded for all
               patients. This report demonstrates a range of symptoms, clinical
               severity, and disease course in heart transplant recipients with
               coronavirus disease 2019, including ten hospitalized patients
               and three patients, managed entirely in the outpatient setting.
               One patient passed away, and none of them experienced an episode
               of clinically overt rejection. CONCLUSIONS: We would like to
               emphasize the importance of being alert in these patients to
               consider testing in a broad range of clinical presentations and
               gathering more data for better management.",
  journal   = "J. Med. Case Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  15,
  number    =  1,
  pages     = "453",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; Heart transplantation; Immunosuppression; Solid-organ
               transplantation",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Napiorkowska-Baran2021-ur,
  title     = "A multicenter survey on the aspects of everyday life in adult
               patients with primary antibody deficiencies treated with
               immunoglobulin {G} replacement during the {COVID-19} pandemic",
  author    = "Napi{\'o}rkowska-Baran, Katarzyna and Rosada, Tomasz and Wi{\k
               e}sik-Szewczyk, Ewa and Zi{\k e}tkiewicz, Marcin and
               Matyja-Bednarczyk, Aleksandra and Baranowska, Karolina and
               Alska, Ewa and Tykwi{\'n}ska, Marta and Szynkiewicz, Ewa and
               Zacniewski, Robert and Grochowalska, Kinga and Bartuzi, Zbigniew",
  abstract  = "INTRODUCTION: The COVID-19 pandemic has changed many aspects of
               everyday life. Patients with primary immunodeficiency (PID) are
               in a particularly difficult situation. The purpose of the
               present study was to contribute to the very limited research on
               the everyday aspects of functioning in PID patients during the
               COVID-19 pandemic. METHODS: The survey included 85 adult PID
               patients treated with immunoglobulin replacement therapy in four
               reference centers for immunology. Everyday functioning of the
               patients as well as their opinion concerning new solutions in
               medical care were analyzed. RESULTS: During the pandemic, the
               percentage of patients experiencing fear/anxiety has increased
               from 47\% to 70\%. The wide dissemination of information about
               the SARS-CoV-2 in the media has increased anxiety in 40\% of the
               patients. Patients diagnosed with PID were most afraid of the
               exposure to contact with strangers, especially in public places.
               As many as 67 respondents (79\%) considered the introduction of
               restrictions concerning social functioning as good. Only every
               fifth person learned about the pandemic from reliable sources.
               Eighty three percent of the patients receiving immunoglobulin
               substitution experienced less fear of SARS-CoV-2 infection. The
               patients positively evaluated the solutions related to the
               direct delivery of drugs to the place of residence in order to
               continue home IgRT therapy. Fifty three respondents (62.5\%)
               believed that the possibility of a remote consultation was a
               very good solution. CONCLUSION: It is necessary to increase
               educational activities concerning the pandemic provided by
               health care professionals, as patients obtain information mainly
               from the media and the Internet, which adversely affects the
               feeling of anxiety. The pandemic, in addition to the very
               negative impact on patients and the deterioration of their daily
               functioning, has made patients appreciate their life more,
               devote more time to family and friends, and do things they like.",
  journal   = "Int. J. Immunopathol. Pharmacol.",
  publisher = "SAGE Publications",
  volume    =  35,
  pages     = "20587384211044344",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; adult; anxiety; fear; immunoglobulin
               treatment; medical care; primary antibody deficiency; primary
               immunodeficiencies; quality of life",
  language  = "en"
}

@ARTICLE{Erlichster2021-qx,
  title     = "Pan-family assays for rapid viral screening: Reducing delays in
               public health responses during pandemics",
  author    = "Erlichster, Michael and Chana, Gursharan and Zantomio, Daniela
               and Goudey, Benjamin and Skafidas, Efstratios",
  abstract  = "BACKGROUND: Coronavirus disease 2019 has highlighted
               deficiencies in the testing capacity of many developed countries
               during the early stages of pandemics. Here we describe a
               strategy using pan-family viral assays to improve early
               accessibility of large-scale nucleic acid testing. METHODS:
               Coronaviruses and severe acute respiratory syndrome coronavirus
               2 (SARS-CoV-2) were used as a case study for assessing utility
               of pan-family viral assays during the early stages of a novel
               pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for a
               novel pathogen was assessed using the frequency of common human
               coronavirus (HCoV) species in key populations. A reported
               Pan-CoV assay was assessed to determine sensitivity to 60
               reference coronaviruses, including SARS-CoV-2. The resilience of
               the primer target regions of this assay to mutation was assessed
               in 8893 high-quality SARS-CoV-2 genomes to predict ongoing
               utility during pandemic progression. RESULTS: Because of common
               HCoV species, a Pan-CoV assay would return false positives for
               as few as 1\% of asymptomatic adults, but up to 30\% of
               immunocompromised patients with respiratory disease. One-half of
               reported Pan-CoV assays identify SARS-CoV-2 and with small
               adjustments can accommodate diverse variation observed in animal
               coronaviruses. The target region of 1 well-established Pan-CoV
               assay is highly resistant to mutation compared to
               species-specific SARS-CoV-2 reverse transcriptase-polymerase
               chain reaction assays. CONCLUSIONS: Despite cross-reactivity
               with common pathogens, pan-family assays may greatly assist
               management of emerging pandemics through prioritization of
               high-resolution testing or isolation measures. Targeting highly
               conserved genomic regions make pan-family assays robust and
               resilient to mutation. A strategic stockpile of pan-family
               assays may improve containment of novel diseases before the
               availability of species-specific assays.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  73,
  number    =  9,
  pages     = "e3047--e3052",
  month     =  nov,
  year      =  2021,
  keywords  = "SARS-CoV-2; pan-family assays; viral screening",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Bou-Fakhredin2021-fh,
  title     = "{SARS-CoV-2} infection in patients with $\beta$-thalassemia:
               Experience from Lebanon",
  author    = "Bou-Fakhredin, Rayan and Daadaa, Hisham and Koussa, Suzanne and
               Abou Nasr, Therese and Noun, Peter and Taher, Ali T",
  journal   = "Am. J. Hematol.",
  publisher = "Wiley",
  volume    =  96,
  number    =  8,
  pages     = "E285--E288",
  month     =  aug,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Hugo2021-xn,
  title     = "Response to Invited Commentary ``Undoubtedly, kidney transplant
               recipients have a higher mortality due to {COVID-19} disease
               compared to the general population''",
  author    = "Hugo, Christian and Vehreschild, J{\"o}rg and Stecher, Melanie",
  journal   = "Transpl. Int.",
  publisher = "Wiley",
  volume    =  34,
  number    =  5,
  pages     = "771--773",
  month     =  may,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Kow2021-hl,
  title     = "Real-world effectiveness of {BNT162b2} {mRNA} vaccine: a
               meta-analysis of large observational studies",
  author    = "Kow, Chia Siang and Hasan, Syed Shahzad",
  abstract  = "This paper aims to summarize through meta-analyses the overall
               vaccine effectiveness of the BNT162b2 mRNA vaccine from
               observational studies. A systematic literature search with no
               language restriction was performed in electronic databases to
               identify eligible observational studies which reported the
               adjusted effectiveness of the BNT162b2 mRNA vaccine to prevent
               RT-PCR confirmed COVID-19. Meta-analyses with the random-effects
               model were used to calculate the pooled hazard ratio (HR) and
               pooled incidence rate ratio (IRR) at 95\% confidence intervals,
               and the vaccine effectiveness was indicated as (pooled HR -
               1)/HR or (pooled IRR - 1)/IRR. Nineteen studies were included
               for this meta-analysis. The meta-analysis revealed significant
               protective effect against RT-PCR confirmed COVID-19 $\geq$ 14
               days after the first dose, with vaccine effectiveness of 53\%
               (95\% confidence interval 32-68\%), and $\geq$ 7 days after the
               second dose, with vaccine effectiveness of 95\% (95\% confidence
               interval: 96-97\%). Despite its effectiveness, reporting vaccine
               safety data by relevant stakeholders should be encouraged as
               BNT162b2 mRNA is a new vaccine that has not gained full
               approval. There have been limited data about vaccine
               effectiveness among immunocompromised patients; thus, the
               vaccine should be used cautiously in this patient population.",
  journal   = "Inflammopharmacology",
  publisher = "Springer Science and Business Media LLC",
  volume    =  29,
  number    =  4,
  pages     = "1075--1090",
  month     =  aug,
  year      =  2021,
  keywords  = "BNT162b2; COVID-19; Real world; SARS-CoV-2; Vaccine",
  language  = "en"
}

@ARTICLE{Irsara2021-mi,
  title     = "Evaluation of four commercial, fully automated {SARS-CoV-2}
               antibody tests suggests a revision of the Siemens {SARS-CoV-2}
               {IgG} assay",
  author    = "Irsara, Christian and Egger, Alexander E and Prokop, Wolfgang
               and Nairz, Manfred and Loacker, Lorin and Sahanic, Sabina and
               Pizzini, Alex and Sonnweber, Thomas and Mayer, Wolfgang and
               Schennach, Harald and Loeffler-Ragg, Judith and Bellmann-Weiler,
               Rosa and Tancevski, Ivan and Weiss, G{\"u}nter and Anliker,
               Markus and Griesmacher, Andrea and Hoermann, Gregor",
  abstract  = "OBJECTIVES: Serological tests detect antibodies against Severe
               Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the
               ongoing coronavirus disease-19 (COVID-19) pandemic. Independent
               external clinical validation of performance characteristics is
               of paramount importance. METHODS: Four fully automated assays,
               Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2 IgG, Siemens
               SARS-CoV-2 total (COV2T) and SARS-CoV-2 IgG (COV2G) were
               evaluated using 350 pre-pandemic samples and 700 samples from
               245 COVID-19 patients (158 hospitalized, 87 outpatients).
               RESULTS: All tests showed very high diagnostic specificity.
               Sensitivities in samples collected at least 14 days after
               disease onset were slightly lower than manufacturers' claims for
               Roche (93.0\%), Abbott (90.8\%), and Siemens COV2T (90.3\%), and
               distinctly lower for Siemens COV2G (78.8\%). Concordantly
               negative results were enriched for immunocompromised patients.
               ROC curve analyses suggest a lowering of the cut-off index for
               the Siemens COV2G assay. Finally, the combination of two
               anti-SARS-CoV-2 antibody assays is feasible when considering
               borderline reactive results. CONCLUSIONS: Thorough on-site
               evaluation of commercially available serologic tests for
               detection of antibodies against SARS-CoV-2 remains imperative
               for laboratories. The potentially impaired sensitivity of the
               Siemens COV2G necessitates a switch to the company's newly filed
               SARS-CoV-2 IgG assay for follow-up studies. A combination of
               tests could be considered in clinical practice.",
  journal   = "Clin. Chem. Lab. Med.",
  publisher = "Walter de Gruyter GmbH",
  volume    =  59,
  number    =  6,
  pages     = "1143--1154",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2 antibody; orthogonal testing; sensitivity;
               serologic tests; specificity",
  language  = "en"
}

@ARTICLE{Bonelli2021-ef,
  title     = "{SARS-CoV-2} vaccination in rituximab-treated patients: evidence
               for impaired humoral but inducible cellular immune response",
  author    = "Bonelli, Michael Markus and Mrak, Daniel and Perkmann, Thomas
               and Haslacher, Helmuth and Aletaha, Daniel",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1355--1356",
  month     =  oct,
  year      =  2021,
  keywords  = "B-lymphocytes; COVID-19; rituximab",
  language  = "en"
}

@ARTICLE{Ludwig2021-wg,
  title     = "Covid-19 vaccination in patients with multiple myeloma: Focus on
               immune response",
  author    = "Ludwig, Heinz and San-Miguel, Jes{\'u}s and Munshi, Nikhil and
               Sonneveld, Pieter and Mateos, Mar{\'\i}a-Victoria and Moreau,
               Philippe and Terpos, Evangelos",
  journal   = "Am. J. Hematol.",
  publisher = "Wiley",
  volume    =  96,
  number    =  8,
  pages     = "896--900",
  month     =  aug,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Muller2021-wb,
  title     = "Sensitivity of two {SARS-CoV-2} variants with spike protein
               mutations to neutralising antibodies",
  author    = "M{\"u}ller, Katharina and Girl, Philipp and Giebl, Andreas and
               Gruetzner, Stefanie and Antwerpen, Markus and Khatamzas, Elham
               and W{\"o}lfel, Roman and von Buttlar, Heiner",
  abstract  = "SARS-CoV-2 infections elicit a humoral immune response capable
               of neutralising the virus. However, multiple variants have
               emerged with mutations in the spike protein amongst others, the
               key target of neutralising antibodies. We evaluated the
               neutralising efficacy of 89 serum samples from patients,
               infected with SARS-CoV-2 in the beginning of 2020, against two
               virus variants isolated from acutely infected patients and
               harbouring spike protein mutations. One isolate was assigned to
               lineage B.1.351 (MUC-IMB-B.1.351) whilst the other (MUC-484) was
               isolated from an immunocompromised patient, sharing some but not
               all mutations with B.1.351 and representing a transitional
               variant. Both variants showed a significant reduction in
               neutralisation sensitivity compared to wild-type SARS-CoV-2 with
               MUC-IMB-B.1.351 being almost completely resistant to
               neutralisation. The observed reduction in neutralising activity
               of wild-type-specific antibodies against both variants suggests
               that individual mutations in the spike protein are sufficient to
               confer a potent escape from the humoral immune response. In
               addition, the effect of escape mutations seems to accumulate, so
               that more heavily mutated variants show a greater loss of
               sensitivity to neutralisation up to complete insensitivity as
               observed for MUC-IMB-B.1.351. From a clinical point of view,
               this might affect the efficacy of (monoclonal) antibody
               treatment of patients with prolonged infections as well as
               patients infected with variants other than the donor. At the
               same, this could also negatively influence the efficacy of
               current vaccines (as they are based on wild-type spike protein)
               emphasising the need to thoroughly surveil the emergence and
               distribution of variants and adapt vaccines and therapeutics
               accordingly.",
  journal   = "Virus Genes",
  publisher = "Springer Science and Business Media LLC",
  volume    =  57,
  number    =  6,
  pages     = "502--509",
  month     =  dec,
  year      =  2021,
  keywords  = "B.1.351; COVID-19; Immune escape; Mutation E484K; Neutralising
               antibodies; SARS-CoV-2; Variants of concern",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Chavarot2021-pq,
  title     = "Decline and loss of {anti-SARS-CoV-2} antibodies in kidney
               transplant recipients in the 6 months following {SARS-CoV-2}
               infection",
  author    = "Chavarot, Nathalie and Leruez-Ville, Marianne and Scemla, Anne
               and Burger, Carole and Amrouche, Lucile and Rouzaud, Claire and
               Lebreton, Xavier and Martinez, Frank and Sberro-Soussan, Rebecca
               and Legendre, Christophe and Zuber, Julien and Anglicheau, Dany",
  journal   = "Kidney Int.",
  publisher = "Elsevier BV",
  volume    =  99,
  number    =  2,
  pages     = "486--488",
  month     =  feb,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ewen2021-zd,
  title     = "{SARS-CoV-2} vaccination in cardiothoracic organ transplant
               recipients: effective strategies wanted",
  author    = "Ewen, Sebastian and Neumann, Frank and Bittenbring, J{\"o}rg T
               and von Scheidt, Wolfgang and B{\"o}hm, Michael",
  journal   = "Clin. Res. Cardiol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  110,
  number    =  8,
  pages     = "1139--1141",
  month     =  aug,
  year      =  2021,
  keywords  = "Cardiothoracic organ transplant recipients; SARS-CoV-2;
               Vaccination",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Shroff2021-qx,
  title     = "Immune responses to two and three doses of the {BNT162b2} {mRNA}
               vaccine in adults with solid tumors",
  author    = "Shroff, Rachna T and Chalasani, Pavani and Wei, Ran and
               Pennington, Daniel and Quirk, Grace and Schoenle, Marta V and
               Peyton, Kameron L and Uhrlaub, Jennifer L and Ripperger, Tyler J
               and Jergovi{\'c}, Mladen and Dalgai, Shelby and Wolf, Alexander
               and Whitmer, Rebecca and Hammad, Hytham and Carrier, Amy and
               Scott, Aaron J and Nikolich-{\v Z}ugich, Janko and Worobey,
               Michael and Sprissler, Ryan and Dake, Michael and LaFleur,
               Bonnie J and Bhattacharya, Deepta",
  abstract  = "Vaccines against severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) have shown high efficacy, but immunocompromised
               participants were excluded from controlled clinical trials. In
               this study, we compared immune responses to the BNT162b2 mRNA
               Coronavirus Disease 2019 vaccine in patients with solid tumors
               (n = 53) who were on active cytotoxic anti-cancer therapy to a
               control cohort of participants without cancer (n = 50).
               Neutralizing antibodies were detected in 67\% of patients with
               cancer after the first immunization, followed by a threefold
               increase in median titers after the second dose. Similar
               patterns were observed for spike protein-specific serum
               antibodies and T cells, but the magnitude of each of these
               responses was diminished relative to the control cohort. In most
               patients with cancer, we detected spike receptor-binding domain
               and other S1-specific memory B cell subsets as potential
               predictors of anamnestic responses to additional immunizations.
               We therefore initiated a phase 1 trial for 20 cancer cohort
               participants of a third vaccine dose of BNT162b2 ( NCT04936997
               ); primary outcomes were immune responses, with a secondary
               outcome of safety. At 1 week after a third immunization, 16
               participants demonstrated a median threefold increase in
               neutralizing antibody responses, but no improvement was observed
               in T cell responses. Adverse events were mild. These results
               suggest that a third dose of BNT162b2 is safe, improves humoral
               immunity against SARS-CoV-2 and could be immunologically
               beneficial for patients with cancer on active chemotherapy.",
  journal   = "Nat. Med.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  27,
  number    =  11,
  pages     = "2002--2011",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Reuken2021-iu,
  title     = "Severe clinical relapse in an immunocompromised host with
               persistent {SARS-CoV-2} infection",
  author    = "Reuken, Philipp A and Stallmach, Andreas and Pletz, Mathias W
               and Brandt, Christian and Andreas, Nico and Hahnfeld, Sabine and
               L{\"o}ffler, Bettina and Baumgart, Sabine and Kamradt, Thomas
               and Bauer, Michael",
  journal   = "Leukemia",
  publisher = "Springer Science and Business Media LLC",
  volume    =  35,
  number    =  3,
  pages     = "920--923",
  month     =  mar,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Werbel2021-dw,
  title     = "Safety and immunogenicity of a third dose of {SARS-CoV-2}
               vaccine in solid organ transplant recipients: A case series",
  author    = "Werbel, William A and Boyarsky, Brian J and Ou, Michael T and
               Massie, Allan B and Tobian, Aaron A R and Garonzik-Wang,
               Jacqueline M and Segev, Dorry L",
  journal   = "Ann. Intern. Med.",
  publisher = "American College of Physicians",
  volume    =  174,
  number    =  9,
  pages     = "1330--1332",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Sahbudak_Bal2021-lc,
  title    = "The longest infectious virus shedding in a child infected with
              the {G614} strain of {SARS-CoV-2}",
  author   = "Sahbudak Bal, Zumrut and Ozkul, Aykut and Bilen, Melis and
              Kurugol, Zafer and Ozkinay, Ferda",
  abstract = "COVID-19 spread globally and caused over 97 million cases with
              more than 2 million deaths. There is still ongoing discussion on
              the duration of infectious interval SARS-CoV-2 infection.
              Symptomatic children had longer virus shedding and there are some
              reports of prolonged infectious virus shedding in adults
              particularly patients having an immunocompromised status. A
              missense mutation, D614G, in the spike protein of SARS-CoV-2,
              which has emerged as a predominant clade in Europe and is
              spreading worldwide that can result in higher viral loads in
              patients. Herein, we described the longest infectious virus
              shedding in a previously healthy child infected with SARS-CoV-2
              expressing spike D614G substitution.",
  journal  = "Pediatr. Infect. Dis. J.",
  volume   =  40,
  number   =  7,
  pages    = "e263--e265",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Devresse2021-gk,
  title    = "T-cell and antibody response after 2 doses of the {BNT162b2}
              vaccine in a Belgian cohort of kidney transplant recipients",
  author   = "Devresse, Arnaud and Saad Albichr, Imane and Georgery,
              H{\'e}l{\`e}ne and Yombi, Jean Cyr and De Greef, Julien and
              Belkhir, Leila and Mzougui, Samy and Scohy, Anais and Darius, Tom
              and Buemi, Antoine and Goffin, Eric and Kabamba, Benoit and
              Kanaan, Nada",
  journal  = "Transplantation",
  volume   =  105,
  number   =  10,
  pages    = "e142--e143",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Hoffman2021-ew,
  title     = "{SARS-CoV-2} neutralization resistance mutations in patient with
               {HIV/AIDS}, California, {USA}",
  author    = "Hoffman, Seth A and Costales, Cristina and Sahoo, Malaya K and
               Palanisamy, Srikanth and Yamamoto, Fumiko and Huang, Chunhong
               and Verghese, Michelle and Solis, Daniel A and Sibai, Mamdouh
               and Subramanian, Aruna and Tompkins, Lucy S and Grant, Philip
               and Shafer, Robert W and Pinsky, Benjamin A",
  abstract  = "We report persistent severe acute respiratory syndrome
               coronavirus 2 infection in a patient with HIV/AIDS; the virus
               developed spike N terminal domain and receptor binding domain
               neutralization resistance mutations. Our findings suggest that
               immunocompromised patients can harbor emerging variants of
               severe acute respiratory syndrome coronavirus 2.",
  journal   = "Emerg. Infect. Dis.",
  publisher = "Centers for Disease Control and Prevention (CDC)",
  volume    =  27,
  number    =  10,
  pages     = "2720--2723",
  month     =  jul,
  year      =  2021,
  keywords  = "2019 novel coronavirus disease; COVID-19; California; HIV/AIDS;
               SARS-CoV-2; United States; antimicrobial resistance; coronavirus
               disease; coronaviruses; immunocompromised; respiratory
               infections; severe acute respiratory syndrome coronavirus 2;
               viral evolution; viruses; zoonoses",
  language  = "en"
}

@ARTICLE{Patrucco2021-ro,
  title     = "Mycotic infection prevalence among patients undergoing
               bronchoalveolar lavage with search of {SARS-CoV-2} after two
               negative nasopharyngeal swabs",
  author    = "Patrucco, Filippo and Airoldi, Chiara and Falaschi, Zeno and
               Bellan, Mattia and Castello, Luigi Mario and Filippone,
               Francesco and Matranga, Simone and Masellis, Serena and
               Smeriglia, Aurora and Solidoro, Paolo and Balbo, Piero Emilio
               and Gavelli, Francesco",
  abstract  = "The evidence that severe coronavirus disease 2019 (COVID-19) is
               a risk factor for development of mycotic respiratory infection
               with an increased mortality is rising. Immunosuppressed are
               among the most susceptible patients andAspergillusspecies is the
               most feared superinfection. In this study we evaluated mycotic
               isolation prevalence on bronchoalveolar lavage (BAL) of patients
               who underwent bronchoscopy in search of severe acute respiratory
               coronavirus 2 (SARS-CoV-2) RNA. Moreover, we described the
               clinical characteristics and main outcomes of these patients. We
               included 118 patients, 35.9\% of them were immunosuppressed for
               different reasons: in 23.7\% we isolated SARS-CoV-2 RNA, in
               33.1\% we identified at least one mycotic agent and both in
               15.4\%. On BAL we observed in three casesAspergillusspp, in six
               casesPneumocystisand in 32Candidaspp. The prevalence of
               significant mold infection was 29.3\% and 70.7\% of cases were
               false positive or clinically irrelevant infections. In-hospital
               mortality of patients with fungal infection was 15.3\%. The most
               frequent computed tomography (CT) pattern, evaluated with the
               Radiological Society of North America consensus statement, among
               patients with a mycotic pulmonary infection was the atypical one
               (p< 0.0001). Mycotic isolation on BAL may be interpreted as an
               innocent bystander, but its identification could influence the
               prognosis of patients, especially in those who need invasive
               investigations during the COVID-19 pandemic; BAL plays a
               fundamental role in resolving clinical complex cases, especially
               in immunosuppressed patients independently from radiological
               features, without limiting its role in ruling out SARS-CoV-2
               infection.",
  journal   = "J. Breath Res.",
  publisher = "IOP Publishing",
  volume    =  15,
  number    =  4,
  pages     = "047101",
  month     =  sep,
  year      =  2021,
  keywords  = "Aspergillus; COVID-19; Candida; Pneumocystis; SARS-CoV-2;
               bronchoalveolar lavage",
  copyright = "https://iopscience.iop.org/page/copyright",
  language  = "en"
}

@ARTICLE{Yi2021-nc,
  title     = "Kidney transplant recipients rarely show an early antibody
               response following the first {COVID-19} vaccine administration",
  author    = "Yi, Stephanie G and Knight, Richard J and Graviss, Edward A and
               Moore, Linda W and Nguyen, Duc T and Ghobrial, R Mark and Gaber,
               A Osama and Huang, Howard J",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  7,
  pages     = "e72--e73",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ruddy2021-wm,
  title     = "High antibody response to two-dose {SARS-CoV-2} messenger {RNA}
               vaccination in patients with rheumatic and musculoskeletal
               diseases",
  author    = "Ruddy, Jake A and Connolly, Caoilfhionn Marie and Boyarsky,
               Brian J and Werbel, William A and Christopher-Stine, Lisa and
               Garonzik-Wang, Jacqueline and Segev, Dorry L and Paik, Julie J",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1351--1352",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; autoimmune diseases; epidemiology; vaccination",
  language  = "en"
}

@ARTICLE{Mirgh2021-xp,
  title     = "Clinical course of severe {COVID19} treated with tocilizumab and
               antivirals post-allogeneic stem cell transplant with extensive
               chronic {GVHD}",
  author    = "Mirgh, Sumeet and Gokarn, Anant and Punatar, Sachin and Chichra,
               Akanksha and Singh, Anuj and Rajendra, Akhil and Babu Goli, Vasu
               and Trivedi, Bhakti and Joshi, Amit and Patkar, Nikhil and
               Tembhare, Prashant and Subramanian, P G and Shetty, Nitin and
               Chavan, Preeti and Bhat, Vivek and Gupta, Sudeep and Khattry,
               Navin",
  abstract  = "Recipients of allogeneic hematopoietic stem cell transplantation
               (allo-HSCT) are an immunocompromised group who are likely to
               develop severe complications and mortality because of
               coronavirus disease 2019 (COVID-19). We report here a
               61-year-old male patient of primary myelofibrosis who underwent
               an allo-HSCT 6 years earlier, had chronic graft-versus-host
               disease (cGVHD) involving the liver, lung, eyes, and skin, (with
               recurrent episodes of pulmonary infections) who developed severe
               COVID-19. The patient was treated with tocilizumab, and a
               combination of lopinavir/ritonavir, ribavirin,
               interferon-$\beta$1b. He was discharged after 31 days with full
               recovery. Tocilizumab, a humanized monoclonal antibody against
               IL6, has been shown to benefit respiratory manifestations in
               severe COVID19. However, this is first report, to our knowledge,
               of its use and benefit in a post HSCT recipient.",
  journal   = "Transpl. Infect. Dis.",
  publisher = "Wiley",
  volume    =  23,
  number    =  4,
  pages     = "e13576",
  month     =  aug,
  year      =  2021,
  keywords  = "GVHD; allogeneic; coronavirus disease (COVID19); stem cell
               transplant; tocilizumab",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Parara2021-rz,
  title     = "Significant rise in neck infections progressing to descending
               necrotizing mediastinitis during the {COVID-19} pandemic
               quarantine",
  author    = "Parara, Eleni and Krasadakis, Christos and Toursounidis,
               Iordanis and Tsekoura, Konstantina and Mourouzis, Constantinos
               and Rallis, George",
  abstract  = "To present five patients with DNM, who were treated during the
               first quarantine for Coronavirus disease 2019 (Covid-19). Five
               patients with DNM were treated in our department during the
               first lockdown. The mean age of the patients was 42,2 years and
               four were male. Two patients were immunocompromised. Repeated
               surgical drainage was performed in all patients, whereas four
               were also subjected to elective tracheostomy during their first
               operation. The mean hospitalization duration was 55,4 days and
               mortality was 40\%. During the first lockdown for the Covid-19,
               a rise in the ratio of DNM cases to the overall incidence of
               cervicofacial infections was observed in our department. All
               patients with DNM were operated on an emergency basis and were
               subsequently admitted to the ICU. We consider the effect of the
               quarantine as a decisive factor for this escalation, because
               according to the department archives, there had not been any
               cases of DNM originating from a dental infection, for the past 5
               years. Additionally, past studies from the same department
               reported no more than 6 cases over a 10 year period.",
  journal   = "J. Craniomaxillofac. Surg.",
  publisher = "Elsevier BV",
  volume    =  49,
  number    =  12,
  pages     = "1182--1186",
  month     =  dec,
  year      =  2021,
  keywords  = "Cervicofacial infection; Covid 19; Descending Necrotizing
               Medastinitis (DNM); Odontogenic infection",
  language  = "en"
}

@ARTICLE{Abid2021-cw,
  title     = "Les maladies inflammatoires chroniques de l'intestin: que se
               passe-t-il quand le {SARS-CoV-2} arrive? R{\'e}sultats
               pr{\'e}liminaires du {CHU} Hassan {II} de F{\`e}s, Maroc",
  author    = "Abid, Hakima and Atmani, Imane and Lahmidani, Nada and El
               Yousfi, Mounia and Benajah, Dafr-Allah and Ibrahimi, Sidi Adil
               and El Abkari, Mohamed",
  abstract  = "SARS-CoV-2 infection is a major concern and a new threat to
               immunocompromised patients. Patients with chronic inflammatory
               bowel diseases (IBDs) are at increased risk of infections, in
               particular when they have active disease and are on
               immunosuppressive treatment. The purpose of this study was to
               assess the clinical, biological and radiological features of
               three patients with COVID-19 associated with chronic IBD as well
               as their management and outcomes. The study was conducted at the
               Hassan II University Teaching Hospital in Fes, Morocco over a
               3-month period. We assessed all patients with disease onset. All
               patients had mild symptoms or were asymptomatic. No changes or
               delays in treatment regimens occurred and none of patients
               developed severe COVID-19. Reverse transcription polymerase
               chain reaction (RT-PCR) test results were positive in all
               patients. Radiological examinations were conducted. Chest
               scanner showed ground-glass opacities in one case. Treatment was
               based on hydroxychloroquine with azithromycin. Outcome was good
               in all cases. This preliminary report suggests that patients
               with chronic IBD aren't at higher risk of developing COVID-19
               compared to the general population.",
  journal   = "Pan Afr. Med. J.",
  publisher = "Pan African Medical Journal",
  volume    =  38,
  pages     = "382",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Chronic IBD; Crohn's disease; case report; ulcerative
               colitis",
  language  = "fr"
}

@ARTICLE{Mokos2021-lw,
  title    = "Diagnostic delays for non-melanoma skin cancers in renal
              transplant recipients during the {COVID-19} pandemic: What is
              hiding behind the mask?",
  author   = "Mokos, Mislav and Ba{\v s}i{\'c}-Juki{\'c}, Nikolina",
  abstract = "Dear Editor, The ongoing pandemic of coronavirus disease 2019
              (COVID-19) was declared by the World Health Organization on March
              11, 2020, and remains a global challenge. COVID-19 is caused by
              severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
              transmitted primarily through respiratory droplets and aerosols.
              Even though the COVID-19 vaccine has become available since
              December 2020, the main preventive measures still include social
              distancing, hand washing, and the use of protective face masks.
              By May 22, 2021, 3,437,545 deaths caused by SARS-CoV-2 have been
              registered by WHO, confirming the burden of this disease (1).
              Consequently, the pandemic has become a challenge for health care
              systems, as they had to be focused on the care of patients with
              COVID-19. During the first lockdown from March to May 2020, it
              was advised to postpone clinical visits whenever this could be
              done without risk. This recommendation was mainly aimed at older
              patients and those with chronic diseases, as it has been shown
              that they are at greater risk for complications from COVID-19.
              Renal transplant recipients (RTRs) are at a greater risk for
              infections and different cancers due to their permanent
              immunosuppressive therapy. The most common malignancies in RTRs
              are skin cancers, particularly non-melanoma skin cancers. It has
              been estimated that RTRs have a 65-250 times higher risk for
              cutaneous squamous cell carcinoma (SCC), 10 times higher risk for
              basal cell carcinoma, and 2-5 times higher risk for melanoma when
              compared with the general population (2-4). RTRs are at a higher
              risk for complications from COVID-19, not only because of their
              immunosuppressive therapy but also because of different
              comorbidities, such as hypertension, cardiovascular disease, and
              diabetes mellitus (5). Therefore, RTRs tend to limit their
              medical visits and postpone clinical examinations for skin cancer
              screenings. Moreover, during clinical visits the patients are
              commonly asked to keep their protective masks on, increasing the
              risk of overlooking their facial skin changes. Herein we present
              two RTRs who developed skin cancers during the COVID-19 pandemic,
              and the tumors were diagnosed with a significant delay. Patient 1
              A 67-year-old woman with unknown primary kidney disease received
              a renal allograft from a deceased donor in 2014. The
              immunosuppressive protocol included antithymocyte globulin
              induction with tacrolimus, mycophenolate mofetil, and steroid
              maintenance. In January 2020, she had noticed a reddish squamous
              lesion on her right cheek, which enlarged slowly. Since there
              were no other symptoms, she postponed the dermatologic
              examination. Additionally, she further postponed the visit to her
              physician during the pandemic as she wanted to avoid social
              contact as much as possible. One year later, at the
              nephrologist's examination, she was asked to take off her face
              mask for a skin check, and two skin tumors on her right cheek
              were noticed (Figure 1). One lesion was located at the angle of
              her mandible and presented as a hypertrophic, sharply marginated
              lesion with central crusting and a diameter of 2 cm. The other
              lesion was at the right zygomatic region and appeared as a scaly,
              erythematous lesion with a diameter of 7 mm. The patient was
              referred to a dermatologist, and a biopsy of both lesions was
              indicated. The pathohistological analysis revealed cutaneous SCC
              in situ for the mandibular lesion and actinic keratosis for the
              zygomatic lesion. SCC in situ has been excised, and actinic
              keratosis was treated by cryosurgery. Patient 2 A 66-year-old
              woman received a renal allograft from a deceased donor in 2010
              due to chronic glomerulonephritis without biopsy. The
              immunosuppressive protocol included basiliximab induction with
              tacrolimus, mycophenolate mofetil, and steroid maintenance. In
              June 2020, an erosion occurred at her left infraocular area and
              did not heal but instead gradually enlarged. The patient
              suspected that the ``wound'' developed due to the friction from
              the rim of her eyeglasses. Six months later, the nephrologist
              noticed the erosion which was 10$\times$5 mm in size with a
              slightly elevated, pearl-colored margin (Figure 2). The patient
              was referred to a dermatologist who indicated tumor excision due
              to suspected basal cell carcinoma. The pathohistological analysis
              confirmed the clinical diagnosis. DISCUSSION Both presented
              patients did not inform their family physicians about their skin
              changes because they avoided all non-nephrological medical visits
              during the pandemic. The additional reason for the diagnostic
              delay was the fact that they kept the masks on their faces during
              most examinations, with the skin lesions behind the mask
              consequently remaining unnoticed. The problem of diagnostic delay
              of skin cancers during the COVID-19 pandemic has been recognized
              by several studies. Canadian authors compared the number of
              biopsies for skin cancers during the first 15 weeks in 2020 and
              during the same period in 2019. They found a decrease in the
              number of biopsies for non-melanoma skin cancers (NMSC) and
              melanoma of 18\% and 27\%, respectively (6). A multicenter study
              performed in northern-central Italy showed that the number of
              skin cancer (NMSC and melanoma) diagnoses fell by 56.7\% in weeks
              11 to 20 of 2020 compared with the average number noted in the
              same periods of 2018 and 2019 (7). Furthermore, a single-center
              retrospective study in Italy demonstrated that the number of
              advanced skin cancers surgically treated between May 18 and
              November 18, 2020, was significantly higher than in the same
              period in 2019. These findings led the authors to conclude that
              the surgical excisions were postponed due to the delay in
              follow-ups, which resulted in increased incidence of advanced
              skin cancers (8). RTRs are at particular risk of severe
              consequences from diagnostic delay with regard to skin cancers.
              Namely, skin cancers in RTRs are more aggressive and are
              associated with a higher incidence rate of metastases and
              recurrences than in the general population (9). Therefore, RTRs
              should be advised to regularly check their skin for potential
              skin cancer, which includes self-examinations and dermatologic
              follow-ups.",
  journal  = "Acta Dermatovenerol. Croat.",
  volume   =  29,
  number   =  2,
  pages    = "111--113",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Basheer2021-zb,
  title     = "Clearance of the {SARS-CoV-2} virus in an immunocompromised
               patient mediated by convalescent plasma without B-cell recovery",
  author    = "Basheer, Maamoun and Saad, Elias and Laskar, Orly and Schuster,
               Ofir and Rechnitzer, Hagai and Zisman-Rozen, Simona and Azoulay,
               David and Assy, Nimer",
  abstract  = "Coronavirus disease (COVID-19) is a contagious disease caused by
               the severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2). This case report presents a patient who had
               difficulty eradicating the corona virus due to being treated
               with Rituximab, which depletes B lymphocyte cells and therefore
               disables the production of neutralizing antibodies. The combined
               use of external anti-viral agents like convalescent plasma, IVIG
               and Remdesivir successfully helped the patient's immune system
               to eradicate the virus without B-cell population recovery. In
               vitro studies showed that convalescent plasma is the main agent
               that helped in eradicating the virus.",
  journal   = "Int. J. Mol. Sci.",
  publisher = "MDPI AG",
  volume    =  22,
  number    =  16,
  pages     = "8902",
  month     =  aug,
  year      =  2021,
  keywords  = "SARS-COV-2; T lymphocytes; immunocompromised; pneumonia",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Chakravarthy2021-eb,
  title    = "An unusual case of severe Pneumocystis jiroveci pneumonia ({PJP})
              presenting as ``recurrent cytokine storm'' following {COVID-19}
              infection",
  author   = "Chakravarthy, K Kalyan and Cherukuri, Bharath and Anne, Suresh
              and Shankar, T Uma and Mohan Reddy, G Murali and Guttikonda,
              Neeraj",
  journal  = "J. Assoc. Physicians India",
  volume   =  69,
  number   =  5,
  pages    = "78",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Curto2021-hh,
  title     = "Case report: Effects of {anti-SARS-CoV-2} convalescent
               antibodies obtained with double filtration plasmapheresis",
  author    = "Curt{\`o}, Diego and Tomatis, Federica and Gastoldi, Sara and
               Galbusera, Miriam and Noris, Marina and Raimondi, Federico and
               Lorini, Ferdinando Luca and Falanga, Anna and Marchetti, Marina
               and Remuzzi, Giuseppe and Ruggenenti, Piero",
  abstract  = "Passive antibody therapy has been used to treat outbreaks of
               viral disease, including the ongoing pandemic of severe
               respiratory acute respiratory syndrome (SARS) coronavirus 2
               (SARS-CoV-2) or COVID-19. However, the real benefits of the
               procedure are unclear. We infused a concentrated solution of
               neutralizing anti-SARS-CoV-2 antibodies obtained from a
               convalescent donor with a single session of double filtration
               plasmapheresis (DFPP) into a 56-year-old woman with long history
               of unremitting, severe COVID-19. She was unable to establish an
               adequate antiviral immune response because of previous
               chemotherapy, including the infusion of the anti-CD20 monoclonal
               antibody rituximab, administered to treat a diffuse large B-cell
               lymphoma. The disease promptly recovered despite evidence of no
               endogenous anti-SARS-CoV-2 antibody production. The observation
               that passive antibody therapy might prove particularly effective
               in immunodepressed COVID-19 patients requires evaluation in
               prospective randomized controlled trial.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "711915",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; case report; coagulation biomarkers; convalescent
               antibodies; double filtration plasmapheresis;
               hypercoagulability; immunosuppression; rituximab",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Al_Jalali2021-zp,
  title     = "Improved immunogenicity against {SARS-CoV-2} in a solid-organ
               transplant recipient by switching vaccines",
  author    = "Al Jalali, Valentin and Scherzer, Sabine and Zeitlinger, Markus",
  journal   = "Clin. Microbiol. Infect.",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  10,
  pages     = "1529--1530",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Nia2021-mw,
  title     = "Septic hip abscess due to Fusobacterium nucleatum and
               Actinomyces turicensis in an immunocompetent {SARS-CoV-2}
               positive patient",
  author    = "Nia, A and Ungersboeck, A and Uffmann, M and Leaper, D and
               Assadian, O",
  abstract  = "A 42-year-old man was referred to the Department of Orthopedic
               Surgery with pain over his right greater trochanter and signs of
               systemic infection. CT showed an enhanced mass in his gluteus
               maximus as well as gas in the biceps femoris over the underlying
               hip joint. Tissue biopsy yielded Fusobacterium nucleatum and
               Actinomyces turicensis. The patient was successfully treated for
               6 weeks with amoxicillin/clavulanic acid 875mg/125mg and
               metronidazole 500mg.",
  journal   = "Anaerobe",
  publisher = "Elsevier BV",
  volume    =  71,
  number    =  102420,
  pages     = "102420",
  month     =  oct,
  year      =  2021,
  keywords  = "Actinomyces turicensis; Fusobacterium nucleatum; SARS-CoV-2
               positive; Septic hip abscess",
  language  = "en"
}

@ARTICLE{Spiera2021-xt,
  title     = "Rituximab, but not other antirheumatic therapies, is associated
               with impaired serological response to {SARS-} {CoV-2}
               vaccination in patients with rheumatic diseases",
  author    = "Spiera, Robert and Jinich, Sarah and Jannat-Khah, Deanna",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1357--1359",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; antirheumatic agents; rituximab; vaccination",
  language  = "en"
}

@ARTICLE{Connolly2021-gy,
  title     = "Absence of humoral response after two-dose {SARS-CoV-2}
               messenger {RNA} vaccination in patients with rheumatic and
               musculoskeletal diseases: A case series",
  author    = "Connolly, Caoilfhionn M and Boyarsky, Brian J and Ruddy, Jake A
               and Werbel, William A and Christopher-Stine, Lisa and
               Garonzik-Wang, Jacqueline M and Segev, Dorry L and Paik, Julie J",
  journal   = "Ann. Intern. Med.",
  publisher = "American College of Physicians",
  volume    =  174,
  number    =  9,
  pages     = "1332--1334",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Westhoff2021-vs,
  title     = "Correspondence on {'SARS-CoV-2} vaccination in rituximab-treated
               patients: evidence for impaired humoral but inducible cellular
               immune response'",
  author    = "Westhoff, Timm H and Seibert, Felix S and Anft, Moritz and
               Blazquez-Navarro, Arturo and Skrzypczyk, Sarah and Doevelaar,
               Adrian and H{\"o}lzer, Bodo and Paniskaki, Krystallenia and
               Dolff, Sebastian and Wilde, Benjamin and Witzke, Oliver and
               Braun, Juergen and Stervbo, Ulrik and Babel, Nina",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "e162",
  month     =  oct,
  year      =  2021,
  keywords  = "Covid-19; rituximab; vaccination",
  language  = "en"
}

@ARTICLE{Georgery2021-ks,
  title    = "Very low immunization rate in kidney transplant recipients after
              one dose of the {BNT162b2} vaccine: Beware not to lower the
              guard!",
  author   = "Georgery, H{\'e}l{\`e}ne and Devresse, Arnaud and Yombi, Jean-Cyr
              and Belkhir, Leila and De Greef, Julien and Darius, Tom and
              Buemi, Antoine and Scohy, Anais and Kabamba, Benoit and Goffin,
              Eric and Kanaan, Nada",
  journal  = "Transplantation",
  volume   =  105,
  number   =  10,
  pages    = "e148--e149",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Alexander2021-nm,
  title     = "Third doses of {SARS-CoV-2} vaccines in immunosuppressed
               patients with inflammatory bowel disease",
  author    = "Alexander, James L and Selinger, Christian P and Powell, Nick
               and {British Society of Gastroenterology Inflammatory Bowel
               Disease section and the Inflammatory Bowel Disease Clinical
               Research Group}",
  journal   = "Lancet Gastroenterol. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  6,
  number    =  12,
  pages     = "987--988",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Furlan2021-hf,
  title     = "Dramatic response to convalescent hyperimmune plasma in
               association with an extended course of remdesivir in 4 {B}
               cell-depleted non-Hodgkin lymphoma patients with {SARS-cov-2}
               pneumonia after rituximab therapy",
  author    = "Furlan, Anna and Forner, Gabriella and Cipriani, Ludovica and
               Vian, Elisa and Rigoli, Roberto and Gherlinzoni, Filippo and
               Scotton, Piergiorgio",
  journal   = "Clin. Lymphoma Myeloma Leuk.",
  publisher = "Elsevier BV",
  volume    =  21,
  number    =  9,
  pages     = "e731--e735",
  month     =  sep,
  year      =  2021,
  keywords  = "B cell depletion convalescent hyperimmune plasma remdesivir;
               Rituximab; SARS-CoV-2; non-Hodgkin lymphoma",
  language  = "en"
}

@ARTICLE{Selim2021-hw,
  title     = "{SARS-CoV-2} vaccination uptake by patients with inflammatory
               bowel disease on biological therapy",
  author    = "Selim, Rania and Wellens, Judith and Marlow, Luke and Satsangi,
               Jack J",
  journal   = "Lancet Gastroenterol. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  6,
  number    =  12,
  pages     = "989",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Bellanger2021-tq,
  title     = "Mixed mold infection with Aspergillus fumigatus and Rhizopus
               microsporus in a severe acute respiratory syndrome Coronavirus 2
               ({SARS-CoV-2}) patient",
  author    = "Bellanger, A-P and Navellou, J-C and Lepiller, Q and Brion, A
               and Brunel, A-S and Millon, L and Berceanu, A",
  journal   = "Infect Dis Now",
  publisher = "Elsevier BV",
  volume    =  51,
  number    =  7,
  pages     = "633--635",
  month     =  oct,
  year      =  2021,
  keywords  = "Aspergillosis; Mixed mold-infection; Mucormycosis; SARS-CoV-2;
               Viral load",
  language  = "en"
}

@ARTICLE{Perez-Lamas2021-jo,
  title     = "Hemolytic crisis due to Covid-19 vaccination in a woman with
               cold agglutinin disease",
  author    = "P{\'e}rez-Lamas, Luc{\'\i}a and Moreno-Jim{\'e}nez, Gemma and
               Tenorio-N{\'u}{\~n}ez, Mar{\'\i}a C and Vel{\'a}zquez-Kennedy,
               Kyra and Jim{\'e}nez-Chill{\'o}n, Carlos and Astibia-Mahillo,
               Beatriz and N{\'u}{\~n}ez-Torr{\'o}n, Claudia and
               Garc{\'\i}a-Guti{\'e}rrez, Valent{\'\i}n and
               Jim{\'e}nez-Mart{\'\i}n, Ana and Vall{\'e}s-Carboneras, Ana and
               L{\'o}pez-Jim{\'e}nez, Javier F",
  journal   = "Am. J. Hematol.",
  publisher = "Wiley",
  volume    =  96,
  number    =  8,
  pages     = "E288--E291",
  month     =  aug,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Palomba2021-qc,
  title     = "Treatment of {SARS-CoV-2} relapse with remdesivir and
               neutralizing antibodies cocktail in a patient with X-linked
               agammaglobulinaemia",
  author    = "Palomba, Emanuele and Carrabba, Maria and Zuglian, Gianluca and
               Alagna, Laura and Saltini, Paola and Fortina, Valeria and Hu,
               Cinzia and Bandera, Alessandra and Fabio, Giovanna and Gori,
               Andrea and Muscatello, Antonio",
  abstract  = "During the coronavirus disease 2019 (COVID-19) pandemic,
               patients with humoral immunodeficiency are at higher risk of
               developing chronic infection and having a negative outcome. Few
               data are available on therapeutic options for this population.
               This case report discusses the treatment of disease relapse with
               remdesivir and monoclonal antibodies in an adult patient with
               X-linked agammaglobulinaemia.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  110,
  pages     = "338--340",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; Casirivimab; Imdevimab; Immunocompromised; Monoclonal
               antibodies; Neutralizing antibodies; Remdesivir; SARS-CoV-2; XLA",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Easdale2021-en,
  title     = "Serologic responses following a single dose of {SARS-CoV-2}
               vaccination in allogeneic stem cell transplantation recipients",
  author    = "Easdale, Sandra and Shea, Robyn and Ellis, Lauren and Bazin,
               Jessica and Davis, Kim and Dallas, Fiona and Thistlethwayte,
               Emma and Ethell, Mark and Potter, Mike and Arias, Carlos and
               Anthias, Chloe and Nicholson, Emma",
  abstract  = "Immunocompromised individuals were not included in formal trials
               of SARS-CoV-2 mRNA vaccines. Subsequent studies in patients with
               hematologic malignancies and solid organ transplantation
               recipients suggest inferior responses to vaccination. We
               determined antibody responses to a single dose of vaccines in
               one of the most vulnerable patient groups, allogeneic
               hematopoietic cell transplantation (allo-HCT) recipients.
               Pfizer-BioNTech (PB) or AstraZeneca (AZ) SARS-CoV-2 vaccines
               were administered at least 3 months post-transplantation to 55
               adult allo-HCT recipients. We found that older age and
               concurrent use of immunosuppressive medications were
               significantly associated with lack of antibody response to
               vaccination. Only 21\% of patients on systemic immunosuppression
               mounted a response, compared with 58\% of patients not on
               immunosuppression (P = .006). We also show that responses to the
               AZ vaccine may be superior to responses to the PB vaccine in
               this cohort. These findings highlight the need for novel
               immunogenic vaccine formulations and schedules in these
               highest-risk patients, as well as continued public healthy
               safety measures to protect the most vulnerable members of our
               society.",
  journal   = "Transplant Cell Ther",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  10,
  pages     = "880.e1--880.e4",
  month     =  oct,
  year      =  2021,
  keywords  = "Allogeneic stem cell transplantation; COVID vaccination;
               SARS-CoV-2 antibody response",
  language  = "en"
}

@ARTICLE{Albach2021-ch,
  title     = "Successful {BNT162b2} booster vaccinations in a patient with
               rheumatoid arthritis and initially negative antibody response",
  author    = "Albach, Fredrik N and Burmester, Gerd R and Biesen, Robert",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1361--1362",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Methotrexate; Rheumatoid Arthritis; Vaccination",
  language  = "en"
}

@ARTICLE{Mrak2021-ed,
  title     = "{SARS-CoV-2} vaccination in rituximab-treated patients: {B}
               cells promote humoral immune responses in the presence of
               T-cell-mediated immunity",
  author    = "Mrak, Daniel and Tobudic, Selma and Koblischke, Maximilian and
               Graninger, Marianne and Radner, Helga and Sieghart, Daniela and
               Hofer, Philipp and Perkmann, Thomas and Haslacher, Helmuth and
               Thalhammer, Renate and Winkler, Stefan and Bl{\"u}ml, Stephan
               and Stiasny, Karin and Aberle, Judith H and Smolen, Josef S and
               Heinz, Leonhard X and Aletaha, Daniel and Bonelli, Michael",
  abstract  = "OBJECTIVES: Evidence suggests that B cell-depleting therapy with
               rituximab (RTX) affects humoral immune response after
               vaccination. It remains unclear whether RTX-treated patients can
               develop a humoral and T-cell-mediated immune response against
               SARS-CoV-2 after immunisation. METHODS: Patients under RTX
               treatment (n=74) were vaccinated twice with either mRNA-1273 or
               BNT162b2. Antibodies were quantified using the Elecsys
               Anti-SARS-CoV-2 S immunoassay against the receptor-binding
               domain (RBD) of the spike protein and neutralisation tests.
               SARS-CoV-2-specific T-cell responses were quantified by
               IFN-$\gamma$ enzyme-linked immunosorbent spot assays.
               Prepandemic healthy individuals (n=5), as well as healthy
               individuals (n=10) vaccinated with BNT162b2, served as controls.
               RESULTS: All healthy controls developed antibodies against the
               SARS-CoV-2 RBD of the spike protein, but only 39\% of the
               patients under RTX treatment seroconverted. Antibodies against
               SARS-CoV-2 RBD significantly correlated with neutralising
               antibodies ($\tau$=0.74, p<0.001). Patients without detectable
               CD19+ peripheral B cells (n=36) did not develop specific
               antibodies, except for one patient. Circulating B cells
               correlated with the levels of antibodies ($\tau$=0.4, p<0.001).
               However, even patients with a low number of B cells (<1\%)
               mounted detectable SARS-CoV-2-specific antibody responses.
               SARS-CoV-2-specific T cells were detected in 58\% of the
               patients, independent of a humoral immune response. CONCLUSIONS:
               The data suggest that vaccination can induce SARS-CoV-2-specific
               antibodies in RTX-treated patients, once peripheral B cells at
               least partially repopulate. Moreover, SARS-CoV-2-specific T
               cells that evolved in more than half of the vaccinated patients
               may exert protective effects independent of humoral immune
               responses.",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1345--1350",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; rituximab; vaccination",
  language  = "en"
}

@ARTICLE{Alshukairi2021-gh,
  title     = "Re-infection with a different {SARS-CoV-2} clade and prolonged
               viral shedding in a hematopoietic stem cell transplantation
               patient",
  author    = "Alshukairi, Abeer N and El-Kafrawy, Sherif A and Dada, Ashraf
               and Yasir, Muhammad and Yamani, Amani H and Saeedi, Mohammed F
               and Aljohaney, Ahmed and AlJohani, Naif I and Bahaudden, Husam A
               and Alam, Intikhab and Gojobori, Takashi and Radovanovic,
               Aleksandar and Alandijany, Thamir A and Othman, Norah A and
               Alsubhi, Tagreed L and Hassan, Ahmed M and Tolah, Ahmed M and
               Al-Tawfiq, Jaffar A and Zumla, Alimuddin and Azhar, Esam I",
  abstract  = "Immunocompromised patients who have a severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2) infection pose many clinical
               and public health challenges. We describe the case of a
               hematopoietic stem cell transplantation patient with lymphoma
               who had a protracted illness requiring three consecutive
               hospital admissions. Whole genome sequencing confirmed two
               different SARS-CoV-2 clades. Clinical management issues and the
               unanswered questions arising from this case are discussed.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  110,
  pages     = "267--271",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; Hematological stem cell transplant; Immunocompromised;
               Prolonged viral shedding; Re-infection; SARS-CoV-2",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Terpos2021-ai,
  title     = "Low neutralizing antibody responses against {SARS-CoV-2} in
               older patients with myeloma after the first {BNT162b2} vaccine
               dose",
  author    = "Terpos, Evangelos and Trougakos, Ioannis P and Gavriatopoulou,
               Maria and Papassotiriou, Ioannis and Sklirou, Aimilia D and
               Ntanasis-Stathopoulos, Ioannis and Papanagnou, Eleni-Dimitra and
               Fotiou, Despina and Kastritis, Efstathios and Dimopoulos,
               Meletios A",
  journal   = "Blood",
  publisher = "American Society of Hematology",
  volume    =  137,
  number    =  26,
  pages     = "3674--3676",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Golding2021-ku,
  title     = "Pause in immunosuppressive treatment results in improved immune
               response to {SARS-CoV-2} vaccine in autoimmune patient: a case
               report",
  author    = "Golding, Basil and Lee, Youri and Golding, Hana and Khurana,
               Surender",
  journal   = "Ann. Rheum. Dis.",
  publisher = "BMJ",
  volume    =  80,
  number    =  10,
  pages     = "1359--1361",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; autoimmune diseases; immune system diseases;
               treatment; vaccination",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Bolukbasi2021-zf,
  title     = "First case of {COVID-19} positive Candida auris fungemia in
               Turkey",
  author    = "B{\"o}l{\"u}kba{\c s}{\i}, Yasemin and Erk{\"o}se Gen{\c c},
               Gonca and Orhun, G{\"u}nseli and Ku{\c s}kucu, Mert Ahmet and
               {\c C}a{\u g}atay, Atahan and {\"O}nel, Mustafa and {\"O}ngen,
               Betig{\"u}l and A{\u g}a{\c c}fidan, Ali and Esen, Figen and
               Erturan, Zayre",
  abstract  = "Candida auris is a species of fungus that has gained importance
               in recent years owing to its ability to cause hospital
               infections and epidemics, resistant to antifungal agents and
               disinfection processes and frequently misidentified by
               commercial systems. Hospital outbreaks caused by C.auris have
               been reported from some countries. It has been determined that
               C.auris has lower virulence than Candida albicans; however, it
               is associated with high mortality rates in immunocompromised
               individuals. An increase in the incidence of invasive fungal
               infections which can lead to serious complications and death,
               has been identified in severe coronavirus-2019 (COVID-19)
               patients or immunocompromised individuals with underlying
               disease. Studies demonstrated an increase in the frequency of
               C.auris isolation in COVID-19 patients with candidemia. In this
               report, the first case of COVID-19 positive C.auris fungemia
               detected in Turkey was presented. A 71-year-old male patient
               with a history of myocardial infarction, diabetes mellitus,
               donation of a single kidney and lobectomy surgery due to lung
               cancer was hospitalized in the pandemic thoracic surgery service
               due to the findings consistent with viral pneumonia on thoracic
               computed tomography. Favipiravir 2 x 600 mg and intravenous
               dexamethasone 1 x 6 mg therapy was administered. The patient
               tested positive for SARS-CoV-2 polymerase chain reaction, and
               severe involvement of the left lung was detected in the
               following days. Antibiotics were administered, followed by
               insertion of a right jugular vein catheter and initation of
               tocilizumab. The patient was transferred to the intensive care
               unit due to increased respiratory distress. Yeast growth was
               detected in the patient's hemoculture. The yeast strain could
               not be identified using API ID 32C (bioMerieux, France)
               (Sacchromyces kluyveri, Candida sake, unacceptable profile), but
               was identified as C.auris using the VITEK MALDI TOF MS
               (bioMerieux, France) (99.9\%) system and confirmed by
               sequencing. The minimum inhibitor concentration values were
               detected as 3 g/ml for amphotericin B; > 256 g/ml for
               fluconazole; 0.19 g/ml for voriconazole; 0.19 g/ml for
               itraconazole; 0.016 g/ml for posaconazole; 1 g/ml for
               caspofungin and 0.094 g/ml for anidulafungin by using the
               antibiotic gradient method. The patient's initial treatment
               comprised meropenem 3 x 1 g, vancomycin 2 x 1 g, caspofungin 1 x
               70 mg, and continued as caspofungine 1 x 50 mg after the loading
               dose, and vancomycin 1 x 1 g/48 hours from the third day of
               treatment. The patient died on the ninth day after developing
               candidemia. The present case is the first case of fungemia
               caused by C.auris in a COVID-19 positive patient in Turkey, and
               it emphasizes the need of caution for fungemia due to C.auris in
               intensive care units in our country which has a high COVID-19
               incidence.",
  journal   = "Mikrobiyol. Bul.",
  publisher = "Bilimsel Tip Publishing House",
  volume    =  55,
  number    =  4,
  pages     = "648--655",
  month     =  oct,
  year      =  2021,
  language  = "tr"
}

@ARTICLE{Quintana-Ortega2021-gq,
  title     = "Fatal outcome of {anti-MDA5} juvenile dermatomyositis in a
               paediatric {COVID-19} patient: a case report",
  author    = "Quintana-Ortega, Cristian and Remesal, Agust{\'\i}n and Ruiz de
               Valbuena, Marta and de la Serna, Olga and Laplaza-Gonz{\'a}lez,
               Mar{\'\i}a and {\'A}lvarez-Rojas, Elena and Udaondo, Clara and
               Alcobendas, Rosa and Murias, Sara",
  abstract  = "Anti-melanoma differentiation-associated gene 5 juvenile
               dermatomyositis (anti-MDA5 JDM) is associated with high risk of
               developing rapidly progressive interstitial lung disease
               (RP-ILD). Here we report an 11-year-old girl with anti-MDA5 JDM
               and RP-ILD which led to a fatal outcome, further aggravated by
               SARS-CoV-2 infection. She was referred to our hospital after
               being diagnosed with anti-MDA5 JDM and respiratory failure due
               to RP-ILD. On admission, fibrobronchoscopy with bronchoalveolar
               lavage (BAL) revealed Pneumocystis jirovecii infection so
               treatment with intravenous trimethoprim-sulfamethoxazole was
               initiated. Due to RP-ILD worsening, immunosuppressive therapy
               was intensified using methylprednisolone pulses,
               cyclophosphamide, tofacitinib and intravenous immunoglobulin
               without response. She developed severe hypoxemic respiratory
               failure, pneumomediastinum and pneumothorax, further complicated
               with severe RP-ILD and cervical subcutaneous emphysema. Three
               real-time RT-PCR for SARS-CoV-2 were made with a negative
               result. In addition, she was complicated with a secondary
               hemophagocytic lymphohistiocytosis and a fourth real-time PCR
               for SARS-CoV-2 performed in BAS sample was positive. Despite
               aggressive treatment of RP-ILD due to anti-MDA5 JDM, there was
               no improvement of respiratory failure in the following days and
               patient developed refractory septic shock and died. Anti-MDA5
               JDM patients with RP-ILD have a poor prognosis with a high
               mortality rate. For this reason, intensive immunosuppressive
               therapy is essential including the use of promising drugs such
               as tofacitinib. COVID-19 in children with underlying health
               conditions like anti-MDA5 JDM may still be at risk for disease
               and severe complications.",
  journal   = "Mod. rheumatol. case rep.",
  publisher = "Informa UK Limited",
  volume    =  5,
  number    =  1,
  pages     = "101--107",
  month     =  jan,
  year      =  2021,
  keywords  = "Anti-MDA5; COVID-19; interstitial lung disease (ILD); juvenile
               dermatomyositis; tofacitinib",
  language  = "en"
}

@ARTICLE{Elgohary2021-bc,
  title     = "Thymoquinone: A tie-breaker in {SARS-CoV2-infected} cancer
               patients?",
  author    = "Elgohary, Sawsan and Elkhodiry, Aya A and Amin, Nada S and
               Stein, Ulrike and El Tayebi, Hend M",
  abstract  = "Since the beginning of the SARS-CoV-2(severe acute respiratory
               syndrome-coronavirus-2) pandemic, arace to develop a vaccine has
               been initiated, considering the massive and rather significant
               economic and healthcare hits that this virus has caused. The
               pathophysiology occurring following COVID-19(coronavirus
               disease-2019) infection has givenhints regarding the supportive
               and symptomatic treatments to establish for patients, as no
               specific anti-SARS-CoV-2 is available yet. Patient symptoms vary
               greatly and range from mild symptoms to severe fatal
               complications. Supportive treatments include antipyretics,
               antiviral therapies, different combinations of broad-spectrum
               antibiotics, hydroxychloroquine and plasma transfusion.
               Unfortunately, cancer patients are at higher risk of viral
               infection and more likely to develop serious complications due
               to their immunocompromised state, the fact that they are already
               administering multiple medications, as well as combined
               comorbidity compared to the general population. It may seem
               impossible to find a drug that possesses both potent antiviral
               and anticancer effects specifically against COVID-19 infection
               and its complications and the existing malignancy, respectively.
               Thymoquinone (TQ) is the most pharmacologically active
               ingredient in Nigella sativa seeds (black seeds); it is reported
               to have anticancer, anti-inflammatory and antioxidant effects in
               various settings. In this review, we will discuss the multiple
               effects of TQ specifically against COVID-19, its beneficial
               effects against COVID-19 pathophysiology and multiple-organ
               complications, its use as an adjuvant for supportive COVID-19
               therapy and cancer therapy, and finally, its anticancer effects.",
  journal   = "Cells",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  2,
  pages     = "302",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; COVID-19 complications; COVID-19 treatments; GRP78;
               Nrf2; RAS; SARS-CoV-2; anticancer drugs; apoptosis; cancer;
               thymoquinone",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Shaunak2021-sy,
  title     = "{COVID-19} symptom surveillance in immunocompromised children
               and young people in the {UK}: a prospective observational cohort
               study",
  author    = "Shaunak, Meera and Patel, Ravin and Driessens, Corine and Mills,
               Lynne and Leahy, Alice and Gbesemete, Diane and Owens, Daniel R
               and Lucas, Jane S and Faust, Saul N and de Graaf, Hans and
               {ImmunoCOVID19 study group}",
  abstract  = "OBJECTIVES: To describe the frequency of symptoms compatible
               with SARS-CoV-2 infection in immunocompromised children and
               young people in the UK during the SARS-CoV-2 pandemic. To
               describe patient/parent anxiety regarding SARS-CoV-2 infection
               in this cohort. DESIGN: A prospective observational cohort
               study. SETTING: 46 centres across the UK between 16 March and 4
               July 2020. A weekly online questionnaire based on the
               International Severe Acute Respiratory and emerging Infections
               Consortium-WHO Case Report Form was used to collect participant
               reported data on symptoms, test results, National Health Service
               attendance, hospital admission and impact on daily life.
               PARTICIPANTS: 1490 immunocompromised children, defined as those
               requiring an annual influenza vaccination due to their
               underlying condition or medication. MAIN OUTCOME MEASURES:
               Incidence of SARS-CoV-2-like symptoms and patient/parent anxiety
               score. RESULTS: Over 16 weeks during the first wave of the
               pandemic, no SARS-CoV-2 infection was diagnosed in this large
               immunocompromised paediatric cohort (median age 11 years, 54.4\%
               female). 110 symptomatic participants underwent a test for
               SARS-CoV-2; all were negative. 922 (67.4\%) participants
               reported at least one symptom consistent with suspected
               SARS-CoV-2 infection over the study period. 476 (34.8\%)
               reported three or more symptoms. The most frequently reported
               symptoms included joint pain, fatigue, headache, nausea and
               muscle pain. SARS-CoV-2 testing during this period was performed
               on admitted patients only. 137 participants had their medication
               suspended or changed during the study period due to assumed
               COVID-19 disease risk. 62\% reported high levels of anxiety
               (scores of 7-10 out of 10) at the start of the study, with
               anxiety levels remaining high throughout the study period.
               CONCLUSIONS: Although symptoms related to SARS-CoV-2 infection
               in children were common, there were no positive tests in this
               large immunocompromised cohort. Symptom-based screening to
               facilitate early detection of SARS-CoV-2 infection may not be
               helpful in these individuals. Patient/parent anxiety about
               SARS-CoV-2 infection was high. TRIAL REGISTRATION NUMBER:
               NCT04382508.",
  journal   = "BMJ Open",
  publisher = "BMJ",
  volume    =  11,
  number    =  3,
  pages     = "e044899",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; immunology; paediatric infectious disease \&
               immunisation; paediatrics",
  language  = "en"
}

@ARTICLE{Suryana_K2021-bh,
  title    = "Coinfection between {SARS-CoV-2} and {HIV} with a low {CD4+}
              T-cells count",
  author   = "Suryana K, C S",
  abstract = "Coronavirus Disease 2019 (COVID-19) is an acute respiratory
              infectious disease caused by the Severe Acute Respiratory
              Syndrome Coronavirus 2 (SARS-CoV-2) infection that started in
              Wuhan, China in December 2019 and has spread rapidly worldwide.
              It's critical to take extra precautions if a person has chronic
              illnesses (comorbidities), such as human immunodeficiency (HIV)
              infection. Concerns about people living with HIV (PLHIV) having a
              higher risk of serious COVID-19 disease may be based on the
              assumption that PLHIV are more likely to be immunocompromised. On
              the other hand, limited information is available in such people
              about the characteristics of co-infection between SARS-CoV-2 and
              Human Immunodeficiency Virus (HIV) who are at greater risk than
              the general population. Our findings, is of a 32 year old patient
              who came to Emergency Unit of Wangaya Hospital, Medical Faculty,
              Udayana University in Denpasar, Bali with complaint of fever, dry
              cough, and shortness of breath since prior 3 days and had also
              the past history prolonged fever, weight loss more than 10\% 4
              weeks. Diagnosis of COVID-19 was confirmed by nasopharyngeal swab
              sample was used for RT-PCR assay and PITC to confirm HIV
              infection. He had prolonged hospitalized and discharge after 18
              days.",
  journal  = "Med. J. Malaysia",
  volume   =  76,
  number   =  3,
  pages    = "446--448",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Barriere2021-td,
  title     = "Current perspectives for {SARS-CoV-2} vaccination efficacy
               improvement in patients with active treatment against cancer",
  author    = "Barri{\`e}re, J{\'e}r{\^o}me and Re, Daniel and Peyrade,
               Fr{\'e}d{\'e}ric and Carles, Michel",
  abstract  = "A higher risk of death from coronavirus disease 19 has been
               shown for patients with solid cancers or haematological
               malignancies (HM). Thanks to the accelerated development of
               anti-SARS-SoV-2 vaccines in less than a year since the start of
               the global pandemic, patients with cancer were quickly
               prioritised in early 2021 for vaccination, however dependent on
               the very unequal availability at the global level. Impaired
               immunogenicity of SARS-CoV-2 mRNA vaccines in immunocompromised
               patients was rapidly reported as early as April 2021, although
               the vaccination fortunately appears to be generally effective
               without increasing the spacing. Worryingly, the humoral response
               of the SARS-CoV-2 vaccination is, however, considered
               insufficient in patients followed for HM, in particular when
               they are on anti-CD20 treatment. Thus, improving vaccination
               coverage by strengthening immune stimulation should be evaluated
               in patients under active treatment against cancer. Here, we
               discuss three different approaches: a third dose of early
               vaccine (repeated immune stimulation), heterologous prime-boost
               vaccination (multimodal immune stimulation) and a double-dose
               strategy (maximisation of immune response). Dedicated
               therapeutic trials, currently almost non-existent, seem rapidly
               necessary.",
  journal   = "Eur. J. Cancer",
  publisher = "Elsevier BV",
  volume    =  154,
  pages     = "66--72",
  month     =  sep,
  year      =  2021,
  keywords  = "ARNm; COVID-19; Cancer; Double-dose; Heterologous prime-boost
               vaccination; Immunogenicity; SARS-CoV-2 vaccination; Third dose;
               Tumours; Vaccine",
  language  = "en"
}

@ARTICLE{Lu2021-hy,
  title     = "A methyltransferase-defective vesicular stomatitis virus-based
               {SARS-CoV-2} vaccine candidate provides complete protection
               against {SARS-CoV-2} infection in hamsters",
  author    = "Lu, Mijia and Zhang, Yuexiu and Dravid, Piyush and Li, Anzhong
               and Zeng, Cong and Kc, Mahesh and Trivedi, Sheetal and Sharma,
               Himanshu and Chaiwatpongsakorn, Supranee and Zani, Ashley and
               Kenney, Adam and Cai, Chuanxi and Ye, Chengjin and Liang, Xueya
               and Qiu, Jianming and Martinez-Sobrido, Luis and Yount, Jacob S
               and Boyaka, Prosper N and Liu, Shan-Lu and Peeples, Mark E and
               Kapoor, Amit and Li, Jianrong",
  abstract  = "The current pandemic of coronavirus disease 2019 (COVID-19)
               caused by severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) has led to dramatic economic and health burdens.
               Although the worldwide SARS-CoV-2 vaccination campaign has
               begun, exploration of other vaccine candidates is needed due to
               uncertainties with the current approved vaccines, such as
               durability of protection, cross-protection against variant
               strains, and costs of long-term production and storage. In this
               study, we developed a methyltransferase-defective recombinant
               vesicular stomatitis virus (mtdVSV)-based SARS-CoV-2 vaccine
               candidate. We generated mtdVSVs expressing SARS-CoV-2
               full-length spike (S) protein, S1, or its receptor-binding
               domain (RBD). All of these recombinant viruses grew to high
               titers in mammalian cells despite high attenuation in cell
               culture. The SARS-CoV-2 S protein and its truncations were
               highly expressed by the mtdVSV vector. These mtdVSV-based
               vaccine candidates were completely attenuated in both
               immunocompetent and immunocompromised mice. Among these
               constructs, mtdVSV-S induced high levels of SARS-CoV-2-specific
               neutralizing antibodies (NAbs) and Th1-biased T-cell immune
               responses in mice. In Syrian golden hamsters, the serum levels
               of SARS-CoV-2-specific NAbs triggered by mtdVSV-S were higher
               than the levels of NAbs in convalescent plasma from recovered
               COVID-19 patients. In addition, hamsters immunized with mtdVSV-S
               were completely protected against SARS-CoV-2 replication in lung
               and nasal turbinate tissues, cytokine storm, and lung pathology.
               Collectively, our data demonstrate that mtdVSV expressing
               SARS-CoV-2 S protein is a safe and highly efficacious vaccine
               candidate against SARS-CoV-2 infection. IMPORTANCE Viral mRNA
               cap methyltransferase (MTase) is essential for mRNA stability,
               protein translation, and innate immune evasion. Thus, viral mRNA
               cap MTase activity is an excellent target for development of
               live attenuated or live vectored vaccine candidates. Here, we
               developed a panel of MTase-defective recombinant vesicular
               stomatitis virus (mtdVSV)-based SARS-CoV-2 vaccine candidates
               expressing full-length S, S1, or several versions of the RBD.
               These mtdVSV-based vaccine candidates grew to high titers in
               cell culture and were completely attenuated in both
               immunocompetent and immunocompromised mice. Among these vaccine
               candidates, mtdVSV-S induces high levels of SARS-CoV-2-specific
               neutralizing antibodies (Nabs) and Th1-biased immune responses
               in mice. Syrian golden hamsters immunized with mtdVSV-S
               triggered SARS-CoV-2-specific NAbs at higher levels than those
               in convalescent plasma from recovered COVID-19 patients.
               Furthermore, hamsters immunized with mtdVSV-S were completely
               protected against SARS-CoV-2 challenge. Thus, mtdVSV is a safe
               and highly effective vector to deliver SARS-CoV-2 vaccine.",
  journal   = "J. Virol.",
  publisher = "American Society for Microbiology",
  volume    =  95,
  number    =  20,
  pages     = "e0059221",
  month     =  sep,
  year      =  2021,
  keywords  = "SARS-CoV-2; VSV; mRNA cap methyltransferase; vaccine",
  copyright = "https://doi.org/10.1128/ASMCopyrightv2",
  language  = "en"
}

@ARTICLE{Parums2021-xy,
  title     = "Editorial: First full regulatory approval of a {COVID-19}
               vaccine, the {BNT162b2} {Pfizer-BioNTech} vaccine, and the
               real-world implications for public health policy",
  author    = "Parums, Dinah V",
  abstract  = "In the past 18 months, accelerated vaccine development to
               prevent or reduce the severity of coronavirus disease 2019
               (COVID-19) has resulted in rapid global emergency regulatory
               approvals, including the US Food and Drug Administration (FDA)
               emergency use authorization (EUA) approvals. On August 23, 2021,
               the US FDA gave the first full regulatory approval for a
               COVID-19 vaccine and approved the Pfizer-BioNTech COVID-19
               vaccine (Comirnaty) for individuals 16 years and older. In the
               US, there is a continued EUA for individuals aged 12-15 years of
               age. Also, the EUA includes the administration of a third or
               booster dose in immunocompromised individuals at increased risk
               for severe COVID-19. This Editorial aims to present an update on
               the first COVID-19 vaccine to receive full regulatory approval,
               the Pfizer-BioNTech vaccine, and the implications for real-world
               public health during the global COVID-19 pandemic and increasing
               concerns for severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) variants of concern.",
  journal   = "Med. Sci. Monit.",
  publisher = "International Scientific Information, Inc.",
  volume    =  27,
  pages     = "e934625",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Gaudino2021-hg,
  title     = "Case report: {SARS-CoV-2} infection in a child with suprasellar
               tumor and hypothalamic-pituitary failure",
  author    = "Gaudino, Rossella and Orlandi, Valentina and Cavarzere, Paolo
               and Chinello, Matteo and Antoniazzi, Franco and Cesaro, Simone
               and Piacentini, Giorgio",
  abstract  = "In early 2020, a novel coronavirus leading to potentially death
               was discovered. Since then, the 2019 coronavirus disease
               (COVID-19) has spread to become a worldwide pandemic. Beyond the
               risks strictly related to the infection, concerns have been
               expressed for the endocrinological impact that COVID-19 may
               have, especially in vulnerable individuals with pre-existing
               endocrinological health conditions. To date new information is
               emerging regarding severe acute respiratory syndrome-related
               coronavirus 2 (SARS-CoV-2) in children but the literature is
               still scarce concerning this infection in patients with
               intracranial malignant neoplasms. We report a 9-year-old child
               infected with SARS-CoV-2 and recent diagnosis of suprasellar
               non-germinomatous germ cell tumor also suffering from diabetes
               insipidus and hypothalamic-pituitary failure (hypothyroidism,
               adrenal insufficiency, hypothalamic obesity and growth hormone
               deficiency) and its clinical course. The patient remained
               asymptomatic for the duration of the infection without requiring
               any change in the replacement therapeutic dosages taken before
               the infection. We then discuss the proposed approach to treat a
               pediatric patient with SARS-CoV-2 infection and
               hypothalamic-pituitary failure and we include a review of the
               literature. Our report suggests that SARS-CoV-2 infection is
               usually mild and self-limiting in children even those
               immunocompromised and with multiple endocrinological deficits.
               Patients are advised to keep any scheduled appointments unless
               informed otherwise.",
  journal   = "Front. Endocrinol. (Lausanne)",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "596654",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; GNS germ cell tumor; Sars-CoV2; diabetes insipidus;
               hypothalamic-pituitary failure; pediatric endocrinology",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Donroe2021-fu,
  title    = "A broader view of risk to health care workers: Perspectives on
              supporting vulnerable health care professional households during
              {COVID-19}",
  author   = "Donroe, Joseph H and Rabin, Tracy L and Hsieh, Evelyn and
              Schwartz, Jeremy I",
  abstract = "The COVID-19 pandemic has highlighted both that frontline workers
              face a new set of personal hazards in health care settings and
              that there are not well-established recommendations to address
              the broader risks to these workers and their families.
              Particularly vulnerable households include dual health care
              professional households, single-parent health care professional
              households, and households with health care professionals
              responsible for a high-risk family member (i.e., an older adult
              or immunocompromised person). While the demographics of these
              households are heterogeneous, it is expected that the
              professional and personal concerns specific to COVID-19 will be
              similar. These concerns include family safety, balancing
              full-time work with home-based schooling for children, the
              looming threat of illness to 1 or both partners, the potential of
              infecting high-risk family members, and the challenges of
              planning for the future during uncertain times. To elucidate
              these concerns in their department, the authors sought input from
              colleagues in dual health care professional households through an
              open-ended email communication. Respondents expressed a range of
              concerns centered on balancing professional and family
              responsibilities during the COVID-19 pandemic. In this
              commentary, the authors propose several recommendations in the
              areas of support networks, leadership and culture, and operations
              and logistics that health care institutions can adopt to minimize
              the burden on these vulnerable households during states of
              emergency. The successful implementation of these recommendations
              hinges on creating a work environment in which all health care
              providers feel comfortable voicing their concerns.",
  journal  = "Acad. Med.",
  volume   =  96,
  number   =  9,
  pages    = "1233--1235",
  month    =  sep,
  year     =  2021,
  language = "en"
}

@ARTICLE{Gupta2021-qq,
  title     = "Cancer patients and {COVID-19}: Mortality, serious
               complications, biomarkers, and ways forward",
  author    = "Gupta, Kush and Gandhi, Shipra and Mebane, 3rd, Alexander and
               Singh, Angelica and Vishnuvardhan, Nivetha and Patel, Eshan",
  abstract  = "The SARS-CoV-2 (COVID-19) pandemic has particularly serious
               consequences for cancer patients, as they are at high risk for
               severe complications and mortality due to the virus since cancer
               patients are immunocompromised. Preliminary evidence suggests
               that patients with hematological, and metastatic malignancies
               are particularly susceptible to developing severe COVID-19
               illness, which leads to poor prognosis. Biomarkers including
               C-reactive protein and interleukin-6 may be predictors of
               outcome and, therefore, crucial in assessing COVID-19 illness
               severity in cancer patients. A patient-specific risk and benefit
               inventory should be completed, and expert guidelines consulted
               when deciding to continue or postpone therapeutic interventions.
               This review presents preliminary evidence of COVID-19 infection
               and its impact on cancer, as well as discussion of general
               guidelines for the treatment and management of cancer patients
               with COVID-19.",
  journal   = "Cancer Treat. Res. Commun.",
  publisher = "Elsevier BV",
  volume    =  26,
  number    =  100285,
  pages     = "100285",
  year      =  2021,
  keywords  = "Biomarkers; C-reactive protein; Covid-19; Interleukin-6; Sever
               acute respiratory syndrome coronavirus 2",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Tenforde2021-jq,
  title    = "Sustained effectiveness of {Pfizer-BioNTech} and Moderna vaccines
              against {COVID-19} associated hospitalizations among adults -
              United States, march-July 2021",
  author   = "Tenforde, Mark W and Self, Wesley H and Naioti, Eric A and Ginde,
              Adit A and Douin, David J and Olson, Samantha M and Talbot, H
              Keipp and Casey, Jonathan D and Mohr, Nicholas M and Zepeski,
              Anne and Gaglani, Manjusha and McNeal, Tresa and Ghamande,
              Shekhar and Shapiro, Nathan I and Gibbs, Kevin W and Files, D
              Clark and Hager, David N and Shehu, Arber and Prekker, Matthew E
              and Erickson, Heidi L and Gong, Michelle N and Mohamed, Amira and
              Henning, Daniel J and Steingrub, Jay S and Peltan, Ithan D and
              Brown, Samuel M and Martin, Emily T and Monto, Arnold S and Khan,
              Akram and Hough, Catherine L and Busse, Laurence W and Ten
              Lohuis, Caitlin C and Duggal, Abhijit and Wilson, Jennifer G and
              Gordon, Alexandra June and Qadir, Nida and Chang, Steven Y and
              Mallow, Christopher and Rivas, Carolina and Babcock, Hilary M and
              Kwon, Jennie H and Exline, Matthew C and Halasa, Natasha and
              Chappell, James D and Lauring, Adam S and Grijalva, Carlos G and
              Rice, Todd W and Jones, Ian D and Stubblefield, William B and
              Baughman, Adrienne and Womack, Kelsey N and Lindsell, Christopher
              J and Hart, Kimberly W and Zhu, Yuwei and Stephenson, Meagan and
              Schrag, Stephanie J and Kobayashi, Miwako and Verani, Jennifer R
              and Patel, Manish M and {IVY Network Investigators} and {IVY
              Network}",
  abstract = "Real-world evaluations have demonstrated high effectiveness of
              vaccines against COVID-19-associated hospitalizations (1-4)
              measured shortly after vaccination; longer follow-up is needed to
              assess durability of protection. In an evaluation at 21 hospitals
              in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or
              Moderna) effectiveness (VE) against COVID-19-associated
              hospitalizations was assessed among adults aged $\geq$18 years.
              Among 3,089 hospitalized adults (including 1,194 COVID-19
              case-patients and 1,895 non-COVID-19 control-patients), the
              median age was 59 years, 48.7\% were female, and 21.1\% had an
              immunocompromising condition. Overall, 141 (11.8\%) case-patients
              and 988 (52.1\%) controls were fully vaccinated (defined as
              receipt of the second dose of Pfizer-BioNTech or Moderna mRNA
              COVID-19 vaccines $\geq$14 days before illness onset), with a
              median interval of 65 days (range = 14-166 days) after receipt of
              second dose. VE against COVID-19-associated hospitalization
              during the full surveillance period was 86\% (95\% confidence
              interval [CI] = 82\%-88\%) overall and 90\% (95\% CI = 87\%-92\%)
              among adults without immunocompromising conditions. VE against
              COVID-19- associated hospitalization was 86\% (95\% CI =
              82\%-90\%) 2-12 weeks and 84\% (95\% CI = 77\%-90\%) 13-24 weeks
              from receipt of the second vaccine dose, with no significant
              change between these periods (p = 0.854). Whole genome sequencing
              of 454 case-patient specimens found that 242 (53.3\%) belonged to
              the B.1.1.7 (Alpha) lineage and 74 (16.3\%) to the B.1.617.2
              (Delta) lineage. Effectiveness of mRNA vaccines against
              COVID-19-associated hospitalization was sustained over a 24-week
              period, including among groups at higher risk for severe
              COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants
              emerge. To reduce their risk for hospitalization, all eligible
              persons should be offered COVID-19 vaccination.",
  journal  = "MMWR Morb. Mortal. Wkly. Rep.",
  volume   =  70,
  number   =  34,
  pages    = "1156--1162",
  month    =  aug,
  year     =  2021,
  language = "en"
}

@ARTICLE{Fields2021-ij,
  title     = "Imaging of {COVID-19}: {CT}, {MRI}, and {PET}",
  author    = "Fields, Brandon K K and Demirjian, Natalie L and Dadgar,
               Habibollah and Gholamrezanezhad, Ali",
  abstract  = "Soon after reports of a novel coronavirus capable of causing
               severe pneumonia surfaced in late 2019, expeditious global
               spread of the Severe Acute Respiratory Distress Syndrome
               Coronavirus 2 (SARS-CoV-2) forced the World Health Organization
               to declare an international state of emergency. Although best
               known for causing symptoms of upper respiratory tract infection
               in mild cases and fulminant pneumonia in severe disease,
               Coronavirus Disease 2019 (COVID-19) has also been associated
               with gastrointestinal, neurologic, cardiac, and hematologic
               presentations. Despite concerns over poor specificity and undue
               radiation exposure, chest imaging nonetheless remains central to
               the initial diagnosis and monitoring of COVID-19 progression, as
               well as to the evaluation of complications. Classic features on
               chest CT include ground-glass and reticular opacities with or
               without superimposed consolidations, frequently presenting in a
               bilateral, peripheral, and posterior distribution. More
               recently, studies conducted with MRI have shown excellent
               concordance with chest CT in visualizing typical features of
               COVID-19 pneumonia. For patients in whom exposure to ionizing
               radiation should be avoided, particularly pregnant patients and
               children, pulmonary MRI may represent a suitable alternative to
               chest CT. Although PET imaging is not typically considered among
               first-line investigative modalities for the diagnosis of lower
               respiratory tract infections, numerous reports have noted
               incidental localization of radiotracer in parenchymal regions of
               COVID-19-associated pulmonary lesions. These findings are
               consistent with data from Middle East Respiratory Syndrome-CoV
               cohorts which suggested an ability for 18F-FDG PET to detect
               subclinical infection and lymphadenitis in subjects without
               overt clinical signs of infection. Though highly sensitive, use
               of PET/CT for primary detection of COVID-19 is constrained by
               poor specificity, as well as considerations of cost, radiation
               burden, and prolonged exposure times for imaging staff. Even
               still, decontamination of scanner bays is a time-consuming
               process, and proper ventilation of scanner suites may
               additionally require up to an hour of downtime to allow for
               sufficient air exchange. Yet, in patients who require nuclear
               medicine investigations for other clinical indications, PET
               imaging may yield the earliest detection of nascent infection in
               otherwise asymptomatic individuals. Especially for patients with
               concomitant malignancies and other states of immunocompromise,
               prompt recognition of infection and early initiation of
               supportive care is crucial to maximizing outcomes and improving
               survivability.",
  journal   = "Semin. Nucl. Med.",
  publisher = "Elsevier BV",
  volume    =  51,
  number    =  4,
  pages     = "312--320",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Theodore2021-mm,
  title     = "Cycle thresholds among solid organ transplant recipients testing
               positive for {SARS-CoV-2}",
  author    = "Theodore, Deborah A and Greendyke, William G and Miko, Benjamin
               and Whittier, Susan and Green, Daniel A and Shoucri, Sherif and
               Verna, Elizabeth C and Zucker, Jason and Sobieszczyk, Magdalena
               E and Aaron, Justin G and Scully, Brian E and Saiman, Lisa and
               Pereira, Marcus and Furuya, E Yoko",
  abstract  = "BACKGROUND: The optimal duration of transmission-based
               precautions among immunocompromised patients with severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown.
               METHODS: Retrospective review of patients with solid organ
               transplant with positive SARS-CoV-2 polymerase chain reaction
               result from nasopharyngeal specimens admitted to the hospital
               between March 13, 2020 and May 15, 2020. RESULTS: Twenty-one
               percent of solid organ transplant recipients with positive
               SARS-CoV-2 polymerase chain reaction detected $\geq$20 d after
               symptom onset (or after first positive test among asymptomatic
               individuals) had a low cycle threshold (ie, high viral load).
               The majority of these patients were asymptomatic or
               symptomatically improved. CONCLUSIONS: Solid organ transplant
               recipients may have prolonged high viral burden of SARS-CoV-2.
               Further data are needed to understand whether cycle threshold
               data can help inform strategies for prevention of
               healthcare-associated transmission of SARS-CoV-2 and for
               appropriate discontinuation of transmission-based precautions.",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  105,
  number    =  7,
  pages     = "1445--1448",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Hause2021-gv,
  title     = "Safety monitoring of an additional dose of {COVID-19} vaccine -
               United States, August 12-September 19, 2021",
  author    = "Hause, Anne M and Baggs, James and Gee, Julianne and Marquez,
               Paige and Myers, Tanya R and Shimabukuro, Tom T and Shay, David
               K",
  abstract  = "On August 12, 2021, the Food and Drug Administration (FDA)
               amended Emergency Use Authorizations (EUAs) for the
               Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize
               administration of an additional dose after completion of a
               primary vaccination series to eligible persons with moderate to
               severe immunocompromising conditions (1,2). On September 22,
               2021, FDA authorized an additional dose of Pfizer-BioNTech
               vaccine $\geq$6 months after completion of the primary series
               among persons aged $\geq$65 years, at high risk for severe
               COVID-19, or whose occupational or institutional exposure puts
               them at high risk for COVID-19 (1). Results from a phase 3
               clinical trial conducted by Pfizer-BioNTech that included 306
               persons aged 18-55 years showed that adverse reactions after
               receipt of a third dose administered 5-8 months after completion
               of a 2-dose primary mRNA vaccination series were similar to
               those reported after receipt of dose 2; these adverse reactions
               included mild to moderate injection site and systemic reactions
               (3). CDC developed v-safe, a voluntary, smartphone-based safety
               surveillance system, to provide information on adverse reactions
               after COVID-19 vaccination. Coincident with authorization of an
               additional dose for persons with immunocompromising conditions,
               the v-safe platform was updated to allow registrants to enter
               information about additional doses of COVID-19 vaccine received.
               During August 12-September 19, 2021, a total of 22,191 v-safe
               registrants reported receipt of an additional dose of COVID-19
               vaccine. Most (97.6\%) reported a primary 2-dose mRNA
               vaccination series followed by a third dose of the same vaccine.
               Among those who completed a health check-in survey for all 3
               doses (12,591; 58.1\%), 79.4\% and 74.1\% reported local or
               systemic reactions, respectively, after dose 3, compared with
               77.6\% and 76.5\% who reported local or systemic reactions,
               respectively, after dose 2. These initial findings indicate no
               unexpected patterns of adverse reactions after an additional
               dose of COVID-19 vaccine; most of these adverse reactions were
               mild or moderate. CDC will continue to monitor vaccine safety,
               including the safety of additional doses of COVID-19 vaccine,
               and provide data to guide vaccine recommendations and protect
               public health.",
  journal   = "MMWR Morb. Mortal. Wkly. Rep.",
  publisher = "Centers for Disease Control MMWR Office",
  volume    =  70,
  number    =  39,
  pages     = "1379--1384",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Maison-Fomotar2021-uq,
  title     = "Bordetella hinzii pneumonia and bacteremia in a patient with
               {SARS-CoV-2} infection",
  author    = "Maison-Fomotar, Michele and Sivasubramanian, Geetha",
  abstract  = "Patients with severe acute respiratory syndrome coronavirus 2
               infection may have bacterial co-infections, including pneumonia
               and bacteremia. Bordetella hinzii infections are rare, may be
               associated with exposure to poultry, and have been reported
               mostly among immunocompromised patients. We describe B. hinzii
               pneumonia and bacteremia in a severe acute respiratory syndrome
               coronavirus 2 patient.",
  journal   = "Emerg. Infect. Dis.",
  publisher = "Centers for Disease Control and Prevention (CDC)",
  volume    =  27,
  number    =  11,
  pages     = "2904--2907",
  month     =  nov,
  year      =  2021,
  keywords  = "Bordetella; Bordetella hinzii; COVID-19; SARS-CoV-2; bacteremia;
               bacteria; cholangitis; coccobacilli; coronavirus disease;
               endocarditis; pneumonia; respiratory infections; severe acute
               respiratory syndrome coronavirus 2; soft tissue infections;
               urinary tract infections; zoonoses",
  language  = "en"
}

@ARTICLE{Epstein2021-rh,
  title     = "Time to {SARS-CoV-2} {PCR} clearance in immunocompromising
               conditions: Is test-based removal from isolation necessary in
               severely immunocompromised individuals?",
  author    = "Epstein, Rachel L and Sperring, Heather and Hofman, Melissa and
               Lodi, Sara and White, Laura F and Barocas, Joshua A and Bouton,
               Tara C and Xiao, Yian and Hsu, Heather E and Miller, Nancy S and
               Linas, Benjamin P and Marathe, Jai G",
  abstract  = "To determine the association between immunosuppression and time
               to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               polymerase chain reaction (PCR) clearance, we studied 3758
               adults retested following initial SARS-CoV-2 infection. Cox
               proportional hazards models demonstrated delayed PCR clearance
               with older age, multiple comorbidities, and solid organ
               transplant but not by degree of immunocompromise. These findings
               challenge current retesting practices.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  6,
  pages     = "ofab164",
  month     =  jun,
  year      =  2021,
  keywords  = "SARS-CoV-2; coronavirus disease 2019 (COVID-19); disease
               severity; immunocompromised host; immunosuppression; polymerase
               chain reaction; virus shedding",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Mbaeyi2021-dc,
  title     = "The Advisory Committee on Immunization Practices' interim
               recommendations for additional primary and booster doses of
               {COVID-19} vaccines - United States, 2021",
  author    = "Mbaeyi, Sarah and Oliver, Sara E and Collins, Jennifer P and
               Godfrey, Monica and Goswami, Neela D and Hadler, Stephen C and
               Jones, Jefferson and Moline, Heidi and Moulia, Danielle and
               Reddy, Sujan and Schmit, Kristine and Wallace, Megan and
               Chamberland, Mary and Campos-Outcalt, Doug and Morgan, Rebecca L
               and Bell, Beth P and Brooks, Oliver and Kotton, Camille and
               Talbot, H Keipp and Lee, Grace and Daley, Matthew F and Dooling,
               Kathleen",
  abstract  = "Three COVID-19 vaccines are currently approved under a Biologics
               License Application (BLA) or authorized under an Emergency Use
               Authorization (EUA) by the Food and Drug Administration (FDA)
               and recommended for primary vaccination by the Advisory
               Committee on Immunization Practices (ACIP) in the United States:
               the 2-dose mRNA-based Pfizer-BioNTech/Comirnaty and Moderna
               COVID-19 vaccines and the single-dose adenovirus vector-based
               Janssen (Johnson \& Johnson) COVID-19 vaccine (1,2) (Box 1). In
               August 2021, FDA amended the EUAs for the two mRNA COVID-19
               vaccines to allow for an additional primary dose in certain
               immunocompromised recipients of an initial mRNA COVID-19
               vaccination series (1). During September-October 2021, FDA
               amended the EUAs to allow for a COVID-19 vaccine booster dose
               following a primary mRNA COVID-19 vaccination series in certain
               recipients aged $\geq$18 years who are at increased risk for
               serious complications of COVID-19 or exposure to SARS-CoV-2 (the
               virus that causes COVID-19), as well as in recipients aged
               $\geq$18 years of Janssen COVID-19 vaccine (1) (Table). For the
               purposes of these recommendations, an additional primary
               (hereafter additional) dose refers to a dose of vaccine
               administered to persons who likely did not mount a protective
               immune response after initial vaccination. A booster dose refers
               to a dose of vaccine administered to enhance or restore
               protection by the primary vaccination, which might have waned
               over time. Health care professionals play a critical role in
               COVID-19 vaccination efforts, including for primary, additional,
               and booster vaccination, particularly to protect patients who
               are at increased risk for severe illness and death.",
  journal   = "MMWR Morb. Mortal. Wkly. Rep.",
  publisher = "Centers for Disease Control MMWR Office",
  volume    =  70,
  number    =  44,
  pages     = "1545--1552",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Di_Giacomo2021-pi,
  title    = "Delirium in the ``young'' covid-19 patient (<65 years):
              preliminary clinical indications",
  author   = "Di Giacomo, Ester and Colmegna, Fabrizia and Santorelli, Mario
              and Pessina, Rodolfo and D'Amico, Emiliano and Marcatili, Matteo
              and Dakanalis, Antonios and Pavone, Fabrizio and Fagiolini,
              Andrea and Clerici, Massimo",
  abstract = "Delirium is a phenomenon classified within neuro-cognitive
              disorders in the DSM-5. It has several etiologies and it is often
              lethal. This contribute aims at analyzing clinical
              characteristics and diagnostic possibilities of delirium in
              patients affected by covid-19. Furthermore, some preliminary
              recommendations on the use of psychopharmacological treatment of
              delirium and their interactions with main drugs used to treat
              covid-19 are given, with a special attention to comorbidities
              like in immunocompromised patients, in those affected by diabetes
              and cancer, in pregnant women or in addicted clients.",
  journal  = "Riv. Psichiatr.",
  volume   =  56,
  number   =  2,
  pages    = "85--92",
  month    =  jan,
  year     =  2021,
  language = "it"
}

@ARTICLE{Avatef_Fazeli2021-uj,
  title     = "Increased incidence of rhino-orbital mucormycosis in an
               educational therapeutic hospital during the {COVID-19} pandemic
               in western Iran: An observational study",
  author    = "Avatef Fazeli, Manouchehr and Rezaei, Leila and Javadirad, Etrat
               and Iranfar, Khosro and Khosravi, Abbas and Amini Saman, Javad
               and Poursabbagh, Pardis and Ghadami, Mohammad Rasoul and
               Parandin, Mohammad Mehdi and Dehghani, Amrollah and Ahmadi
               Jouybari, Touraj and Mahdavian, Behzad and Eivazi, Nastaran and
               Rezaei, Sohbat and Rezaei, Alireza and Emami, Bashir and Haqgou,
               Mohadeseh and Bozorgomid, Arezoo and Sayad, Babak",
  abstract  = "BACKGROUND: COVID-19 patients, especially the patients requiring
               hospitalisation, have a high risk of several complications such
               as opportunistic bacterial and fungal infections. Mucormycosis
               is a rare and opportunistic fungal infection that mainly affects
               diabetic and immunocompromised patients. An increase has been
               observed in the number of rhino-orbital mucormycosis in patients
               with COVID-19 admitted to Imam Khomeini Hospital, Kermanshah,
               Iran, since October 2020. This is a report of the frequency,
               risk factors, clinical manifestations, treatment and prognosis
               of COVID-19 associated with mucormycosis infection. METHODS: The
               medical records of COVID-19 patients with rhino-orbital
               mucormycosis who were diagnosed in an educational therapeutic
               hospital in Kermanshah, west of Iran were surveyed. Several
               parameters were analysed including demographic, clinical,
               therapeutic and laboratory characteristics. RESULTS: Twelve
               patients with COVID-19-associated rhino-orbital mucormycosis
               were identified from 12 October to 18 November 2020. All cases
               reported as proven mucormycosis had a history of hospitalisation
               due to COVID-19. Comorbidities mainly included diabetes mellitus
               (83.33\%) and hypertension (58.33\%). Seventy-five per cent of
               patients received corticosteroids for COVID- 19 treatment. The
               sites of involvement were rhino-sino-orbital (83\%) and
               rhino-sino (17\%). Amphotericin B/liposomal amphotericin B alone
               or in combination with surgical debridement or orbital
               exenteration was used as the first-line therapy. The overall
               mortality rate was 66.7\% (8/12). CONCLUSIONS: We found a high
               incidence of mucormycosis among COVID-19 patients. Diabetes
               mellitus and corticosteroid use were the dominant predisposing
               factor of mucormycosis. Mucormycosis is a life-threatening and
               opportunistic infection; therefore, physicians should know the
               signs and symptoms of the disease so that a timely diagnosis and
               therapy can be performed.",
  journal   = "Mycoses",
  publisher = "Wiley",
  volume    =  64,
  number    =  11,
  pages     = "1366--1377",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Iran; SARS-CoV-2; co-infection; mucormycosis",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Arya2021-yk,
  title     = "{COVID-19} in solid organ transplantation: Disease severity and
               clinical update",
  author    = "Arya, Akanksha and Li, Michael and Aburjania, Nana and Singh,
               Pooja and Royer, Tricia and Moss, Sean and Belden, Katherine A",
  abstract  = "BACKGROUND: Solid organ transplant (SOT) recipients are a
               complex, immunocompromised population in whom greater
               coronavirus disease 2019 (COVID-19) mortality has been reported
               compared with the general population. METHODS: We examined a
               retrospective cohort of 58 SOT recipients with first-wave
               COVID-19, comparing patients with severe and nonsevere illness.
               Additionally, SOT recipients are compared with general patients
               with first-wave COVID-19. RESULTS: Organs transplanted included
               38 kidneys, 8 livers, 5 hearts, and 3 pancreases. Average SOT
               recipient age was 57.4 years; 62\% were male; 46.6\% were
               African American 36.2\% were white. Comorbidities included
               hypertension (86\%), chronic kidney disease (86\%), diabetes
               mellitus (50\%), coronary artery disease (26\%), and chronic
               obstructive pulmonary disease (14\%). Twenty patients had severe
               COVID-19 (34.5\%) and 38 had nonsevere disease (65.5\%). Severe
               disease was more common in older SOT recipients with
               comorbidities and was associated with cough, dyspnea, pneumonia,
               C-reactive protein >10 mg/L, and platelet count <150/$\mu$L.
               Sex, race, body mass index, time from transplant, baseline
               immunosuppression, and diagnosis month did not differ among
               those with severe and nonsevere COVID-19. Seventy percent of SOT
               recipients were hospitalized vs 27.2\% of general patients with
               COVID-19 and inpatient SOT recipients had a higher mechanical
               ventilation rate. Though a trend toward longer length of stay,
               higher intensive care unit admission, and greater inpatient
               mortality was observed (19.5\% vs 14.8\%), these differences
               were not significant. CONCLUSIONS: The severe acute respiratory
               syndrome coronavirus 2 has greatly impacted SOT recipients.
               One-third of our SOT recipients seen during the first wave had
               severe illness with associated standard risk factors for poor
               outcome. Compared with general first-wave patients, more SOT
               recipients were hospitalized, although inpatient COVID-19
               mortality did not significantly differ.",
  journal   = "Transplant. Proc.",
  publisher = "Elsevier BV",
  volume    =  53,
  number    =  4,
  pages     = "1227--1236",
  month     =  may,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Hu2021-wu,
  title     = "Infection control precautions and care delivery in hemodialysis
               unit during Coronavirus Disease 2019 outbreak: A case series",
  author    = "Hu, Shou-Ci and Fu, En-Qing and Fan, Jun-Fen and Ye, Qing-Qing
               and Xia, Cong and Gan, Tie-Er and Ma, Hong-Zhen",
  abstract  = "BACKGROUND: With an estimated basic reproductive number of 3.77,
               the Coronavirus Disease 2019 (COVID-19) continues to spread. It
               is urgent to exert adequate efforts for the management of
               dialysis patients, caregivers, and healthcare personnel (HCP).
               This study aimed at reporting practical workflow, identification
               of high-risk or suspected cases of CO-VID-19, and subsequent
               response measures. METHODS: At the time of the COVID-19
               outbreak, precautions and practice protocols were applied in our
               dialysis units (DUs). This single-center study retrospectively
               reviewed all high-risk/suspected cases from January 23, 2020, to
               February 10, 2020. Epidemiological, clinical feature, and
               detailed data on all cases were recorded. RESULTS: Practical
               workflow for the clinical management of dialysis patients,
               caregivers, and HCP was initiated. A total of 6
               high-risk/suspected cases were identified. Female gender, older
               age, presence of cardiovascular disease, diabetes, anuresis,
               immunocompromised status, hypoalbuminemia, and underweight were
               noticeable features in these cases. Direct evidence of infection
               or epidemiological risk was detected in five cases. Close
               monitoring for temperature and oxygen saturation during
               hemodialysis sessions may be reasonable. No confirmed COVID-19
               cases were reported in our DU, but certain cases showed rapid
               deterioration due to other critically severe condition needing
               hospitalization. Portable dialysis machines are of great need to
               ensure dialysis care provision. CONCLUSIONS: Our study described
               a practical workflow for patient-centered management during
               COVID-19 outbreak. Potential risk factors and underlying
               clinical patterns were reported. Further studies regarding the
               efficacy of infection control precautions and practice protocols
               tailored for dialysis settings are warranted.",
  journal   = "Blood Purif.",
  publisher = "S. Karger AG",
  volume    =  50,
  number    =  1,
  pages     = "57--64",
  year      =  2021,
  keywords  = "Care delivery; Coronavirus disease 2019; Dialysis unit;
               Hemodialysis; Infection control precautions",
  copyright = "https://www.karger.com/Services/SiteLicenses",
  language  = "en"
}

@ARTICLE{Akhtar2021-lm,
  title     = "An overview of the treatment options used for the management of
               {COVID-19} in Pakistan: Retrospective observational study",
  author    = "Akhtar, Hashaam and Akhtar, Samar and Rahman, Fazal-Ul and
               Afridi, Maham and Khalid, Sundas and Ali, Sabahat and Akhtar,
               Nasim and Khader, Yousef S and Ahmad, Hamaad and Khan, Muhammad
               Mujeeb",
  abstract  = "BACKGROUND: Since the first reports of COVID-19 infection, the
               foremost requirement has been to identify a treatment regimen
               that not only fights the causative agent but also controls the
               associated complications of the infection. Due to the
               time-consuming process of drug discovery, physicians have used
               readily available drugs and therapies for treatment of
               infections to minimize the death toll. OBJECTIVE: The aim of
               this study is to provide a snapshot analysis of the major drugs
               used in a cohort of 1562 Pakistani patients during the period
               from May to July 2020, when the first wave of COVID-19 peaked in
               Pakistan. METHODS: A retrospective observational study was
               performed to provide an overview of the major drugs used in a
               cohort of 1562 patients with COVID-19 admitted to the four major
               tertiary-care hospitals in the Rawalpindi-Islamabad region of
               Pakistan during the peak of the first wave of COVID-19 in the
               country (May-July 2020). RESULTS: Antibiotics were the most
               common choice out of all the therapies employed, and they were
               used as first line of treatment for COVID-19. Azithromycin was
               the most prescribed drug for treatment. No monthly trend was
               observed in the choice of antibiotics, and these drugs appeared
               to be a random but favored choice throughout the months of the
               study. It was also noted that even antibiotics used for
               multidrug resistant infections were prescribed irrespective of
               the severity or progression of the infection. The results of the
               analysis are alarming, as this approach may lead to antibiotic
               resistance and complications in immunocompromised patients with
               COVID-19. A total of 1562 patients (1064 male, 68.1\%, and 498
               female, 31.9\%) with a mean age of 47.35 years (SD 17.03) were
               included in the study. The highest frequency of patient
               hospitalizations occurred in June (846/1562, 54.2\%).
               CONCLUSIONS: Guidelines for a targeted treatment regime are
               needed to control related complications and to limit the misuse
               of antibiotics in the management of COVID-19.",
  journal   = "JMIR Public Health Surveill.",
  publisher = "JMIR Publications Inc.",
  volume    =  7,
  number    =  5,
  pages     = "e28594",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Pakistan; antibiotic resistance; antibiotics; first
               wave; multidrug resistant infections",
  language  = "en"
}

@ARTICLE{Agarwal2021-nx,
  title     = "Endogenous endophthalmitis A complication of {COVID-19}
               pandemic: A case series",
  author    = "Agarwal, Manisha and Sachdeva, Mani and Pal, Surendra and Shah,
               Harita and Kumar R, Madhu and Banker, Alay",
  abstract  = "PURPOSE: To report six patients with endogenous endophthalmitis
               as a complication of COVID-19 infection. METHODS: A multicentric
               retrospective database review of patients with a diagnosis of
               endogenous endophthalmitis and a history of COVID-19 infection.
               RESULTS: Four of six patients were diabetics. All presented
               after an average duration of 40 days (Range 17-90 days) of
               COVID-19 infection. Two of six patients had bilateral
               involvement. Five of six patients had received intravenous
               corticosteroid for COVID-19. Two of six vitreous samples showed
               fungi (Candida and Bipolaris species), two showed bacteria
               (Staphylococcus species) and two samples were culture negative.
               Control of infection with good visual outcome in four out of
               eight eyes. CONCLUSIONS: COVID-19 patients with a history of
               hospitalization and prolonged use of systemic corticosteroids
               and comorbidities, for example, diabetes mellitus have a high
               risk of endogenous endophthalmitis. A high index of clinical
               suspicion with timely intervention can salvage many eyes.",
  journal   = "Ocul. Immunol. Inflamm.",
  publisher = "Informa UK Limited",
  volume    =  29,
  number    =  4,
  pages     = "726--729",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Endogenous endophthalmitis; corticosteroids;
               immunocompromised",
  language  = "en"
}

@ARTICLE{Ducatez2021-gr,
  title     = "Primary meningococcal arthritis in a {COVID-19} 18-year-old man:
               a case report and review of the literature",
  author    = "Ducatez, Norman and Chancel, Marine and Douadi, Youcef and
               Dayen, Charles and Suguenot, R{\'e}mi and Lecuyer, Emmanuelle
               and Brihaye, Benoit and Bentayeb, Houcine",
  abstract  = "Abstract Background SARS-CoV-2 (severe acute respiratory
               syndrome coronavirus 2) infection is associated with various
               complications. PMA (primary meningococcal arthritis) is a rare
               meningococcus-associated disease causing arthritis of the knee
               usually, without any signs of invasive meningococcal disease. No
               case of PMA in a COVID-19 (coronavirus disease, 2019) patient
               has yet been described. PMA mainly strikes young adults. PMA is
               not associated with any immunocompromising condition. It has a
               better outcome than usual septic arthritis Case presentation
               Herein, we report an 18-year-old man diagnosed with COVID-19,
               later admitted with persistent fever, right knee arthralgia and
               maculopapular rash. Due to family history, psoriasis and
               Henoch-Sch{\"o}nlein purpura were hypothesized and ruled out.
               Finally, synovial fluid culture confirmed Neisseria meningitidis
               serogroup B arthritis without any other symptoms of invasive
               meningococcal disease. Healing was achieved quickly with surgery
               and antibiotics. We concluded in a PMA. Conclusion We describe
               here the first primary meningococcal arthritis in a COVID-19
               patient and we hope to shine a light on this rare but serious
               complication.",
  journal   = "BMC Infect. Dis.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  21,
  number    =  1,
  pages     = "499",
  month     =  may,
  year      =  2021,
  keywords  = "Arthritis; COVID-19; Neisseria meningitidis",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Brosh-Nissimov2021-kn,
  title     = "{BNT162b2} vaccine breakthrough: clinical characteristics of 152
               fully vaccinated hospitalized {COVID-19} patients in Israel",
  author    = "Brosh-Nissimov, Tal and Orenbuch-Harroch, Efrat and Chowers,
               Michal and Elbaz, Meital and Nesher, Lior and Stein, Michal and
               Maor, Yasmin and Cohen, Regev and Hussein, Khetam and
               Weinberger, Miriam and Zimhony, Oren and Chazan, Bibiana and
               Najjar, Ronza and Zayyad, Hiba and Rahav, Galia and Wiener-Well,
               Yonit",
  abstract  = "OBJECTIVES: The mRNA coronavirus disease 2019 (COVID-19)
               vaccines have shown high effectiveness in the prevention of
               symptomatic COVID-19, hospitalization, severe disease and death.
               Nevertheless, a minority of vaccinated individuals might become
               infected and experience significant morbidity. Characteristics
               of vaccine breakthrough infections have not been studied. We
               sought to portray the population of Israeli patients, who were
               hospitalized with COVID-19 despite full vaccination. METHODS: A
               retrospective multicentre cohort study of 17 hospitals included
               patients fully vaccinated with Pfizer/BioNTech's BNT162b2
               vaccine who developed COVID-19 more than 7 days after the second
               vaccine dose and required hospitalization. The risk for poor
               outcome, defined as a composite of mechanical ventilation or
               death, was assessed. RESULTS: A total of 152 patients were
               included, accounting for half of hospitalized fully vaccinated
               patients in Israel. Poor outcome was noted in 38 patients and
               mortality rate reached 22\% (34/152). Notably, the cohort was
               characterized by a high rate of co-morbidities predisposing to
               severe COVID-19, including hypertension (108; 71\%), diabetes
               (73; 48\%), congestive heart failure (41; 27\%), chronic kidney
               and lung diseases (37; 24\% each), dementia (29; 19\%) and
               cancer (36; 24\%), and only six (4\%) had no co-morbidities.
               Sixty (40\%) of the patients were immunocompromised. Higher
               viral load was associated with a significant risk for poor
               outcome. Risk also appeared higher in patients receiving
               anti-CD20 treatment and in patients with low titres of
               anti-Spike IgG, but these differences did not reach statistical
               significance. CONCLUSIONS: We found that severe COVID-19
               infection, associated with a high mortality rate, might develop
               in a minority of fully vaccinated individuals with multiple
               co-morbidities. Our patients had a higher rate of co-morbidities
               and immunosuppression compared with previously reported
               non-vaccinated hospitalized individuals with COVID-19. Further
               characterization of this vulnerable population may help to
               develop guidance to augment their protection, either by
               continued social distancing, or by additional active or passive
               vaccinations.",
  journal   = "Clin. Microbiol. Infect.",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  11,
  pages     = "1652--1657",
  month     =  nov,
  year      =  2021,
  keywords  = "BNT162b2; Breakthrough infection; Coronavirus disease 2019;
               Immune compromised; Serology; Severe acute respiratory syndrome
               coronavirus 2; Vaccine effectiveness; mRNA vaccine",
  language  = "en"
}

@ARTICLE{Viceconte2021-uu,
  title     = "Pneumocystis jirovecii pneumonia in an immunocompetent patient
               recovered from {COVID-19}",
  author    = "Viceconte, Giulio and Buonomo, Antonio Riccardo and Lanzardo,
               Amedeo and Pinchera, Biagio and Zappulo, Emanuela and Scotto,
               Riccardo and Schiano Moriello, Nicola and Vargas, Maria and
               Iacovazzo, Carmine and Servillo, Giuseppe and Gentile, Ivan and
               {``Federico II'' COVID-19 Team}",
  abstract  = "BACKGROUND: Several cases of invasive fungal diseases in
               patients with COVID-19 have been reported, mostly due to
               Aspergillus spp., with anecdotic reports of Pneumocystis
               jirovecii pneumonia (PJP) as co-infections in immunocompromised
               patients. We describe the first case of PJP in an
               immunocompetent patient who recovered from COVID-19 pneumonia.
               CASE DESCRIPTION: Our patient was hospitalized for 18 d for
               respiratory failure due to Severe Acute Respiratory
               Syndrome-Coronavirus-2 (SARS-CoV-2) pneumonia and successfully
               treated with continuous positive airway pressure (CPAP)
               respiratory support, enoxaparin, ceftaroline and intravenous 6
               mg of dexamethasone for 10 d, then with oral prednisone
               tapering. Despite his improved radiological and clinical
               conditions at discharge, he was admitted again after 18 d for
               worsening of respiratory conditions. Upon the second admission,
               a high-resolution CT-scan of the chest showed the development of
               new ground-glass opacities and P. jirovecii was detected on
               bronchoalveolar lavage fluid. A therapy with
               trimethoprim-sulphamethoxazole 20 mg/kg and methylprednisolone
               40 mg i.v. bis in die (BID) was started, with improvement of
               clinical, biochemical and radiological conditions. CONCLUSIONS:
               COVID-19 patients may have multiple risk factors for development
               of PJP, in particular lymphopaenia and use of steroids. PJP must
               be ruled out with direct microbiological methods in patients
               presenting with radiologic and clinical features of possible or
               probable PJP, even in immunocompetent hosts.",
  journal   = "Infect. Dis. (Lond.)",
  publisher = "Informa UK Limited",
  volume    =  53,
  number    =  5,
  pages     = "382--385",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Pneumocystis jirovecii; SARS-CoV-2; invasive fungal
               disease; lymphopaenia",
  language  = "en"
}

@ARTICLE{Esteban_Ronda2021-ob,
  title     = "Aplicaci{\'o}n de escalas pron{\'o}sticas de gravedad en la
               neumon{\'\i}a por {SARS-CoV-2}",
  author    = "Esteban Ronda, Violeta and Ruiz Alcaraz, Sandra and Ruiz
               Torregrosa, Paloma and Gim{\'e}nez Suau, Mario and Nofuentes
               P{\'e}rez, Ester and Le{\'o}n Ram{\'\i}rez, Jos{\'e} Manuel and
               Andr{\'e}s, Mariano and Moreno-P{\'e}rez, {\'O}scar and Candela
               Blanes, Alfredo and Gil Carbonell, Joan and Merino de Lucas,
               Esperanza",
  abstract  = "OBJECTIVES: Compare the accuracy of PSI, CURB-65, MuLBSTA and
               COVID-GRAM prognostic scores to predict mortality, the need for
               invasive mechanical ventilation in patients with pneumonia
               caused by SARS-CoV-2 and assess the coexistence of bacterial
               respiratory tract infection during admission. METHODS:
               Retrospective observational study that included hospitalized
               adults with pneumonia caused by SARS-CoV-2 from 15/03 to
               15/05/2020. We excluded immunocompromised patients, nursing home
               residents and those admitted in the previous 14 days for another
               reasons. Analysis of ROC curves was performed, calculating the
               area under the curve for the different scales, as well as
               sensitivity, specificity and predictive values. RESULTS: A total
               of 208 patients were enrolled, aged 63$\pm$17 years, 57,7\% were
               men; 38 patients were admitted to ICU (23,5\%), of these
               patients 33 required invasive mechanical ventilation (86,8\%),
               with an overall mortality of 12,5\%. Area under the ROC curves
               for mortality of the scores were: PSI 0,82 (95\% CI: 0,73-0,91),
               CURB-65 0,82 (0,73-0,91), MuLBSTA 0,72 (0,62-0,81) and
               COVID-GRAM 0,86 (0,70-1). Area under the curve for needing
               invasive mechanical ventilation was: PSI 0,73 (95\% CI:
               0,64-0,82), CURB-65 0,66 (0,55-0,77), MuLBSTA 0,78 (0,69-0,86)
               and COVID-GRAM 0,76 (0,67-0,85), respectively. Patients with
               bacterial co-infections of the respiratory tract were 20
               (9,6\%), the most frequent strains being Pseudomonas aeruginosa
               and Klebsiella pneumoniae. CONCLUSIONS: In our study, the
               COVID-GRAM score was the most accurate to identify patients with
               higher mortality with pneumonia caused by SARS-CoV-2; however,
               none of these scores accurately predicts the need for invasive
               mechanical ventilation with ICU admission. The 10\% of patients
               admitted presented bacterial respiratory co-infection.",
  journal   = "Med. Clin. (Barc.)",
  publisher = "Elsevier BV",
  volume    =  157,
  number    =  3,
  pages     = "99--105",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus; Escalas pron{\'o}sticas; Neumon{\'\i}a;
               Penumonia; Severity scores",
  language  = "en"
}

@ARTICLE{Bisgin2021-ln,
  title     = "Current update on severe acute respiratory syndrome Coronavirus
               2 vaccine development with a special emphasis on gene therapy
               viral vector design and construction for vaccination",
  author    = "Bisgin, Atil and Sanlioglu, Ahter D and Eksi, Yunus Emre and
               Griffith, Thomas S and Sanlioglu, Salih",
  abstract  = "Severe acute respiratory syndrome (SARS) is a newly emerging
               infectious disease (COVID-19) caused by the novel coronavirus
               SARS-coronavirus 2 (CoV-2). To combat the devastating spread of
               SARS-CoV-2, extraordinary efforts from numerous laboratories
               have focused on the development of effective and safe vaccines.
               Traditional live-attenuated or inactivated viral vaccines are
               not recommended for immunocompromised patients as the attenuated
               virus can still cause disease via phenotypic or genotypic
               reversion. Subunit vaccines require repeated dosing and adjuvant
               use to be effective, and DNA vaccines exhibit lower immune
               responses. mRNA vaccines can be highly unstable under
               physiological conditions. On the contrary, naturally antigenic
               viral vectors with well-characterized structure and safety
               profile serve as among the most effective gene carriers to
               provoke immune response via heterologous gene transfer. Viral
               vector-based vaccines induce both an effective cellular immune
               response and a humoral immune response owing to their natural
               adjuvant properties via transduction of immune cells.
               Consequently, viral vectored vaccines carrying the SARS-CoV-2
               spike protein have recently been generated and successfully used
               to activate cytotoxic T cells and develop a neutralizing
               antibody response. Recent progress in SARS-CoV-2 vaccines, with
               an emphasis on gene therapy viral vector-based vaccine
               development, is discussed in this review.",
  journal   = "Hum. Gene Ther.",
  publisher = "Mary Ann Liebert Inc",
  volume    =  32,
  number    = "11-12",
  pages     = "541--562",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; vaccines; viral vectors",
  language  = "en"
}

@ARTICLE{Boyarsky2021-kz,
  title     = "Immunogenicity of a single dose of {SARS-CoV-2} messenger {RNA}
               vaccine in solid organ transplant recipients",
  author    = "Boyarsky, Brian J and Werbel, William A and Avery, Robin K and
               Tobian, Aaron A R and Massie, Allan B and Segev, Dorry L and
               Garonzik-Wang, Jacqueline M",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  325,
  number    =  17,
  pages     = "1784--1786",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Thompson2021-ua,
  title     = "A health economic analysis for oral Poliovirus vaccine to
               prevent {COVID-19} in the United States",
  author    = "Thompson, Kimberly M and Kalkowska, Dominika A and Badizadegan,
               Kamran",
  abstract  = "COVID-19 led to a recent high-profile proposal to reintroduce
               oral poliovirus vaccine (OPV) in the United States (U.S.),
               initially in clinical trials, but potentially for widespread and
               repeated use. We explore logistical challenges related to U.S.
               OPV administration in 2020, review the literature related to
               nonspecific effects of OPV to induce innate immunity, and model
               the health and economic implications of the proposal. The costs
               of reintroducing a single OPV dose to 331 million Americans
               would exceed \$4.4 billion. Giving a dose of bivalent OPV to the
               entire U.S. population would lead to an expected 40 identifiable
               cases of vaccine-associated paralytic polio, with young
               Americans at the highest risk. Reintroducing any OPV use in the
               U.S. poses a risk of restarting transmission of OPV-related
               viruses and could lead to new infections in immunocompromised
               individuals with B-cell related primary immunodeficiencies that
               could lead to later cases of paralysis. Due to the lack of a
               currently licensed OPV in the U.S., the decision to administer
               OPV to Americans for nonspecific immunological effects would
               require purchasing limited global OPV supplies that could impact
               polio eradication efforts. Health economic modeling suggests no
               role for reintroducing OPV into the U.S. with respect to
               responding to COVID-19. Countries that currently use OPV
               experience fundamentally different risks, costs, and benefits
               than the U.S. Successful global polio eradication will depend on
               sufficient OPV supplies, achieving and maintaining high OPV
               coverage in OPV-using countries, and effective global OPV
               cessation and containment in all countries, including the U.S.",
  journal   = "Risk Anal.",
  publisher = "Wiley",
  volume    =  41,
  number    =  2,
  pages     = "376--386",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; health economics; oral poliovirus vaccine; polio",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Colmenero2021-uj,
  title     = "Epidemiological pattern, incidence, and outcomes of {COVID-19}
               in liver transplant patients",
  author    = "Colmenero, Jordi and Rodr{\'\i}guez-Per{\'a}lvarez, Manuel and
               Salcedo, Magdalena and Arias-Milla, Ana and Mu{\~n}oz-Serrano,
               Alejandro and Graus, Javier and Nu{\~n}o, Javier and Gastaca,
               Mikel and Bustamante-Schneider, Javier and Cachero, Alba and
               Llad{\'o}, Laura and Caballero, Ar{\'a}nzazu and
               Fern{\'a}ndez-Yunquera, Ainhoa and Loinaz, Carmelo and
               Fern{\'a}ndez, Inmaculada and Fondevila, Constantino and Navasa,
               Miquel and I{\~n}arrairaegui, Mercedes and Castells, Lluis and
               Pascual, Sonia and Ram{\'\i}rez, Pablo and Vinaixa, Carmen and
               Gonz{\'a}lez-Dieguez, Mar{\'\i}a Luisa and Gonz{\'a}lez-Grande,
               Roc{\'\i}o and Hierro, Loreto and Nogueras, Flor and Otero,
               Alejandra and {\'A}lamo, Jos{\'e} Mar{\'\i}a and
               Blanco-Fern{\'a}ndez, Gerardo and F{\'a}brega, Emilio and
               Garc{\'\i}a-Pajares, Fernando and Montero, Jos{\'e} Luis and
               Tom{\'e}, Santiago and De la Rosa, Gloria and Pons, Jos{\'e}
               Antonio",
  abstract  = "BACKGROUND \& AIMS: The incidence and outcomes of coronavirus
               disease 2019 (COVID-19) in immunocompromised patients are a
               matter of debate. METHODS: We performed a prospective nationwide
               study including a consecutive cohort of liver transplant
               patients with COVID-19 recruited during the Spanish outbreak
               from 28 February to 7 April, 2020. The primary outcome was
               severe COVID-19, defined as the need for mechanical ventilation,
               intensive care, and/or death. Age- and gender-standardised
               incidence and mortality ratios (SIR and SMR) were calculated
               using data from the Ministry of Health and the Spanish liver
               transplant registry. Independent predictors of severe COVID-19
               among hospitalised patients were analysed using multivariate Cox
               regression. RESULTS: A total of 111 liver transplant patients
               were diagnosed with COVID-19 (SIR = 191.2 [95\% CI
               190.3-192.2]). The epidemiological curve and geographic
               distribution overlapped widely between the liver transplant and
               general populations. After a median follow-up of 23 days, 96
               patients (86.5\%) were admitted to hospital and 22 patients
               (19.8\%) required respiratory support. A total of 12 patients
               were admitted to the ICU (10.8\%). The mortality rate was 18\%,
               which was lower than in the matched general population (SMR =
               95.5 [95\% CI 94.2-96.8]). Overall, 35 patients (31.5\%) met
               criteria of severe COVID-19. Baseline immunosuppression
               containing mycophenolate was an independent predictor of severe
               COVID-19 (relative risk = 3.94; 95\% CI 1.59-9.74; p = 0.003),
               particularly at doses higher than 1,000 mg/day (p = 0.003). This
               deleterious effect was not observed with calcineurin inhibitors
               or everolimus and complete immunosuppression withdrawal showed
               no benefit. CONCLUSIONS: Being chronically immunosuppressed,
               liver transplant patients have an increased risk of acquiring
               COVID-19 but their mortality rates are lower than the matched
               general population. Upon hospital admission, mycophenolate dose
               reduction or withdrawal could help in preventing severe
               COVID-19. However, complete immunosuppression withdrawal should
               be discouraged. LAY SUMMARY: In liver transplant patients,
               chronic immunosuppression increases the risk of acquiring
               COVID-19 but it could reduce disease severity. Complete
               immunosuppression withdrawal may not be justified. However,
               mycophenolate withdrawal or temporary conversion to calcineurin
               inhibitors or everolimus until disease resolution could be
               beneficial in hospitalised patients.",
  journal   = "J. Hepatol.",
  publisher = "Elsevier BV",
  volume    =  74,
  number    =  1,
  pages     = "148--155",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; Calcineurin inhibitors; Epidemiology; Everolimus;
               Immunosuppression; Mycophenolate; Pneumonia; SARS-CoV-2;
               Standardised incidence; Standardised mortality; Tacrolimus;
               Transplantation",
  language  = "en"
}

@ARTICLE{Abolghasemi2021-ir,
  title     = "{COVID-19} reinfection or reactivation in a renal transplant
               patient",
  author    = "Abolghasemi, Sara and Zolfaghari, Farnaz and Naeimipoor,
               Mohammad and Azhdari Tehrani, Hamed and Hakamifard, Atousa",
  abstract  = "Recurrences of COVID-19 infection may occur in immunocompromised
               patients. Reinfection or reactivation of COVID-19 virus is a
               challenging issue in these patients.",
  journal   = "Clin. Case Rep.",
  publisher = "Wiley",
  volume    =  9,
  number    =  8,
  pages     = "e04672",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunity; immunocompromised host; kidney
               transplantation; recrudescence; recurrence; relapse",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Fadavi2021-xk,
  title     = "Review on the oncology practice in the midst of {COVID-19}
               crisis: The challenges and solutions",
  author    = "Fadavi, Pedram and Houshyari, Mohammad and Yousefi Kashi, Amir
               Shahram and Jarrahi, Alireza Mosavi and Roshanmehr, Farnaz and
               Broomand, Mohammad Ali and Sandoughdaran, Saleh and
               Taghizadeh-Hesary, Farzad",
  abstract  = "As of late 2019, the outbreak of novel coronavirus disease
               (COVID-19) -that started in China- has rapidly afflicted all
               over the world. The COVID-19 pandemic has challenged health-care
               facilities to provide optimal care. In this context, cancer care
               requires special attention because of its peculiar status by
               including patients who are commonly immunocompromised and
               treatments that are often highly toxic. In this review article,
               we have classified the main impacts of the COVID-19 pandemic on
               oncology practices -followed by their solutions- into ten
               categories, including impacts on (1) health care providers, (2)
               medical equipment, (3) access to medications, (4) treatment
               approaches, (5) patients' referral, (6) patients' accommodation,
               (7) patients' psychological health, (8) cancer research, (9)
               tumor board meetings, and (10) economic income of cancer
               centers. The effective identification and management of all
               these challenges will improve the standards of cancer care over
               the viral pandemic and can be a practical paradigm for possible
               future crises..",
  journal   = "Asian Pac. J. Cancer Prev.",
  publisher = "EpiSmart Science Vector Ltd",
  volume    =  22,
  number    =  1,
  pages     = "19--24",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; Pandemic; cancer care",
  language  = "en"
}

@ARTICLE{Tamargo2021-os,
  title     = "{COVID-19} testing and the impact of the pandemic on the Miami
               Adult Studies on {HIV} cohort",
  author    = "Tamargo, Javier A and Martin, Haley R and Diaz-Martinez, Janet
               and Trepka, Mary Jo and Delgado-Enciso, Ivan and Johnson,
               Angelique and Mandler, Raul N and Siminski, Suzanne and Gorbach,
               Pamina M and Baum, Marianna K",
  abstract  = "BACKGROUND: Socioeconomic disadvantages and potential
               immunocompromise raise particular concerns for people living
               with HIV (PLWH) and other marginalized communities during the
               COVID-19 pandemic. In this study, we explored COVID-19 testing
               and the impact of the pandemic among participants from the Miami
               Adult Studies on HIV cohort, predominantly composed of
               low-income minorities living with and without HIV. METHODS:
               Between July and August 2020, a telephone survey was
               administered to 299 Miami Adult Studies on HIV participants to
               assess COVID-19 testing, prevention behaviors, and psychosocial
               stressors. Health care utilization, antiretroviral adherence,
               food insecurity, and substance use during the pandemic were
               compared with those of their last cohort visit (7.8 $\pm$ 2.9
               months earlier). RESULTS: Half of surveyed participants had been
               tested for COVID-19, 8 had tested positive and 2 had been
               hospitalized. PLWH (n = 183) were 42\% times less likely than
               HIV-uninfected participants to have been tested. However, after
               adjustment for age, employment, COVID-19 symptoms, mental health
               care, and substance use, the effect of HIV status was no longer
               significant. PLWH were more likely to have seen a health care
               provider, use face coverings, and avoid public transportation
               and less likely to be food insecure and drink hazardously. There
               were significant changes in substance use patterns during the
               pandemic when compared with those before. CONCLUSION: PLWH,
               compared with their HIV-uninfected peers, were more likely to
               engage in preventive measures and health care during the
               pandemic, potentially reducing their exposure to COVID-19. There
               were no reported changes in antiretroviral adherence or health
               care utilization, but there were changes in substance use; these
               need to be monitored as this crisis progresses.",
  journal   = "J. Acquir. Immune Defic. Syndr.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  87,
  number    =  4,
  pages     = "1016--1023",
  month     =  aug,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Ferrando-Vivas2021-re,
  title     = "Prognostic factors for 30-day mortality in critically ill
               patients with Coronavirus disease 2019: An observational cohort
               study",
  author    = "Ferrando-Vivas, Paloma and Doidge, James and Thomas, Karen and
               Gould, Doug W and Mouncey, Paul and Shankar-Hari, Manu and
               Young, J Duncan and Rowan, Kathryn M and Harrison, David A and
               {ICNARC COVID-19 Team}",
  abstract  = "OBJECTIVES: To identify characteristics that predict 30-day
               mortality among patients critically ill with coronavirus disease
               2019 in England, Wales, and Northern Ireland. DESIGN:
               Observational cohort study. SETTING: A total of 258 adult
               critical care units. PATIENTS: A total of 10,362 patients with
               confirmed coronavirus disease 2019 with a start of critical care
               between March 1, 2020, and June 22, 2020, of whom 9,990 were
               eligible (excluding patients with a duration of critical care
               less than 24 hr or missing core variables). MEASUREMENTS AND
               MAIN RESULTS: The main outcome measure was time to death within
               30 days of the start of critical care. Of 9,990 eligible
               patients (median age 60 yr, 70\% male), 3,933 died within 30
               days of the start of critical care. As of July 22, 2020, 189
               patients were still receiving critical care and a further 446
               were still in acute hospital. Data were missing for between
               0.1\% and 7.2\% of patients across prognostic factors. We
               imputed missing data ten-fold, using fully conditional
               specification and continuous variables were modeled using
               restricted cubic splines. Associations between the candidate
               prognostic factors and time to death within 30 days of the start
               of critical care were determined after adjustment for multiple
               variables with Cox proportional hazards modeling. Significant
               associations were identified for age, ethnicity, deprivation,
               body mass index, prior dependency, immunocompromise, lowest
               systolic blood pressure, highest heart rate, highest respiratory
               rate, Pao2/Fio2 ratio (and interaction with mechanical
               ventilation), highest blood lactate concentration, highest serum
               urea, and lowest platelet count over the first 24 hours of
               critical care. Nonsignificant associations were found for sex,
               sedation, highest temperature, and lowest hemoglobin
               concentration. CONCLUSIONS: We identified patient
               characteristics that predict an increased likelihood of death
               within 30 days of the start of critical care for patients with
               coronavirus disease 2019. These findings may support development
               of a prediction model for benchmarking critical care providers.",
  journal   = "Crit. Care Med.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  49,
  number    =  1,
  pages     = "102--111",
  month     =  jan,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Peled2021-ww,
  title     = "{BNT162b2} vaccination in heart transplant recipients: Clinical
               experience and antibody response",
  author    = "Peled, Yael and Ram, Eilon and Lavee, Jacob and Sternik, Leonid
               and Segev, Amit and Wieder-Finesod, Anat and Mandelboim, Michal
               and Indenbaum, Victoria and Levy, Itzchak and Raanani, Ehud and
               Lustig, Yaniv and Rahav, Galia",
  abstract  = "BACKGROUND: Data on the safety and efficacy of SARS-CoV-2
               vaccines in immunocompromised populations are sparse. METHODS:
               We conducted a prospective study of 77 heart transplant (HT)
               recipients vaccinated with two doses of BNT162b2 vaccine and
               monitored for adverse events following both doses, the
               receptor-binding domain (RBD) IgG response, and neutralizing
               antibodies. RESULTS: BNT162b2 vaccination was associated with a
               low rate of adverse events, characterized mostly by pain at the
               injection site. By a mean 41 days post second dose there were no
               clinical episodes of rejection, as suggested by a troponin leak
               or allograft dysfunction. At a mean 21 days following the second
               dose, IgG anti-RBD antibodies were detectable in 14 (18\%) HT
               recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8
               (57\%) of those with IgG anti-RBD antibodies. Immunosuppressive
               regimen containing mycophenolic acid was associated with lower
               odds of an antibody response (OR = 0.12, p = 0.042).
               CONCLUSIONS: Whether a longer time-frame for observation of an
               antibody response is required after vaccination in
               immunosuppressed individuals remains unknown.",
  journal   = "J. Heart Lung Transplant.",
  publisher = "Elsevier BV",
  volume    =  40,
  number    =  8,
  pages     = "759--762",
  month     =  aug,
  year      =  2021,
  keywords  = "BNT162b2 vaccine; antibody response; heart transplantation",
  language  = "en"
}

@ARTICLE{Sims2021-xh,
  title     = "A cross-sectional analysis of tobacco use and concurrent alcohol
               and substance use among patients living with {HIV/HCV}
               co-infection: Findings from a large urban tertiary center",
  author    = "Sims, Omar T and Jackson, Asti and Guo, Yuqi and Truong, Duong N
               and Odame, Emmanuel A and Mamudu, Hadii M",
  abstract  = "This study aimed to assess the prevalence of and factors
               associated with tobacco use among patients living with HIV/HCV
               co-infection. Patient reported outcomes (PROs) were analyzed of
               patients living with HIV/HCV co-infection (n = 313) who
               presented for clinical evaluation and treatment of HCV between
               2013 and 2017 at a university-affiliated HIV/HCV Co-infection
               Clinic. The prevalence of tobacco use in patients living with
               HIV/HCV co-infection was 48\%. Compared to non-smokers, a higher
               proportion of tobacco smokers had substance use disorders and
               concurrent alcohol and substance use. In the multivariate
               analysis, concurrent alcohol and substance use was positively
               associated with tobacco use. The findings suggest clinical
               interventions are urgently needed to reduce tobacco use among
               patients living with HIV/HCV co-infection-a doubly-vulnerable
               immunocompromised population. Otherwise, failed efforts to
               dedicate resources and targeted behavioral interventions for
               this respective population will inhibit survival-especially
               considering the recent and evolving COVID-19 pandemic.",
  journal   = "J. Clin. Psychol. Med. Settings",
  publisher = "Springer Science and Business Media LLC",
  volume    =  28,
  number    =  3,
  pages     = "553--561",
  month     =  sep,
  year      =  2021,
  keywords  = "Alcohol use; HCV; HIV; Smoking; Substance use; Tobacco",
  language  = "en"
}

@ARTICLE{Kappelman2021-dh,
  title     = "Humoral immune response to messenger {RNA} {COVID-19} vaccines
               among patients with inflammatory bowel disease",
  author    = "Kappelman, Michael D and Weaver, Kimberly N and Boccieri, Margie
               and Firestine, Ann and Zhang, Xian and Long, Millie D and
               {PREVENT-COVID Study Group}",
  journal   = "Gastroenterology",
  publisher = "Elsevier BV",
  volume    =  161,
  number    =  4,
  pages     = "1340--1343.e2",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Hanna2021-vy,
  title     = "Clinical strategies for optimizing infusion center care through
               a pandemic",
  author    = "Hanna, Kirollos S and Segal, Eve M and Barlow, Ashley and
               Barlow, Brooke",
  abstract  = "The national pandemic resulting from the novel coronavirus,
               COVID-19, has made the delivery of care for patients with cancer
               a challenge. There are competing risks of mortality from cancer
               versus serious complications and higher risk of death from
               COVID-19 in immunocompromised hosts. Furthermore, compounding
               these concerns is the inadequate supply of personal protective
               equipment, decreased hospital capacity, and paucity of effective
               treatments or vaccines to date for COVID-19. Guidance measures
               and recommendations have been published by national
               organizations aiming to facilitate the delivery of care in a
               safe and effective manner, many of which, are permanently
               adoptable interventions. Given the critical importance to
               continue chemotherapy, there remains additional interventions to
               further enhance patient safety while conserving healthcare
               resources such as adjustments in medication administration,
               reduction in laboratory or drug monitoring, and home delivery of
               specialty infusions. In this manuscript, we outline how to
               implement these actionable interventions of chemotherapy and
               supportive care delivery to further enhance the current
               precautionary measures while maintaining safe and effective
               patient care. Coupled with current published standards, these
               strategies can help alleviate the numerous challenges associated
               with this pandemic.",
  journal   = "J. Oncol. Pharm. Pract.",
  publisher = "SAGE Publications",
  volume    =  27,
  number    =  1,
  pages     = "165--179",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; Cancer; home infusion; infusion center; pandemic",
  language  = "en"
}

@ARTICLE{Gupta2021-ht,
  title     = "A rare entity to major outbreak: a case report on mucormycosis",
  author    = "Gupta, Dhaman and Dosi, Tanvi",
  abstract  = "Mucormycosis is relatively uncommon, fulminant, progressive,
               life threatening fungal disease which is most often seen in
               debilitating patients with immunocompromised condition.
               Mucormycosis cases are seen in patients with the use of systemic
               steroids in the treatment of severely affected COVID-19 cases
               and also in the patients with uncontrolled diabetes which causes
               immunosuppression are being reported with mucormycosis. The main
               symptoms of this disease include pain on the temporal and the
               orbital region of the affected side which could be throbbing or
               lancinating type, mobility of the teeth, jaw pain and often
               swelling is present which could be extraoral and intraoral both
               or sometimes only intraorally. The diagnostic approach in such
               cases is done with the help of clinical diagnosis,
               histopathology and with advanced imaging like cone beam computed
               tomography, magnetic resonance imaging and computed tomography.
               We here used cone beam computed tomography imaging that revealed
               haziness in the sinuses and breach in cortical bone of the
               affected area which confirmed the diagnosis of mucormycosis.
               Early treatment planning like administration of antifungal drugs
               and surgical debridement will be life saving in such a deadly
               disease.",
  journal   = "Pan Afr. Med. J.",
  publisher = "Pan African Medical Journal",
  volume    =  39,
  pages     = "183",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Mucormycosis; case report; diabetes mellitus",
  language  = "en"
}

@ARTICLE{Steele2021-ur,
  title     = "The role of sialylation in respiratory viral infection and
               treatment",
  author    = "Steele, Harrison and Tague, Andrew J and Skropeta, Danielle",
  abstract  = "Respiratory infections caused by viruses such as influenza and
               coronavirus are a serious global problem due to their high
               infection rates and potential to spark pandemics, such as the
               current COVID-19 pandemic. Although preventing these infections
               by using vaccines has been the most successful strategy to date,
               effective vaccines are not always available. Therefore,
               developing broad-spectrum anti-viral drugs to treat such
               infections is essential, especially in the case of
               immunocompromised patients or for outbreaks of novel virus
               strains. Sialic acids have been highlighted as a key molecule in
               the viral infection cycle, with terminally sialylated glycans
               acting as a target for several viral proteins involved in
               infection, particularly respiratory infection. Inhibitors of one
               such protein, neuraminidase, are the only anti-influenza drugs
               currently on the market. Problems with neuraminidase inhibitors,
               including the development of resistance and a relatively narrow
               spectrum of activity, drive the need for an improved
               understanding of the viral infection cycle and the development
               of more resilient, broader-spectrum anti-viral treatments.
               Hence, this review outlines the various roles played by sialic
               acids in respiratory viral infection and provides examples of
               drugs that exploit sialic acids to inhibit viral infections. It
               has been concluded that drugs targeting host cell expression of
               sialic acid could be especially well suited to inhibiting a
               broad spectrum of respiratory infections. This warrants the
               continued design and improvement of such drugs in an attempt to
               lessen the burden of respiratory infections.",
  journal   = "Curr. Med. Chem.",
  publisher = "Bentham Science Publishers Ltd.",
  volume    =  28,
  number    =  26,
  pages     = "5251--5267",
  year      =  2021,
  keywords  = "Sialic acid; anti-viral; coronavirus.; drug discovery;
               influenza; neuraminidase; sialyltransferase",
  language  = "en"
}

@ARTICLE{Medeiros-Ribeiro2021-wz,
  title     = "Immunogenicity and safety of the {CoronaVac} inactivated vaccine
               in patients with autoimmune rheumatic diseases: a phase 4 trial",
  author    = "Medeiros-Ribeiro, Ana C and Aikawa, Nadia E and Saad, Carla G S
               and Yuki, Emily F N and Pedrosa, Tatiana and Fusco, Solange R G
               and Rojo, Priscila T and Pereira, Rosa M R and Shinjo, Samuel K
               and Andrade, Danieli C O and Sampaio-Barros, Percival D and
               Ribeiro, Carolina T and Deveza, Giordano B H and Martins, Victor
               A O and Silva, Clovis A and Lopes, Marta H and Duarte, Alberto J
               S and Antonangelo, Leila and Sabino, Ester C and Kallas, Esper G
               and Pasoto, Sandra G and Bonfa, Eloisa",
  abstract  = "CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved
               for emergency use in several countries. However, its
               immunogenicity in immunocompromised individuals has not been
               well established. We initiated a prospective phase 4 controlled
               trial (no. NCT04754698, CoronavRheum) in 910 adults with
               autoimmune rheumatic diseases (ARD) and 182 age- and
               sex-frequency-matched healthy adults (control group, CG), who
               received two doses of CoronaVac. The primary outcomes were
               reduction of $\geq$15\% in both anti-SARS-CoV-2 IgG
               seroconversion (SC) and neutralizing antibody (NAb) positivity 6
               weeks (day 69 (D69)) after the second dose in the ARD group
               compared with that in the CG. Secondary outcomes were IgG SC and
               NAb positivity at D28, IgG titers and neutralizing activity at
               D28 and D69 and vaccine safety. Prespecified endpoints were met,
               with lower anti-SARS-Cov-2 IgG SC (70.4 versus 95.5\%, P <
               0.001) and NAb positivity (56.3 versus 79.3\%, P < 0.001) at D69
               in the ARD group than in the CG. Moreover, IgG titers (12.1
               versus 29.7, P < 0.001) and median neutralization activity (58.7
               versus 64.5\%, P = 0.013) were also lower at D69 in patients
               with ARD. At D28, patients with ARD presented with lower IgG
               frequency (18.7 versus 34.6\%, P < 0.001) and NAb positivity
               (20.6 versus 36.3\%, P < 0.001) than that of the CG. There were
               no moderate/severe adverse events. These data support the use of
               CoronaVac in patients with ARD, suggesting reduced but
               acceptable short-term immunogenicity. The trial is still ongoing
               to evaluate the long-term effectiveness/immunogenicity.",
  journal   = "Nat. Med.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  27,
  number    =  10,
  pages     = "1744--1751",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Wong2021-zm,
  title     = "A vaccination update for {rheumatologists-SARS-CoV-2}, influenza
               and herpes zoster",
  author    = "Wong, Peter K K and Lahiri, Manjari and Lye, David Chien and
               Johnson, Douglas and Charles, Patrick G P",
  journal   = "Int. J. Rheum. Dis.",
  publisher = "Wiley",
  volume    =  24,
  number    =  8,
  pages     = "979--983",
  month     =  aug,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Shiferaw2021-jd,
  title    = "Healthcare providers' acceptance of telemedicine and preference
              of modalities during {COVID-19} pandemics in a low-resource
              setting: An extended {UTAUT} model",
  author   = "Shiferaw, Kirubel Biruk and Mengiste, Shegaw Anagaw and
              Gullslett, Monika Knudsen and Zeleke, Atinkut Alamirrew and
              Tilahun, Binyam and Tebeje, Tsion and Wondimu, Robel and
              Desalegn, Surafel and Mehari, Eden Abetu",
  abstract = "BACKGROUND: In almost all lower and lower middle-income
              countries, the healthcare system is structured in the customary
              model of in-person or face to face model of care. With the
              current global COVID-19 pandemics, the usual health care service
              has been significantly altered in many aspects. Given the fragile
              health system and high number of immunocompromised populations in
              lower and lower-middle income countries, the economic impacts of
              COVID-19 are anticipated to be worse. In such scenarios,
              technological solutions like, Telemedicine which is defined as
              the delivery of healthcare service remotely using
              telecommunication technologies for exchange of medical
              information, diagnosis, consultation and treatment is critical.
              The aim of this study was to assess healthcare providers'
              acceptance and preferred modality of telemedicine and factors
              thereof among health professionals working in Ethiopia. METHODS:
              A multi-centric online survey was conducted via social media
              platforms such as telegram channels, Facebook groups/pages and
              email during Jul 1- Sep 21, 2020. The questionnaire was adopted
              from previously validated model in low income setting. Internal
              consistency of items was assessed using Cronbach alpha
              ($\alpha$), composite reliability (CR) and average variance
              extracted (AVE) to evaluate both discriminant and convergent
              validity of constructs. The extent of relationship among
              variables were evaluated by Structural equation modeling (SEM)
              using SPSS Amos version 23. RESULTS: From the expected 423
              responses, 319 (75.4\%) participants responded to the survey
              questionnaire during the data collection period. The majority of
              participants were male (78.1\%), age <30 (76.8\%) and had less
              than five years of work experience (78.1\%). The structural model
              result confirmed the hypothesis ``self-efficacy has a significant
              positive effect on effort expectancy'' with a standardized
              coefficient estimate ($\beta$) of 0.76 and p-value <0.001. The
              result also indicated that self-efficacy, effort expectancy,
              performance expectancy, facilitating conditions and social
              influence have a significant direct effect on user's attitude
              toward using telemedicine. User's behavioral intention to use
              telemedicine was also influenced by effort expectancy and
              attitude. The model also ruled out that performance expectancy,
              facilitating conditions and social influence does not directly
              influence user's intention to use telemedicine. The squared
              multiple correlations (r2) value indicated that 57.1\% of the
              variance in attitude toward using telemedicine and 63.6\% of the
              variance in behavioral intention to use telemedicine is explained
              by the current structural model. CONCLUSION: This study found
              that effort expectancy and attitude were significantly predictors
              of healthcare professionals' acceptance of telemedicine. Attitude
              toward using telemedicine systems was also highly influenced by
              performance expectancy, self-efficacy and facilitating
              conditions. effort expectancy and attitude were also significant
              mediators in predicting users' acceptance of telemedicine. In
              addition, mHealth approach was the most preferred modality of
              telemedicine and this opens an opportunity to integrate
              telemedicine systems in the health system during and post
              pandemic health services in low-income countries.",
  journal  = "PLoS One",
  volume   =  16,
  number   =  4,
  pages    = "e0250220",
  month    =  apr,
  year     =  2021,
  language = "en"
}

@ARTICLE{Cherian2021-bk,
  title     = "Safety of the {ChAdOx1} {nCoV-19} and the {BBV152} vaccines in
               724 patients with rheumatic diseases: a post-vaccination
               cross-sectional survey",
  author    = "Cherian, Somy and Paul, Aby and Ahmed, Sakir and Alias, Bazil
               and Manoj, Manesh and Santhosh, Ansu K and Varghese, Delcey
               Rachel and Krishnan, Narayanan and Shenoy, Padmanabha",
  abstract  = "Patients with rheumatic and musculoskeletal (RMD) diseases may
               be at higher risks for COVID-19 infection. Data on the safety of
               the adenoviral vector-borne ChAdOx1 nCoV-19 and the
               heat-inactivated BBV152 Vaccines in this group are limited. 724
               patients with RMD who had received at least one dose of either
               the ChAdOx1 or the BBV152 were audited to find out
               post-vaccination adverse effect (AE) or disease flares. The AE
               rates in patients with autoimmune rheumatic disease (AIRD) were
               compared with those with non-AIRD RMDs. The mean age of the
               cohort was 59.9 ($\pm$ 10.43) years with a female (n = 581;
               80.24\%) majority. 523 (70.8\%) had AIRD. The ChAdOx1 and the
               BBV152 vaccines were received by 624 (86.18\%) and 77 (10.63\%),
               respectively. 23 (3.17\%) were unaware of which vaccine they had
               received. 238 (32.87\%) of patients had at least one
               comorbidity. 436 (60.22\%) participants [306 (59.64\%) of those
               with AIRD and 130 (61.61\%) with other RMDs] had at least one
               adverse effect (AE). Four patients reported flare of arthritis
               that resolved within 5 days. No patient had any severe AE or
               required hospitalization. All AEs were self-limiting. Both the
               ChAdOx1 and the BBV152 vaccines appear safe in RMDs. AEs do not
               differ between patients with AIRD or non-AIRD. This information
               can help negate vaccine hesitancy amongst all stakeholders.",
  journal   = "Rheumatol. Int.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  8,
  pages     = "1441--1445",
  month     =  aug,
  year      =  2021,
  keywords  = "Adenoviral vector; Adjuvant; Adverse effects;
               Immunosuppressants; Rheumatic diseases; Vaccination; Vaccine
               safety",
  language  = "en"
}

@ARTICLE{Wright2021-bf,
  title     = "Pandemic-related mental health risk among front line personnel",
  author    = "Wright, Hannah M and Griffin, Brandon J and Shoji, Kotaro and
               Love, Tiffany M and Langenecker, Scott A and Benight, Charles C
               and Smith, Andrew J",
  abstract  = "The mental health of frontline workers is critical to a
               community's ability to manage crises and disasters. This study
               assessed risks for mental health problems (traumatic stress,
               depression, anxiety, alcohol use, insomnia) in association with
               pandemic-related stressors in a sample of emergency and hospital
               personnel (N = 571). Respondents completed self-report surveys
               online from April 1st to May 7th, 2020 in the Rocky Mountain
               region of the United States. Results showed that roughly fifteen
               to thirty percent of respondents screened positive for each
               disorder. Odds of screening positive were similar between groups
               for probable acute traumatic stress, depressive disorder,
               anxiety disorder, and alcohol use disorder; emergency personnel
               reported significantly higher rates of insufficient sleep than
               healthcare workers. Logistic regressions showed that respondents
               who reported having an immunocompromised condition had higher
               odds of acute traumatic stress, anxiety, and depression. Having
               an immunocompromised household member was associated with higher
               odds of insufficient sleep and anxiety. Being in a direct care
               provision role was associated with higher odds of screening
               positive for risky alcohol use. Being in a management role over
               direct care providers was associated with higher odds of
               screening positive for anxiety, risky alcohol use, and
               insufficient sleep. There was an inverse relationship between
               number of positive COVID-19 cases and anxiety, such that as
               positive cases went up, anxiety decreased. Overall, the mental
               health risks that we observed early in the COVID-19 pandemic are
               elevated above previous viral outbreaks (SARS) and comparable to
               rates shown in disasters (9/11 attacks; Hurricane Katrina).",
  journal   = "J. Psychiatr. Res.",
  publisher = "Elsevier BV",
  volume    =  137,
  pages     = "673--680",
  month     =  may,
  year      =  2021,
  keywords  = "Acute traumatic stress; COVID-19; Frontline responders; Mental
               health",
  language  = "en"
}

@ARTICLE{Oku2021-nl,
  title     = "Prevention of infective complications in systemic lupus
               erythematosus: A systematic literature review for the {APLAR}
               consensus statements",
  author    = "Oku, Kenji and Hamijoyo, Laniyati and Kasitanon, Nuntana and Li,
               Meng Tao and Navarra, Sandra and Morand, Eric and Tanaka,
               Yoshiya and Mok, Chi Chiu",
  abstract  = "Systemic lupus erythematosus (SLE) is a more common autoimmune
               rheumatic disease in the Asia-Pacific region. The prognosis of
               SLE remains unsatisfactory in some Asian countries because of
               delayed diagnosis, limited access to medications, increased
               complications and issues of tolerability and adherence to
               treatment. The Asia-Pacific League of Associations for
               Rheumatology SLE special interest group has recently published a
               set of consensus recommendations on the management of SLE for
               specialists, family physicians, specialty nurses, and other
               healthcare professionals in the Asia-Pacific region. This
               article reports a systematic literature review of the infective
               complications of SLE in Asia and evidence for prevention of
               these infections by pre-emptive antimicrobial therapy and
               vaccination.",
  journal   = "Int. J. Rheum. Dis.",
  publisher = "Wiley",
  volume    =  24,
  number    =  7,
  pages     = "880--895",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; hepatitis B; hepatitis C; infection; lupus;
               pneumocystis; tuberculosis; vaccine",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Cher2021-ba,
  title     = "Utility of a telephone triage hotline in response to the
               {COVID-19} pandemic: Longitudinal observational study",
  author    = "Cher, Benjamin A Y and Wilson, Eric A and Pinsky, Alexa M and
               Townshend, Ryan F and Wolski, Ann V and Broderick, Michael and
               Milen, Allison M and Lau, Audrey and Singh, Amrit and Cinti,
               Sandro K and Engelke, Carl G and Saha, Anjan K",
  abstract  = "BACKGROUND: During the initial months of the COVID-19 pandemic,
               rapidly rising disease prevalence in the United States created a
               demand for patient-facing information exchanges that addressed
               questions and concerns about the disease. One approach to
               managing increased patient volumes during a pandemic involves
               the implementation of telephone-based triage systems. During a
               pandemic, telephone triage hotlines can be employed in
               innovative ways to conserve medical resources and offer useful
               population-level data about disease symptomatology and risk
               factor profiles. OBJECTIVE: The aim of this study is to describe
               and evaluate the COVID-19 telephone triage hotline used by a
               large academic medical center in the midwestern United States.
               METHODS: Michigan Medicine established a telephone hotline to
               triage inbound patient calls related to COVID-19. For calls
               received between March 24, 2020, and May 5, 2020, we described
               total call volume, data reported by callers including COVID-19
               risk factors and symptomatology, and distribution of callers to
               triage algorithm endpoints. We also described symptomatology
               reported by callers who were directed to the institutional
               patient portal (online medical visit questionnaire). RESULTS: A
               total of 3929 calls (average 91 calls per day) were received by
               the call center during the study period. The maximum total
               number of daily calls peaked at 211 on March 24, 2020. Call
               volumes were the highest from 6 AM to 11 AM and during evening
               hours. Callers were most often directed to the online patient
               portal (1654/3929, 42\%), nursing hotlines (1338/3929, 34\%), or
               employee health services (709/3929, 18\%). Cough (126/370 of
               callers, 34\%), shortness of breath (101/370, 27\%), upper
               respiratory infection (28/111, 25\%), and fever (89/370, 24\%)
               were the most commonly reported symptoms. Immunocompromised
               state (23/370, 6\%) and age >65 years (18/370, 5\%) were the
               most commonly reported risk factors. CONCLUSIONS: The triage
               algorithm successfully diverted low-risk patients to suitable
               algorithm endpoints, while directing high-risk patients onward
               for immediate assessment. Data collected from hotline calls also
               enhanced knowledge of symptoms and risk factors that typified
               community members, demonstrating that pandemic hotlines can aid
               in the clinical characterization of novel diseases.",
  journal   = "J. Med. Internet Res.",
  publisher = "JMIR Publications Inc.",
  volume    =  23,
  number    =  11,
  pages     = "e28105",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; concern; hospital; implementation; innovation; patient
               information; telehealth; telemedicine; telephone; triage;
               utility",
  language  = "en"
}

@ARTICLE{Casarola2021-bt,
  title     = "Efficacy of convalescent plasma therapy in immunocompromised
               patients with {COVID-19}: A case report",
  author    = "Casarola, Genni and D'Abbondanza, Marco and Curcio, Rosa and
               Alcidi, Riccardo and Campanella, Tommaso and Rossi, Rachele and
               Fusaro, Jessica and Gandolfo, Vito and Di Giuli, Cinzia and
               Laoreti, Chiara and Veca, Vito and Leone, Maria Comasia and
               Pucci, Giacomo and Vaudo, Gaetano",
  abstract  = "Background: Management of immunocompromised COVID-19 patients is
               the object of current debate. Accumulating evidence suggest that
               treatment with high-titer COVID-19 convalescent plasma (CCP) may
               be effective in this characteristic clinical scenario. Case
               report: A 52-years old immunocompromised female patient,
               previously treated with rituximab for low grade B-cell lymphoma,
               showed prolonged SARS-CoV-2 shedding and a long-term course of
               signs of severe COVID-19. A first cycle of treatment with
               remdesivir, a nucleotide analogue prodrug effective in
               inhibiting SARS-CoV-2 replication, did not provide fully and
               sustained clinical remission. A second hospitalization was
               deemed necessary after 10 days from the first hospital discharge
               due to recrudescence of symptoms of severe COVID-19 and the
               evidence of bilateral interstitial pneumonia at the chest-CT
               scan. Clinical and radiological findings completely disappeared
               after CCP administration. The viral culture confirmed the
               absence of SARS-CoV-2-related cytopathic effect. The clinical
               evaluation, performed two months after hospital discharge, was
               unremarkable. Results: Findings from our case report suggest
               that the host T-cell specific response to SARS-CoV-2 is not
               sufficient to reduce viral load in the absence of neutralizing
               antibodies. Acquired immune antibodies and/or related components
               passively infused with CCP might help in boosting the plasma
               recipient response to the virus and promoting complete viral
               clearance. Conclusions: Independently from negative results in
               immunocompetent individuals, the potential effectiveness of CCP
               infusion in selected cohorts of patients with primary or
               secondary impaired immune response should be tested. Further
               research about mechanisms of host response in immunocompromised
               patients with SARS-CoV-2 infection is required.",
  journal   = "Clin Infect Pract",
  publisher = "Elsevier BV",
  volume    =  12,
  number    =  100096,
  pages     = "100096",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Convalescent plasma; Hypogammaglobulinemia; Immune
               deficiency; Remdesivir; Rituximab",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Seyahi2021-sk,
  title     = "Antibody response to inactivated {COVID-19} vaccine
               ({CoronaVac}) in immune-mediated diseases: a controlled study
               among hospital workers and elderly",
  author    = "Seyahi, Emire and Bakhdiyarli, Guldaran and Oztas, Mert and
               Kuskucu, Mert Ahmet and Tok, Yesim and Sut, Necdet and Ozcifci,
               Guzin and Ozcaglayan, Ali and Balkan, Ilker Inanc and Saltoglu,
               Nese and Tabak, Fehmi and Hamuryudan, Vedat",
  abstract  = "OBJECTIVE: To assess antibody response to inactivated COVID-19
               vaccine in patients with immune-mediated diseases (IMD) among
               hospital workers and people aged 65 and older. METHODS: In this
               cross-sectional study, we studied 82 hospital workers with IMD
               (mean age: 42.2 $\pm$ 10.0 years) and 300 (mean age: 41.7 $\pm$
               9.9 years) controls. Among + 65 aged population, we studied 22
               (mean age: 71.4 $\pm$ 4.5 years) patients and 47 controls (mean
               age: 70.9 $\pm$ 4.8 years). All study subjects had a negative
               history for COVID-19. Sera were obtained after at least 21 days
               following the second vaccination. Anti-spike IgG antibody titers
               were measured quantitatively using a commercially available
               immunoassay method. RESULTS: Patients with IMD were
               significantly less likely to have detectable antibodies than
               healthy controls both among the hospital workers (92.7\% vs
               99.7\%, p < 0.001) and elderly population (77.3\% vs 97.9\%, p =
               0.011). Among patients with IMD, those using immunosuppressive
               or immune-modulating drugs (64/75, 85.3\%) were significantly
               less likely to have detectable antibodies compared to those off
               treatment (29/29, 100\%) (p = 0.029). Additionally, a negative
               association between age and the antibody titer categories among
               patients (r = - 0.352; p < 0.001) and controls (r = - 0.258; p <
               0.001) were demonstrated. CONCLUSIONS: Among hospital workers,
               the vast majority of patients with IMD and immunocompetent
               controls developed a significant humoral response following the
               administration of the second dose of inactivated COVID-19
               vaccine. This was also true for the elderly population, albeit
               with lower antibody titers. Immunosuppressive use, particularly
               rituximab significantly reduced antibody titers. Antibody titers
               were significantly lower among those aged $\geq$ 60 years both
               in patient and control populations. Whether these individuals
               should get a booster dose warrants further studies.",
  journal   = "Rheumatol. Int.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  41,
  number    =  8,
  pages     = "1429--1440",
  month     =  aug,
  year      =  2021,
  keywords  = "Antibody to S1 spike protein; COVID-19; CoronaVac; Elderly;
               Hospital workers; Inflammatory diseases; Seroprevalence;
               Vaccination",
  language  = "en"
}

@ARTICLE{Leelayuwatanakul2021-ej,
  title     = "Multimodality treatment in immunocompromised patients with
               severe {COVID-19}: the role of {IL-6} inhibitor, intravenous
               immunoglobulin, and haemoperfusion",
  author    = "Leelayuwatanakul, Nophol and Kongpolprom, Napplika and
               Sriprasart, Thitiwat and Phoophiboon, Vorakamol and
               Thanthitaweewat, Vorawut and Thawanaphong, Sarita and Sirichana,
               Worawan and Chirakalwasan, Naricha and Kawkitinarong, Kamon and
               Sittipunt, Chanchai and Putcharoen, Opass and Paitoonpong,
               Leilani and Suwanpimolkul, Gompol and Jantarabenjakul, Watsamon
               and Srisawat, Nattachai and Pachinburavan, Monvasi",
  abstract  = "Cytokine release syndrome (CRS) is known to be associated with
               severe coronavirus disease 2019 (COVID-19). Multiple
               anti-inflammatory therapies such as tocilizumab,
               corticosteroids, intravenous immunoglobulin (IVIG), and
               haemoadsorption or haemoperfusion have been used to combat this
               life-threatening condition. However, immunocompromised hosts are
               often omitted from research studies, and knowledge on the
               clinical efficacy of these therapies in immunocompromised
               patients is therefore limited. We report two cases of
               immunocompromised patients with severe COVID-19-related CRS
               requiring mechanical ventilation who were treated with
               multimodality treatment consisting of tocilizumab, IVIG, and
               haemoperfusion. Within 48 h, both patients showed clinical
               improvement with PaO2:FiO2 ratio and haemodynamic stability.
               Both survived to discharge. There were no adverse events
               following these therapies. In conclusion, combined therapeutic
               modalities, possibly tailored to individual inflammatory
               profiles, are promising treatment for severe COVID-19 infection
               in the immunocompromised host. Timely administration of
               adjunctive therapies that alleviate overwhelming inflammation
               may provide the best outcome.",
  journal   = "Respirol. Case Rep.",
  publisher = "Wiley",
  volume    =  9,
  number    =  4,
  pages     = "e0733",
  month     =  apr,
  year      =  2021,
  keywords  = "COVD-19; IVIG; SARS-CoV-2; haemoperfusion; tocilizumab",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Focosi2021-uo,
  title     = "Potential use of convalescent plasma for {SARS-CoV-2}
               prophylaxis and treatment in immunocompromised and vulnerable
               populations",
  author    = "Focosi, Daniele and Franchini, Massimo",
  abstract  = "INTRODUCTION: : The ongoing SARS-CoV-2 pandemic is a serious
               threat for the health of immunocompromised patients. Among
               neutralizing antibody-based therapeutics, convalescent plasma
               containing polyclonal anti-SARS-CoV-2 immunoglobulins has
               promising results in both congenital and iatrogenic
               immunodeficiencies in oncohematological and transplant patients.
               AREAS COVERED: : This article discusses case reports, case
               series and controlled studies detailing the efficacy of
               convalescent plasma in immunocompromised patients. EXPERT
               OPINION: : Convalescent plasma, when administered at high
               neutralizing antibody titers, is a safe and effective treatment
               for frail immunocompromised patients. Genetic monitoring of
               refractory patients is recommended to intercept intra-host
               emergence of SARS-CoV-2 variants.",
  journal   = "Expert Rev. Vaccines",
  publisher = "Informa UK Limited",
  pages     = "1--8",
  month     =  may,
  year      =  2021,
  keywords  = "Convalescent plasma; covid-19; hyperimmune serum; neutralizing
               antibodies; polyclonal immunoglobulins; sars-cov-2",
  language  = "en"
}

@ARTICLE{Leung2021-pd,
  title     = "{COVID-19} in an immunocompromised host: persistent shedding of
               viable {SARS-CoV-2} and emergence of multiple mutations: a case
               report",
  author    = "Leung, Wayne F and Chorlton, Samuel and Tyson, John and
               Al-Rawahi, Ghada N and Jassem, Agatha N and Prystajecky, Natalie
               and Masud, Shazia and Deans, Gregory D and Chapman, Michael G
               and Mirzanejad, Yazdan and Murray, Melanie C M and Wong, Patrick
               H P",
  abstract  = "This article reports a case of a 21-year-old woman with
               refractory B-cell acute lymphocytic leukaemia who presented with
               severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
               She remained positive for SARS-CoV-2 by viral culture for 78
               days and by polymerase chain reaction (PCR) for 97 days.
               Sequencing of repeat samples over time demonstrated an
               increasing and dynamic repertoire of mutations.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  volume    =  114,
  pages     = "178--182",
  month     =  oct,
  year      =  2021,
  keywords  = "Case report; Immunocompromised; Mutation; SARS-CoV-2;
               Sequencing; Viral culture",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Duly2021-yy,
  title     = "{COVID-19} vaccine use in immunocompromised patients: A
               commentary on evidence and recommendations",
  author    = "Duly, Kristine and Farraye, Francis A and Bhat, Shubha",
  abstract  = "DISCLAIMER: In an effort to expedite the publication of articles
               related to the COVID-19 pandemic, AJHP is posting these
               manuscripts online as soon as possible after acceptance.
               Accepted manuscripts have been peer-reviewed and copyedited, but
               are posted online before technical formatting and author
               proofing. These manuscripts are not the final version of record
               and will be replaced with the final article (formatted per AJHP
               style and proofed by the authors) at a later time. PURPOSE:
               While COVID-19 vaccine emergency use authorization (EUA) deemed
               the vaccines to be effective and safe for public use, the phase
               3 trials leading to EUA predominantly excluded patients with
               immunocompromising conditions. Immunocompromised patients make
               up a significant proportion of the population, and in light of
               recent mass vaccination efforts, we aim to review current
               evidence and recommendations of COVID-19 vaccines in 4 patient
               populations with immunocompromising disorders or conditions:
               human immunodeficiency virus (HIV) infection, solid organ
               transplantation, rheumatoid arthritis, and inflammatory bowel
               disease. SUMMARY: Given the evolving data on safety and efficacy
               of the approved COVID-19 vaccines in the immunocompromised
               population, it is vital that pharmacists and other immunizing
               providers understand the current data and recommendations and
               provide the public with accurate information. To date, the only
               immunocompromised subgroup included in phase 3 COVID-19 vaccine
               trials have been those with HIV infection. However, recent
               retrospective trials have provided reassuring safety data of the
               COVID-19 vaccine in immunocompromised patients, and the interim
               analysis of the Moderna phase 3 trial produced promising
               efficacy data on HIV-infected patients. Presently, the US
               Centers for Disease Control and Prevention, British Society for
               Immunology, and various other governmental and professional
               societies and organizations endorse COVID-19 vaccination in the
               immunocompromised population. CONCLUSION: While additional data
               is warranted to determine the effects of immunocompromising
               medical conditions and immunosuppressing medications on the
               efficacy of the vaccine, the benefits of the vaccine is
               anticipated to outweigh theoretical risks. Thus, the COVID-19
               vaccine is recommended to be given to immunocompromised patients
               at this time, and providers should make efforts to decrease
               vaccine hesitancy in this population through education and
               reassurance.",
  journal   = "Am. J. Health. Syst. Pharm.",
  publisher = "Oxford University Press (OUP)",
  month     =  aug,
  year      =  2021,
  keywords  = ": COVID-19 vaccines; HIV; immunocompromised; inflammatory bowel
               disease; rheumatoid arthritis; solid organ transplant",
  language  = "en"
}

@ARTICLE{Ghosh2021-eg,
  title     = "A rare case of herpes zoster in an adult patient recovered from
               symptomatic reinfection of {COVID-19}",
  author    = "Ghosh, Binita and Gajjar, Rohan A and Modi, Vaishnavi K and
               Jadeja, Dhigishaba M",
  abstract  = "In coronavirus disease 2019 (COVID-19) patients, various
               dermatological conditions have been observed. Varicella zoster
               virus (VZV) and herpes simplex virus must be ruled out before
               considering vesicular exanthems linked to COVID-19. The
               immunological status of the host has an impact on the natural
               history of herpes zoster (HZ). Age is a major risk factor for
               most of the cases of HZ. Reactivation of VZV can be triggered by
               iatrogenic immunosuppression or disease-related
               immunocompromised state or age-related immunosenescence. Rarely,
               dermatological symptoms have been reported in recovered COVID-19
               patients. We hereby present a rare case of HZ in a recovered
               patient from symptomatic reinfection of COVID-19.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  7,
  pages     = "e16274",
  month     =  jul,
  year      =  2021,
  keywords  = "adult; covid-19; herpes zoster; sars-cov-2; varicella zoster",
  language  = "en"
}

@ARTICLE{Narasimhan2021-us,
  title     = "Serological response in lung transplant recipients after two
               doses of {SARS-CoV-2} {mRNA} vaccines",
  author    = "Narasimhan, Madhusudhanan and Mahimainathan, Lenin and Clark,
               Andrew E and Usmani, Amena and Cao, Jing and Araj, Ellen and
               Torres, Fernando and Sarode, Ravi and Kaza, Vaidehi and Lacelle,
               Chantale and Muthukumar, Alagarraju",
  abstract  = "BACKGROUND: Lung-transplant (LT) recipients are at high risk for
               COVID-19 due to immunosuppression and respiratory tropism of
               SARS-CoV-2. The information on the effect of COVID-19 mRNA
               vaccines to elicit immunogenic responses after a two-dose (2D)
               regimen in LT recipients is sparse. Thus, we assessed the effect
               of Pfizer-BioNTech and Moderna mRNA vaccines' 2D regimen on
               anti-spike responses in immunocompromised LT recipients.
               METHODS: We utilized serum samples from LT recipients vaccinated
               for SARS-CoV-2 with 2D of either the Pfizer-BioNTech or Moderna
               vaccines and 2D-vaccinated na{\"\i}ve (non-transplanted and
               non-exposed to COVID-19) group. Antibody responses were assessed
               using the FDA-approved SARS-CoV-2 anti-nucleocapsid protein IgG
               assay (IgGNC), the SARS-CoV-2 anti-spike protein IgM assay
               (IgMSP), and the SARS-CoV-2 anti-spike protein IgG II assay
               (IgGSP). CD4+ T-cell activity was assessed as a marker of immune
               competence using the ImmuKnow\textregistered{} assay. RESULTS:
               About 25\% (18/73) of SARS-CoV-2 uninfected-LT patients
               generated a positive spike-IgG response following 2D of
               vaccines, with 36\% (9/25) in the Moderna cohort and only 19\%
               (9/48) in the Pfizer cohort. 2D in LT patients elicited a
               significantly lesser median IgGSP response (1.7 AU/mL, 95\% CI:
               0.6-7.5 AU/mL) compared to non-transplanted, uninfected
               na{\"\i}ve subjects (14,209 AU/mL, 95\% CI: 11,261-18,836 AU/mL;
               p < 0.0001). In LT patients, the Moderna-evoked seropositivity
               trend was higher than Pfizer. CONCLUSION: 2D COVID-19
               vaccination elicits a dampened serological response in LT
               patients. Whether assessing other arms of host immunity combined
               with a higher vaccine dose can better capture and elicit
               improved immunogenicity in this immunocompromised population
               warrants investigation.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  7,
  pages     = "708",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19 mRNA vaccines; IgG; IgM; SARS-CoV-2; Spike; lung
               transplantation; nucleocapsid; serological response; two doses",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Asano2021-bq,
  title     = "X-linked recessive {TLR7} deficiency in ~1\% of men under 60
               years old with life-threatening {COVID-19}",
  author    = "Asano, Takaki and Boisson, Bertrand and Onodi, Fanny and
               Matuozzo, Daniela and Moncada-Velez, Marcela and Maglorius
               Renkilaraj, Majistor Raj Luxman and Zhang, Peng and Meertens,
               Laurent and Bolze, Alexandre and Materna, Marie and Korniotis,
               Sarantis and Gervais, Adrian and Talouarn, Estelle and Bigio,
               Benedetta and Seeleuthner, Yoann and Bilguvar, Kaya and Zhang,
               Yu and Neehus, Anna-Lena and Ogishi, Masato and Pelham, Simon J
               and Le Voyer, Tom and Rosain, J{\'e}r{\'e}mie and Philippot,
               Quentin and Soler-Palac{\'\i}n, Pere and Colobran, Roger and
               Martin-Nalda, Andrea and Rivi{\`e}re, Jacques G and
               Tandjaoui-Lambiotte, Yacine and Cha{\"\i}bi, Khalil and
               Shahrooei, Mohammad and Darazam, Ilad Alavi and Olyaei, Nasrin
               Alipour and Mansouri, Davood and Hatipo{\u g}lu, Nevin and
               Palabiyik, Figen and Ozcelik, Tayfun and Novelli, Giuseppe and
               Novelli, Antonio and Casari, Giorgio and Aiuti, Alessandro and
               Carrera, Paola and Bondesan, Simone and Barzaghi, Federica and
               Rovere-Querini, Patrizia and Tresoldi, Cristina and Franco, Jose
               Luis and Rojas, Julian and Reyes, Luis Felipe and Bustos, Ingrid
               G and Arias, Andres Augusto and Morelle, Guillaume and
               Christ{\`e}le, Kyheng and Troya, Jes{\'u}s and Planas-Serra,
               Laura and Schl{\"u}ter, Agatha and Gut, Marta and Pujol, Aurora
               and Allende, Luis M and Rodriguez-Gallego, Carlos and Flores,
               Carlos and Cabrera-Marante, Oscar and Pleguezuelo, Daniel E and
               de Diego, Rebeca P{\'e}rez and Keles, Sevgi and Aytekin, Gokhan
               and Akcan, Ozge Metin and Bryceson, Yenan T and Bergman, Peter
               and Brodin, Petter and Smole, Daniel and Smith, C I Edvard and
               Norlin, Anna-Carin and Campbell, Tessa M and Covill, Laura E and
               Hammarstr{\"o}m, Lennart and Pan-Hammarstr{\"o}m, Qiang and
               Abolhassani, Hassan and Mane, Shrikant and Marr, Nico and Ata,
               Manar and Al Ali, Fatima and Khan, Taushif and Spaan, Andr{\'a}s
               N and Dalgard, Clifton L and Bonfanti, Paolo and Biondi, Andrea
               and Tubiana, Sarah and Burdet, Charles and Nussbaum, Robert and
               Kahn-Kirby, Amanda and Snow, Andrew L and {COVID Human Genetic
               Effort} and {COVID-STORM Clinicians} and {COVID Clinicians} and
               {Imagine COVID Group} and {French COVID Cohort Study Group} and
               {CoV-Contact Cohort} and {Amsterdam UMC Covid-} and {Biobank}
               and {NIAID-USUHS COVID Study Group} and Bustamante, Jacinta and
               Puel, Anne and Boisson-Dupuis, St{\'e}phanie and Zhang,
               Shen-Ying and B{\'e}ziat, Vivien and Lifton, Richard P and
               Bastard, Paul and Notarangelo, Luigi D and Abel, Laurent and Su,
               Helen C and Jouanguy, Emmanuelle and Amara, Ali and Soumelis,
               Vassili and Cobat, Aur{\'e}lie and Zhang, Qian and Casanova,
               Jean-Laurent",
  abstract  = "Autosomal inborn errors of type I IFN immunity and
               autoantibodies against these cytokines underlie at least 10\% of
               critical COVID-19 pneumonia cases. We report very rare,
               biochemically deleterious X-linked TLR7 variants in 16 unrelated
               male individuals aged 7 to 71 years (mean: 36.7 years) from a
               cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9
               years) with unexplained critical COVID-19 pneumonia. None of the
               331 asymptomatically or mildly infected male individuals aged
               1.3 to 102 years (mean: 38.7 years) tested carry such TLR7
               variants (p = 3.5 $\times$ 10-5). The phenotypes of five
               hemizygous relatives of index cases infected with SARS-CoV-2
               include asymptomatic or mild infection (n=2, 5 and 38 years), or
               moderate (n=1, 5 years), severe (n=1, 27 years), or critical
               (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a
               cohort of 262 male patients with severe COVID-19 pneumonia
               (mean: 51.0 years) are hemizygous for a deleterious TLR7
               variant. The cumulative allele frequency for deleterious TLR7
               variants in the male general population is < 6.5x10-4 We also
               show that blood B cell lines and myeloid cell subsets from the
               patients do not respond to TLR7 stimulation, a phenotype rescued
               by wild-type TLR7 The patients' blood plasmacytoid dendritic
               cells (pDCs) produce low levels of type I IFNs in response to
               SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a
               highly penetrant genetic etiology of critical COVID-19
               pneumonia, in about 1.8\% of male patients below the age of 60
               years. Human TLR7 and pDCs are essential for protective type I
               IFN immunity against SARS-CoV-2 in the respiratory tract.",
  journal   = "Sci. Immunol.",
  publisher = "American Association for the Advancement of Science (AAAS)",
  volume    =  6,
  number    =  62,
  month     =  aug,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Ghelfenstein-Ferreira2021-iw,
  title     = "Recovery of a triazole-resistant Aspergillus fumigatus in
               respiratory specimen of {COVID-19} patient in {ICU} - A case
               report",
  author    = "Ghelfenstein-Ferreira, Th{\'e}o and Saade, Anastasia and Alanio,
               Alexandre and Bretagne, St{\'e}phane and Araujo de Castro,
               Raffael and Hamane, Samia and Azoulay, Elie and Bredin, Swann
               and Delli{\`e}re, Sarah",
  abstract  = "Although invasive pulmonary aspergillosis (IPA) is typically
               described in immunocompromised host, patient with severe
               influenzae can develop IPA. Similarly, patients with severe
               COVID-19 complicated with IPA are increasingly reported. Here,
               we describe a case of invasive aspergillosis with
               triazole-resistant A. fumigatus (TR34/L98H mutation) in a
               56-year-old patient with COVID-19 in intensive care unit. This
               report highlights the need to define the available tools for
               diagnosis of invasive aspergillosis in severe COVID-19 patients.",
  journal   = "Med. Mycol. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  31,
  pages     = "15--18",
  month     =  mar,
  year      =  2021,
  keywords  = "Aspergillosis; COVID-19; Coronavirus; ICU; SARS-CoV2;
               Triazole-resistance",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Sun2021-mt,
  title    = "Dual roles of a novel oncolytic viral vector-based {SARS-CoV-2}
              vaccine: preventing {COVID-19} and treating tumor progression",
  author   = "Sun, Yaping and Dong, Wenjuan and Tian, Lei and Rao, Youliang and
              Qin, Chao and Jaramillo, Sierra A and Settles, Erik W and Ma,
              Shoubao and Zhang, Jianying and Yu, Kang and Xu, Bo and Yan,
              Jiazhuo and Ma, Rui and Li, Zhuo and Dadwal, Sanjeet S and
              Barker, Bridget M and Keim, Paul S and Feng, Pinghui and
              Caligiuri, Michael A and Yu, Jianhua",
  abstract = "The ongoing coronavirus disease 2019 (COVID-19) pandemic is
              caused by infection with severe acute respiratory syndrome
              coronavirus 2 (SARS-CoV-2). Cancer patients are usually
              immunocompromised and thus are particularly susceptible to
              SARS-CoV-2 infection resulting in COVID-19. Although many
              vaccines against COVID-19 are being preclinically or clinically
              tested or approved, none have yet been specifically developed for
              cancer patients or reported as having potential dual functions to
              prevent COVID-19 and treat cancer. Here, we confirmed that
              COVID-19 patients with cancer have low levels of antibodies
              against the spike (S) protein, a viral surface protein mediating
              the entry of SARS-CoV-2 into host cells, compared with COVID-19
              patients without cancer. We developed an oncolytic herpes simplex
              virus-1 vector-based vaccine named oncolytic virus (OV)-spike.
              OV-spike induced abundant anti-S protein neutralization
              antibodies in both tumor-free and tumor-bearing mice, which
              inhibit infection of VSV-SARS-CoV-2 and wild-type (WT) live
              SARS-CoV-2 as well as the B.1.1.7 variant in vitro. In the
              tumor-bearing mice, OV-spike also inhibited tumor growth, leading
              to better survival in multiple preclinical tumor models than the
              untreated control. Furthermore, OV-spike induced anti-tumor
              immune response and SARS-CoV-2-specific T cell response without
              causing serious adverse events. Thus, OV-spike is a promising
              vaccine candidate for both preventing COVID-19 and enhancing the
              anti-tumor response. One Sentence Summary: A herpes oncolytic
              viral vector-based vaccine is a promising vaccine with dual roles
              in preventing COVID-19 and treating tumor progression.",
  journal  = "bioRxivorg",
  month    =  jun,
  year     =  2021,
  language = "en"
}

@ARTICLE{Alaiya2021-tq,
  title     = "Alterations in the plasma proteome induced by {SARS-CoV-2} and
               {MERS-CoV} reveal biomarkers for disease outcomes for {COVID-19}
               patients",
  author    = "Alaiya, Ayodele and Alshukairi, Abeer and Shinwari, Zakia and
               Al-Fares, Mariam and Alotaibi, Jawaher and AlOmaim, Waleed and
               Alsharif, Ibtihaj and Bakheet, Razan and Alharbi, Layla and
               Allam, Rabab and Asiri, Ayed and Memish, Ziad and Alromaih,
               Khaldoun and Al-Mozaini, Maha",
  abstract  = "Purpose: This study aimed to understand the pathophysiology of
               host responses to infections caused by severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) and Middle East
               respiratory syndrome coronavirus (MERS-CoV) and to identify
               proteins for patient stratification with different grades of
               illness severity. Patients and Methods: Peripheral blood samples
               from 43 patients with different grades of COVID-19, 7 MERS-CoV
               patients admitted to the ICU, and 10 healthy subjects were
               analyzed using label-free quantitative liquid
               chromatography-mass spectrometry (LC-MS). Results: We identified
               193 and 91 proteins that differed significantly between COVID-19
               and MERS-CoV sample groups, respectively, and 49 overlapped
               between datasets. Only 10 proteins are diagnostic of
               asymptomatic cases, 12 are prognostic of recovery from severe
               illness, and 28 are prognostic of a fatal outcome of COVID-19.
               These proteins are implicated in virus-specific/related
               signaling networks. Notable among the top canonical pathways are
               humoral immunity, inflammation, acute-phase response signaling,
               liver X receptor/retinoid X receptor (LXR/RXR) activation,
               coagulation, and the complement system. Furthermore, we
               confirmed positive viral shedding in 11.76\% of 51 additional
               peripheral blood samples, indicating that caution should be
               taken to avoid the possible risk of transfusion of infected
               blood products. Conclusion: We identified COVID-19 and MERS-CoV
               protein panels that have potential as biomarkers and might
               assist in the prognosis of SARS-CoV-2 infection. The identified
               markers further our understanding of COVID-19 disease
               pathophysiology and may have prognostic or therapeutic potential
               in predicting or managing host cell responses to human COVID-19
               and MERS-CoV infections.",
  journal   = "J. Inflamm. Res.",
  publisher = "Informa UK Limited",
  volume    =  14,
  pages     = "4313--4328",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; MERS-CoV; SARS-CoV; biomarkers; expression proteomics",
  language  = "en"
}

@ARTICLE{Nussenblatt2021-gf,
  title    = "Year-long {COVID-19} infection reveals within-host evolution of
              {SARS-CoV-2} in a patient with {B} cell depletion",
  author   = "Nussenblatt, Veronique and Roder, Allison E and Das, Sanchita and
              de Wit, Emmie and Youn, Jung-Ho and Banakis, Stephanie and
              Mushegian, Alexandra and Mederos, Christopher and Wang, Wei and
              Chung, Matthew and P{\'e}rez-P{\'e}rez, Lizzette and Palmore,
              Tara and Brudno, Jennifer N and Kochenderfer, James N and Ghedin,
              Elodie",
  abstract = "Background: B-cell depleting therapies may lead to protracted
              disease and prolonged viral shedding in individuals infected with
              SARS-CoV-2. Viral persistence in the setting of immunosuppression
              raises concern for viral evolution. Methods: Amplification of
              sub-genomic transcripts for the E gene (sgE) was done on
              nasopharyngeal samples over the course of 355 days in a patient
              infected with SARS-CoV-2 who had previously undergone CAR T cell
              therapy and had persistently positive SARS-CoV-2 nasopharyngeal
              swabs. Whole genome sequencing was performed on samples from the
              patient's original presentation and 10 months later. Results:
              Over the course of almost a year, the virus accumulated a unique
              in-frame deletion in the amino-terminal domain of the spike
              protein, and complete deletion of ORF7b and ORF8, the first
              report of its kind in an immunocompromised patient. Also,
              minority variants that were identified in the early
              samples-reflecting the heterogeneity of the initial
              infection-were found to be fixed late in the infection.
              Remdesivir and high-titer convalescent plasma treatment were
              given, and the infection was eventually cleared after 335 days of
              infection. Conclusions: The unique viral mutations found in this
              study highlight the importance of analyzing viral evolution in
              protracted SARS-CoV-2 infection, especially in immunosuppressed
              hosts, and the implication of these mutations in the emergence of
              viral variants. Summary: We report an immunocompromised patient
              with persistent symptomatic SARS-CoV-2 infection for 335 days.
              During this time, the virus accumulated a unique in-frame
              deletion in the spike, and a complete deletion of ORF7b and ORF8
              which is the first report of its kind in an immunocompromised
              patient.",
  journal  = "medRxiv",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Yang2021-nf,
  title     = "Impact of chronic {HIV} infection on {SARS-CoV-2} infection,
               {COVID-19} disease and vaccines",
  author    = "Yang, Yexin and Iwasaki, Akiko",
  abstract  = "PURPOSE OF REVIEW: The severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) has developed into a global pandemic
               that affect the health of hundreds of millions worldwide. In
               particular, SARS-CoV-2 infection in people with chronic human
               immune deficiency virus (HIV) infection is of concern, due to
               their already immunocompromised status. Yet, whether and how the
               immunological changes brought about by HIV will affect the
               immune responses against SARS-CoV-2 acute infection and impact
               the effectiveness of vaccines remain unclear. We discuss the
               intersection of COVID-19 in HIV-infected individuals. RECENT
               FINDINGS: People living with HIV (PLWH) may be at increased risk
               of severe SARS-CoV-2 mediated disease complication due to
               functional impairment of the immune system and persistent
               inflammation, which can be ameliorated by antiretroviral
               therapy. Importantly, limited data suggest that current approved
               vaccines may be safe and efficacious in PLWH. To address
               remaining questions and supplement limited experimental
               evidence, more studies examining the interplay between HIV and
               SARS-CoV-2 through their impact on the host immune system are
               required.",
  journal   = "Curr. HIV/AIDS Rep.",
  publisher = "Springer Science and Business Media LLC",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; HIV chronic infection; SARS-CoV-2 infection; Vaccines",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Voiriot2021-jp,
  title    = "Combined use of a broad-panel respiratory multiplex {PCR} and
              procalcitonin to reduce duration of antibiotics exposure in
              patients with severe community-acquired pneumonia ({MULTI-CAP)}:
              a multicentre, parallel-group, open-label, individual randomised
              trial conducted in French intensive care units",
  author   = "Voiriot, Guillaume and Fartoukh, Muriel and Durand-Zaleski,
              Isabelle and Berard, Laurence and Rousseau, Alexandra and
              Armand-Lefevre, Laurence and Verdet, Charlotte and Argaud,
              Laurent and Klouche, Kada and Megarbane, Bruno and Patrier,
              Juliette and Richard, Jean-Christophe and Reignier, Jean and
              Schwebel, Carole and Souweine, Bertrand and Tandjaoui-Lambiotte,
              Yacine and Simon, Tabassome and Timsit, Jean-Fran{\c c}ois and
              {MULTI-CAP study group}",
  abstract = "INTRODUCTION: At the time of the worrying emergence and spread of
              bacterial resistance, reducing the selection pressure by reducing
              the exposure to antibiotics in patients with community-acquired
              pneumonia (CAP) is a public health issue. In this context, the
              combined use of molecular tests and biomarkers for guiding
              antibiotics discontinuation is attractive. Therefore, we have
              designed a trial comparing an integrated approach of diagnosis
              and treatment of severe CAP to usual care. METHODS AND ANALYSIS:
              The multiplex PCR and procalcitonin to reduce duration of
              antibiotics exposure in patients with severe-CAP (MULTI-CAP)
              trial is a multicentre (n=20), parallel-group, superiority,
              open-label, randomised trial. Patients are included if adult
              admitted to intensive care unit for a CAP. Diagnosis of pneumonia
              is based on clinical criteria and a newly appeared parenchymal
              infiltrate. Immunocompromised patients are excluded. Subjects are
              randomised (1:1 ratio) to either the intervention arm
              (experimental strategy) or the control arm (usual strategy). In
              the intervention arm, the microbiological diagnosis combines a
              respiratory multiplex PCR (mPCR) and conventional microbiological
              investigations. An algorithm of early antibiotic de-escalation or
              discontinuation is recommended, based on mPCR results and the
              procalcitonin value. In the control arm, only conventional
              microbiological investigations are performed and antibiotics
              de-escalation remains at the clinician's discretion. The primary
              endpoint is the number of days alive without any antibiotic from
              the randomisation to day 28. Based on our hypothesis of 2 days
              gain in the intervention arm, we aim to enrol a total of 450
              patients over a 30-month period. ETHICS AND DISSEMINATION: The
              MULTI-CAP trial is conducted according to the principles of the
              Declaration of Helsinki, is registered in Clinical Trials and has
              been approved by the Committee for Protection of Persons and the
              National French Drug Safety Agency. Written informed consents are
              obtained from all the patients (or representatives). The results
              will be disseminated through educational institutions, submitted
              to peer-reviewed journals for publication and presented at
              medical congresses. TRIAL REGISTRATION NUMBER: NCT03452826;
              Pre-results.",
  journal  = "BMJ Open",
  volume   =  11,
  number   =  8,
  pages    = "e048187",
  month    =  aug,
  year     =  2021,
  keywords = "adult intensive \& critical care; adult thoracic medicine;
              diagnostic microbiology; molecular diagnostics; respiratory
              infections",
  language = "en"
}

@ARTICLE{Abdallah2021-gy,
  title     = "The experience of Hamad General Hospital collaborative
               anticoagulation clinic in Qatar during the {COVID-19} pandemic",
  author    = "Abdallah, Ibtihal and Eltahir, Asma and Fernyhough, Liam and
               El-Bardissy, Ahmed and Ahmed, Rana and Abdulgelil, Mohammed and
               Elgaily, Dina and Mohammed, Abdulmoqeeth and Jassim, Ameena and
               Barakat, Loluwa and Al-Ansari, Mazen and Javed, Mehak and
               Alkhawaja, Raja and Elzouki, Abdel-Nasser",
  abstract  = "Hamad General Hospital Anticoagulation Clinic is one of the
               largest collaborative-practice clinics of its type in Qatar. The
               patients being followed at this clinic are typically complex and
               vulnerable. During the coronavirus disease 2019 pandemic,
               measures were implemented at the clinic to minimize the exposure
               of patients and healthcare providers to the acute respiratory
               syndrome coronavirus-2 and to promote social distancing. These
               measures included extending INR-recall period, transitioning to
               direct oral anticoagulant drugs whenever feasible, home visits
               to elderly and immunocompromised patients for INR testing,
               establishing an anticoagulation hotline, and relocation of
               warfarin dispensing from the main pharmacy to the
               anticoagulation clinic. In addition, the clinic shifted its
               multidisciplinary team meetings onto an online platform using
               Microsoft Teams. Telehealth consultations were extensively
               utilized to closely follow up with the patients and ensure that
               anticoagulation efficacy and safety remained optimal. The aim of
               this paper is to share our experience and describe the measures
               adopted by the clinic as part of the Hamad Medical Corporation
               response to the emerging situation.",
  journal   = "J. Thromb. Thrombolysis",
  publisher = "Springer Science and Business Media LLC",
  volume    =  52,
  number    =  1,
  pages     = "308--314",
  month     =  jul,
  year      =  2021,
  keywords  = "Anticoagulation; COVID-19; Clinical pharmacy; Collaborative
               practice; Social distancing; Warfarin",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Vander_Leek2021-qh,
  title     = "{COVID-19} vaccine testing \& administration guidance for
               allergists/immunologists from the Canadian Society of Allergy
               and Clinical Immunology ({CSACI})",
  author    = "Vander Leek, Timothy K and Chan, Edmond S and Connors, Lori and
               Derfalvi, Beata and Ellis, Anne K and Upton, Julia E M and
               Abrams, Elissa M",
  abstract  = "BACKGROUND: Safe and effective vaccines provide the first hope
               for mitigating the devastating health and economic impacts
               resulting from coronavirus disease 2019 (COVID-19) and related
               public health orders. Recent case reports of reactions to
               COVID-19 vaccines have raised questions about their safety for
               use in individuals with allergies and those who are
               immunocompromised. In this document, we aim to address these
               concerns and provide guidance for allergists/immunologists.
               METHODS: Scoping review of the literature regarding COVID-19
               vaccination, adverse or allergic reactions, and immunocompromise
               from PubMed over the term of December 2020 to present date. We
               filtered our search with the terms ``human'' and ``English'' and
               limited the search to the relevant subject age range with the
               term ``adult.'' Reports resulting from these searches and
               relevant references cited in those reports were reviewed and
               cited on the basis of their relevance. RESULTS: Assessment by an
               allergist is warranted in any individual with a suspected
               allergy to a COVID-19 vaccine or any of its components.
               Assessment by an allergist is NOT required for individuals with
               a history of unrelated allergies, including to allergies to
               foods, drugs, insect venom or environmental allergens. COVID-19
               vaccines should be offered to immunocompromised patients if the
               benefit is deemed to outweigh any potential risks of
               vaccination. INTERPRETATION: This review provides the first
               Canadian guidance regarding assessment of an adolescent and
               adult with a suspected allergy to one of the COVID-19 vaccines
               currently available, or any of their known allergenic
               components, and for patients who are immunocompromised who
               require vaccination for COVID-19. As information is updated this
               guidance will be updated accordingly.",
  journal   = "Allergy Asthma Clin. Immunol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  17,
  number    =  1,
  pages     = "29",
  month     =  mar,
  year      =  2021,
  keywords  = "Allergy; Anaphylaxis; COVID-19; Immune deficiency;
               Immunocompromise; PEG; Vaccine",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Gordon2021-ap,
  title     = "Defective severe acute respiratory syndrome Coronavirus 2 immune
               responses in an immunocompromised individual with prolonged
               viral replication",
  author    = "Gordon, Claire L and Smibert, Olivia C and Holmes, Natasha E and
               Chua, Kyra Y L and Rose, Morgan and Drewett, George and James,
               Fiona and Mouhtouris, Effie and Nguyen, Thi H O and Zhang, Wuji
               and Kedzierski, Lukasz and Rowntree, Louise C and Chua, Brendon
               Y and Caly, Leon and Catton, Mike G and Druce, Julian and Sait,
               Michelle and Seemann, Torsten and Sherry, Norelle L and Howden,
               Benjamin P and Kedzierska, Katherine and Kwong, Jason C and
               Trubiano, Jason A",
  abstract  = "We describe severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2)-specific immune responses in a patient with
               lymphoma and recent programmed death 1 (PD-1) inhibitor therapy
               with late onset of severe coronavirus disease 2019 disease and
               prolonged SARS-CoV-2 replication, in comparison to age-matched
               and immunocompromised controls. High levels of HLA-DR+/CD38+
               activation, interleukin 6, and interleukin 18 in the absence of
               B cells and PD-1 expression was observed. SARS-CoV-2-specific
               antibody responses were absent and SARS-CoV-2-specific T cells
               were minimally detected. This case highlights challenges in
               managing immunocompromised hosts who may fail to mount effective
               virus-specific immune responses.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  9,
  pages     = "ofab359",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; cellular immunity; humoral immunity;
               immunocompromise; lymphoma",
  copyright = "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Siddique2020-st,
  title     = "An insight into {COVID-19}: A 21st century disaster and its
               relation to immunocompetence and food antioxidants",
  author    = "Siddique, Faisal and Abbas, Rao Zahid and Mansoor, Muhammad
               Khalid and Alghamdi, Etab Saleh and Saeed, Muhammad and Ayaz,
               Muhammad Mazhar and Rahman, Moazur and Mahmood, Muhammad Shahid
               and Iqbal, Asif and Manzoor, Maida and Abbas, Asghar and Javaid,
               Asif and Hussain, Irshad",
  abstract  = "Coronavirus Disease 2019 (COVID-19) ranks third in terms of
               fatal coronavirus diseases threatening public health, coming
               after SARS-CoV (severe acute respiratory syndrome coronavirus),
               and MERS-CoV (Middle East respiratory syndrome coronavirus).
               SARS-CoV-2 (severe acute respiratory syndrome coronavirus type
               2) causes COVID-19. On January 30, 2020, the World Health
               Organization (WHO) announced that the current outbreak of
               COVID-19 is the sixth global health emergency. As of December 3,
               2020, 64 million people worldwide have been affected by this
               malaise, and the global economy has experienced a loss of more
               than \$1 trillion. SARS-CoV-2 is a positive-sense
               single-stranded RNA virus belonging to the Betacoronavirus
               genus. The high nucleotide sequence identity of SARS-CoV-2 with
               the BatCoV RaTG13 genome has indicated that bats could be the
               possible host of SARS-CoV-2. SARS-CoV-2 penetrates the host cell
               via binding its spike protein to the angiotensin-converting
               enzyme 2 (ACE2) receptor, which is similar to the mechanisms of
               SARS-CoV and MERS-CoV. COVID-19 can spread from person to person
               via respiratory droplets and airborne and contaminated fomites.
               Moreover, it poses a significant risk to smokers, the elderly,
               immunocompromised people, and those with preexisting
               comorbidities. Two main approaches are used to control viral
               infections, namely, vaccination, and biosecurity. Studies to
               analyze the antigenicity and immunogenicity of SARS-CoV-2
               vaccine candidates are underway, and few vaccines may be
               available in the near future. In the current situation, the
               Human Biosecurity Emergency (HBE) may be the only way to cope
               effectively with the novel SARS-CoV-2 strain. Here, we summarize
               current knowledge on the origin of COVID-19 as well as its
               epidemiological relationship with humans and animals, genomic
               resemblance, immunopathogenesis, clinical-laboratory signs,
               diagnosis, control and prevention, and treatment. Moreover, we
               discuss the interventional effects of various nutrients on
               COVID-19 in detail. However, multiple possibilities are explored
               to fight COVID-19, and the greatest efforts targeted toward
               finding an effective vaccine in the near future. Furthermore,
               antioxidants, polyphenols, and flavonoids, both synthetic and
               natural, could play a crucial role in the fight against
               COVID-19.",
  journal   = "Front. Vet. Sci.",
  publisher = "Frontiers Media SA",
  volume    =  7,
  pages     = "586637",
  year      =  2020,
  keywords  = "ACE2; COVID-19; antioxidants; genome; health emergency;
               immune-competence; viral pneumonia",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Bodilsen2021-tu,
  title     = "Partial oral antibiotic treatment for bacterial brain abscess:
               an open-label randomized non-inferiority trial ({ORAL})",
  author    = "Bodilsen, Jacob and Brouwer, Matthijs C and van de Beek,
               Diederik and Tattevin, Pierre and Tong, Steven and Naucler,
               Pontus and Nielsen, Henrik",
  abstract  = "BACKGROUND: The advised standard treatment for bacterial brain
               abscess following surgery is 6 to 8 weeks of intravenous (IV)
               antibiotic treatment, but an early switch to oral antibiotic
               treatment has been suggested to be equally effective. METHODS:
               This investigator-initiated, international, multi-center,
               parallel group, open-label, randomized (1:1 allocation)
               controlled trial will examine if oral treatment after 2 weeks of
               IV antibiotic therapy is non-inferior to standard 6-8 weeks of
               IV antibiotics for bacterial brain abscess in adults ($\geq$ 18
               years of age). The study will be conducted at hospitals across
               Denmark, the Netherlands, France, Australia, and Sweden.
               Exclusion criteria are severe immunocompromise or impaired
               gastro-intestinal absorption, pregnancy, device-related brain
               abscesses, and brain abscess caused by nocardia, tuberculosis,
               or Pseudomonas spp. The primary objective is a composite
               endpoint at 6 months after randomization consisting of all-cause
               mortality, intraventricular rupture of brain abscess, unplanned
               re-aspiration or excision of brain abscess, relapse, or
               recurrence. The primary endpoint will be adjudicated by an
               independent blinded endpoint committee. Secondary outcomes
               include extended Glasgow Outcome Scale scores and all-cause
               mortality at end of treatment as well as 3, 6, and 12 months
               since randomization, completion of assigned treatment, IV
               catheter associated complications, durations of admission and
               antibiotic treatment, severe adverse events, quality of life
               scores, and cognitive evaluations. The planned sample size is
               450 patients for a one-sided alpha of 0.025 and a power of 90\%
               to exclude a difference in favor of standard treatment of more
               than 10\%. Date of initiation of first study center was November
               3, 2020, with active recruitment for 3 years and follow-up for 1
               year of all patients. DISCUSSION: The results of this study may
               guide future recommendations for treatment of bacterial brain
               abscess. If early transition to oral antibiotics proves
               non-inferior to standard IV treatment, this will provide
               considerable health and costs benefits. TRIAL REGISTRATION:
               ClinicalTrials.gov NCT04140903, first registered 28.10.2019.
               EudraCT number: 2019-002845-39, first registered 03.07.2019.",
  journal   = "Trials",
  publisher = "Springer Science and Business Media LLC",
  volume    =  22,
  number    =  1,
  pages     = "796",
  month     =  nov,
  year      =  2021,
  keywords  = "Antibiotics; Brain abscess; Cerebral abscess; Intravenous;
               Non-inferiority; Oral; Randomized controlled trial; Treatment",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Monrad2021-fb,
  title     = "Persistent severe acute respiratory syndrome Coronavirus 2
               infection in immunocompromised host displaying treatment induced
               viral evolution",
  author    = "Monrad, Ida and Sahlertz, Signe Risgaard and Nielsen, Stine
               Sofie Frank and Pedersen, Louise {\O}rnskov and Petersen, Mikkel
               Steen and Kobel, Carl Mathias and Tarpgaard, Irene Harder and
               Storgaard, Merete and Mortensen, Klaus Leth and Schleimann,
               Mariane H and Tolstrup, Martin and Vibholm, Line K",
  abstract  = "We report a coronavirus disease 2019 case with severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) persisting
               beyond 333 days in an immunocompromised patient with chronic
               lymphocytic leukemia, asymptomatically carrying infectious
               SARS-CoV-2 at day 197 postdiagnosis. In addition, viral
               sequencing indicates major changes in the spike protein over
               time, temporally associated with convalescent plasma treatment.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  7,
  pages     = "ofab295",
  month     =  jul,
  year      =  2021,
  keywords  = "CLL; SARS-CoV-2; persistent infection; viral evolution",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Bronstein2021-uu,
  title     = "Evolution of spike mutations following antibody treatment in two
               immunocompromised patients with persistent {COVID-19} infection",
  author    = "Bronstein, Yotam and Adler, Amos and Katash, Haytham and Halutz,
               Ora and Herishanu, Yair and Levytskyi, Katia",
  abstract  = "Immunocompromised patients have an increased risk of persistent
               COVID-19 disease. We report here the clinical course of two
               patients with hematologic malignancies hospitalized due to
               severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               infection. In both patients, viral evolution including new spike
               gene mutations that occurred following treatment with
               anti-SARS-CoV-2 antibodies preparations, including convalescent
               plasma and bamlanivimab. These cases demonstrate the possibility
               of antibody-resistant SARS-CoV-2 infections evolution in
               immunocompromised patients.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; Spike gene; bamlanivimab; convalescent
               plasma; immunocompromised",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Rubiano2021-nb,
  title     = "Pneumocystis and severe acute respiratory syndrome Coronavirus 2
               coinfection: A case report and review of an emerging diagnostic
               dilemma",
  author    = "Rubiano, Carlos and Tompkins, Kathleen and Sellers, Subhashini A
               and Bramson, Brian and Eron, Joseph and Parr, Jonathan B and
               Schranz, Asher J",
  abstract  = "We present a case of a critically ill patient with coronavirus
               disease 2019 (COVID-19) found to have acquired immune deficiency
               syndrome and Pneumocystis jirovecii pneumonia (PCP). Coronavirus
               disease 2019 and PCP co-occurrence is increasingly reported and
               may complicate diagnostic and therapeutic strategies. Patients
               with severe COVID-19 should be screened for underlying
               immunocompromise and coinfections should be considered.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  1,
  pages     = "ofaa633",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; HIV; Pneumocystis; SARS-CoV-2; coinfection",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Wang2021-hu,
  title     = "Sequence analysis of the Emerging {Sars-CoV-2} Variant Omicron
               in South Africa",
  author    = "Wang, Lulan and Cheng, Genhong",
  abstract  = "Despite the worldwide vaccination, COVID-19 pandemic continues
               as SARS-CoV-2 evolves into numerous variants. Since the first
               identification of the novel SARS-CoV-2 variant of concern (VOC)
               Omicron on November 24th , 2021, from an immunocompromised
               patient in South Africa, the variant has overtaken Delta as the
               predominant lineage in South Africa and has quickly spread to
               over 40 countries. Here we provide an initial molecular
               characterization of the Omicron variant through analyzing the
               large number of mutations especially in the spike protein
               receptor-binding domain (RBD) with their potential effects on
               viral infectivity and host immunity. Our analysis indicates that
               the Omicron variant has two subclades and may evolve from clade
               20B instead of the currently dominant Delta variant. In
               addition, we have also identified mutations that may affect the
               ACE2 receptor and/or antibody bindings. Our study has raised
               additional questions on the evolution, transmission, virulence,
               and immune escape properties of this new Omicron variant. This
               article is protected by copyright. All rights reserved.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  month     =  dec,
  year      =  2021,
  keywords  = "Omicron variant; VOC; emerging viruses",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Guchelaar2021-bg,
  title     = "Characteristics of {COVID-19} infection and antibody formation
               in patients known at a tertiary immunology department",
  author    = "Guchelaar, Niels A D and van Laar, Jan A M and Hermans, Maud A W
               and van der Houwen, Tim B and Atmaca, Sibel and van Maaren,
               Maurits S and Brkic, Zana and van Daele, Paul L A and Dalm,
               Virgil A S H and van Hagen, P Martin and Rombach, Saskia M",
  abstract  = "Background: Knowledge about COVID-19 infections is expanding,
               although knowledge about the disease course and antibody
               formation in patients with an auto-immune disease or
               immunodeficiency is not fully unraveled yet. It could be
               hypothesized that immunodeficient patients, due to
               immunosuppressive drugs or their disease, have a more severe
               disease course due to their immunocompromised state. However, it
               could also be hypothesized that some of the immunosuppressive
               drugs protect against a hyperinflammatory state. Methods: We
               collected data on the incidence of COVID-19, disease course and
               SARS-CoV-2 antibody formation in COVID-19 positive patients in a
               cohort of patients (n = 4497) known at the Clinical Immunology
               outpatient clinic in a tertiary care hospital in the
               Netherlands. Results: In the first six months of the pandemic,
               16 patients were identified with COVID-19, 14 by nasal swab PCR,
               and 2 patients by SARS-CoV-2 antibodies. Eight patients were
               admitted to the hospital. SARS-CoV-2 antibodies were measured in
               8 patients and were detectable in all, including one patient on
               B-cell ablative therapy and one patient with Common Variable
               Immunodeficiency Disorder. Conclusion: This study indicates that
               the disease course differs among immunocompromised patients,
               independently of (dis)continuation of immunosuppressive drugs.
               Antibody production for SARS-CoV-2 in immunocompromised patients
               was shown. More research needs to be conducted to confirm these
               observations and guidelines regarding (dis)continuation of
               immunosuppressive drugs in COVID-19 positive immunocompromised
               patients should be developed.",
  journal   = "J Transl Autoimmun",
  publisher = "Elsevier BV",
  volume    =  4,
  number    =  100084,
  pages     = "100084",
  month     =  jan,
  year      =  2021,
  keywords  = "Antibodies; COVID-19; Immunocompromised; Immunologic deficiency
               syndromes; Immunosuppressive agents",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Verma2021-ca,
  title     = "Machine learning based predictive model and systems-level
               network of host-microbe interactions in {post-COVID-19}
               mucormycosis",
  author    = "Verma, Anukriti and Rathi, Bhawna",
  abstract  = "Mucormycosis, a rare infection is caused by fungi Mucorales. The
               affiliation of mucormycosis with Coronavirus disease (COVID-19)
               is a rising issue of concern in India. There have been numerous
               case reports of association of rhino-cerebral-orbital,
               angioinvasive, pulmonary, respiratory and gastrointestinal tract
               related mucormycosis in patients with history of COVID-19. The
               immune dysregulation, preposterous use of steroids,
               interleukin-6-directed therapies and mechanical ventilation in
               COVID-19 immunocompromised individuals hypothesizes and
               predisposes to advancement of mucormycosis. The gaps in mode of
               presentation, disease course, diagnosis and treatment of
               post-COVID-19 mucormycosis requires critical analysis in order
               to control its morbidity and incidence and for prevention and
               management of opportunistic infections in COVID-19 patients. Our
               study performs machine learning, systems biology and
               bioinformatics analysis of post-COVID-19 mucormycosis in India
               incorporating multitudinous techniques. Text mining identifies
               candidate characteristics of post-COVID-19 mucormycosis cases
               including city, gender, age, symptoms, clinical parameters,
               microorganisms and treatment. The characteristics are
               incorporated in a machine learning based disease model resulting
               in predictive potentiality of characteristics of post-COVID-19
               mucormycosis. The characteristics are used to create a
               host-microbe interaction disease network comprising of
               interactions between microorganism, host-microbe proteins,
               non-specific markers, symptoms and drugs resulting in candidate
               molecules. R1A (Replicase polyprotein 1a) and RPS6 (Ribosomal
               Protein S6) are yielded as potential drug target and biomarker
               respectively via potentiality analysis and expression in
               patients. The potential risk factors, drug target and biomarker
               can serve as prognostic, early diagnostic and therapeutic
               molecules in post-COVID-19 mucormycosis requiring further
               experimental validation and analysis on post-COVID-19
               mucormycosis cases.",
  journal   = "Microb. Pathog.",
  publisher = "Elsevier BV",
  volume    =  162,
  number    =  105324,
  pages     = "105324",
  month     =  nov,
  year      =  2021,
  keywords  = "Bioinformatics; Biomarkers; Diagnosis; Disease model; Drug
               targets; Host-microbe interaction network; Machine learning;
               Post-COVID-19 mucormycosis; Prognosis; Risk factors; Systems
               biology; Treatment",
  language  = "en"
}

@ARTICLE{Horiuchi2021-el,
  title     = "Recovery from severe persistent {COVID-19} without evidence of
               an {anti-SARS-CoV-2} antibody response in a man with mantle cell
               lymphoma treated with rituximab",
  author    = "Horiuchi, Hiroshi and Sasaki, Hiroaki and Miyazaki, Kazuhito and
               Miyata, Nobuyuki and Yoshimura, Yukihiro and Tachikawa, Natsuo",
  abstract  = "Lymphoma has been reported to worsen the prognosis of COVID-19
               partly because it disturbs the normal production of antibodies.
               We treated a man with mantle cell lymphoma treated with
               rituximab, who developed severe COVID-19 with viral shedding
               that lasted for 78 days. He stayed in the intensive care unit
               for 28 days and did not respond to any treatment against
               COVID-19. His increased oxygen demand at rest eventually
               resolved despite the absence of anti-SARS-CoV-2-IgG. This case
               illustrates that recovery from COVID-19 can occur without
               antibody production, and that even patients with an inability to
               produce antibodies can recover from severe COVID-19. It also
               illustrates that lymphoma patients who develop severe COVID-19
               while on rituximab therapy can recover from a prolonged viral
               shedding state if the acute lung injury can be overcome.",
  journal   = "J. Infect. Chemother.",
  publisher = "Elsevier BV",
  month     =  nov,
  year      =  2021,
  keywords  = "Antibody; COVID-19; Immunocompromised state; Lymphoma;
               Rituximab; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Mohseni2021-ry,
  title     = "A case of {COVID-19} re-infection in a liver transplant patient",
  author    = "Mohseni, Michael and Albus, Michael and Kaminski, Ann and
               Harrison, Michael F",
  abstract  = "Coronavirus disease 2019 (COVID-19) is an ongoing worldwide
               pandemic infection. The exact incidence of disease re-infection
               or recurrence remains unknown. One particular at-risk population
               includes individuals with solid organ transplantation on
               immunosuppression. We present a case of COVID-19 re-infection in
               a chronically immunocompromised liver transplant patient. A
               53-year-old female presented to the Emergency Department (ED)
               with nausea, vomiting, diarrhea, and myalgias. She was found to
               test positive for COVID-19. Her relevant medical history
               included liver transplantation on chronic immunosuppression.
               More recently, she had tested positive for COVID-19
               approximately three months prior to this and was hospitalized at
               that time for encephalopathy and treated with remdesivir and
               convalescent plasma. She had subsequently recovered with
               negative COVID-19 testing in the interim. On the ED presentation
               with presumed re-infection, her disease was deemed to be mild
               with lack of severe symptoms or pulmonary involvement, and she
               was discharged with outpatient follow-up for monoclonal antibody
               infusion therapy. We describe a scenario of presumed COVID-19
               re-infection in a liver transplant patient. To our knowledge,
               this is a rare event and has been reported internationally in
               only a handful of individuals. We surmise that immunosuppression
               could offer some protection from the inflammatory cascade of the
               initial disease process in COVID-19 given the relatively mild
               disease observed in our patient. On the other hand, a less
               robust immune response may decrease humoral immunity and leave
               patients at greater risk of re-infection. Further investigation
               is necessary to delineate COVID-19 disease re-infection versus
               relapse, especially in the setting of an immunocompromised
               state.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  5,
  pages     = "e14916",
  month     =  may,
  year      =  2021,
  keywords  = "coronavirus; covid-19; immunosuppression; re-infection;
               sars-cov-2; transplant",
  language  = "en"
}

@ARTICLE{Collier2021-zx,
  title     = "{COVID-19} {mRNA} vaccine immunogenicity in immunosuppressed
               individuals",
  author    = "Collier, Ai-Ris Y and Yu, Jingyou and Mcmahan, Katherine and
               Liu, Jinyan and Atyeo, Caroline and Ansel, Jessica L and
               Fricker, Zachary P and Pavlakis, Martha and Curry, Michael P and
               Jacob-Dolan, Catherine and Patel, Het and Sellers, Daniel and
               Barrett, Julia and Rowe, Marjorie and Ahmad, Kunza and Gompers,
               Annika and Aguayo, Ricardo and Chandrashekar, Abishek and Alter,
               Galit and Hacker, Michele R and Barouch, Dan H",
  abstract  = "Individuals on immunosuppressive (IS) therapy have increased
               mortality from SARS-CoV-2 infection, and delayed viral clearance
               may lead to new viral variants.1 IS therapy reduces antibody
               responses following COVID-19 messenger RNA (mRNA)
               vaccination;2-5 however, a comprehensive assessment of vaccine
               immunogenicity is lacking. Here we show that IS therapy reduced
               neutralizing, binding, and non-neutralizing antibody functions
               in addition to CD4 and CD8 T cell IFN-$\gamma$responses
               following COVID-19 mRNA vaccination compared to immunocompetent
               individuals. Moreover, IS therapy reduced cross-reactivity
               against SARS-CoV-2 variants. These data suggest that the current
               COVID-19 mRNA vaccine regimens will likely not provide optimal
               protection in immunocompromised individuals.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19 vaccine; Immunocompromised; SARS-CoV-2; T cells;
               vaccine immunogenicity",
  language  = "en"
}

@ARTICLE{Solanki2021-pp,
  title     = "Mucor alert: Triad of {COVID-19}, corticosteroids therapy and
               uncontrolled glycemic index",
  author    = "Solanki, Bharti and Chouhan, Mahendra and Shakrawal, Neha",
  journal   = "Indian J. Otolaryngol. Head Neck Surg.",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--3",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Diabetes mellitus; Immunocompromise; Mucormycosis",
  language  = "en"
}

@ARTICLE{Serrano_Martins2021-gj,
  title     = "{COVID-19} in a patient newly diagnosed with {AIDS}:
               Asymptomatic disease",
  author    = "Serrano Martins, Manuel and Pimentel, Fabiana and Costa,
               Wildemar and Fernandes, Claudia",
  abstract  = "The COVID-19 pandemic has posed new challenges for the
               scientific community. The behaviour of the virus and outcomes in
               people living with HIV have not yet been properly studied. We
               report the case of a 34-year-old man with newly diagnosed HIV
               infection stage 4 and asymptomatic SARS-CoV-2 infection.
               Although immunocompromised patients are classified as being at
               high risk of developing severe COVID-19, HIV-related
               immunosuppression may have a protective role. LEARNING POINTS:
               It is important to remember that not every respiratory infection
               during this pandemic is due to SARS-CoV-2.We need more studies
               to elucidate the behaviour of COVID-19 in people living with
               HIV.There is still doubt about the best time for antiretroviral
               therapy (ART) initiation in this context.",
  journal   = "Eur. J. Case Rep. Intern. Med.",
  publisher = "SMC Media",
  volume    =  8,
  number    =  1,
  pages     = "002204",
  month     =  jan,
  year      =  2021,
  keywords  = "AIDS; COVID-19; HIV; SARS-CoV-2; immunosuppression",
  language  = "en"
}

@ARTICLE{Parsons2021-uw,
  title     = "The trilogy of {SARS-CoV-2} in pediatrics (part 1): Acute
               {COVID-19} in special populations",
  author    = "Parsons, Sarah and Tran, Van L",
  abstract  = "With the emergence of the SARS-CoV-2 (severe acute respiratory
               syndrome coronavirus 2) virus, the pandemic has resulted in a
               severe respiratory disease known as COVID-19. Data and
               literature are limited in the evaluation, treatment, and
               considerations for pediatric patients including special
               populations (e.g., neonates, children, immunocompromised
               patients, and those with sickle cell disease). There exists a
               need for a comprehensive review of pediatric proven and
               disproven treatments as therapies continue to emerge. This
               article evaluates the pharmacologic treatment and prevention
               therapies used in pediatric patients to date, including
               emergency use authorizations, as well as rationales for
               pharmacotherapies not routinely used to treat acute COVID-19
               infection. It is important to note this review article is
               current as of January 25, 2021, given the rapid evolvement of
               the pandemic.",
  journal   = "J. Pediatr. Pharmacol. Ther.",
  publisher = "Pediatric Pharmacy Advocacy Group",
  volume    =  26,
  number    =  3,
  pages     = "220--239",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; children; pandemic; pediatric; review",
  language  = "en"
}

@ARTICLE{Loconsole2021-dy,
  title     = "Severe {COVID-19} by {SARS-CoV-2} lineage B.1.1.7 in vaccinated
               solid-organ transplant recipients: New preventive strategies
               needed to protect immunocompromised patients",
  author    = "Loconsole, Daniela and Stea, Emma Diletta and Sallustio, Anna
               and Font{\`o}, Giulia and Pronzo, Virginia and Simone, Simona
               and Centrone, Francesca and Accogli, Marisa and Gesualdo, Loreto
               and Chironna, Maria",
  abstract  = "BACKGROUND: Solid-organ transplant (SOT) recipients are at a
               high risk of severe COVID-19, and are priority for vaccination.
               Here, we describe three cases of severe COVID-19 caused by
               SARS-CoV-2 B.1.1.7 lineage in vaccinated SOT recipients.
               METHODS: Three SOT patients were hospitalized in the Policlinico
               Hospital of Bari (southern Italy) and underwent nasopharyngeal
               swabs for molecular detection of SARS-CoV-2 genes and spike
               protein mutations by real-time PCR. One sample was subjected to
               whole-genome sequencing. RESULTS: One patient was a heart
               transplant recipient and two were kidney transplant recipients.
               All were hospitalized with severe COVID-19 between March and May
               2021. Two patients were fully vaccinated and one had received
               only one dose of the BNT162b2 mRNA vaccine. All the patients
               showed a high viral load at diagnosis, and molecular typing
               revealed the presence of B.1.1.7 lineage SARS-CoV-2. In all
               three cases, prolonged viral shedding was reported. CONCLUSIONS:
               The three cases pose concern about the role of the B.1.1.7
               lineage in severe COVID-19 and about the efficacy of COVID-19
               vaccination in immunocompromised patients. Protecting
               immunocompromised patients from COVID-19 is a challenge. SOT
               recipients show a suboptimal response to standard vaccination,
               and thus, an additive booster or a combined vaccination strategy
               with mRNA, protein/subunit, and vector-based vaccines may be
               necessary. This population should continue to practice strict
               COVID-19 precautions post-vaccination, until new strategies for
               protection are available.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  8,
  pages     = "806",
  month     =  jul,
  year      =  2021,
  keywords  = "B.1.1.7 lineage; COVID-19 vaccine; SARS-CoV-2 infection;
               solid-organ transplant recipients; whole-genome sequencing",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Kondle2021-ka,
  title     = "Treatment of {COVID-19} in patients with sarcoidosis",
  author    = "Kondle, Shreya and Hou, Titus and Manansala, Michael and Ascoli,
               Christian and Novak, Richard M and Sweiss, Nadera",
  abstract  = "Recent case reports and studies on treating COVID-19 in patients
               with chronic sarcoidosis describe different treatment modalities
               ranging from glucocorticoids to biologic medications. This
               review article summarizes seven case series and reports totaling
               46 patients. While one case report suggested that sarcoidosis
               medications such as glucocorticoids may lengthen the COVID-19
               disease course, another study with a larger registry suggests
               they do not. More studies are needed to elucidate an improvement
               in outcomes. It is possible that addition of TNF-alpha
               inhibitors at COVID-19 diagnosis decreases hospitalization rate.
               Overall, it is difficult to make firm conclusions regarding
               treatment given the heterogeneity of treatment modalities in the
               current literature. Our summarized findings are outlined with
               the opinions of sarcoidosis, pulmonary, and infectious disease
               experts in a flow chart that provides clinicians with our
               proposed management algorithm for sarcoidosis patients who
               develop COVID-19. We emphasize a need for exchange of
               information regarding management of COVID-19 in the setting of
               sarcoidosis to further improve treatment in this vulnerable
               population of patients.",
  journal   = "Front. Med. (Lausanne)",
  publisher = "Frontiers Media SA",
  volume    =  8,
  pages     = "689539",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunocompromised; management;
               sarcoidosis; treatment",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Surie2021-ll,
  title     = "Infectious period of severe acute respiratory syndrome
               Coronavirus 2 in 17 nursing home residents-Arkansas, June-august
               2020",
  author    = "Surie, Diya and Huang, Jennifer Y and Brown, Allison C and
               Gable, Paige and Biedron, Caitlin and Gilbert, Sarah E and
               Garner, Kelley and Bollinger, Susan and Gulley, Trent and Haney,
               Tafarra and Lyons, Amanda K and Beshearse, Elizabeth and
               Gregory, Christopher J and Sabour, Sarah and Clemmons, Nakia S
               and James, Allison E and Tamin, Azaibi and Reese, Natashia and
               Perry-Dow, K Allison and Brown, Robin and Harcourt, Jennifer L
               and Campbell, Davina and Houston, Hollis and Chakravorty, Rohan
               and Paulick, Ashley and Whitaker, Brett and Murdoch, Jordan and
               Spicer, Lori and Stumpf, Megan M and Mills, Lisa and Coughlin,
               Melissa M and Higdem, Pamela and Rasheed, Mohammad Ata Ur and
               Lonsway, David and Bhatnagar, Amelia and Kothari, Atul and
               Anderson, Karen and Thornburg, Natalie J and Breaker, Erin and
               Adamczyk, Michelle and McAllister, Gillian A and Halpin, Alison
               L and Seely, Kathryn A and Patil, Naveen and McDonald, L
               Clifford and Kutty, Preeta K",
  abstract  = "Background: To estimate the infectious period of severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adults
               with underlying conditions, we assessed duration of coronavirus
               disease 2019 (COVID-19) symptoms, reverse-transcription
               polymerase chain reaction (RT-PCR) positivity, and culture
               positivity among nursing home residents. Methods: We enrolled
               residents within 15 days of their first positive SARS-CoV-2 test
               (diagnosis) at an Arkansas facility from July 7 to 15, 2020 and
               instead them for 42 days. Every 3 days for 21 days and then
               weekly, we assessed COVID-19 symptoms, collected specimens
               (oropharyngeal, anterior nares, and saliva), and reviewed
               medical charts. Blood for serology was collected on days 0, 6,
               12, 21, and 42. Infectivity was defined by positive culture.
               Duration of culture positivity was compared with duration of
               COVID-19 symptoms and RT-PCR positivity. Data were summarized
               using measures of central tendency, frequencies, and
               proportions. Results: We enrolled 17 of 39 (44\%) eligible
               residents. Median participant age was 82 years (range, 58-97
               years). All had $\geq$3 underlying conditions. Median duration
               of RT-PCR positivity was 22 days (interquartile range [IQR],
               8-31 days) from diagnosis; median duration of symptoms was 42
               days (IQR, 28-49 days). Of 9 (53\%) participants with any
               culture-positive specimens, 1 (11\%) severely immunocompromised
               participant remained culture-positive 19 days from diagnosis; 8
               of 9 (89\%) were culture-positive $\leq$8 days from diagnosis.
               Seroconversion occurred in 12 of 12 (100\%) surviving
               participants with $\geq$1 blood specimen; all participants were
               culture-negative before seroconversion. Conclusions: Duration of
               infectivity was considerably shorter than duration of symptoms
               and RT-PCR positivity. Severe immunocompromise may prolong
               SARS-CoV-2 infectivity. Seroconversion indicated noninfectivity
               in this cohort.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  3,
  pages     = "ofab048",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; RT-PCR; SARS-CoV-2; infectivity; nursing homes",
  language  = "en"
}

@ARTICLE{Colombo2021-ci,
  title     = "Post-mortem differential diagnosis from {COVID-19}: A case of
               fulminant myocarditis {HHV-6} related",
  author    = "Colombo, Daniele and Cecannecchia, Camilla and Albore, Marco and
               Taglietti, Fabrizio and Nardacci, Roberta and Bolino, Giorgio
               and Del Nonno, Franca",
  journal   = "Pathol. Int.",
  publisher = "Wiley",
  month     =  nov,
  year      =  2021,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Van_Laarhoven2021-gw,
  title     = "Interferon gamma immunotherapy in five critically ill {COVID-19}
               patients with impaired cellular immunity: A case series",
  author    = "van Laarhoven, Arjan and Kurver, Lisa and Overheul, Gijs J and
               Kooistra, Emma J and Abdo, Wilson F and van Crevel, Reinout and
               Duivenvoorden, Rapha{\"e}l and Kox, Matthijs and Ten Oever, Jaap
               and Schouten, Jeroen and van de Veerdonk, Frank L and van der
               Hoeven, Hans and Rahamat-Langendoen, Janette and van Rij, Ronald
               P and Pickkers, Peter and Netea, Mihai G",
  abstract  = "Background: Prolonged severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) shedding has been described in
               immunocompromised coronavirus disease 2019 (COVID-19) patients,
               resulting in protracted disease and poor outcome. Specific
               therapy to improve viral clearance and outcome for this group of
               patients is currently unavailable. Methods: Five critically ill
               COVID-19 patients with severe defects in cellular immune
               responses, high SARS-CoV-2 viral RNA loads, and no respiratory
               improvement were treated with interferon gamma, 100 $\mu$g
               subcutaneously, thrice weekly. Bronchial secretion was collected
               every 48 h for routine diagnostic SARS-CoV-2 RT-PCR and viral
               culture. Findings: Interferon gamma administration was followed
               by a rapid decline in SARS-CoV-2 load and a positive-to-negative
               viral culture conversion. Four patients recovered, and no signs
               of hyperinflammation were observed. Conclusions: Interferon
               gamma may be considered as adjuvant immunotherapy in a subset of
               immunocompromised COVID-19 patients. Funding: A.v.L. and R.v.C.
               are supported by National Institutes of Health (R01AI145781).
               G.J.O. and R.P.v.R. are supported by a VICI grant
               (016.VICI.170.090) from the Dutch Research Council (NWO). W.F.A.
               is supported by a clinical fellowship grant (9071561) of
               Netherlands Organization for Health Research and Development.
               M.G.N. is supported by an ERC advanced grant (833247) and a
               Spinoza grant of the Netherlands Organization for Scientific
               Research.",
  journal   = "Med (N Y)",
  publisher = "Elsevier BV",
  volume    =  2,
  number    =  10,
  pages     = "1163--1170.e2",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; immunocompromised; immunotherapy;
               interferon gamma",
  language  = "en"
}

@ARTICLE{Shekhar2021-cd,
  title    = "{COVID-19} vaccine booster: To boost or not to boost",
  author   = "Shekhar, Rahul and Garg, Ishan and Pal, Suman and Kottewar, Saket
              and Sheikh, Abu Baker",
  abstract = "Developing safe and effective vaccines against severe acute
              respiratory syndrome coronavirus 2 (SARS-CoV-2) at a breakneck
              speed has been an exceptional human achievement. It remains our
              best hope of containing the coronavirus disease 2019 (COVID-19)
              pandemic. However, newer, more aggressive SARS-CoV-2 viral
              strains, as well as the possibility of fading immunity following
              vaccination, have prompted health officials to investigate the
              necessity for additional immunization. This has put further
              pressure on disregarded human life in lower-income countries that
              already have minimal access to COVID-19 vaccines. The Centers for
              Disease Control and Prevention (CDC) have recommended a third
              COVID-19 vaccine dose in immunocompromised individuals in a
              recent announcement. Governments and health care officials need
              to develop usage guidelines for COVID-19 vaccine booster doses
              while considering the dangers of potential waning immunity and
              new viral strains and prioritizing vulnerable populations
              everywhere, including those living in lower-income countries.",
  journal  = "Infect. Dis. Rep.",
  volume   =  13,
  number   =  4,
  pages    = "924--929",
  month    =  oct,
  year     =  2021,
  keywords = "COVID-19; COVID-19 vaccines; booster; coronavirus 2019;
              immunocompromised; third dose; vaccine; vaccine inequity",
  language = "en"
}

@ARTICLE{Nasa2021-kt,
  title     = "{COVID-19} and the liver: What do we know so far?",
  author    = "Nasa, Prashant and Alexander, George",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has caused
               unprecedented pressure on public health and healthcare. The
               pandemic surge and resultant lockdown have affected the
               standard-of-care of many medical conditions and diseases. The
               initial uncertainty and fear of cross transmission of severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
               changed the routine management of patients with pre-existing
               liver diseases, hepatocellular carcinoma, and patients either
               listed for or received a liver transplant. COVID-19 is best
               described as a multisystem disease caused by SARS-CoV-2, and it
               can cause acute liver injury or decompensation of the
               pre-existing liver disease. There has been considerable research
               on the pathophysiology, infection transmission, and treatment of
               COVID-19 in the last few months. The pathogenesis of liver
               involvement in COVID-19 includes viral cytotoxicity, the
               secondary effect of immune dysregulation, hypoxia resulting from
               respiratory failure, ischemic damage caused by vascular
               endotheliitis, congestion because of right heart failure, or
               drug-induced liver injury. Patients with chronic liver diseases,
               cirrhosis, and hepatocellular carcinoma are at high risk for
               severe COVID-19 and mortality. The phase III trials of recently
               approved vaccines for SARS-CoV-2 did not include enough patients
               with pre-existing liver diseases and excluded immunocompromised
               patients or those on immunomodulators. This article reviews the
               currently published research on the effect of COVID-19 on the
               liver and the management of patients with pre-existing liver
               disease, including SARS-CoV-2 vaccines.",
  journal   = "World J. Hepatol.",
  publisher = "Baishideng Publishing Group Inc.",
  volume    =  13,
  number    =  5,
  pages     = "522--532",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Chronic liver disease; Liver and SARS-CoV-2 vaccines;
               Liver transplant; SARS-CoV-2; SARS-CoV-2 induced liver injury;
               Severe acute respiratory syndrome coronavirus",
  language  = "en"
}

@ARTICLE{Aran2021-od,
  title     = "Dealing with lung cancer in the {COVID-19} scenario (A review)",
  author    = "Aran, Veronica and De Marchi, Pedro and Zamboni, Mauro and
               Ferreira, Carlos Gil",
  abstract  = "The severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2), which has caused the coronavirus disease 2019
               (COVID-19), first appeared in December 2019 in Wuhan (China) and
               quickly spread worldwide and has since been assigned a pandemic
               status. This affected the worlds' social interactions, including
               within medical practices, thus interfering with routine
               treatments for a variety of diseases including cancer. Different
               studies have addressed the fact that patients with cancer are
               often immunocompromised, making them more susceptible to
               infections. Since COVID-19 frequently causes respiratory
               distress, patients with lung cancer are considered to be a
               high-risk group. Genes that have been indicated to mediate viral
               entry into host cells such as angiotensin-converting enzyme 2
               and transmembrane protease serine 2 are expressed in the lung
               tissue, a fact that could partially explain COVID-19
               pathogenesis and lung involvement. Therefore, the current study
               offers a disease overview including molecular aspects behind the
               infection and provide a perspective on already published Chinese
               data plus recommendations for the management of lung cancer
               patients according to the two main lung cancer types and stages:
               non-small cell lung cancer and small cell lung cancer. This
               review aimed to add to the collective effort of selecting the
               most appropriate guidelines to follow for the treatment of these
               patients.",
  journal   = "Mol. Clin. Oncol.",
  publisher = "Spandidos Publications",
  volume    =  14,
  number    =  2,
  pages     = "27",
  month     =  feb,
  year      =  2021,
  keywords  = "angiotensin-converting enzyme 2; coronavirus disease 2019; lung
               cancer; non-small cell lung cancer; severe acute respiratory
               syndrome coronavirus 2; small-cell lung cancer; transmembrane
               protease serine 2",
  language  = "en"
}

@ARTICLE{Lanza2021-dr,
  title     = "Therapeutic use of convalescent plasma in {COVID-19} infected
               patients with concomitant hematological disorders",
  author    = "Lanza, Francesco and Agostini, Vanessa and Monaco, Federica and
               Passamonti, Francesco and Seghatchian, Jerard",
  abstract  = "The use of convalescent plasma (CP) from individuals recovered
               from severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) is a promising therapeutic modality for the
               coronavirus disease 2019 (COVID-19). CP has been in use for at
               least a century to provide passive immunity against a number of
               diseases, and was recently proposed by the World Health
               Organization for human Ebola virus infection. Only a few small
               studies have so far been published on patients with COVID-19 and
               concomitant hematological malignancies (HM). The Italian
               Hematology Alliance on HM and COVID-19 has found that HM
               patients with COVID-19 clinically perform more poorly than those
               with either HM or COVID-19 alone. A COVID-19 infection in
               patients with B-cell lymphoma is associated with impaired
               generation of neutralizing antibody titers and lowered clearance
               of SARS-CoV-2. Treatment with CP was seen to increase antibody
               titers in all patients and to improve clinical response in 80\%
               of patients examined. However, a recent study has reported
               impaired production of SARS-CoV-2-neutralizing antibodies in an
               immunosuppressed individual treated with CP, possibly supporting
               the notion of virus escape, particularly in immunocompromised
               individuals where prolonged viral replication occurs. This may
               limit the efficacy of CP treatment in at least some HM patients.
               More recently, it has been shown that CP may provide a
               neutralising effect against B.1.1.7 and other SARS-CoV-2
               variants, thus expanding its application in clinical practice.
               More extensive studies are needed to further assess the use of
               CP in COVID-19-infected HM patients.",
  journal   = "Clin Hematol Int",
  publisher = "Atlantis Press",
  volume    =  3,
  number    =  3,
  pages     = "77--82",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 antibodies; COVID-19 mutation; SARS-CoV-2; convalescent
               plasma preparations; hematological disorders; neutralising
               antibodies; plasmapheresis; prolonged viral shedding",
  language  = "en"
}

@ARTICLE{Casalini2021-eb,
  title     = "Invasive fungal infections complicating {COVID-19}: A narrative
               review",
  author    = "Casalini, Giacomo and Giacomelli, Andrea and Ridolfo, Annalisa
               and Gervasoni, Cristina and Antinori, Spinello",
  abstract  = "Invasive fungal infections (IFIs) can complicate the clinical
               course of COVID-19 and are associated with a significant
               increase in mortality, especially in critically ill patients
               admitted to an intensive care unit (ICU). This narrative review
               concerns 4099 cases of IFIs in 58,784 COVID-19 patients involved
               in 168 studies. COVID-19-associated invasive pulmonary
               aspergillosis (CAPA) is a diagnostic challenge because its
               non-specific clinical/imaging features and the fact that the
               proposed clinically diagnostic algorithms do not really apply to
               COVID-19 patients. Forty-seven observational studies and 41 case
               reports have described a total of 478 CAPA cases that were
               mainly diagnosed on the basis of cultured respiratory specimens
               and/or biomarkers/molecular biology, usually without
               histopathological confirmation. Candidemia is a widely described
               secondary infection in critically ill patients undergoing
               prolonged hospitalisation, and the case reports and
               observational studies of 401 cases indicate high crude mortality
               rates of 56.1\% and 74.8\%, respectively. COVID-19 patients are
               often characterised by the presence of known risk factors for
               candidemia such as in-dwelling vascular catheters, mechanical
               ventilation, and broad-spectrum antibiotics. We also describe
               3185 cases of mucormycosis (including 1549 cases of
               rhino-orbital mucormycosis (48.6\%)), for which the main risk
               factor is a history of poorly controlled diabetes mellitus
               (>76\%). Its diagnosis involves a histopathological examination
               of tissue biopsies, and its treatment requires anti-fungal
               therapy combined with aggressive surgical resection/debridement,
               but crude mortality rates are again high: 50.8\% in case reports
               and 16\% in observational studies. The presence of other
               secondary IFIs usually diagnosed in severely immunocompromised
               patients show that SARS-CoV-2 is capable of stunning the host
               immune system: 20 cases of Pneumocystis jirovecii pneumonia, 5
               cases of cryptococcosis, 4 cases of histoplasmosis, 1 case of
               coccidioides infection, 1 case of pulmonary infection due to
               Fusarium spp., and 1 case of pulmonary infection due to
               Scedosporium.",
  journal   = "J. Fungi (Basel)",
  publisher = "MDPI AG",
  volume    =  7,
  number    =  11,
  pages     = "921",
  month     =  oct,
  year      =  2021,
  keywords  = "CAM; CAPA; COVID-19; PCP; aspergillosis; candidemia;
               cryptococcosis; histoplasmosis; invasive fungal infections;
               mucormycosis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Kralj2021-df,
  title     = "Vitamin {D} and {COVID-19} in an immunocompromised patient with
               multiple comorbidities-A Case Report",
  author    = "Kralj, Martina and Jakovac, Hrvoje",
  abstract  = "Routine 25-OH-Vitamin D3 measurement in COVID-19 patients could
               be of great importance, either for clinical course estimation or
               deciding on supplementation.",
  journal   = "Clin. Case Rep.",
  publisher = "Wiley",
  volume    =  9,
  number    =  4,
  pages     = "2269--2275",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; methotrexate; risk factors; severity;
               vitamin D3",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Stainer2021-jo,
  title     = "{COVID-19} in immunocompromised patients: A systematic review",
  author    = "Stainer, Anna and Amati, Francesco and Suigo, Giulia and
               Simonetta, Edoardo and Gramegna, Andrea and Voza, Antonio and
               Aliberti, Stefano",
  abstract  = "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was
               first identified as a novel coronavirus in Wuhan, Hubei
               province, central China, in December 2019, and is responsible
               for the 2019-to-present pandemic. According to the most recent
               data released by the World Health Organization, more than 200
               million people have been infected by SARS-CoV-2 so far, and more
               than 4 million people died worldwide. Although our knowledge on
               SARS-CoV-2 and COVID-19 is constantly growing, data on COVID-19
               in immunocompromised patients are still limited. The aim of the
               present systematic review is to describe clinical picture,
               disease severity, proposed treatment regimen, and response to
               vaccination in patients with different types and severity of
               immunosuppression.",
  journal   = "Semin. Respir. Crit. Care Med.",
  publisher = "Georg Thieme Verlag KG",
  volume    =  42,
  number    =  6,
  pages     = "839--858",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Mohindra2021-po,
  title     = "{COVID-19} infection in a {HIV} positive health care worker:
               first case report from a tertiary care hospital of North India",
  author    = "Mohindra, Ritin and Kanta, Poonam and Porchezhian, Pradakshana
               and Goyal, Kapil and Suri, Vikas and Singh, Mini P and Pvm,
               Lakshmi and Bhalla, Ashish",
  abstract  = "People living with Human Immunodeficiency Virus (PLHIV) are at
               greater risk of developing prolonged illness due to COVID 19
               leading to longer duration of virus shedding owing to their
               underlying immune defects. The present study compared SARS-CoV-2
               infection developing at the same time among two health care
               workers living with and without a history of HIV and working in
               the same ward of a tertiary care hospital of North India. A
               higher viral load was reported in the SARS-CoV-2 infected worker
               who was immunocompromised as compared to immunocompetent patient
               (19,193 copies/L vs 9.4 copies/L). In this preliminary case
               report, no difference was observed in the clinical presentation
               of both patients at the time of diagnosis. Further studies are
               required to investigate the COVID-19 susceptibility and severity
               among HIV-infected patients.",
  journal   = "Virusdisease",
  publisher = "Springer Science and Business Media LLC",
  volume    =  32,
  number    =  2,
  pages     = "1--5",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19 and human immunodeficiency virus; immunocompromised;
               people living with human immunodeficiency virus",
  language  = "en"
}

@ARTICLE{Agrawal2021-tx,
  title    = "{COVID-19} associated pulmonary aspergillosis ({CAPA}) in a
              pregnant woman",
  author   = "Agrawal, Shruti and Phulware, Ravi Hari",
  abstract = "Viral or bacterial co-infections with severe acute respiratory
              syndrome coronavirus 2 (SARS-CoV-2) have been reported in the
              literature. However, the knowledge on Aspergillus co-infection
              among patients with coronavirus disease 2019 (COVID-19) is
              limited. COVID-19-associated pulmonary aspergillosis (CAPA) has
              been seen in critically ill COVID-19 patients with acute
              respiratory distress syndrome (ARDS), which has raised concerns
              about the worsening disease course of COVID-19 and increasing
              mortality. We describe a clinical case of CAPA infection and
              acute respiratory distress syndrome (ARDS) with a deathly outcome
              in a previously well, non-immunocompromised pregnant woman with
              intrauterine death of the fetus. Hence, we suggest that
              clinicians and pathologists keep alerting the possible occurrence
              of pulmonary aspergillosis in severe/critical COVID-19 patients,
              and aggressive investigations should be done to rule out the
              possibility of CAPA so that early treatment can be administrated.",
  journal  = "Autops. Case Rep.",
  volume   =  11,
  pages    = "e2021313",
  month    =  aug,
  year     =  2021,
  keywords = "COVID-19, Pulmonary Aspergillosis; Fungi; Respiratory Distress
              Syndrome,; SARS-CoV-2",
  language = "en"
}

@ARTICLE{Goto2021-tm,
  title     = "The therapeutic dilemma of immunosuppressive drugs for
               refractory cardiac sarcoidosis in {COVID-19} infection",
  author    = "Goto, Kohsaku and Uehara, Masae and Okamoto, Koh and Takeda,
               Norifumi and Morita, Hiroyuki and Hatano, Masaru and Komuro,
               Issei",
  abstract  = "Patients with refractory cardiac sarcoidosis (CS) take a high
               dose of corticosteroid and immunosuppressive agents. During the
               pandemic outbreak of severe acute respiratory syndrome
               coronavirus 2, appropriate treatment of corticosteroids or
               immunosuppressive agents in CS patients with coronavirus disease
               2019 (COVID-19) is unknown. Here, the woman with refractory CS
               receiving maintenance therapy with 15 mg of prednisolone daily
               and 10 mg of methotrexate weekly was emergently admitted to our
               hospital because of COVID-19. This case was successfully treated
               by the intravenous administration of dexamethasone 6 mg/day
               instead of prednisolone and interruption of methotrexate without
               resulting in recurrent life-threatening ventricular lethal
               arrhythmias or obvious sarcoidosis flare-ups. She started taking
               prednisolone and methotrexate at the maintenance dose
               immediately and at 2 weeks after discharge, respectively.
               Although the optimal regimen of immunosuppressive agents during
               COVID-19 is under intense debate, this report might provide an
               effective treatment strategy for CS patients with COVID-19.",
  journal   = "ESC Heart Fail.",
  publisher = "Wiley",
  month     =  oct,
  year      =  2021,
  keywords  = "Immunocompromised patient; Immunology; Refractory cardiac
               sarcoidosis; Severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2)",
  copyright = "http://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Sutandi2021-iy,
  title     = "Vitreoretinal abnormalities in corona virus disease 2019
               patients: What we know so far",
  author    = "Sutandi, Nathania and Lee, Felix",
  abstract  = "The coronavirus disease 2019 (COVID-19) has become a global
               pandemic since December 2019. Although COVID-19 primarily
               affects the respiratory systems, it has become abundantly clear
               that it involves multiple organs including the heart, kidney,
               skin, and brain. Neuro-ophthalmic signs and anterior segment
               inflammation of the eyes were documented in COVID-19 patients
               recently. Small but growing number of literatures has also
               reported the cases of new onset vitreoretinal disorders related
               to COVID-19 infection. A comprehensive search from four online
               databases was done. Findings show vitreoretinal involvement in
               COVID-19 patients including the central retinal vein occlusion,
               central retinal artery occlusion, reactivation of previous
               uveitis, chorioretinitis, macular hemorrhage, acute macular
               neuroretinopathy, paracentral acute middle maculopathy, vitritis
               with outer retinal abnormalities, varicella zoster virus-related
               acute retinal necrosis in immunocompromised patient, and other
               posterior segment pathological changes. The hypotheses for
               potential pathogenesis of these manifestations are direct viral
               ocular infection and thromboembolic complications secondary to
               the hyperinflammatory response. This is the first review
               article, which provides an overview of current evidence
               regarding the vitreoretinal manifestations in COVID-19 patients.",
  journal   = "Taiwan J. Ophthalmol.",
  publisher = "Medknow",
  volume    =  11,
  number    =  3,
  pages     = "232--243",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; funduscopy; posterior segment;
               vitreoretinal abnormalities",
  language  = "en"
}

@ARTICLE{Pan2021-eg,
  title    = "Management and thinking on the treatment of cancer patients
              during the {COVID-19}",
  author   = "Pan, Shuangyue and Jiang, Jiahong and Chen, Zheling and Yang, Liu",
  abstract = "Coronavirus disease-2019 (COVID-19) has spread rapidly around the
              world and has become a public health emergency of international
              concern. The weekly epidemiological report issued by the WHO
              pointed out that new coronavirus variants have appeared in 131
              countries and regions, which demonstrates that the current
              epidemic situation is still severe. As of now, the severe acute
              respiratory syndrome coronavirus (SARS-CoV-2) has been widespread
              worldwide for more than one year and poses a serious threat to
              the health of vulnerable groups such as those with malignancies,
              the elderly, and the immunocompromised. Compared with the general
              population, cancer patients with COVID-19 infection are more
              likely to have serious clinical adverse events, leading to higher
              mortality. There is no doubt that during the COVID-19 epidemic,
              whether it is with regards to how to prevent infection or how to
              continue anti-tumor treatment, cancer patients are in a difficult
              situation. Meanwhile, an international patient with malignant
              Hodgkin's lymphoma who was cured after being infected with the
              new coronavirus surprised us, and it inspires more scientists to
              explore the relationship between infection, immunity, and tumors.
              Relevantly, through multi-disciplinary discussion, scientists put
              forward more new perspectives on the treatment of future tumors
              and the management of SARS-CoV-2 diseases. In this review, the
              impact of COVID-19 on cancer patients is discussed in detail and
              the recommendations for the diagnosis, treatment and management
              of cancer patients will be put forward under the challenge of the
              COVID-19 epidemic. Furthermore, the safety and effectiveness of
              the SARS-CoV-2 vaccine will be discussed, and we will also put
              forward our insights on cancer immunity.",
  journal  = "Front. Mol. Biosci.",
  volume   =  8,
  pages    = "673360",
  month    =  jul,
  year     =  2021,
  keywords = "COVID-19; SARS-CoV-2; cancer immunity; cancer patients;
              management; vaccine",
  language = "en"
}

@ARTICLE{Moragas2021-rv,
  title    = "Case report: Hyperinflammatory status in an immunocompromised
              child with a highly sustained viral load of {SARS-CoV-2}",
  author   = "Moragas, Matias and Gomez, Sandra and Fern{\'a}ndez, Mar{\'\i}a
              Florencia and Golemba, Marcelo Dario and Palladino, Marcela and
              Borgnia, Daniela and Ruvinsky, Silvina and Fraquelli, Lidia and
              Buchovsky, Ana and Bologna, Rosa and Mangano, Andrea",
  abstract = "Coronavirus disease 2019 (COVID-19) is spreading throughout the
              world. Limited data are available for the dynamics of severe
              acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load
              (VL) in immunocompromised pediatric patients. Here, we report the
              clinical characteristics and the dynamics of SARS-CoV-2 VL of a
              pediatric patient with acute myeloid leukemia who developed a
              hyperinflammatory status mimicked MIS-C. The clinical course was
              characterized by the late onset of fever, GI symptoms, rash, and
              respiratory distress, including oxygen requirement with sustained
              VL of SARS-CoV-2 around 7 log10 RNA copies/mL for 6 weeks. It is
              important to note that the hyperinflammatory status developed
              early at the third week of hospitalization-in a context of high
              VL and immunocompromised status. All these characteristics make
              this clinical case unique. On the other hand, while many reports
              have characterized the dynamics of SARS-CoV-2 VL in adults and
              immunocompetent hosts, it remains unreported in pediatrics-even
              less in immunosuppressed children.",
  journal  = "Front. Med. (Lausanne)",
  volume   =  8,
  pages    = "675282",
  month    =  aug,
  year     =  2021,
  keywords = "COVID-19; SARS-CoV-2; hyperinflammatory status; immunocompromised
              state; pediatrics; viral load",
  language = "en"
}

@ARTICLE{Laiq2022-tr,
  title     = "Fonsecaea associated cerebral phaeohyphomycosis in a
               {post-COVID-19} patient: A first case report",
  author    = "Laiq, Simin and Al Yaqoobi, Mubarak and Al Saadi, Maimuna and
               Rizvi, Semee and Al Hajri, Zahra and Al Azri, Saleh and Al
               Ramadhani, Khalsa and Al Hinai, Qasim",
  abstract  = "Phaeohyphomycosis, previously known as chromoblastomycosis, is a
               chronic mycosis, usually affecting the skin. It is caused by
               dematiaceous fungi, which are a group of fungi that produce
               melanin in their cell walls. Cerebral phaeohyphomycosis occurs
               as a part of invasive presentation of the fungi, which usually
               affects immunocompromised patients, but may affect
               immunocompetent individuals as well. Cerebral infection in
               phaeohyphomycosis is associated with a poor prognosis regardless
               of the immune status of the patient. COVID-19 SARS-CoV-2
               infection and/or medications used for its treatment may
               compromise the immune system, including in the post-COVID-19
               period, resulting in invasive fungal infections, which have
               frequently been reported recently during the COVID-19 pandemic.
               We report a case of Fonsecaea associated cerebral
               phaeohyphomycosis in a recently diagnosed diabetic Omani lady,
               who presented to our hospital 6 weeks after recovery and
               discharge from hospitalization for moderate COVID-19 pneumonia.",
  journal   = "Clin Infect Pract",
  publisher = "Elsevier BV",
  volume    =  13,
  number    =  100126,
  pages     = "100126",
  month     =  jan,
  year      =  2022,
  keywords  = "Brain abscess; COVID-19; Cerebral phaeohyphomycosis;
               Chromoblastomycosis; Dematiaceous fungi; Fonsecaea; Pigmented
               fungi; SARS-CoV-2",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Heldman2021-bz,
  title     = "{COVID-19} in solid organ transplant recipients: A review of the
               current literature",
  author    = "Heldman, Madeleine R and Kates, Olivia S",
  abstract  = "Purpose of review: The approach to ongoing organ transplantation
               and management of COVID-19 in solid organ transplant recipients
               (SOTR) has evolved tremendously since the pandemic's beginning.
               We summarize the current literature surrounding the virology of
               SARS-CoV-2, epidemiology of COVID-19 in transplant recipients,
               review the clinical features and complications of COVID-19 in
               SOTR, and discuss the safety and efficacy of current therapies
               and candidate vaccines in this population. Recent findings:
               Despite initial suspensions in organ transplantation during
               early 2020, routine donor testing and de-crowding of hospitals
               have allowed transplant activity to resume at pre-pandemic
               rates. COVID-19-associated mortality in SOTR is similar to that
               of the general population, and lower than that of patients with
               end-organ disease awaiting transplant. The optimal approach to
               immunosuppression in SOTR with COVID-19 is unknown and disease
               severity may influence management decisions. Many vaccines in
               development are likely to be safe for immunocompromised hosts,
               though post-marketing investigations will be required to
               determine the efficacy in the SOTR. Summary: Though there are
               multiple unique considerations in the care of SOTR with
               COVID-19, immunosuppression does not appear to have a
               detrimental impact on overall outcome. Organ transplantation
               remains a lifesaving intervention and can be safely performed
               despite a global pandemic.",
  journal   = "Curr. Treat. Options Infect. Dis.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  13,
  number    =  3,
  pages     = "1--16",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; SARS-CoV-2; Solid organ transplant",
  language  = "en"
}

@ARTICLE{Cheng2021-hf,
  title     = "The paradox of immunosuppressants and {COVID-19}",
  author    = "Cheng, Guang-Shing and Evans, Scott E",
  journal   = "Eur. Respir. J.",
  publisher = "European Respiratory Society (ERS)",
  pages     = "2102828",
  month     =  nov,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Fatehi2021-jw,
  title     = "Comparing antiviral strategies against {COVID-19} via multiscale
               within-host modelling",
  author    = "Fatehi, F and Bingham, R J and Dykeman, E C and Stockley, P G
               and Twarock, R",
  abstract  = "Within-host models of COVID-19 infection dynamics enable the
               merits of different forms of antiviral therapy to be assessed in
               individual patients. A stochastic agent-based model of COVID-19
               intracellular dynamics is introduced here, that incorporates
               essential steps of the viral life cycle targeted by treatment
               options. Integration of model predictions with an intercellular
               ODE model of within-host infection dynamics, fitted to patient
               data, generates a generic profile of disease progression in
               patients that have recovered in the absence of treatment. This
               is contrasted with the profiles obtained after variation of
               model parameters pertinent to the immune response, such as
               effector cell and antibody proliferation rates, mimicking
               disease progression in immunocompromised patients. These
               profiles are then compared with disease progression in the
               presence of antiviral and convalescent plasma therapy against
               COVID-19 infections. The model reveals that using both therapies
               in combination can be very effective in reducing the length of
               infection, but these synergistic effects decline with a delayed
               treatment start. Conversely, early treatment with either therapy
               alone can actually increase the duration of infection, with
               infectious virions still present after the decline of other
               markers of infection. This suggests that usage of these
               treatments should remain carefully controlled in a clinical
               environment.",
  journal   = "R. Soc. Open Sci.",
  publisher = "The Royal Society",
  volume    =  8,
  number    =  8,
  pages     = "210082",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; adaptive immune response; intercellular infection
               model; intracellular infection model",
  language  = "en"
}

@ARTICLE{Lafarge2021-ze,
  title    = "Coronavirus disease 2019 in immunocompromised patients: a
              comprehensive review of coronavirus disease 2019 in hematopoietic
              stem cell recipients",
  author   = "Lafarge, Antoine and Mabrouki, Asma and Yvin, Elise and Bredin,
              Swann and Binois, Yannick and Clere-Jehl, Raphael and Azoulay,
              Elie",
  abstract = "PURPOSE OF REVIEW: Immunocompromised patients are notably
              vulnerable to severe coronavirus disease 2019. This review
              summarizes COVID-19 features and outcomes in autologous and
              allogeneic hematopoietic stem cell transplantation (HSCT)
              recipients. RECENT FINDINGS: Recent findings suggest that HSCT
              recipients exhibit a high burden of comorbidities and COVID-19
              clinical features almost similar to the general COVID population.
              Furthermore, HSCT recipients exhibit a protracted SARS-CoV-2
              shedding, prolonging duration of symptoms and promoting the
              generation of highly mutated viruses. Last, most of studies
              report a higher COVID-19 mortality in HSCT recipients, mainly
              driven by age, comorbidities, time from transplantation, and
              immunosuppression because of both treatments and underlying
              hematological malignancy. SUMMARY: Further studies are warranted
              to determine the proper impact of HSCT-related immune disorders
              on COVID-19 outcomes, and to evaluate specific treatments and
              vaccination strategy in this high-risk population. Taken
              together, those findings emphasize the need for more rigorous
              surveillance and preemptive measures for all HSCT recipients.",
  journal  = "Curr. Opin. Crit. Care",
  month    =  nov,
  year     =  2021,
  language = "en"
}

@ARTICLE{Caci2021-kx,
  title    = "Bronchoalveolar lavage-detected {SARS-CoV-2} infection in
              presence of serial negative nasopharyngeal swabs: a case report",
  author   = "Caci, Grazia and Minervini, Fabrizio and Fechner, Carsten and
              Roos, Justus E and Obermann, Ellen C and Azzola, Andrea",
  abstract = "We describe a case of a SARS coronavirus 2 (SARS-CoV-2) infection
              in a Swiss 54-years-old immunocompromised patient (lymphoma,
              therapy with the anti-CD20 antibody Rituximab\textregistered{} ),
              with initial scarce respiratory symptoms but typical coronavirus
              disease 2019 (COVID-19) radiological presentation, and symptoms
              onset during a holiday trip to Texas (USA). Three nasopharyngeal
              swabs in the 96 hours following hospital admission were negative,
              despite a CT thorax suggestive for an early stage of infection.
              COVID-infection was finally confirmed in the bronchoalveolar
              lavage (BAL) fluid, performed for exclusion of an alternative
              diagnosis in immunocompromised. In the BAL an increased
              cellularity with marked lymphocytosis of 35\%, a reduced CD4/CD8
              ratio of 0.1 and borderline neutrophilia of 3\% were found. This
              finding might be due to the concomitant therapy with anti-CD20
              antibodies, but the presence of lymphocytosis in the BAL despite
              peripheral lymphopenia with decreased CD4/CD8 T-cells ratio are
              described here for the first time in a SARS-CoV-2 infection.
              Persistent gastrointestinal symptoms (diarrhea), fever and
              initially headache were the predominant symptoms. The respiratory
              symptoms were scarce (variable mild dyspnea mMRC1). The
              respiratory conditions worsened during the hospital stay, with
              tachypnea up to 35/min, increased need for supplemental oxygen up
              to 8 L/min and worsening lung infiltrates on CT thorax on day 5.
              A therapy with hydroxychloroquine (HCQ) and an
              immunoglobulin-supplementation were given, with clinical and
              respiratory improvement, without need for intensive care or any
              ventilator support, and hospital discharge on day 16. Our case
              highlights some diagnostic and therapeutical challenges occurring
              in patients with COVID-19 infection. As take-home message, in the
              presence of clinical and radiological findings compatible with
              SARS-CoV-2 infection we outline the importance of treating
              patients accordingly, also in presence of repeated negative
              nasopharyngeal swabs. In selected patients as in our case a
              bronchoscopic BAL should be considered to exclude other
              infections, but in our opinion not primarily to confirming
              COVID-19 infection. Our unique finding of a lymphocytosis in the
              BAL during a COVID-19 infection needs further investigations.",
  journal  = "Ann. Transl. Med.",
  volume   =  9,
  number   =  7,
  pages    = "583",
  month    =  apr,
  year     =  2021,
  keywords = "SARS coronavirus 2 (SARS-CoV-2); bronchoalveolar lavage (BAL);
              coronavirus disease 2019 (COVID-19); lymphocytosis; swab",
  language = "en"
}

@ARTICLE{Brown2021-fz,
  title     = "Triple-negative breast cancer and the {COVID-19} pandemic:
               Clinical management perspectives and potential consequences of
               infection",
  author    = "Brown, Justin M and Wasson, Marie-Claire D and Marcato, Paola",
  abstract  = "The COVID-19 pandemic has caused the need for prioritization
               strategies for breast cancer treatment, where patients with
               aggressive disease, such as triple-negative breast cancer (TNBC)
               are a high priority for clinical intervention. In this review,
               we summarize how COVID-19 has thus far impacted the management
               of TNBC and highlighted where more information is needed to hone
               shifting guidelines. Due to the immunocompromised state of most
               TNBC patients receiving treatment, TNBC management during the
               pandemic presents challenges beyond the constraints of
               overburdened healthcare systems. We conducted a literature
               search of treatment recommendations for both primary and
               targeted TNBC therapeutic strategies during the COVID-19
               outbreak and noted changes to treatment timing and drugs of
               choice. Further, given that SARS-CoV-2 is a respiratory virus,
               which has systemic consequences, management of TNBC patients
               with metastatic versus localized disease has additional
               considerations during the COVID-19 pandemic. Published dataset
               gene expression analysis of critical SARS-CoV-2 cell entry
               proteins in TNBCs suggests that the virus could in theory infect
               metastasized TNBC cells it contacts. This may have unforeseen
               consequences in terms of both the dynamics of the resulting
               acute viral infection and the progression of the chronic
               metastatic disease. Undoubtedly, the results thus far suggest
               that more research is required to attain a full understanding of
               the direct and indirect clinical impacts of COVID-19 on TNBC
               patients.",
  journal   = "Cancers (Basel)",
  publisher = "MDPI AG",
  volume    =  13,
  number    =  2,
  pages     = "296",
  month     =  jan,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; clinical management; metastasis;
               triple-negative breast cancer",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tepasse2021-fq,
  title     = "Vaccination against {SARS-CoV-2} in patients with inflammatory
               bowel diseases: Where do we stand?",
  author    = "Tepasse, Phil-Robin and Vollenberg, Richard and Nowacki, Tobias
               Max",
  abstract  = "Crohn's disease and ulcerative colitis are chronic inflammatory
               bowel diseases (IBDs). Immunosuppressive medication is the main
               therapeutic approach to reducing inflammation of the
               gastrointestinal tract. Immunocompromised patients are more
               vulnerable to severe courses of illness after infection with
               common pathogens. The severe acute respiratory syndrome
               coronavirus-2 (SARS-CoV-2) is the pathogen of the coronavirus
               disease 2019 (COVID-19) pandemic. COVID-19 leads to acute
               respiratory distress syndrome (ARDS) following severe pulmonal
               damage in a significant number of cases. The worldwide
               circulation of SARS-CoV-2 has led to major concerns about the
               management of IBD patients during the pandemic, as these
               patients are expected to be at greater risk of complications
               because of their underlying altered immunological condition and
               immunosuppressive therapies. Vaccination against SARS-CoV-2 is
               considered the main approach in containing the pandemic. Today,
               several vaccines have been shown to be highly effective in the
               prevention of SARS-CoV-2 infection and severe disease course in
               subjects without underlying conditions in respective
               registration studies. Patients with underlying conditions such
               as IBD and/or immunosuppressive therapies were not included in
               the registration studies, so little is known about effectiveness
               and safety of SARS-CoV-2 vaccination in immunocompromised IBD
               patients. This review provides an overview of the recent
               knowledge about vaccine response in IBD patients after
               vaccination against SARS-CoV-2.",
  journal   = "Life (Basel)",
  publisher = "MDPI AG",
  volume    =  11,
  number    =  11,
  pages     = "1220",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Crohn's disease; IBD; SARS-CoV-2; ulcerative colitis;
               vaccination",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{R2021-yh,
  title     = "{COVID-19} coinfection with mucormycosis in a diabetic patient",
  author    = "R, Roopa and Thanthoni, Malarkodi and Warrier, Aravind S",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a
               form of $\beta$-Coronavirus of the Coronaviridae family, has
               been causing infection among humans worldwide leading to a
               pandemic emergency. New strains of SARS-CoV-2 have been evolving
               unceasingly, presenting with various systemic and oral
               manifestations. There has been an increase in the incidence of
               secondary infection in the coronavirus infected individual
               either due to pre-existing factors or the virus by itself is
               causing such infection, which is still unclear. As it is already
               known, immunocompromised and uncontrolled diabetic patients have
               an increased chance of developing mucormycosis. Herein, we
               report a case who presented with a swelling in the left cheek,
               eye, and avascular necrosis intraorally, post COVID-19
               infection.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  6,
  pages     = "e15820",
  month     =  jun,
  year      =  2021,
  keywords  = "coronavirus; covid-19; diabetes mellitus; mucormycosis;
               opportunistic fungal infection",
  language  = "en"
}

@ARTICLE{Saidha2021-bz,
  title     = "Mucormycosis of paranasal sinuses of odontogenic origin post
               {COVID19} infection: A case series",
  author    = "Saidha, Poonam Kumar and Kapoor, Sahil and Das, Pooja and Gupta,
               Ayushi and Kakkar, Vikas and Kumar, Arun and Arya, Varun",
  abstract  = "The Severe acute respiratory syndrome and the Middle East
               respiratory syndromes emerged in 2002 and 2012 respectively.
               Currently the world is witnessing a global pandemic caused by a
               novel coronavirus, the severe acute respiratory syndrome
               coronavirus 2 (SARS CoV- 2) causing the Coronavirus 2019
               (COVID-19). Mucormycosis is a fungal infection primarily
               affecting individuals with an immunocompromised state like
               diabetes mellitus, malignancies etc. Patients who have or have
               had COVID-19 infection with pre-existing uncontrolled Type 2
               Diabetes mellitus are presumably more vulnerable for emergence
               of fungal infections cases. This article presents a report of 6
               cases with histopathological proven mucormycosis associated with
               COVID-19 and uncontrolled Diabetes mellitus.",
  journal   = "Indian J. Otolaryngol. Head Neck Surg.",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--5",
  month     =  jun,
  year      =  2021,
  keywords  = "Amphotericin B; COVID-19; Immunocompromised; Mucormycosis; Type
               2 diabetes mellitus",
  language  = "en"
}

@ARTICLE{Chaudhry2021-zv,
  title     = "Longest reported case of symptomatic {COVID-19} reporting
               positive for over 230 days in an immunocompromised patient in
               the United States",
  author    = "Chaudhry, Bilal and Didenko, Lidiya and Chaudhry, Maaria and
               Malek, Andrew and Alekseyev, Kirill",
  abstract  = "Coronavirus 2019 (COVID-19) pneumonia was first noted in Wuhan,
               China. Since the start of the pandemic, there have been millions
               of cases diagnosed. The average time from onset of symptoms to
               testing negative SARS-CoV-2 via reverse transcription polymerase
               chain reaction is roughly 25 days. In patients who continually
               test positive for COVID-19, it is essential to determine
               precisely which risk factors contribute to the increase in viral
               shedding duration. We present a case about a 62-year-old man who
               has persistently tested positive for COVID-19 for more than 230
               days. We followed his treatment course, in which he had been
               hospitalized multiple times since the onset of symptoms back in
               April 2020. We have determined that patients with
               immunosuppression, especially those taking corticosteroids, are
               at increased risk of prolonged viral shedding. It is essential
               to continually monitor these immunocompromised patients as they
               required a greater time period in order to have an appropriate
               immune response in which antibodies are created.",
  journal   = "SAGE Open Med. Case Rep.",
  publisher = "SAGE Publications",
  volume    =  9,
  pages     = "2050313X211040028",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; corticosteroids; immunocompromised; reverse
               transcription polymerase chain reaction; viral shedding",
  language  = "en"
}

@ARTICLE{Spinicci2021-xj,
  title     = "{AIDS} patient with severe {T} cell depletion achieved control
               but not clearance of {SARS-CoV-2} infection",
  author    = "Spinicci, Michele and Mazzoni, Alessio and Borchi, Beatrice and
               Graziani, Lucia and Mazzetti, Marcello and Bartalesi, Filippo
               and Botta, Annarita and Tilli, Marta and Pieralli, Filippo and
               Coppi, Marco and Giovacchini, Nicla and Colao, Maria Grazia and
               Saccardi, Riccardo and Rossolini, Gian Maria and Annunziato,
               Francesco and Bartoloni, Alessandro",
  abstract  = "A late presenter AIDS patient with severe T cell depletion
               presented non-severe COVID-19 symptoms, with prolonged viral
               shedding. Our case report supports the hypothesis that an
               effective T cell response may be dispensable for the control of
               COVID-19 progression to severe forms, while it may be necessary
               for SARS-CoV-2 clearance.",
  journal   = "Eur. J. Immunol.",
  publisher = "Wiley",
  month     =  nov,
  year      =  2021,
  keywords  = "CD4; COVID-19; HIV; convalescent plasma; immunocompromised;
               monoclonal",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Crone2021-ld,
  title     = "Pulmonary mucormycosis in the aftermath of critical {COVID-19}
               in an immunocompromised patient: Mind the diagnostic gap",
  author    = "Crone, Cornelia Geisler and Helweg-Larsen, Jannik and Steensen,
               Morten and Arendrup, Maiken Cavling and Helleberg, Marie",
  abstract  = "Mucormycosis has recently been recognized as a severe
               complication of COVID-19 with high fatality rates. We report a
               fatal case of COVID-19 associated mucormycosis (CAM) in a
               non-diabetic immunocompromised patient, who was first
               misdiagnosed and treated for COVID-19 associated aspergillosis
               (CAPA). The risk factors and initial clinical presentation of
               CAPA and CAM are similar, but CAM has a more aggressive course
               and CAPA and CAM are treated differently. Dedicated diagnostic
               workup is essential to ensure early treatment of CAM with
               surgical debridement and targeted antifungal therapy.",
  journal   = "J. Mycol. Med.",
  publisher = "Elsevier BV",
  volume    =  32,
  number    =  1,
  pages     = "101228",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; Invasive fungal infection;
               Mucormycosis; Rhizopus microsporum; SARS-COV-2",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Boedecker2021-ue,
  title     = "{COVID-19-importance} for patients on the waiting list and after
               kidney transplantation-A single center evaluation in 2020-2021",
  author    = "Boedecker, Simone C and Klimpke, Pascal and Kraus, Daniel and
               Runkel, Stefan and Galle, Peter R and Koch, Martina and
               Weinmann-Menke, Julia",
  abstract  = "(1) Background: Dialysis patients and recipients of a kidney
               allograft are at high risk for infection with SARS-CoV-2. It has
               been shown that the development of potent neutralizing humoral
               immunity against SARS CoV-2 leads to an increased probability of
               survival. However, the question of whether immunocompromised
               patients develop antibodies has not yet been sufficiently
               investigated; (2) Methods: SARS-CoV-2 antibodies were examined
               in hemodialysis patients on the waiting list for kidney
               transplantation as well as patients after kidney
               transplantation. Patients were interviewed about symptoms and
               comorbidities, BMI, and smoking history; (3) Results: SARS-CoV-2
               antibodies were found in 16 out of 259 patients (6\%). The trend
               of infections here reflects the general course of infection in
               Germany with a peak in November/December of 2020. Remarkably,
               patients on the waiting list experienced only mild disease. In
               contrast, transplanted patients had to be hospitalized but
               recovered rapidly from COVID-19. Most interesting is that all
               immunosuppressed patients developed antibodies against
               SARS-CoV-2 after infection; (4) Conclusions: Even with extensive
               hygiene concepts, an above-average number of patients were
               infected with SARS-CoV-2 during the second wave of infections in
               Germany. Because SARS-CoV-2 infection triggered the formation of
               antibodies even in these immunocompromised patients, we expect
               vaccination to be effective in this group of patients. Thus,
               dialysis patients and patients after kidney transplantation
               should be given high priority in vaccination programs.",
  journal   = "Pathogens",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  4,
  pages     = "429",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; hemodialysis; kidney transplantation; waiting list",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Stampfer2022-lp,
  title     = "Severe breakthrough {COVID-19} with a heavily mutated variant in
               a multiple myeloma patient 10 weeks after vaccination",
  author    = "Stampfer, Samuel D and Goldwater, Marissa-Skye and Bujarski,
               Sean and Regidor, Bernard and Zhang, Wenjuan and Feinstein,
               Aaron J and Swift, Regina and Eshaghian, Shahrooz and Vail, Eric
               and Berenson, James R",
  abstract  = "Background: Patients with multiple myeloma have unpredictable
               responses to vaccination for COVID-19. Anti-spike antibody
               levels can determine which patients develop antibodies at levels
               similar to healthy controls, and are a known correlate of
               protection. Case report: A multiple myeloma patient developed
               protective anti-spike antibodies after vaccination (608 IU/mL),
               but nonetheless developed severe breakthrough COVID-19 just 10
               weeks following his second vaccination with mRNA-1273. Results:
               Sequencing of the viral isolate revealed an extensively mutated
               variant with 10 spike protein mutations, including E484Q and
               N440K. Serology testing showed a dramatic decline in anti-spike
               antibodies immediately prior to virus exposure. Conclusions:
               Multiple myeloma patients who do develop detectable antibody
               responses to vaccination may be at increased risk for
               breakthrough infections due to rapid decline in antibody levels.
               Viral variants with immune escape mutations such as N440K, also
               seen independently in the SARS-CoV-2 Omicron variant (B.1.1.529)
               and in viral passaging experiments, likely require a higher
               level of anti-spike antibodies to prevent severe COVID-19.",
  journal   = "Clin Infect Pract",
  publisher = "Elsevier BV",
  volume    =  13,
  number    =  100130,
  pages     = "100130",
  month     =  jan,
  year      =  2022,
  keywords  = "Antibody; B.1.628; Breakthrough; COVID-19; Correlate of
               protection; E484Q; Immunocompromised; Multiple myeloma; N440K;
               S194L; SARS-CoV-2; Severe; Spike",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Elliott2021-wd,
  title    = "Interferon gamma runs interference on persistent {COVID-19}",
  author   = "Elliott, Eric Isaac and Wang, Andrew",
  abstract = "COVID-19 represents a collection of disease endotypes stemming
              from infection with SARS-CoV-2 and thus requires precision
              medicine approaches to target specific viral variants and stages
              of illness. In this issue, van Laarhoven et al.1 describe five
              immunocompromised patients with prolonged COVID-19 successfully
              treated with interferon gamma (IFN$\gamma$).",
  journal  = "Med (N Y)",
  volume   =  2,
  number   =  10,
  pages    = "1111--1113",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Talwar2021-jq,
  title     = "Sirolimus in a renal transplant recipient infected with
               {COVID-19}: A blessing in disguise?",
  author    = "Talwar, Dhruv and Kumar, Sunil and Acharya, Sourya and Hulkoti,
               Vidyashree and Annadatha, Akhilesh",
  abstract  = "Immunocompromised status Is often associated with severe
               coronavirus infection given the inability of the immune system
               to combat the deadly severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2). Patients with multiple comorbidities
               such as diabetes mellitus, hypertension, and chronic kidney
               disease along with patients on immunosuppressants or
               chemotherapy are at higher risk of getting infected during the
               ongoing pandemic with more probability of adverse outcomes.
               However, we report a rare case of a renal transplant recipient
               who was on sirolimus and contracted coronavirus disease
               (COVID-19). His immunosuppressants were continued and he was
               managed with antiviral, steroids and low molecular weight
               heparin and the patient responded well to the treatment and
               recovered completely after a span of one week. Use of sirolimus
               in a patient with renal transplant recipient helped in
               preventing intensification of the severity in COVID-19
               attributing to its inhibiting effect on mammalian target of
               rapamycin (mTOR) which he was using post his renal transplant,
               therefore, proving to be a blessing in disguise.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  8,
  pages     = "e17102",
  month     =  aug,
  year      =  2021,
  keywords  = "chronic kidney disease; covid19; immunocompromised; mtor
               inhibitors; renal transplant",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Chappell2021-lw,
  title     = "Immunocompromised children and young people are at no increased
               risk of severe {COVID-19}",
  author    = "Chappell, H and Patel, R and Driessens, C and Tarr, A W and
               Irving, W L and Tighe, P J and Jackson, H J and
               Harvey-Cowlishaw, T and Mills, L and Shaunak, M and Gbesemete, D
               and Leahy, A and Lucas, J S and Faust, S N and de Graaf, H",
  abstract  = "OBJECTIVES: We aimed to prospectively describe the incidence and
               clinical spectrum of SARS-CoV-2 infection in immunocompromised
               paediatric patients in the UK. METHODS: From March 2020 to 2021
               weekly questionnaires were sent to immunocompromised paediatric
               patients or their parents. Information, including symptom
               presentation and SARS-CoV-2 PCR test results, was collected from
               1527 participants from 46 hospitals. Cross-sectional serology
               was investigated in February and March 2021. RESULTS: Until the
               end of September 2020, no cases were reported. From September
               28th 2020 to March 2021 a total of 38 PCR-detected SARS-CoV-2
               infections were reported. Of these, four children were admitted
               to hospital but none had acute severe COVID-19. Increasing age
               in association with immunodeficiency increased reporting of
               SARS-CoV-2 infection. Worsening of fever, cough, and sore throat
               were associated with participants reporting SARS-CoV-2
               infection. Serology data included 452 unvaccinated participants.
               In those reporting prior positive SARS-CoV-2 PCR, there were
               detectable antibodies in 9 of 18 (50\%). In those with no prior
               report of infection, antibodies were detected in 32 of 434
               (74\%). CONCLUSIONS: This study shows SARS-CoV-2 infections
               have occurred in immunocompromised children and young people
               with no increased risk of severe disease. No children died.",
  journal   = "J. Infect.",
  publisher = "Elsevier BV",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Children; Immunocompromised; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Kapoor2021-bo,
  title     = "Reinfection or reactivation of Coronavirus-19 in patients with
               hematologic malignancies: Case report series",
  author    = "Kapoor, Rajan and Nair, Ranjith K and Nayan, Neelabh and Bhalla,
               Sharad and Singh, Jasdeep",
  abstract  = "Infection with severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2) has been relentless. We are into the 10th month of
               the pandemic, and we are still getting surprised every day.
               Although neutralizing antibodies are generated in response to
               coronavirus disease-19 (COVID-19), these antibodies do not
               appear to confer lifelong immunity, as lately there have been
               reports from various parts of the world of reinfection with the
               virus, starting from Hong Kong, Belgium, and the USA. The Indian
               Council of Medical Research (ICMR) has been on-record claiming
               three cases of reinfection in India. Herein, we report three
               patients of hematologic malignancy who most probably had
               reinfection with SARS-CoV-2, after complete documented recovery
               from first infection. All three patients were immunocompromised
               owing to their primary hematologic malignancy coupled with
               ongoing therapy, and the second infection was documented to be
               severe in all the three cases from the first episode.",
  journal   = "SN Compr Clin Med",
  publisher = "Springer Science and Business Media LLC",
  volume    =  3,
  number    =  2,
  pages     = "1--5",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; Hematologic malignancy; Reactivation; Reinfection;
               Severe COVID-19",
  language  = "en"
}

@ARTICLE{Mohseni_Afshar2021-in,
  title     = "Coronavirus disease 2019 (Covid-19) vaccination recommendations
               in special populations and patients with existing comorbidities",
  author    = "Mohseni Afshar, Zeinab and Babazadeh, Arefeh and Janbakhsh,
               Alireza and Mansouri, Feizollah and Sio, Terence T and Sullman,
               Mark J M and Carson-Chahhoud, Kristin and Hosseinzadeh, Rezvan
               and Barary, Mohammad and Ebrahimpour, Soheil",
  abstract  = "Vaccination against severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) is a crucial step in ending the
               current worldwide pandemic. However, several particularly
               vulnerable groups in the population were not included in
               sufficient numbers in coronavirus disease 2019 (Covid-19)
               vaccine trials. Therefore, as science advances, the advice for
               vaccinating these special populations against Covid-19 will
               continue to evolve. This focused review provides the latest
               recommendations and considerations for these special populations
               (i.e., patients with rheumatologic and autoimmune disorders,
               cancer, transplant recipients, chronic liver diseases, end-stage
               renal disease, neurologic disorders, psychiatric disorders,
               diabetes mellitus, obesity, cardiovascular diseases, chronic
               obstructive pulmonary disease, human immunodeficiency virus,
               current smokers, pregnant and breastfeeding women, the elderly,
               children, and patients with allergic reactions) using the
               currently available research evidence.",
  journal   = "Rev. Med. Virol.",
  publisher = "Wiley",
  pages     = "e2309",
  month     =  oct,
  year      =  2021,
  keywords  = "Covid-19; SARS-CoV-2; efficacy; immunocompromise; safety;
               vaccination",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Unsal2021-yu,
  title     = "Clinical and laboratory outcomes of the solid cancer patients
               reinfected with {SARS-CoV-2}",
  author    = "{\"U}nsal, Oktay and Yaz{\i}c{\i}, Ozan and {\"O}zdemir, Nuriye
               and {\c C}ubuk{\c c}u, Erdem and Ocak, Birol and {\"U}ner,
               Aytu{\u g} and {\"O}zet, Ahmet",
  abstract  = "Introduction: The objective of this study was to evaluate the
               clinical and laboratory outcomes of solid cancer patients who
               were reinfected with COVID-19. Methods: Patients who were tested
               negative on the Coronavirus disease 2019 (COVID-19) PCR test and
               those with improved clinical conditions after infection with
               COVID-19 were enrolled in this study. Patients who received a
               positive COVID-19 PCR test 28 days after the initial positive
               PCR test were considered as reinfected. Results: A total of 1024
               patients with the diagnosis of solid malignancy and COVID-19 PCR
               positivity were examined. The reinfection rate was 3.1\%.
               Mortality rate of reinfection was 34.3\%. The serum ferritin and
               creatinine values in reinfection were found to be significantly
               higher than the first infection (respectively; p = 0.015, p =
               0.014). Conclusion: This study has demonstrated one of the first
               preliminary clinical results of COVID-19 reinfection in solid
               cancer patients.",
  journal   = "Future Oncol.",
  publisher = "Future Medicine Ltd",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; reinfection; solid cancer",
  language  = "en"
}

@ARTICLE{Singh2021-op,
  title     = "Coronavirus disease-associated mucormycosis from a tertiary care
               hospital in India: A case series",
  author    = "Singh, Yudhyavir and Ganesh, Venkata and Kumar, Shailendra and
               Patel, Nishant and Aggarwala, Richa and Soni, Kapil Dev and
               Trikha, Anjan",
  abstract  = "BACKGROUND: Coronavirus disease (COVID-19) remains a health
               concern with new challenges emerging as the pandemic progresses.
               The recent rise of opportunistic infections especially
               mucormycosis in COVID-19 patients is further complicating their
               outcomes. Mucormycosis is well known to infect patients with
               diabetes mellitus, malignancy, chemotherapy, and other
               immunocompromised conditions. The treatment of COVID-19 largely
               remains systemic steroids and other immunomodulators that add to
               the risk of invasive fungal infection. METHODOLOGY: Here, we
               present a retrospective case series of 13 patients with
               individual clinical characteristics along with the demography
               and treatment details. The data were collected retrospectively
               in a single center that caters to a large population of COVID-19
               patients with varying severity. RESULTS: Thirteen patients were
               presented with COVID-19 associated mucormycosis (CAM). The
               median age was higher in non-survivors (49.5 years), with a
               higher odds of death (23.8) in those with severe COVID, having
               overall mortality of 64.3\%. Moreover, diabetes mellitus was
               present in 61.5\% of patients with a mortality of 75\%. About 11
               (84.6\%) patients had received prior steroids for COVID-19. The
               incidence of hyperglycemia at admission was equal among both
               survivors and non-survivors. CONCLUSION: The prevalence of
               mucormycosis seems to be increasing among COVID-19 patients
               which may be associated with increased use of steroids, the
               possible immunocompromised state imposed by SARS-CoV-2, or
               co-existing conditions such as diabetes mellitus. The mortality
               of CAM is remarkably high and apart from preventive practices
               and rational use of immunomodulators, a high index of suspicion
               with early diagnosis would be key to survival.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  7,
  pages     = "e16152",
  month     =  jul,
  year      =  2021,
  keywords  = "cam; covid-19; diabetes mellitus; mucormycosis; steroids",
  language  = "en"
}

@ARTICLE{Via2021-ox,
  title     = "Possible reactivation of {SARS-CoV-2} in a patient with acute
               myeloid leukemia undergoing allogeneic hematopoietic stem cell
               transplantation: A case report",
  author    = "Via, Vera Dalla and von Rotz, Matthias and B{\"a}ttig, Veronika
               and Leuzinger, Karoline and Hirsch, Hans H and Passweg, Jakob
               and St{\"u}ssi, Georg and Medinger, Michael",
  abstract  = "Reactivation or reinfection cases of SARS-CoV-2 are known but
               there is scarce evidence about reactivation in immunocompromised
               patients. Here, we report the case of a 61-year-old male
               undergoing a conditioning regimen with fludarabine,
               cyclophosphamide, and 2-Gy total body irradiation in preparation
               of a haplo-identical allogeneic hematopoietic stem cell
               transplantation (allo-HSCT) for acute myeloid leukemia (AML). He
               received the first dose of a COVID-19 vaccine 6 weeks prior
               allo-HSCT and was hospitalized a month prior because of a
               COVID-19 bilateral pneumonia. On discharge, he showed two
               negative SARS-CoV-2 nasopharyngeal PCR swabs as well as a high
               SARS-CoV-2 antibody titer. On admission for allo-HSCT, he tested
               negative for SARS-CoV-2 again. Conditioning with fludarabine,
               cyclophosphamide, and 2-Gy total body irradiation was started
               and the patient developed lymphopenia. During his hospital stay,
               he tested positive for SARS-CoV-2 in a PCR test twice but
               remained asymptomatic. The conditioning regimen was continued as
               planned. Later during his stay, the patient showed undetectable
               SARS-CoV-2 load four times. This case documents possible
               reactivation of SARS-CoV-2 and raises questions about
               reactivation risks among recipients of stem cell transplants and
               other immunocompromised patients.",
  journal   = "SN Compr Clin Med",
  publisher = "Springer Science and Business Media LLC",
  volume    =  3,
  number    =  10,
  pages     = "1--5",
  month     =  jul,
  year      =  2021,
  keywords  = "Acute myeloid leukemia; Allogeneic hematopoietic stem cell
               transplantation; COVID-19; SARS-CoV-2",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{McGinnis2021-sn,
  title     = "A pneumococcal pneumonia and influenza vaccination quality
               improvement program for women receiving chemotherapy for
               gynecologic cancers at a major tertiary cancer Centre",
  author    = "McGinnis, Justin M and Jones, Rebecca and Hillis, Christopher
               and Kokus, Heather and Thomas, Heidi and Thomas, Jason and
               Alyafi, Mohammad and Bernard, Laurence and Eiriksson, Lua R and
               Elit, Lorraine M and Hirte, Hal and Jimenez, Waldo and Reade,
               Clare J and Kumar Tyagi, Nidhi and Helpman, Limor",
  abstract  = "OBJECTIVE: International guidelines recommend pneumococcal
               pneumonia and influenza vaccination for all patients with solid
               organ malignancies prior to initiating chemotherapy. Baseline
               vaccination rates (March 2019) for pneumococcal pneumonia and
               influenza at our tertiary cancer centre were 8\% and 40\%,
               respectively. The aim of this study was to increase the number
               of gynecologic chemotherapy patients receiving pneumococcal and
               influenza vaccinations to 80\% by March 2020. METHODS: We
               performed an interrupted time series study using structured
               quality improvement methodology. Three interventions were
               introduced to address vaccination barriers: an in-house
               vaccination program, a staff education campaign, and a patient
               care bundle (pre-printed prescription, information brochure,
               vaccine record booklet). Process and outcome data were collected
               by patient survey and pharmacy audit and analyzed on statistical
               process control charts. RESULTS: We identified 195 eligible
               patients. Pneumococcal and influenza vaccination rates rose
               significantly from 5\% to a monthly mean of 61\% and from 36\%
               to a monthly mean of 67\%, respectively. The 80\% target was
               reached for both vaccines during one or more months of study.
               The in-house vaccination and staff education programs were major
               contributors to the improvement, whereas the information
               brochure and record booklet were minor contributors.
               CONCLUSIONS: Three interventions to promote pneumococcal and
               influenza vaccination among chemotherapy patients resulted in
               significantly improved vaccination rates. Lessons learned about
               promoting vaccine uptake may be generalizable to different
               populations and vaccine types. In response to the global
               COVID-19 pandemic, initiatives to expand the program to all
               chemotherapy patients at our centre are underway.",
  journal   = "Gynecol. Oncol.",
  publisher = "Elsevier BV",
  volume    =  161,
  number    =  1,
  pages     = "236--243",
  month     =  apr,
  year      =  2021,
  keywords  = "Immunocompromised host; Quality improvement; Vaccine-preventable
               diseases",
  language  = "en"
}

@ARTICLE{Chen2021-yd,
  title     = "All that coughs is not {COVID-19}: A delayed diagnosis of
               disseminated coccidioidomycosis following severe acute
               respiratory syndrome Coronavirus 2 infection",
  author    = "Chen, Joshua C and Wong, Darren and Rabi, Sina and Worswick,
               Scott and DeClerck, Brittney and Gibb, Jean",
  abstract  = "Coccidioides immitis (and Coccidioides posadasii) are endemic
               fungi of the southwestern United States and northern Mexico.
               Uncomplicated, symptomatic Coccidioides infection most commonly
               causes a self-limited pneumonia; however, immunocompromised
               patients can manifest severe pneumonia with an additional risk
               of dissemination to bone, joints, soft tissues, and in the most
               severe cases, the central nervous system. In 2020, clinicians
               were challenged with a previously unseen volume of acute
               respiratory complaints as a result of the severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We
               present a patient with respiratory failure secondary to
               SARS-CoV-2 who experienced prolonged hypoxia and neurologic
               deterioration, eventually leading to a diagnosis of occult
               disseminated coccidiomycosis involving meningitis,
               miliary-pattern pneumonia, and cutaneous lesions.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  7,
  pages     = "ofab246",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; coccidiodomycosis; coinfection; valley
               fever",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Lozahic2021-ax,
  title    = "Anti-cancer therapy leads to increased cardiovascular
              susceptibility to {COVID-19}",
  author   = "Lozahic, Caroline and Maddock, Helen and Sandhu, Hardip",
  abstract = "Anti-cancer treatment regimens can lead to both acute- and
              long-term myocardial injury due to off-target effects. Besides,
              cancer patients and survivors are severely immunocompromised due
              to the harsh effect of anti-cancer therapy targeting the bone
              marrow cells. Cancer patients and survivors can therefore be
              potentially extremely clinically vulnerable and at risk from
              infectious diseases. The recent global outbreak of the novel
              coronavirus severe acute respiratory syndrome coronavirus 2
              (SARS-CoV-2) and its infection called coronavirus disease 2019
              (COVID-19) has rapidly become a worldwide health emergency, and
              on March 11, 2020, COVID-19 was declared a global pandemic by the
              World Health Organization (WHO). A high fatality rate has been
              reported in COVID-19 patients suffering from underlying
              cardiovascular diseases. This highlights the critical and crucial
              aspect of monitoring cancer patients and survivors for potential
              cardiovascular complications during this unprecedented health
              crisis involving the progressive worldwide spread of COVID-19.
              COVID-19 is primarily a respiratory disease; however, COVID-19
              has shown cardiac injury symptoms similar to the cardiotoxicity
              associated with anti-cancer therapy, including arrhythmia,
              myocardial injury and infarction, and heart failure. Due to the
              significant prevalence of micro- and macro-emboli and damaged
              vessels, clinicians worldwide have begun to consider whether
              COVID-19 may in fact be as much a vascular disease as a
              respiratory disease. However, the underlying mechanisms and
              pathways facilitating the COVID-19-induced cardiac injury in
              cancer and non-cancer patients remain unclear. Investigations
              into whether COVID-19 cardiac injury and anti-cancer drug-induced
              cardiac injury in cancer patients and survivors might
              synergistically increase the cardiovascular complications and
              comorbidity risk through a ``two-hit'' model are needed.
              Identification of cardiac injury mechanisms and pathways
              associated with COVID-19 development overlapping with anti-cancer
              therapy could help clinicians to allow a more optimized prognosis
              and treatment of cancer survivors suffering from COVID-19. The
              following review will focus on summarizing the harmful
              cardiovascular risk of COVID-19 in cancer patients and survivors
              treated with an anti-cancer drug. This review will improve the
              knowledge of COVID-19 impact in the field of cardio-oncology and
              potentially improve the outcome of patients.",
  journal  = "Front. Cardiovasc. Med.",
  volume   =  8,
  pages    = "634291",
  month    =  apr,
  year     =  2021,
  keywords = "ACE2; COVID-19; SARS-CoV-2; anti-cancer drug-induced cardiac
              injury; cytokine storm",
  language = "en"
}

@ARTICLE{Yusuf2021-vc,
  title     = "Aspergillus in critically ill {COVID-19} patients: A scoping
               review",
  author    = "Yusuf, Erlangga and Seghers, Leonard and Hoek, Rogier A S and
               van den Akker, Johannes P C and Bode, Lonneke G M and Rijnders,
               Bart J A",
  abstract  = "Several reports have been published on Aspergillus findings in
               COVID-19 patients leading to a proposition of new disease entity
               COVID-19-associated pulmonary aspergillosis. This scoping review
               is designed at clarifying the concepts on how the findings of
               Aspergillus spp. in COVID-19 patients were interpreted. We
               searched Medline to identify the studies on Aspergillus spp.
               findings in COVID-19 patients. Included were observational
               studies containing the following information: explicit mention
               of the total number of the study population, study period,
               reason for obtaining respiratory samples, case definition, and
               clinical outcomes. Excluded were case series, case reports and
               reviews. Identified were 123 publications, and 8 observational
               studies were included. From the included studies the following
               issues were identified. The proportion of immunocompromised
               patients considered as host factors varied from 0 to 17\%. Most
               of the studies did not mention radiographic findings explicitly.
               Respiratory samples were mostly obtained to investigate clinical
               deterioration. Aspergillus culture, antigen or PCR testing on
               bronchoalveolar lavage (BAL) fluid were performed in between
               23.3\% and 66.3\% of the study population. Two studies performed
               periodic samples of BAL. Galactomannan index (GI) positivity in
               BAL was between 10\% and 28\%. GI in blood was found in 0.9\% to
               6.7\% of the available samples. The prevalence of
               COVID-19-associated pulmonary aspergillosis ranged from 2.7\% to
               27.7\%. Studies compared the mortality between defined cases and
               non-cases, and all showed increased mortality in cases. No
               studies showed that antifungal treatment reduced mortality.
               Concluding, this review showed how studies defined the clinical
               entity COVID-19-associated pulmonary aspergillosis where
               positive Aspergillus test in the respiratory sample was the main
               driver for the diagnosis. There were many differences between
               studies in terms of test algorithm and Aspergillus test used
               that largely determined the prevalence. Whether antifungal
               therapy, either as prophylaxis, pre-emptive or targeted therapy
               will lead to better outcomes of COVID-19-associated pulmonary
               aspergillosis patients is still need to be answered.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  11,
  pages     = "2469",
  month     =  jun,
  year      =  2021,
  keywords  = "Aspergillus; COVID-19; mortality; scoping review",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Licata2021-oh,
  title     = "Liver injury, {SARS-COV-2} infection and {COVID-19}: What
               physicians should really know?",
  author    = "Licata, Anna and Minissale, Maria Giovanna and Distefano, Marco
               and Montalto, Giuseppe",
  abstract  = "Background \& Aims: Severe acute respiratory syndrome
               coronavirus-2 (SARS-CoV-2) is responsible for coronavirus
               disease 2019 (COVID-19), which in males, especially in advanced
               age, can sometimes evolve into acute respiratory distress
               syndrome. In addition, mild to moderate alterations in liver
               function tests (LFTs) have been reported in the worst affected
               patients. Our review aims to analyse data on the incidence and
               prognostic value of LFT alterations, the underlying mechanisms
               and the management of pre-existing liver disease in COVID-19
               affected patients. Methods: We searched available literature
               through online PubMed database using terms as ``SARS-CoV-2,''
               ``Liver damage,'' ``Liver Function tests,'' ``COVID-19,''
               ``pre-existing liver disease,'' ``drug-induced liver injury.''
               Results: Available evidence suggest that there could be a
               relationship between SARS-CoV-2 infection and liver damage,
               although the underlying involved mechanism remains unclear.
               Cohort studies have shown that high ALT levels, low platelet
               counts and low albumin levels at admission and during
               hospitalisation are associated with a high mortality rate.
               Unfortunately, little is known about the impact of COVID-19 on
               pre-existing liver damage. While chronic viral infections or
               NAFLD are associated with an increased risk of COVID-19
               progression, patients with cirrhosis may have increased
               susceptibility to SARS-CoV-2 infection due to their systemic
               immunocompromised status. DILI seems common among hospitalised
               patient with severe pneumonia. Conclusion: Mild to moderate
               liver impairment during Covid-19 is common, especially in
               patients with pre-existing liver disease. Further studies should
               be performed in order to understand how pre-existing liver
               conditions may influence and worsen progression of liver disease
               in COVID-19 patients.",
  journal   = "GastroHep",
  publisher = "Wiley",
  volume    =  3,
  number    =  3,
  pages     = "121--130",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Liver Function tests (LTFs); SARS-CoV-2; liver injury",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Kuczborska2021-hu,
  title     = "Prevalence and course of {SARS-CoV-2} infection among
               immunocompromised children hospitalised in the tertiary referral
               hospital in Poland",
  author    = "Kuczborska, Karolina and Ksi{\k a}{\.z}yk, Janusz",
  abstract  = "The aim of this retrospective study was the assessment of the
               prevalence, clinical characteristics, and the comparison of the
               course of SARS-CoV-2 infection in children with and without
               immunodeficiency that were admitted to the COVID-19 Subunit of
               the tertiary referral hospital in Warsaw, Poland. We analysed
               313 children hospitalised in the COVID-19 Subunit. The analysis
               was performed on the total study group and subgroups of children
               with and without immunodeficiency. In each group, clinical data
               and laboratory test results were analysed. Of the 68 children
               with isolated fevers, only seven (11.76\%) were diagnosed with
               COVID-19, whereas among those with the accompanying features of
               respiratory or gastrointestinal infection, only one (3.23\%) and
               ten (16.95\%) patients tested positive, respectively. In both
               groups, the course of the infection was mainly asymptomatic or
               mild. The children with immunodeficiencies had lower white blood
               cell and lymphocyte counts, lower haemoglobin levels, and higher
               urea levels but did not differ in other biochemical variables.
               To conclude, the most frequently reported symptoms of COVID-19
               indicate that this disease among children is only a small
               percentage. In both groups, the responses to the infection were
               comparable in terms of the mild clinical symptoms and the
               laboratory test results. Therefore, SARS-CoV-2 infection should
               not alter the chronic treatment of underlying diseases.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  19,
  pages     = "4556",
  month     =  sep,
  year      =  2021,
  keywords  = "SARS-CoV-2; cancer; immunodeficiency; liver transplant;
               paediatric population",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Chang2021-vi,
  title     = "Corticosteroid use in otolaryngology: Current considerations
               during the {COVID-19} era",
  author    = "Chang, C W David and McCoul, Edward D and Briggs, Selena E and
               Guardiani, Elizabeth A and Durand, Marlene L and Hadlock, Tessa
               A and Hillel, Alexander T and Kattar, Nrusheel and Openshaw,
               Peter J M and Osazuwa-Peters, Nosayaba and Poetker, David M and
               Shin, Jennifer J and Chandrasekhar, Sujana S and Bradford, Carol
               R and Brenner, Michael J",
  abstract  = "OBJECTIVE: To offer pragmatic, evidence-informed advice on
               administering corticosteroids in otolaryngology during the
               coronavirus disease 2019 (COVID-19) pandemic, considering
               therapeutic efficacy, potential adverse effects, susceptibility
               to COVID-19, and potential effects on efficacy of vaccination
               against SARS-CoV-2, which causes COVID-19. DATA SOURCES: PubMed,
               Cochrane Library, EMBASE, CINAHL, and guideline databases.
               REVIEW METHODS: Guideline search strategies, supplemented by
               database searches on sudden sensorineural hearing loss (SSNHL),
               idiopathic facial nerve paralysis (Bell's palsy), sinonasal
               polyposis, laryngotracheal disorders, head and neck oncology,
               and pediatric otolaryngology, prioritizing systematic reviews,
               randomized controlled trials, and COVID-19-specific findings.
               CONCLUSIONS: Systemic corticosteroids (SCSs) reduce long-term
               morbidity in individuals with SSNHL and Bell's palsy, reduce
               acute laryngotracheal edema, and have benefit in perioperative
               management for some procedures. Topical or locally injected
               corticosteroids are preferable for most other otolaryngologic
               indications. SCSs have not shown long-term benefit for sinonasal
               disorders. SCSs are not a contraindication to vaccination with
               COVID-19 vaccines approved by the US Food and Drug
               Administration. The Centers for Disease Control and Prevention
               noted that these vaccines are safe for immunocompromised
               patients. IMPLICATIONS FOR PRACTICE: SCS use for SSNHL, Bell's
               palsy, laryngotracheal edema, and perioperative care should
               follow prepandemic standards. Local or topical corticosteroids
               are preferable for most other otolaryngologic indications.
               Whether SCSs attenuate response to vaccination against COVID-19
               or increase susceptibility to SARS-CoV-2 infection is unknown.
               Immunosuppression may lower vaccine efficacy, so
               immunocompromised patients should adhere to recommended
               infection control practices. COVID-19 vaccination with
               Pfizer-BioNTech, Moderna, or Johnson \& Johnson vaccines is safe
               for immunocompromised patients.",
  journal   = "Otolaryngol. Head Neck Surg.",
  publisher = "SAGE Publications",
  pages     = "1945998211064275",
  month     =  dec,
  year      =  2021,
  keywords  = "Bell palsy; Bell's palsy; COVID-19; ERAS; SARS-CoV-2; adenoid;
               cancer; chemoradiation; coronavirus; corticosteroid; dupilumab;
               edema; enhanced recovery after surgery; facia palsy; facial
               paralysis; head and neck; hearing loss; inflammation;
               interleukin 4; laryngotracheal stenosis; mRNA vaccine; nasal
               polyposis; nausea; osteoradionecrosis; otitis media; pediatric;
               perioperative; posterior glottic stenosis; radiation; rhinology;
               rhinosinusitis; severe acute respiratory syndrome; sinonasal;
               sinusitis; steroid; subglottic stenosis; sudden sensorineural
               hearing loss; tonsillectomy; tracheostomy; vaccination; vaccine;
               vomiting",
  language  = "en"
}

@ARTICLE{Karaolidou2021-yv,
  title     = "Convalescent plasma therapy in an immunocompromised patient with
               multiple {COVID-19} flares: a case report",
  author    = "Karaolidou, Frini and Loutsidi, Natasa-Eleni and Mellios, Zois
               and Jahaj, Edison and Eleftheriou, Konstantinos and Pagoni,
               Maria and Mpaltadakis, Ioannis and Dimopoulos,
               Athanasios-Meletios and Kalomenidis, Ioannis and Pappas,
               Apostolos G",
  abstract  = "Convalescent plasma (CP) transfusion has been utilized as a
               salvage therapy in immunocompromised patients with severe
               COVID-19 pneumonia. We describe the case of a 45-year-old
               immunocompromised patient, who received CP, in order to control
               multiple COVID-19 flares and prolonged SARS-CoV-2 viraemia
               lasting for 2 months after the initial diagnosis.",
  journal   = "Respirol. Case Rep.",
  publisher = "Wiley",
  volume    =  9,
  number    =  12,
  pages     = "e0858",
  month     =  dec,
  year      =  2021,
  keywords  = "B-cell acute lymphocytic leukaemia; COVID-19; convalescent
               plasma; immunosuppression",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Gesiotto2021-rs,
  title     = "{COVID-19} virus infection in three patients with
               hypogammaglobulinemia",
  author    = "Gesiotto, Quinto and Cheema, Asima and Avaiya, Kishan and Shah,
               Bijal and Greene, John",
  abstract  = "The world is experiencing the COVID-19 outbreak and there are no
               evidence-based treatment strategies available for
               immunocompromised patients. COVID-19 is a novel beta coronavirus
               known as severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2). Patients with cancer are more susceptible to
               infection than individuals without cancer due to their impaired
               humoral and cellular immune function caused by the malignancy
               itself and chemotherapy. We present three cases of cancer
               patients with hypogammaglobulinemia with varying clinical
               outcomes associated with infection. These include one mantle
               cell lymphoma patient with recurrent respiratory infection
               requiring intravenous immunoglobulin (IVIG) support and two
               multiple myeloma patients with continued viral shedding.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  5,
  pages     = "e15256",
  month     =  may,
  year      =  2021,
  keywords  = "covid 19; hypogammaglobulinemia; intravenous immunoglobulin
               (ivig); lymphoma; mantle cell lymphoma; multiple myeloma",
  language  = "en"
}

@ARTICLE{Puing2021-pz,
  title     = "{SARS-CoV-2} specific monoclonal antibody for the treatment of
               mild-to-moderate {COVID-19} in cancer patients: A single-center
               experience",
  author    = "Puing, Alfredo G and Ho, Stephanie and Frankel, Paul and
               Tegtmeier, Bernard and Martin, Abigail and Ross, Justine and
               Nanayakkara, Deepa and Dickter, Jana and Seto, Tyler and
               Nakamura, Ryotaro and Taplitz, Randy and Dadwal, Sanjeet",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; cancer; immunocompromised; monoclonal antibody",
  language  = "en"
}

@ARTICLE{Ghanem2021-qf,
  title     = "Cryptococcus neoformans meningoencephalitis in an
               immunocompetent patient after {COVID-19} infection",
  author    = "Ghanem, Hebah and Sivasubramanian, Geetha",
  abstract  = "Cryptococcus neoformans is a saprophytic fungus that causes
               fatal disseminated infections in immunocompromised hosts. Since
               the onset of the COVID-19 pandemic, multiple cases of secondary
               viral, bacterial, and fungal infections have been reported in
               patients after SARS-CoV-2 infection. We describe here a case of
               severe cryptococcal meningitis that developed in a previously
               healthy patient one week after treatment of SARS-CoV-2 infection
               with dexamethasone. This case adds to the growing knowledge of
               emerging secondary infectious complications including
               opportunistic pathogens after SARS-CoV-2 infection. While few
               reports allude to depressed T-cell function and lymphopenia due
               to SARS-CoV-2 infection, further studies are needed to evaluate
               the effects of this infection and its treatment on the immune
               system and its contribution to the emergence of secondary
               opportunistic infections.",
  journal   = "Case Rep. Infect. Dis.",
  publisher = "Hindawi Limited",
  volume    =  2021,
  pages     = "5597473",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Truong2021-kr,
  title    = "Persistent {SARS-CoV-2} infection and increasing viral variants
              in children and young adults with impaired humoral immunity",
  author   = "Truong, Thao T and Ryutov, Alex and Pandey, Utsav and Yee,
              Rebecca and Goldberg, Lior and Bhojwani, Deepa and
              Aguayo-Hiraldo, Paibel and Pinsky, Benjamin A and Pekosz, Andrew
              and Shen, Lishuang and Boyd, Scott D and Wirz, Oliver F and
              R{\"o}ltgen, Katharina and Bootwalla, Moiz and Maglinte, Dennis T
              and Ostrow, Dejerianne and Ruble, David and Han, Jennifer H and
              Biegel, Jaclyn A and Li, Maggie and Huang, Chunhong and Sahoo,
              Mayala K and Pannaraj, Pia S and O'Gorman, Maurice and Judkins,
              Alexander R and Gai, Xiaowu and Bard, Jennifer Dien",
  abstract = "Background: There is increasing concern that persistent infection
              of SARS-CoV-2 within immunocompromised hosts could serve as a
              reservoir for mutation accumulation and subsequent emergence of
              novel strains with the potential to evade immune responses.
              Methods: We describe three patients with acute lymphoblastic
              leukemia who were persistently positive for SARS-CoV-2 by
              real-time polymerase chain reaction. Viral viability from
              longitudinally-collected specimens was assessed. Whole-genome
              sequencing and serological studies were performed to measure
              viral evolution and evidence of immune escape. Findings: We found
              compelling evidence of ongoing replication and infectivity for up
              to 162 days from initial positive by subgenomic RNA,
              single-stranded RNA, and viral culture analysis. Our results
              reveal a broad spectrum of infectivity, host immune responses,
              and accumulation of mutations, some with the potential for immune
              escape. Interpretation: Our results highlight the need to
              reassess infection control precautions in the management and care
              of immunocompromised patients. Routine surveillance of mutations
              and evaluation of their potential impact on viral transmission
              and immune escape should be considered. Funding: The work was
              partially funded by The Saban Research Institute at Children's
              Hospital Los Angeles intramural support for COVID-19 Directed
              Research (X.G. and J.D.B.), the Johns Hopkins Center of
              Excellence in Influenza Research and Surveillance
              HHSN272201400007C (A.P.), NIH/NIAID R01AI127877 (S.D.B.),
              NIH/NIAID R01AI130398 (S.D.B.), NIH 1U54CA260517 (S.D.B.), an
              endowment to S.D.B. from the Crown Family Foundation, an Early
              Postdoc.Mobility Fellowship Stipend to O.F.W. from the Swiss
              National Science Foundation (SNSF), and a Coulter COVID-19 Rapid
              Response Award to S.D.B. L.G. is a SHARE Research Fellow in
              Pediatric Hematology-Oncology.",
  journal  = "medRxiv",
  month    =  mar,
  year     =  2021,
  language = "en"
}

@ARTICLE{Grinshpun2021-wm,
  title     = "Serologic response to {COVID-19} infection and/or vaccine in
               cancer patients on active treatment",
  author    = "Grinshpun, A and Rottenberg, Y and Ben-Dov, I Z and Djian, E and
               Wolf, D G and Kadouri, L",
  abstract  = "BACKGROUND: It was shown that immunocompromised patients have
               significantly reduced immunologic responses to COVID-19
               vaccines. The immunogenicity of COVID-19 vaccine/infection in
               patients with solid tumors is reduced. We evaluated the
               immunologic response to COVID-19 and/or the BNT162b2 mRNA
               COVID-19 vaccine among cancer patients on active treatments and
               reviewed previous literature to identify subgroups that may
               require third vaccination. PATIENTS AND METHODS: Anti-SARS-CoV-2
               S1/S2 antibodies were measured in a cohort of 202 cancer
               patients on active treatment with chemotherapy (96), immunologic
               (52), biologic (46), and hormonal (12) treatments for early (n =
               66, 32.7\%) or metastatic disease (n = 136, 67.3\%). Of those,
               172 had received two vaccine doses, and 30 had COVID-19
               infection (20/30 also received one dose of vaccine). Specific
               anti-S receptor-binding domain antibodies were further measured
               in patients with equivocal anti-S1/S2 results. RESULTS: Among
               cancer patients, the SARS-CoV-2 antibody response rate was
               89.1\% (180/202) after COVID-19 vaccination or infection and
               87.2\% (150/172) in patients after vaccination without a history
               of COVID-19, compared with 100\% positive serologic tests in a
               control group of 30 health care workers (P 60 AU/ml) was more
               likely with immunotherapy (odds ratio 2.44) and less likely with
               chemotherapy (odds ratio 0.39). CONCLUSIONS: Overall, both
               COVID-19 vaccine and natural infection are highly immunogenic
               among cancer patients. Our study, however, identifies those
               under chemotherapy as significantly less responsive, and with
               lower antibody levels. These findings justify close virological
               and serological surveillance along with consideration of these
               patients for booster (third dose) vaccine prioritization, as new
               highly spreading SARS-CoV-2 variants emerge.",
  journal   = "ESMO Open",
  publisher = "Elsevier BV",
  volume    =  6,
  number    =  6,
  pages     = "100283",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; cancer; chemotherapy; serologic response; solid
               tumors; vaccine",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Nicastro2021-iv,
  title    = "{COVID-19} in immunosuppressed children",
  author   = "Nicastro, Emanuele and Verdoni, Lucio and Bettini, Laura Rachele
              and Zuin, Giovanna and Balduzzi, Adriana and Montini, Giovanni
              and Biondi, Andrea and D'Antiga, Lorenzo",
  abstract = "Following the spread of the SARS-CoV-2 infection and coronavirus
              disease 2019 (COVID-19) to a global pandemic, concerns have
              arisen for the disease impact in at-risk populations, especially
              in immunocompromised hosts. On the other hand, clinical studies
              have clarified that the COVID-19 clinical burden is mostly due to
              over-inflammation and immune-mediated multiorgan injury. This has
              led to downsizing the role of immunosuppression as a determinant
              of outcome, and early reports confirm the hypothesis that
              patients undergoing immunosuppressive treatments do not have an
              increased risk of severe COVID-19 with respect to the general
              population. Intriguingly, SARS-CoV-2 natural reservoirs, such as
              bats and mice, have evolved mechanisms of tolerance involving
              selection of genes optimizing viral clearance through interferon
              type I and III responses and also dampening inflammasome response
              and cytokine expression. Children exhibit resistance to COVID-19
              severe manifestations, and age-related features in innate and
              adaptive response possibly explaining this difference are
              discussed. A competent recognition by the innate immune system
              and controlled pro-inflammatory signaling seem to be the pillars
              of an effective response and the premise for pathogen clearance
              in SARS-CoV-2 infection. Immunosuppression-if not associated with
              other elements of fragility-do not represent per se an obstacle
              to this competent/tolerant phenotype in children. Several reports
              confirm that children receiving immunosuppressive medications
              have similar clinical involvement and outcomes as the pediatric
              general population, indicating that maintenance treatments should
              not be interrupted in suspect or confirmed SARS-CoV-2 infection.",
  journal  = "Front. Pediatr.",
  volume   =  9,
  pages    = "629240",
  month    =  apr,
  year     =  2021,
  keywords = "SARS-CoV2; autoimmune disease; cancer; immunosuppression; innate
              immunity; kidney transplant; liver transplant; rheumatologic
              diseases",
  language = "en"
}

@ARTICLE{Kumar2021-bm,
  title     = "Respiratory failure in an extremely premature neonate with
               {COVID-19}",
  author    = "Kumar, Vasantha H S and Prasath, Arun and Blanco, Clariss and
               Kenney, Patrick O and Ostwald, Christina M and Meyer, Tracy S
               and Clementi, Cara F and Maciejewski, Richard and Wilby, Mark T
               and Reynolds, Anne Marie and Hpa, N Ja and Yu, Karl O A",
  abstract  = "Coronavirus disease 2019 (COVID-19), a condition associated with
               SARS-CoV-2, typically results in mild infection in infants and
               children. However, children with risk factors such as chronic
               lung disease and immunosuppression have higher risk of severe
               illness from COVID-19. We report a case of a 27-week-gestation
               extremely premature infant born to a mother with COVID-19
               infection. The infant, initially treated for surfactant
               deficiency, developed worsening hypoxic respiratory failure on
               the fifth day of life requiring escalating ventilatory support,
               an elevated level of C-reactive protein, thrombocytopenia, and
               an elevated level of d-dimer. The infant was positive for
               SARS-CoV-2 by RT-PCR from Day 1 to Day 42 of his life. The
               infant responded to a seven-day course of dexamethasone with a
               gradually decreasing oxygen requirement and could be extubated
               to non-invasive ventilation by the end of the fifth week after
               birth. The infant is currently on home oxygen by nasal cannula.
               Prolonged shedding of the virus may be a unique feature of the
               disease in premature infants. Extreme prematurity, immature
               lungs, and an immunocompromised status may predispose these
               infants to severe respiratory failure and a prolonged clinical
               course. Instituting appropriate COVID-19 protocols to prevent
               the spread of the disease in the neonatal intensive care unit
               (NICU) is of utmost importance. Infection with SARS-CoV-2 may
               have implications in the management of extremely premature
               infants in the NICU.",
  journal   = "Children (Basel)",
  publisher = "MDPI AG",
  volume    =  8,
  number    =  6,
  pages     = "477",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; infant; prematurity; respiratory failure",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tuan2021-xh,
  title     = "Qualitative assessment of {anti-SARS-CoV-2} spike protein
               immunogenicity ({QUASI}) after {COVID-19} vaccination in older
               people living with {HIV}",
  author    = "Tuan, Jessica J and Zapata, Heidi and Critch-Gilfillan, Terese
               and Ryall, Linda and Turcotte, Barbara and Mutic, Suzana and
               Andrews, Laurie and Roh, Michelle E and Friedland, Gerald and
               Barakat, Lydia and Ogbuagu, Onyema",
  abstract  = "OBJECTIVES: Effective and safe COVID-19 vaccines have been
               developed and have resulted in decreased incidence and severity
               of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               infection and can decrease secondary transmission. However,
               there are concerns about dampened immune responses to COVID-19
               vaccination among immunocompromised patients, including people
               living with HIV (PLWH), which may blunt the vaccine's efficacy
               and durability of protection. This study aimed to assess the
               qualitative SARS-CoV-2 vaccine immunogenicity among PLWH after
               vaccination. METHODS: We conducted targeted COVID-19 vaccination
               (all received BNT162b2 vaccine) of PLWH (aged $\geq$ 55 years
               per state guidelines) at Yale New Haven Health System and
               established a longitudinal survey to assess their qualitative
               antibody responses at 3 weeks after the first vaccination (and
               prior to receipt of the second dose of the COVID-19 vaccine)
               (visit 1) and at 2-3 weeks after the second vaccination (visit
               2) but excluded patients with prior COVID-19 infection. Our goal
               was to assess vaccine-induced immunity in the population we
               studied. Qualitative immunogenicity testing was performed using
               Healgen COVID-19 anti-Spike IgG/IgM rapid testing. Poisson
               regression with robust standard errors was used to determine
               factors associated with a positive IgG response. RESULTS: At
               visit 1, 45 of 78 subjects (57.7\%) tested positive for
               SARS-CoV-2 anti-Spike IgG after the first dose of COVID-19
               vaccine. Thirty-nine subjects returned for visit 2. Of these, 38
               had positive IgG (97.5\%), including 20 of 21 subjects (95.2\%)
               with an initial negative anti-Spike IgG. Our bivariate analysis
               suggested that participants on an antiretroviral regimen
               containing integrase strand transfer inhibitors [relative risk
               (RR) = 1.81, 95\% confidence interval (CI): 0.92-3.56, p =
               0.085] were more likely to seroconvert after the first dose of
               the COVID-19 vaccine, while those with a CD4 count < 500
               cells/$\mu$L (RR = 0.59, 95\% CI: 0.33-1.05, p = 0.071), and
               those diagnosed with cancer or another immunosuppressive
               condition (RR = 0.49, 95\% CI: 0.18-1.28, p = 0.15) may have
               been less likely to seroconvert after the first dose of the
               COVID-19 vaccine. The direction of these associations was
               similar in the multivariate model, although none of these
               findings reached statistical significance (RRintegrase inhibitor
               = 1.71, 95\% CI: 0.90-3.25, p = 0.10; RRCD4 count = 0.68, 95\%
               CI: 0.39-1.19, p = 0.18; RRcancer or another immunosuppressive
               condition = 0.50, 95\% CI: 0.19-1.33, p = 0.16). With regard to
               immunogenicity, we were able to record very high rates of new
               seroconversion following the second dose of the COVID-19
               vaccine. CONCLUSIONS: Our study suggests that completing a
               two-dose series of BNT162b2 vaccine is critical for PLWH given
               suboptimal seroconversion rates after the first dose and
               subsequent improved seroconversion rates after the second dose.",
  journal   = "HIV Med.",
  publisher = "Wiley",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; HIV; SARS-CoV-2; immunogenicity; vaccination",
  copyright = "http://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Klein2021-uo,
  title     = "Longitudinal immune profiling of a {SARS-CoV-2} reinfection in a
               solid organ transplant recipient",
  author    = "Klein, Jonathan and Brito, Anderson F and Trubin, Paul and Lu,
               Peiwen and Wong, Patrick and Alpert, Tara and
               Pe{\~n}a-Hern{\'a}ndez, Mario A and Haynes, Winston and Kamath,
               Kathy and Liu, Feimei and Vogels, Chantal B F and Fauver, Joseph
               R and Lucas, Carolina and Oh, Jieun and Mao, Tianyang and Silva,
               Julio and Wyllie, Anne L and Muenker, M Catherine and
               Casanovas-Massana, Arnau and Moore, Adam J and Petrone, Mary E
               and Kalinich, Chaney C and Dela Cruz, Charles and Farhadian,
               Shelli and Ring, Aaron and Shon, John and Ko, Albert I and
               Grubaugh, Nathan D and Israelow, Benjamin and Iwasaki, Akiko and
               Azar, Marwan M",
  abstract  = "BACKGROUND: The underlying immunologic deficiencies enabling
               SARS-CoV-2 reinfection are currently unknown. We describe deep
               longitudinal immune profiling of a transplant recipient
               hospitalized twice for COVID-19. METHODS: A 66-year-old male
               renal transplant recipient was hospitalized with COVID-19 March
               2020 then readmitted to the hospital with COVID-19 233 days
               after initial diagnosis. Virologic and immunologic investigation
               were performed on samples from the primary and secondary
               infections. RESULTS: Whole viral genome sequencing and
               phylogenic analysis revealed that viruses causing both
               infections were caused by distinct genetic lineages without
               evidence of immune escape mutations. Longitudinal comparison of
               cellular and humoral responses during primary SARS-CoV-2
               infection revealed that this patient responded to the primary
               infection with low neutralization titer anti-SARS-CoV-2
               antibodies that were likely present at the time of reinfection.
               DISCUSSION: The development of neutralizing antibodies and
               humoral memory responses in this patient failed to confer
               protection against reinfection, suggesting that they were below
               a neutralizing titer threshold or that additional factors may be
               required for efficient prevention of SARS-CoV-2 reinfection.
               Development of poorly neutralizing antibodies may have been due
               to profound and relatively specific reduction in na{\"\i}ve CD4
               T-cell pools. Seropositivity alone may not be a perfect
               correlate of protection in immunocompromised patients.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  oct,
  year      =  2021,
  keywords  = "SARS-CoV-2; humoral response; immunocompromised; neutralizing
               antibodies; reinfection; transplant",
  language  = "en"
}

@ARTICLE{Arafat2021-zx,
  title     = "{COVID-19}, acute lymphoblastic leukemia, and Down syndrome: A
               short review and a case report",
  author    = "Arafat, Ahmed and Sadykova, Dinara and Ziatdinov, Ayrat and
               Senek, Svetlana and Samoilova, Natalya and Makarova, Tamara",
  abstract  = "SARS-CoV-2 which causes COVID-19 has been a great challenge to
               treat and deal with; despite strict measures that had been
               implemented by governments and organizations, worrying rates of
               morbidity and mortality are still being reported. Although
               available data have expressed that moderate or even mild forms
               of the disease are expected amongst most pediatrics cases,
               minimal data are available on the prognosis and the disease's
               complications on the immunocompromised, especially oncology
               patients. We report a case of relapsed precursor B-cell acute
               lymphoblastic leukemia of a child with Down syndrome and
               COVID-19 and outline the treatment regimen that we used.",
  journal   = "Case Rep. Oncol.",
  publisher = "S. Karger AG",
  volume    =  14,
  number    =  2,
  pages     = "1031--1039",
  month     =  may,
  year      =  2021,
  keywords  = "Acute lymphoblastic leukemia; Corona virus disease 2019; Down
               syndrome; Infectious disease",
  copyright = "https://creativecommons.org/licenses/by-nc/4.0/",
  language  = "en"
}

@ARTICLE{Eswaran2021-rt,
  title     = "Acute fulminant mucormycosis triggered by covid 19 infection in
               a young patient",
  author    = "Eswaran, Sudhagar and Balan, Sarath Kumar and Saravanam,
               Prasanna Kumar",
  abstract  = "Covid 19 infection can result in various opportunistic
               infections. Altered immune response, associated comorbid
               conditions like diabetes, prolonged steroid and broad spectrum
               antibiotics usage with ICU interventions lead to increased
               chance of such superadded infections in covid 19 patients. Here
               we report a case of 31 year old male with covid 19 infection who
               had new onset Diabetes Mellitus, developed severe acute
               fulminant Mucormycosis during the treatment for covid 19
               infection. He presented with severe headache, nasal obstruction
               and discharge, bilateral ophthalmoplegia and blindness with
               Cavernous Sinus Thrombosis. Patient underwent aggressive
               surgical debridement with frontal craniectomy, maxillectomy and
               right orbital evisceration and left endoscopic orbital
               decompression and judicious efforts to revert back the
               immunocompromised status with high dose of Liposomal
               amphotericin. Post operatively patient developed right temporal
               lobe abscess which was drained through Endonasal Endoscopic
               Trans Cavernous drainage of Temporal Lobe Abscess. Patient is in
               2 months follow up, with bilateral blindness and tolerating oral
               feeds with improved left eye ophthalmoplegia. It is imperative
               to note that the rising trend of mucormycosis is there in Covid
               19 infections and it should be dealt with high index of
               suspicion in high risk patients and early aggressive treatment
               can save the patient as the survival rate is not high in such
               infections.",
  journal   = "Indian J. Otolaryngol. Head Neck Surg.",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--5",
  month     =  jul,
  year      =  2021,
  keywords  = "Cavernous sinus thrombosis; Corona virus SARS-CoV-2; Covid 19
               infection; Frontal craniectomy; Ophthalmoplegia; Osteomyelitis;
               Rhino orbito cerebral mucormycosis",
  language  = "en"
}

@ARTICLE{Han2021-rp,
  title     = "Persistent {SARS-CoV-2} infectivity greater than 50 days in a
               case series of allogeneic peripheral blood stem cell transplant
               recipients",
  author    = "Han, Alice and Rodriguez, Tulio E and Beck, Eric T and Relich,
               Ryan F and Udeoji, Dioma U and Petrak, Robert and Chundi, Vishnu
               V",
  abstract  = "The coronavirus disease 19 (COVID-19) pandemic has infected tens
               of millions across the world, but there is a significant gap in
               our understanding about COVID-19 in the hematopoietic stem
               transplant (HSCT) recipient population. Prolonged viral shedding
               is frequently observed with severe acute respiratory syndrome
               coronavirus-2 (SARSCoV-2), but studies suggest viral loads
               decline 10 days after symptom onset. Current CDC guidance
               suggests that severely ill and immunocompromised hosts are no
               longer infectious after 20 days from symptom onset. Cycle
               threshold (Ct) values are inversely proportional to the viral
               load and are used to detect SARS-CoV-2 RNA concentration.
               Specimens with reverse transcriptase PCR (RT-PCR) Ct values >
               33-34 have been associated with inability to culture virus, and
               have been used as a surrogate for diminished infectivity. We
               report two cases of allogeneic peripheral blood stem cell
               transplant (PBSCT) recipients who had prolonged durations of
               infectivity with SARSCov-2, based on culture positivity and
               persistently low Ct values for greater than 50 days.",
  journal   = "Curr Probl Cancer Case Rep",
  publisher = "Elsevier BV",
  volume    =  3,
  number    =  100057,
  pages     = "100057",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; HSCT; PBSCT; Persistent infection; Positive culture;
               Sars-CoV-2",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Dergham2021-pq,
  title     = "Isolation of viable {SARS-CoV-2} virus from feces of an
               immunocompromised patient suggesting a possible fecal mode of
               transmission",
  author    = "Dergham, Julie and Delerce, Jeremy and Bedotto, Marielle and La
               Scola, Bernard and Moal, Val{\'e}rie",
  abstract  = "(1) Background: Severe Acute Respiratory Syndrome Coronavirus 2
               (SARS-CoV-2) excretion in stools is well documented by RT-PCR,
               but evidences that stools contain infectious particles are
               scarce. (2) Methods: After observing a Corona Virus 2019 Disease
               (COVID-19) epidemic cluster associated with a ruptured sewage
               pipe, we search for such a viable SARS-CoV-2 particle in stool
               by inoculating 106 samples from 46 patients. (3) Results: We
               successfully obtained two isolates from a unique patient with
               kidney transplantation under immunosuppressive therapy who was
               admitted for severe diarrhea. (4) Conclusions: This report
               emphasizes that SARS-CoV-2 is an enteric virus, and infectious
               virus particles can be isolated from the stool of
               immune-compromised patients like, in our case, kidney transplant
               recipient. Immune-compromised patients are likely to have
               massive multiplication of the virus in the gastrointestinal
               tract and this report suggests possible fecal transmission of
               SARS-CoV-2.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  12,
  pages     = "2696",
  month     =  jun,
  year      =  2021,
  keywords  = "Covid-19; SARS-CoV-2; cell culture; organ transplantation;
               stools",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Shah2021-ll,
  title     = "{COVID-19} vaccine responses in patients with plasma cell
               dyscrasias after complete vaccination",
  author    = "Shah, Mansi R and Gabel, Alissa and Beers, Stephanie and Salaru,
               Gratian and Lin, Yong and Cooper, Dennis L",
  abstract  = "INTRODUCTION: Due to functional hypogammaglobulinemia, patients
               with multiple myeloma are at increased risk for infection and
               generally have poorer responses to vaccines. In this study, we
               examined antibody responses after complete COVID-19 vaccination
               in patients with plasma cell dyscrasias, most of whom were
               receiving treatment. PATIENTS AND METHODS: Real world study of
               consecutive patients with multiple myeloma and other plasma cell
               dyscrasias (PCD) were evaluated after complete vaccination with
               either the 2-shot mRNA vaccines from BioNTech and Moderna or the
               1-shot adenoviral vector vaccine from Johnson \& Johnson (J\&J).
               Patients received vaccines 1-4 months before antibody testing
               without controlling for the type of vaccine or the timing of
               drug therapy. Patients with a clinical history or antibody
               evidence of prior infection were excluded. Antinucleocapsid and
               quantitative anti-spike antibody levels were measured with the
               Roche Elecys assay. RESULTS: Ninety-five percent of patients had
               detectable antibody responses. Multivariate analysis showed that
               higher age, ongoing anti-CD38 monoclonal antibody therapy and
               the J\&J vaccine negatively affected quantitative response. A
               small number of ineffectively vaccinated patients receiving IVIG
               subsequently had detectable nucleocapsid and spike antibodies
               confirming the presence of the latter in currently administered
               IVIG. CONCLUSIONS: Nearly all PCD had detectable anti-spike
               antibodies after vaccination but age, anti-CD38 monoclonal
               antibody therapy, and the single-shot J\&J vaccine negatively
               affected responses. In patients who received the J\&J vaccine,
               second doses or heterologous mRNA vaccines should be tested.
               Quantitative antibody testing might make future management more
               rational, particularly in patients with poor responses.",
  journal   = "Clin. Lymphoma Myeloma Leuk.",
  publisher = "Elsevier BV",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Immunocompromised; Monoclonal antibody; Multiple
               myeloma; SARS-CoV-2; Serologic response; Spike antibody
               detection; Vaccine boosters",
  language  = "en"
}

@ARTICLE{Manansala2021-gx,
  title    = "{COVID-19} and sarcoidosis, readiness for vaccination: Challenges
              and opportunities",
  author   = "Manansala, Michael and Chopra, Amit and Baughman, Robert P and
              Novak, Richard and Lower, Elyse E and Culver, Daniel A and
              Korsten, Peter and Drake, Wonder P and Judson, Marc A and Sweiss,
              Nadera",
  abstract = "Sarcoidosis is an immune mediated chronic inflammatory disorder
              that is best characterized by non-caseating granulomas found in
              one or more affected organs. The COVID-19 pandemic poses a
              challenge for clinicians caring for sarcoidosis patients who may
              be at increased risk of infection compared to the general
              population. With the recent availability of COVID-19 vaccines, it
              is expected that clinicians raise questions regarding efficacy
              and safety in sarcoidosis. However, studies examining safety and
              efficacy of vaccines in sarcoidosis are lacking. In this review,
              we examine the current literature regarding vaccination in
              immunocompromised populations and apply them to sarcoidosis
              patients. The available literature suggests that vaccines are
              safe and effective in patients with autoimmune disorders and in
              those taking immunosuppressive medications. We strongly recommend
              the administration of COVID-19 vaccines in patients with
              sarcoidosis. We also present a clinical decision algorithm to
              provide guidance on vaccination of sarcoidosis patients against
              COVID-19.",
  journal  = "Front. Med. (Lausanne)",
  volume   =  8,
  pages    = "672028",
  month    =  apr,
  year     =  2021,
  keywords = "SARS-CoV-2; coronavirus - COVID-19; immunosuppression;
              sarcoidosis; vaccination",
  language = "en"
}

@ARTICLE{Cappuccilli2021-xz,
  title     = "Persistence of antibody responses to the {SARS-CoV-2} in
               dialysis patients and renal transplant recipients recovered from
               {COVID-19}",
  author    = "Cappuccilli, Maria and Bruno, Paolo Ferdinando and Spazzoli,
               Alessandra and Righini, Matteo and Flachi, Marta and Semprini,
               Simona and Grumiro, Laura and Marino, Maria Michela and
               Schiavone, Pasqua and Fabbri, Elisabetta and Fantini, Michela
               and Buscaroli, Andrea and Rigotti, Angelo and La Manna, Gaetano
               and Sambri, Vittorio and Mosconi, Giovanni",
  abstract  = "Nephropathic subjects with impaired immune responses show
               dramatically high infection rates of coronavirus disease 2019
               (COVID-19). This work evaluated the ability to acquire and
               maintain protective antibodies over time in 26 hemodialysis
               patients and 21 kidney transplant recipients. The subjects were
               followed-up through quantitative determination of circulating
               SARS-CoV-2 S1/S2 IgG and neutralizing antibodies in the 6-month
               period after clinical and laboratory recovery. A group of 143
               healthcare workers with no underlying chronic pathologies or
               renal diseases recovered from COVID was also evaluated. In both
               dialysis and transplanted patients, antibody titers reached a
               zenith around the 3rd month, and then a decline occurred on
               average between the 270th and 300th day. Immunocompromised
               patients who lost antibodies around the 6th month were more
               common than non-renal subjects, although the difference was not
               significant (38.5\% vs. 26.6\%). Considering the decay of
               antibody levels below the positivity threshold (15 AU/mL) as
               ``failure'', a progressive loss of immunisation was found in the
               overall population starting 6 months after recovery. A longer
               overall antibody persistence was observed in severe forms of
               COVID-19 (p = 0.0183), but within each group, given the small
               number of patients, the difference was not significant
               (dialysis: p = 0.0702; transplant: p = 0.1899). These data
               suggest that immunocompromised renal patients recovered from
               COVID-19 have weakened and heterogeneous humoral responses that
               tend to decay over time. Despite interindividual variability, an
               association emerged between antibody persistence and clinical
               severity, similar to the subjects with preserved immune
               function.",
  journal   = "Pathogens",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  10,
  pages     = "1289",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2 S1/S2; antibody persistence; humoral immune
               response; immunodepressed patients; neutralizing antibodies;
               renal transplant recipients",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Boodman2021-mi,
  title     = "Nosocomial mucormycosis of the thigh",
  author    = "Boodman, Carl and Cheng, Matthew P",
  abstract  = "We describe a case of nosocomial mucormycosis of the thigh in an
               immunocompromised patient admitted with COVID-19 acute
               respiratory distress syndrome.",
  journal   = "IDCases",
  publisher = "Elsevier BV",
  volume    =  25,
  number    = "e01225",
  pages     = "e01225",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Cutaneous; Fungi; Immunocompromised; Mucormycosis;
               musculoskeletal",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Jiwani2021-yq,
  title    = "Discontinuation of transmission precautions for {COVID-19}
              patients: Polymerase chain reaction diagnostics, patient delays,
              and cycle threshold values",
  author   = "Jiwani, Rahim A and Mao, Yuxuan and Pona, Adrian and Bradner,
              Evan and Hussain, Jaffer and Stalls, J Stephen and Cook, Paul and
              Burch, Ashley and Afriyie, Felix and Labbe, Jonathan and Younes,
              Ahmed and Badr, Mai and Lee, Elisabeth and Roper, Rachel L",
  abstract = "Background: The decision of when it is safe to discontinue
              transmission-based precautions for SARS-CoV-2 coronavirus disease
              2019 (COVID-19) hospitalized patients has been controversial. The
              Centers for Disease Control and Prevention offered reverse
              transcriptase polymerase chain reaction (PCR) diagnostic test- or
              symptom-based guidelines. Methods: A retrospective chart review
              of Vidant Health system, Eastern North Carolina, was conducted.
              Length of stay, days in isolation unit, and date appropriate for
              discharge or isolation discontinuation based on the symptom-based
              strategy were recorded. Results: Of 196 COVID hospitalized
              patients, 34 had repeated COVID PCR tests 3 or more days from
              their first positive test result. Half of these patients
              experienced delays in release from transmission-based precautions
              because of repeated positive PCR test results and use of the
              test-based approach. This resulted in an additional 166 days of
              hospitalization, costing an estimated \$415,000. Furthermore, 2
              subjects had a combined 16-day delay in necessary medical
              procedures. Most of the COVID PCR platforms yield quantitative
              results in the form of cycle threshold (Ct) values, the number of
              cycles needed to detect the genome. These values have also been
              used to assess whether patients are likely to remain contagious.
              None of our patients who met the criteria for symptom-based
              strategy for transmission-based precaution discontinuation had
              positive PCR test results with Ct values lower than 25, but 4 had
              Ct values lower than 30. Conclusions: Concerns surround
              immunocompromised patients and those treated with steroids who
              might be delayed or incapable of stopping viral replication and
              thus remain contagious. Our results suggest that clinicians use
              all available data including Ct values to evaluate the safety of
              discontinuation of transmission precautions.",
  journal  = "Infect. Dis. Clin. Pract. (Baltim. Md.)",
  volume   =  29,
  number   =  5,
  pages    = "e287--e293",
  month    =  sep,
  year     =  2021,
  keywords = "COVID-19; PCR; SARS-CoV-2; diagnostics; isolation precautions",
  language = "en"
}

@ARTICLE{Ljungquist2021-xd,
  title     = "Convalescent plasma treatment in severely immunosuppressed
               patients hospitalized with {COVID-19}: an observational study of
               28 cases",
  author    = "Ljungquist, Oskar and Lundgren, Maria and Iliachenko, Elena and
               M{\aa}nsson, Fredrik and B{\"o}ttiger, Blenda and Landin-Olsson,
               Mona and Wik{\'e}n, Christian and Rosendal, Ebba and {\"O}verby,
               Anna K and Wigren, Bystr{\"o}m J and Forsell, Mattias N E and
               Kjeldsen-Kragh, Jens and Rasmussen, Magnus and Kahn, Fredrik and
               Holm, Karin",
  abstract  = "BACKGROUND: Immunosuppressed patients are particularly
               vulnerable to severe infection from the severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2), risking prolonged viremia
               and symptom duration. In this study we describe clinical and
               virological treatment outcomes in a heterogeneous group of
               patients with severe immunosuppression due to various causes
               suffering from COVID-19 infection, who were all treated with
               convalescent plasma (CCP) along with standard treatment.
               METHODS: We performed an observational, retrospective case
               series between May 2020 to March 2021 at three sites in
               Sk{\aa}ne, Sweden, with a population of nearly 1.4 million
               people. All patients hospitalized for COVID-19 who received CCP
               with the indication severe immunosuppression as defined by the
               treating physician were included in the study (n = 28). RESULTS:
               In total, 28 severely immunocompromised patients, half of which
               previously had been treated with rituximab, who had received
               in-hospital convalescent plasma treatment of COVID-19 were
               identified. One week after CCP treatment, 13 of 28 (46\%)
               patients had improved clinically defined as a decrease of at
               least one point at the WHO-scale. Three patients had increased
               score points of whom two had died. For 12 patients, the
               WHO-scale was unchanged. CONCLUSION: As one of only few studies
               on CCP treatment of COVID-19 in hospitalized patients with
               severe immunosuppression, this study adds descriptive data. The
               study design prohibits conclusions on safety and efficacy, and
               the results should be interpreted with caution. Prospective,
               randomized trials are needed to investigate this further.",
  journal   = "Infect. Dis. (Lond.)",
  publisher = "Informa UK Limited",
  pages     = "1--9",
  month     =  dec,
  year      =  2021,
  keywords  = "Antibodies; COVID-19; PCR; SARS-CoV-2; convalescent plasma;
               immunosuppression; lymphoma; pandemic; rituximab",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Talwar2021-ns,
  title     = "Managing {COVID-19} infection in a young acute myeloid leukemia
               patient successfully with antiviral and granulocyte colony
               stimulating factor: Playing on a sticky wicket",
  author    = "Talwar, Dhruv and Kumar, Sunil and Acharya, Sourya and Khanna,
               Shivam and Hulkoti, Vidyashree",
  abstract  = "The COVID-19 pandemic has drastically affected healthcare
               systems throughout the world. Though all domains of healthcare
               are busy battling this deadly pandemic, oncology care has taken
               a drastic hit due to cancer patients being immunocompromised and
               predisposed to acquire COVID-19 infection. Patients suffering
               from acute myeloid leukemia are at greater risk of acquiring
               Severe Acute Respiratory Syndrome Coronavirus 2(SARS CoV 2)
               infection along with developing complications related to
               COVID-19 due to the immunosuppression caused by the malignancy,
               as well as the high-intensity chemotherapy provided in acute
               myeloid leukemia. We report a case of 28-year-old male who was a
               known case of acute myeloid leukemia diagnosed three months ago,
               presented with high-grade fever with cough and breathlessness.
               Nasopharyngeal swab of the patient for SARS CoV2 by reverse
               transcriptase-polymerase chain reaction turned out to be
               positive. The patient was managed successfully with steroids,
               remdesavir, granulocyte colony-stimulating factor, and other
               supportive measures, and was discharged in a stable condition.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  7,
  pages     = "e16589",
  month     =  jul,
  year      =  2021,
  keywords  = "acute myeloid leukemia; antiviral; covid19; granulocyte colony
               stimulating factor; steroid",
  language  = "en"
}

@ARTICLE{Simioli2021-qn,
  title     = "Therapeutic approach for severe {COVID-19} and immunocompromised
               patients. A case series",
  author    = "Simioli, Francesca and Martino, Maria and Annunziata, Anna and
               Carannante, Novella and Fiorentino, Giuseppe",
  abstract  = "Background: COVID-19 is a potentially critical infectious
               disease. Inflammatory response and disease severity may vary
               according to immune system status. The aim of this case series
               is to investigate different presentation of COVID-19 in
               immunocompromised patients. Methods: this is a single centre
               case series about 17 immunocompromised patients admitted to our
               respiratory department during the recent COVID-19 pandemic.
               White blood cell count, C reactive protein, interleukin 6,
               lymphocytic subpopulation count (CD4+, CD8+, CD20+) and
               immunoglobulin count (IgG, IgM, IgA) were measured at
               hospitalization. Results: the most common causes of
               immunosuppression observed in our severe COVID-19 population are
               hematological malignancies, immunosuppressant drugs for
               transplant, primary immunodeficiency and inflammatory bowel
               disease. Onset symptoms were fever (88\%), cough (53\%),
               dyspnoea (24\%), asthenia (35\%), anosmia and/or ageusia (17\%),
               expectoration (12\%). Compared to benign conditions, patients
               with malignancies show a lower lymphocytic count (490 vs 1100
               cells/uL) and higher interleukin 6 (33 vs 13 pg/mL).
               Conclusions: immunocompromised patients are at risk of adverse
               outcome from COVID-19. Hematological malignancies and anti-CD20
               therapies induce a high risk. Primary immunodeficiency and
               classical immunosuppressant such as calcineurin inhibitors and
               antimetabolites share an intermediate risk.",
  journal   = "Respir. Med. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  33,
  number    =  101397,
  pages     = "101397",
  month     =  mar,
  year      =  2021,
  keywords  = "Anti-CD20; Immunodeficiency; Immunosuppressant; Lymphoma;
               SARS-CoV2 persistence; SARS-CoV2 relapse",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Pereska2021-vj,
  title     = "Acute severe poisoning with disinfectant in senior aged
               patient-case report and overview of literature considering age
               influence on treatment decision in alcohol-based intoxications",
  author    = "Pereska, Zanina and Simonovska, Natasha and Babulovska,
               Aleksandra and Berat-Huseini, Afrodita and Naumoski, Kiril and
               Kostadinoski, Kristin",
  abstract  = "We present our experiences in the first case of severe suicidal
               poisoning with 70\% ethanol-disinfectant in North Macedonia, in
               an elderly patient with immunocompromising comorbidities. A
               66-year-old unconscious woman was admitted at our clinic, with a
               history of seropositive rheumatoid arthritis treated with
               methotrexate. She was in a coma, without signs of serotonin
               syndrome, recurrent episodes of cardio-respiratory insufficiency
               under supportive treatment without invasive ventilation,
               metabolic acidosis, increased D-dimer 3254 ng/mL. The toxicology
               screening confirmed low benzodiazepines levels and alcoholaemia
               of 526 mg/dL (5.26 g/L), due to ingestion of 70\% ethanol.
               Considering the decreased biotransformation in the elderly,
               immunocompromising comorbidities, reports of fatal outcome in
               poisoned elderly patients with disinfectants under standard
               fluids supportive protocol, haemodialysis was initiated, with
               registered associated hypercoagulability which resulted in
               complete stabilization after 48 h of admission. Treatment
               protocols of poisoning with ethanol-based disinfectant in the
               elderly should consider timely performing haemodialysis at lower
               alcoholaemia levels than recommended.",
  journal   = "SAGE Open Med. Case Rep.",
  publisher = "SAGE Publications",
  volume    =  9,
  pages     = "2050313X211047717",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 pandemic; elderly; ethanol-based disinfectant;
               haemodialysis; poisoning",
  language  = "en"
}

@ARTICLE{Colson2021-gk,
  title     = "A possible role of remdesivir and plasma therapy in the
               selective sweep and emergence of new {SARS-CoV-2} variants",
  author    = "Colson, Philippe and Devaux, Christian A and Lagier,
               Jean-Christophe and Gautret, Philippe and Raoult, Didier",
  abstract  = "Since summer 2020, SARS-CoV-2 strains at the origin of the
               COVID-19 pandemic have suddenly been replaced by new SARS-CoV-2
               variants, some of which are highly transmissible and spread at a
               high rate. These variants include the Marseille-4 lineage
               (Nextclade 20A.EU2) in Europe, the 20I/501Y.V1 variant first
               detected in the UK, the 20H/501Y.V2 variant first detected in
               South Africa, and the 20J/501Y.V3 variant first detected in
               Brazil. These variants are characterized by multiple mutations
               in the viral spike protein that is targeted by neutralizing
               antibodies elicited in response to infection or vaccine
               immunization. The usual coronavirus mutation rate through
               genetic drift alone cannot account for such rapid changes.
               Recent reports of the occurrence of such mutations in
               immunocompromised patients who received remdesivir and/or
               convalescent plasma or monoclonal antibodies to treat prolonged
               SARS-CoV-2 infections led us to hypothesize that experimental
               therapies that fail to cure the patients from COVID-19 could
               favor the emergence of immune escape SARS-CoV-2 variants. We
               review here the data that support this hypothesis and urge
               physicians and clinical trial promoters to systematically
               monitor viral mutations by whole-genome sequencing for patients
               who are administered these treatments.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  15,
  pages     = "3276",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; anti-spike antibodies; mutants; plasma
               therapy; remdesivir; variant",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Slezak2021-br,
  title     = "Rate and severity of suspected {SARS-Cov-2} reinfection in a
               cohort of {PCR-positive} {COVID-19} patients",
  author    = "Slezak, Jeff and Bruxvoort, Katia and Fischer, Heidi and Broder,
               Benjamin and Ackerson, Bradley and Tartof, Sara",
  abstract  = "OBJECTIVES: To estimate the burden and severity of suspected
               reinfection with severe acute respiratory syndrome coronavirus 2
               (SARS-CoV-2). METHODS: A retrospective cohort of members of
               Kaiser Permanente Southern California with PCR-positive
               SARS-CoV-2 infection between 1st March 2020 and 31st October
               2020 was followed through electronic health records for
               subsequent positive SARS-CoV-2 tests (suspected reinfection)
               $\geq$90 days after initial infection, through 31st January
               2021. Incidence of suspected reinfection was estimated using the
               Kaplan-Meier method. Cox proportional hazards models estimated
               the association of suspected reinfection with demographic and
               clinical characteristics, hospitalization, and date of initial
               infection. RESULTS: The cohort of 75 149 was predominantly
               Hispanic (49 648/75 149, 66.1\%) and included slightly more
               females than males (39 736, 52.9\%), with few immunocompromised
               patients (953, 1.3\%); 315 suspected reinfections were
               identified, with a cumulative incidence at 270 days of 0.8\%
               (95\% confidence interval (CI) 0.7-1.0\%). Hospitalization was
               more common at suspected reinfection (36/315, 11.4\%) than
               initial infection (4094/75 149, 5.4\%). Suspected reinfection
               rates were higher in females (1.0\%, CI 0.8-1.2\% versus 0.7\%,
               CI 0.5-0.9\%, p 0.002) and immunocompromised patients (2.1\%, CI
               1.0-4.2\% versus 0.8\%, CI 0.7-1.0\%, p 0.004), and lower in
               children than adults (0.2\%, CI 0.1-0.4\% versus 0.9\%, CI
               0.7-1.0\%, p 0.023). Patients hospitalized at initial infection
               were more likely to have suspected reinfection (1.2\%, CI
               0.6-1.7\% versus 0.8\%, CI 0.7-1.0\%, p 0.030), as were those
               with initial infections later in 2020 (150-day incidence 0.4\%,
               CI 0.2-0.5\% September-October versus 0.2\%, CI 0.1-0.3\%
               March-May and 0.3\%, CI 0.2-0.3\% June-August, p 0.008). In an
               adjusted Cox proportional hazards model, being female (hazard
               ratio (HR) 1.44, CI 1.14-1.81), adult (age 18-39, HR 2.71, CI
               1.38-5.31, age 40-59 HR 2.22, CI 1.12-4.41, age $\geq$60 HR
               2.52, CI 1.23-5.17 versus <18 years), immunocompromised (HR
               2.48, CI 1.31-4.68), hospitalized (HR 1.60, CI 1.07-2.38), and
               initially infected later in 2020 (HR 2.26, CI 1.38-3.71
               September-October versus March-May) were significant independent
               predictors of suspected reinfection. CONCLUSIONS: Reinfection
               with SARS-CoV-2 is uncommon, with suspected reinfections more
               likely in women, adults, immunocompromised subjects, and those
               previously hospitalized for coronavirus 2019 (COVID-19). This
               suggests a need for continued precautions and vaccination in
               patients with COVID-19 to prevent reinfection.",
  journal   = "Clin. Microbiol. Infect.",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  12,
  pages     = "1860.e7--1860.e10",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; Epidemiology; Hospitalization; Reinfection; Risk
               factors",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Gatto2021-of,
  title     = "Correlates of {COVID-19} vaccine acceptance, hesitancy and
               refusal among employees of a safety net California county health
               system with an early and aggressive vaccination program: Results
               from a cross-sectional survey",
  author    = "Gatto, Nicole M and Lee, Jerusha E and Massai, Donatella and
               Zamarripa, Susanna and Sasaninia, Bijan and Khurana, Dhruv and
               Michaels, Kelsey and Freund, Deborah and Nightingale, Judi and
               Firek, Anthony",
  abstract  = "Since health professionals provide frontline care to COVID-19
               patients, information on vaccine acceptance among healthcare
               workers is needed. We developed and implemented an anonymous
               internet-based cross-sectional survey with direct solicitation
               among employees of a safety net health system. Items queried
               demographic and health-related characteristics, experience with
               and knowledge of COVID-19, and determinants of decisions to
               vaccinate. COVID-19 vaccine acceptance groups (acceptors,
               hesitant, refusers) were defined; an adapted version of the WHO
               vaccine hesitancy scale was included. The survey demonstrated
               good reliability (Cronbach's alpha = 0.92 for vaccine hesitancy
               scale; 0.93 for determinants). General linear and logistic
               regression methods examined factors which were univariately
               associated with vaccine hesitancy and vaccine acceptance,
               respectively. Multivariable models were constructed with
               stepwise model-building procedures. Race/ethnicity, marital
               status, job classification, immunocompromised status, flu
               vaccination and childhood vaccination opinions independently
               predicted hesitancy scale scores. Gender, education, job
               classification and BMI independently predicted acceptance,
               hesitancy, and refusal groups. Among hesitant employees,
               uncertainty was reflected in reports of motivating factors
               influencing their indecision. Despite a strong employee-support
               environment and job protection, respondents reported physical
               and mental health effects. The appreciation of varied reasons
               for refusing vaccination should lead to culturally sensitive
               interventions to increase vaccination rates amongst healthcare
               workers.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  10,
  pages     = "1152",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; determinants; healthcare workers; nurses;
               pandemic; physicians; vaccine acceptance; vaccine hesitancy",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Perez-Lago2021-nr,
  title     = "Different within-host viral evolution dynamics in severely
               immunosuppressed cases with persistent {SARS-CoV-2}",
  author    = "P{\'e}rez-Lago, Laura and Ald{\'a}miz-Echevarr{\'\i}a, Teresa
               and Garc{\'\i}a-Mart{\'\i}nez, Rita and P{\'e}rez-Latorre, Leire
               and Herranz, Marta and Sola-Campoy, Pedro J and
               Su{\'a}rez-Gonz{\'a}lez, Julia and Mart{\'\i}nez-Laperche,
               Carolina and Comas, I{\~n}aki and Gonz{\'a}lez-Candelas,
               Fernando and Catal{\'a}n, Pilar and Mu{\~n}oz, Patricia and
               Garc{\'\i}a de Viedma, Dar{\'\i}o and {On Behalf Of Gregorio
               Mara{\~n}{\'o}n Microbiology-Id Covid Study Group}",
  abstract  = "A successful Severe Acute Respiratory Syndrome Coronavirus 2
               (SARS-CoV-2) variant, B.1.1.7, has recently been reported in the
               UK, causing global alarm. Most likely, the new variant emerged
               in a persistently infected patient, justifying a special focus
               on these cases. Our aim in this study was to explore certain
               clinical profiles involving severe immunosuppression that may
               help explain the prolonged persistence of viable viruses. We
               present three severely immunosuppressed cases (A, B, and C) with
               a history of lymphoma and prolonged SARS-CoV-2 shedding (2, 4,
               and 6 months), two of whom finally died. Whole-genome sequencing
               of 9 and 10 specimens from Cases A and B revealed extensive
               within-patient acquisition of diversity, 12 and 28 new single
               nucleotide polymorphisms, respectively, which suggests ongoing
               SARS-CoV-2 replication. This diversity was not observed for Case
               C after analysing 5 sequential nasopharyngeal specimens and one
               plasma specimen, and was only observed in one bronchoaspirate
               specimen, although viral viability was still considered based on
               constant low Ct values throughout the disease and recovery of
               the virus in cell cultures. The acquired viral diversity in
               Cases A and B followed different dynamics. For Case A, new
               single nucleotide polymorphisms were quickly fixed (13-15 days)
               after emerging as minority variants, while for Case B, higher
               diversity was observed at a slower emergence: fixation pace (1-2
               months). Slower SARS-CoV-2 evolutionary pace was observed for
               Case A following the administration of hyperimmune plasma. This
               work adds knowledge on SARS-CoV-2 prolonged shedding in severely
               immunocompromised patients and demonstrates viral viability,
               noteworthy acquired intra-patient diversity, and different
               SARS-CoV-2 evolutionary dynamics in persistent cases.",
  journal   = "Biomedicines",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  7,
  pages     = "808",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; diversity; genomics; immunosuppressed;
               persistence; viral viability",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Barkati2021-yx,
  title     = "Strongyloidiasis in immunocompromised migrants to non-endemic
               countries in the era of {COVID-19}: What is the role for
               presumptive ivermectin?",
  author    = "Barkati, Sapha and Greenaway, Christina and Libman, Michael D",
  abstract  = "The COVID-19 pandemic has led to widespread use of
               dexamethasone. Corticosteroid therapy is an important risk
               factor for Strongyloides hyperinfection. Challenges associated
               with the performance of Strongyloides tests, and the poor
               availability of high quality and timely diagnostic testing,
               makes the use of presumptive ivermectin reasonable in selected
               situations.",
  journal   = "J. Travel Med.",
  publisher = "Oxford University Press (OUP)",
  month     =  sep,
  year      =  2021,
  keywords  = "SARS-CoV-2; Strongyloides; Strongyloides serology;
               corticosteroids; dexamethasone; hyperinfection; migrants",
  language  = "en"
}

@ARTICLE{Chehade2021-cg,
  title     = "{COVID-19} vaccination immune response in patients with solid
               organ and haematologic malignancies: call for active monitoring",
  author    = "Chehade, Laudy and Zeitoun, Jad and Bejjany, Rachelle and
               Charafeddine, Maya and Kreidieh, Firas and Hassan, Mona and
               Taher, Ali and Saghir, Nagi El and Shamseddine, Ali and Salem,
               Ziad and Temraz, Sally and Tfayli, Arafat and Assi, Hazem and
               Bazarbachi, Ali and El Cheikh, Jean and Dalle, Iman Abou and
               Rizk, Nesrine and Mahfouz, Rami and Mukherji, Deborah",
  abstract  = "Vaccines against COVID-19 have demonstrated a remarkable
               efficacy in decreasing hospitalisations and deaths; however,
               clinical trials leading to vaccine approvals did not include
               immunocompromised individuals such as patients receiving
               antineoplastic therapies. Emerging data suggest that patients on
               active anti-cancer therapy may have a reduced immune response to
               COVID-19 vaccination compared to the general population and may
               be at greater risk of COVID-19 infection as measures to reduce
               transmission in the community are relaxed. We report preliminary
               data from the American University of Beirut Medical Center in
               Lebanon demonstrating relatively low seroconversion rates. Of 36
               patients on active anti-cancer therapy who had received two
               doses of vaccine, 17\% were negative for Severe Acute
               Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) anti-spike IgG.
               These results highlight the importance of maintaining strict
               precautionary measures against COVID-19 in patients on
               immunosuppressive treatment. There is an urgent need for active
               monitoring of immune response post-vaccination in prospective
               studies involving populations from diverse resource settings.",
  journal   = "Ecancermedicalscience",
  publisher = "Ecancer Global Foundation",
  volume    =  15,
  pages     = "1284",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; chemotherapy; immune response; vaccine",
  language  = "en"
}

@ARTICLE{Lino2021-sa,
  title     = "Presence and clinical impact of human herpesvirus-6 infection in
               patients with moderate to critical coronavirus disease-19",
  author    = "Lino, Katia and Alves, Lilian S and Raposo, Jessica V and
               Medeiros, Thalia and Souza, Cintia F and Silva, Andrea A da and
               de Paula, Vanessa S and Almeida, Jorge R",
  abstract  = "Human herpesvirus-6 (HHV-6) may cause serious diseases in
               immunocompromised individuals. SARS-CoV-2/HHV-6 coinfection has
               been emphasized in previous works, mostly case reports, small
               series, or epidemiological studies, but few are known about its
               real clinical outcomes. Here we present a real-world pilot study
               aiming to understand the frequency and the clinical impact of
               HHV-6 coinfection in moderate to critically ill patients
               hospitalized due to COVID-19. SARS-CoV-2 and HHV-6 were
               evaluated in nasopharyngeal samples at the hospital admission of
               suspected COVID-19 patients. From 173 consecutive cases, 60 were
               SARS-CoV-2 positive and 13/60 (21.7\%) were HHV-6 positive after
               identified as the HHV-6B species by a Sanger sequencing. The
               SARS-CoV-2+/HHV-6+ group was younger but not significant for
               cardiovascular diseases, diabetes, obesity, and cancer, but
               significant among therapeutic immunosuppressed patients (as
               systemic lupus erythematosus and kidney transplant patients). In
               the medical records, only sparse data on cutaneous or
               neurological manifestations were found. Biochemical and
               hematological data showed only a trend towards hyperferritinemic
               status and lymphopenia. In conclusion, despite the impressive
               high frequency of HHV-6 coinfection in SARS-CoV-2 positive
               cases, it did not impact general mortality. We suggest larger
               future prospective studies to better elucidate the influence of
               HHV-6 reactivation in cases of COVID-19, designed to specific
               assessment of clinical outcomes and viral reactivation
               mechanisms.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; HHV-6; herpesvirus-6",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Corvol2021-or,
  title     = "Atypical severe organizing pneumonia following {COVID-19} in an
               immunocompromised teenager",
  author    = "Corvol, Harriet and Alimi, Aurelia and Prevost, Blandine and
               Schnuriger, Aur{\'e}lie and Le Pointe, Hubert Ducou and Rambaud,
               J{\'e}rome and Tabone, Marie-Dominique",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  jul,
  year      =  2021,
  keywords  = "ARDS; COVID-19; immunocompromised child; organizing pneumonia;
               teenager",
  language  = "en"
}

@ARTICLE{Erice2021-kt,
  title     = "Decline of antibody titres 3 months after two doses of
               {BNT162b2} in non-immunocompromised adults",
  author    = "Erice, Alejo and Varillas-Delgado, David and Caballero, Cristina",
  abstract  = "OBJECTIVE: To assess the antibody response in
               non-immunocompromised adults after two doses of BNT162b2.
               METHODS: Prospective, single-centre observational study in
               non-immunocompromised adults aged 18 years or more who received
               two doses of BNT162b2. The study contemplates analyses of serum
               samples collected 1.5, 3, 6, 9 and 12 months after the second
               dose of BNT162b2; results of the 1.5- and 3-month time-points
               are presented in this report. Antibodies against the receptor
               binding domain of the S1 subunit of the spike protein of severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (anti-RBD
               antibodies) were measured using a commercial quantitative
               immunoassay. A threshold of 4160 AU/mL (corresponding to an ID50
               of 1:250) was used as surrogate marker for serum neutralizing
               activity. RESULTS: Of 273 hospital workers who received two
               doses of BNT162b2, 260 (95\%) agreed to participate in the
               study; 2/260 (0.8\%) were excluded because of immunocompromised
               conditions. At the time of this report, 230/258 (89\%)
               participants (mean age 46.0 years (SD 11.4 years); 143/230
               (62\%) female; 87/230 (38\%) male) had completed 3 months of
               follow up after the second dose of BNT162b2. Thirty-six (16\%)
               of the 230 had documented mild SARS-CoV-2 infection before
               receiving the first dose of BNT162b2. Median (interquartile
               range (IQR)) anti-RBD titres 1.5 months after vaccination were
               9356 (5844-16 876) AU/mL; 3 months after vaccination, median
               anti-RBD titres had declined to 3952 (2190-8561) AU/mL (p <
               0.001). Of 199/230 (86.5\%) participants who had anti-RBD titres
               above 4160 AU/mL 1.5 months after the second dose of BNT162b2,
               only 95/230 (41\%) maintained anti-RBD titres above this level 3
               months after vaccination (p < 0.001). CONCLUSIONS: The decline
               of anti-RBD antibodies 3 months after the second dose of
               BNT162b2 is of concern because it raises the possibility of a
               short-lived humoral immunity after vaccination. Booster doses of
               BNT162b2 might be required to maintain high titres of anti-RBD
               antibodies over time.",
  journal   = "Clin. Microbiol. Infect.",
  publisher = "Elsevier BV",
  volume    =  28,
  number    =  1,
  pages     = "139.e1--139.e4",
  month     =  sep,
  year      =  2021,
  keywords  = "BNT162b2; COVID-19; Immunogenicity; SARS-CoV-2; Vaccine",
  language  = "en"
}

@ARTICLE{Raghav2021-vf,
  title     = "Newer horizon of mesenchymal stem cell-based therapy in the
               management of {SARS-CoV-2-associated} mucormycosis: A safe hope
               for future medicine",
  author    = "Raghav, Alok and Ali, Syed Ghazanfar and Jeong, Goo-Bo and
               Gautam, Kirti Amresh and Banday, Shahid and Mateen, Qazi Noorul
               and Tripathi, Prashant and Giri, Richa and Agarwal, Saurabh and
               Singh, Manish and Khan, Haris M",
  abstract  = "SARS-CoV-2-infected patients are reported to show
               immunocompromised behavior that gives rise to a wide variety of
               complications due to impaired innate immune response, cytokine
               storm, and thrombo-inflammation. Prolonged use of steroids,
               diabetes mellitus, and diabetic ketoacidosis (DKA) are some of
               the factors responsible for the growth of Mucorales in such
               immunocompromised patients and, thus, can lead to a
               life-threatening condition referred to as mucormycosis.
               Therefore, an early diagnosis and cell-based management cosis is
               the need of the hour to help affected patients overcome this
               severe condition. In addition, extended exposure to antifungal
               drugs/therapeutics is found to initiate hormonal and
               neurological complications. More recently, mesenchymal stem
               cells (MSCs) have been used to exhibit immunomodulatory function
               and proven to be beneficial in a clinical cell-based
               regenerative approach. The immunomodulation ability of MSCs in
               mucormycosis patient boosts the immunity by the release of
               chemotactic proteins. MSC-based therapy in mucormycosis along
               with the combination of short-term antifungal drugs can be
               utilized as a prospective approach for mucormycosis treatment
               with promising outcomes. However, preclinical and in mucormyIn
               mucormycosis, the hyphae of clinical trials are needed to
               establish the precise mechanism of MSCs in mucormycosis
               treatment.",
  journal   = "Front. Microbiol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "738983",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Mucormycosis; SARS-CoV-2; immunomodulation;
               mesenchymal stem cells",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Van_Cleemput2021-gh,
  title     = "Organ-specific genome diversity of replication-competent
               {SARS-CoV-2}",
  author    = "Van Cleemput, Jolien and van Snippenberg, Willem and Lambrechts,
               Laurens and Dendooven, Am{\'e}lie and D'Onofrio, Valentino and
               Couck, Liesbeth and Trypsteen, Wim and Vanrusselt, Jan and
               Theuns, Sebastiaan and Vereecke, Nick and van den Bosch, Thierry
               P P and Lammens, Martin and Driessen, Ann and Achten, Ruth and
               Bracke, Ken R and Van den Broeck, Wim and Von der Th{\"u}sen,
               Jan and Nauwynck, Hans and Van Dorpe, Jo and Gerlo, Sarah and
               Maes, Piet and Cox, Janneke and Vandekerckhove, Linos",
  abstract  = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               infection is not always confined to the respiratory system, as
               it impacts people on a broad clinical spectrum from asymptomatic
               to severe systemic manifestations resulting in death. Further,
               accumulation of intra-host single nucleotide variants during
               prolonged SARS-CoV-2 infection may lead to emergence of variants
               of concern (VOCs). Still, information on virus infectivity and
               intra-host evolution across organs is sparse. We report a
               detailed virological analysis of thirteen postmortem coronavirus
               disease 2019 (COVID-19) cases that provides proof of viremia and
               presence of replication-competent SARS-CoV-2 in extrapulmonary
               organs of immunocompromised patients, including heart, kidney,
               liver, and spleen (NCT04366882). In parallel, we identify
               organ-specific SARS-CoV-2 genome diversity and mutations of
               concern N501Y, T1027I, and Y453F, while the patient had died
               long before reported emergence of VOCs. These mutations appear
               in multiple organs and replicate in Vero E6 cells, highlighting
               their infectivity. Finally, we show two stages of fatal disease
               evolution based on disease duration and viral loads in lungs and
               plasma. Our results provide insights about the pathogenesis and
               intra-host evolution of SARS-CoV-2 and show that COVID-19
               treatment and hygiene measures need to be tailored to specific
               needs of immunocompromised patients, even when respiratory
               symptoms cease.",
  journal   = "Nat. Commun.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  12,
  number    =  1,
  pages     = "6612",
  month     =  nov,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Garcia-Botella2021-rw,
  title     = "Booster or additional vaccination doses in patients vaccinated
               against {COVID-19}",
  author    = "Garc{\'\i}a-Botella, A and Garc{\'\i}a-Lled{\'o}, A and
               G{\'o}mez-Pav{\'o}n, J and Gonz{\'a}lez Del Castillo, J and
               Hern{\'a}ndez-Sampelayo, T and Mart{\'\i}n-Delgado, M C and
               Mart{\'\i}n S{\'a}nchez, F J and Mart{\'\i}nez-Sell{\'e}s, M and
               Molero Garc{\'\i}a, J M and Moreno Guill{\'e}n, S and
               Rodr{\'\i}guez-Artalejo, F J and Ruiz-Galiana, J and Cant{\'o}n,
               R and De Lucas Ramos, P and Bouza, E",
  abstract  = "Several health organizations, mainly in Western countries, have
               recently authorized the use of a booster dose of the COVID-19
               vaccine for patients previously vaccinated with mRNA vaccines,
               with criteria that do not always coincide. The COVID Scientific
               Committee of the Illustrious College of Physicians of Madrid
               (ICOMEM) has received and asked several questions about this
               situation, to which the group has tried to give answers, after
               deliberation and consensus. The efficacy of the vaccines
               administered so far is beyond doubt and they have managed to
               reduce, fundamentally, the severe forms of the disease. The
               duration of this protection is not well known, is different in
               different individuals and for different variants of the virus
               and is not easily predictable with laboratory tests. Data on the
               real impact of a supplementary or ``booster'' dose in the
               scientific literature are scarce for the moment and its
               application in large populations such as those in the state of
               Israel may be associated with a decrease in the risk of new and
               severe episodes in the short observation period available. We
               also lack sufficient data on the safety and potential adverse
               effects of these supplementary doses and we do not know the
               ideal time to administer them in different situations. In this
               state of affairs, it seems prudent to administer supplemental
               doses to those exposed to a higher risk, such as
               immunocompromised individuals and the elderly. On the other
               hand, we consider that this is not the time to accelerate, on
               the spur of the moment, a massive administration of a third dose
               to other population groups that are less exposed and at lower
               risk, without waiting for adequate scientific information, which
               will undoubtedly arrive gradually. We do not believe that this
               position is incompatible with the practical and ethical warnings
               made by the World Health Organization in this respect.",
  journal   = "Rev. Esp. Quimioter.",
  publisher = "Sociedad Espanola de Quimioterapia",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; additional doses; booster; third dose;
               vaccines",
  language  = "en"
}

@ARTICLE{Kaminska2021-km,
  title     = "Comparing humoral and cellular adaptive immunity during
               convalescent phase of {COVID-19} in hemodialysis patients and
               kidney transplant recipients",
  author    = "Kami{\'n}ska, Dorota and Augustyniak-Bartosik, Hanna and
               Ko{\'s}cielska-Kasprzak, Katarzyna and {\.Z}abi{\'n}ska,
               Marcelina and Bartoszek, Dorota and Pozna{\'n}ski, Pawe{\l} and
               Kuriata-Kordek, Magdalena and Kusztal, Mariusz and Mazanowska,
               Oktawia and Krajewska, Magdalena",
  abstract  = "BACKGROUND: It is still unclear whether COVID-19 convalescent
               kidney transplant recipients (KTR) and hemodialysis (HD)
               patients can develop anti-SARS-CoV-2 adaptive immunity. The aim
               was to characterize and compare the immune response to the virus
               in HD patients and KTR. METHODS: The study included 26 HD
               patients and 54 KTR-both convalescent (14 HD, 25 KTR) and
               unexposed. The immune response was assessed by determining the
               anti-SARS-CoV-2 antibodies in serum and specific T cell response
               via the interferon-gamma release assay (IGRA). Moreover,
               blood-morphology-derived parameters, immune cell phenotypes, and
               acute phase reactants were evaluated. RESULTS: KRT and HD
               convalescents presented similar serum levels of anti-SARS-CoV-2
               IgG and IgA. A negative correlation occurred between IgG and
               time after the infection was observed. There was a strong
               relationship between the prevalence of anti-SARS-CoV-2 cellular
               and humoral responses in both groups. Convalescent IGRA response
               was significantly higher in HD patients compared to KTR.
               CONCLUSIONS: HD patients and KTR develop humoral and cellular
               responses after COVID-19. The antibodies levels are similar in
               both groups of patients. SARS-CoV-2-reactive T cell response is
               stronger in HD patients compared to KTR. The SARS-CoV-2-specific
               IgG level decreases with time while IgA and a cellular response
               are maintained. IGRA proved to be a valuable test for the
               assessment of specific cellular immunity in immunocompromised HD
               patients and KTR.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  21,
  pages     = "4833",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; antibodies; cellular immunity;
               hemodialysis; humoral immunity; interferon-gamma release assay
               (IGRA); kidney transplantation",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{McIntyre2021-ld,
  title     = "{COVID-19} vaccines - are we there yet?",
  author    = "McIntyre, Peter and Joo, Ye Jin and Chiu, Clayton and Flanagan,
               Katie and Macartney, Kristine",
  abstract  = "The novel coronavirus SARS-CoV-2, the cause of the COVID-19
               pandemic, is a highly infectious human respiratory pathogen to
               which the global population had no prior immunity. The virus
               will likely continue to cause significant morbidity until there
               is a broadly effective vaccine As of mid-December 2020, more
               than 200 COVID-19 vaccine candidates are in development and 11
               have entered phase III clinical trials globally. All generate
               immunity to the viral spike glycoprotein Three vaccine
               candidates have agreements for procurement and use in Australia
               if efficacy and safety requirements are met - one protein-based
               vaccine, one vaccine using a simian-derived adenovirus vector
               and one messenger RNA vaccine. The latter two vaccines have
               published interim analyses and efficacy results of their phase
               III trials. The messenger RNA vaccine is being rolled out in the
               UK, USA and Canada Significant uncertainties remain. How well
               will some of those at highest risk of severe disease (such as
               older people aged >75 years and those with immunocompromising
               conditions) be protected by a vaccine, and for how long? Also,
               to what extent will vaccination protect against infection? This
               will determine the degree of indirect 'herd' protection needed
               through broad vaccine coverage of younger age groups.",
  journal   = "Aust. Prescr.",
  publisher = "NPS MedicineWise",
  volume    =  44,
  number    =  1,
  pages     = "19--25",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; clinical trials; coronavirus; immunisation; vaccine
               safety",
  language  = "en"
}

@ARTICLE{Persad2021-sk,
  title     = "Fair allocation of scarce therapies for {COVID-19}",
  author    = "Persad, Govind and Peek, Monica E and Shah, Seema K",
  abstract  = "The U.S. FDA has issued emergency use authorizations (EUAs) for
               monoclonal antibodies (mAbs) for non-hospitalized patients with
               mild or moderate COVID-19 disease and for individuals exposed to
               COVID-19 as post-exposure prophylaxis. One EUA for an oral
               antiviral drug, molnupiravir, has also been recommended by FDA's
               Antimicrobial Drugs Advisory Committee, and others appear likely
               in the near future. Due to increased demand because of the Delta
               variant, the federal government resumed control over the supply
               and asked states to ration doses. As future variants with
               increased infectivity and/or severity (e.g., potentially the
               Omicron variant) emerge, further rationing may be required. We
               identify relevant ethical principles (i.e., benefiting people
               and preventing harm, equal concern, and mitigating health
               inequities) and priority groups for access to therapies based on
               an integrated approach to population health and medical factors
               (e.g. urgently scarce healthcare workers, persons in
               disadvantaged communities hard hit by COVID-19). Using priority
               categories to allocate scarce therapies effectively
               operationalizes important ethical values. This strategy is
               preferable to the current approach of categorical rules based on
               vaccination, immunocompromise status, or older age, or the ad
               hoc consideration of clinical risk factors.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Shi2021-bd,
  title    = "Rapalogs downmodulate intrinsic immunity and promote cell entry
              of {SARS-CoV-2}",
  author   = "Shi, Guoli and Chiramel, Abhilash I and Majdoul, Saliha and Lai,
              Kin Kui and Das, Sudipto and Beare, Paul A and Andresson,
              Thorkell and Best, Sonja M and Compton, Alex A",
  abstract = "Infection by SARS-CoV-2 generally causes mild symptoms but can
              lead to severe disease and death in certain populations,
              including the immunocompromised. Drug repurposing efforts are
              underway to identify compounds that interfere with SARS-CoV-2
              replication or the immunopathology it can elicit. Rapamycin is
              among those being currently tested in clinical trials for impacts
              on COVID-19 severity. While rapamycin and rapamycin analogs
              (rapalogs) are FDA-approved for use as mTOR inhibitors in
              multiple clinical settings, including cancer, we previously found
              that rapamycin can increase the susceptibility of cells to
              infection by Influenza A virus. In this study, we tested the
              impact of rapalogs on cellular susceptibility to SARS-CoV-2
              infection. We report that rapamycin and rapalogs increased
              SARS-CoV-2 titers in human cervical epithelial and lung
              epithelial cell lines to different extents, and a similar pattern
              of enhancement was observed using pseudovirus incorporating viral
              fusion proteins from SARS-CoV-2, SARS-CoV, MERS, and Influenza A
              Virus. Rapalogs also promoted cell entry driven by SARS-CoV-2
              Spike in nasal cells and primary small airway cells, representing
              proximal and distal ends of the human respiratory tract,
              respectively. Interestingly, cell entry enhancement by the
              rapalog ridaforolimus was cell type-dependent, revealing a
              previously unrecognized functional divergence between rapalogs.
              The differential activity of rapalogs was associated with their
              capacity to induce the degradation of interferon-inducible
              transmembrane (IFITM) proteins, restriction factors that broadly
              inhibit virus infection. Our findings will spur the development
              of mTOR inhibitors that do not suppress the cell's first line of
              antiviral defense.",
  journal  = "bioRxivorg",
  month    =  apr,
  year     =  2021,
  keywords = "COVID-19; IFITM; Influenza; SARS; coronavirus; interferon; mTOR
              inhibitor; membrane fusion; rapalog; rapamycin",
  language = "en"
}

@ARTICLE{Kute2021-qd,
  title     = "{NOTTO} {COVID-19} vaccine guidelines for transplant recipients",
  author    = "Kute, Vivek B and Agarwal, Sanjay K and Prakash, Jai and
               Guleria, Sandeep and Shroff, Sunil and Sharma, Ashish and Varma,
               Prem and Prasad, Narayan and Sahay, Manisha and Gupta, Subhash
               and Sudhindran, S and Krishan, Kewal and Ramesh, Vasanthi and
               Kumar, Sunil",
  abstract  = "In December 2019, novel coronavirus (SARS-CoV-2) infection
               started in Wuhan and resulted in a pandemic within a few weeks'
               time. Organ transplant recipients being at a risk for more
               severe COVID-19 if they get SARS CoV-2 viral infection, COVID-19
               vaccine has a significant role in these patients. The vaccine is
               a safer way to help build protection and would either prevent
               COVID-19 infection or at least diminish the severity of the
               disease. It would also reduce the risk of the continuing
               transmission and enhance herd immunity. Immuno-compromised
               patients should not receive live vaccines as they can cause
               vaccine-related disease and hence the guidelines suggest that
               all transplant recipients should receive age-appropriate
               'inactivated vaccine' as recommended for general population.
               Though trials have not been undertaken on transplant recipients,
               efficacy and safety of COVID-19 vaccine have been scientifically
               documented for few vaccines among the general population.",
  journal   = "Indian J. Nephrol.",
  publisher = "Medknow",
  volume    =  31,
  number    =  2,
  pages     = "89--91",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19 vaccine; NOTTO; guidelines; transplant recipients",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Cihakova2021-jb,
  title     = "High-value laboratory testing for hospitalized {COVID-19}
               patients: a review",
  author    = "Cihakova, Daniela and Streiff, Michael B and Menez, Steven P and
               Chen, Teresa K and Gilotra, Nisha A and Michos, Erin D and Marr,
               Kieren A and Karaba, Andrew H and Robinson, Matthew L and Blair,
               Paul W and Dioverti, Maria V and Post, Wendy S and Cox, Andrea L
               and R Antar, Annukka A",
  abstract  = "We present here an evidence-based review of the utility, timing,
               and indications for laboratory test use in the domains of
               inflammation, cardiology, hematology, nephrology and
               co-infection for clinicians managing the care of hospitalized
               COVID-19 patients. Levels of IL-6, CRP, absolute lymphocyte
               count, neutrophils and neutrophil-to-lymphocyte ratio obtained
               upon admission may help predict the severity of COVID-19.
               Elevated lactate dehydrogenase, ferritin, aspartate
               aminotransferase, and -dimer are associated with severe illness
               and mortality. Elevated cardiac troponin at hospital admission
               can alert clinicians to patients at risk for cardiac
               complications. Elevated proBNP may help distinguish a cardiac
               complication from noncardiac etiologies. Evaluation for
               co-infection is typically unnecessary in nonsevere cases but is
               essential in severe COVID-19, intensive care unit patients, and
               immunocompromised patients.",
  journal   = "Future Virol.",
  publisher = "Future Medicine Ltd",
  volume    =  16,
  number    =  10,
  pages     = "691--705",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; CRP; IL-6; SARS-CoV-2; d-dimer; high value care;
               inpatient; laboratory test; labs; troponin",
  language  = "en"
}

@ARTICLE{Esteban_Ronda2021-tc,
  title     = "Application of validated severity scores for pneumonia caused by
               {SARS-CoV-2}",
  author    = "Esteban Ronda, Violeta and Ruiz Alcaraz, Sandra and Ruiz
               Torregrosa, Paloma and Gim{\'e}nez Suau, Mario and Nofuentes
               P{\'e}rez, Ester and Le{\'o}n Ram{\'\i}rez, Jos{\'e} Manuel and
               Andr{\'e}s, Mariano and Moreno-P{\'e}rez, {\'O}scar and Candela
               Blanes, Alfredo and Gil Carbonell, Joan and Merino de Lucas,
               Esperanza",
  abstract  = "Objectives: Compare the accuracy of PSI, CURB-65, MuLBSTA and
               COVID-GRAM prognostic scores to predict mortality, the need for
               invasive mechanical ventilation (IMV) in patients with pneumonia
               caused by SARS-CoV-2 and assess the coexistence of bacterial
               respiratory tract infection during admission. Methods:
               Retrospective observational study that included hospitalized
               adults with pneumonia caused by SARS-CoV-2 from 15/03 to
               15/05/2020. We excluded immunocompromised patients, nursing home
               residents and those admitted in the previous 14 days for another
               reasons. Analysis of ROC curves was performed, calculating the
               area under the curve for the different scales, as well as
               sensitivity, specificity and predictive values. Results: 208
               patients were enrolled, aged 63 $\pm$ 17 years, 577\% were men.
               38 patients were admitted to ICU (235\%), of these patients 33
               required IMV (868\%), with an overall mortality of 125\%. Area
               under the ROC curves for mortality of the scores were: PSI 082
               (95\% CI 073-091), CURB-65 082 (073-091), MuLBSTA 072 (062-081)
               and COVID-GRAM 086 (070-1). Area under the curve for needing IMV
               was: PSI 073 (95\% CI 064-082), CURB-65 066 (055-077), MuLBSTA
               078 (069-086) and COVID-GRAM 076 (067-085), respectively.
               Patients with bacterial co-infections of the respiratory tract
               were 20 (9,6\%), the most frequent strains being Pseudomonas
               aeruginosa and Klebsiella pneumoniae. Conclusions: In our study,
               the COVID-GRAM score was the most accurate to identify patients
               with higher mortality with pneumonia caused by SARS-CoV-2;
               however, none of these scores accurately predicts the need for
               IMV with ICU admission. 10\% of patients admitted presented
               bacterial respiratory co-infection.",
  journal   = "Med. Cl{\'\i}n. (Engl. Ed.)",
  publisher = "Elsevier BV",
  volume    =  157,
  number    =  3,
  pages     = "99--105",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus; Penumonia; Severity scores",
  language  = "en"
}

@ARTICLE{Gerber2021-jz,
  title     = "Detection of Pneumocystis jirovecii in patients with severe
               {COVID-19}: Diagnostic and therapeutic challenges",
  author    = "Gerber, Victor and Ruch, Yvon and Chamaraux-Tran, Thi{\^e}n-Nga
               and Oulehri, Walid and Schneider, Francis and Lindner, Veronique
               and Greigert, Valentin and Denis, Julie and Brunet, Julie and
               Danion, Fran{\c c}ois",
  abstract  = "Cases of Pneumocystis jirovecii pneumonia (PCP) in patients
               suffering from COVID-19 were described in patients with various
               comorbidities and outcomes. The diagnosis of PCP in these
               patients is difficult due to clinical and radiological
               similarities. We carried out this study in order to better
               describe potentially at-risk patients and their outcomes. We
               retrospectively analyzed all patients with a P. jirovecii PCR
               performed in bronchoalveolar lavage fluid, tracheal aspirate, or
               sputum within a month after the COVID-19 diagnosis. Fifty-seven
               patients with COVID-19 infection were tested for P. jirovecii.
               Among 57 patients with COVID-19, four patients had a concomitant
               positive P. jirovecii PCR. These four patients were elderly with
               a mean age of 78. Two patients were immunocompromised, and the
               two others presented only diabetes mellitus. Three patients
               presented an ARDS requiring transfer to the ICU and mechanical
               ventilation. All patients presented lymphocytopenia. Three
               patients had probable PCP, and one had proven PCP. All patients
               died within two months after hospital admission. These
               co-infections are rare but severe, therefore, PCP should be
               considered in case of worsening of the condition of patients
               with severe COVID-19.",
  journal   = "J. Fungi (Basel)",
  publisher = "MDPI AG",
  volume    =  7,
  number    =  8,
  pages     = "585",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Pneumocystis jirovecii; SARS-CoV-2; fungi;
               pneumocystosis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Malik2021-yf,
  title     = "Outpatient management of {COVID-19} with monoclonal antibody
               therapy in a young renal transplant patient",
  author    = "Malik, Bilal and Kalantary, Atefeh and Rikabi, Kamal and
               Abdelazeem, Basel and Kunadi, Arvind",
  abstract  = "At baseline, solid organ transplant recipients are at an
               increased risk for infectious complications due to the complex
               immunosuppressive regimens. The available data in renal
               transplant patients who contract coronavirus disease 2019
               (COVID-19) demonstrates dangerously high mortality rates (33\%)
               in those who require hospitalization and/or ICU level care.
               Interestingly, the data for transplant patients who do not
               require hospitalization shows significantly lower mortality
               (3\%) despite being on an immunosuppressive regimen. We present
               the case of a young male patient with a history of renal
               transplant who tested positive for COVID-19; he was mildly
               symptomatic with cough, sinusitis, and headache, was worked up
               as an outpatient, and treated as an outpatient with bamlanivimab
               monotherapy with no adjustment to his immunosuppressive regimen.
               This case aims to highlight the possibility of safely managing
               mild cases of COVID-19 in solid organ transplant patients
               receiving immunosuppression as an outpatient with monoclonal
               antibody (mAb) therapy.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  9,
  pages     = "e17672",
  month     =  sep,
  year      =  2021,
  keywords  = "covid-19; immunocompromised patient; monoclonal antibodies;
               renal transplant; solid organ transplant",
  language  = "en"
}

@ARTICLE{Cronyn2021-se,
  title     = "Trichosporon asahii urinary tract infection in a patient with
               severe {COVID-19}",
  author    = "Cronyn, Verschoyle and Howard, John and Chiang, Leslie and Le,
               Lisa and Tims-Cook, Zandraetta and Gertz, Alida M",
  abstract  = "Trichosporon asahii is a yeast-like basidiomycete that is an
               emerging opportunistic infection in immunocompromised patients.
               Urinary tract infections due to T. asahii are rarely reported in
               the literature and typically seen only in immunocompromised
               patients. In addition to being immunocompromised, critically ill
               COVID-19 patients often have prolonged exposure to antibiotics,
               corticosteroids, and Foley catheters, which further increases
               their susceptibility to infection with T. asahii. There are
               limited case reports documenting successful treatment of T.
               asahii among hospitalized patients, particularly among COVID-19
               patients, in the literature. Therefore, it is important that
               successful treatment regimens be reported. Here, we report a
               case of T. asahii urinary tract infection successfully treated
               with fluconazole and voriconazole in a 73-year-old male
               recovering from COVID-19. Urinary tract infections with T.
               asahii should be considered in persistently febrile COVID-19
               patients with fungal urinary tract infections since prompt
               recognition and treatment can reduce the risk of disseminated
               disease and early mortality.",
  journal   = "Case Rep. Infect. Dis.",
  publisher = "Hindawi Limited",
  volume    =  2021,
  pages     = "6841393",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Demaret2021-ne,
  title     = "Impaired functional T-cell response to {SARS-CoV-2} after two
               doses of {BNT162b2} {mRNA} vaccine in older people",
  author    = "Demaret, Julie and Corroyer-Simovic, B{\'e}n{\'e}dicte and
               Alidjinou, Enagnon Kazali and Goffard, Anne and Trauet, Jacques
               and Miczek, Sophie and Vuotto, Fanny and Dendooven, Arnaud and
               Huvent-Grelle, Dominique and Podvin, Juliette and Dreuil, Daniel
               and Faure, Karine and Deplanque, Dominique and Bocket, Laurence
               and Duhamel, Alain and Labreuche, Julien and Sobaszek, Annie and
               Hisbergues, Michael and Puisieux, Francois and Labalette, Myriam
               and Lef{\`e}vre, Guillaume",
  abstract  = "Long-term care facility (LTCF) older residents display
               physiological alterations of cellular and humoral immunity that
               affect vaccine responses. Preliminary reports suggested a low
               early postvaccination antibody response against severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this
               study was to focus on the specific T-cell response. We
               quantified S1-specific IgG, neutralizing antibody titers, total
               specific IFN$\gamma$-secreting T cells by ELISpot, and
               functionality of CD4+- and CD8+-specific T cells by flow
               cytometry, after two doses of the BNT162b2 vaccine in younger
               and older people, with and without previous COVID-19 infection
               (hereafter referred to as COVID-19-recovered and COVID-19-naive
               subjects, respectively). Frailty, nutritional, and
               immunosenescence parameters were collected at baseline in
               COVID-19-naive older people. We analyzed the immune response in
               129 young adults (median age 44.0 years) and 105 older residents
               living in a LCTF (median age 86.5 years), 3 months after the
               first injection. Humoral and cellular memory responses were
               dramatically impaired in the COVID-19-naive older (n = 54)
               compared with the COVID-19-naive younger adults (n = 121).
               Notably, older participants' neutralizing antibodies were 10
               times lower than the younger's antibody titers (p < 0.0001) and
               LCTF residents also had an impaired functional T-cell response:
               the frequencies of IFN$\gamma$+ and
               IFN$\gamma$+IL-2+TNF$\alpha$+ cells among specific CD4+ T cells,
               and the frequency of specific CD8+ T cells were lower in
               COVID-19-naive older participants than in COVID-19-naive young
               adults (p < 0.0001 and p = 0.0018, respectively). However,
               COVID-19-recovered older participants (n = 51) had greater
               antibody and T-cell responses, including IFN$\gamma$+ and
               IFN$\gamma$+IL-2+TNF$\alpha$+-specific CD4+ T cells (p <
               0.0001), as well as TNF$\alpha$+-specific CD8+ T cells (p <
               0.001), than COVID-19-naive older adults. We also observed that
               ``inflammageing'' and particularly high plasma levels of
               TNF$\alpha$ was associated to poor antibody response in the
               older participants. In conclusion, our results show that the
               COVID-19-naive older people had low counts and impaired specific
               CD4+ and CD8+ T cells, in addition to impaired antibody
               response, and that specific studies are warranted to assess the
               efficiency of SARS-CoV-2 mRNA-based vaccines, as in other
               immunocompromised subjects. Our study also shows that, despite
               their physiological alterations of immunity, vaccination is
               highly efficient in boosting the prior natural memory response
               in COVID-19-recovered older people.",
  journal   = "Front. Immunol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "778679",
  month     =  nov,
  year      =  2021,
  keywords  = "SARS - CoV - 2; T cells response; mRNA vaccination; older people
               and ageing; vaccine",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Scalia2021-tu,
  title    = "Spontaneous anterior cervicothoracic spinal epidural hematoma
              extending to clivus in {SARS-CoV-2} infection",
  author   = "Scalia, Gianluca and Umana, Giuseppe Emmanuele and Marrone,
              Salvatore and Graziano, Francesca and Giuffrida, Angelo and
              Ponzo, Giancarlo and Giuffrida, Massimiliano and Furnari, Massimo
              and Galvano, Gianluca and Bonanno, Santo and Nicoletti, Giovanni
              Federico",
  abstract = "Background: The treatment of spontaneous spinal epidural
              hematomas (SSEHs), depending on the lesion size and
              myeloradicular involvement, can be surgical or conservative.
              Here, we present a 55-year-old patient who sustained a SSEH
              several months following a systemic SARS-CoV-2 infection. Case
              Description: A 55-year-old immunocompromised female (i.e.,
              history 17 years ago of Hodgkin's lymphoma, nodular sclerosis
              variant) recently developed a SARS-CoV-2 infection treated with
              nonsteroidal anti-inflammatory agents. She then reported the
              sudden onset of cervicodorsalgia after a slight cervical
              flexion/extension maneuver. The brain and cervicothoracic spine
              MRI studies documented a clival anterior spinal epidural hematoma
              with maximum spinal compression at the T1-T2 level; it also
              extended inferiorly to the T6 level. Two weeks later, the
              follow-up MRI showed a remarkable reduction in the
              anteroposterior diameter of the hematoma that correlated with
              significant neurological improvement and almost complete pain
              regression. She was discharged after a total 15-day hospital
              stay, with complete symptoms relief. Conclusion: We present a
              55-year-old chronically immunocompromised (i.e., due to the
              history of Hodgkin's lymphoma) female who, following a SARS-CoV-2
              infection, developed an anterior SSEH extending from the clivus
              to the T6 spinal level that spontaneously regressed without
              surgical intervention.",
  journal  = "Surg. Neurol. Int.",
  volume   =  12,
  pages    = "181",
  month    =  apr,
  year     =  2021,
  keywords = "COVID-19; Epidural; Hematoma; Spinal; Spontaneous",
  language = "en"
}

@ARTICLE{Panda2021-vf,
  title     = "Management of {COVID-19-related} severe acute respiratory
               distress syndrome in a patient with active human
               immunodeficiency virus infection",
  author    = "Panda, Rajesh and Singh, Pooja and Saigal, Saurabh and Karna,
               Sunaina T",
  abstract  = "Our understanding of the risk of developing severe coronavirus
               disease 2019 (COVID-19) infection in the population living with
               HIV is still evolving. In this report, we discuss the successful
               management of COVID-19-related acute respiratory distress
               syndrome (ARDS) in an active case of the human immunodeficiency
               virus (HIV) infection; the patient had an atypical presentation
               characterized by very rapid progression in the severity of
               respiratory symptoms needing invasive mechanical ventilation.
               The way the case was managed broke with the custom that
               mechanical ventilation in patients with COVID-19-related ARDS
               should be deferred as much as possible since the chances of
               survival are minimal, especially in immunocompromised patients.
               Although patients with HIV infection are immunocompromised and
               at risk of secondary infection, young age, lack of
               comorbidities, and early intubation may result in a good
               prognosis. ARDS ventilation strategy, good infection control
               practices, and individualized patient care can help to wean
               patients off mechanical ventilation. Recent evidence does not
               support the use of antiretroviral drugs for prophylaxis or
               treatment of COVID-19 infection.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  9,
  pages     = "e18045",
  month     =  sep,
  year      =  2021,
  keywords  = "acute respiratory distress syndrome; co-infection; covid-19;
               human immunodeficiency virus; sars-cov2",
  language  = "en"
}

@ARTICLE{Du_Plessis2021-ci,
  title     = "Cancer and Covid-19: Collectively catastrophic",
  author    = "du Plessis, M and Fourie, C and Riedemann, J and de Villiers, W
               J S and Engelbrecht, A M",
  abstract  = "The Covid-19 panactivated in most cancers and is associated with
               prolonged demic has spread rapidly across the globe, resulting
               in more than 3 million deaths worldwide. The symptoms of
               Covid-19 are usually mild and non-specific, however in some
               cases patients may develop acute respiratory distress syndrome
               (ARDS) and systemic inflammation. Individuals with inflammatory
               or immunocompromising illnesses, such as cancer, are more
               susceptible to develop ARDS and have higher rates of mortality.
               This is mediated through an initial hyperstimulated immune
               response which results in elevated levels of pro-inflammatory
               cytokines and a subsequent cytokine storm. This potentiates
               positive feedback loops which are unable to be balanced by
               anti-inflammatory mediators. Therefore, elevated levels of
               IL-1$\beta$, as a result of NLRP3 inflammasome activation, as
               well as IL-6 and TNF-$\alpha$ amongst many others, contribute to
               the progression of various cancer types. Furthermore, Covid-19
               progression is associated with the depletion of CD8+ and CD4+ T
               cells, B cell and natural killer cell numbers. Collectively, a
               Covid-19-dependent pro-inflammatory profile and immune
               suppression promotes the optimal microenvironment for
               tumourigenesis, initiation and immune evasion of malignant
               cells, tumour progression and metastasis as well as cancer
               recurrence. There are, however, therapeutic windows of
               opportunity that may combat both Covid-19 and cancer to improve
               patient outcomes.",
  journal   = "Cytokine Growth Factor Rev.",
  publisher = "Elsevier BV",
  month     =  oct,
  year      =  2021,
  keywords  = "Cancer; Covid-19; Inflammation; NLRP3 inflammasome",
  language  = "en"
}

@ARTICLE{Marsh2021-wu,
  title     = "{COVID-19} and vaccination in the setting of neurologic disease:
               An emerging issue in neurology",
  author    = "Marsh, Elisabeth B and Kornberg, Michael and Kessler, Kevin and
               Haq, Ihtsham and Patel, Anup D and Nath, Avindra and Schierman,
               Becky and Jones, Jr, Lyell K and {Quality Committee of the
               American Academy of Neurology*}",
  abstract  = "The COVID-19 pandemic caused by the SARS-CoV-2 virus has left
               many unanswered questions for patients with neurological
               disorders and the providers caring for them. Elderly and
               immunocompromised patients are at increased risk for severe
               symptoms due to COVID-19, and the virus may increase symptoms of
               underlying neurological illness, particularly for those with
               significant bulbar and respiratory weakness or other neurologic
               disability. Emerging SARS-CoV-2 vaccines offer substantial
               protection from symptomatic infection, but both patients and
               providers may have concerns regarding theoretical risks of
               vaccination, including vaccine safety and efficacy in the
               context of immunotherapy and the potential for precipitating or
               exacerbating neurological symptoms. In this statement on behalf
               of the Quality Committee of the AAN we review the current
               literature, focusing on COVID-19 infection in adults with
               neurological disease, in order to elucidate risks and benefits
               of vaccination in these individuals. Based on existing evidence,
               neurologists should recommend COVID-19 vaccination to their
               patients. For those patients being treated with immunotherapies,
               attention should be paid to timing of vaccination with respect
               to treatment and the potential for an attenuated immune
               response.",
  journal   = "Neurology",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  97,
  number    =  15,
  pages     = "720--728",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19 vaccine; immunosuppression; infection; neurological
               disease",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Kula2021-kv,
  title     = "Invasive mould disease in fatal {COVID-19}: a systematic review
               of autopsies",
  author    = "Kula, Brittany E and Clancy, Cornelius J and Hong Nguyen, M and
               Schwartz, Ilan S",
  abstract  = "Invasive mould disease (IMD) might affect up to a third of
               critically ill patients with COVID-19. COVID-19-associated
               pulmonary aspergillosis (CAPA) is typically diagnosed on the
               basis of a combination of non-specific clinical, radiographical,
               and mycological findings, but whether most cases represent
               invasive disease is unresolved. We systematically reviewed
               autopsy series of three or more decedents with COVID-19 for
               evidence of IMD. We searched PubMed, Web of Science, OVID
               (Embase), and medRxiv for studies in English or French published
               from Jan 1, 2019, to Sept 26, 2020. We identified 1070
               references, of which 50 studies met the criteria. These studies
               described autopsies from 677 decedents, with individual-level
               data for 443 decedents. The median age was 700 years (IQR
               570-790). Of decedents with individual-level data, 133 (30\%)
               had diabetes, 97 (22\%) had pre-existing lung disease, and 27
               (6\%) had immunocompromising conditions. Of 548 decedents with
               such data, 320 (58\%) received invasive mechanical ventilation;
               among 140 decedents for whom this was known, ventilation was for
               a median of 90 days (IQR 50-200). Treatment included
               immunomodulation in 60 decedents and antifungals in 50
               decedents. Autopsy-proven IMD occurred in 11 (2\%) of 677
               decedents, including eight CAPA, two unspecified IMD, and one
               disseminated mucormycosis. Among 320 decedents who received
               mechanical ventilation, six (2\%) had IMD. We conclude that IMD,
               including CAPA, is an uncommon autopsy finding in COVID-19.",
  journal   = "Lancet Microbe",
  publisher = "Elsevier BV",
  volume    =  2,
  number    =  8,
  pages     = "e405--e414",
  month     =  aug,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Georgakopoulou2021-gq,
  title     = "Exacerbation of bronchiectasis by Pseudomonas putida
               complicating {COVID-19} disease: A case report",
  author    = "Georgakopoulou, Vasiliki Epameinondas and Avramopoulos, Pantelis
               and Papalexis, Petros and Bitsani, Aikaterini and Damaskos,
               Christos and Garmpi, Anna and Gkoufa, Aikaterini and Garmpis,
               Nikolaos and Mantzouranis, Konstantinos and Chlapoutakis,
               Serafeim and Sklapani, Pagona and Trakas, Nikolaos and
               Spandidos, Demetrios A",
  abstract  = "Novel coronavirus infection presents with greater severity in
               individuals with comorbid chronic lung diseases. Bronchiectasis
               is an illness characterized by permanent enlargement of the
               airways, presenting with chronic cough and sputum production and
               vulnerability to lung infections. Bronchiectasis is not a common
               comorbid disease in patients with COVID-19 disease and
               bronchiectasis exacerbation rates were decreased during the
               pandemic. However, COVID-19 disease is associated with worse
               outcomes in patients with bronchiectasis and patients with
               bronchiectasis are more susceptible to SARS-CoV-2 infection
               development. Pseudomonas putida is an opportunistic pathogen,
               causing infections mostly in immunocompromised hosts and is not
               a frequent bacterial colonizer in patients with bronchiectasis.
               This present study reports a rare case of exacerbation of
               bronchiectasis by Pseudomonas putida complicating COVID-19
               disease in an immunocompetent 70-year-old woman. Clinicians
               should be aware that SARS-CoV-2 infection is probably a
               precipitating factor of bronchiectasis exacerbation while
               bronchiectasis is a risk factor for greater severity of
               SARS-CoV-2 infection.",
  journal   = "Exp. Ther. Med.",
  publisher = "Spandidos Publications",
  volume    =  22,
  number    =  6,
  pages     = "1452",
  month     =  dec,
  year      =  2021,
  keywords  = "bronchiectasis; coronavirus; disease exacerbation;
               immunocompetence; infection",
  language  = "en"
}

@ARTICLE{Liu2021-jr,
  title    = "A retrospective analysis of {COVID-19} {mRNA} vaccine
              breakthrough infections - risk factors and vaccine effectiveness",
  author   = "Liu, Cong and Lee, Junghwan and Ta, Casey and Soroush, Ali and
              Rogers, James R and Kim, Jae Hyun and Natarajan, Karthik and
              Zucker, Jason and Weng, Chunhua",
  abstract = "Importance: Little is known about COVID vaccine breakthrough
              infections and their risk factors. Objective: To identify risk
              factors associated with COVID-19 breakthrough infections among
              vaccinated individuals and to reassess the effectiveness of
              COVID-19 vaccination against severe outcomes using real-world
              data. Design Setting and Participants: We conducted a series of
              observational retrospective analyses using the electronic health
              records (EHRs) of Columbia University Irving Medical Center/New
              York Presbyterian (CUIMC/NYP) up to September 21, 2021. New York
              adult residence with PCR test records were included in this
              analysis. Main Outcomes and Measures: Poisson regression was used
              to assess the association between breakthrough infection rate in
              vaccinated individuals and multiple risk factors - including
              vaccine brand, demographics, and underlying conditions - while
              adjusting for calendar month, prior number of visits and
              observational days. Logistic regression was used to assess the
              association between vaccine administration and infection rate by
              comparing a vaccinated cohort to a historically matched cohort in
              the pre-vaccinated period. Infection incident rate was also
              compared between vaccinated individuals and longitudinally
              matched unvaccinated individuals. Cox regression was used to
              estimate the association of the vaccine and COVID-19 associated
              severe outcomes by comparing breakthrough cohort and two matched
              unvaccinated infection cohorts. Results: Individuals vaccinated
              with Pfizer/BNT162b2 (IRR against Moderna/mRNA-1273 [95\% CI]:
              1.66 [1.17 - 2.35]); were male (1.47 [1.11 - 1.94\%]); and had
              compromised immune systems (1.48 [1.09 - 2.00]) were at the
              highest risk for breakthrough infections. Vaccinated individuals
              had a significant lower infection rate among all subgroups. An
              increased incidence rate was found in both vaccines over the
              time. Among individuals infected with COVID-19, vaccination
              significantly reduced the risk of death (adj. HR: 0.20 [0.08 -
              0.49]). Conclusion and Relevance: While we found both mRNA
              vaccines were effective, Moderna/mRNA-1273 had a lower incidence
              rate of breakthrough infections. Both vaccines had increased
              incidence rates over the time. Immunocompromised individuals were
              among the highest risk groups experiencing breakthrough
              infections. Given the rapidly changing nature of the SARS-CoV-2,
              continued monitoring and a generalizable analysis pipeline are
              warranted to inform quick updates on vaccine effectiveness in
              real time. Key Points: Question: What risk factors contribute to
              COVID-19 breakthrough infections among mRNA vaccinated
              individuals? How do clinical outcomes differ between vaccinated
              but still SARS-CoV-2 infected individuals and non-vaccinated,
              infected individuals?Findings: This retrospective study uses
              CUIMC/NYP EHR data up to September 21, 2021. Individuals who were
              vaccinated with Pfizer/BNT162b2, male, and had compromised immune
              systems had significantly higher incidence rate ratios of
              breakthrough infections. Comparing demographically matched
              pre-vaccinated and unvaccinated individuals, vaccinated
              individuals had a lower incidence rate of SARS-CoV-2 infection
              among all subgroups.Meaning: Leveraging real-world EHR data
              provides insight on who may optimally benefit from a booster
              COVID-19 vaccination.",
  journal  = "medRxiv",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Nambiar2021-bh,
  title     = "Mycotic infections - mucormycosis and oral candidiasis
               associated with Covid-19: a significant and challenging
               association",
  author    = "Nambiar, Manjusha and Varma, Sudhir Rama and Jaber, Mohamed and
               Sreelatha, S V and Thomas, Biju and Nair, Arathi S",
  abstract  = "Introduction: Bacterial and fungal secondary infections
               following COVID-19 disease are widely being reported and are an
               area that should receive careful attention. Mucormycosis is a
               fatal fungal condition affecting immunocompromised patients
               caused by a group of mold mucoromycetes. Candida albicans (C.
               albicans) is an oral commensal present in almost 40-65\% of
               healthy oral cavities in adults. Several cases of mucormycosis
               and oral candidiasis have been reported lately in COVID-19
               patients, and it may elevate the associated risks of morbidity
               and mortality. Materials and Methods: Articles were taken from a
               period of 2020 to April 2021 using search sources such as
               Cochrane, PubMed, Fungiscope and Mycobank using keywords
               mucormycosis, Black fungus, oral candidiasis, white fungus,
               COVID-19, Sars-Cov-2. Discussion: The development of oral
               mucocutaneous lesions, such as mucormycosis and candidiasis in
               COVID-19 patients could be due to inhaling spores resulting in
               pulmonary and/or sinus congestion and prolonged mechanical
               ventilation in the ICU settings and the long-term use of
               broad-spectrum antibiotics respectively. The onset of
               candidiasis after the emergence of COVID-19 clinical signs and
               symptoms varied considerably and is reported within 1-30 days in
               most of the cases reported in the literature. Biofilms present
               on the denture surfaces are predisposing factors to oral
               candidiasis. We aim to summarize the limited data available
               regarding diagnosis, clinical presentation, and therapeutic
               approaches for the management of Mucormycosis and oral
               candidiasis in COVID-19 patients. Conclusion: Careful monitoring
               of oral lesions should be instituted through interdisciplinary
               telemedicine and teleconsultation to aid in primary diagnosis,
               thereby avoiding personal attendance during the pandemic. Dental
               practitioners should be included among the interdisciplinary
               teams for exhaustive intraoral examination and reduce the risk
               of morbidity and mortality.",
  journal   = "J. Oral Microbiol.",
  publisher = "Informa UK Limited",
  volume    =  13,
  number    =  1,
  pages     = "1967699",
  month     =  aug,
  year      =  2021,
  keywords  = "Mucormycosis; Oral candidiasis; black fungus; covid-19;
               sars-coV-2; white fungus",
  language  = "en"
}

@ARTICLE{Ma2021-oo,
  title    = "{CAR-NK} cells effectively target the {D614} and {G614}
              {SARS-CoV-2-infected} cells",
  author   = "Ma, Minh and Badeti, Saiaditya and Chen, Chih-Hsiung and Pinter,
              Abraham and Jiang, Qingkui and Shi, Lanbo and Zhou, Renping and
              Xu, Huanbin and Li, Qingsheng and Gause, William and Liu,
              Dongfang",
  abstract = "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is
              highly contagious presenting a significant public health issue.
              Current therapies used to treat coronavirus disease 2019
              (COVID-19) include monoclonal antibody cocktail, convalescent
              plasma, antivirals, immunomodulators, and anticoagulants, though
              the current therapeutic options remain limited and expensive. The
              vaccines from Pfizer and Moderna have recently been authorized
              for emergency use, which are invaluable for the prevention of
              SARS-CoV-2 infection. However, their long-term side effects are
              not yet to be documented, and populations with immunocompromised
              conditions (e.g., organ-transplantation and immunodeficient
              patients) may not be able to mount an effective immune response.
              In addition, there are concerns that wide-scale immunity to
              SARS-CoV-2 may introduce immune pressure that could select for
              escape mutants to the existing vaccines and monoclonal antibody
              therapies. Emerging evidence has shown that chimeric antigen
              receptor (CAR)- natural killer (NK) immunotherapy has potent
              antitumor response in hematologic cancers with minimal adverse
              effects in recent studies, however, the potentials of CAR-NK
              cells in preventing and treating severe cases of COVID-19 has not
              yet been fully exploited. Here, we improve upon a novel approach
              for the generation of CAR-NK cells for targeting SARS-CoV-2 and
              its D614G mutant. CAR-NK cells were generated using the scFv
              domain of S309 (henceforward, S309-CAR-NK), a SARS-CoV and
              SARS-CoV-2 neutralizing antibody that targets the highly
              conserved region of SARS-CoV-2 spike (S) glycoprotein, therefore
              would be more likely to recognize different variants of
              SARS-CoV-2 isolates. S309-CAR-NK cells can specifically bind to
              pseudotyped SARS-CoV-2 virus and its D614G mutant. Furthermore,
              S309-CAR-NK cells can specifically kill target cells expressing
              SARS-CoV-2 S protein in vitro and show superior killing activity
              and cytokine production, compared to that of the recently
              published CR3022-CAR-NK cells. Thus, these results pave the way
              for generating 'off-the-shelf' S309-CAR-NK cells for treatment in
              high-risk individuals as well as provide an alternative strategy
              for patients unresponsive to current vaccines.",
  journal  = "bioRxivorg",
  month    =  jan,
  year     =  2021,
  language = "en"
}

@ARTICLE{Guguloth2021-pp,
  title     = "A mechanistic review on plant-derived natural inhibitors of
               human coronaviruses with emphasis on {SARS-COV-1} and
               {SARS-COV-2}",
  author    = "Guguloth, Sai Krishna and {Lakshmi A R} and Rajendran, Radhika
               and Rajaram, Kaushik and Chinnasamy, Thirunavukkarasu and Huang,
               Jian-Dong and Zhang, Hongjie and Senapati, Sanjib and
               Durairajan, Siva Sundara Kumar",
  abstract  = "Coronaviruses have been receiving continuous attention worldwide
               as they have caused a serious threat to global public health.
               This group of viruses is named so as they exhibit characteristic
               crown-like spikes on their protein coat. SARS-CoV-2, a type of
               coronavirus that emerged in 2019, causes severe infection in the
               lower respiratory tract of humans and is often fatal in
               immunocompromised individuals. No medications have been approved
               so far for the direct treatment of SARS-CoV-2 infection, and the
               currently available treatment options rely on relieving the
               symptoms. The medicinal plants occurring in nature serve as a
               rich source of active ingredients that could be utilized for
               developing pharmacopeial and non-pharmacopeial/synthetic drugs
               with antiviral properties. Compounds obtained from certain
               plants have been used for directly and selectively inhibiting
               different coronaviruses, including SARS-CoV, MERS-CoV, and
               SARS-CoV-2. The present review discusses the potential natural
               inhibitors against the highly pathogenic human coronaviruses,
               with a systematic elaboration on the possible mechanisms of
               action of these natural compounds while acting in the different
               stages of the life cycle of coronaviruses. Moreover, through a
               comprehensive exploration of the existing literature in this
               regard, the importance of such compounds in the research and
               development of effective and safe antiviral agents is discussed.
               We focused on the mechanism of action of several natural
               compounds along with their target of action. In addition, the
               immunomodulatory effects of these active components in the
               context of human health are elucidated. Finally, it is suggested
               that the use of traditional medicinal plants is a novel and
               feasible remedial strategy against human coronaviruses.",
  journal   = "Curr. Drug Targets",
  publisher = "Bentham Science Publishers Ltd.",
  volume    =  22,
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Human Coronaviruses; MERS-CoV; Natural inhibitors;
               SARS-CoV; SARS-CoV-2",
  language  = "en"
}

@ARTICLE{Pratapa2021-yt,
  title    = "Caring for cancer patients during corona {pandemic-(COVID-19)-A}
              narrative review",
  author   = "Pratapa, Sree Karthik and Acharya, Sourya and Mamidipalli, Sai
              Spoorthy and Andhale, Amol",
  abstract = "Background Coronavirus disease 2019, the third pandemic of 21st
              century which has brought the whole world under panic, is caused
              by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
              a zoonotic beta coronavirus sharing phylogenetic, genomic
              similarities with SARS virus and Middle East Respiratory Syndrome
              virus. Specific Concerns Cancer patients are at double the risk
              than normal patients since these patients are at
              immunocompromised state. WHO guidelines advice the patients to
              plan only emergency hospital visits only till the pandemic
              persists. Should meet patient/visitors in a well-ventilated room
              or outdoors and maintain at least 2 m distance between the
              visitor/patients. It also encourages the patient to refill the
              prescribed medications in well advance and to stay physically
              active, if possible. Discussion The World Health Organizations'
              isolate, trace, test, treat policy needs to be followed to
              protect these high-risk patients from this global pandemic.].",
  journal  = "South Asian J. Cancer",
  volume   =  10,
  number   =  1,
  pages    = "19--22",
  month    =  jan,
  year     =  2021,
  keywords = "COVID-19; cancer; coronavirus; immunosuppressive state; myths;
              pandemic",
  language = "en"
}

@ARTICLE{Bailly2021-gq,
  title     = "Persistent {COVID-19} in an immunocompromised host treated by
               {SARS-CoV-2-specific} monoclonal antibodies",
  author    = "Bailly, Benoit and P{\'e}r{\'e}, Helene and Veyer, David and
               Berceanu, Ana and Daguindau, Etienne and Roux, Pauline and
               Hermine, Olivier and de Lamballerie, Xavier and Bastard, Paul
               and Lacombe, Karine and Autran, Brigitte and Angelot Delettre,
               Fanny and Casanova, Jean Laurent and Imbeaud, Sandrine and
               Clairet, Anne Laure and Kroemer, Marie and Spehner, Laurie and
               Robillard, Nicolas and Puech, Julien and Marty-Quinternet,
               Sol{\`e}ne and Lepiller, Quentin and Chirouze, Catherine and
               Bouiller, Kevin",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Bergman2021-tf,
  title     = "Safety and efficacy of the {mRNA} {BNT162b2} vaccine against
               {SARS-CoV-2} in five groups of immunocompromised patients and
               healthy controls in a prospective open-label clinical trial",
  author    = "Bergman, Peter and Blennow, Ola and Hansson, Lotta and Mielke,
               Stephan and Nowak, Piotr and Chen, Puran and S{\"o}derdahl,
               Gunnar and {\"O}sterborg, Anders and Smith, C I Edvard and
               Wullimann, David and Vesterbacka, Jan and Lindgren, Gustaf and
               Blixt, Lisa and Friman, Gustav and Wahren-Borgstr{\"o}m, Emilie
               and Nordlander, Anna and Gomez, Angelica Cuapio and Akber, Mira
               and Valentini, Davide and Norlin, Anna-Carin and Thalme, Anders
               and Bogdanovic, Gordana and Muschiol, Sandra and Nilsson, Peter
               and Hober, Sophia and Lor{\'e}, Karin and Chen, Margaret
               S{\"a}llberg and Buggert, Marcus and Ljunggren, Hans-Gustaf and
               Ljungman, Per and Aleman, Soo and {COVAXID-collaborator group
               (shown separately)}",
  abstract  = "BACKGROUND: Patients with immunocompromised disorders have
               mainly been excluded from clinical trials of vaccination against
               COVID-19. Thus, the aim of this prospective clinical trial was
               to investigate safety and efficacy of BNT162b2 mRNA vaccination
               in five selected groups of immunocompromised patients and
               healthy controls. METHODS: 539 study subjects (449 patients and
               90 controls) were included. The patients had either primary
               (n=90), or secondary immunodeficiency disorders due to human
               immunodeficiency virus infection (n=90), allogeneic
               hematopoietic stem cell transplantation/CAR T cell therapy
               (n=90), solid organ transplantation (SOT) (n=89), or chronic
               lymphocytic leukemia (CLL) (n=90). The primary endpoint was
               seroconversion rate two weeks after the second dose. The
               secondary endpoints were safety and documented SARS-CoV-2
               infection. FINDINGS: Adverse events were generally mild, but one
               case of fatal suspected unexpected serious adverse reaction
               occurred. 72.2\% of the immunocompromised patients seroconverted
               compared to 100\% of the controls (p=0.004). Lowest
               seroconversion rates were found in the SOT (43.4\%) and CLL
               (63.3\%) patient groups with observed negative impact of
               treatment with mycophenolate mofetil and ibrutinib,
               respectively. INTERPRETATION: The results showed that the mRNA
               BNT162b2 vaccine was safe in immunocompromised patients. Rate of
               seroconversion was substantially lower than in healthy controls,
               with a wide range of rates and antibody titres among predefined
               patient groups and subgroups. This clinical trial highlights the
               need for additional vaccine doses in certain immunocompromised
               patient groups to improve immunity. FUNDING: Knut and Alice
               Wallenberg Foundation, the Swedish Research Council,
               Nordstjernan AB, Region Stockholm, Karolinska Institutet, and
               organizations for PID/CLL-patients in Sweden.",
  journal   = "EBioMedicine",
  publisher = "Elsevier BV",
  volume    =  74,
  number    =  103705,
  pages     = "103705",
  month     =  nov,
  year      =  2021,
  keywords  = "CAR-T; HIV; Immunocompromised patients; Primary
               Immunodeficiency; chronic lymphocytic leukemia; human stem-cell
               transplantation; mRNA BNT162b2 vaccine; solid organ
               transplantation",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tenforde2021-sn,
  title     = "Effectiveness of {SARS-CoV-2} {mRNA} vaccines for preventing
               Covid-19 hospitalizations in the United States",
  author    = "Tenforde, Mark W and Patel, Manish M and Ginde, Adit A and
               Douin, David J and Talbot, H Keipp and Casey, Jonathan D and
               Mohr, Nicholas M and Zepeski, Anne and Gaglani, Manjusha and
               McNeal, Tresa and Ghamande, Shekhar and Shapiro, Nathan I and
               Gibbs, Kevin W and Files, D Clark and Hager, David N and Shehu,
               Arber and Prekker, Matthew E and Erickson, Heidi L and Exline,
               Matthew C and Gong, Michelle N and Mohamed, Amira and Henning,
               Daniel J and Peltan, Ithan D and Brown, Samuel M and Martin,
               Emily T and Monto, Arnold S and Khan, Akram and Hough, C Terri
               and Busse, Laurence and Ten Lohuis, Caitlin C and Duggal,
               Abhijit and Wilson, Jennifer G and Gordon, Alexandra June and
               Qadir, Nida and Chang, Steven Y and Mallow, Christopher and
               Gershengorn, Hayley B and Babcock, Hilary M and Kwon, Jennie H
               and Halasa, Natasha and Chappell, James D and Lauring, Adam S
               and Grijalva, Carlos G and Rice, Todd W and Jones, Ian D and
               Stubblefield, William B and Baughman, Adrienne and Womack,
               Kelsey N and Lindsell, Christopher J and Hart, Kimberly W and
               Zhu, Yuwei and Olson, Samantha M and Stephenson, Meagan and
               Schrag, Stephanie J and Kobayashi, Miwako and Verani, Jennifer R
               and Self, Wesley H and {Influenza and Other Viruses in the
               Acutely Ill (IVY) Network}",
  abstract  = "BACKGROUND: As SARS-CoV-2 vaccination coverage increases in the
               United States (US), there is a need to understand the real-world
               effectiveness against severe Covid-19 and among people at
               increased risk for poor outcomes. METHODS: In a multicenter
               case-control analysis of US adults hospitalized March 11-May 5,
               2021, we evaluated vaccine effectiveness to prevent Covid-19
               hospitalizations by comparing odds of prior vaccination with an
               mRNA vaccine (Pfizer-BioNTech or Moderna) between cases
               hospitalized with Covid-19 and hospital-based controls who
               tested negative for SARS-CoV-2. RESULTS: Among 1212
               participants, including 593 cases and 619 controls, median age
               was 58 years, 22.8\% were Black, 13.9\% were Hispanic, and
               21.0\% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 (Alpha)
               was the most common variant (67.9\% of viruses with lineage
               determined). Full vaccination (receipt of two vaccine doses
               $\geq$14 days before illness onset) had been received by 8.2\%
               of cases and 36.4\% of controls. Overall vaccine effectiveness
               was 87.1\% (95\% CI: 80.7 to 91.3\%). Vaccine effectiveness was
               similar for Pfizer-BioNTech and Moderna vaccines, and highest in
               adults aged 18-49 years (97.4\%; 95\% CI: 79.3 to 99.7\%). Among
               45 patients with vaccine-breakthrough Covid hospitalizations, 44
               (97.8\%) were $\geq$50 years old and 20 (44.4\%) had
               immunosuppression. Vaccine effectiveness was lower among
               patients with immunosuppression (62.9\%; 95\% CI: 20.8 to
               82.6\%) than without immunosuppression (91.3\%; 95\% CI: 85.6 to
               94.8\%). CONCLUSION: During March-May 2021, SARS-CoV-2 mRNA
               vaccines were highly effective for preventing Covid-19
               hospitalizations among US adults. SARS-CoV-2 vaccination was
               beneficial for patients with immunosuppression, but
               effectiveness was lower in the immunosuppressed population.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; hospitalized; immunocompromised; mRNA vaccines;
               vaccine effectiveness",
  language  = "en"
}

@ARTICLE{Rahav2021-ul,
  title     = "{BNT162b2} {mRNA} {COVID-19} vaccination in immunocompromised
               patients: A prospective cohort study",
  author    = "Rahav, Galia and Lustig, Yaniv and Lavee, Jacob and {Ohad
               Benjamini} and Magen, Hila and Hod, Tammy and {Noga Shem-Tov}
               and Shmueli, Einat Shacham and {Drorit Merkel} and Ben-Ari, Ziv
               and Halperin, Rebecca and Indenbaum, Victoria and Olmer, Liraz
               and Huppert, Amit and Mor, Eytan and Regev-Yochay, Gili and
               Cohen, Carmit and Finesod, Anat Wieder- and Levy, Itzchak",
  abstract  = "Background: Trials of the Pfizer-BioNTech BNT162b2 mRNA vaccine
               showed 95\% efficacy in preventing symptomatic disease; however,
               the trials excluded immunocompromised patients (ICPs). We aim at
               analyzing antibody response in ICPs. Methods: A prospective
               cohort study was conducted at Sheba Medical Center, Israel,
               between January and April 2020, in 1274 participants who
               received the vaccine, including 1002 ICPs and 272
               immunocompetent healthcare workers (HCWs). Antibodies were
               measured two-four weeks after vaccination by SARS-CoV-2
               anti-receptor binding domain IgG antibodies (RBD IgG) and
               pseudo-virus neutralization assays. Multivariable logistic
               regression analyses were used to identify factors associated
               with vaccine-induced antibody response. Adverse events (AEs)
               were monitored. Findings: RBD-IgG antibodies were detected in
               154/156 (98.7\%) of patients with HIV, 75/90 (83.3\%) with solid
               malignancies, 149/187 (79.7\%) with myeloma, 83/111 (74.8\%)
               following hematopoietic stem cell transplants, 25/36 (69.4\%)
               following liver transplantation, 26/43 (60.5\%) with
               myelodysplastic syndrome, 96/188 (51.0\%) with chronic
               lymphocytic leukemia/non-Hodgkin's lymphoma, 50/110 (45.5\%)
               following kidney transplantation, 15/80 (18.8\%) following heart
               transplantation, and 269/272 (98.9\%) in controls. There was a
               significant correlation r = 0.74 (95\%CI 0.69,0.78) between
               RBD-binding IgG and neutralizing antibodies in all groups.
               Multivariate logistic regression analysis showed that age > 65
               years (OR 0.41,95\%CI 0.30,0.57) and underlying
               immunosuppression (OR 0.02,95\%CI 0.01,0.07) were significantly
               associated with a non-reactive response of IgG antibodies. HIV
               patients showed a similar immunological response as healthy
               adults. The vaccine was safe without any episodes of rejection,
               graft-versus-host disease (GVHD) or allergy. Immunocompetent
               HCWs experienced significantly more AEs than ICPs.
               Interpretation: Antibody response to the Pfizer-BioNTech vaccine
               was highly variable among different ICPs; thus, individual
               recommendations should be provided for the different
               immunosuppression states.",
  journal   = "EClinicalMedicine",
  publisher = "Elsevier BV",
  volume    =  41,
  number    =  101158,
  pages     = "101158",
  month     =  nov,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Da_Cruz2021-cl,
  title     = "Mental health of older people in social isolation: the role of
               physical activity at home during the {COVID-19} pandemic",
  author    = "da Cruz, Whyllerton Mayron and D' Oliveira, Anderson and
               Dominski, F{\'a}bio Hech and Diotaiuti, Pierluigi and Andrade,
               Alexandro",
  abstract  = "The COVID-19 pandemic involves a new coronavirus characterized
               by a respiratory disease resulting from an infection with severe
               acute respiratory syndrome by coronavirus 2 (SARS-CoV-2). The
               severity and fatality of COVID-19 are directly related to age
               and immunocompromised states, with older adults making up the
               vast majority of cases. The elderly with a higher risk of
               serious complications due to COVID-19 and deaths are also the
               group most susceptible to the damage of social isolation,
               impacting on mental health, resulting in a more sedentary
               lifestyle, and health problems due to several causes, implying
               need for greater attention, care and protection. Physical
               activity has shown excellent results for mental health, being
               used in different treatments and populations, when considering
               the elderly, one of the ways to mitigate this impact on mental
               health is the practice of physical activity. Here, we discuss
               the impacts of social isolation on mental health and the role of
               physical activity and exercise in the homes of the elderly as a
               way to protect the spread of other diseases from all causes
               during the COVID-19 pandemic period. To this end, we discuss
               some possibilities that can be used by the elderly in the period
               of social isolation, to the point of remaining active within
               their homes.",
  journal   = "Sport Sci. Health",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--6",
  month     =  aug,
  year      =  2021,
  keywords  = "Aged; Exercise; Frail elderly; Public health; SARS-CoV-2;
               Sedentary behavior",
  language  = "en"
}

@ARTICLE{Loinaz-Segurola2021-ng,
  title     = "Coronavirus disease 2019 in liver transplant patients: Clinical
               and therapeutic aspects",
  author    = "Loinaz-Segurola, Carmelo and Marcacuzco-Quinto, Alberto and
               Fern{\'a}ndez-Ruiz, Mario",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has profoundly
               impacted liver transplant (LT) activity across the world, with
               notable decreases in the number of donations and procedures in
               most Western countries, in particular throughout the first wave.
               The cumulative incidence of COVID-19 in LT recipients (with
               estimates ranging from 0.34\% to 1.56\%) appears to be at least
               comparable to that observed for the general population. Clinical
               and radiological features at presentation are also similar to
               non-transplant patients. The risk of death among LT recipients
               requiring hospital admission is high (from 12\% to 19\%),
               although some authors have suggested that overall mortality may
               be actually lower compared to the general non-transplant
               population. It is likely that these poor outcomes may be mainly
               influenced by the older age and higher comorbidity burden of LT
               recipients, rather than by the transplant status itself. In
               fact, it has been hypothesized that post-transplant
               immunosuppression would exert a protective role, with special
               focus on tacrolimus-containing regimens. There is scarce
               evidence to guide the optimal management of post-transplant
               COVID-19 and the use of antiviral or immunomodulatory therapies,
               although both clinical practice and guidelines support the dose
               reduction or withdrawal of anti-proliferative agents such as
               mofetil mycophenolate. Preliminary reports suggest that the
               antibody response to messenger RNA vaccines is significantly
               impaired as compared to non-immunocompromised individuals, in
               line with other transplant populations. Finally, it is
               foreseeable that the future will be conditioned by the emerging
               variants of severe acute respiratory syndrome coronavirus 2 with
               increased transmissibility among LT recipients.",
  journal   = "World J. Hepatol.",
  publisher = "Baishideng Publishing Group Inc.",
  volume    =  13,
  number    =  10,
  pages     = "1299--1315",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Clinical features; Immunosuppression; Liver
               transplantation; SARS-CoV-2; Therapy",
  language  = "en"
}

@ARTICLE{Puri2021-ht,
  title     = "{COVID-19} rekindling herpes zoster in an immunocompetent
               patient",
  author    = "Puri, Piyush and Parnami, Pankul and Athwal, Pal Satyajit Singh
               and Kumari, Sima and Kumar, Chandan and Suri, Yogita",
  abstract  = "During the coronavirus 2019 (COVID-19) pandemic, sundry
               dermatological conditions related to COVID-19 pneumonia have
               been published. COVID-19 primarily affects the respiratory
               system, but secondarily it also affects the heart, kidney,
               brain, skin, spinal cord, etc. Herpes Zoster (HZ) is
               considerably important morbidity associated with COVID-19
               pneumonia. Recrudescence of HZ occurs because of the latent
               varicella-zoster virus (VZV) predominantly because of the
               decline in cell-mediated immunity (CMI). Abating CMI is due to
               the increasing age, but could also occur if the patient is
               suffering from an immunosuppressive disease or is using
               immunosuppressive drugs. In our case, the patient had no
               lymphopenia unlike the other cases, yet still, he developed HZ.
               HZ is associated with post-herpetic neuralgia (PHN), HZ
               ophthalmicus (HZO), and cerebral arteritis increasing morbidity
               and mortality, especially in elderly people and those who are
               immunocompromised.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  9,
  pages     = "e18049",
  month     =  sep,
  year      =  2021,
  keywords  = "covid; covid 19; covid and skin; herpes simplex; shingles",
  language  = "en"
}

@ARTICLE{Marlet2021-ac,
  title     = "Antibody responses after a third dose of {COVID-19} vaccine in
               kidney transplant recipients and patients treated for chronic
               Lymphocytic leukemia",
  author    = "Marlet, Julien and Gatault, Philippe and Maakaroun, Zoha and
               Longuet, H{\'e}l{\`e}ne and Stefic, Karl and Handala, Lynda and
               Eymieux, S{\'e}bastien and Gyan, Emmanuel and Dartigeas,
               Caroline and Gaudy-Graffin, Catherine",
  abstract  = "The impact of a third dose of COVID-19 vaccine on antibody
               responses is unclear in immunocompromised patients. The
               objective of this retrospective study was to characterize
               antibody responses induced by a third dose of mRNA COVID-19
               vaccine in 160 kidney transplant recipients and 20 patients
               treated for chronic lymphocytic leukemia (CLL). Prevalence of
               anti-spike IgG $\geq$ 7.1 and $\geq$ 30 BAU/mL after the third
               dose were 47\% (75/160) and 39\% (63/160) in kidney transplant
               recipients, and 57\% (29/51) and 50\% (10/20) in patients
               treated for CLL. Longitudinal follow-up identified a moderate
               increase in SARS-CoV-2 anti-spike IgG levels after a third dose
               of vaccine in kidney transplant recipients (0.19 vs. 5.28
               BAU/mL, p = 0.03) and in patients treated for CLL (0.63 vs. 10.7
               BAU/mL, p = 0.0002). This increase in IgG levels had a limited
               impact on prevalence of anti-spike IgG $\geq$ 30 BAU/mL in
               kidney transplant recipients (17\%, 2/12 vs. 33\%, 4/12, p =
               0.64) and in patients treated for CLL (5\%, 1/20 vs. 45\%, 9/20,
               p = 0.008). These results highlight the need for vaccination of
               the general population and the importance of non-medical
               preventive measures to protect immunocompromised patients.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  10,
  pages     = "1055",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; antibody; chronic lymphocytic leukemia; kidney
               transplant; vaccine",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Nitpolprasert2021-ee,
  title     = "A qualitative study of the impact of coronavirus disease
               ({COVID-19}) on psychological and financial wellbeing and
               engagement in care among men who have sex with men living with
               {HIV} in Thailand",
  author    = "Nitpolprasert, Chattiya and Anand, Tarandeep and Phanuphak,
               Nittaya and Reiss, Peter and Ananworanich, Jintanat and Peay,
               Holly Landrum",
  abstract  = "OBJECTIVES: The coronavirus disease (COVID-19) pandemic is an
               unprecedented event with massive global health and
               socio-economic impacts on vulnerable populations, especially
               people living with HIV. The epidemic has severely affected
               Thailand's economy and potentially impacted the financial and
               psychological wellbeing of Thai HIV-positive men who have sex
               with men (MSM). METHODS: Between 15 June and 10 December 2020,
               we conducted qualitative interviews with 26 MSM living with HIV
               in Thailand who participate in an Adam's Love We Care Study. We
               intentionally recruited individuals who may have experienced a
               greater impact of COVID-19. Interviews explored worry, stigma
               and stress surrounding COVID-19, and multiple domains of
               potential COVID-19 impact: financial/employment, HIV service
               delivery and antiretroviral (ART) adherence during the first 10
               months of the COVID-19 pandemic. RESULTS: Participants perceived
               themselves as immunocompromised and susceptible, and feared
               contracting COVID-19. Participants worried that contracting
               COVID-19 would lead to HIV status disclosure and stigmatization.
               Participants had considerable worry about job loss as a result
               of the economic downturn, and some shared challenges associated
               with relocation and re-engaging with HIV care. Financial stress
               and lack of basic necessities caused by job losses were commonly
               reported. Participants reported optimal ART adherence as a
               consequence of local HIV service delivery responses, convenient
               ART refills and Adam's Love online support interventions.
               CONCLUSIONS: Our study highlights that the COVID-19 pandemic
               produced high levels of anxiety and concerns about additional
               stigma among MSM living with HIV. It had a significant negative
               effect on the daily lives of our participants. These findings
               indicate a need for the provision of confidential COVID-19
               diagnosis and care, relief programmes, vaccination roll-out
               equity, and addressing employment needs of vulnerable
               populations.",
  journal   = "HIV Med.",
  publisher = "Wiley",
  month     =  oct,
  year      =  2021,
  keywords  = "coronavirus disease (COVID-19); economic disparities; men who
               have sex with men; people living with HIV; severe acute
               respiratory syndrome coronavirus 2 (SARS-CoV-2)",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Sharma2021-fv,
  title     = "{COVID-19} associated pulmonary aspergillosis ({CAPA)}: An
               Australian case report",
  author    = "Sharma, Avinash and Hofmeyr, Ann and Bansal, Anup and Thakkar,
               Devesh and Lam, Leon and Harrington, Zinta and Bhonagiri, Deepak",
  abstract  = "As the COVID-19 pandemic has developed, concern for invasive
               fungal infections in critically ill COVID-19 patients with acute
               respiratory distress syndrome (ARDS) has emerged. We describe a
               clinical case of coronavirus disease (COVID-19) associated
               pulmonary aspergillus (CAPA) infection and acute respiratory
               distress syndrome (ARDS) with a good clinical outcome, in a
               previously well, non-immunocompromised Australian woman.",
  journal   = "Med. Mycol. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  31,
  pages     = "6--10",
  month     =  mar,
  year      =  2021,
  keywords  = "ARDS; COVID-19 associated pulmonary aspergillosis (CAPA); Fungal
               infection; ICU",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Ali2021-br,
  title     = "Trichosporon asahii fungemia and {COVID-19} co-infection: An
               emerging fungal pathogen; case report and review of the
               literature",
  author    = "Ali, Gawahir A and Husain, Ahmed and Salah, Husam and Goravey,
               Wael",
  abstract  = "With the evolving COVID-19 pandemic, increasing concerns about
               invasive fungal infections have been reported particularly with
               the use of potent immunosuppressant medications to treat the
               immunological storms in patients with severe COVID-19 illnesses.
               Trichosporon asahii (T. asahii) is an emerging highly resistant
               pathogen with considerable mortality particularly in critically
               ill patients and immunocompromised individuals. We describe a
               case of a 58-year-old patient who developed T. asahii fungemia
               after using immunosuppressant agents for his severe COVID-19
               related cytokines release syndrome. Pseudohyphae, arthroconidia,
               and lateral blastoconidia were seen in the stain, and later
               confirmed to be T. asahii. Voriconazole successfully treated
               this multi-drug-resistant fungal infection. The clinical
               presentation, assessment, and management are reviewed to raise
               awareness of the circumstances leading to coinfection with this
               emerging resistant yeast.",
  journal   = "IDCases",
  publisher = "Elsevier BV",
  volume    =  25,
  number    = "e01244",
  pages     = "e01244",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Central venous catheters; Fungemia; Trichosporon
               asahii; Voriconazole",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Dokania2021-ie,
  title     = "Emergence of invasive fungal rhinosinusitis in recently
               recovered {COVID-19} patients",
  author    = "Dokania, Vivek and Gaikwad, Ninad Subhash and Gite, Vinod and
               Mhashal, Shashikant and Shetty, Neeraj and Shinde, Pravin and
               Balakrishnan, Anju",
  abstract  = "OBJECTIVE: The risk of invasive fungal rhinosinusitis is
               increased in Coronavirus disease 2019 (COVID-19) because of its
               direct impact in altering innate immunity and is further
               exacerbated by widespread use of steroids/antibiotics/monoclonal
               antibodies. The study aims to describe this recently increased
               clinical entity in association with COVID-19. METHOD: A
               prospective, longitudinal study including patients diagnosed
               with acute invasive fungal rhinosinusitis (AIFRS) who recently
               recovered from COVID-19 infection or after an asymptomatic
               carrier state. A single-center, descriptive study investigating
               demographic details, clinical presentation, radio-pathological
               aspects, and advocated management. RESULT: A total of 21
               patients were included with a mean age of 49.62 years (SD:
               14.24). Diabetes mellitus (DM) was the most common underlying
               disorder (90.48\%), and 63.16\% of all patients with DM had a
               recent onset DM, either diagnosed during or after COVID-19
               infection. Nineteen patients (90.48\%) had recently recovered
               from active COVID-19 infection, and all had a history of prior
               steroid treatment (oral/parenteral). Remaining 2 patients were
               asymptomatic COVID-19 carriers. Surprisingly, 2 patients had no
               underlying disorder, and 5 (23.81\%) recently received the
               Covishield vaccine. Fungal analysis exhibited Mucor (95.24\%)
               and Aspergillus species (14.29\%). Most common sign/symptom was
               headache and facial/periorbital pain (85.71\%), followed by
               facial/periorbital swelling (61.90\%). Disease involvement:
               sinonasal (100\%), orbital (47.62\%), pterygopalatine fossa
               (28.58\%), infratemporal fossa (14.29\%), intracranial
               (23.81\%), and skin (9.52\%). Exclusive endoscopic debridement
               and combined approach were utilized in 61.90\% and 38.10\%,
               respectively. Both liposomal amphotericin B and posaconazole
               were given in all patients except one. CONCLUSION: A high
               suspicion of AIFRS should be kept in patients with recent
               COVID-19 infection who received steroids and presenting with
               headache, facial pain, and/or facial swelling. Asymptomatic
               COVID-19 carriers and COVID-19 vaccinated candidates are also
               observed to develop AIFRS, although the exact
               immuno-pathogenesis is still unknown. Prompt diagnosis and early
               management are vital for a favorable outcome.",
  journal   = "Ann. Otol. Rhinol. Laryngol.",
  publisher = "SAGE Publications",
  pages     = "34894211060923",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; immunocompromised; invasive fungal infection; mucor;
               rhinosinusitis",
  language  = "en"
}

@ARTICLE{Levi2021-pz,
  title     = "Hyperimmune plasma infusion in an immunocompromised Covid-19
               patient previously treated for follicular lymphoma",
  author    = "Levi, Guido and Rocchetti, Chiara and Magri, Roberto and
               Uccelli, Silvia and Bottone, Damiano and Quadri, Federico and
               Novali, Mauro and Santin, Alessandro D and Bezzi, Michela",
  abstract  = "Covid-19 in immunocompromised patients shows a prolonged course
               and may lead to a poor prognosis. Although data on hyperimmune
               plasma for treatment of Covid-19 suggest an improved outcome in
               immunocompetent patients, limited data are currently available
               in immunocompromised patients. We present the case of a
               62-year-old Caucasian woman, who was previously treated with
               obinutuzumab and bendamustine for follicular lymphoma and showed
               a prolonged positive test for Covid-19. Since no improvement was
               observed with standard of care (including remdesivir), the
               possibility of hyperimmune plasma infusion was discussed. A
               first dose of hyperimmune plasma was administered, with
               subsequent onset of fever, increasing inflammatory indexes and
               worsening radiological findings. Three days later a second dose
               of plasma was administered. Within twelve hours cough and fever
               disappeared, and oxygen at rest was discontinued. The patient
               was discharged 5 days later, and nasopharyngeal swabs resulted
               negative 16 days after discharge.",
  journal   = "Monaldi Arch. Chest Dis.",
  publisher = "PAGEPress Publications",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Tatu2021-xn,
  title     = "A working hypothesis on vesicular lesions related to {COVID-19}
               infection, koebner phenomena type V, and a short review of
               related data",
  author    = "Tatu, Alin Laurentiu and Baroiu, Liliana and Fotea, Silvia and
               Anghel, Lucretia and Drima Polea, Eduard and Nadasdy, Thomas and
               Chioncel, Valentin and Nwabudike, Lawrence Chukwudi",
  abstract  = "SARS-CoV-2 has recently been associated with the reactivation of
               varicella zoster virus in patients. This is potentially an
               observation of a local susceptibility of the skin in areas of
               vesicle formation. This article explores the dermatologic
               manifestations that have been linked to the SARS-CoV-2 virus,
               their infectious risk, as well as potential confounding factors.
               An isotopic response may be occurring due to the occurrence of
               an immunocompromised district incited by sustained inflammation
               mediated by inflammatory cytokines.",
  journal   = "Clin. Cosmet. Investig. Dermatol.",
  publisher = "Informa UK Limited",
  volume    =  14,
  pages     = "419--423",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Koebner phenomenon; SARS-CoV-2; locus minoris
               resistentiae; vesicular rash; wolf isotopic response",
  language  = "en"
}

@ARTICLE{Farooq2021-jf,
  title     = "Multisystem Inflammatory Syndrome in children and adolescents
               ({MIS-C}) under the setting of {COVID-19}: A review of clinical
               presentation, workup and management",
  author    = "Farooq, Ayesha and Alam, Fatima and Saeed, Asma and Butt, Farooq
               and Khaliq, Muhammad Azeem and Malik, Ayesha and Chaudhry,
               Manahil and Abdullah, Mohammad",
  abstract  = "Earlier in its course, SARS-CoV-2 was primarily identified to
               cause an acute respiratory illness in adults, the elderly and
               immunocompromised, while children were known to be afflicted
               with milder symptoms. However, since mid-April of 2020, latent
               effects of the virus have begun emerging in children and
               adolescents, which is characterised by a multisystem
               hyperinflammatory state; thus, the term Multisystem Inflammatory
               Syndrome in Children (MIS-C) was introduced by the WHO and CDC.
               The syndrome manifests itself approximately 4 weeks after
               COVID-19 infection, with symptoms mimicking Kawasaki Disease and
               Kawasaki Disease Shock Syndrome. Demographically, MIS-C peaks in
               children aged 5 to 14 years, with clusters in Europe, North and
               Latin America seen, later followed by Asia. Although the exact
               pathophysiology behind the syndrome is unknown, recent studies
               have proposed a post-infectious immune aetiology, which explains
               the increased levels of immunoglobulins seen in affected
               patients. Patient presentation includes, but is not limited to,
               persistent fever, rash, gastrointestinal symptoms and cardiac
               complications including myocarditis. These patients also have
               raised inflammatory markers including C reactive protein,
               ferritin and interleukin-6. In poorly controlled patients, the
               syndrome can lead to multiorgan failure and death. The mainstay
               of treatment includes the use of intravenous immunoglobulins,
               steroids, immune modulators and aspirin. Adjunct therapy
               includes the use of low molecular weight heparin or warfarin for
               long term anticoagulation. Currently very little is known about
               the syndrome, highlighting the need for awareness amongst
               healthcare workers and parents. Moreover, with increased cases
               of COVID-19 as a result of the second wave, it is essential to
               keep MIS-C in mind when attending patients with a past history
               of COVID-19 exposure or infection. Additionally, once these
               patients have been identified and treated, strict follow-up must
               be done in order carry out long term studies, and to identify
               possible sequelae and complications.",
  journal   = "Infect. Dis. (Auckl.)",
  publisher = "SAGE Publications",
  volume    =  14,
  pages     = "11786337211026642",
  month     =  jun,
  year      =  2021,
  keywords  = "COVID-19; infectious diseases; kawasaki disease; management;
               multisystem inflammatory syndrome; pandemic; pathophysiology;
               pediatric; workup",
  language  = "en"
}

@ARTICLE{Nambiar2021-mr,
  title     = "{Post-Covid} alliance-mucormycosis, a fatal sequel to the
               pandemic in India",
  author    = "Nambiar, Manjusha and Varma, Sudhir Rama and Damdoum, Marah",
  abstract  = "As the battle against the deadly Covid-19 pandemic is still
               continuing worldwide, several complications are being reported
               in patients who have recovered post-covid. One such lethal
               complication being reported in patients in India in recent
               times, who have tested positive for Covid-19 and are gradually
               recovering, is a fungal disease called Mucormycosis or the black
               fungus. With several hundreds of cases being reported all over
               the country, it has triggered an additional wave of panic among
               the general public. Post-Covid-19 patients who are more
               vulnerable to Mucormycosis are those with a history of poorly
               controlled diabetes mellitus and also those who are
               immuno-compromised and have been treated with steroids and other
               drugs for Covid-19. The aim of this short review is to briefly
               cover the epidemiology of mucormycosis, its possible
               pathophysiology in Post Covid scenario, the clinical
               presentation and its diagnosis and management.",
  journal   = "Saudi J. Biol. Sci.",
  publisher = "Elsevier BV",
  volume    =  28,
  number    =  11,
  pages     = "6461--6464",
  month     =  nov,
  year      =  2021,
  keywords  = "Black fungus; COVID-19; Mucormycosis; Post Covid 19;
               Rhinoorbitocerebral mucormycosis; Zygomycosis",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Gupta2021-oq,
  title     = "Clinical study of surge of mucormycosis in {COVID-19} pandemic:
               A tertiary care center study",
  author    = "Gupta, Devang P and Gupta, Shalu and Shah, Chaitry K and
               Sreevidya, S R",
  abstract  = "The aim of this study is to evaluate the prevalence,
               pathogenesis and management of mucormycosis in post covid 19
               patients in our tertiary care covid dedicated hospital. A
               prospective cross sectional study was done in 70 patients who
               were admitted in the covid department of BJ Medical College,
               Civil hospital Ahmedabad and presented with mucormycosis during
               admission or after discharge over a period of 10 months from
               March 2020 to December 2020. Middle aged to elderly population
               were found to be most commonly affected with mucormycosis. It
               was found that majority of the affected population was
               uncontrolled diabeteic and had a delayed presentation to
               hospital due to ongoing covid pandemic crisis. Covid infection
               had major effect on the hormonal balance of the body as evident
               from the uncontrolled blood glucose levels of affected patients.
               In patients with mucormycosis, early detection, surgical
               debridement, suitable antifungal therapy, and control of risk
               factors like diabetes mellitus are the main parameters of
               successful management of this lethal infection. Early diagnosis
               and treatment of mucormycosis can be life saving as it is a
               rapidly progressing disease and have been proven fatal.",
  journal   = "Indian J. Otolaryngol. Head Neck Surg.",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--8",
  month     =  aug,
  year      =  2021,
  keywords  = "Amphoterecin B; COVID 19; Debridement; Diabetes mellitus;
               Fungal; Immunocompromised; Modified denker; Mucormycosis; Open
               maxillectomy; Palatal erosion",
  language  = "en"
}

@ARTICLE{Benedetti2021-wn,
  title     = "{COVID-19} associated pulmonary aspergillosis in {ICU} patients:
               Report of five cases from Argentina",
  author    = "Benedetti, Mar{\'\i}a Fernanda and Alava, Katherine Hermida and
               Sagardia, Judith and Cadena, Roberto Corella and Laplume, Diego
               and Capece, Paula and Posse, Gladys and Nusblat, Alejandro David
               and Cuestas, Mar{\'\i}a Luj{\'a}n",
  abstract  = "Invasive pulmonary aspergillosis is a complication in critically
               ill patients with acute respiratory distress syndrome,
               especially those with severe coronavirus disease-associated
               pneumonia. In this study, five cases of presumed invasive
               pulmonary aspergillosis in one immunocompromised and four
               immunocompetent patients with COVID-19 in Buenos Aires are
               described. In all cases, the underlying conditions, clinical
               presentation, fungal diagnostic tests used and their results,
               features of the chest scan images, antifungals used and clinical
               outcomes are detailed.",
  journal   = "Med. Mycol. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  31,
  pages     = "24--28",
  month     =  mar,
  year      =  2021,
  keywords  = "Amphotericin B; ICU; Invasive pulmonary aspergillosis;
               SARS-CoV-2; Voriconazole",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Abbasi2021-cc,
  title     = "Immunocompromised patients with {COVID-19} receive interferon
               gamma",
  author    = "Abbasi, Jennifer",
  journal   = "JAMA",
  publisher = "American Medical Association (AMA)",
  volume    =  326,
  number    =  22,
  pages     = "2250",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Alamin2021-kl,
  title     = "Rhino-orbital Mucormycosis as a complication of severe
               {COVID-19} pneumonia",
  author    = "Alamin, Mohammed A and Abdulgayoom, Mohammed and Niraula, Sushil
               and Abdelmahmuod, Elabbass and Ahmed, Ashraf O and Danjuma,
               Mohammed I",
  abstract  = "Mucormycosis has multiple clinical phenotypes, which are more
               common in immunocompromised patients, especially those with
               diabetes mellitus. Debilitating rhino-orbital-cerebral and
               pulmonary infections by far represent the most typical clinical
               phenotypes associated with these fungi. Mucormycosis is an
               uncommon infection; however, there have been isolated sporadic
               tiny outbreaks around the world. With the substantial increase
               in COVID-19 cases in India, there is a parallel increase in the
               number of cases of Mucormycosis. A few reports raising unusual
               concomitant mucormycosis in COVID-19 patients have raised a
               possible association between the two diseases. We report a
               59-year-old male with an established history of uncontrolled
               diabetes mellitus admitted to the hospital with severe COVID-19
               pneumonia (severity ascertained according to WHO classification)
               treated with steroids and discharged home following full
               recovery. However, one week later, he presented with right eye
               ophthalmoplegia and complete loss of vision, which was
               subsequently established as orbital Mucormycosis. This case
               highlights the need for heightened awareness of this atypical
               secondary infection (especially systemic mycosis) in patients
               recovering from COVID-19 infection.",
  journal   = "IDCases",
  publisher = "Elsevier BV",
  volume    =  26,
  number    = "e01293",
  pages     = "e01293",
  month     =  sep,
  year      =  2021,
  keywords  = "Black Fungus; COVID-19; Mucormycosis; Rhizopus; SARS-CoV2",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Rahman2021-bd,
  title     = "Mucormycosis (black fungus) in {COVID-19} patients-Will it be
               another matter of concern in the midst of the {COVID-19}
               flare-up in Bangladesh?",
  author    = "Rahman, Md Tanvir and Hossain, Md Golzar and Rahman, A M M
               Taufiquer and Huq, A K M Moyeenul and Farzana, Shahnur and
               Nazir, K H M Nazmul Hussain",
  abstract  = "Many countries of the world have been combating the new variant
               of severe acute respiratory syndrome coronavirus 2. Black fungus
               is an opportunistic foe that may cause fatal infection in
               immunocompromised and steroid-treated coronavirus disease 2019
               (COVID-19) patients. The COVID-19 associated mucormycosis (CAM)
               is now a serious concern throughout the world, including many
               Asian countries. Therefore, along with early and accurate
               diagnostic facilities, special care, and prompt, but coordinated
               approach are recommended to combat the CAM in patients.",
  journal   = "J. Adv. Vet. Anim. Res.",
  publisher = "ScopeMed",
  volume    =  8,
  number    =  3,
  pages     = "367--369",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; Risk factors; mucormycosis; steroid",
  language  = "en"
}

@ARTICLE{Yan2021-wk,
  title     = "{COVID-19} vaccinations: A comprehensive review of their safety
               and efficacy in special populations",
  author    = "Yan, Zhipeng and Yang, Ming and Lai, Ching-Lung",
  abstract  = "COVID-19 has been spreading worldwide since late 2019. There is
               no definitive cure to date. Global vaccination programs are
               urgently required to confer herd immunity, reducing the
               incidence of COVID-19 infections and associated morbidity and
               mortality. However, a significant proportion of special
               populations are hesitant to receive vaccination due to their
               special conditions, namely, age (pediatrics and geriatrics),
               immunocompromised state, autoimmune diseases, chronic
               cardiovascular and pulmonary conditions, active or treated
               cancers, and pregnancy. This review aims to evaluate the
               existing evidence of COVID-19 vaccinations on these special
               populations and to provide clues to guide vaccination decision
               making to balance the benefits and risks of vaccinations.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  10,
  pages     = "1097",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 vaccinations; comorbidities; frailty; pregnancy",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tsai2021-sl,
  title     = "{COVID-19} vaccine hesitancy and acceptance among individuals
               with cancer, autoimmune diseases, and other serious comorbid
               conditions: A cross-sectional internet-based survey",
  author    = "Tsai, Richard and Hervey, John and Hoffman, Kathleen and Wood,
               Jessica and Johnson, Jennifer and Deighton, Dana and Clermont,
               Donald and Loew, Brian and Goldberg, Stuart",
  abstract  = "BACKGROUND: Background: Individuals with comorbid conditions
               have been disproportionately affected by COVID-19. Since
               regulatory trials with COVID-19 vaccines excluded those with
               immunocompromising conditions, few patients with cancer and
               autoimmune diseases were enrolled. With limited vaccine safety
               data available vulnerable populations may have conflicted
               vaccine attitudes. OBJECTIVE: Objective: We sought to assess the
               prevalence and independent predictors of COVID-19 vaccine
               hesitancy and acceptance among individuals with serious
               comorbidities, and to assess self-reported side-effects among
               those who had received the vaccine. METHODS: Methods: We
               conducted a cross-sectional 55-item online survey, fielded
               January 15, 2021 through February 22, 2021, among a random
               sample of members of Inspire, an online health community of over
               2.2 million individuals with comorbid conditions. Multivariable
               regression analysis was utilized to determine factors
               independently associated with vaccine hesitancy and acceptance.
               RESULTS: Results: Of the 996,500 members of the Inspire health
               community who were invited to participate responses were
               received from 21,943 individuals (2.2\%). Respondents resided in
               123 countries (74\% USA), had a median age range 56-65 years,
               were highly educated (60\% holding college or post-graduate
               degrees), and had diverse political leanings. All respondents
               self-reported at least one co-morbidity, with 27\% having
               cancer, 23\% autoimmune diseases, and 38\% chronic lung
               diseases. COVID-19 vaccine hesitancy was identified in 18.6\%,
               with 2190 (10.3\%) declaring that they would not, 742 (3.4\%)
               stating that they probably would not, and 1028 (4.8\%) not sure
               whether they would agree to be vaccinated. Hesitancy was
               expressed by 13.4\% cancer patients, 19.4\% with autoimmune
               diseases, and 17.8\% with chronic lung diseases. Positive
               predictors of vaccine acceptance included routine influenza
               vaccination (odds ratio 1.53), trust in responsible vaccine
               development (odds ratio 14.04), residing in the USA (odds ratio
               1.31) and never smoker status (odds ratio 1.06). Hesitancy was
               increased with a history of prior COVID-19 (odds ratio .86),
               conservative political leaning (odds ratio .93), younger age
               (odds ratio .83), and lower education level (odds ratio .90).
               One quarter (5501 participants) had received at least one
               COVID-19 vaccine injection and 1390 (6.2\%) completed a two-dose
               series. Following the first injection, 69\% self-reported local
               and 40\% systemic reactions, which increased following the
               second injection to 76\% and 67\%, respectively. CONCLUSIONS:
               Conclusions: In this survey of individuals with serious comorbid
               conditions significant vaccine hesitancy remains. Assumptions
               that the most vulnerable would automatically accept COVID-19
               vaccination are erroneous and thus call for healthcare team
               members to initiate discussions focusing on the impact of the
               vaccine on an individual's underlying condition. Early
               self-reported side-effect experiences among those who have
               already been vaccinated, as expressed by our population, should
               be reassuring and might be utilized to alleviate vaccine fears.
               Healthcare related social media forums which rapidly disseminate
               accurate information about the COVID-19 vaccine may play an
               important role.",
  journal   = "JMIR Public Health Surveill.",
  publisher = "JMIR Publications Inc.",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Martinez-Urbistondo2021-qe,
  title     = "Severe lymphopenia as a predictor of {COVID-19} mortality in
               immunosuppressed patients",
  author    = "Mart{\'\i}nez-Urbistondo, Mar{\'\i}a and Guti{\'e}rrez-Rojas,
               {\'A}ngela and Andr{\'e}s, Ane and Guti{\'e}rrez, Isabel and
               Escudero, Gabriela and Garc{\'\i}a, Sonia and Guti{\'e}rrez,
               Andrea and S{\'a}nchez, Enrique and Herr{\'a}iz, Jes{\'u}s and
               De La Fuente, Sara and Callejas, Alejandro and De Mendoza,
               Carmen and Moreno-Torres, V{\'\i}ctor",
  abstract  = "BACKGROUND: Coronavirus disease 2019 (COVID-19) has a high
               mortality in certain group of patients. We analysed the impact
               of baseline immunosuppression in COVID-19 mortality and the role
               of severe lymphopenia in immunocompromised subjects. METHODS: We
               analysed all patients admitted with COVID-19 in a tertiary
               hospital in Madrid between March 1st and April 30th 2020.
               Epidemiological and clinical data, including severe lymphopenia
               (<500 lymphocytes/mm3) during admission, were analysed and
               compared based on their baseline immunosuppression condition.
               RESULTS: A total of 1594 patients with COVID-19 pneumonia were
               hospitalised during the study period. 166 (10.4\%) were
               immunosuppressed. Immunocompromised patients were younger (64
               vs. 67 years, p = 0.02) but presented higher rates of
               hypertension, diabetes, heart, neurological, lung, kidney and
               liver disease (p < 0.05). They showed more severe lymphopenia
               (53\% vs 24.1\%, p < 0.001), lower SapO2/FiO2 ratios (251 vs
               276, p = 0.02) during admission and higher mortality rates
               (27.1\% vs 13.5\%, p < 0.001). After adjustment,
               immunosuppression remained as an independent factor related to
               mortality (Odds Ratio (OR): 2.24, p < 0.001). In the
               immunosuppressed group, age (OR = 1.06, p = 0.01), acute
               respiratory distress syndrome (ARDS) (OR = 12.27, p = 0.017) and
               severe lymphopenia (OR = 3.48, p = 0.04) were the factors
               related to high mortality rate. CONCLUSION: Immunosuppression is
               an independent mortality risk factor in COVID-19. Severe
               lymphopenia should be promptly identified in these patients.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  16,
  pages     = "3595",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; immunosuppression; severe lymphopenia",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Poorna_T2021-wg,
  title     = "Ludwig's angina in a {COVID} positive patient-An atypical case
               report",
  author    = "Poorna T, Anish and J R, Lokesh and Ek, Joshna and John, Bobby",
  abstract  = "The management of odontogenic infections is established and
               several guidelines have been proposed for its effective
               treatment. Outbreak of COVID-19 has posed serious challenge in
               the management of odontogenic infections, further complicated by
               immunocompromised status of the patient, where adequate
               evaluation and prompt attention is mandatory to avoid untoward
               consequences. Ludwig's angina being a life threatening infection
               by itself, association or simultaneous presentation with
               COVID-19 infection can add further complexity in the management
               for a maxillofacial surgeon. Here we present a case report of
               Ludwig's angina in a patient who tested positive for Coronavirus
               infection and how we treated her successfully.",
  journal   = "Spec. Care Dentist.",
  publisher = "Wiley",
  number    = "scd.12643",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Ludwig's angina; extraction; odontogenic infection",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Alekseyev2021-uy,
  title     = "Rhinocerebral mucormycosis and {COVID-19} pneumonia",
  author    = "Alekseyev, Kirill and Didenko, Lidiya and Chaudhry, Bilal",
  abstract  = "As the coronavirus disease 2019 (COVID-19) pandemic is evolving,
               more complications associated with COVID-19 are emerging. In
               this case report, we present a case of rhinocerebral
               mucormycosis concurrent with COVID-19 pneumonia in a 41-year-old
               man with a history of type 1 diabetes mellitus (T1DM). COVID-19
               pneumonia was diagnosed with reverse transcription-polymerase
               chain reaction (RT-PCR). He was promptly treated with steroids
               and hydroxychloroquine, as this was the recommended regional
               COVID-19 practice patterns at the time. He was treated with
               intravenous (IV) fluids and an insulin drip for his diabetic
               ketoacidosis (DKA), cefepime and IV abelcet, along with three
               surgical debridements for the rhinocerebral mucormycosis. The
               pneumonia resolved during the course of his stay in the
               hospital. With prompt diagnosis and treatment of rhinocerebral
               mucormycosis, the patient was cleared for discharge and was
               instructed to complete his course of treatment with coumadin and
               IV abelcet at home. Saprophytic fungi cause rhinocerebral
               mucormycosis, a rare opportunistic infection of the sinuses,
               nasal passages, oral cavity and brain. It usually occurs in
               patients with poorly controlled diabetes mellitus or those who
               are immunocompromised, which is again demonstrated in this case
               report. In the setting of COVID-19 pneumonia and an underlying
               condition, healthcare professionals should act promptly. In
               cases where mucormycosis infection is suspected, a prompt
               diagnosis and treatment should be started because of the
               angioinvasive character and rapid disease progression that
               contribute to the severity of the mucormycosis infection.",
  journal   = "J. Med. Cases",
  publisher = "Elmer Press, Inc.",
  volume    =  12,
  number    =  3,
  pages     = "85--89",
  month     =  mar,
  year      =  2021,
  keywords  = "Amphotericin B; COVID-19; Debridement; Mucormycosis",
  language  = "en"
}

@ARTICLE{Rana2021-xa,
  title     = "Massive hemoptysis causing mortality in a post {COVID-19}
               infected Asian male patient: Presenting as pulmonary
               mucormycosis, pulmonary tuberculosis and later sino-nasal
               mucormycosis",
  author    = "Rana, Gunjan and Gautam, Sachin and Mawari, Govind and Daga,
               Mradul Kumar and Kumar, Naresh and Raghu, R V",
  abstract  = "While the developed nations are discussing giving a third dose
               of the COVID-19 vaccine to immunocompromised individuals, there
               are still challenges that are of global concern, especially in
               developing countries. The Delta variant which is predominantly
               responsible for the disease burden has now been reported in over
               148 countries. The catastrophe caused in the Indian subcontinent
               has highlighted some associations, most notable being the
               unprecedented rise in the cases of mucormycosis in COVID-19
               patients referred to as CAM (COVID-19 associated mucormycosis).
               This life-threatening opportunistic fungal infection which was
               historically associated with immunosuppression has reached a new
               peak as its incidence has increased many folds with the advent
               of COVID-19. Here we present one of the very first Case reports
               on how to post COVID immunosuppression state, uncontrolled blood
               sugar levels in the background of diabetic ketoacidosis led to
               the development of pulmonary mucormycosis with superimposed
               pulmonary tuberculosis and later Sino-nasal mucormycosis
               eventually leading to life-threatening massive hemoptysis,
               causing mortality of a post-COVID-19 infected middle-aged
               diabetic Asian male patient who presented twenty days after
               COVID-19 infection. However, our patient did not have risk
               factors such as severe COVID-19 infection requiring
               hospitalization, use of steroids or other immunomodulatory drugs
               like remdesivir or tocilizumab. Our case report aims to bring
               forth this post COVID pulmonary mucormycosis with pulmonary
               tuberculosis association as well as highlight the fact that
               tuberculosis is still a major public health burden that should
               not be forgotten in the fight to combat the pandemic.",
  journal   = "Respir. Med. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  34,
  number    =  101511,
  pages     = "101511",
  month     =  sep,
  year      =  2021,
  keywords  = "Bronchospopy; Co-infection; Haemoptysis; Massive; Post COVID-19;
               Pulmonary mucormycosis; Pulmonary tuberculosis",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Kullar2021-wl,
  title     = "{COVID-19} in liver transplant recipients",
  author    = "Kullar, Ravina and Patel, Ankur Prakash and Saab, Sammy",
  abstract  = "Background and Aims: Coronavirus disease 2019 (COVID-19) has
               infected over 93 million people worldwide as of January 14,
               2021. Various studies have gathered data on liver transplant
               patients infected with COVID-19. Here, we discuss the
               presentation of COVID-19 in immunosuppressed patients with prior
               liver transplants. We also evaluate patient outcomes after
               infection. Methods: We searched the PubMed database for all
               studies focused on liver transplant patients with COVID-19.
               Results: We identified eight studies that evaluated COVID-19
               infection in liver transplant patients (n=494). Hypertension was
               the most prevalent comorbidity in our cohort. Calcineurin
               inhibitors were the most common immunosuppressant medications in
               the entire cohort. The average time from liver transplant to
               COVID-19 infection in our cohort was 74.1 months. Fever and
               cough, at 70\% and 62\% respectively, were the most common
               symptoms in our review. In total, 50\% of the patients received
               hydroxychloroquine as treatment for COVID-19. The next most
               prevalent treatment was azithromycin, given to 30\% of patients
               in our cohort. In total, 80\% of the patients were admitted to a
               hospital and 17\% required intensive care unit-level care, with
               21\% having required mechanical ventilation. Overall mortality
               was 17\% in our review. Conclusions: Given the immunocompromised
               status of liver transplant patients, more intensive surveillance
               is necessary for severe cases of COVID-19 infection. As liver
               transplantations have been restricted during the COVID-19
               pandemic, further investigation is warranted for studying the
               risk of COVID-19 infection in liver transplant patients.",
  journal   = "J. Clin. Transl. Hepatol.",
  publisher = "Xia \& He Publishing",
  volume    =  9,
  number    =  4,
  pages     = "545--550",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Immunosuppression; Liver transplantation",
  language  = "en"
}

@ARTICLE{Hashemi2021-it,
  title    = "A rare presentation of an elderly patient with acute lymphocytic
              leukemia and platelet count of zero associated with
              {ST-elevation} myocardial infarction, pulmonary thromboembolism
              in the setting of {SARS-CoV} 2: a case report",
  author   = "Hashemi, Arash and Gerges, Fady and Naqvi, Haseeb Raza and
              Kotlar, Irina and Moscatelli, Sara and Hashemi, Ashkan and
              Rustamova, Yasmin and Almaghraby, Abdallah",
  abstract = "BACKGROUND: Novel coronavirus disease 2019 (COVID-19) is known to
              lead not only to severe acute respiratory syndrome, but also can
              result in thromboembolic events in both the venous and the
              arterial circulation by inducing coagulation disorders. The
              potential causes of coagulopathy are inflammation, platelet
              activation, endothelial dysfunction, and stasis. The thrombotic
              events including pulmonary embolism, deep venous thrombosis as
              well as intracatheter thrombosis are more likely to develop in
              patients infected with severe form of SARS-CoV-2 who are admitted
              to ICU. Furthermore, these events contribute to multi-organ
              failure. CASE PRESENTATION: Herein, we report a case of an
              immunocompromised COVID-19 elderly patient with acute lymphocytic
              leukemia who developed myocardial infarction with ST elevation in
              the setting of acute pulmonary thromboembolism in the presence of
              zero platelet count. Despite successful urgent coronary
              revascularization and platelet transfusion, the patient
              eventually died after failed resuscitation efforts. CONCLUSION:
              Patients with COVID-19 infection are at a greater risk of
              developing cardiovascular complications, but their appropriate
              management can decrease the risk of fatal events. Coronary
              thrombosis associated with pulmonary thromboembolism in the
              setting of thrombocytopenia is a rare and a complex to manage
              condition. Significance of single antiplatelet agent in STEMI
              with thrombocytopenia merits further studies. According to expert
              opinions and literature reviews, we must avoid dual antiplatelet
              therapy in these patients and keep platelet transfusion as a
              standard therapy to avoid drastic bleeding complications.",
  journal  = "Egypt. Heart J.",
  volume   =  73,
  number   =  1,
  pages    = "39",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Aggarwal2021-zh,
  title     = "Impact of {COVID-19} on patient trends and outcome: Results from
               a tertiary care burn and plastic unit in northern India",
  author    = "Aggarwal, Nupur and Srivastava, Rakesh Kumar",
  abstract  = "Background Burn and trauma injuries need emergency care and
               resuscitation, which required uninterrupted delivery of
               inpatient care services during the coronavirus disease 2019
               (COVID-19) pandemic. Burn patients are physiologically
               immunocompromised, increasing the risk of COVID-19 infection in
               them. This study analyzes the impact of COVID-19 pandemic on
               patient trends in a burn and plastic unit and assesses the
               effect of COVID-19 infection in burns. Methods This
               single-center, retrospective observational case-control study
               was conducted in the Department of Burns, Plastic and
               Maxillofacial Surgery of a tertiary care hospital in New Delhi,
               India. Patient data was collected from April 1, 2019 to August
               10, 2019 and from April 1, 2020 to August 10, 2020. All data of
               burns and trauma patients collected was analyzed and compared.
               Results There were total 350 admissions during COVID time period
               and 562 admissions during non-COVID time period. The admission
               rate, type of burn injury, and death rate did not vary
               significantly during the two time periods. Thermal burn was the
               most common type of burn injury. There were total 18 cases
               diagnosed to be COVID-19 positive during the pandemic. There
               were two deaths among COVID-19 positive burn cases. Conclusion
               This study finds no difference in patient patterns during COVID
               and non-COVID time period. Amongst burn patients, no increased
               risk of COVID-19 infection is seen with larger body surface area
               of burns. No increase in mortality is seen in burn patients
               infected with COVID-19.",
  journal   = "Indian J. Plast. Surg.",
  publisher = "Georg Thieme Verlag KG",
  volume    =  54,
  number    =  2,
  pages     = "172--176",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; burn injuries; effect; impact; mortality; outcome;
               risk factors; trends",
  copyright = "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Coloretti2021-lo,
  title     = "Rationale for polyclonal intravenous immunoglobulin adjunctive
               therapy in {COVID-19} patients: Report of a structured
               multidisciplinary consensus",
  author    = "Coloretti, Irene and Berlot, Giorgio and Busani, Stefano and De
               Rosa, Francesco Giuseppe and Donati, Abele and Forfori,
               Francesco and Grasselli, Giacomo and Mirabella, Lucia and
               Tascini, Carlo and Viale, Pierluigi and Girardis, Massimo",
  abstract  = "INTRODUCTION: Adjunctive therapy with polyclonal intravenous
               immunoglobins (IVIg) is currently used for preventing or
               managing infections and sepsis, especially in immunocompromised
               patients. The pathobiology of COVID-19 and the mechanisms of
               action of Ig led to the consideration of this adjunctive
               therapy, including in patients with respiratory failure due to
               the SARS-CoV-2 infection. This manuscript reports the rationale,
               the available data and the results of a structured consensus on
               intravenous Ig therapy in patients with severe COVID-19.
               METHODS: A panel of multidisciplinary experts defined the
               clinical phenotypes of COVID-19 patients with severe respiratory
               failure and, after literature review, voted for the agreement on
               the rationale and the potential role of IVIg therapy for each
               phenotype. Due to the scarce evidence available, a modified
               RAND/UCLA appropriateness method was used. RESULTS: Three
               different phenotypes of COVID-19 patients with severe
               respiratory failure were identified: patients with an abrupt and
               dysregulated hyperinflammatory response (early phase), patients
               with suspected immune paralysis (late phase) and patients with
               sepsis due to a hospital-acquired superinfection (sepsis by
               bacterial superinfection). The rationale for intravenous Ig
               therapy in the early phase was considered uncertain whereas the
               panelists considered its use in the late phase and patients with
               sepsis/septic shock by bacterial superinfection appropriate.
               CONCLUSION: As with other immunotherapies, IVIg adjunctive
               therapy may have a potential role in the management of COVID-19
               patients. The ongoing trials will clarify the appropriate target
               population and the true effectiveness.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  16,
  pages     = "3500",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; intravenous immunoglobulin therapy; respiratory
               failure",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Shafiekhani2021-iv,
  title     = "Evaluation of the therapeutic regimen in {COVID-19} in
               transplant patients: where do immunomodulatory and antivirals
               stand?",
  author    = "Shafiekhani, Mojtaba and Shahabinezhad, Farbod and Niknam,
               Tahmoores and Tara, Seyed Ahmad and Haem, Elham and Mardani,
               Parviz and Zare, Zahra and Jafarian, Sedigheh and Mirzad
               Jahromi, Khatereh and Arabsheybani, Sara and Moeini, Yalda Sadat
               and Alavi, Jalile and Jalali, Seyed Soroush and Salimi, Maryam
               and Shahriarirad, Reza and Malekhosseini, Seyed Ali",
  abstract  = "BACKGROUND: The management of COVID-19 in organ transplant
               recipients is among the most imperative, yet less discussed,
               issues based on their immunocompromised status along with their
               vast post-transplant medication regimens. No conclusive study
               has been published to evaluate proper anti-viral and
               immunomodulator medications effect in treating COVID-19 patients
               to this date. METHOD: This retrospective study was conducted in
               Shiraz Transplant Hospital, Iran from March 2020 to May 2021 and
               included COVID-19 diagnosed patients based on SARS-CoV-2 RT-PCR
               positive test who had been hospitalized for at least 48 h before
               enrolling in the study. Clinical and demographic information of
               patients, along with their treatment course and the medication
               used were evaluated and analyzed using multiple regression
               analysis. RESULTS: A total of 245 patients with a mean age of
               49.59 years were included with a mortality rate of 8.16\%. The
               administration of Remdesivir as an anti-viral drug (P value <
               0.001) and Tocilizumab as an immunomodulator drug (P value <
               0.001) could reduce the hospitalization period in the hospital
               and the intensive care unit, as well as the mortality rates
               significantly. Meanwhile, the patients treated with
               Lopinavir/Ritonavir experienced a lower chance of survival (OR <
               1, P value = 0.04). No significant difference was observed
               between various therapeutic regimens in clinical complications
               such as bacterial coinfections, cardiovascular and
               gastrointestinal adverse reactions, and liver or kidney
               dysfunctions. CONCLUSION: The administration of Remdesivir as an
               anti-viral and Tocilizumab as an immunomodulatory drug in
               solid-organ transplant recipients could be promising treatments
               of choice to manage COVID-19.",
  journal   = "Virol. J.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  18,
  number    =  1,
  pages     = "228",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Coronavirus disease 2019; Remdesivir; Tocilizumab;
               Transplant",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Taylor2021-ep,
  title     = "Disseminated histoplasmosis in an immunocompetent patient after
               {COVID-19} pneumonia",
  author    = "Taylor, Matthew and Ghodasara, Arjun and Ismail, Ali and Gauhar,
               Umair and El-Kersh, Karim",
  abstract  = "Disseminated histoplasmosis can occur in immunocompromised
               patients such as in HIV disease and patients with
               medication-induced immunosuppression. Most of these patients
               present with fever, weight loss, hepatosplenomegaly,
               lymphadenopathy, and pancytopenia. There are increasing reports
               of coronavirus disease 2019 (COVID-19) pneumonia associated with
               fungal infections including aspergillus and mucormycosis. It is
               not typical for immunocompetent patients to present with
               disseminated fungal disease. We herein report a case of a
               50-year-old immunocompetent male with a recent recovery from
               COVID-19 pneumonia who presented with fever and pancytopenia.
               Chest computed tomography (CT) demonstrated new-onset right
               upper lobe lung mass, subcarinal lymphadenopathy, and
               splenomegaly. Mediastinal lymph nodes and bone marrow biopsies
               were performed, and the patient was diagnosed with disseminated
               histoplasmosis. The association between COVID-19 pneumonia and
               fungal infections is increasingly reported. Diagnosis requires a
               high index of suspicion, especially in immunocompetent patients.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  8,
  pages     = "e17269",
  month     =  aug,
  year      =  2021,
  keywords  = "covid-19; dexamethasone; disseminated histoplasmosis; fungal;
               immunocompetent",
  language  = "en"
}

@ARTICLE{Palou2021-gp,
  title     = "{COVID-19} associated rhino-orbital mucormycosis complicated by
               gangrenous and bone necrosis-A case report from Honduras",
  author    = "Palou, Elsa Yolanda and Ramos, Mar{\'\i}a Auxiliadora and
               Cherenfant, Emec and Duarte, Adoni and Fuentes-Barahona, Itzel
               Carolina and Zambrano, Lysien I and Mu{\~n}oz-Lara, Fausto and
               Montoya-Ramirez, Sandra Aracely and Cardona-Ortiz, Alex
               Francisco and Valle-Reconco, Jorge Alberto and
               Montenegro-Idrogo, Juan J and Bonilla-Aldana, D Katterine and
               Paniz-Mondolfi, Alberto E and Rodriguez-Morales, Alfonso J",
  abstract  = "BACKGROUND: Mucormycosis is a life-threatening invasive fungal
               infection most commonly observed in immunocompromised patients.
               Throughout the COVID-19 pandemic, a growing number of Mucorales
               associated infections, now termed COVID-19 associated
               mucormycosis (CAM), have been reported. Despite an increase in
               fatality reports, no cases of rhino-orbital CAM complicated with
               gangrenous bone necrosis have been described in the literature
               to date. CASE: A 56-year-old male with a recent COVID-19
               diagnosis developed rhino-orbital mucormycosis after 22 days of
               treatment with dexamethasone. Cultures and histopathological
               assessment of tissue biopsy confirmed the diagnosis. The patient
               survived after treatment with amphotericin B. CONCLUSIONS:
               Mucormycosis is an invasive fungal infection affecting mostly
               immunocompromised patients. Along with the COVID-19 pandemic,
               the inappropriate use of steroids, in addition to concurrent
               risk factors, such as diabetes, has led to an increase in the
               occurrence of these devastating mycoses, leading to the
               development of severe presentations and complications, as
               observed in many cases. Early diagnosis and prompt treatment are
               crucial in order to avoid dissemination and fatal outcomes.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  8,
  pages     = "826",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; SARS-CoV-2; coinfection; honduras; mucorales;
               mucormycosis; opportunistic",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Manda2021-td,
  title     = "Invasive fungal infection in {COVID-19-recovered} patient
               detected on {18F-FDG-labeled} leukocytes {PET/CT} scan",
  author    = "Manda, Divya and Sen, Ishita and Thakral, Parul and Das, Subha
               Shankar and Cb, Virupakshappa and Malik, Dharmender",
  abstract  = "ABSTRACT: Occurrence of invasive fungal infections has gained
               significant attention during recent times in patients with
               COVID-19. Patients with severe form of COVID-19, such as those
               treated in the intensive care unit with prolonged steroid use,
               are particularly vulnerable to secondary bacterial and fungal
               infections. Disseminated systemic mycosis is a life-threatening
               condition, especially in immunocompromised patients. Here, we
               report a case of a recovered severe COVID-19 patient, who
               presented with persistent fever. 18F-FDG-labeled leukocyte scan
               revealed focal accumulation of radiotracer in the small
               intestine and right lung lower lobe. Subsequently, performed
               biopsy revealed mucormycosis.",
  journal   = "Clin. Nucl. Med.",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    = "Publish Ahead of Print",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Furlow2021-qg,
  title     = "Immunocompromised patients in the {USA} and {UK} should receive
               third dose of {COVID-19} vaccine",
  author    = "Furlow, Bryant",
  journal   = "Lancet Rheumatol",
  publisher = "Elsevier BV",
  volume    =  3,
  number    =  11,
  pages     = "e756",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Lu2021-yd,
  title     = "Risk factors for {COVID-19} deaths among elderly nursing home
               Medicare beneficiaries in the pre-vaccine period",
  author    = "Lu, Yun and Jiao, Yixin and Graham, David J and Wu, Yue and
               Wang, Jing and Menis, Mikhail and Chillarige, Yoganand and
               Wernecke, Michael and Kelman, Jeffrey and Forshee, Richard A and
               Izurieta, Hector S",
  abstract  = "BACKGROUND: Evaluate pre-vaccine pandemic period COVID-19 death
               risk factors among nursing home (NH) residents. METHODS:
               Retrospective cohort study covering Medicare fee-for-service
               beneficiaries ages $\geq$65 residing in U.S. NHs. We estimated
               adjusted hazard ratios (HRs) using multivariate Cox proportional
               hazards regressions. RESULTS: Among 608,251 elderly NH
               residents, 57,398 (9.4\%) died of COVID-related illness April 1
               to December 22, 2020. About 46.9\% (26,893) of these COVID-19
               deaths occurred without prior COVID-19 hospitalizations. We
               observed a consistently increasing age trend for COVID-19
               deaths. Racial/ethnic minorities generally shared a similarly
               high risk of NH COVID-19 deaths with Whites. NH facility
               characteristics including for-profit ownership and low health
               inspection ratings were associated with higher death risk.
               Resident characteristics, including male (HR 1.69), end-stage
               renal disease (HR 1.42), cognitive impairment (HR 1.34), and
               immunocompromised status (HR 1.20) were important death risk
               factors. Other individual-level characteristics were less
               predictive of death than they were in community-dwelling
               population. CONCLUSIONS: Low NH health inspection ratings and
               private ownership contributed to COVID-19 death risks. Nearly
               half of NH COVID-19 deaths occurred without prior COVID-19
               hospitalization and older residents were less likely to get
               hospitalized with COVID-19. No substantial differences were
               observed by race/ethnicity and socioeconomic status for NH
               COVID-19 deaths.",
  journal   = "J. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Medicare; deaths; elderly; hospitalizations; nursing
               home; pandemic; risk factors",
  language  = "en"
}

@ARTICLE{Li2021-gi,
  title     = "Successful recovery of a patient with multiple myeloma from
               severe coronavirus disease 2019 ({COVID-19}) pneumonia during
               the first chemotherapy cycle: A case report",
  author    = "Li, Ziping and Chen, Yan and Yang, Bohan and Song, Haiping and
               Chen, Wanxin and Zhou, Hao",
  abstract  = "A continuing outbreak of pneumonia associated with the 2019
               novel coronavirus (2019-nCoV) was initially described in Wuhan,
               China in December 2019. Weak and elderly individuals, and those
               with chronic diseases such as hematological malignancies are
               prone to develop severe pneumonia. The humoral immunity of
               patients with multiple myeloma is prevalently low, and their
               inferior immunity further deteriorates during chemotherapy. For
               patients with onco-hematological malignancies infected with
               2019-nCoV during the first chemotherapy cycle, the clinical
               treatment experience is lacking. The present study is a report
               of a 61-year-old patient newly diagnosed with multiple myeloma
               in the key 2019-nCoV outbreak area, who suffered severe
               2019-nCoV pneumonia during the first chemotherapy cycle. The
               present case report demonstrated that a rapidly progressive and
               severe form of pneumonia was a specific clinical feature of
               COVID-19, especially in immunocompromised patients with cancer.
               The treatment strategy combining timely suspending chemotherapy,
               early intervention using intravenous immunoglobulin, interferon
               $\alpha$ inhalation and oral antiviral drugs was effective.
               Therefore, in the pandemic environment, it is strongly recommend
               that the risk of 2019-nCoV infection is assessed prior to
               chemotherapy.",
  journal   = "Exp. Ther. Med.",
  publisher = "Spandidos Publications",
  volume    =  21,
  number    =  4,
  pages     = "392",
  month     =  apr,
  year      =  2021,
  keywords  = "2019 novel coronavirus; SARS-CoV-2; coronavirus disease 2019;
               multiple myeloma; severe pneumonia",
  language  = "en"
}

@ARTICLE{Ortega2021-rp,
  title     = "Rhinovirus and asthma: Challenges and opportunities",
  author    = "Ortega, Hector and Nickle, David and Carter, Laura",
  abstract  = "Human rhinoviruses (RVs) are the primary aetiological agent of
               the common cold. Generally, the associated infection is mild and
               self-limiting, but may also be associated with bronchiolitis in
               infants, pneumonia in the immunocompromised and exacerbation in
               patients with pulmonary conditions such as asthma or chronic
               obstructive pulmonary disease. Viral infection accounts for as
               many as two thirds of asthma exacerbations in children and more
               than half in adults. Allergy and asthma are major risk factors
               for more frequent and severe RV-related illnesses. The
               prevalence of RV-induced wheezing will likely continue to
               increase given that asthma affects a significant proportion of
               the population, with allergic asthma accounting for the
               majority. Several new respiratory viruses and their subgroups
               have been discovered, with various degrees of relevance. This
               review will focus on RV infection in the context of the
               epidemiologic evidence, genetic variability, pathobiology,
               clinical studies in the context of asthma, differences with
               other viruses including COVID-19 and current treatment
               interventions.",
  journal   = "Rev. Med. Virol.",
  publisher = "Wiley",
  volume    =  31,
  number    =  4,
  pages     = "e2193",
  month     =  jul,
  year      =  2021,
  keywords  = "SARS-Cov-2; asthma exacerbations; influenza; rhinovirus",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Agolli2021-me,
  title     = "Fetal complications in {COVID-19} infected pregnant woman: A
               systematic review and meta-analysis",
  author    = "Agolli, Arjola and Agolli, Olsi and Velazco, Diana Fiorela
               S{\'a}nchez and Ahammed, Md Ripon and Patel, Mehrie and
               Cardona-Guzman, Jose and Garimella, Radhika and Rummaneethorn,
               Natcha and Bista, Seema and Abreu, Rafael and Czapp, Nikole and
               Garcia, Manuel",
  abstract  = "Background Pregnancy is an immunocompromised state and, for this
               reason, a pregnant woman is at a higher risk of getting infected
               as compared with a healthy individual. There is limited data
               available regarding the impact of COVD-19 on pregnancy; however,
               the case of miscarriage due to placental infection caused by
               severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
               second trimester has already been reported. Methods We searched
               for all published articles in PubMed, Science Direct, Cochrane,
               Scopus, and Embase. The literature search produced 167 relevant
               publications; 67 manuscripts were further excluded because they
               did not satisfy our inclusion criteria. Out of the remaining 100
               articles, 78 were excluded after full text screening. Therefore,
               a total of 22 articles were eligible for review in our study.
               Results Overall, these 22 studies included a total of 7,034
               participants: 2,689 (38.23\%) SARS-CoV-2 positive pregnant
               women, of which 2,578 (95.87\%) were laboratory confirmed and
               111 (4.13\%) were clinically diagnosed. Among the positive
               patients, there were 174 (6.47\%) cases of abortion, of them 168
               (96.55\%) were spontaneous abortions and 6 (3.45\%) were missed.
               Most patients either reported mild symptoms of fever, cough,
               fatigue, and anosmia or they presented asymptomatic. Conclusion
               Additional investigation and rigorous research are warranted to
               confirm placental pathology mechanisms concerning COVID-19 to
               protect maternal and fetal health.",
  journal   = "Avicenna J. Med.",
  publisher = "Georg Thieme Verlag KG",
  volume    =  11,
  number    =  4,
  pages     = "200--209",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; abortion; coronavirus; pregnancy; pregnancy loss",
  copyright = "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Blot2021-ep,
  title     = "Specific features of the coagulopathy signature in severe
               {COVID-19} pneumonia",
  author    = "Blot, Mathieu and de Maistre, Emmanuel and Bourredjem,
               Abderrahmane and Quenot, Jean-Pierre and Nguyen, Maxime and
               Bouhemad, Belaid and Charles, Pierre-Emmanuel and Binquet,
               Christine and Piroth, Lionel",
  abstract  = "Rationale: COVID-19 displays distinct characteristics that
               suggest a unique pathogenesis. The objective of this study was
               to compare biomarkers of coagulopathy and outcomes in COVID-19
               and non-COVID-19 patients with severe pneumonia. Methods:
               Thirty-six non-COVID-19 and 27 COVID-19 non-immunocompromised
               patients with severe pneumonia were prospectively enrolled, most
               requiring intensive care. Clinical and biological
               characteristics (including plasma biomarkers of coagulopathy)
               were compared. Results: At similar baseline severity, COVID-19
               patients required mechanical ventilation (MV) for significantly
               longer than non-COVID-19 patients (p = 0.0049) and more
               frequently developed venous thrombotic complications (p =
               0.031). COVID-19 patients had significantly higher plasma
               concentrations of soluble VCAM1 (sVCAM1) (5,739 $\pm$ 3,293 vs.
               3,700 $\pm$ 2,124 ng/ml; p = 0.009), but lower levels of
               D-dimers, vWF-A2, sICAM1, sTREM1, VEGF, and P-selectin, compared
               to non-COVID-19 patients. Principal component analysis
               identified two main patterns, with a clear distinction between
               non-COVID-19 and COVID-19 patients. Multivariable regression
               analysis confirmed that sVCAM1 rising levels were independently
               associated with a longer duration of MV. Finally, we identified
               close correlations between sVCAM1 and some features of COVID-19
               immune dysregulation (ie. CXCL10, GM-CSF, and IL-10).
               Conclusion: We identified specific features of the coagulopathy
               signature in severe COVID-19 patients, with higher plasma sVCAM1
               levels, that were independently associated with the longer
               duration of mechanical ventilation. Clinical Trial
               Registration:ClinicalTrials.gov, identifier: NCT03505281.",
  journal   = "Front. Med. (Lausanne)",
  publisher = "Frontiers Media SA",
  volume    =  8,
  pages     = "675191",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; VCAM1; acute respiratory distress syndrome;
               coagulopathy; pneumonia; thrombosis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Mohamed2021-id,
  title     = "{COVID-19} vaccinations: The unknowns, challenges, and hopes",
  author    = "Mohamed, Kawthar and Rzymski, Piotr and Islam, Md Shahidul and
               Makuku, Rangarirai and Mushtaq, Ayesha and Khan, Amjad and
               Ivanovska, Mariya and Makka, Sara A and Hashem, Fareeda and
               Marquez, Leander and Cseprekal, Orsolya and Filgueiras, Igor
               Salerno and Fonseca, Dennyson Leandro M and Mickael, Essouma and
               Ling, Irene and Arero, Amanuel Godana and Cuschieri, Sarah and
               Minakova, Kseniia and Rodr{\'\i}guez-Rom{\'a}n, Eduardo and
               Abarikwu, Sunny O and Faten, Attig-Bahar and Grancini, Giulia
               and Cabral-Marques, Otavio and Rezaei, Nima",
  abstract  = "The entire world has been suffering from the coronavirus disease
               2019 (COVID-19) pandemic since March 11, 2020. More than a year
               later, the COVID-19 vaccination brought hope to control this
               viral pandemic. Here, we review the unknowns of the COVID-19
               vaccination, such as its longevity, asymptomatic spread,
               long-term side effects, and its efficacy on immunocompromised
               patients. In addition, we discuss challenges associated with the
               COVID-19 vaccination, such as the global access and distribution
               of vaccine doses, adherence to hygiene guidelines after
               vaccination, the emergence of novel severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2) variants, and vaccine
               resistance. Despite all these challenges and the fact that the
               end of the COVID-19 pandemic is still unclear, vaccines have
               brought great hope for the world, with several reports
               indicating a significant decline in the risk of COVID19-related
               infection and hospitalizations.",
  journal   = "J. Med. Virol.",
  publisher = "Wiley",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; COVID-19 vaccination; SARS-CoV-2; global assessment;
               global challenges; herd immunity",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Abedi2021-my,
  title     = "Protecting high-risk oncology patients during the {COVID-19}
               pandemic by creating an isolated outpatient clinic",
  author    = "Abedi, Seyed Mohammad and Lekkala, Manidhar and Moftakhar, Bahar
               and Clarke, Tammy and Patel, Arpan",
  abstract  = "PURPOSE: Delivering care for immunocompromised, high-risk
               patients with cancer during a pandemic has proven challenging.
               Patients with cancer on chemotherapy have a high risk of
               mortality if contracted COVID-19. If a patient goes directly to
               the emergency room, multiple contact points with other
               individuals can lead to unnecessary exposures from any airborne
               virus, such as COVID-19. Our cancer center has implemented an
               isolated clinic with personal protective equipment and direct
               access to a COVID-19 rule-out floor to manage those with febrile
               neutropenia (FN). METHODS: We implemented an outpatient,
               isolated, extended-hour clinic with access to personal
               protective equipment, laboratories, and antibiotics for patients
               with FN as a pilot project from April 1 to December 31, 2020,
               with the aim to decrease emergency department (ED) visits for FN
               by 50\%. RESULTS: Since the implementation of our clinic, we
               have screened 74 unique patients during 102 visits, of which 76
               led to a discharge and 26 led to a direct admit, thus avoiding
               the ED. Thirty-nine of these visits were for patients with
               recent travel or a known COVID-19 exposure. Bringing these
               patients to our isolated clinic ensured safety of the
               approximately 200 patients undergoing active treatment in our
               infusion center daily. CONCLUSION: Implementing this clinic has
               thus far successfully decreased the social footprint of our
               highest-risk patients with cancer in the ED considerably. Our
               efforts and hopes of decreasing the possible exposure of our
               immunocompromised patients to COVID-19 as well as the
               unnecessary exposure of the infusion center patients and
               personnel have thus far been effective.",
  journal   = "JCO Oncol Pract",
  publisher = "American Society of Clinical Oncology (ASCO)",
  pages     = "OP2100126",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Mohapatra2021-dj,
  title    = "The microbiota-related coinfections in {COVID-19} patients: a
              real challenge",
  author   = "Mohapatra, Ranjan K and Dhama, Kuldeep and Mishra, Snehasish and
              Sarangi, Ashish K and Kandi, Venkataramana and Tiwari, Ruchi and
              Pintilie, Lucia",
  abstract = "Background: The severe acute respiratory syndrome coronavirus 2
              (SARS-CoV-2), the cause of ongoing global pandemic of coronavirus
              disease 2019 (COVID-19), has infected millions of people around
              the world, especially the elderly and immunocompromised
              individuals. The infection transmission rate is considered more
              rapid than other deadly pandemics and severe epidemics
              encountered earlier, such as Ebola, Zika, Influenza, Marburg,
              SARS, and MERS. The public health situation therefore is really
              at a challenging crossroads. Main body: The internal and external
              and resident microbiota community is crucial in human health and
              is essential for immune responses. This community tends to be
              altered due to pathogenic infections which would lead to severity
              of the disease as it progresses. Few of these resident microflora
              become negatively active during infectious diseases leading to
              coinfection, especially the opportunistic pathogens. Once such a
              condition sets in, it is difficult to diagnose, treat, and manage
              COVID-19 in a patient. Conclusion: This review highlights the
              various reported possible coinfections that arise in COVID-19
              patients vis-{\`a}-vis other serious pathological conditions. The
              local immunity in lungs, nasal passages, oral cavity, and
              salivary glands are involved with different aspects of COVID-19
              transmission and pathology. Also, the role of adaptive immune
              system is discussed at the site of infection to control the
              infection along with the proinflammatory cytokine therapy.",
  journal  = "Beni-Suef Univ. J. Basic Appl. Sci.",
  volume   =  10,
  number   =  1,
  pages    = "47",
  month    =  aug,
  year     =  2021,
  keywords = "Black fungus; COVID-19; Coinfection; Microbiota; Resident
              microflora; SARS-CoV-2",
  language = "en"
}

@ARTICLE{Varshney2021-vk,
  title     = "Synchronous small bowel gangrene with pyelonephritis secondary
               to mucormycosis: A disastrous complication of {COVID-19}
               pandemic",
  author    = "Varshney, Vaibhav K and Swami, Ashish and Thirunavukkarasu,
               Balamurugan and Agarwal, Ashish and Baid, Gaurav",
  abstract  = "Mucormycosis is a rare infection caused by fungi of the order
               Mucorales. The infection frequently involves the rhino-cerebral
               or respiratory system and involvement of the gastrointestinal
               (GI) tract and kidney are rare. It usually infects
               immunocompromised individuals due to various causes and an
               upsurge is hypothesized to be linked with irrational use of
               steroids during coronavirus disease 2019 (COVID-19) pandemic. We
               encountered a rare case of systemic mucormycosis that involved
               both renal as well as mesenteric vessels and led to ischemia of
               both vital organs. The patient developed massive bowel gangrene
               involving the duodenum, proximal jejunum, and left kidney due to
               angioinvasive mucormycosis. The diagnosis of GI mucormycosis may
               further increase during the current pandemic. The physicians, as
               well as surgeons, should be aware of this unwanted complication
               and keep a high index of suspicion for this rare disease.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  6,
  pages     = "e15911",
  month     =  jun,
  year      =  2021,
  keywords  = "angioinvasive; bowel gangrene; covid-19; gastrointestinal
               mucormycosis; vascular necrosis",
  language  = "en"
}

@ARTICLE{West2021-kz,
  title     = "``A double stress'': The mental health impacts of the {COVID-19}
               pandemic among people living with {HIV} in Rakai, Uganda",
  author    = "West, N S and Ddaaki, W and Nakyanjo, N and Isabirye, D and
               Nakubulwa, R and Nalugoda, F and Kagaayi, J and Kennedy, C E",
  abstract  = "Mental health impacts of the COVID-19 pandemic for people living
               with HIV are poorly understood, especially in low-income
               settings. We conducted qualitative semi-structured in-depth
               interviews among people living with HIV (n = 16) and health
               workers (n = 10) in rural Rakai, southcentral Uganda. Data were
               analyzed thematically. We found mental stress during COVID-19
               was compounded by worry about antiretroviral therapy (ART)
               access, distress over inadvertent disclosure of HIV status, fear
               that coronavirus infection would have more severe outcomes for
               immunocompromised individuals, and exacerbated poverty and
               economic stress. Mental health support for people living with
               HIV deserves greater attention during the COVID-19 pandemic and
               beyond.",
  journal   = "AIDS Behav.",
  publisher = "Springer Science and Business Media LLC",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Distress; HIV; Mental health",
  language  = "en"
}

@ARTICLE{Goswami2021-yx,
  title     = "{COVID-19} pandemic and preparedness of anesthesia team in a
               stand-alone cancer centre in Eastern India",
  author    = "Goswami, Jyotsna and Sarkar, Anshuman and Mukherjee, Sudipta and
               Ghosh, Pralay S and Pal, Angshuman R and Barman, Suparna M and
               Banerjee, Sumantra S and Nandi, Rudranil and Bhattacharyya,
               Sanjay",
  abstract  = "India came under the grip of the coronavirus disease-2019
               (COVID-19) pandemic and is now seeing rising graph. Cancer
               patients are specially in the high-risk group because of their
               immunocompromised status on one hand and progressive disease on
               the other hand. Hence, cancer care facility needs to prepare a
               clear strategy to manage their space, staff and supplies so that
               optimum patient care can be continued in the face of COVID-19
               pandemic. In addition, infection prevention measures need to be
               robust to reduce in-hospital transmission. The working area of
               anesthesia and Critical Care is spread over the whole hospital
               such as operating room, ICU, isolation area, out-patient dept
               (OPD) area, various diagnostic areas and in-patient dept (IPD)
               to attend code blue calls. In this article, we describe the
               preparedness and initial response measures of the anesthesia and
               Critical Care department of a stand-alone tertiary level cancer
               care centre in eastern part of India. These include engineering
               controls such as identification and preparation of an isolation
               operating room, administrative measures such as modification of
               workflow, introduction and adequate supply of personal
               protective equipment for staff and formulation of clinical
               guidelines for anesthetic management. These containment measures
               are necessary to continue care of cancer patients, optimize the
               quality of care provided to COVID-19 positive cancer patients
               and to reduce the risk of viral transmission to other patients
               or healthcare providers.",
  journal   = "J. Anaesthesiol. Clin. Pharmacol.",
  publisher = "Medknow",
  volume    =  37,
  number    =  2,
  pages     = "284--289",
  month     =  apr,
  year      =  2021,
  keywords  = "COVID-19; Cancer care; pandemic; preparedness",
  language  = "en"
}

@ARTICLE{Boekel2021-xr,
  title     = "Immunity after {COVID-19} vaccinations in immunocompromised
               patients with psoriasis",
  author    = "Boekel, Laura",
  journal   = "Lancet Rheumatol",
  publisher = "Elsevier BV",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Coggins2021-ph,
  title    = "Adverse effects and antibody titers in response to the {BNT162b2}
              {mRNA} {COVID-19} vaccine in a prospective study of healthcare
              workers",
  author   = "Coggins, Si{\^a} Ana A and Laing, Eric D and Olsen, Cara H and
              Goguet, Emilie and Moser, Matthew and Jackson-Thompson, Belinda M
              and Samuels, Emily C and Pollett, Simon D and Tribble, David R
              and Davies, Julian and Illinik, Luca and Hollis-Perry, Monique
              and Maiolatesi, Santina E and Duplessis, Christopher A and
              Ramsey, Kathleen F and Reyes, Anatalio E and Alcorta, Yolanda and
              Wong, Mimi A and Wang, Gregory and Ortega, Orlando and Parmelee,
              Edward and Lindrose, Alyssa R and Snow, Andrew L and Malloy,
              Allison M W and Letizia, Andrew G and Powers, John H and Burgess,
              Timothy H and Broder, Christopher C and Mitre, Edward",
  abstract = "Background: mRNA COVID-19 vaccines are playing a key role in
              controlling the COVID-19 pandemic. The relationship between
              post-vaccination symptoms and strength of antibody responses is
              unclear. Objective: To determine whether adverse effects caused
              by vaccination with the Pfizer/BioNTech BNT162b2 vaccine are
              associated with the magnitude of vaccine-induced antibody levels.
              Design: Single center, prospective, observational cohort study.
              Setting: Participants worked at Walter Reed National Military
              Medical Center and were seen monthly at the Naval Medical
              Research Center Clinical Trials Center. Participants: Generally
              healthy adults that were not severely immunocompromised, had no
              history of COVID-19, and were seronegative for SARS-CoV-2 spike
              protein prior to vaccination. Measures: Severity of
              vaccine-associated symptoms was obtained through participant
              completed questionnaires. Testing for IgG antibodies against
              SARS-CoV-2 spike protein and receptor binding domain was
              conducted using microsphere-based multiplex immunoassays.
              Results: 206 participants were evaluated (69.4\% female, median
              age 41.5 years old). We found no correlation between
              vaccine-associated symptom severity scores and vaccine-induced
              antibody titers one month after vaccination. We also observed
              that 1) post-vaccination symptoms were inversely correlated with
              age and weight and more common in women, 2) systemic symptoms
              were more frequent after the second vaccination, 3) high symptom
              scores after first vaccination were predictive of high symptom
              scores after second vaccination, and 4) older age was associated
              with lower titers. Limitations: Study only observes antibody
              responses and consists of healthy participants. Conclusions: Lack
              of post-vaccination symptoms following receipt of the BNT162b2
              vaccine does not equate to lack of vaccine-induced antibodies one
              month after vaccination. This study also suggests that it may be
              possible to design future mRNA vaccines that confer robust
              antibody responses with lower frequencies of vaccine-associated
              symptoms. Funding: This study was executed by the Infectious
              Disease Clinical Research Program (IDCRP), a Department of
              Defense (DoD) program executed by the Uniformed Services
              University of the Health Sciences (USUHS) through a cooperative
              agreement by the Henry M. Jackson Foundation for the Advancement
              of Military Medicine, Inc. (HJF). This project has been funded by
              the Defense Health Program, U.S. DoD, under award HU00012120067.
              Project funding for JHP was in whole or in part with federal
              funds from the National Cancer Institute, National Institutes of
              Health, under Contract No. HHSN261200800001E. The funding bodies
              have had no role in the study design or the decision to submit
              the manuscript for publication.",
  journal  = "medRxiv",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Ahirwar2021-kw,
  title     = "The second wave of {COVID-19} results in outbreak of
               mucormycosis: diabetes and immunological perspective",
  author    = "Ahirwar, Ashok Kumar and Kaim, Kirti and Ahirwar, Pradeep and
               Kumawat, Rajani",
  abstract  = "OBJECTIVES: To evaluate the potential relationship between
               COVID-19 pandemic and mucormycosis outbreak. METHODS: PubMed,
               Embase, Cochrane Library and Google Scholar were searched for
               the term ``COVID-19 and mucormycosis'' up to May 31, 2021.
               RESULTS: After the second wave of COVID-19, the mucormycosis
               outbreak complicates the natural course of COVID-19. COVID-19
               patients with uncontrolled diabetes mellitus with diabetic
               ketoacidosis, excessive glucocorticoid use, prolonged
               neutropenia, malnutrition and any underlying immunocompromised
               conditions are at risk of developing mucormycosis. CONCLUSIONS:
               Hyperglycaemia impairs the motility of phagocytes and also
               decreases the oxidative and non-oxidative mechanism of killing
               the causative pathogen. Chronic hyperglycemia also leads to the
               formation of advanced glycation end-products (AGE), which leads
               to cross-linking between key proteins of inflammation and
               connective tissue such as collagen which makes tissue
               susceptible to immunological dysregulation. The receptor for AGE
               (RAGE) is expressed on various inflammatory cells including
               neutrophils and its activation by AGEs leads to activation of
               many down signaling pathways which ultimately leads to
               impairment of the inflammatory response. Hyperglycemia also
               increases serum Nitric Oxide (NO), which decreases neutrophil
               motility and reduces the synthesis and release of various
               inflammatory mediators such as TNF-$\alpha$ and IL-1$\beta$,
               IL-6. It also decreases the expression of adhesion molecules
               such as LFA-1 and ICAM-2, on neutrophils. Steroids cause
               immunosuppression majorly by inhibiting the NF-$\kappa$B pathway
               which is a transcription factor involved in the synthesis of
               many immunological mediators such as Interleukins, cytokines,
               chemokines, etc., and various adhesion molecules.",
  journal   = "Horm. Mol. Biol. Clin. Investig.",
  publisher = "Walter de Gruyter GmbH",
  volume    =  0,
  number    =  0,
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; diabetes mellitus; diabetic ketoacidosis;
               mucormycosis; steroid",
  language  = "en"
}

@ARTICLE{Medrzycka-Dabrowska2021-df,
  title     = "Carbapenem-resistant Klebsiella pneumoniae infections in {ICU}
               {COVID-19} patients-A scoping review",
  author    = "M{\k e}drzycka-D{\k a}browska, Wioletta and Lange, Sandra and
               Zorena, Katarzyna and D{\k a}browski, Sebastian and Ozga, Dorota
               and Tomaszek, Lucyna",
  abstract  = "INTRODUCTION: The spread of multidrug-resistant pathogens is a
               serious problem and challenge for the whole medical community.
               Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in
               immunocompromised patients have a severe course and may be
               fatal. Increasingly, these bacteria are exhibiting resistance to
               carbapenem antibiotics, which have been used as so-called drugs
               of last resort. The emergence of the new coronavirus and the
               pandemic that it has caused require changes to protect against
               the spread of the new SARS-CoV-2. These changes paradoxically
               may contribute to the spread of other infections. METHODS:
               PubMed, Cochrane Library databases were searched using relevant
               keywords. A literature review of carbapenem-resistant Klebsiella
               pneumoniae infection in patients hospitalized for COVID-19 was
               conducted according to PRISMA recommendations. A written review
               protocol was not prepared. RESULTS: 1016 studies in scientific
               databases were searched. After rejecting duplicate studies, 964
               results were obtained. Inclusion and exclusion criteria were
               then applied, and studies were qualitatively analyzed. Finally,
               11 studies were included in the review. The results of infected
               patients were from six countries. The prevalence of CRKP in
               Covid-19 patients ranged from 0.35-53\%. The majority of CRKP
               infected patients were male (85\%), with a mean age of 61 years.
               Among isolates, the predominant genes were KPC, OXY-48, CTX-M,
               TEM, NDM and SHV. CONCLUSION: The results presented in our
               review indicate the necessity of paying attention to
               carbapenem-resistant Klebsiella pneumoniae infections in
               patients with COVID-19. In order to prevent the increase of
               bacterial resistance, rational antibiotic therapy should be
               used, as well as continuous control and surveillance of hospital
               infections caused by multidrug-resistant organisms.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  10,
  pages     = "2067",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Klebsiella pneumoniae; carbapenem-resistance",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Desai2021-kl,
  title     = "Epidemiology, clinical features and management of rhino orbital
               mucormycosis in post {COVID} 19 patients",
  author    = "Desai, Esha J and Pandya, Achal and Upadhya, Ila and Patel,
               Trupal and Banerjee, Sourav and Jain, Vaishali",
  abstract  = "COVID 19 infections may be associated with a wide range of
               bacterial and fungal co-infections. Mucormycosis is a fungal
               infection primarily affecting immunocompromised individuals. We
               have observed sudden rise of mucormycosis cases in post COVID 19
               patients. Here we have reported 100 cases of mucormycosis
               associated with COVID 19. To study epidemiology and clinical
               features of rhino orbital mucormycosis in post COVID 19
               patients. To evaluate efficacy of medical as well as surgical
               treatment in such patients. This was an observational mixed
               (retrospective + prospective) study with a duration of 2 months.
               After noting demographic data, necessary radiological
               investigation was advised and representative tissue was sent for
               KOH and histopathological examination. Medical and surgical
               treatment was planned accordingly. Most patients (55\%)
               presented with complaint of headache and facial pain. Hard
               palate involvement was observed in 45\% patients. Unilateral
               presentation (68\%) was more common. Only 25\% patients who
               presented early had normal vision. We reported 22 patients with
               complete loss of vision. Eye movements were restricted in 58\%
               patients. Diabetes mellitus is most common predisposing factor
               (65\%). 9 patients required orbital exentration. Only 18\%
               patients required Amphotericin for more than 14 days. Immune
               dysregulation caused by COVID 19 infection in addition to
               widespread use of steroids and broad-spectrum antibiotics may
               lead to the development mucormycosis. Diabetes Mellitus type II
               is another important risk factor and the presence of both have
               additional effect in causing mucormycosis. Headache and facial
               pain should be considered highly suspicious of mucormycosis.
               Early diagnosis with efficient treatment can improve prognosis.",
  journal   = "Indian J. Otolaryngol. Head Neck Surg.",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--5",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID 19; Fungal rhinosinusitis; Mucormycosis; Rhino orbital",
  language  = "en"
}

@ARTICLE{Shinjo2021-pg,
  title     = "Systemic autoimmune myopathies: A prospective phase 4 controlled
               trial of an inactivated virus vaccine against {SARS-CoV-2}",
  author    = "Shinjo, Samuel K and de Souza, Fernando H C and Borges, Isabela
               B P and Dos Santos, Alexandre M and Miossi, Renata and Misse,
               Rafael G and Medeiros-Ribeiro, Ana C and Saad, Carla G S and
               Yuki, Emily F N and Pasoto, Sandra G and Kupa, L{\'e}onard V K
               and Ceneviva, Carina and Seraphim, J{\'u}lia C and Pedrosa,
               Tatiana N and Vendramini, Margarete B G and Silva, Cl{\'o}vis A
               and Aikawa, N{\'a}dia E and Bonf{\'a}, Eloisa",
  abstract  = "OBJECTIVES: To evaluate immunogenicity and safety of an
               inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies
               (SAMs) and the possible influence of baseline disease
               parameters, comorbidities, and therapy on immune response.
               METHODS: This prospective controlled study included 53 patients
               with SAMs and 106 non-immunocompromised control group (CTRL).
               All participants received two doses of the Sinovac-CoronaVac
               vaccine (28-day interval). Immunogenicity was assessed by
               anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC), anti-S1/S2 IgG
               geometric mean titer (GMT), factor increase GMT (FI-GMT),
               neutralizing antibodies (NAb) positivity, and median
               neutralizing activity after each vaccine dose (D0 and D28) and
               six weeks after the second dose (D69). Participants with
               pre-vaccination positive IgG serology and/or NAb and those with
               RT-PCR confirmed COVID-19 during the protocol were excluded from
               immunogenicity analysis. RESULTS: Patients and CTRL had
               comparable sex (P>0.99) and age (P=0.90). Immunogenicity of 37
               patients and 79 CTRL na{\"\i}ve participants revealed at D69, a
               moderate but significantly lower SC (64.9\% vs. 91.1\%, P0.05).
               CONCLUSION: Sinovac-CoronaVac is safe and has a moderate
               short-term immunogenicity in SAMs, but reduced compared to CTRL.
               We further identified that immunosuppression is associated with
               diminished NAb positivity. CLINICAL TRIAL REGISTRATION NUMBER:
               \#NCT04754698.",
  journal   = "Rheumatology (Oxford)",
  publisher = "Oxford University Press (OUP)",
  month     =  oct,
  year      =  2021,
  keywords  = "Anti-SARS-CoV-2 vaccine; COVID-19; immunogenicity; myositis;
               neutralizing antibodies; safety",
  language  = "en"
}

@ARTICLE{Jeronimo2021-ps,
  title    = "Oral candidiasis and {COVID-19} in users of removable dentures:
              Is special oral care needed?",
  author   = "Jer{\^o}nimo, Laura Silva and Esteves Lima, Rafael Paschoal and
              Suzuki, Tha{\'\i}s Yumi Umeda and Discacciati, Jos{\'e} Augusto
              C{\'e}sar and Bhering, Cl{\'a}udia Lopes Brilhante",
  abstract = "Elderly patients with systemic disorders and immunocompromised
              patients seem to have a higher risk of developing morbidity from
              COVID-19. Candida albicans (C. albicans) is a potentially
              dangerous pathogen for these patients, especially for denture
              wearers with prosthetic stomatitis who require mechanical
              ventilation. C. albicans infection, the main candidiasis
              infection associated with denture wear, can complicate COVID-19
              and increase the associated morbidity and mortality. Therefore,
              early diagnosis of C. albicans infection in COVID-19 patients is
              important to establish more effective antifungal treatment
              methods and prophylaxis strategies. Hospitalized COVID-19
              patients should undergo an oral examination to assess their oral
              health, and those with poor oral health should receive the
              appropriate care and monitoring.",
  journal  = "Gerontology",
  pages    = "1--6",
  month    =  apr,
  year     =  2021,
  keywords = "Coronavirus disease 2019; Dental care; Denture; Mechanical
              ventilation; Oral candidiasis; Stomatitis",
  language = "en"
}

@ARTICLE{Panwar2021-uj,
  title     = "Mucormycosis in {COVID} Diabetic Patients: A horrifying triad!",
  author    = "Panwar, Parshika and Gupta, Anish and Kumar, Amit and Gupta,
               Bhavna and Navriya, Shiv C",
  abstract  = "Infectious diseases with the coronavirus disease-2019 (COVID-19)
               can be linked to various microbial and fungal coinfections.
               Mucormycosis is an invasive opportunistic infection that enters
               as inhalation of fungal spores through the nose or paranasal
               sinuses in diabetic and immunocompromised patients. We present
               our experience of managing seven cases of recent COVID-19
               infection with uncontrolled diabetes who developed rhino-orbital
               mucormycosis. All patients were diagnosed by clinical
               examination and imaging and managed by emergency surgical
               debridement and liposomal amphotericin-B. A lethal triad of
               impaired immunity due to COVID-19 infection, state of
               hyperglycemia, increased use of steroids, or rampant
               broad-spectrum antimicrobials works as fertile soil and may
               assist in the growth or alleviation of a fungal infection.
               Healthcare professionals must be aware of the potential of
               secondary invasive fungal infections in diabetic patients with
               moderate to severe category of COVID-19 infectious disease,
               especially on steroid therapy. How to cite this article: Panwar
               P, Gupta A, Kumar A, Gupta B, Navriya SC. Mucormycosis in COVID
               Diabetic Patients: A Horrifying Triad! Indian J Crit Care Med
               2021;25(11):1314-1317.",
  journal   = "Indian J. Crit. Care Med.",
  publisher = "Jaypee Brothers Medical Publishing",
  volume    =  25,
  number    =  11,
  pages     = "1314--1317",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID; Diabetes mellitus; Hyperglycemia; Mucormycosis; Steroid",
  language  = "en"
}

@ARTICLE{Katz2021-ef,
  title     = "Herpes simplex and herpes zoster viruses in {COVID-19} patients",
  author    = "Katz, Joseph and Yue, Sijia and Xue, Wei",
  abstract  = "BACKGROUND: Reactivation of herpes family viruses in
               immunocompromised patients may result in detrimental outcomes
               for the hosts; therefore, herpes simplex virus-1 and varicella
               zoster virus infections in the context of COVID-19 may have
               clinical and prognostic implications. Several reports associated
               this human herpes virus with COVID-19 infection and have claimed
               that it can be an indicator for latent COVID-19 infection.
               However, since most of these were case reports, it is impossible
               to assess the prevalence of these associations. METHODS: The
               University of Florida patient registry i2b2 with ICD-10
               diagnosis codes was used for retrieval of patients with
               diagnosis of COVID-19 and each of the other viruses over the
               period of October 2015-June 2020. RESULTS: The prevalence of the
               herpes simplex-1 occurrence in the COVID-19 group was 2.81\%
               compared to 0.77\% in the hospital population odds ratio of
               5.27. When adjusted for gender, race, and age, the odds were
               5.18, 4.48, and 4.61, respectively. After adjustment for
               respiratory disease, endocrine disease, obesity, diabetes,
               circulatory disease, and smoking, the odds were 1.94, 3.18,
               1.37, 3.54, 3.7, and 5.1, respectively. The prevalence of the
               varicella zoster virus in COVID-19 patients was 1.8\% compared
               to 0.43\% in the hospital population, odds ratio of 5.26 before
               adjustment, and 5.2, 5.47, and 4.76 after adjusting for gender,
               age, and race, respectively. When adjusted for respiratory
               disease, endocrine disease, obesity, diabetes, and circulatory
               and neurological diseases, the odds were 1.3, 2.2, 1.48, 2.33,
               2.85, and 2.6, respectively. CONCLUSION: Herpes simplex-1 and
               varicella zoster viruses are strongly associated with COVID-19
               infection.",
  journal   = "Ir. J. Med. Sci.",
  publisher = "Springer Science and Business Media LLC",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Herpes simplex virus; Herpes zoster virus",
  language  = "en"
}

@ARTICLE{Nguyen2021-nz,
  title     = "Vaccine effectiveness against {COVID-19} hospitalization in
               adults in France: a test negative case control study",
  author    = "Nguyen, Liem Binh Luong and Bauer, Rebecca and Lesieur, Zineb
               and Galtier, Florence and Duval, Xavier and Vanhems, Philippe
               and Lain{\'e}, Fabrice and Tattevin, Pierre and Durier,
               Christine and Launay, Odile and {FLUVAC Study group}",
  abstract  = "BACKGROUND: Measuring vaccine effectiveness (VE) using real-life
               data is critical to confirm the effectiveness of licensed
               vaccine, which could strengthen vaccination adherence. METHODS:
               We measured VE against adult COVID-19 hospitalization in five
               hospitals in France using a test negative design. We compared
               the odds of vaccinated patients hospitalized with COVID-19 with
               the odds of vaccinated patients hospitalized for the same
               symptoms with a negative test. RESULTS: A total of 853 patients
               (463 cases and 390 controls) were included, with a total of 170
               patients vaccinated (104 with one dose, 65 with two doses, and
               one with three doses). There were four cases of breakthrough
               infections, all in immunocompromised patients. The VE was 84.0\%
               (CI0.95=[72.6 ; 90.6]) for one dose and 96.2\% (CI0.95=[86.8 ;
               98.9]) for two doses. CONCLUSION: Our results confirm the high
               VE of COVID-19 vaccine in France to prevent hospitalizations due
               to the alpha variant.",
  journal   = "Infect Dis Now",
  publisher = "Elsevier BV",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; France; alpha variant; vaccine; vaccine effectiveness",
  language  = "en"
}

@ARTICLE{Cordero2021-jv,
  title     = "Fight of the unfit: protecting the immunocompromised and those
               with certain medical conditions during the {COVID-19} pandemic",
  author    = "Cordero, Dalmacito A",
  journal   = "J. Public Health (Oxf.)",
  publisher = "Oxford University Press (OUP)",
  month     =  may,
  year      =  2021,
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Yuvaraj2021-tt,
  title    = "Gastric mucormycosis with splenic invasion a rare abdominal
              complication of {COVID-19} pneumonia",
  author   = "Yuvaraj, M and Mathapati, Pavankumar M and Seena, C R and
              Ramaswami, Sukumar",
  abstract = "Mucormycosis (previously called zygomycosis or phycomycosis) is
              an uncommon opportunistic infection with the gastrointestinal
              form being the rarest occurrence and one of the most lethal
              infections known to humanity. The most common risk factors
              predisposing to develop gastric mucormycosis are uncontrolled
              diabetes mellitus, stem cell transplantation, or underlying any
              hematologic malignancy and major trauma. Pain abdomen,
              hematemesis, and melena are common symptoms which the patient
              presents. The exact diagnosis of gastric mucormycosis can be
              missed due rarity of the disease. A high level of suspicion is
              required in the early diagnosis and management of disease,
              particularly in immunocompromised patients. The radiological
              imaging modalities such as CT scan or MRI of the abdomen
              initially usually reveal non-specific findings such as mucosal
              wall thickening, mass, and reactive lymphadenopathy and prompt
              additional investigation with endoscopic or surgical biopsy of
              the lesions. The disease outcome and mortality are very high with
              gastrointestinal mucormycosis.",
  journal  = "J. Clin. Imaging Sci.",
  volume   =  11,
  pages    = "62",
  month    =  nov,
  year     =  2021,
  keywords = "COVID-19 pneumonia; Gastric mucormycosis; Phycomycosis; Rhizopus;
              Zygomycosis",
  language = "en"
}

@ARTICLE{Tehrani2021-fb,
  title     = "{COVID-19} re-infection or persistent infection in patient with
               acute myeloid leukaemia M3: a mini review",
  author    = "Tehrani, H A and Darnahal, M and Nadji, S A and Haghighi, S",
  abstract  = "Coronavirus disease 2019 (COVID-19) pandemic has affected more
               than 40 million people worldwide. Some patients had episodes of
               symptom recurrence after the first episode of infection with
               variable intervals. There are multiple issues and hypotheses
               about re-infection or re-activation of the virus, especially in
               immunocompromised patients. In this paper, we present details of
               an individual with a recent history of COVID-19 who proceeded to
               acute myeloid leukaemia M3 and immunosuppression by
               chemotherapy, then we review some recently published articles
               about possible re-infection or re-activation.",
  journal   = "New Microbes New Infect.",
  publisher = "Elsevier BV",
  volume    =  39,
  number    =  100830,
  pages     = "100830",
  month     =  jan,
  year      =  2021,
  keywords  = "Acute myeloid leukaemia; coronavirus disease-19; re-infection",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Momenimovahed2021-vk,
  title     = "Psychological distress among cancer patients during {COVID-19}
               pandemic in the world: A systematic review",
  author    = "Momenimovahed, Zohre and Salehiniya, Hamid and Hadavandsiri,
               Fatemeh and Allahqoli, Leila and G{\"u}nther, Veronika and
               Alkatout, Ibrahim",
  abstract  = "Aim: Patients with malignancies, experience high rates of
               psychological distress. Fear of Corona-infection combined with
               the interruptions in some treatment programs might affect the
               psychological health of cancer patients. This review study was
               conducted to investigate the psychological distress among cancer
               patients during COVID-19 pandemic to offer system-adapted
               individual solutions. Materials and methods: To identify the
               psychological distress of cancer patients, a comprehensive
               search was carried out in PubMed, Web of Science, and Scopus.
               English language and original articles were included in this
               study. Articles that addressed any psychological distress among
               cancer patients during COVID-19 pandemic were included. Results:
               At first 1,410 articles, were included in the study. After
               removing duplicate articles and reviewing the title and
               abstract, 55 articles were selected for the review. The findings
               of this study revealed COVID-19 greatly affects psychological
               health of cancer patients. Fear of COVID-19, fear of disease
               progression, disruption of oncology services, cancer stage, and
               immunocompromised status were the most common causes of
               psychological distress in oncology patients which can influence
               patients' decisions about treatment. Conclusion: The COVID-19
               related anxiety is an expected reaction to the current
               situation. Although psychological distress affects many people,
               it can confuse cancer patients to the point that they refuse to
               continue treatment for the fear of infection and worsening of
               their condition. Since the end of this pandemic is unknown, this
               action can endanger the health and prognosis of this group of
               patients, so it seems that using psychological interventions and
               intensive counseling in the current situation is one of the main
               priorities for cancer patients.",
  journal   = "Front. Psychol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "682154",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; anxiety; cancer; depression; distress; fear",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Izumiya2022-fl,
  title     = "A case of influenza-associated invasive aspergillosis with
               cerebral hemorrhage due to infectious vasculopathy",
  author    = "Izumiya, Ryou and Fujita, Yasuhiko and Amagai, Teruyoshi",
  abstract  = "An invasive aspergillosis (IA) primarily occurs among
               immunocompromised patients. Recently with an influenzae
               infection prevalently spreading, influenzae-associated invasive
               aspergillosis (IAIA) has been reported occasionally. By
               contrast, neuroleptic malignant syndrome (NMS) occurs rarely in
               psychiatric patients who are treated with Olanzapine. We report
               a 43 years old male with psychiatric disorder who had developed
               IAIA followed by NMS and cerebral hemorrhage as the result of
               aspergillus invasion to cerebral vessels. He had also
               super-infection of COVID-19, 13 months later to be saved
               completely after invasive mechanical respiratory supports. From
               clinical aspects, we would emphasize that it is of importance to
               find earlier co-occurrence of IAIA patients with cerebral
               hemorrhage due to secondary infectious vasculopathy of IA.",
  journal   = "Radiol. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  17,
  number    =  2,
  pages     = "326--331",
  month     =  feb,
  year      =  2022,
  keywords  = "COVID-19; Cerebral hemorrhage; Co-infection; Infectious
               vasculopathy; Influenza-associated IA; Invasive aspergillosis
               (IA); Neuroleptic malignant syndrome; Super-infection",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Knight2021-jp,
  title     = "Symptoms and clinical outcomes of Coronavirus disease 2019 in
               the outpatient setting",
  author    = "Knight, Dacre and Downes, Katheryne and Munipalli, Bala and
               Halkar, Meghana G and Logvinov, Ilana I and Speicher, Leigh L
               and Hines, Stephanie L",
  abstract  = "Because most cases of coronavirus disease 2019 (COVID-19) are
               not severe, understanding the epidemiology of mild cases has
               important clinical implications. We aimed to describe the
               symptom profile and associated outcomes in a virtual outpatient
               COVID-19 clinic. We conducted a prospective cohort study from
               March through June 2020. We included 106 patients with positive
               results for SARS-CoV-2, followed up until they had 2 sequential
               negative tests. Exploratory regression analyses identified
               potential prognostic symptoms or risk factors associated with
               outcomes, including emergency department (ED) visits,
               hospitalizations, and time to resolution of viral shedding. The
               mean (range) patient age was 51 (18-86) years, 50\% were men,
               and 36.5\% had at least 1 risk factor, most commonly asthma
               (16\%) and diabetes (10\%). Most patients (98.1\%) had
               symptoms-cough (80.4\%), fatigue (67.6\%), fever (66.0\%),
               headache (49.0\%), and ageusia (46.9\%). Nine (8.5\%) patients
               were admitted to the ED, 5 (4.7\%) were hospitalized, and none
               died. Asthma (RR = 7.13, P = .001) and being immunocompromised
               (RR = 3.44, P = .03) were associated with higher risks of
               adverse outcomes. Asthma (HR = 0.56, P = .04) and early symptoms
               of ageusia (HR= 0.50, P = .01) or myalgia (HR = 0.63, P = .04)
               were associated with significantly longer duration of viral
               shedding. In contrast to reports about severe cases of COVID-19,
               we found a higher incidence of sinus symptoms, gastrointestinal
               symptoms, and myalgia and a lower incidence of fever, anosmia,
               and ageusia among our mild/moderate cases. Asthma and
               immunocompromised status were associated with adverse outcomes,
               and asthma and early symptoms of ageusia or myalgia with
               significantly longer duration of viral shedding.",
  journal   = "SN Compr Clin Med",
  publisher = "Springer Science and Business Media LLC",
  volume    =  3,
  number    =  1,
  pages     = "1--8",
  month     =  jan,
  year      =  2021,
  keywords  = "Clinical epidemiology; Disease management; Infectious disease;
               Pulmonary diseases; Telemedicine",
  language  = "en"
}

@ARTICLE{Boongird2021-jj,
  title     = "Short-term immunogenicity profiles and predictors for suboptimal
               immune responses in patients with end-stage kidney disease
               immunized with inactivated {SARS-CoV-2} vaccine",
  author    = "Boongird, Sarinya and Chuengsaman, Piyatida and Setthaudom,
               Chavachol and Nongnuch, Arkom and Assanatham, Montira and
               Phanprasert, Salinnart and Kitpermkiat, Rungthiwa and
               Kiertiburanakul, Sasisopin and Malathum, Kumthorn and
               Phuphuakrat, Angsana and Davenport, Andrew and Bruminhent,
               Jackrapong",
  abstract  = "INTRODUCTION: Patients with end-stage kidney disease (ESKD) are
               at risk of severe coronavirus disease and mortality.
               Immunogenicity of severe acute respiratory syndrome coronavirus
               2 (SARS-CoV-2) inactivated whole-virus vaccine in patients with
               ESKD has never been explored. METHODS: We conducted a
               prospective cohort study of 60 patients with ESKD and 30 healthy
               controls. All participants received two doses of an inactivated
               whole-virus SARS-CoV-2 vaccine (Sinovac Biotech Ltd) 4 weeks
               apart. SARS-CoV-2-specific humoral and cell-mediated immune
               responses were investigated and referenced with healthy
               controls. RESULTS: After two doses, an anti-receptor-binding
               domain immunoglobulin G of 50 AU/ml or greater was present in 53
               of 60 patients (88\%) in the ESKD group and all participants
               (100\%) in the control group (P = 0.05). The percentage of
               patients with ESKD and controls with neutralizing antibodies of
               35\% threshold or greater was 58\% and 88\%, respectively (P =
               0.01). Furthermore, the proportion of patients with ESKD and
               S1-specific T cell response was comparable with controls (82\%
               vs. 77\%, P = 0.45). Old age, high ferritin level, and low
               absolute lymphocyte count were independently associated with
               poor humoral immune responses. CONCLUSIONS: Patients with ESKD
               could develop similar SARS-CoV-2-specific cell-mediated immune
               responses compared to healthy controls, although suboptimal
               humoral immune responses were observed following two doses of
               SARS-CoV-2 vaccination. Therefore, patients with ESKD and the
               abovementioned factors are at risk of generating inadequate
               humoral immune responses, and a vaccine strategy to elicit
               greater immunogenicity among these relatively immunocompromised
               patients is warranted. (Thai Clinical Trials Registry,
               TCTR20210226002).",
  journal   = "Infect. Dis. Ther.",
  publisher = "Springer Science and Business Media LLC",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; Dialysis; Inactivated vaccine; Neutralizing antibody;
               Receptor-binding domain",
  copyright = "https://creativecommons.org/licenses/by-nc/4.0",
  language  = "en"
}

@ARTICLE{Loubet2021-gw,
  title     = "Patients' perception and knowledge about influenza and
               pneumococcal vaccination during the {COVID-19} pandemic: An
               online survey in patients at risk of infections",
  author    = "Loubet, Paul and Rouvi{\`e}re, Jalini and Merceron, Adeline and
               Launay, Odile and Sotto, Albert and {On Behalf Of The Avnir
               Group}",
  abstract  = "INTRODUCTION: The objective of our study was to assess, in an
               at-risk population, perception and knowledge about influenza and
               pneumococcal vaccinations. METHODS: An anonymous web-based
               survey was submitted to patients recruited in France, from both
               an Ipsos internal panel and AVNIR patient associations. The
               study was conducted between July and October 2020, in the
               context of the COVID-19 pandemic. RESULTS: Overall, 2177
               questionnaires from patients at risk of infection were analyzed.
               Almost all respondents (86\%, 1869/2177) declared themselves to
               be favorable to vaccination. Nearly half of the patients (49\%,
               1069/2177) were aware of which vaccine was recommended for their
               specific situation. This percentage was significantly (p <
               0.001) higher for members of a patient association and for
               people affected by multiple chronic conditions and varied
               according to the type of condition. Almost two-thirds of
               patients (1373/2177) declared having been vaccinated during the
               2019/2020 influenza season, and 41\% (894/2177) were certain
               about being up to date with the pneumococcal vaccination. The
               main barriers to vaccination for influenza are the fear of side
               effects, doubt regarding the efficacy of the vaccine and for
               pneumococcal vaccination, and the absence of suggestions by the
               healthcare professionals (HCPs), as 64\% of respondents were not
               recommended to obtain pneumococcal vaccination. To improve
               vaccine coverage, information is of prime importance and GPs are
               recognized as the main HCP to inform about vaccination. Nearly
               two-thirds (62\%, 1360/2177) of patients declared that the
               COVID-19 pandemic convinced them to have all the recommended
               vaccines. CONCLUSION: Our study highlighted the nonoptimal
               vaccine coverage in at-risk populations despite a highly
               positive perception of vaccines and confirmed that physicians
               are on the front lines to suggest and recommend these
               vaccinations, especially in the current pandemic context, which
               may be used to promote other vaccines.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  11,
  pages     = "1372",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19 vaccines; immunization; immunocompromised; pneumococcal
               vaccines; seasonal influenza vaccines; vaccination; vaccination
               coverage",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Alpert2021-ti,
  title     = "Secure messaging and {COVID-19}: A content analysis of
               patient-clinician communication during the pandemic",
  author    = "Alpert, Jordan M and Campbell-Salome, Gemme and Gao, Cayle and
               Markham, Merry Jennifer and Murphy, Martina and Harle,
               Christopher A and Paige, Samantha R and Krenz, Till and Bylund,
               Carma L",
  abstract  = "Background: Coronavirus disease 2019 (COVID-19) immediately
               impacted patient-clinician communication, particularly in the
               oncology setting. Relatedly, secure messaging (SM) usage greatly
               increased, yet it is unknown what was discussed and whether the
               technology was utilized to disseminate information. Aims: This
               study aimed at identifying the most frequently discussed topics
               using SM as well as at understanding how the communication
               process transpired during the early stages of the pandemic.
               Materials and Methods: A mixed-methods design was utilized,
               consisting of a content analysis of more than 4,200 secure
               messages, aggregated into 1,454 patient-clinician discussions.
               Data were collected from February 2020 to May 2020. Discussions
               were from various oncology departments and included physicians,
               physician assistants, and nurses. Based on the identified
               categories, a thematic analysis was conducted to understand the
               nuances occurring within discussions. Results: Out of the 1,454
               discussions, 26\% (n = 373) related to COVID-19. Of the COVID-19
               discussion, the most frequently coded category was ``changes,
               adjustments, and re-arranging care'' (65\%, n = 241), followed
               by ``risk for COVID-19'' (24\%, n = 90), ``precautions inside
               the hospital'' (18\%, n = 66), and ``precautions outside the
               hospital'' (14\%, n = 52). Natural language processing
               techniques were used to confirm the validity of the results.
               Thematic analysis revealed that patients were proactive in
               rescheduling appointments, expressed anxiety about being
               immunocompromised, and clinicians were uncertain about providing
               recommendations related to COVID-19. Conclusions: The COVID-19
               outbreak revealed the need for responsive and effective public
               health communication. The SM can disseminate information from
               trusted sources, clinicians, but can be better utilized to
               deliver tailored information for specific patient populations.",
  journal   = "Telemed. J. E. Health.",
  publisher = "Mary Ann Liebert Inc",
  month     =  nov,
  year      =  2021,
  keywords  = "content analysis; electronic health records; patient-clinician
               communication; secure messaging; telehealth; telemedicine",
  language  = "en"
}

@ARTICLE{Abd_Elmohsen2021-nv,
  title     = "Consequences of {COVID-19} on uveitis patients from their own
               perspective: A questionnaire-based study",
  author    = "Abd Elmohsen, Mai Nasser and Youssef, Maha Mohamed and Mamdouh
               Esmat, Sara and Teleb, Doaa Ahmed and Tolba, Doaa Ahmad",
  abstract  = "PURPOSE: Given their immunocompromised status, uveitis patients
               should be particularly careful during the COVID-19 pandemic.
               Treatment compliance and adherence are among the most important
               patient-related determinants of treatment success.To assess the
               effect of the COVID-19 pandemic on the management of uveitis
               patients from their own perspective. METHODS: A questionnaire
               was performed on uveitis patients at Cairo University Hospital
               in the period between June and August 2020. RESULTS: Overall,
               150 responses were received. Almost 20\% patients stopped their
               medications. A total of 61.7\% patients reported no fears
               regarding getting infected with the novel coronavirus. In
               addition, 54\% patients found medical services easily, 26\%
               patients received them through telemedicine, and 34\% patients
               reported worsening of their ocular condition. CONCLUSIONS:
               COVID-19 has caused a decrease in uveitis patient compliance
               with follow-ups, leading to worsening of their ocular condition.
               Economic and psychological effects of COVID-19 pandemic on any
               chronic patient should be addressed to prevent further
               deterioration as the pandemic continues.",
  journal   = "Ocul. Immunol. Inflamm.",
  publisher = "Informa UK Limited",
  pages     = "1--6",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; compliance; immunosuppression; uveitis",
  language  = "en"
}

@ARTICLE{Klein2021-tu,
  title     = "Use of anti-spike monoclonal antibodies in kidney transplant
               recipients with {COVID-19}: Efficacy, ethnic and racial
               disparities",
  author    = "Klein, Elizabeth J and Hardesty, Anna and Vieira, Kendra and
               Farmakiotis, Dimitrios",
  abstract  = "Organ transplant recipients may not mount an adequate immune
               response to COVID-19 infection and therefore may benefit greatly
               from passive immunization with anti-spike monoclonal antibodies
               (mAbs), which have been shown to decrease hospitalization rates
               in the general outpatient population. We evaluated the efficacy
               of mAb therapy in decreasing hospitalizations or emergency room
               (ER) visits among kidney transplant recipients (KTR) with
               COVID-19. We identified KTR with COVID-19 between March 1, 2020
               and April 30, 2021. Patients were excluded if they had
               multi-organ transplant or hospital-acquired COVID-19. We studied
               95 KTR; 20 received mAb. mAb administration was associated with
               a significant decrease in hospitalizations or ER visits (15\%
               vs. 76\%, p < 0.001). This association remained significant
               after adjustment for potential confounders, and analysis of mAb
               administration as a time-dependent variable, with day of symptom
               onset as day 1 (adjusted HR 0.216, p = 0.04). Black or Hispanic
               patients were less likely to receive mAb and more likely to be
               admitted to the hospital or visit the ER. In our KTR population,
               mAb therapy for COVID-19 may have helped decrease
               hospitalizations and ER visits. Healthcare inequities, including
               access to investigational treatments, have been exacerbated by
               the COVID-19 pandemic. Antiviral mAbs are a promising
               therapeutic modality, especially for immunocompromised patients.",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  month     =  sep,
  year      =  2021,
  keywords  = "health services and outcomes research; infection and infectious
               agents-viral; infectious disease; kidney
               transplantation/nephrology; patient survival",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Banerjee2020-kj,
  title     = "``the graying minority'': Lived experiences and psychosocial
               challenges of older transgender adults during the {COVID-19}
               pandemic in India, A qualitative exploration",
  author    = "Banerjee, Debanjan and Rao, T S Sathyanarayana",
  abstract  = "Background: The Coronavirus disease 2019 (COVID-19) has emerged
               as a global health threat. Certain factors like age, an
               immunocompromised state, and social impoverishment, etc. can add
               to health vulnerabilities during this pandemic. One such group
               is older transgender adults, who often bear a combination of
               these risks. As the world is aging fast, their numbers have also
               been increasing. With this in mind, this study explores the
               lived experiences and psychosocial challenges of older
               transgender adults during the COVID-19 pandemic in India.
               Methods: A qualitative approach was used. Ten individuals with
               ``transgender'' identity above the age of 60 were recruited with
               consent through purposive sampling. In-depth interviews were
               conducted on the telephone using a pre-designed interview
               schedule. They were recorded, translated, and transcribed
               verbatim. Hasse's adaptation of Colaizzi's phenomenological
               method was used for analysis. Independent coding and respondent
               validation were used to ensure the rigor of data. Results: The
               super-arching categories (with themes) were marginalization
               (``second'' priority, stigma, social disconnection), the dual
               burden of ``age'' and ``gender'' (ageism, othering, and
               psychosexual difficulties), and multi-faceted survival threats
               (physical, emotional, financial) during the pandemic. Social
               rituals, spirituality, hope, and acceptance of ``gender
               dissonance'' emerged as the main coping factors, whereas their
               unmet needs were social inclusion, awareness related to
               COVID-19, mental health care, and audience to their distress.
               Conclusion: The elderly gender minorities are at increased
               emotional and social risks during the ongoing pandemic, and
               their voices are mostly unheard. The need for policy
               implementation and community awareness about their social
               welfare is vital to improving their health and well-being.",
  journal   = "Front. Psychiatry",
  publisher = "Frontiers Media SA",
  volume    =  11,
  pages     = "604472",
  year      =  2020,
  keywords  = "COVID-19; coronavirus; gender minorities; lived experiences;
               older adults; pandemic; qualitative; transgender",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Elashry2021-ui,
  title     = "Pre and retroperitoneal necrotizing fasciitis after {COVID-19}
               infection: A case report",
  author    = "Elashry, Mohamed M and Alagha, Mohammed and Salama, Modea",
  abstract  = "Necrotizing fasciitis is a serious infection that originates in
               the subcutaneous tissues. We present a case of 52 years old male
               patient who developed preperitoneal and retroperitoneal
               necrotizing fasciitis 2 weeks after the start of Coronavirus-19
               infection. Preoperative abdominal computed tomography with
               intravenous and oral contrast revealed pre and retroperitoneal
               spread of air loculi with turbid fluid patches within necrotic
               tissues. After surgical excision of the lesion,
               histopathological and microbiological examinations of the
               samples revealed necrotizing fasciitis. This is the first report
               of preperitoneal and retroperitoneal necrotizing fasciitis after
               Coronavirus-19 infection in 52 years old male with no history of
               trauma or immunocompromised condition. Coronavirus-19 infection
               may increase the liability of patients to develop overwhelming
               infection and it may also delay the patient presentation causing
               serious health-related emergencies. The findings of necrotizing
               fasciitis on clinical grounds or imaging studies can help in
               diagnosis as well as the surgical intervention and appropriate
               antibiotics can highly impact the prognosis and survival of the
               patient.",
  journal   = "Radiol. Case Rep.",
  publisher = "Elsevier BV",
  volume    =  16,
  number    =  10,
  pages     = "2949--2952",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; Diagnosis; Infection; Necrotizing fasciitis",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Prentice2021-ik,
  title     = "{SARS-CoV-2} vaccination in patients with inflammatory bowel
               disease",
  author    = "Prentice, Ralley E and Rentsch, Clarissa and Al-Ani, Aysha H and
               Zhang, Eva and Johnson, Douglas and Halliday, John and Bryant,
               Robert and Begun, Jacob and Ward, Mark G and Lewindon, Peter J
               and Connor, Susan J and Ghaly, Simon and Christensen, Britt",
  abstract  = "Background: The current COVID-19 pandemic, caused by Severe
               Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has
               drastically impacted societies worldwide. Vaccination against
               SARS-CoV-2 is expected to play a key role in the management of
               this pandemic. Inflammatory conditions such as inflammatory
               bowel disease (IBD) often require chronic immunosuppression,
               which can influence vaccination decisions. Aim: This review
               article aims to describe the most commonly available SARS-CoV-2
               vaccination vectors globally, assess the potential benefits and
               concerns of vaccination in the setting of immunosuppression and
               provide medical practitioners with guidance regarding SARS-CoV-2
               vaccination in patients with IBD. Methods: All published Phase
               1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were
               reviewed. IBD international society position papers, safety
               registry data and media releases from pharmaceutical companies
               as well as administrative and medicines regulatory bodies were
               included. General vaccine evidence and recommendations in
               immunosuppressed patients were reviewed for context. Society
               position papers regarding special populations, including
               immunosuppressed, pregnant and breast-feeding individuals were
               also evaluated. Literature was critically analysed and
               summarised. Results: Vaccination against SARS-CoV-2 is supported
               in all adult, non-pregnant individuals with IBD without
               contraindication. There is the potential that vaccine efficacy
               may be reduced in those who are immunosuppressed; however,
               medical therapies should not be withheld in order to undertake
               vaccination. SARS-CoV-2 vaccines are safe, but data specific to
               immunosuppressed patients remain limited. Conclusions:
               SARS-CoV-2 vaccination is essential from both an individual
               patient and community perspective and should be encouraged in
               patients with IBD. Recommendations must be continually updated
               as real-world and trial-based evidence emerges.",
  journal   = "GastroHep",
  publisher = "Wiley",
  volume    =  3,
  number    =  4,
  pages     = "212--228",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Crohn's disease; SARS-CoV-2; immunocompromised;
               immunosuppression; inflammatory bowel disease; ulcerative
               colitis; vaccination",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Ljubimov2021-rv,
  title     = "Neurosurgery at the crossroads of immunology and nanotechnology.
               New reality in the {COVID-19} pandemic",
  author    = "Ljubimov, Vladimir A and Ramesh, Arshia and Davani, Saya and
               Danielpour, Moise and Breunig, Joshua J and Black, Keith L",
  abstract  = "Neurosurgery as one of the most technologically demanding
               medical fields rapidly adapts the newest developments from
               multiple scientific disciplines for treating brain tumors.
               Despite half a century of clinical trials, survival for brain
               primary tumors such as glioblastoma (GBM), the most common
               primary brain cancer, or rare ones including primary central
               nervous system lymphoma (PCNSL), is dismal. Cancer therapy and
               research have currently shifted toward targeted approaches, and
               personalized therapies. The orchestration of novel and effective
               blood-brain barrier (BBB) drug delivery approaches, targeting of
               cancer cells and regulating tumor microenvironment including the
               immune system are the key themes of this review. As the global
               pandemic due to SARS-CoV-2 virus continues, neurosurgery and
               neuro-oncology must wrestle with the issues related to
               treatment-related immune dysfunction. The selection of
               chemotherapeutic treatments, even rare cases of hypersensitivity
               reactions (HSRs) that occur among immunocompromised people, and
               number of vaccinations they have to get are emerging as a new
               chapter for modern Nano neurosurgery.",
  journal   = "Adv. Drug Deliv. Rev.",
  publisher = "Elsevier BV",
  number    =  114033,
  pages     = "114033",
  month     =  nov,
  year      =  2021,
  keywords  = "Blood-Brain Barrier (BBB); Brain cancer; Drug delivery; Nano
               immunology; Nano neurosurgery; SARS-CoV-2 Virus",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Stone2021-br,
  title     = "{COVID-19} pandemic increased anxiety among patients with
               inflammatory bowel disease: A patient survey in a tertiary
               referral center",
  author    = "Stone, Molly L and Feng, Minjun and Forster, Erin M",
  abstract  = "BACKGROUND: COVID-19 is the first global pandemic in more than
               100 years, and at its onset, the effects were largely unknown.
               Immunocompromised patients, including IBD, were presumed to have
               higher risk. AIMS: We hypothesized patients with IBD would have
               higher-than-baseline anxiety, high perceived vulnerability and
               significant lifestyle impacts as a result of the pandemic. We
               sought to assess the impact of these changes on disease and
               management. METHODS: A cross-sectional study of patients with
               Crohn's disease, ulcerative colitis and IBD-unspecified was
               conducted. Patients were invited to participate by email in an
               IRB-approved brief, voluntary survey. Survey questions focused
               on disease characteristics, healthcare access and self-reported
               psychological well-being. RESULTS: Responses from 492 (CD = 337,
               UC = 141,IC = 14) patients were included in the analysis. The
               majority of patients with IBD had increased anxiety since the
               pandemic, which correlated with an increase in GI symptoms. This
               risk of symptoms was mitigated by communication with their
               provider. Many patients had lifestyle changes including
               requesting time off work due to perceived vulnerability and
               changes in eating habits. CONCLUSIONS: Our findings support an
               increase in illness-associated anxiety and perceived
               vulnerability among patients with IBD during the COVID-19
               pandemic. Open communication with providers is important to
               maintain adequate control of disease and reduce symptoms of
               flares triggered by ongoing stress.",
  journal   = "Dig. Dis. Sci.",
  publisher = "Springer Science and Business Media LLC",
  month     =  jun,
  year      =  2021,
  keywords  = "Anxiety; COVID-19; Inflammatory bowel disease; Perceived
               vulnerability",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Estella2021-hn,
  title     = "Vaccinated patients admitted in {ICU} with severe pneumonia due
               to {SARS-CoV-2}: A multicenter pilot study",
  author    = "Estella, {\'A}ngel and Cant{\'o}n, M Luisa and Mu{\~n}oz, Laura
               and Higueras, Isabel Rodriguez and Recuerda N{\'u}{\~n}ez,
               Mar{\'\i}a and Tejero Aranguren, Julia and Zaya, Benito and
               G{\'o}mez, Carmen and Amaya, Rosario and Hurtado Martinez,
               {\'A}ngela and Del Valle Odero Bernal, Mar{\'\i}a and De la
               Fuente, Carmen and Alados, Juan Carlos and Garnacho-Montero,
               Jose and {On Behalf Of The Group Of Infectious Diseases Of The
               Andalusian Society Of Intensive Care And Coronary Units Samiuc}",
  abstract  = "Background: The aim of this study was to analyze the percentage
               of patients admitted to the ICU having received the vaccine
               against COVID-19, to describe the clinical profile of vaccinated
               patients admitted to the ICU, and to assess the humoral immune
               response to vaccination. Methods: In this multicenter
               prospective descriptive cohort study, consecutive critically ill
               patients with confirmed SARS-CoV-2 pneumonia who received at
               least one dose of the SARS-CoV-2 vaccine were included. The time
               of study was from 1 July to 10 August of 2021. Results: Of the
               94 consecutive patients from seven Andalusian ICUs admitted
               during the time of study, 50 (53.2\%) received at least one dose
               of anti SARS-CoV-2 vaccine. No patient was admitted having
               previously had SARS-CoV-2 infection. The B.1.617.2 (Delta)
               variant was the most frequently identified, in 80.76\% of cases.
               Patients with a complete vaccination with non-optimal antibody
               levels were immunocompromised. Fifteen patients were admitted to
               the ICU with Acute Respiratory Distress Syndrome (ARDS) without
               having completed their vaccination; the clinical profile was
               younger and with less comorbidities compared to patients with
               full vaccination. There were no differences in severity of ARDS.
               Conclusions: Most of the patients who were admitted to the ICU
               having received a dose of the vaccine were not optimally
               vaccinated; fully vaccinated patients who did not obtain optimal
               serum antibody levels were patients considered
               immunocompromised.",
  journal   = "J. Pers. Med.",
  publisher = "MDPI AG",
  volume    =  11,
  number    =  11,
  pages     = "1086",
  month     =  oct,
  year      =  2021,
  keywords  = "Delta variant SARS-CoV-2; ICU; SARS-CoV-2; acute respiratory
               distress syndrome; severe pneumonia; vaccine",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Barbari2021-qi,
  title     = "{COVID-19} vaccine concerns: Fact or fiction?",
  author    = "Barbari, Antoine",
  abstract  = "One year has elapsed since a team of Chinese scientists reported
               the first case of COVID-19 in Wuhan, China on January 8, 2020,
               after sequencing the first viral genetic material. Since then,
               many vaccines were rushed into testing, bypassing animal
               experimentations, with more than 200 pharma companies in
               different countries declaring the development of different
               vaccines, each with their own strategy for generating immunity,
               despite the arguments of many infectious disease experts that 18
               months for a first vaccine is an incredibly aggressive schedule
               because it takes an average of 10 years to develop a vaccine.
               Ten vaccine candidates have already entered phase 3 clinical
               trials in humans. These vaccines rely on different types of
               technology, the most innovative of which use the genetic
               material messenger RNA. Many provocative questions and genuine
               concerns have been raised, such as short durations of efficacy
               and safety follow-ups, lack of identified correlates of
               protection, morbidity and mortality cases reported shortly after
               vaccination, uncertainties regarding the risk of enhanced
               disease on exposure to the virus in the long-term, the
               possibility of viral transmission after vaccination, the
               reported reduced efficacies of these vaccines against new
               variants, the efficacy and safety of these vaccines in the
               previously excluded subgroups (such as children, pregnant women,
               the frail elderly high-risk population, and immunocompromised
               individuals), the unknown risk of immunogenicity-induced
               autoimmune diseases, cancer and chronic inflammation, the risk
               of genome transformation (mainly in the presence of reverse
               transcriptase), and finally the potential coercion that may be
               imposed by either public or private sectors on citizens to
               receive the vaccine. Many plausible questions are apparent, with
               no clear and convincing answers.",
  journal   = "Exp. Clin. Transplant.",
  publisher = "Baskent University",
  volume    =  19,
  number    =  7,
  pages     = "627--634",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Panet2021-hq,
  title     = "The risks associated with the widespread use of telemedicine in
               oncology: Four cases and review of the literature",
  author    = "Panet, Fran{\c c}ois and T{\'e}treault-Langlois, Marianne and
               Morin, Vincent and Sultanem, Khalil and Melnychuk, David and
               Panasci, Lawrence",
  abstract  = "BACKGROUND: COVID-19 changed the way we practice oncology in
               multiple ways. Because most cancer patients are comorbid or
               immunocompromised, we are trying as much as possible to reduce
               their risk of infection. Marginal just 2 years ago, telemedicine
               quickly became preeminent with the pandemic to reduce hospital
               exposure. However, using only virtual visits in oncology
               patients risk delaying cancer diagnosis or the identification of
               a complication. CASE SERIES: We present here four cases where a
               serious medical problem evident on physical exam was overlooked
               during a virtual visit. Two of our patients experienced a delay
               in cancer diagnosis thus putting them at risk of local or
               distant spread. The two others were established oncology
               patients where a serious medical complication was missed on a
               virtual visit. CONCLUSIONS: Now more than a year into the
               pandemic, telemedicine has clearly been a useful tool by
               limiting unnecessary hospital visits. Yet, as our cases
               illustrate, its use in oncology without clear boundary can
               undermine the quality of care. Now that effective vaccines are
               reducing the transmission and the severity of infection, most
               oncology patients can be evaluated by a real-time visit.",
  journal   = "Cancer rep.",
  publisher = "Wiley",
  pages     = "e1531",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; oncology; telemedicine",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Sepulcri2021-at,
  title     = "The longest persistence of viable {SARS-CoV-2} with recurrence
               of viremia and relapsing symptomatic {COVID-19} in an
               immunocompromised patient-A case study",
  author    = "Sepulcri, Chiara and Dentone, Chiara and Mikulska, Malgorzata
               and Bruzzone, Bianca and Lai, Alessia and Fenoglio, Daniela and
               Bozzano, Federica and Bergna, Annalisa and Parodi, Alessia and
               Altosole, Tiziana and Delfino, Emanuele and Bartalucci, Giulia
               and Orsi, Andrea and Di Biagio, Antonio and Zehender,
               Gianguglielmo and Ballerini, Filippo and Bonora, Stefano and
               Sette, Alessandro and De Palma, Raffaele and Silvestri, Guido
               and De Maria, Andrea and Bassetti, Matteo",
  abstract  = "Background: Immunocompromised patients show prolonged shedding
               of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
               in nasopharyngeal swabs. We report a case of prolonged
               persistence of viable SARS-CoV-2 associated with clinical
               relapses of coronavirus disease 2019 (COVID-19) in a patient
               with mantle cell lymphoma who underwent treatment with
               rituximab, bendamustine, cytarabine with consequent lymphopenia
               and hypogammaglobulinemia. Methods: Nasopharyngeal swabs and
               blood samples were tested for SARS-CoV-2 by real-time polymerase
               chain reaction (RT-PCR). On 5 positive nasopharyngeal swabs, we
               performed viral culture and next-generation sequencing. We
               analyzed the patient's adaptive and innate immunity to
               characterize T- and NK-cell subsets. Results: SARS-CoV-2 RT-PCR
               on nasopharyngeal swabs samples remained positive for 268 days.
               All 5 performed viral cultures were positive, and genomic
               analysis confirmed a persistent infection with the same strain.
               Viremia resulted positive in 3 out of 4 COVID-19 clinical
               relapses and cleared each time after remdesivir treatment. The
               T- and NK-cell dynamic was different in aviremic and viremic
               samples, and no SARS-CoV-2-specific antibodies were detected
               throughout the disease course. Conclusions: In our patient,
               SARS-CoV-2 persisted with proven infectivity for >8 months.
               Viremia was associated with COVID-19 relapses, and remdesivir
               treatment was effective in viremia clearance and symptom
               remission, although it was unable to clear the virus from the
               upper respiratory airways. During the viremic phase, we observed
               a low frequency of terminal effector CD8+ T lymphocytes in
               peripheral blood; these are probably recruited in inflammatory
               tissue for viral eradication. In addition, we found a high level
               of NK-cell repertoire perturbation with relevant involvement
               during SARS-CoV-2 viremia.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  11,
  pages     = "ofab217",
  month     =  nov,
  year      =  2021,
  keywords  = "SARS-CoV-2; hematological; immunological response; viral
               shedding; viremia",
  copyright = "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Hearn2021-tp,
  title     = "Isolated and anxious: A qualitative exploration of the impact of
               the {COVID-19} pandemic on individuals living with spinal cord
               injury in the {UK}",
  author    = "Hearn, Jasmine Heath and Rohn, Edward J and Monden, Kimberley R",
  abstract  = "Objective: People living with spinal cord injury (SCI) are often
               immunocompromised, and at increased risk of respiratory
               infection. Given the restrictions in response to the COVID-19
               pandemic, those with SCI may be at increased risk of health
               deterioration, though how this is experienced is poorly
               understood. This study explored the experiences of people living
               with SCI during the COVID-19 pandemic.Design: Participants
               completed an online survey consisting of demographic questions,
               and open-ended qualitative questions pertaining to their
               experiences during the pandemic. Thematic analysis was utilized
               for the analytical approach.Setting: Community-based sample in
               the UK.Participants: Participants were recruited via social
               media outlets of UK-based SCI-specific support charities, and
               snowball sampling (N = 42, F = 34, M = 8).Results: Key themes
               included: (1) lost access to health services and support,
               capturing concerns surrounding barriers to healthcare and
               rehabilitation, which intensified secondary consequences of SCI
               such as spasm and pain; (2) health anxiety, which was
               perpetuated by perceived heightened vulnerabilities to
               respiratory complications; (3) social isolation, with
               significantly reduced social contact, even with care providers,
               compounding health experiences.Conclusion: People living with
               SCI during the COVID-19 pandemic experienced a variety of
               personal physical, psychological, and social challenges, each of
               which could disrupt daily functioning and quality of life.
               Increased utilization of telehealth is recommended to support
               continued engagement in rehabilitation, and foster connection
               and community amongst others with SCI and health professionals.",
  journal   = "J. Spinal Cord Med.",
  publisher = "Informa UK Limited",
  pages     = "1--9",
  month     =  jul,
  year      =  2021,
  keywords  = "COVID-19; Infection; Isolation; Pandemic; SCI; Thematic analysis",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Sebastian2021-kn,
  title     = "Covid assossiated invasive fungal sinusitis",
  author    = "Sebastian, Susan K and Kumar, Vibhor B and Gupta, Manu and
               Sharma, Yukti",
  abstract  = "Acute invasive fungal sinusitis is an aggressive infection
               affecting immunocomprosmised patients and carries a high
               mortality. Patients with Covid-pneumonia are at an increased
               risk of developing invasive pulmonary fungal infections probably
               due to their reduced immunological competence. Here, we review
               three cases of Covid-associated invasive fungal sinusitis.",
  journal   = "Indian J. Otolaryngol. Head Neck Surg.",
  publisher = "Springer Science and Business Media LLC",
  pages     = "1--4",
  month     =  feb,
  year      =  2021,
  keywords  = "Covid-19; Immunocompromised state; Invasive fungal sinusitis",
  language  = "en"
}

@ARTICLE{Eybpoosh2021-ni,
  title     = "Severity and mortality of {COVID-19} infection in {HIV-infected}
               individuals: Preliminary findings from Iran",
  author    = "Eybpoosh, Sana and Afshari, Mahdi and Haghdoost, Ali-Akbar and
               Afsar Kazerooni, Parvin and Gouya, Mohammad Mehdi and Tayeri,
               Katayoon",
  abstract  = "Background: Higher mortality due to coronavirus disease 2019
               (COVID-19) is reported among some immunocompromised patients;
               however, the relation between immunosuppression due to HIV
               infection and severity of COVID-19 infection remains unclear. We
               aimed to investigate the severity and mortality of COVID-19
               infection in HIV-infected patients. Methods: This was a
               retrospective cohort study on all COVID-19 suspected and
               confirmed cases hospitlized in Iran between Febuary 19 (epidemic
               onset date) and April 8, 2020, whose data were recorded in the
               national database for Medical Care Monitoring Center.
               Hospitalized patients were followed from admittion to
               death/discharge. Patients' HIV status was recorded based on
               their self report. Logistic and Cox regression models were used
               to evaluate the association between HIV infection and the
               severity (according to the Glascow-Coma Scale situation, need
               for intubation and hypoxemia) and mortality of COVID-19
               infection, respectively. Analyses were performed separately for
               COVID-19 suspected and confirmed cases. Results: Out of 122 206
               severe acute respiratory infection (SARI) cases, 90 were
               HIV-positive (0.07\%), with a similar mean age (Pt-test= 0.750)
               and distrubtion of gender (PChi-square= 0.887) and nationality
               (PChi-square= 0.202) as HIV-negative patients. A comparable
               proportion of HIV-positive and HIV-negative cases were tested
               for COVID-19 (p= 0.170); however, the frequency of positive
               results was lower among HIV-positives (p= 0.038). The frequency
               of COVID-19 and HIV coinfection was lower than expected among
               confirmed cases (adjusted OR= 0.54; 95\% CI: 0.29-1.02) and
               suspected cases (adjusted OR= 0.68; 95\% CI: 0.45- 1.02), which
               means that the frequency of COVID-19 infection was lower among
               HIV-positive cases. HIV infection decreased the risk of death
               among confirmed (adjusted HR= 0.33; 95\% CI: 0.05-2.32),
               suspected cases (adjusted HR= 0.81; 95\% CI: 0.33-1.94), and
               among SARI cases (adjusted HR= 0.73; 95\% CI: 0.35-1.54).
               Conclusion: Our findings support the concept that HIV infection
               was not a risk factor to increase the severity and risk of death
               among COVID-19 infected patients.",
  journal   = "Med. J. Islam. Repub. Iran",
  publisher = "Academic World Research",
  volume    =  35,
  pages     = "33",
  month     =  mar,
  year      =  2021,
  keywords  = "COVID-19; HIV; Severity",
  language  = "en"
}

@ARTICLE{Darvishnia2021-vw,
  title     = "Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a
               patient with Hodgkin's lymphoma history from north of Iran",
  author    = "Darvishnia, David and Sadeghi, Mahdieh and Sharifpour, Ali and
               Zakariaei, Zakaria and Banimostafavi, Elham Sadat and Fakhar,
               Mahdi and Tabaripour, Rabeeh",
  abstract  = "Immunocompromised patients, especially those hospitalized, are
               at higher risk for infection with opportunistic pathogens such
               as Stenotrophomonas maltophilia (S. maltophilia) which is a
               multidrug-resistant gram-negative bacillus and can cause a
               challenge in the management of patients with concomitant
               COVID-19 and S. maltophilia pneumonia. A 71-year-old man with
               Hodgkin's lymphoma presented with severe respiratory symptoms of
               COVID-19 and was intubated upon admission and the initial
               standard treatment for COVID-19 was started for him. The patient
               subsequently developed superimposed bacterial pneumonia with S.
               maltophilia. According to that, the patient's intubation tube
               was removed and a tracheostomy was performed for him. Also,
               antibiotic treatment was replaced with Colistin and
               Co-trimoxazole drugs. Finally, after 31 days of hospitalization
               in the ICU and the aappropriate drug treatment, he was
               discharged with reduced symptoms and partial recovery. It should
               be noted that the occurrence of co-infection with
               multidrug-resistant pathogens such as S. maltophilia requires
               proper management to select appropriate treatment methods and
               drugs so that in addition to proper effectiveness, it does not
               lead to side effects and complications associated with COVID-19
               disease.",
  journal   = "Infect. Disord. Drug Targets",
  publisher = "Bentham Science Publishers Ltd.",
  volume    =  21,
  month     =  feb,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Eifer2021-lp,
  title    = "Covid-19 {mRNA} vaccination: Age and immune status and its
              association with axillary lymph node {PET/CT} uptake",
  author   = "Eifer, Michal and Tau, Noam and Alhoubani, Yousef and Kanana,
              Nayroz and Domachevsky, Liran and Shams, Jala and Keret, Nir and
              Gorfine, Malka and Eshet, Yael",
  abstract = "With hundreds of millions of coronavirus disease 2019 (COVID-19)
              mRNA-based vaccine doses planned to be delivered worldwide in the
              upcoming months, it is important to recognize positron emission
              tomography with computed tomography (PET/CT) findings in recently
              vaccinated immunocompetent or immunocompromised patients. We
              aimed to assess PET/CT uptake in the deltoid muscle and axillary
              lymph nodes of patients that received a COVID-19 mRNA-based
              vaccine, and to evaluate its association with patients' age and
              immune status. Methods: All consecutive adult subjects undergoing
              PET/CT scans with any radiotracer at our center during the first
              month of a national COVID-19 vaccination rollout (between 23
              December 2020 and January 27, 2021) were included. Data regarding
              clinical status, laterality and time interval from recent
              COVID-19 mRNA vaccination was prospectively collected and
              retrospectively analyzed, and correlated with deltoid muscle and
              axillary lymph nodes uptake. Results: Of 426 eligible, recently
              vaccinated, subjects (median age, 67$\pm$12 years; 49\% female),
              377 (88\%) underwent PET/CT with F-18-fluorodeoxyglucose (FDG)
              and positive axillary lymph node uptake was seen in 45\% of them.
              Multivariate logistic regression analysis revealed a strong
              inverse association between positive FDG uptake in ipsilateral
              lymph nodes and patients' age (Odds Ratio [OR]=0.57, 95\% CI,
              0.45-0.72; p<.001), immunosuppressive treatment (OR=0.37, 95\%
              CI, 0.20-0.64; P = 0.003) and presence of hematological disease
              (OR=0.44, 95\% CI, 0.24-0.8; P = 0.021). No such association was
              found for deltoid muscle uptake. The number of days from the last
              vaccination and the number of vaccination doses were also
              significantly associated with increased odds of positive lymph
              nodes uptake. Conclusion: Following mRNA-based COVID-19
              vaccination, a high proportion of patients showed ipsilateral
              lymph node axillary uptake, which was more common in
              immunocompetent patients. This information will help recognize
              PET/CT pitfalls and may hint about the patient's immune response
              to the vaccine.",
  journal  = "J. Nucl. Med.",
  month    =  apr,
  year     =  2021,
  keywords = "COVID-19; Infectious Disease; Molecular Imaging; PET/CT; axillary
              lymphadenopathy; immunogenicity; mRNA vaccine",
  language = "en"
}

@ARTICLE{Lang-Meli2021-kq,
  title     = "Case series: Convalescent plasma therapy for patients with
               {COVID-19} and primary antibody deficiency",
  author    = "Lang-Meli, Julia and Fuchs, Jonas and Math{\'e}, Philipp and Ho,
               Hsi-En and Kern, Lisa and Jaki, Lena and Rusignuolo, Giuseppe
               and Mertins, Susanne and Somogyi, Vivien and Neumann-Haefelin,
               Christoph and Trinkmann, Frederik and M{\"u}ller, Michael and
               Thimme, Robert and Umhau, Markus and Quinti, Isabella and
               Wagner, Dirk and Panning, Marcus and Cunningham-Rundles,
               Charlotte and Laubner, Katharina and Warnatz, Klaus",
  abstract  = "Patients with primary antibody deficiency are at risk for severe
               and in many cases for prolonged COVID-19. Convalescent plasma
               treatment of immunocompromised individuals could be an option
               especially in countries with limited access to monoclonal
               antibody therapies. While studies in immunocompetent COVID19
               patients have demonstrated only a limited benefit, evidence for
               the safety, timing, and effectiveness of this treatment in
               antibody-deficient patients is lacking. Here, we describe 16
               cases with primary antibody deficiency treated with convalescent
               plasma in four medical centers. In our cohort, treatment was
               associated with a reduction in viral load and improvement of
               clinical symptoms, even when applied over a week after onset of
               infection. There were no relevant side effects besides a
               short-term fever reaction in one patient. Longitudinal
               full-genome sequencing revealed the emergence of mutations in
               the viral genome, potentially conferring an antibody escape in
               one patient with persistent viral RNA shedding upon plasma
               treatment. However, he resolved the infection after a second
               course of plasma treatment. Thus, our data suggest a therapeutic
               benefit of convalescent plasma treatment in patients with
               primary antibody deficiency even months after infection. While
               it appears to be safe, PCR follow-up for SARS-CoV-2 is advisable
               and early re-treatment might be considered in patients with
               persistent viral shedding.",
  journal   = "J. Clin. Immunol.",
  publisher = "Springer Science and Business Media LLC",
  month     =  dec,
  year      =  2021,
  keywords  = "COVID-19; Common variable immunodeficiency; Convalescent plasma;
               Hypogammaglobulinemia; Inborn errors of immunity; Primary
               immunodeficiencies; SARS-CoV-2",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Panthee2021-tl,
  title     = "Novel pathogenic Mucorales identified using the silkworm
               infection model",
  author    = "Panthee, Suresh and Hamamoto, Hiroshi and Nishiyama, Yayoi and
               Paudel, Atmika and Sekimizu, Kazuhisa",
  abstract  = "Mucormycosis, a rare but highly fatal infection, is caused by
               fungi of the order Mucorales. Due to their ubiquitous nature,
               reduced susceptibility to antifungals, acid tolerance, and
               ability to infect immunocompromised patients through rapid
               dissemination, these fungi have been frequently reported to
               infect the COVID-19 patients. In order to develop strategies to
               overcome mucormycosis, it is essential to understand and
               identify novel Mucorales present in the environment. In this
               study, we report the identification of four novel pathogenic
               Mucorales using the silkworm (Bombyx mori) model. The strains'
               phylogeny was analyzed using the genome sequence of the large
               subunit ribosomal ribonucleic acid (LSU rRNA) and the internal
               transcribed spacer (ITS) region, where strains 1-3, 5-3, and
               S286-1101 claded with Mucor orantomantidis, and strain 827-14
               claded with Backusella lamprospora. All the strains had a
               cold-sensitive phenotype with their inability to grow
               prominently at 4 C. Mucor sp. 1-3 and 5-3 were characterized by
               their filamentous and yeast-like growth under aerobic and
               anaerobic conditions, respectively. The yeast colonies of Mucor
               sp. 5-3 had multipolar budding cells often observed with cleaved
               cell surfaces under a scanning electron microscope. We further
               found that these strains were able to kill immunocompromised
               mice suggesting their pathogenicity to mammals. Our study
               established an invertebrate model-based screening system to
               identify novel pathogenic Mucorales from the natural environment
               and provided a clue towards the rapid increase in COVID-19
               related mucormycosis.",
  journal   = "J. Fungi (Basel)",
  publisher = "MDPI AG",
  volume    =  7,
  number    =  11,
  pages     = "995",
  month     =  nov,
  year      =  2021,
  keywords  = "COVID-19; Mucorales; animal-model; opportunistic infection;
               silkworm",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Lindoso2021-bn,
  title     = "Physical and mental health impacts during {COVID-19} quarantine
               in adolescents with preexisting chronic immunocompromised
               conditions",
  author    = "Lindoso, Livia and Astley, Camilla and Queiroz, Ligia Bruni and
               Gualano, Bruno and Pereira, Rosa Maria Rodrigues and Tannuri,
               Uenis and Campos, L{\'u}cia Maria Mattei de Arruda and Louren{\c
               c}o, Benito and Toma, Ricardo Katsuya and Medeiros, Karina and
               Watanabe, Andr{\'e}ia and Moreno Grangeiro, Patricia and Barros,
               Vera da Penha Martellini Ferrari Rego and Casella, Caio Borba
               and Farhat, Sylvia and Polanczyk, Guilherme Vanoni and Silva,
               Clovis Artur",
  abstract  = "OBJECTIVE: To evaluate physical and mental health indicators in
               adolescents with preexisting chronic immunocompromised
               conditions during coronavirus disease 2019 (COVID-19)
               quarantine. METHODS: A cross-sectional study included 355
               adolescents with chronic conditions and 111 healthy adolescents.
               An online self-rated survey was used to investigate
               socio-demographic features, healthcare routine, and the
               quarantine impact on physical and mental health. The validated
               self-reported version of the Strengths and Difficulties
               Questionnaire (SDQ) was also applied. RESULTS: The median of age
               [14 (10-18) vs. 15 (10-18) years, p = 0.733] and frequencies of
               female (61\% vs. 60\%, p = 0.970) were similar between
               adolescents with preexisting chronic conditions and healthy
               adolescents during quarantine of COVID-19 pandemic. The
               frequencies of abnormal total difficulties score of SDQ were
               similar in patients and controls (30\% vs. 31\%, p = 0.775).
               Logistic regression analysis showed that being female (OR =
               1.965; 95\% CI = 1.091-3.541, p = 0.024), fear of underlying
               disease activity/complication (OR = 1.009; 95\%CI = 1.001-1.018,
               p = 0.030) were associated with severe psychosocial dysfunction
               in adolescents with chronic conditions, whereas school homework
               (OR = 0.449; 95\% CI = 0.206-0.981, p = 0.045) and physical
               activity (OR = 0.990; 95\% CI = 0.981-0.999, p = 0.030) were
               protective factors. Further analysis of patients with chronic
               immunocompromised conditions and previous diagnosis of mental
               disorders (9\%) compared with patients without diagnosis showed
               higher median of total difficulties score (p = 0.001), emotional
               (p = 0.005), conduct (p = 0.007), peer problems (p = 0.001) and
               hyperactivity (p = 0.034) in the former group. CONCLUSION:
               Adolescents with preexisting chronic immunocompromised
               conditions during COVID-19 quarantine were not at higher risk of
               adverse health indicators. Being female, fear of underlying
               disease activity/complication, and household members working
               outside of the home were relevant issues for adolescents with
               preexisting chronic conditions. This study reinforces the need
               to establish mental health strategies for teens with chronic
               conditions, particularly during the pandemic.",
  journal   = "J. Pediatr. (Rio J.)",
  publisher = "Elsevier BV",
  month     =  oct,
  year      =  2021,
  keywords  = "Adolescents; COVID-19 pandemic; Chronic diseases; Mental health",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Pannone2021-qe,
  title     = "Lung histopathological findings in {COVID-19} disease - a
               systematic review",
  author    = "Pannone, Giuseppe and Caponio, Vito Carlo Alberto and De
               Stefano, Ilenia Sara and Ramunno, Maria Antonietta and
               Meccariello, Mario and Agostinone, Alessio and Pedicillo, Maria
               Carmela and Troiano, Giuseppe and Zhurakivska, Khrystyna and
               Cassano, Tommaso and Bizzoca, Maria Eleonora and Papagerakis,
               Silvana and Buonaguro, Franco Maria and Advani, Shailesh and
               Muzio, Lorenzo Lo",
  abstract  = "Since December 2019, the global burden of the COVID-19 pandemic
               has increased rapidly and has impacted nearly every country in
               the world, affecting those who are elderly or with underlying
               comorbidities or immunocompromised states. Aim of this
               systematic review is to summarize lung histopathological
               characteristics of COVID-19, not only for diagnostic purpose but
               also to evaluate changes that can reflect pathophysiological
               pathways that can inform clinicians of useful treatment
               strategies. We identified following histopathological changes
               among our patients:: hyaline membranes; endothelial cells/
               interstitial cells involvement; alveolar cells, type I
               pneumocytes/ type II pneumocytes involvement; interstitial and/
               or alveolar edema; evidence of hemorrhage, of inflammatory
               cells, evidence of microthrombi; evidence of fibrin deposition
               and of viral infection in the tissue samples.The scenario with
               proliferative cell desquamation is typical of Acute Respiratory
               Distress Syndrome (ARDS) that can be classified as diffuse
               alveolar damage (DAD) and not DAD-ARDS. The proposed
               pathological mechanism concerns the role of both innate and
               adaptive components of the immune system. COVID-19 lethal cases
               present themselves as a heterogeneous disease, characterized by
               the different simultaneous presence of different histological
               findings, which reflect histological phases with corresponding
               different pathological pathways (epithelial, vascular and
               fibrotic changes), in the same patient.",
  journal   = "Infect. Agent. Cancer",
  publisher = "Springer Science and Business Media LLC",
  volume    =  16,
  number    =  1,
  pages     = "34",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; Histopathology; Lung; Systematic review; Therapy",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Destras2021-xj,
  title     = "Bamlanivimab as monotherapy in two immunocompromised patients
               with {COVID-19}",
  author    = "Destras, Gr{\'e}gory and Assaad, Souad and Bal, Antonin and
               Bouscambert-Duchamp, Maude and Avrillon, Virginie and Simon,
               Bruno and Valette, Martine and Blay, Jean-Yves and Lina, Bruno
               and Frobert, Emilie and Josset, Laurence",
  journal   = "Lancet Microbe",
  publisher = "Elsevier BV",
  volume    =  2,
  number    =  9,
  pages     = "e424",
  month     =  sep,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Delvino2021-hl,
  title    = "Safety of {BNT162b2} {mRNA} {COVID-19} vaccine in a cohort of
              elderly, immunocompromised patients with systemic vasculitis",
  author   = "Delvino, Paolo and Bozzalla Cassione, Emanuele and Biglia,
              Alessandro and Quadrelli, Verdiana Serena and Bartoletti, Alice
              and Montecucco, Carlomaurizio and Monti, Sara",
  journal  = "Clin. Exp. Rheumatol.",
  month    =  sep,
  year     =  2021,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Zeng2021-kc,
  title    = "Impaired neutralizing antibody response to {COVID-19} {mRNA}
              vaccines in cancer patients",
  author   = "Zeng, Cong and Evans, John P and Reisinger, Sarah and Woyach,
              Jennifer and Liscynesky, Christina and Boghdadly, Zeinab El and
              Rubinstein, Mark P and Chakravarthy, Karthik and Saif, Linda and
              Oltz, Eugene M and Gumina, Richard J and Shields, Peter G and Li,
              Zihai and Liu, Shan-Lu",
  abstract = "There is currently a critical need to determine the efficacy of
              SARS-CoV-2 vaccination for immunocompromised patients. In this
              study, we determined the neutralizing antibody response in 160
              cancer patients diagnosed with chronic lymphocytic leukemia
              (CLL), lung cancer, breast cancer, and various non-Hodgkin's
              lymphomas (NHL), after they received two doses of mRNA vaccines.
              Serum from 46 mRNA vaccinated health care workers (HCWs) served
              as healthy controls. We discovered that (1) cancer patients
              exhibited reduced neutralizing antibody titer (NT 50 ) compared
              to HCWs; (2) CLL and NHL patients exhibited the lowest NT 50
              levels, with 50-60\% of them below the detection limit; (3) mean
              NT 50 levels in patients with CLL and NHL was 2.6 fold lower
              than those with solid tumors; and (4) cancer patients who
              received anti-B cell therapy exhibited significantly reduced NT
              50 levels. Our results demonstrate an urgent need for novel
              immunization strategies for cancer patients against SARS-CoV-2,
              particularly those with hematological cancers and those on anti-B
              cell therapies.",
  journal  = "medRxiv",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Migliore2021-uk,
  title     = "Intradermal vaccination: A potential tool in the battle against
               the {COVID-19} pandemic?",
  author    = "Migliore, Alberto and Gigliucci, Gianfranco and Di Marzo,
               Raffaele and Russo, Domenico and Mammucari, Massimo",
  abstract  = "This narrative review is the final output of an initiative of
               the SIM (Italian Society of Mesotherapy). A narrative review of
               scientific literature on the efficacy of fractional intradermal
               vaccination in comparison with full doses has been conducted for
               the following pathogens: influenza virus, rabies virus,
               poliovirus (PV), hepatitis B virus (HBV), hepatitis A virus
               (HAV), diphtheria-tetanus-pertussis bacterias (DTP), human
               papillomavirus (HPV), Japanese encephalitis virus (JE),
               meningococcus, varicella zoster virus (VZV) and yellow fever
               virus. The findings suggest that the use of the intradermal
               route represents a valid strategy in terms of efficacy and
               efficiency for influenza, rabies and HBV vaccines. Some
               systematic reviews on influenza vaccines suggest the absence of
               a substantial difference between immunogenicity induced by a
               fractional ID dose of up to 20\% and the IM dose in healthy
               adults, elderly, immunocompromised patients and children.
               Clinical studies of remaining vaccines against other pathogens
               (HAV, DTP bacterias, JE, meningococcal disease, VZV, and yellow
               fever virus) are scarce, but promising. In the context of a
               COVID-19 vaccine shortage, countries should investigate if a
               fractional dosing scheme may help to save doses and achieve herd
               immunity quickly. SIM urges the scientific community and health
               authorities to investigate the potentiality of fractionate
               intradermal administration in anti-COVID-19 vaccination.",
  journal   = "Risk Manag. Healthc. Policy",
  publisher = "Informa UK Limited",
  volume    =  14,
  pages     = "2079--2087",
  month     =  may,
  year      =  2021,
  keywords  = "COVID-19; dose sparing; intradermal; vaccination",
  language  = "en"
}

@ARTICLE{Peled2021-hp,
  title     = "Third dose of the {BNT162b2} vaccine in heart transplant
               recipients: Immunogenicity and clinical experience",
  author    = "Peled, Yael and Ram, Eilon and Lavee, Jacob and Segev, Amit and
               Matezki, Shlomi and Wieder-Finesod, Anat and Halperin, Rebecca
               and Mandelboim, Michal and Indenbaum, Victoria and Levy, Itzchak
               and Sternik, Leonid and Raanani, Ehud and Afek, Arnon and
               Kreiss, Yitshak and Lustig, Yaniv and Rahav, Galia",
  abstract  = "BACKGROUND: The repeated waves of the COVID-19 pandemic have
               highlighted the necessity to optimize vaccine responses in
               immunocompromised populations. We investigated the safety and
               immunogenicity of a third, booster, dose of the Pfizer BNT162b2
               vaccine in heart transplant (HT) patients. METHODS: The cohort
               comprised 96 adult HT patients who received a third homologous
               dose of the BNT162b2 vaccine 168 days after the second dose. The
               vaccine-induced antibody responses of both receptor-binding
               domain (RBD) IgG and neutralizing antibodies were assessed in
               all patients, with a positive antibody response being defined as
               the presence of either IgG anti-RBD or neutralizing antibodies.
               For a subset of patients, T cell response was also studied.
               RESULTS: The third dose was associated with a low rate of
               adverse events, mostly mild pain at the injection site. No
               serious adverse events were recorded, and there were no episodes
               of rejection. At 18 days following the third dose of the
               vaccine, the positive antibody response increased from 23\% to
               67\%, with a corresponding increase in neutralizing capacity.
               The third dose elicited SARS-CoV-2 neutralization titers >9-fold
               and IgG anti-RBD antibodies >3-fold of the range achieved after
               the two primary doses. Mycophenolate use, lower eGFR and higher
               C-reactive protein were independently associated with a reduced
               likelihood of generating an immune response. Importantly, a
               specific T-cell response following the third dose was evident in
               the majority of transplant recipients. CONCLUSIONS: An
               homologous third booster dose of the BNT162b2 vaccine gave
               overall consistent tolerability and a good safety profile, while
               eliciting humoral and cellular immune responses.",
  journal   = "J. Heart Lung Transplant.",
  publisher = "Elsevier BV",
  month     =  aug,
  year      =  2021,
  keywords  = "BNT162b2 vaccine; COVID-19 pandemic; IgG anti-RBD; booster;
               heart transplantation; neutralizing antibodies",
  language  = "en"
}

@ARTICLE{Luitel2021-ay,
  title     = "Successful treatment of persistent Coronavirus disease 2019
               infection in a patient with hypogammaglobulinemia with
               {REGN-COV2}: A case report",
  author    = "Luitel, Pankaj and Vais, Dana and Gidron, Adi",
  abstract  = "A 55-year-old man with hypogammaglobulinemia due to previous
               rituximab treatment developed persistent coronavirus disease
               2019 pneumonia. Treatment with REGN-COV2 (casirivimab and
               imdevimab) resulted in the clearance of the infection. Targeted
               antiviral antibodies may be an important weapon in the
               management of immunocompromised patients infected with severe
               acute respiratory syndrome coronavirus 2 who fail to mount an
               immune response.",
  journal   = "Open Forum Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  volume    =  8,
  number    =  8,
  pages     = "ofab335",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; REGN-COV2; hypogammaglobulinemia; rituximab",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Mehta2021-im,
  title     = "{COVID-19} infection in reproductive age group females:
               Experience of a tertiary care urban teaching hospital",
  author    = "Mehta, Ami V and Patel, Rina V and Shah, Parul T and Deliwala,
               Kruti J and Mehta, Shital T and Vyas, Rupa C and Shah, Akshay C
               and Khambhojia, Janak and Gupta, Aishwarya and Saiyed, Fiza",
  abstract  = "Background: The objective of this study was to find out the
               effect, course of disease and management of the COVID-19
               infection in pregnant women and compare it with non-pregnant
               population. Method: This is a retrospective study done at Sardar
               Vallabhbhai Patel Institute of Medical Science and Research
               (SVPIMSR), Smt. NHL MMC, Ahmedabad, from April 1, 2020, to
               September 30, 2020. All COVID-19-positive patients were divided
               into two groups: group A was comprised of pregnant/postpartum
               and group B of non-pregnant patients. Result: A total of 709
               women (Group A-205, Group B-504) were included in the study, In
               group A 90\% of patients were asymptomatic, while in group B
               48\% asymptomatic patients. Group A had 5.9\% and group B had
               13.1\% patients having comorbidities. In group A, smaller number
               of patients had raised inflammatory markers as compared to group
               B. Only 4\% patients of group A showed significant changes on
               chest X-ray as compared to 16\% in group B. Only 2.9\% patients
               of group A required intensive care unit admission as compared to
               10.31\% patients of group B. Mean hospital stay of group A was
               10.6 days, and that of group B was 12.1 days. Conclusion: In
               pregnancy, due to the physiological alterations in
               cardiovascular, respiratory and immune system, the pregnant
               women are vulnerable to infections. Although pregnancy is
               immunocompromised state, the severity of Coivd-19 disease is
               milder as compared to non-pregnant COVID-19-positive patients.",
  journal   = "J. Obstet. Gynaecol. India",
  publisher = "Springer Science and Business Media LLC",
  volume    =  71,
  number    = "S1",
  pages     = "1--5",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID-19; Disease course; Inflammatory markers; Pregnancy;
               Reproductive age",
  language  = "en"
}

@ARTICLE{Diaz2021-kx,
  title     = "Prevention and treatment of {SARS-CoV2} infection in people
               living with {HIV}: The need for specific data",
  author    = "D{\'\i}az, Natalia A and de Miguel, Rosa and Ag{\"u}ero,
               Fernando and Sued, Omar and Arribas, Jos{\'e} R and Ambrosioni,
               Juan and {Hospital Clinic COVID-19 in HIV Investigators}",
  abstract  = "The HIV pandemic has led to close to 40 million people living
               with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220
               million people, and unprecedented global efforts have resulted
               in almost 6000 million doses of SARS-CoV2 vaccines being
               administered. Although several specific COVID-19 antiviral and
               anti-inflammatory treatments and SARS-CoV2 vaccines have been
               approved, the data available to support their use in specific
               populations such as PLWH remain limited. PLWH includes a range
               of individuals from practically unaffected immunity to severely
               immunocompromised individuals, and preventive and therapeutic
               interventions should be tailored for these subgroups . However,
               in most randomized clinical trials regarding antivirals,
               immunomodulators and vaccines for COVID-19, PLWH have been
               excluded or only enrolled in small numbers leading to a paucity
               of data. We briefly discuss the current evidence for prevention
               and treatment of COVID-19 in PLWH and identify key areas where
               more information is required.",
  journal   = "Infect. Dis. Ther.",
  publisher = "Springer Science and Business Media LLC",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; HIV; HIV infection; PLWH; Prevention; SARS-CoV2;
               SARS-CoV2 vaccines; Treatment",
  copyright = "https://creativecommons.org/licenses/by-nc/4.0",
  language  = "en"
}

@ARTICLE{Hernandez2021-rt,
  title     = "Safety of {COVID-19} vaccines administered in the {EU}: Should
               we be concerned?",
  author    = "Hern{\'a}ndez, Antonio F and Calina, Daniela and Poulas,
               Konstantinos and Docea, Anca Oana and Tsatsakis, Aristidis M",
  abstract  = "The COVID-19 pandemic has had an unprecedented and devastating
               impact on public health, society and economics around the world.
               As a result, the development of vaccines to protect individuals
               from symptomatic COVID-19 infections has represented the only
               feasible health tool to combat the spread of the disease.
               However, at the same time the development and regulatory
               assessment of different vaccines has challenged pharmaceutical
               industries and regulatory agencies as this process has occurred
               in the shorter time ever though. So far, two mRNA and two
               adenovirus-vectored vaccines have received a conditional
               marketing authorisation in the EU and other countries. This
               review summarized and discusses the assessment reports of the
               European Medicine Agency (EMA) concerning the safety of the 3
               vaccines currently used in the EU (Pfizer, Moderna and
               Astra-Zeneca). A particular focus has been paid to safety
               information from pre-clinical (animal) and clinical (phase 3
               trials) studies. Overall, the most frequent adverse effects
               reported after the administration of these vaccines consisted of
               local reactions at the injection site (sore arm and erythema)
               followed by non-specific systemic effects (myalgia, chills,
               fatigue, headache, and fever), which occurred soon after
               vaccination and resolved shortly. Rare cases of vaccine-induced
               immune thrombotic thrombocytopenia have been reported for
               Vaxzevria. Data on long-term studies, interaction with other
               vaccines, use in pregnancy/breast-feeding, use in
               immunocompromised subjects, and in subjects with comorbidities,
               autoimmune or inflammatory disorders are still missing for these
               vaccines. Therefore, careful follow-up and surveillance studies
               for continued vaccine safety monitoring will be needed to
               ascertain the potential risks of such adverse events or
               diseases. In conclusion, the benefits and risks of current
               COVID-19 vaccines must be weighed against the real possibility
               of contract the disease and develop complications and long-term
               sequels; all this on the basis of the available scientific
               evidence and in the absence of unmotivated biases.",
  journal   = "Toxicol. Rep.",
  publisher = "Elsevier BV",
  volume    =  8,
  pages     = "871--879",
  month     =  apr,
  year      =  2021,
  keywords  = "Clinical trials; Covid-19; Public health; Safety; Side effects;
               Thrombosis; Vaccines",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Mustahsin2021-bw,
  title     = "{COVID-19} pneumonia in kyphoscoliosis: The success stories",
  author    = "Mustahsin, Mohd and Choubey, Sanjay and Singh, Garima and Dubey,
               Madhulika and Khanduri, Sachin and Sharma, Rachit and
               Srivastava, Amit",
  abstract  = "Coronavirus disease (COVID-19) pandemic has led to millions of
               deaths worldwide. Old age, immunocompromised state and multiple
               comorbidities are described as risk factors. Kyphoscoliosis (KS)
               is the most common spine abnormality and a risk factor of
               respiratory failure. Management of pneumonia in a patient with
               severe kyphoscoliosis is challenging to the intensivist. We
               report successful management of two patients with severe
               kyphoscoliosis who developed severe COVID-19 pneumonia.",
  journal   = "Monaldi Arch. Chest Dis.",
  publisher = "PAGEPress Publications",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Vaid2021-sg,
  title    = "Indian expert opinion on cancer care during {COVID-19} pandemic",
  author   = "Vaid, Ashok K and Malhotra, Hemant and Thirumalairaj, Raja and
              Nair, Reena and Bapna, Ajay and Rajappa, Senthil J and
              Somashekhar, S P and Goswami, Chanchal and Bajpai, Jyoti",
  abstract = "Coronavirus pandemic has increased human disease burden, as well
              as economic distress globally. Being in an immunocompromised
              state, patients with cancer comprise an important at-risk
              population for novel coronavirus disease 2019 (COVID-19)
              infection. It is necessary to modify individualized clinical
              management for every cancer patient in the context of the ongoing
              COVID-19 pandemic. Simultaneously, additional safety precautions
              for the cancer care providers are mandatory. This review will
              provide general recommendations in the Indian context optimizing
              the same.",
  journal  = "South Asian J. Cancer",
  volume   =  10,
  number   =  1,
  pages    = "9--18",
  month    =  jan,
  year     =  2021,
  keywords = "India; oncology management; patient safety; recommendations",
  language = "en"
}

@ARTICLE{Kemp2020-ou,
  title    = "Neutralising antibodies in Spike mediated {SARS-CoV-2} adaptation",
  author   = "Kemp, S A and Collier, D A and Datir, R and Ferreira, Iatm and
              Gayed, S and Jahun, A and Hosmillo, M and Rees-Spear, C and
              Mlcochova, P and Lumb, Ines Ushiro and Roberts, David J and
              Chandra, Anita and Temperton, N and {CITIID-NIHR BioResource
              COVID-19 Collaboration} and {COVID-19 Genomics UK (COG-UK)
              Consortium} and Sharrocks, K and Blane, E and Briggs, Jag and
              Van, Gils Mj and Smith, Kgc and Bradley, J R and Smith, C and
              Doffinger, R and Ceron-Gutierrez, L and Barcenas-Morales, G and
              Pollock, D D and Goldstein, R A and Smielewska, A and Skittrall,
              J P and Gouliouris, T and Goodfellow, I G and Gkrania-Klotsas, E
              and Illingworth, Cjr and McCoy, L E and Gupta, R K",
  abstract = "SARS-CoV-2 Spike protein is critical for virus infection via
              engagement of ACE2, and amino acid variation in Spike is
              increasingly appreciated. Given both vaccines and therapeutics
              are designed around Wuhan-1 Spike, this raises the theoretical
              possibility of virus escape, particularly in immunocompromised
              individuals where prolonged viral replication occurs. Here we
              report chronic SARS-CoV-2 with reduced sensitivity to
              neutralising antibodies in an immune suppressed individual
              treated with convalescent plasma, generating whole genome
              ultradeep sequences by both short and long read technologies over
              23 time points spanning 101 days. Although little change was
              observed in the overall viral population structure following two
              courses of remdesivir over the first 57 days, N501Y in Spike was
              transiently detected at day 55 and V157L in RdRp emerged.
              However, following convalescent plasma we observed large, dynamic
              virus population shifts, with the emergence of a dominant viral
              strain bearing D796H in S2 and $\Delta$ H69/ $\Delta$ V70 in the
              S1 N-terminal domain NTD of the Spike protein. As passively
              transferred serum antibodies diminished, viruses with the escape
              genotype diminished in frequency, before returning during a
              final, unsuccessful course of convalescent plasma. In vitro, the
              Spike escape double mutant bearing $\Delta$ H69/ $\Delta$ V70 and
              D796H conferred decreased sensitivity to convalescent plasma,
              whilst maintaining infectivity similar to wild type. D796H
              appeared to be the main contributor to decreased susceptibility,
              but incurred an infectivity defect. The $\Delta$ H69/ $\Delta$
              V70 single mutant had two-fold higher infectivity compared to
              wild type and appeared to compensate for the reduced infectivity
              of D796H. Consistent with the observed mutations being outside
              the RBD, monoclonal antibodies targeting the RBD were not
              impacted by either or both mutations, but a non RBD binding
              monoclonal antibody was less potent against $\Delta$ H69/
              $\Delta$ V70 and the double mutant. These data reveal strong
              selection on SARS-CoV-2 during convalescent plasma therapy
              associated with emergence of viral variants with reduced
              susceptibility to neutralising antibodies.",
  journal  = "medRxiv",
  month    =  dec,
  year     =  2020,
  language = "en"
}

@ARTICLE{Howland2021-po,
  title     = "Tofacitinib use in adults with chronic inflammatory disease
               during the severe acute respiratory syndrome Coronavirus 2
               pandemic: What is known so far?",
  author    = "Howland, Samantha and Deuring, J Jasper and Zhou, Xiaofeng and
               Chen, Yan and Mota, Licia Mh and Ungaro, Ryan C",
  abstract  = "Background: Concerns have been raised that the risk of severe
               acute respiratory syndrome coronavirus 2 infection, or more
               severe or critical coronavirus disease 2019 (COVID-19), may be
               higher in immunocompromised individuals receiving
               immunomodulatory therapies compared with immunocompetent
               individuals. Tofacitinib is an oral Janus kinase inhibitor for
               the treatment of rheumatoid arthritis, psoriatic arthritis,
               ulcerative colitis, and polyarticular course juvenile idiopathic
               arthritis. To date, data on tofacitinib treatment during the
               COVID-19 pandemic are limited. Objectives: To summarize current
               understanding of the use of tofacitinib in adults during the
               COVID-19 pandemic, and discuss research questions that are yet
               to be addressed, to further inform the safe and effective use of
               tofacitinib in clinical practice. Methods: We conducted a review
               of the literature (as of February 2021), to summarize the expert
               recommendations for the management of rheumatoid arthritis,
               psoriatic arthritis, and ulcerative colitis in the context of
               COVID-19, and to assess the current data regarding the use of
               tofacitinib in adult patients during the pandemic. Results:
               Current recommendations for rheumatoid arthritis, psoriatic
               arthritis, and ulcerative colitis state that tofacitinib
               treatment should be continued during the pandemic, except in
               cases of positive or presumed severe acute respiratory syndrome
               coronavirus 2 infection. However, limited data are available;
               analyses of data from international rheumatology and
               gastroenterology registries have suggested that tofacitinib may
               not be associated with an increased risk of hospitalization or
               treatment switching in adults with COVID-19. Conclusions:
               Further assessment of tofacitinib use in patients with
               rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis
               will be required to elucidate and establish the benefit:risk
               profile of tofacitinib during the current COVID-19 pandemic.",
  journal   = "Curr. Ther. Res. Clin. Exp.",
  publisher = "Elsevier BV",
  volume    =  95,
  number    =  100639,
  pages     = "100639",
  month     =  jul,
  year      =  2021,
  keywords  = "gastroenterology; immunosuppressive treatment; rheumatology;
               virology",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Ella2021-iw,
  title     = "Efficacy, safety, and lot-to-lot immunogenicity of an
               inactivated {SARS-CoV-2} vaccine ({BBV152)}: interim results of
               a randomised, double-blind, controlled, phase 3 trial",
  author    = "Ella, Raches and Reddy, Siddarth and Blackwelder, William and
               Potdar, Varsha and Yadav, Pragya and Sarangi, Vamshi and Aileni,
               Vinay K and Kanungo, Suman and Rai, Sanjay and Reddy, Prabhakar
               and Verma, Savita and Singh, Chandramani and Redkar, Sagar and
               Mohapatra, Satyajit and Pandey, Anil and Ranganadin, Pajanivel
               and Gumashta, Raghavendra and Multani, Manish and Mohammad,
               Shameem and Bhatt, Parul and Kumari, Laxmi and Sapkal, Gajanan
               and Gupta, Nivedita and Abraham, Priya and Panda, Samiran and
               Prasad, Sai and Bhargava, Balram and Ella, Krishna and Vadrevu,
               Krishna Mohan and {COVAXIN Study Group}",
  abstract  = "BACKGROUND: We report the clinical efficacy against COVID-19
               infection of BBV152, a whole virion inactivated SARS-CoV-2
               vaccine formulated with a toll-like receptor 7/8 agonist
               molecule adsorbed to alum (Algel-IMDG) in Indian adults.
               METHODS: We did a randomised, double-blind, placebo-controlled,
               multicentre, phase 3 clinical trial in 25 Indian hospitals or
               medical clinics to evaluate the efficacy, safety, and
               immunological lot consistency of BBV152. Adults (age $\geq$18
               years) who were healthy or had stable chronic medical conditions
               (not an immunocompromising condition or requiring treatment with
               immunosuppressive therapy) were randomised 1:1 with a
               computer-generated randomisation scheme (stratified for the
               presence or absence of chronic conditions) to receive two
               intramuscular doses of vaccine or placebo administered 4 weeks
               apart. Participants, investigators, study coordinators,
               study-related personnel, the sponsor, and nurses who
               administered the vaccines were masked to treatment group
               allocation; an unmasked contract research organisation and a
               masked expert adjudication panel assessed outcomes. The primary
               outcome was the efficacy of the BBV152 vaccine in preventing a
               first occurrence of laboratory-confirmed (RT-PCR-positive)
               symptomatic COVID-19 (any severity), occurring at least 14 days
               after the second dose in the per-protocol population. We also
               assessed safety and reactogenicity throughout the duration of
               the study in all participants who had received at least one dose
               of vaccine or placebo. This report contains interim results
               (data cutoff May 17, 2021) regarding immunogenicity and safety
               outcomes (captured on days 0 to 56) and efficacy results with a
               median of 99 days for the study population. The trial was
               registered on the Indian Clinical Trials Registry India,
               CTRI/2020/11/028976, and ClinicalTrials.gov, NCT04641481
               (active, not recruiting). FINDINGS: Between Nov 16, 2020, and
               Jan 7, 2021, we recruited 25 798 participants who were randomly
               assigned to receive BBV152 or placebo; 24 419 received two doses
               of BBV152 (n=12 221) or placebo (n=12 198). Efficacy analysis
               was dependent on having 130 cases of symptomatic COVID-19, which
               occurred when 16 973 initially seronegative participants had at
               least 14 days follow-up after the second dose. 24 (03\%) cases
               occurred among 8471 vaccine recipients and 106 (12\%) among
               8502 placebo recipients, giving an overall estimated vaccine
               efficacy of 778\% (95\% CI 652-864). In the safety population
               (n=25 753), 5959 adverse events occurred in 3194 participants.
               BBV152 was well tolerated; the same proportion of participants
               reported adverse events in the vaccine group (1597 [124\%] of
               12 879) and placebo group (1597 [124\%] of 12 874), with no
               clinically significant differences in the distributions of
               solicited, unsolicited, or serious adverse events between the
               groups, and no cases of anaphylaxis or vaccine-related deaths.
               INTERPRETATION: BBV152 was highly efficacious against
               laboratory-confirmed symptomatic COVID-19 disease in adults.
               Vaccination was well tolerated with no safety concerns raised in
               this interim analysis. FUNDING: Bharat Biotech International and
               Indian Council of Medical Research.",
  journal   = "Lancet",
  publisher = "Elsevier BV",
  volume    =  398,
  number    =  10317,
  pages     = "2173--2184",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Azgomi2021-nc,
  title     = "A rapid and simple multiparameter assay to quantify
               Spike-specific {CD4} and {CD8} {T} cells after {SARS-CoV-2}
               vaccination: A preliminary report",
  author    = "Azgomi, Mojtaba Shekarkar and La Manna, Marco Pio and Badami,
               Giusto Davide and Ragonese, Paolo and Trizzino, Antonino and
               Dieli, Francesco and Caccamo, Nadia",
  abstract  = "mRNA and Adenovirus vaccines for COVID-19 are used to induce
               humoral and cell-mediated immunity, with the aim to generate
               both SARS-CoV-2 B and T memory cells. In present study, we
               described a simple assay to detect and quantify Spike-specific
               CD4+ and CD8+ T cell responses induced by vaccination in healthy
               donors and in subjects with B cell compart impairment, in which
               antibody response is absent due to primary immunodeficiencies or
               CD20 depleting therapy. We detect and quantified memory T cell
               immune responses against SARS-CoV-2 evocated by vaccination in
               both groups, irrespective to the humoral response. Furthermore,
               we identified TNF-$\alpha$ as the main cytokine produced by T
               memory cells, after antigen-specific stimulation in vitro, that
               could be considered, other than IFN-$\gamma$, an additional
               biomarker of induction of T memory cells upon vaccination.
               Further studies on the vaccine-induced T cell responses could be
               crucial, not only in healthy people but also in
               immunocompromised subjects, where antigen specific T cells
               responses play a protective role against SARS-CoV-2.",
  journal   = "Biomedicines",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  11,
  pages     = "1576",
  month     =  oct,
  year      =  2021,
  keywords  = "CD4+; CD8+; Pfizer/BioNTech; SARS-CoV-2; cytokines; memory T
               cell",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Tang2021-tj,
  title     = "Host predictors of broadly cross-reactive antibodies against
               {SARS-CoV-2} variants of concern differ between infection and
               vaccination",
  author    = "Tang, Li and Cherry, Sean and Tuomanen, Elaine I and Roubidoux,
               Ericka Kirkpatrick and Lin, Chun-Yang and Allison, Kim J and
               Gowen, Ashleigh and Freiden, Pamela and Allen, E Kaitlynn and
               Su, Yin and Gaur, Aditya H and Estepp, Jeremie H and McGargill,
               Maureen A and Krammer, Florian and Thomas, Paul G and
               Schultz-Cherry, Stacey and Wolf, Joshua and {St. Jude
               Investigative Team}",
  abstract  = "BACKGROUND: Following SARS-CoV-2 infection or vaccination there
               is significant variability between individuals in protective
               antibody levels against SARS-CoV-2, and within individuals
               against different virus variants. However, host demographic or
               clinical characteristics that predict variability in
               cross-reactive antibody levels are not well-described. These
               data could inform clinicians, researchers, and policy makers on
               the populations most likely to require vaccine booster shots.
               METHODS: In an institutional review board-approved prospective
               observational cohort study of staff at St. Jude Children's
               Research Hospital, we identified participants with plasma
               samples collected after SARS-CoV-2 infection, after mRNA
               vaccination, and after vaccination following infection, and
               quantitated IgG levels by ELISA to the spike receptor binding
               domain (RBD) from five important SARS-CoV-2 variants (Wuhan
               Hu-1, B.1.1.7, B.1.351, P.1 and B.1.617.2). We used regression
               models to identify factors that contributed to cross-reactive
               IgG against one or multiple viral variants. RESULTS: Following
               infection, a minority of the cohort generated cross-reactive
               antibodies, IgG antibodies that bound all tested variants. Those
               that did had increased disease severity, poor metabolic health,
               and were of a particular ancestry. Vaccination increased the
               levels of cross-reactive IgG levels in all populations including
               immunocompromised, elderly and persons with poor metabolic
               health. Younger people with a healthy weight mounted the highest
               responses. CONCLUSIONS: Our findings provide important new
               information on individual antibody responses to
               infection/vaccination that could inform clinicians on the
               populations that may require follow-on immunization.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  dec,
  year      =  2021,
  keywords  = "Antibody Response; BMI; Metabolic Health; SARS-CoV-2; Variants
               of Concern",
  copyright = "https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model",
  language  = "en"
}

@ARTICLE{Bavaro2021-zd,
  title     = "Cefiderocol-based combination therapy for ``difficult-to-treat''
               Gram-negative severe infections: Real-life case series and
               future perspectives",
  author    = "Bavaro, Davide Fiore and Belati, Alessandra and Diella, Lucia
               and Stufano, Monica and Romanelli, Federica and Scalone, Luca
               and Stolfa, Stefania and Ronga, Luigi and Maurmo, Leonarda and
               Dell'Aera, Maria and Mosca, Adriana and Dalfino, Lidia and
               Grasso, Salvatore and Saracino, Annalisa",
  abstract  = "Cefiderocol is a new cephalosporin displaying against
               extensively resistant (XDR) Gram-negative bacteria. We report
               our experience with cefiderocol-based combination therapies as
               ``rescue'' treatments in immunocompromised or critically ill
               patients or in patients with post-surgical infections who had
               failed previous regimens. A total of 13 patients were treated
               from 1 September 2020 to 31 March 2021. In total, 5/13 (38\%)
               patients were classified as critically ill, due to severe
               COVID-19 lung failure; 4/13 (31\%) patients had post-surgical
               infections and 4/13 (31\%) had severe infections in
               immunocompromised subjects due to solid organ transplantation
               (2/4) or hematological malignancy (2/4). Overall, 10/13
               infections were caused by carbapenem-resistant Acinetobacter
               baumannii, one by KPC-positive ceftazidime/avibactam-resistant
               Klebsiella pneumonia and two by Pseudomonas aeruginosa XDR.
               Based on clinical, microbiological and hematobiochemical
               evaluation, cefiderocol was associated with different companion
               drugs, particularly with fosfomycin, high-dose tigecycline
               and/or colistin. Microbiological eradication was achieved in all
               cases and the 30-day survival rate was 10/13; two patients died
               due to SARS-CoV-2 lung failure, whereas one death was attributed
               to subsequent infections. No recurrent infections within 30 days
               were reported. Finally, we hereby discuss the therapeutic
               potential of cefiderocol and the possible place in the therapy
               of this novel drug.",
  journal   = "Antibiotics (Basel)",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  6,
  pages     = "652",
  month     =  may,
  year      =  2021,
  keywords  = "Acinetobacter baumannii; Klebsiella pneumoniae; Pseudomonas
               aeruginosa; cefiderocol; critically ill patients;
               immunocompromised hosts; multidrug resistant gram-negative
               bacteria; novel antimicrobial strategies",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{George2021-tu,
  title    = "A review of the presentation and outcome of sarcoidosis in
              coronavirus disease 2019",
  author   = "George, Lina James and Philip, Anil Mathew and John, Kevin John
              and George, Anu Anna and Nayar, Jemimah and Mishra, Ajay Kumar
              and Lal, Amos",
  abstract = "Background: In the setting of the current pandemic, concerns have
              arisen regarding the multisystemic involvement of sarcoidosis and
              the possible exacerbations in response to the exposure to severe
              acute respiratory syndrome coronavirus 2. Aim: This study aims to
              compare the differences in clinical presentation, management, and
              outcome of coronavirus disease 2019 (COVID-19) between patients
              with sarcoidosis and those in the general population. Methods: A
              literature search was conducted by reviewing original research
              articles such as case reports, case series, observational
              studies, and questionnaire-based surveys published in
              PubMed/Medline, Web of Science, and Google scholar. Data from
              individual patients in case series and case reports have been
              pooled to create a data set that was compared with larger such
              cohorts obtained from several other observational studies.
              Results: Twenty-seven patients were identified from 14 original
              articles. No significant differences were found in the clinical
              manifestations of patients with sarcoidosis presenting with
              COVID-19 as compared to the general population. The rate of
              hospitalization in our study was found to be 48.1\%. The overall
              mortality in our study was 7.4\%, which is higher than the global
              average of 2.1\%. Conclusion: Our observations have reinforced
              the hypothesis that the presence of additional medical
              comorbidities is associated with a higher risk of intensive care
              unit admission. Furthermore, the presence of moderate to a severe
              limitation in pulmonary functions is an additional risk factor
              associated with increased hospital admissions and mortality in
              sarcoidosis. However, neither the diagnosis of sarcoidosis nor
              ongoing treatment with steroids, methotrexate, or other
              immunosuppressants was associated with a poorer prognosis in
              patients with sarcoidosis. Relevance for patients: Patients with
              sarcoidosis must take added precautions to mitigate the risk of
              acquiring COVID-19 infection in view of the COVID-19-related
              mortality rate in this group of patients. Specifically,
              immunocompromised patients (on immunomodulator drugs and high
              dose steroids) have been found to have an increased risk of
              contracting COVID-19. Overall impact on prognostication and
              outcome in cases requiring hospitalization remains yet to be
              determined.",
  journal  = "J. Clin. Transl. Res.",
  volume   =  7,
  number   =  5,
  pages    = "657--665",
  month    =  oct,
  year     =  2021,
  keywords = "coronavirus disease 2019; sarcoidosis",
  language = "en"
}

@ARTICLE{Ahanchian2021-do,
  title     = "{COVID-19} in a child with primary antibody deficiency",
  author    = "Ahanchian, Hamid and Moazzen, Nasrin and Sezavar, Majid and
               Khalighi, Negar and Khoshkhui, Maryam and Aelami, Mohammad
               Hassan and Motevalli Haghi, Nasrin Sadat and Rezaei, Nima",
  abstract  = "Although presentation of COVID-19 in patients with
               immunodeficiency could be mild, it should not be missed, while
               early diagnosis and appropriate treatment can survive infected
               patients. Because even severe infections in PID patients may be
               presented with few symptoms and signs, this diagnosis should be
               considered in those immunocompromised patients who have
               exacerbating preexisting symptoms.",
  journal   = "Clin. Case Rep.",
  publisher = "Wiley",
  volume    =  9,
  number    =  2,
  pages     = "755--758",
  month     =  feb,
  year      =  2021,
  keywords  = "COVID-19; SARS-Cov2; primary antibody deficiency; primary
               immunodeficiency",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Sahu2021-gu,
  title     = "Mucormycosis in Indian {COVID-19} patients: Insight into its
               patho-genesis, clinical manifestation, and management strategies",
  author    = "Sahu, Ram Kumar and Salem-Bekhit, Mounir M and Bhattacharjee,
               Bedanta and Almoshari, Yosif and Ikbal, Abu Md Ashif and
               Alshamrani, Meshal and Bharali, Alakesh and Salawi, Ahmad and
               Widyowati, Retno and Alshammari, Abdulrahman and Elbagory,
               Ibrahim",
  abstract  = "Mucormycosis in patients who have COVID-19 or who are otherwise
               immunocompromised has become a global problem, causing
               significant morbidity and mortality. Infection is debilitating
               and fatal, leading to loss of organs and emotional trauma.
               Radiographic manifestations are not specific, but diagnosis can
               be made through microscopic examination of materials collected
               from necrotic lesions. Treatment requires multidisciplinary
               expertise, as the fungus enters through the eyes and nose and
               may even reach the brain. Use of the many antifungal drugs
               available is limited by considerations of resistance and
               toxicity, but nanoparticles can overcome such limitations by
               reducing toxicity and increasing bioavailability. The lipid
               formulation of amphotericin-B (liposomal Am-B) is the first-line
               treatment for mucormycosis in COVID-19 patients, but its high
               cost and low availability have prompted a shift toward surgery,
               so that surgical debridement to remove all necrotic lesions
               remains the hallmark of effective treatment of mucormycosis in
               COVID-19. This review highlights the pathogenesis, clinical
               manifestation, and management of mucormycosis in patients who
               have COVID-19.",
  journal   = "Antibiotics (Basel)",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  9,
  pages     = "1079",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; amphotericin-B; mucormycosis; nanoparticles;
               pathogenesis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Kaplan2021-xb,
  title     = "Crohn's and colitis Canada's 2021 impact of {COVID-19} \&
               inflammatory bowel disease in Canada: A knowledge translation
               strategy",
  author    = "Kaplan, Gilaad G and Windsor, Joseph W and Crain, Janet and
               Barrett, Lisa and Bernstein, Charles N and Bitton, Alain and
               Chauhan, Usha and Coward, Stephanie and Fowler, Sharyle and
               Ghia, Jean-Eric and Gibson, Deanna L and Griffiths, Anne M and
               Jones, Jennifer L and Khanna, Reena and Kuenzig, M Ellen and
               Lakatos, Peter L and Lee, Kate and Mack, David R and Marshall,
               John K and Mawani, Mina and Murthy, Sanjay K and Panaccione,
               Remo and Seow, Cynthia H and Targownik, Laura E and Zelinsky,
               Sandra and Benchimol, Eric I",
  abstract  = "The prevalence of inflammatory bowel diseases (IBD), Crohn's
               disease and ulcerative colitis, in Canada, is over 0.75\% in
               2021. Many individuals with IBD are immunocompromised.
               Consequently, the World Health Organization's declaration of a
               global pandemic uniquely impacted those with IBD. Crohn's and
               Colitis Canada (CCC) formed the COVID-19 and IBD Taskforce to
               provide evidence-based guidance during the pandemic to
               individuals with IBD and their families. The Taskforce met
               regularly through the course of the pandemic, synthesizing
               available information on the impact of COVID-19 on IBD. At
               first, the information was extrapolated from expert consensus
               guidelines, but eventually, recommendations were adapted for an
               international registry of worldwide cases of COVID-19 in people
               with IBD. The task force launched a knowledge translation
               initiative consisting of a webinar series and online resources
               to communicate information directly to the IBD community.
               Taskforce recommendations were posted to CCC's website and
               included guidance such as risk stratification, management of
               immunosuppressant medications, physical distancing, and mental
               health. A weekly webinar series communicated critical
               information directly to the IBD community. During the pandemic,
               traffic to CCC's website increased with 484,755 unique views of
               the COVID-19 webpages and 126,187 views of the 23 webinars,
               including their video clips. CCC's COVID-19 and IBD Taskforce
               provided critical guidance to the IBD community as the pandemic
               emerged, the nation underwent a lockdown, the economy reopened,
               and the second wave ensued. By integrating public health
               guidance through the unique prism of a vulnerable population,
               CCC's knowledge translation platform informed and protected the
               IBD community.",
  journal   = "J. Can. Assoc. Gastroenterol.",
  publisher = "Oxford University Press (OUP)",
  volume    =  4,
  number    = "Suppl 2",
  pages     = "S10--S19",
  month     =  dec,
  year      =  2021,
  keywords  = "Coronavirus; Crohn's disease; SARS-CoV-2; Ulcerative colitis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Davies2021-cf,
  title     = "Persistence of clinically-relevant levels of {SARS-CoV2}
               envelope gene subgenomic {RNAs} in non-immunocompromised
               individuals",
  author    = "Davies, Merlin and Bramwell, Laura R and Jeffery, Nicola and
               Bunce, Ben and Lee, Ben P and Knight, Bridget and Auckland,
               Cressida and Masoli, Jane A H and Harries, Lorna W",
  abstract  = "OBJECTIVES: We aimed to evaluate associations between COVID19
               severity and active viral load, and to characterise the dynamics
               of active SARS-CoV-2 clearance in a series of archival samples
               taken from patients in the first wave of COVID-19 infection in
               the South West of the UK. METHODS: We measured subgenomic RNA
               (sgRNA) and E gene genomic sequences in a retrospective
               collection of 176 PCR-confirmed SARS-CoV-2 positive individuals,
               and related these to disease severity. We then assessed viral
               clearance dynamics in relation to symptom onset and last
               positive test. RESULTS: Whilst E-gene sgRNAs declined before
               E-gene genomic sequences, some individuals retained sgRNA
               positivity for up to 68 days. 13\% of sgRNA positive cases still
               exhibited clinically-relevant levels of virus after 10 days,
               with no clinical features previously associated with prolonged
               viral clearance times. CONCLUSIONS: Our results suggest that
               potentially active virus may sometimes persist beyond a 10 day
               period, and could pose a potential risk of onward transmission.
               Where this would pose a serious public health threat, additional
               mitigation strategies may be necessary to reduce the risk of
               secondary cases in vulnerable settings.",
  journal   = "Int. J. Infect. Dis.",
  publisher = "Elsevier BV",
  month     =  dec,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Perricone2021-aw,
  title     = "Intravenous immunoglobulins at the crossroad of autoimmunity and
               viral infections",
  author    = "Perricone, Carlo and Triggianese, Paola and Bursi, Roberto and
               Cafaro, Giacomo and Bartoloni, Elena and Chimenti, Maria Sole
               and Gerli, Roberto and Perricone, Roberto",
  abstract  = "Intravenous immunoglobulins (IVIG) are blood preparations pooled
               from the plasma of donors that have been first employed as
               replacement therapy in immunodeficiency. IVIG interact at
               multiple levels with the different components of the immune
               system and exert their activity against infections. Passive
               immunotherapy includes convalescent plasma from subjects who
               have recovered from infection, hyperimmune globulin formulations
               with a high titer of neutralizing antibodies, and monoclonal
               antibodies (mAbs). IVIG are used for the prevention and
               treatment of several infections, especially in immunocompromised
               patients, or in case of a poorly responsive immune system. The
               evolution of IVIG from a source of passive immunity to a
               powerful immunomodulatory/anti-inflammatory agent results in
               extensive applications in autoimmune diseases. IVIG composition
               depends on the antibodies of the donor population and the
               alterations of protein structure due to the processing of
               plasma. The anti-viral and anti-inflammatory activity of IVIG
               has led us to think that they may represent a useful therapeutic
               tool even in COVID-19. The human origin of IVIG carries specific
               criticalities including risks of blood products, supply, and
               elevated costs. IVIG can be useful in critically ill patients,
               as well as early empirical treatment. To date, the need for
               further well-designed studies stating protocols and the
               efficacy/tolerability profile of IVIG and convalescent plasma in
               selected situations are awaited.",
  journal   = "Microorganisms",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  1,
  pages     = "121",
  month     =  jan,
  year      =  2021,
  keywords  = "SARS-CoV-2; autoimmunity; infection; intravenous
               immunoglobulins; virus",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Gude2021-it,
  title     = "Emerging needs and viability of telepsychiatry during and post
               {COVID-19} era: A literature review",
  author    = "Gude, Jayasudha and Subhedar, Rashmi V and Zhang, Michelle H and
               Jain, Pratik and Bhela, Jatminderpal and Bangash, Fariha and
               Veluri, Nikhila and Hsieh, Ya-Ching and Sheikh, Batool Z and
               Shah, Mansi R and Mansuri, Zeeshan and Aedma, Kapil and Patel,
               Urvish K and Parikh, Tapan",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has resulted in
               nationwide stay-at-home orders in an effort to slow the spread
               severely impacting the healthcare sector. Telepsychiatry
               provides a platform bridging the gap through advanced
               technologies connecting mental health providers and patients who
               need their services, overcoming previous barriers of great
               distances, lack of transportation, and even time constraints.
               The most obvious benefit is increased accessibility to mental
               healthcare, especially in underserved and remote areas where
               there is no easy access for in-person care. It is important to
               note that benefits are not limited to patients, but also allow
               clinicians greater flexibility in scheduling and reduced
               practice overhead costs, both of which aid with physician
               burnout and burden. Telepsychiatry during COVID-19 provides its
               own unique advantages over in-person visits. The risk of
               exposure to healthcare workers and patients receiving care is
               reduced, allowing immunocompromised patients to receive
               much-needed psychiatric care. Without the need to meet in
               person, self-isolating psychiatrists can still provide care,
               decreasing strain on their co-workers. Although telepsychiatry
               is relatively new, it has already exhibited considerable success
               in its effectiveness at treating psychiatric conditions and
               widespread corollary benefits. Telepsychiatric consults may be
               carried out synchronously and asynchronously, each having
               benefits and setbacks. Different mobile application
               interventions have been explored, which are available for the
               purpose of both monitoring/assessing patients and/or providing
               treatment. The scope of conditions these applications address is
               broad, from anxiety disorders to schizophrenia to depression. As
               promising and beneficial telepsychiatry may seem, it is
               necessary to recognize that building the program can be
               challenging. It involves adapting to new methods in medicine. We
               highlighted barriers to general telepsychiatry, the most
               prominent being technological literacy of both physician and
               patient, and possible negative effects of eliminating the
               in-person patient-doctor interaction.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  8,
  pages     = "e16974",
  month     =  aug,
  year      =  2021,
  keywords  = "communication; covid 19; technology; tele mental health; tele
               psychiatry; viability of telepsychiatry; virtual clinics",
  language  = "en"
}

@ARTICLE{Pai2021-xw,
  title    = "Rhino-orbito-cerebral mucormycosis: Pictorial review",
  author   = "Pai, Vivek and Sansi, Rima and Kharche, Ritesh and Bandili,
              Sridevi Chaitanya and Pai, Bhujang",
  abstract = "Mucormycosis (MCR) is a fulminant, potentially lethal,
              opportunistic fungal infection. Diabetes, immunocompromised
              states and elevated serum iron levels are the most important risk
              factors for contracting MCR infection. Recently, MCR
              co-infections have been observed in patients with COVID-19
              disease owing to a complex interplay of metabolic factors and
              corticosteroid therapy. Rhino-orbito-cerebral mucormycosis (ROCM)
              is the most common clinical form of MCR infection and refers to
              infection of the nasal cavities, paranasal sinuses, neck spaces,
              orbits and intracranial structures. Sinonasal inoculation is
              typically the primary site of infection; the necrotising and
              angioinvasive properties of the fungus facilitate its spread into
              adjacent structures. In this review, we discuss the pertinent
              mycology and risk factors of MCR infection. The review also aims
              to acquaint the reader with the cross-sectional imaging
              appearances of ROCM and its complications. All the cases
              discussed in this pictorial essay are microbiologically and/or
              histopathologically proven cases of ROCM with concomitant
              COVID-19 infection.",
  journal  = "Insights Imaging",
  volume   =  12,
  pages    = "167",
  month    =  dec,
  year     =  2021,
  keywords = "Invasive fungal sinusitis; Mucormycosis; Rhino-orbito-cerebral
              Mucormycosis",
  language = "en"
}

@ARTICLE{Pai2021-uv,
  title     = "Rhino-orbito-cerebral mucormycosis: Pictorial review",
  author    = "Pai, Vivek and Sansi, Rima and Kharche, Ritesh and Bandili,
               Sridevi Chaitanya and Pai, Bhujang",
  abstract  = "Mucormycosis (MCR) is a fulminant, potentially lethal,
               opportunistic fungal infection. Diabetes, immunocompromised
               states and elevated serum iron levels are the most important
               risk factors for contracting MCR infection. Recently, MCR
               co-infections have been observed in patients with COVID-19
               disease owing to a complex interplay of metabolic factors and
               corticosteroid therapy. Rhino-orbito-cerebral mucormycosis
               (ROCM) is the most common clinical form of MCR infection and
               refers to infection of the nasal cavities, paranasal sinuses,
               neck spaces, orbits and intracranial structures. Sinonasal
               inoculation is typically the primary site of infection; the
               necrotising and angioinvasive properties of the fungus
               facilitate its spread into adjacent structures. In this review,
               we discuss the pertinent mycology and risk factors of MCR
               infection. The review also aims to acquaint the reader with the
               cross-sectional imaging appearances of ROCM and its
               complications. All the cases discussed in this pictorial essay
               are microbiologically and/or histopathologically proven cases of
               ROCM with concomitant COVID-19 infection.",
  journal   = "Insights Imaging",
  publisher = "Springer Science and Business Media LLC",
  volume    =  12,
  number    =  1,
  pages     = "167",
  month     =  nov,
  year      =  2021,
  keywords  = "Invasive fungal sinusitis; Mucormycosis; Rhino-orbito-cerebral
               Mucormycosis",
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Seidel2021-ih,
  title     = "Results from a national survey on {COVID-19-associated}
               mucormycosis in Germany: 13 patients from six tertiary hospitals",
  author    = "Seidel, Danila and Simon, Michaela and Sprute, Rosanne and
               Lubnow, Matthias and Evert, Katja and Speer, Claudius and
               See{\ss}le, Jessica and Khatamzas, Elham and Merle, Uta and
               Behrens, Christopher and Blau, Igor Wolfgang and Enghard,
               Philipp and Haas, Christian S and Steinmann, Joerg and Kurzai,
               Oliver and Cornely, Oliver A",
  abstract  = "BACKGROUND: Most COVID-19-associated mucormycosis (CAM) cases
               are reported from India and neighbouring countries. Anecdotally
               cases from Europe have been presented. OBJECTIVE: To estimate
               the disease burden and describe the clinical presentation of CAM
               in Germany. METHODS: We identified cases through German mycology
               networks and scientific societies, and collected anonymised
               clinical information via FungiScope\textregistered{}. RESULTS:
               We identified 13 CAM cases from six tertiary referral hospitals
               diagnosed between March 2020 and June 2021. Twelve patients had
               severe or critical COVID-19, eleven were mechanically ventilated
               for a median of 8 days (range 1-27 days) before diagnosis of
               CAM. Eleven patients received systemic corticosteroids.
               Additional underlying medical conditions were reported for all
               but one patient, five were immunocompromised because of
               malignancy or organ transplantation, three were diabetic. Eleven
               patients developed pneumonia. Mortality was 53.8\% with a median
               time from diagnosis of mucormycosis to death of 9 days (range
               0-214 days) despite treatment with liposomal amphotericin B
               and/or isavuconazole in 10 of 13 cases. CAM prevalence amongst
               hospitalised COVID-19 patients overall (0.67\% and 0.58\% in two
               centres) and those admitted to the intensive care unit (ICU)
               (1.47\%, 1.78\% and 0.15\% in three centres) was significantly
               higher compared to non-COVID-19 patients (P < .001 for
               respective comparisons). CONCLUSION: COVID-19-associated
               mucormycosis is rare in Germany, mostly reported in patients
               with comorbidities and impaired immune system and severe
               COVID-19 treated in the ICU with high mortality compared to
               mainly rhino-orbito-cerebral CAM in patients with mild COVID-19
               in India. Risk for CAM is higher in hospitalised COVID-19
               patients than in other patients.",
  journal   = "Mycoses",
  publisher = "Wiley",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; COVID-19 vaccination; amphotericin B; fungal
               infection; isavuconazole; mortality; mucormycosis; prevalence",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Zomerdijk2021-jh,
  title     = "Experiences and needs of people with haematological cancers
               during the {COVID-19} pandemic: A qualitative study",
  author    = "Zomerdijk, Nienke and Jongenelis, Michelle and Yuen, Eva and
               Turner, Jane and Huntley, Kathryn and Smith, Andrew and
               McIntosh, Megan and Short, Camille E",
  abstract  = "OBJECTIVE: Haematological cancer patients are particularly
               vulnerable to the effects of COVID-19. In addition to being
               immunocompromised, pandemic-related travel restrictions have
               impacted access to treatments and overseas stem cell donations
               for patients requiring transplantation. Given this
               vulnerability, people with haematological cancers are at risk of
               experiencing heightened distress during the pandemic. This study
               aimed to explore haematological cancer patients' experiences and
               needs. METHODS: Twenty-four Australian haematological cancer
               patients completed semi-structured interviews exploring their
               concerns and worries during the pandemic, impact of pandemic on
               management of disease, access to information and support,
               lifestyle changes, and attitudes towards emerging models of
               healthcare during the pandemic. Interview transcripts were
               thematically analysed. RESULTS: Four themes reflecting the
               experiences of haematological cancer patients during the
               pandemic were identified: 'Fears about contracting COVID-19'
               (behaviour changes to protect health, impact on daily routine
               and habits, annoyance at dismissive attitude of others toward
               COVID-19); 'Reduced sense of connection and support' (reduced
               social support and access to external support services); 'New
               challenges' (increased financial hardship, worsened health),
               and; 'Underlying system and communication issues' (access to
               trusted information, satisfaction/dissatisfaction with care,
               navigating telehealth). Participants expressed a need for
               improved access to support services and trusted information.
               CONCLUSIONS: The findings emphasise the additional challenges
               experienced by haematological cancer patients during the
               COVID-19 pandemic and their impact on daily life. Results point
               to the importance of validation of increased distress during
               periods of uncertainty; reinforcing recommendations about
               high-quality sources of information; and facilitating access to
               support services when face-to-face care is limited.",
  journal   = "Psychooncology",
  publisher = "Wiley",
  number    = "pon.5819",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19 pandemic; cancer; haematology; oncology;
               psycho-oncology; qualitative research; supportive care",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Nair2021-ig,
  title     = "Transcutaneous retrobulbar injection of amphotericin {B} in
               rhino-orbital-cerebral mucormycosis: a review",
  author    = "Nair, Akshay Gopinathan and Dave, Tarjani Vivek",
  abstract  = "Mucormycosis is an aggressive and potentially fatal invasive
               fungal infection. The most common form of mucormycosis is
               rhino-orbital-cerebral mucormycosis (ROCM). While it is commonly
               seen in immunocompromised patients, it is also known to affect
               healthy individuals. The global disease burden of ROCM has
               increased significantly following the surge in cases during the
               COVID-19 pandemic. Endoscopic sinus debridement, systemic
               antifungal therapy, and control of the underlying
               immunosuppressive condition are essential for the management of
               ROCM. Orbital involvement, however, presents a challenge to
               clinicians. Intervention strategies that have been described to
               treat orbital disease include orbital exenteration, conservative
               orbital debridement with or without irrigation with amphotericin
               B and transcutaneous retrobulbar injection of amphotericin B
               (TRAMB). Currently, there is a lack of clarity regarding the
               indications and outcomes of TRAMB as a treatment modality. In
               this review, the drug formulations used, the complications, and
               outcomes of previously described cases that have used TRAMB in
               cases of ROCM are discussed. Favorable outcomes following TRAMB
               depend on appropriate patient selection and radiological
               evidence of the orbital burden of the disease. This review aims
               to familiarize clinicians with objective parameters for patient
               selection for TRAMB, namely the extent of the disease, the
               clinical features, and radiological findings; viz. the clinical
               interpretation of areas of contrast uptake and those of
               necrosis. TRAMB can be considered as a viable option in select
               cases of orbital mucormycosis where exenteration or debridement
               are not indicated, or when there is limited orbital disease.",
  journal   = "Orbit",
  publisher = "Informa UK Limited",
  pages     = "1--12",
  month     =  oct,
  year      =  2021,
  keywords  = "COVID-19; exenteration; fungal disease; invasive sinus disease;
               mucorales",
  language  = "en"
}

@ARTICLE{Chan2021-fz,
  title     = "Review of influenza virus vaccines: The qualitative nature of
               immune responses to infection and vaccination is a critical
               consideration",
  author    = "Chan, Lily and Alizadeh, Kasra and Alizadeh, Kimia and Fazel,
               Fatemeh and Kakish, Julia E and Karimi, Negar and Knapp, Jason P
               and Mehrani, Yeganeh and Minott, Jessica A and Morovati, Solmaz
               and Rghei, Amira and Stegelmeier, Ashley A and Vanderkamp,
               Sierra and Karimi, Khalil and Bridle, Byram W",
  abstract  = "Influenza viruses have affected the world for over a century,
               causing multiple pandemics. Throughout the years, many
               prophylactic vaccines have been developed for influenza;
               however, these viruses are still a global issue and take many
               lives. In this paper, we review influenza viruses, associated
               immunological mechanisms, current influenza vaccine platforms,
               and influenza infection, in the context of immunocompromised
               populations. This review focuses on the qualitative nature of
               immune responses against influenza viruses, with an emphasis on
               trained immunity and an assessment of the characteristics of the
               host-pathogen that compromise the effectiveness of immunization.
               We also highlight innovative immunological concepts that are
               important considerations for the development of the next
               generation of vaccines against influenza viruses.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  9,
  pages     = "979",
  month     =  sep,
  year      =  2021,
  keywords  = "influenza virus; mRNA vaccine; sex-mediated antiviral response;
               trained immunity",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Chen2021-dv,
  title     = "Femtomolar {SARS-CoV-2} antigen detection using the
               Microbubbling digital assay with smartphone readout enables
               antigen burden quantitation and tracking",
  author    = "Chen, Hui and Li, Zhao and Feng, Sheng and Richard-Greenblatt,
               Melissa and Hutson, Emily and Andrianus, Stefen and Glaser,
               Laurel J and Rodino, Kyle G and Qian, Jianing and Jayaraman,
               Dinesh and Collman, Ronald G and Glascock, Abigail and Bushman,
               Frederic D and Lee, Jae Seung and Cherry, Sara and Fausto,
               Alejandra and Weiss, Susan R and Koo, Hyun and Corby, Patricia M
               and Oceguera, Alfonso and O'Doherty, Una and Garfall, Alfred L
               and Vogl, Dan T and Stadtmauer, Edward A and Wang, Ping",
  abstract  = "BACKGROUND: High sensitivity SARS-CoV-2 antigen assays are
               desirable to mitigate false negative results. Limited data are
               available to quantify and track SARS-CoV-2 antigen burden in
               respiratory samples from different populations. METHODS: We
               developed the Microbubbling SARS-CoV-2 Antigen Assay (MSAA) with
               smartphone readout, with a limit of detection (LOD) of 0.5 pg/mL
               (10.6 fmol/L) nucleocapsid (N) antigen or 4000 copies/mL
               inactivated SARS-CoV-2 virus in nasopharyngeal (NP) swabs. We
               developed a computer vision and machine learning-based automatic
               microbubble image classifier to accurately identify positives
               and negatives, and quantified and tracked antigen dynamics in
               ICU COVID inpatients and immunocompromised COVID patients.
               RESULTS: Compared to qualitative RT-PCR methods, the MSAA
               demonstrated a positive percent agreement (PPA) of 97\% (95\%
               confidence interval (CI), 92-99\%) and a negative percent
               agreement (NPA) of 97\% (95\% CI, 94-100\%) in a clinical
               validation study with 372 residual clinical NP swabs. In
               immunocompetent individuals, the antigen positivity rate in
               swabs decreased as days-after-symptom-onset increased, despite
               persistent nucleic acid positivity. Antigen was detected for
               longer and variable periods of time in immunocompromised
               patients with hematologic malignancies. Total microbubble
               volume, a quantitative marker of antigen burden, correlated
               inversely with Ct values and days-after-symptom-onset. Viral
               sequence variations were detected in patients with long duration
               of high antigen burden. CONCLUSIONS: The MSAA enables sensitive
               and specific detection of acute infections, quantification and
               tracking of antigen burden, and may serve as a screening method
               in longitudinal studies to identify patients who are likely
               experiencing active rounds of ongoing replication and warrant
               close viral sequence monitoring.",
  journal   = "Clin. Chem.",
  publisher = "Oxford University Press (OUP)",
  month     =  aug,
  year      =  2021,
  keywords  = "SARS-CoV-2; longitudinal NP swab samples; microbubbling assay;
               viral antigen",
  language  = "en"
}

@ARTICLE{Bagacean2021-yb,
  title     = "Humoral response to {mRNA} {anti-COVID-19} vaccines {BNT162b2}
               and {mRNA-1273} in patients with chronic lymphocytic leukemia",
  author    = "Bagacean, Cristina and Letestu, R{\'e}mi and Al-Nawakil, Chadi
               and Brichler, S{\'e}gol{\`e}ne and L{\'e}vy, Vincent and
               Sritharan, Nanthara and Delmer, Alain Jacques and Dartigeas,
               Caroline and Leblond, V{\'e}ronique and Roos-Weil, Damien and
               Tomowiak, C{\'e}cile and Merabet, Fatiha and B{\'e}n{\'e}, Marie
               C and Clavert, Aline and Chaoui, Driss and Genet, Philippe and
               Guieze, Romain and Laribi, Kamel and Dr{\'e}nou, Bernard and
               Willems, Lise and Puppinck, Christian and Legendre, Hugo and
               Troussard, Xavier and Malartre, St{\'e}phanie and Cymbalista,
               Florence and Michallet, Anne-Sophie",
  abstract  = "Immunocompromised individuals such as chronic lymphocytic
               leukemia (CLL) patients are at risk of impaired immune responses
               to vaccination. The objective of our study was to evaluate
               SARS-CoV-2-specific antibody responses in CLL patients, after
               the first, second and third doses of the BNT162b2 and mRNA-1273,
               and after a single dose for patients with confirmed prior
               COVID-19. Five hundred and thirty patients were included in the
               study. Patients received 2 doses at a 4-week interval, and a
               third dose if seronegative after the second dose. Response rate
               was 27\% post-dose 1 and 52\% post-dose 2. Post-dose 2
               treatment-na{\"\i}ve patients had the highest response rate
               (72\%) followed by patients previously treated by
               chemoimmunotherapy (60\%). Among patients on therapy, patients
               on BTKi alone (22\%) or in combination with anti-CD20 monoclonal
               antibodies or venetoclax (0\%) had the poorer response rate
               whereas patients on venetoclax monotherapy achieved a
               significantly higher response rate (52\%). A multivariate
               analysis identified as independent predictors of the absence of
               seroconversion: age >65 years, ongoing CLL treatment and
               gamma-globulins $\leq$6g/L. Post-dose 2 seronegative patients
               had a global post-dose 3 response rate of 35\%. This study
               provides an argument for the use of a third dose and for
               prophylactic SARS-CoV-2 neutralizing monoclonal antibodies.",
  journal   = "Blood Adv.",
  publisher = "American Society of Hematology",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Bruminhent2021-sf,
  title     = "{SARS-CoV-2-specific} humoral and cell-mediated immune responses
               after immunization with inactivated {COVID-19} vaccine in kidney
               transplant recipients ({CVIM} 1 study)",
  author    = "Bruminhent, Jackrapong and Setthaudom, Chavachol and Chaumdee,
               Pongsathon and Boongird, Sarinya and Kiertiburanakul, Sasisopin
               and Malathum, Kumthorn and Nongnuch, Arkom and Phuphuakrat,
               Angsana and Jirasiritham, Sopon and Janphram, Chitimaporn and
               Thotsiri, Sansanee and Upama, Supparat and Assanatham, Montira
               and {Ramathibodi Transplant Infectious Diseases (RTID) Study
               Group}",
  abstract  = "Immunogenicity following inactivated SARS-CoV-2 vaccination
               among solid organ transplant recipients has not been assessed.
               Seventy-five patients (37 kidney transplant [KT] recipients and
               38 healthy controls) received two doses, at 4-week intervals, of
               an inactivated whole-virus SARS-CoV-2 vaccine.
               SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity
               (CMI) were measured before, 4 weeks post-first dose, and 2 weeks
               post-second dose. The median (IQR) age of KT recipients was 50
               (42-54) years and 89\% were receiving calcineurin
               inhibitors/mycophenolate/corticosteroid regimens. The median
               (IQR) time since transplant was 4.5 (2-9.5) years. Among 35 KT
               patients, the median (IQR) of anti-RBD IgG level measured by
               CLIA after vaccination was not different from baseline, but was
               significantly lower than in controls (2.4 [1.1-3.7] vs. 1742.0
               [747.7-3783.0] AU/ml, p < .01) as well as percentages of
               neutralizing antibody inhibition measured by surrogate viral
               neutralization test (0 [0-0] vs. 71.2 [56.8-92.2]\%, p < .01).
               However, the median (IQR) of SARS-CoV-2 mixed peptides-specific
               T cell responses measured by ELISpot was significantly increased
               compared with baseline (30 [4-120] vs. 12 [0-56] T cells/106
               PBMCs, p = .02) and not different from the controls. Our
               findings revealed weak HMI but comparable CMI responses in fully
               vaccinated KT recipients receiving inactivated SARS-CoV-2
               vaccination compared to immunocompetent individuals (Thai
               Clinical Trials Registry, TCTR20210226002).",
  journal   = "Am. J. Transplant",
  publisher = "Wiley",
  month     =  oct,
  year      =  2021,
  keywords  = "coronavirus; immunocompromised; neutralizing antibody; receptor
               binding domain; renal transplant; spike protein; vaccine",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Lederer2021-hf,
  title    = "Germinal center responses to {SARS-CoV-2} {mRNA} vaccines in
              healthy and immunocompromised individuals",
  author   = "Lederer, Katlyn and Parvathaneni, Kalpana and Painter, Mark M and
              Bettini, Emily and Agarwal, Divyansh and Lundgreen, Kendall A and
              Weirick, Madison and Goel, Rishi R and Xu, Xiaoming and Drapeau,
              Elizabeth M and Gouma, Sigrid and Greenplate, Allison R and Coz,
              Carole Le and Romberg, Neil and Jones, Lisa and Rosen, Mark and
              Besharatian, Behdad and Kaminiski, Mary and Weiskopf, Daniela and
              Sette, Alessandro and Hensley, Scott E and Bates, Paul and
              Wherry, E John and Naji, Ali and Bhoj, Vijay and Locci, Michela",
  abstract = "Vaccine-mediated immunity often relies on the generation of
              protective antibodies and memory B cells, which commonly stem
              from germinal center (GC) reactions. An in-depth comparison of
              the GC responses elicited by SARS-CoV-2 mRNA vaccines in healthy
              and immunocompromised individuals has not yet been performed due
              to the challenge of directly probing human lymph nodes. In this
              study, through a fine-needle-aspiration-based approach, we
              profiled the immune responses to SARS-CoV-2 mRNA vaccines in
              lymph nodes of healthy individuals and kidney transplant (KTX)
              recipients. We found that, unlike healthy subjects, KTX
              recipients presented deeply blunted SARS-CoV-2-specific GC B cell
              responses coupled with severely hindered T follicular helper
              cells, SARS-CoV-2 receptor-binding-domain-specific memory B cells
              and neutralizing antibodies. KTX recipients also displayed
              reduced SARS-CoV-2-specific CD4 and CD8 T cell frequencies.
              Broadly, these data indicate impaired GC-derived immunity in
              immunocompromised individuals, and suggest a GC-origin for
              certain humoral and memory B cell responses following mRNA
              vaccination.",
  journal  = "medRxiv",
  month    =  sep,
  year     =  2021,
  language = "en"
}

@ARTICLE{Gross2021-hp,
  title     = "{ATS} core curriculum 2021. Pediatric pulmonary medicine:
               Pulmonary infections",
  author    = "Gross, Jane E and McCown, Michael Y and Okorie, Caroline U A and
               Bishay, Lara C and Dy, Fei J and Astudillo, Carmen Leon and
               Muhlebach, Marianne S and Abu-Nassar, Sara and Chen, Diana Y and
               Hossain, Nazia and Wang, Ruobing and Klouda, Timothy and
               Martiniano, Stacey L and Lenhart-Pendergrass, Patricia and
               Kirkby, Stephen and Ortenberg, Robin and McSparron, Jakob I and
               Wang, Tisha and Hayes, Margaret M and {\c C}oruh, Ba{\c s}ak",
  abstract  = "The following is a concise review of the Pediatric Pulmonary
               Medicine Core reviewing pediatric pulmonary infections,
               diagnostic assays, and imaging techniques presented at the 2021
               American Thoracic Society Core Curriculum. Molecular methods
               have revolutionized microbiology. We highlight the need to
               collect appropriate samples for detection of specific pathogens
               or for panels and understand the limitations of the assays.
               Considerable progress has been made in imaging modalities for
               detecting pediatric pulmonary infections. Specifically, lung
               ultrasound and lung magnetic resonance imaging are promising
               radiation-free diagnostic tools, with results comparable with
               their radiation-exposing counterparts, for the evaluation and
               management of pulmonary infections. Clinicians caring for
               children with pulmonary disease should ensure that patients at
               risk for nontuberculous mycobacteria disease are identified and
               receive appropriate nontuberculous mycobacteria screening,
               monitoring, and treatment. Children with coronavirus disease
               (COVID-19) typically present with mild symptoms, but some may
               develop severe disease. Treatment is mainly supportive care, and
               most patients make a full recovery. Anticipatory guidance and
               appropriate counseling from pediatricians on social distancing
               and diagnostic testing remain vital to curbing the pandemic. The
               pediatric immunocompromised patient is at risk for invasive and
               opportunistic pulmonary infections. Prompt recognition of
               predisposing risk factors, combined with knowledge of clinical
               characteristics of microbial pathogens, can assist in the
               diagnosis and treatment of specific bacterial, viral, or fungal
               diseases.",
  journal   = "ATS Sch",
  publisher = "American Thoracic Society",
  volume    =  2,
  number    =  3,
  pages     = "452--467",
  month     =  sep,
  year      =  2021,
  keywords  = "COVID-19; imaging; immune compromise; molecular diagnostics;
               nontuberculous mycobacteria",
  language  = "en"
}

@ARTICLE{Pinana2021-hr,
  title     = "Booster effect after {SARS-CoV-2} vaccination in hematological
               immunocompromised patients with prior {COVID-19}",
  author    = "Pi{\~n}ana, Jose Luis L and Garcia-Sanz, Ramon and Martino,
               Rodrigo and Garcia-Roa, Maria and Martin-Martin, Gabriel-Andres
               and Risco-Galvez, Irene and Tormo, Mar and Martinez-Barranco,
               Pilar and Marcos-Corrales, Sara and Calabuig, Marisa and Conesa,
               Venancio and Teruel, Anabel and Ruiz Perez, Sara and Solano,
               Carlos and Navarro, David and Cedillo, Angel and Sureda, Anna",
  journal   = "Blood Adv.",
  publisher = "American Society of Hematology",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Chen2021-vj,
  title    = "Femtomolar {SARS-CoV-2} antigen detection using the Microbubbling
              Digital Assay with smartphone readout enables antigen burden
              quantitation and dynamics tracking",
  author   = "Chen, Hui and Li, Zhao and Feng, Sheng and Wang, Anni and
              Richard-Greenblatt, Melissa and Hutson, Emily and Andrianus,
              Stefen and Glaser, Laurel J and Rodino, Kyle G and Qian, Jianing
              and Jayaraman, Dinesh and Collman, Ronald G and Glascock, Abigail
              and Bushman, Frederic D and Lee, Jae Seung and Cherry, Sara and
              Fausto, Alejandra and Weiss, Susan R and Koo, Hyun and Corby,
              Patricia M and O'Doherty, Una and Garfall, Alfred L and Vogl, Dan
              T and Stadtmauer, Edward A and Wang, Ping",
  abstract = "Background: Little is known about the dynamics of SARS-CoV-2
              antigen burden in respiratory samples in different patient
              populations at different stages of infection. Current rapid
              antigen tests cannot quantitate and track antigen dynamics with
              high sensitivity and specificity in respiratory samples. Methods:
              We developed and validated an ultra-sensitive SARS-CoV-2 antigen
              assay with smartphone readout using the Microbubbling Digital
              Assay previously developed by our group, which is a platform that
              enables highly sensitive detection and quantitation of protein
              biomarkers. A computer vision-based algorithm was developed for
              microbubble smartphone image recognition and quantitation. A
              machine learning-based classifier was developed to classify the
              smartphone images based on detected microbubbles. Using this
              assay, we tracked antigen dynamics in serial swab samples from
              COVID patients hospitalized in ICU and immunocompromised COVID
              patients. Results: The limit of detection (LOD) of the
              Microbubbling SARS-CoV-2 Antigen Assay was 0.5 pg/mL (10.6 fM)
              recombinant nucleocapsid (N) antigen or 4000 copies/mL
              inactivated SARS-CoV-2 virus in nasopharyngeal (NP) swabs,
              comparable to many rRT-PCR methods. The assay had high analytical
              specificity towards SARS-CoV-2. Compared to EUA-approved rRT-PCR
              methods, the Microbubbling Antigen Assay demonstrated a positive
              percent agreement (PPA) of 97\% (95\% confidence interval (CI),
              92-99\%) in symptomatic individuals within 7 days of symptom
              onset and positive SARS-CoV-2 nucleic acid results, and a
              negative percent agreement (NPA) of 97\% (95\% CI, 94-100\%) in
              symptomatic and asymptomatic individuals with negative nucleic
              acid results. Antigen positivity rate in NP swabs gradually
              decreased as days-after-symptom-onset increased, despite
              persistent nucleic acid positivity of the same samples. The
              computer vision and machine learning-based automatic microbubble
              image classifier could accurately identify positives and
              negatives, based on microbubble counts and sizes. Total
              microbubble volume, a potential marker of antigen burden,
              correlated inversely with Ct values and days-after-symptom-onset.
              Antigen was detected for longer periods of time in
              immunocompromised patients with hematologic malignancies,
              compared to immunocompetent individuals. Simultaneous detectable
              antigens and nucleic acids may indicate the presence of
              replicating viruses in patients with persistent infections.
              Conclusions: The Microbubbling SARS-CoV-2 Antigen Assay enables
              sensitive and specific detection of acute infections, and
              quantitation and tracking of antigen dynamics in different
              patient populations at various stages of infection. With
              smartphone compatibility and automated image processing, the
              assay is well-positioned to be adapted for point-of-care
              diagnosis and to explore the clinical implications of antigen
              dynamics in future studies.",
  journal  = "medRxiv",
  month    =  mar,
  year     =  2021,
  language = "en"
}

@ARTICLE{Bhat2021-eu,
  title     = "Intestinal perforation secondary to mucormycosis associated with
               puerperal sepsis",
  author    = "Bhat, Vivek and S, Anitha and Thomas, Anu and Kanavi, Jayashree
               V and Thomas, Annamma",
  abstract  = "Mucormycosis is a rare opportunistic infection, usually seen in
               diabetics, immunocompromised, or those with coronavirus disease
               2019 (COVID-19). Gastrointestinal involvement is uncommon but
               often deadly. We report a case of gastrointestinal mucormycosis
               causing intestinal perforation in a non-diabetic, COVID-19
               negative, immunocompetent woman, associated with puerperal
               sepsis. A 22-year-old woman presented to our center on
               post-natal day five, following delivery with insertion of an
               intrauterine contraceptive device (IUCD). She had complaints of
               breathlessness, fatigue, and giddiness. Examination revealed
               tachycardia, tachypnea, hypotension, and bilateral pedal edema.
               Following appropriate investigations, she was diagnosed with
               puerperal sepsis with pre-renal acute kidney injury. Imaging was
               suggestive of retained products of conception, and she
               subsequently underwent dilation and evacuation (D\&E) on day
               eight of admission. Following brief symptomatic improvement, on
               day 10 of admission, she developed vomiting, abdominal
               distension, and pain, with obstipation. Erect X-ray showed air
               under the diaphragm, suggestive of perforation. She emergently
               underwent laparotomy with limited right hemicolectomy, ileostomy
               with mucous fistula. Intraoperative findings revealed a
               closed-loop obstruction involving terminal ileum, with two
               perforations. The biopsy report later revealed colonization of
               Mucor and hemorrhagic necrosis along the entire length of the
               resected specimen. She was started on amphotericin B, and after
               a slow recovery, was discharged. Gastrointestinal mucormycosis
               is rare and has a mortality rate of 94\%. It is usually seen in
               those with predisposing factors for mucormycosis. This is the
               first report of mucormycosis associated with puerperal sepsis.
               It is typically acquired via ingestion and may cause
               perforation, where mortality is further increased. Diagnosis can
               only be confirmed by histopathology demonstrating the
               characteristic morphology of Mucor. Treatment requires resection
               of necrotic tissues, intensive treatment with amphotericin B,
               and correction of predisposing factors. Our case highlights the
               need for a high degree of suspicion for mucormycosis in patients
               with intestinal perforation, even if immunocompetent, and its
               potential association with puerperal sepsis.",
  journal   = "Cureus",
  publisher = "Cureus, Inc.",
  volume    =  13,
  number    =  8,
  pages     = "e17428",
  month     =  aug,
  year      =  2021,
  keywords  = "fungal infection; immunocompetent; peritonitis; postpartum;
               pregnant",
  language  = "en"
}

@ARTICLE{Jensen2021-jo,
  title     = "Emergence of the {E484K} mutation in {SARS-COV-2-infected}
               immunocompromised patients treated with bamlanivimab in Germany",
  author    = "Jensen, Bjoern and Luebke, Nadine and Feldt, Torsten and Keitel,
               Verena and Brandenburger, Timo and Kindgen-Milles, Detlef and
               Lutterbeck, Matthias and Freise, Noemi F and Schoeler, David and
               Haas, Rainer and Dilthey, Alexander and Adams, Ortwin and
               Walker, Andreas and Timm, Joerg and Luedde, Tom",
  abstract  = "Background: Monoclonal antibodies (mAb) have been introduced as
               a promising new therapeutic approach against SARS-CoV-2. At
               present, there is little experience regarding their clinical
               effects in patient populations underrepresented in clinical
               trials, e.g. immunocompromised patients. Additionally, it is not
               well known to what extent SARS-CoV-2 treatment with monoclonal
               antibodies could trigger the selection of immune escape viral
               variants. Methods: After identifying immunocompromised patients
               with viral rebound under treatment with bamlanivimab, we
               characterized the SARS-CoV-2-isolates by whole genome
               sequencing. Viral load measurements and sequence analysis were
               performed consecutively before and after bamlanivimab
               administration. Findings: After initial decrease of viral load,
               viral clearance was not achieved in five of six
               immunocompromised patients treated with bamlanivimab. Instead,
               viral replication increased again over the course of the
               following one to two weeks. In these five patients, the E484K
               substitution - known to confer immune escape - was detected at
               the time of viral rebound but not before bamlanivimab treatment.
               Interpretation: Treatment of SARS-CoV-2 with bamlanivimab in
               immunocompromised patients results in the rapid development of
               immune escape variants in a significant proportion of cases.
               Given that the E484K mutation can hamper natural immunity, the
               effectiveness of vaccination as well as antibody-based
               therapies, these findings may have important implications not
               only for individual treatment decisions but may also pose a risk
               to general prevention and treatment strategies. Funding: All
               authors are employed and all expenses covered by governmental,
               federal state, or other publicly funded institutions.",
  journal   = "Lancet Reg Health Eur",
  publisher = "Elsevier BV",
  volume    =  8,
  number    =  100164,
  pages     = "100164",
  month     =  sep,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Mehrabi2021-sp,
  title     = "Sinoorbital mucormycosis associated with corticosteroid therapy
               in {COVID-19} infection",
  author    = "Mehrabi, Zeinab and Salimi, Maryam and Niknam, Kianoush and
               Mohammadi, Farzaneh and Mamaghani, Hesan Jelodari and Sasani,
               Mohammad Reza and Ashraf, Mohammad Javad and Salimi, Amirhossein
               and Zahedroozegar, Mohammad Hassan and Erfani, Zohreh",
  abstract  = "Background: Mucormycosis is a rare and invasive fungal
               infection, affecting almost exclusively immunocompromised
               individuals. Immunosuppressive effects of corticosteroids which
               are widely prescribed in COVID-19 patients might be a
               predisposing factor for opportunistic infections even though the
               other factors should also be considered. Case Presentation. A
               middle-aged man without any significant past medical history was
               admitted to the hospital due to a severe COVID-19 infection. He
               received a high dose of corticosteroids as a part of the
               treatment. Five days after discharge, he presents with a
               headache and fever. Eventually, orbital mucormycosis was
               diagnosed for him and he was treated with antifungal
               medications. Conclusion: Opportunistic infections should be
               considered during the current pandemic of COVID-19, during which
               corticosteroids are widely prescribed.",
  journal   = "Case Rep. Ophthalmol. Med.",
  publisher = "Hindawi Limited",
  volume    =  2021,
  pages     = "9745701",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Tamari2021-gp,
  title     = "Predictors of humoral response to {SARS-CoV-2} vaccination after
               hematopoietic cell transplantation and {CAR} T-cell therapy",
  author    = "Tamari, Roni and Politikos, Ioannis and Knorr, David A and
               Vardhana, Santosha A and Young, Jennifer C and Marcello, Leeann
               T and Doddi, Sital and Devlin, Sean M and Ramanathan, Lakshmi V
               and Pessin, Melissa S and Dunn, Erica and Palazzo, Meighan and
               Bravo, Christina D and Papanicolaou, Genovefa A and Kamboj, Mini
               and Perales, Miguel Angel and Chung, David J and Shah, Gunjan L",
  abstract  = "Cellular therapies including allogeneic hematopoietic cell
               transplant (allo-HCT) and autologous hematopoietic cell
               transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell
               therapy render patients severely immunocompromised for extended
               periods after therapy, and data on responses to COVID-19
               vaccines are limited. We analyzed anti-SARS-CoV-2 spike IgG Ab
               (spike Ab) titers and neutralizing Ab among 217 recipients of
               cellular treatments (allo-HCT, n = 149; auto-HCT, n = 61; CAR
               T-cell therapy, n = 7). At 3 months after vaccination, 188
               patients (87\%) had positive spike Ab levels and 139 (77\%) had
               positive neutralization activity compared with 100\% for both in
               54 concurrent healthy controls. Time from cellular therapy to
               vaccination and immune recovery post-cellular therapy were
               associated with response. Vaccination against COVID-19 is an
               important component of post-cellular therapy care, and
               predictors of quantitative and qualitative response are critical
               in informing clinical decisions about optimal timing of vaccines
               and the requirement for booster doses. Significance: Identifying
               predictors of response to vaccination against SARS-CoV-2 in
               patients following cellular therapy is critical to managing this
               highly vulnerable patient population. To date, this is the most
               comprehensive study evaluating quantitative and qualitative
               responses to vaccination, providing parameters most predictive
               of response and potentially informing booster vaccination
               strategies.See related article by Chung et al., p. 568. This
               article is highlighted in the In This Issue feature, p. 549.",
  journal   = "Blood Cancer Discov",
  publisher = "American Association for Cancer Research (AACR)",
  volume    =  2,
  number    =  6,
  pages     = "577--585",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Reuken2021-qi,
  title     = "{T} cell response after {SARS-CoV-2} vaccination in
               immunocompromised patients with inflammatory bowel disease",
  author    = "Reuken, P A and Andreas, N and Grunert, P C and Gl{\"o}ckner, S
               and Kamradt, T and Stallmach, A",
  abstract  = "BACKGROUND: Vaccination is a promising strategy to protect
               vulnerable groups like immunocompromised inflammatory bowel
               disease (IBD) patients from an infection with SARS-CoV-2. These
               patients may have lower immune responses. Little is known about
               the cellular and humoral immune response after a SARS-CoV-2
               vaccination in IBD. METHODS: 28 patients with IBD and 27 age-
               and sex-matched healthy controls were recruited at Jena
               University Hospital. Blood samples were taken before, after the
               first and in a subgroup of 11 patients after second dose of a
               SARS-CoV-2 vaccination. Cellular immune response including
               IFN-$\gamma$ and TNF-$\alpha$ response and antibody titers were
               analyzed. RESULTS: Overall, 71.4\% of the IBD-patients and
               85.2\% of the controls showed levels of anti-SARS-CoV-2
               antibodies above the cutoff of 33.8 BAU/ml (p=0.329) after the
               first dose. Even in the absence of SARS-CoV-2 antibodies, IBD
               patients showed significant T cell responses after first
               SARS-CoV-2 vaccination compared to healthy controls, which was
               not influenced by different immunosuppressive regimens.
               Associated with the vaccination, we could also detect a slight
               increase of the TNF production among SARS-CoV-2-reactive TH
               cells in HD and IBD patients. After the second dose of
               vaccination, in IBD patients a further increase of humoral
               immune response in all but one patient was observed.
               CONCLUSIONS: Already after the first dose of a SARS-CoV-2
               vaccination, cellular immune response in IBD patients is
               comparable to controls, indicating a similar efficacy. However,
               close monitoring of long-term immunity in these patients should
               be considered.",
  journal   = "J. Crohns. Colitis",
  publisher = "Oxford University Press (OUP)",
  month     =  aug,
  year      =  2021,
  keywords  = "COVID19; Cellular immunity; IBD; SARS-CoV-2; immunosuppression;
               vaccination",
  language  = "en"
}

@ARTICLE{Bergsneider2021-hu,
  title     = "Analysis of {SARS-CoV-2} infection associated cell entry
               proteins {ACE2}, {CD147}, {PPIA}, and {PPIB} in datasets from
               non {SARS-CoV-2} infected neuroblastoma patients, as potential
               prognostic and infection biomarkers in neuroblastoma",
  author    = "Bergsneider, Brandon and Bailey, Elise and Ahmed, Yusuf and
               Gogineni, Namrata and Huntley, Derek and Montano, Ximena",
  abstract  = "SARS-CoV-2 viral contagion has given rise to a worldwide
               pandemic. Although most children experience minor symptoms from
               SARS-CoV-2 infection, some have severe complications including
               Multisystem Inflammatory Syndrome in Children. Neuroblastoma
               patients may be at higher risk of severe infection as treatment
               requires immunocompromising chemotherapy and SARS-CoV-2 has
               demonstrated tropism for nervous cells. To date, there is no
               sufficient epidemiological data on neuroblastoma patients with
               SARS-CoV-2. Therefore, we evaluated datasets of non-SARS-CoV-2
               infected neuroblastoma patients to assess for key genes involved
               with SARS-CoV-2 infection as possible neuroblastoma prognostic
               and infection biomarkers. We hypothesized that ACE2, CD147, PPIA
               and PPIB, which are associated with viral-cell entry, are
               potential biomarkers for poor prognosis neuroblastoma and
               SARS-CoV-2 infection. We have analysed three publicly available
               neuroblastoma gene expression datasets to understand the
               specific molecular susceptibilities that high-risk neuroblastoma
               patients have to the virus. Gene Expression Omnibus (GEO)
               GSE49711 and GEO GSE62564 are the microarray and RNA-Seq data,
               respectively, from 498 neuroblastoma samples published as part
               of the Sequencing Quality Control initiative. TARGET, contains
               microarray data from 249 samples and is part of the
               Therapeutically Applicable Research to Generate Effective
               Treatments (TARGET) initiative. ACE2, CD147, PPIA and PPIB were
               identified through their involvement in both SARS-CoV-2
               infection and cancer pathogenesis. In-depth statistical analysis
               using Kaplan-Meier, differential gene expression, and Cox
               multivariate regression analysis, demonstrated that
               overexpression of ACE2, CD147, PPIA and PPIB is significantly
               associated with poor-prognosis neuroblastoma samples. These
               results were seen in the presence of amplified MYCN,
               unfavourable tumour histology and in patients older than 18
               months of age. Previously, we have shown that high levels of the
               nerve growth factor receptor NTRK1 together with low levels of
               the phosphatase PTPN6 and TP53 are associated with increased
               relapse-free survival of neuroblastoma patients. Interestingly,
               low levels of expression of ACE2, CD147, PPIA and PPIB are
               associated with this NTRK1-PTPN6-TP53 module, suggesting that
               low expression levels of these genes are associated with good
               prognosis. These findings have implications for clinical care
               and therapeutic treatment. The upregulation of ACE2, CD147, PPIA
               and PPIB in poor-prognosis neuroblastoma samples suggests that
               these patients may be at higher risk of severe SARS-CoV-2
               infection. Importantly, our findings reveal ACE2, CD147, PPIA
               and PPIB as potential biomarkers and therapeutic targets for
               neuroblastoma.",
  journal   = "Biochem. Biophys. Rep.",
  publisher = "Elsevier BV",
  volume    =  27,
  number    =  101081,
  pages     = "101081",
  month     =  sep,
  year      =  2021,
  keywords  = "ACE2; Biomarkers; CD147; NTRK1; Neuroblastoma; PPIA; PPIB;
               PTPN6; SARS-CoV-2; TP53",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Sherman2021-gp,
  title     = "{SARS-CoV-2} {mRNA} vaccines in allogeneic hematopoietic stem
               cell transplant recipients: Immunogenicity and reactogenicity",
  author    = "Sherman, Amy C and Desjardins, Micha{\"e}l and Cheng, Chi An and
               Bausk, Bruce and Izaguirre, Natalie and Zhou, Guohai and Krauss,
               Jonathan and Tolan, Nicole and Walt, David R and Soiffer, Robert
               and Ho, Vincent T and Issa, Nicolas C and Baden, Lindsey R",
  abstract  = "The SARS-CoV-2 mRNA vaccine-induced humoral response and
               reactogenicity profile are described in allogeneic hematopoietic
               stem cell transplant (HSCT) recipients. 75.0\% (by Simoa assay)
               or 80.0\% (by Roche assay) of the HSCT cohort had a positive
               antibody response upon series completion, as compared to 100\%
               in the healthy cohort.",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  nov,
  year      =  2021,
  keywords  = "SARS-CoV-2; immunocompromised; immunogenicity; mRNA vaccines",
  language  = "en"
}

@ARTICLE{Kyriakidis2021-md,
  title     = "Acinetobacter baumannii Antibiotic Resistance Mechanisms",
  author    = "Kyriakidis, Ioannis and Vasileiou, Eleni and Pana, Zoi Dorothea
               and Tragiannidis, Athanasios",
  abstract  = "Acinetobacter baumannii is a Gram-negative ESKAPE microorganism
               that poses a threat to public health by causing severe and
               invasive (mostly nosocomial) infections linked with high
               mortality rates. During the last years, this pathogen displayed
               multidrug resistance (MDR), mainly due to extensive antibiotic
               abuse and poor stewardship. MDR isolates are associated with
               medical history of long hospitalization stays, presence of
               catheters, and mechanical ventilation, while immunocompromised
               and severely ill hosts predispose to invasive infections.
               Next-generation sequencing techniques have revolutionized
               diagnosis of severe A. baumannii infections, contributing to
               timely diagnosis and personalized therapeutic regimens according
               to the identification of the respective resistance genes. The
               aim of this review is to describe in detail all current
               knowledge on the genetic background of A. baumannii resistance
               mechanisms in humans as regards beta-lactams (penicillins,
               cephalosporins, carbapenems, monobactams, and beta-lactamase
               inhibitors), aminoglycosides, tetracyclines, fluoroquinolones,
               macrolides, lincosamides, streptogramin antibiotics, polymyxins,
               and others (amphenicols, oxazolidinones, rifamycins, fosfomycin,
               diaminopyrimidines, sulfonamides, glycopeptide, and lipopeptide
               antibiotics). Mechanisms of antimicrobial resistance refer
               mainly to regulation of antibiotic transportation through
               bacterial membranes, alteration of the antibiotic target site,
               and enzymatic modifications resulting in antibiotic
               neutralization. Virulence factors that may affect antibiotic
               susceptibility profiles and confer drug resistance are also
               being discussed. Reports from cases of A. baumannii coinfection
               with SARS-CoV-2 during the COVID-19 pandemic in terms of
               resistance profiles and MDR genes have been investigated.",
  journal   = "Pathogens",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  3,
  pages     = "373",
  month     =  mar,
  year      =  2021,
  keywords  = "Acinetobacter baumannii; CRAB; antibiotic; antimicrobial;
               extensive drug resistant; multidrug resistant; next-generation
               sequencing; pandrug resistant; resistance",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Coward2021-pn,
  title     = "Crohn's and colitis Canada's 2021 impact of {COVID-19} and
               inflammatory bowel disease in Canada: Epidemiology-the trends of
               disease over time",
  author    = "Coward, Stephanie and Windsor, Joseph W and Kuenzig, M Ellen and
               Bitton, Alain and Bernstein, Charles N and Jones, Jennifer L and
               Khanna, Reena and Lee, Kate and Murthy, Sanjay K and Targownik,
               Laura and Benchimol, Eric and Huang, James Guoxian and Mukhtar,
               Mariam S and Tandon, Parul and Kaplan, Gilaad G",
  abstract  = "At the beginning of the coronavirus disease 2019 (COVID-19)
               pandemic, there were many unknowns: transmission vectors of the
               virus, appropriate intervention strategies and if being
               immunocompromised due to inflammatory bowel disease (IBD), for
               example, or medications put a person at increased risk for
               severe COVID-19. Imposing and relaxing of public health
               restrictions at different times and in different regions in
               Canada led to different epidemiologies of the virus in different
               provinces and territories. In order to understand the waxing and
               waning of waves of the COVID-19 pandemic, it is necessary to
               understand the effective reproductive number (R t ) and the
               countervailing forces that exert upward or downward pressure on
               the spread of the virus at a given point in time. As many
               regions in Canada deal with a third wave, the primary forces
               affecting the R t of severe acute respiratory syndrome
               coronavirus 2 are variants of concern and the increasing
               vaccinations of Canadians leading to increased population-level
               immunity. Fortunately, for the IBD population, current research
               suggests that those with IBD are not at increased risk of
               contracting COVID-19, nor of having a more severe disease course
               when compared to the general population.",
  journal   = "J. Can. Assoc. Gastroenterol.",
  publisher = "Oxford University Press (OUP)",
  volume    =  4,
  number    = "Suppl 2",
  pages     = "S20--S26",
  month     =  dec,
  year      =  2021,
  keywords  = "Crohn's disease; coronavirus; epidemiology; inflammatory bowel
               disease; reproduction number; ulcerative colitis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Rastogi2021-bx,
  title     = "Jalaneti (saline nasal irrigation) as primary intervention in
               suspected rhino-orbito-cerebral mucormycosis helps improving the
               recovery: A case report",
  author    = "Rastogi, Sanjeev and Verma, Ankita",
  abstract  = "The ongoing COVID-19 pandemic has resulted in several
               opportunistic infections like mucormycosis (MCR) to surface.
               Although this is commonly afflicting immunocompromised people
               managed through prolonged ICU care, epidemiological observations
               suggest that it is also associated with conditions like
               uncontrolled diabetes. Due to its invasive nature and systemic
               reach, MCR has high mortality warranting an early diagnosis and
               treatment. We present here a case of a non-COVID, diabetic
               patient having acute onset paranasal and periorbital swelling
               with headache suspected for rhino-orbito-cerebral MCR. The case
               was innovatively dealt with jalaneti (saline nasal irrigation)
               seeing a delay in the institution of definitive anti-fungal
               therapy. Six sittings of jalaneti in four days had been able to
               give near complete symptomatic relief in paranasal swelling and
               headache even before the endoscopic nasal debridement and
               anti-fungal therapy was initiated. Seeing the urgency of
               diagnosis and treatment in any suspected case of MCR, a simple
               and self-administrable procedure like jalaneti seems to have a
               high value for its possible role in reducing the sinus
               inflammation and reducing the disease intensity in order to find
               more time for the proper diagnosis and treatment initiation.
               Negligible cost of jalaneti, its easy administration, and
               minimal adversity potential are additional advantages for
               proposing jalaneti as a possible prophylaxis in MCR. More
               serious clinical research is urgently required to confirm the
               observations made in this single case report and to extend its
               benefits to the people suffering with MCR.",
  journal   = "J. Ayurveda Integr. Med.",
  publisher = "Elsevier BV",
  number    =  100516,
  pages     = "100516",
  month     =  nov,
  year      =  2021,
  keywords  = "Case report; Diabetes; Jalaneti; Mucormycosis; Saline nasal
               irrigation",
  copyright = "http://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Rodionov2021-ov,
  title     = "Potential benefit of convalescent plasma transfusions in
               immunocompromised patients with {COVID-19}",
  author    = "Rodionov, Roman N and Biener, Anne and Spieth, Peter and
               Achleitner, Martin and H{\"o}lig, Kristina and Aringer, Martin
               and Mingrone, Geltrude and Corman, Victor M and Drosten,
               Christian and Bornstein, Stefan R and Tonn, Torsten and Kolditz,
               Martin",
  journal   = "Lancet Microbe",
  publisher = "Elsevier BV",
  volume    =  2,
  number    =  4,
  pages     = "e138",
  month     =  apr,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Park2021-es,
  title     = "Impact analysis of virtual ambulatory transplant pharmacists
               during {COVID-19}",
  author    = "Park, Lindsay and Kim, Ju Hee and Waldman, Georgina and Marks,
               Christin Rogers and Clark, Jacqueline E",
  abstract  = "Introduction: During the coronavirus disease 2019 (COVID-19)
               pandemic, transplant centers were challenged to meet the demand
               for new telemedicine strategies. The ability of lung transplant
               providers (LTP) to conduct face-to-face clinic visits for
               high-risk immunocompromised patients, such as lung transplant
               recipients (LTR), was limited. Through the implementation of
               comprehensive medication management visits, pharmacists were
               able to assist LTP in the transition to telemedicine. Methods: A
               retrospective chart review of telephone encounters from
               cardiothoracic (CT) transplant pharmacists at our center from
               March to September 2020 was completed. LTR scheduled for clinic
               visits with LTP were called prior to the visit by CT transplant
               pharmacists who conducted medication list reviews, adherence
               assessments, and medication access assistance. Clinical
               recommendations were communicated directly to the LTP and
               documented in patient electronic medical records. The primary
               outcome was the number of pharmacist-driven clinical
               interventions. Secondary endpoints included the clinical
               severity and value of service of each intervention, percentage
               of accepted recommendations, patient cost savings interventions,
               prevention of adverse events, and avoidance of inappropriate
               doses. Results: From March to September 2020, the CT transplant
               pharmacists conducted 385 virtual visits on 157 LTR with a
               median of 20 minutes spent per visit. There were 891 total
               interventions made by CT transplant pharmacists, including 778
               medication discrepancies identified. Over 60\% of encounters
               demonstrated some form of medication error and over 55\% of
               encounters exhibited value of pharmacy services. Conclusion:
               Implementation of CT transplant pharmacist telehealth visits has
               potential for increased patient access to pharmacy care and
               improved accuracy of medication lists. When focusing on the
               severity of errors and value of services, most demonstrated a
               level of significance. Further investigation is needed to
               analyze the impact of this service on patient outcomes as well
               as cost-effectiveness.",
  journal   = "J. Am. Coll. Clin. Pharm.",
  publisher = "Wiley",
  volume    =  4,
  number    =  8,
  pages     = "978--987",
  month     =  aug,
  year      =  2021,
  keywords  = "collaborative practice; comprehensive medication management;
               medication optimization; patient communication; telemedicine;
               transplant",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Shroff2021-nh,
  title    = "Immune responses to {COVID-19} {mRNA} vaccines in patients with
              solid tumors on active, immunosuppressive cancer therapy",
  author   = "Shroff, Rachna T and Chalasani, Pavani and Wei, Ran and
              Pennington, Daniel and Quirk, Grace and Schoenle, Marta V and
              Peyton, Kameron L and Uhrlaub, Jennifer L and Ripperger, Tyler J
              and Jergovi{\'c}, Mladen and Dalgai, Shelby and Wolf, Alexander
              and Whitmer, Rebecca and Hammad, Hytham and Carrier, Amy and
              Scott, Aaron J and Nikolich-{\v Z}ugich, Janko and Worobey,
              Michael and Sprissler, Ryan and Dake, Michael and LaFleur, Bonnie
              J and Bhattacharya, Deepta",
  abstract = "Vaccines against SARS-CoV-2 have shown high efficacy, but
              immunocompromised participants were excluded from controlled
              clinical trials. We evaluated immune responses to the
              Pfizer/BioNTech mRNA vaccine in solid tumor patients (n=52) on
              active cytotoxic anti-cancer therapy. These responses were
              compared to a control cohort that also received the
              Pfizer/BioNTech vaccine (n=50). Using live SARS-CoV-2 assays,
              neutralizing antibodies were detected in 67\% and 80\% of cancer
              patients after the first and second immunizations, respectively,
              with a 3-fold increase in median titers after the booster.
              Similar trends were observed in serum antibodies against the
              receptor-binding domain (RBD) and S2 regions of Spike protein,
              and in IFN$\gamma$+Spike-specific T cells. The magnitude of each
              of these responses was diminished relative to the control cohort.
              We therefore quantified RBD- and Spike S1-specific memory B cell
              subsets as predictors of anamnestic responses to viral exposures
              or additional immunizations. After the second vaccination,
              Spike-specific plasma cell-biased memory B cells were observed in
              most cancer patients at levels similar to those of the control
              cohort after the first immunization. These data suggest that a
              third immunization might elevate antibody responses in cancer
              patients to levels seen in healthy individuals after the second
              dose. Trials should be conducted to test these predictions.",
  journal  = "medRxiv",
  month    =  may,
  year     =  2021,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Gandhi2021-mt,
  title    = "De novo emergence of a remdesivir resistance mutation during
              treatment of persistent {SARS-CoV-2} infection in an
              immunocompromised patient: A case report",
  author   = "Gandhi, Shiv and Klein, Jonathan and Robertson, Alexander and
              Pe{\~n}a-Hern{\'a}ndez, Mario A and Lin, Michelle J and
              Roychoudhury, Pavitra and Lu, Peiwen and Fournier, John and
              Ferguson, David and Mohamed Bakhash, Shah A and Catherine
              Muenker, M and Srivathsan, Ariktha and Wunder, Elsio A and
              Kerantzas, Nicholas and Wang, Wenshuai and Lindenbach, Brett and
              Pyle, Anna and Wilen, Craig B and Ogbuagu, Onyema and Greninger,
              Alexander L and Iwasaki, Akiko and Schulz, Wade L and Ko, Albert
              I",
  abstract = "SARS-CoV-2 remdesivir resistance mutations have been generated in
              vitro but have not been reported in patients receiving treatment
              with the antiviral agent. We present a case of an
              immunocompromised patient with acquired B-cell deficiency who
              developed an indolent, protracted course of SARS-CoV-2 infection.
              Remdesivir therapy alleviated symptoms and produced a transient
              virologic response, but her course was complicated by
              recrudescence of high-grade viral shedding. Whole genome
              sequencing identified a mutation, E802D, in the nsp12
              RNA-dependent RNA polymerase, which was not present in
              pre-treatment specimens. In vitro experiments demonstrated that
              the mutation conferred a 6-fold increase in remdesivir IC50 but
              resulted in a fitness cost in the absence of remdesivir.
              Sustained clinical and virologic response was achieved after
              treatment with casirivimab-imdevimab. Although the fitness cost
              observed in vitro may limit the risk posed by E802D, this case
              illustrates the importance of monitoring for remdesivir
              resistance and the potential benefit of combinatorial therapies
              in immunocompromised patients with SARS-CoV-2 infection.",
  journal  = "medRxiv",
  month    =  dec,
  year     =  2021,
  language = "en"
}

@ARTICLE{Beyoglu2021-gl,
  title     = "Vaccine breakthrough severe {COVID-19} in a lung recipient",
  author    = "Beyoglu, Muhammet Ali and Sahin, Mehmet Furkan and Turkkan,
               Sinan and Basaran, Fatmanur Celik and Yazicioglu, Alkin and
               Bektas, Serife Gokbulut and Tekce, Yasemin Tezer and Yekeler,
               Erdal",
  abstract  = "The vaccines developed against severe acute respiratory syndrome
               coronavirus 2 are seen as the most crucial weapon in controlling
               the epidemic. It has been reported in early-stage vaccine
               studies that vaccines provide up to 95\% protection against
               severe disease and mortality, even in the absence of symptomatic
               infection. Reports on vaccine breakthrough infections that
               developed after widespread vaccination are available in the
               literature. In addition to the general population, the course of
               vaccine breakthrough infections in immunocompromised patients is
               a matter of concern. This case report aimed to define severe
               coronavirus disease 2019 developing in a lung recipient who
               received 3 doses of inactivated virus vaccine.",
  journal   = "Transplant. Proc.",
  publisher = "Elsevier BV",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Epstein2021-rm,
  title     = "Payer perspectives on intravenous versus subcutaneous
               administration of drugs",
  author    = "Epstein, Robert S",
  abstract  = "The coronavirus disease 2019 (COVID-19) pandemic has brought
               increased attention to vulnerable populations such as older or
               immunocompromised patients and heightened the focus on
               alternatives to intravenous (IV) formulations, particularly
               those that may be administered in a non-clinical setting. Among
               these alternative formulations are subcutaneous (SC) injections,
               which comprise an increasing share of commercialized and
               pipeline therapies. While much has been published about the
               benefits and limitations of IV versus SC administration to
               patients and health systems, less attention has been given to
               payer considerations regarding these routes of administration.
               Accordingly, this article provides payer perspectives on some of
               the key differences between IV and SC administration as they
               relate to management and billing, cost, treatment adherence and
               safety, and patient preference and quality of life. The benefits
               and limitations of these drug administration routes to key
               healthcare stakeholders-namely patients, physicians, and
               payers-are also discussed. Considerations of relevance are
               highlighted, including the potential for misalignment of
               stakeholder interests and countervailing factors that may impact
               decision-making about IV and SC formulations.",
  journal   = "Clinicoecon. Outcomes Res.",
  publisher = "Informa UK Limited",
  volume    =  13,
  pages     = "801--807",
  month     =  sep,
  year      =  2021,
  keywords  = "drug utilization management; formularies; pharmacy benefits
               management",
  language  = "en"
}

@ARTICLE{Thompson2021-em,
  title    = "Association of convalescent plasma therapy with survival in
              patients with hematologic cancers and {COVID-19}",
  author   = "Thompson, Michael A and Henderson, Jeffrey P and Shah, Pankil K
              and Rubinstein, Samuel M and Joyner, Michael J and Choueiri, Toni
              K and Flora, Daniel B and Griffiths, Elizabeth A and Gulati,
              Anthony P and Hwang, Clara and Koshkin, Vadim S and Papadopoulos,
              Esperanza B and Robilotti, Elizabeth V and Su, Christopher T and
              Wulff-Burchfield, Elizabeth M and Xie, Zhuoer and Yu, Peter Paul
              and Mishra, Sanjay and Senefeld, Jonathon W and Shah, Dimpy P and
              Warner, Jeremy L and {COVID-19 and Cancer Consortium}",
  abstract = "Importance: COVID-19 is a life-threatening illness for many
              patients. Prior studies have established hematologic cancers as a
              risk factor associated with particularly poor outcomes from
              COVID-19. To our knowledge, no studies have established a
              beneficial role for anti-COVID-19 interventions in this at-risk
              population. Convalescent plasma therapy may benefit
              immunocompromised individuals with COVID-19, including those with
              hematologic cancers. Objective: To evaluate the association of
              convalescent plasma treatment with 30-day mortality in
              hospitalized adults with hematologic cancers and COVID-19 from a
              multi-institutional cohort. Design, Setting, and Participants:
              This retrospective cohort study using data from the COVID-19 and
              Cancer Consortium registry with propensity score matching
              evaluated patients with hematologic cancers who were hospitalized
              for COVID-19. Data were collected between March 17, 2020, and
              January 21, 2021. Exposures: Convalescent plasma treatment at any
              time during hospitalization. Main Outcomes and Measures: The main
              outcome was 30-day all-cause mortality. Cox proportional hazards
              regression analysis with adjustment for potential confounders was
              performed. Hazard ratios (HRs) are reported with 95\% CIs.
              Secondary subgroup analyses were conducted on patients with
              severe COVID-19 who required mechanical ventilatory support
              and/or intensive care unit admission. Results: A total of 966
              individuals (mean [SD] age, 65 [15] years; 539 [55.8\%] male)
              were evaluated in this study; 143 convalescent plasma recipients
              were compared with 823 untreated control patients. After
              adjustment for potential confounding factors, convalescent plasma
              treatment was associated with improved 30-day mortality (HR,
              0.60; 95\% CI, 0.37-0.97). This association remained significant
              after propensity score matching (HR, 0.52; 95\% CI, 0.29-0.92).
              Among the 338 patients admitted to the intensive care unit,
              mortality was significantly lower in convalescent plasma
              recipients compared with nonrecipients (HR for propensity
              score-matched comparison, 0.40; 95\% CI, 0.20-0.80). Among the
              227 patients who required mechanical ventilatory support,
              mortality was significantly lower in convalescent plasma
              recipients compared with nonrecipients (HR for propensity
              score-matched comparison, 0.32; 95\% CI, 0.14-0.72). Conclusions
              and Relevance: The findings of this cohort study suggest a
              potential survival benefit in the administration of convalescent
              plasma to patients with hematologic cancers and COVID-19.",
  journal  = "JAMA Oncol.",
  month    =  jun,
  year     =  2021,
  language = "en"
}

@ARTICLE{Palma2021-mo,
  title     = "Perspectives on passive antibody therapy and peptide-based
               vaccines against emerging pathogens like {SARS-CoV-2}",
  author    = "Palma, Marco",
  abstract  = "The current epidemic of the severe acute respiratory syndrome
               coronavirus 2 (SARS-CoV-2) is raising awareness of the need to
               act faster when dealing with new pathogens. Exposure to an
               emerging pathogen generates an antibody response that can be
               used for preventing and treating the infection. These antibodies
               might have a high specificity to a target, few side effects, and
               are useful in the absence of an effective vaccine for treating
               immunocompromised individuals. The approved antibodies against
               the receptor-binding domain (RBD) of the viral spike protein of
               SARS-CoV-2 (e.g., regdanvimab, bamlanivimab, etesevimab, and
               casirivimab/imdevimab) have been selected from the antibody
               repertoire of B cells from convalescent patients using flow
               cytometry, next-generation sequencing, and phage display. This
               encourages use of these techniques especially phage display,
               because it does not require expensive types of equipment and can
               be performed on the lab bench, thereby making it suitable for
               labs with limited resources. Also, the antibodies in blood
               samples from convalescent patients can be used to screen
               pre-made peptide libraries to identify epitopes for vaccine
               development. Different types of vaccines against SARS-CoV-2 have
               been developed, including inactivated virus vaccines, mRNA-based
               vaccines, non-replicating vector vaccines, and protein subunits.
               mRNA vaccines have numerous advantages over existing vaccines,
               such as efficacy, ease of manufacture, safety, and
               cost-effectiveness. Additionally, epitope vaccination may
               constitute an attractive strategy to induce high levels of
               antibodies against a pathogen and phages might be used as
               immunogenic carriers of such peptides. This is a point worth
               considering further, as phage-based vaccines have been shown to
               be safe in clinical trials and phages are easy to produce and
               tolerate high temperatures. In conclusion, identification of the
               antibody repertoire of recovering patients, and the epitopes
               they recognize, should be an attractive alternative option for
               developing therapeutic and prophylactic antibodies and vaccines
               against emerging pathogens.",
  journal   = "Germs",
  publisher = "Asociatia Pentru Cresterea Vizibilitatii Cercetarii Stiintifice
               (ACVCS)",
  volume    =  11,
  number    =  2,
  pages     = "287--305",
  month     =  jun,
  year      =  2021,
  keywords  = "Emerging pathogen; SARS-CoV-2; passive antibody therapy; peptide
               vaccine; phage display; therapeutic antibody",
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Smith2021-sz,
  title     = "Mental health risks differentially associated with
               immunocompromised status among healthcare workers and family
               members at the pandemic outset",
  author    = "Smith, Andrew J and Wright, Hannah and Griffin, Brandon J and
               Ehman, Anandi C and Shoji, Kotaro and Love, Tiffany M and
               Morrow, Ellen and Locke, Amy and Call, Megan and Kerig, Patricia
               K and Olff, Miranda and Benight, Charles C and Langenecker,
               Scott A",
  abstract  = "The mental health of healthcare workers (HCWs) is critical to
               their long-term well-being and future disaster preparedness.
               Goal 1 of this study was to identify rates of mental health
               problems experienced by HCWs. Goal 2 was to test a model of risk
               stemming from pandemic-related stressors and vulnerability
               factors. This cross-sectional study included HCWs (N = 2,246
               [1,573 clinical providers; 673 non-clinical staff]) in the Rocky
               Mountain West who voluntarily completed an online survey in
               April/May 2020. Respondents completed measures for traumatic
               stress symptoms, depression, anxiety, alcohol use, and sleep.
               Logistic regressions stratified by professional role (clinical
               versus non-clinical) were specified to predict clinical
               screening cutoff (positive/negative) as a function of five
               pandemic-related stressors (immunocompromised self;
               immunocompromised household member; care provision to infected
               patients; clinical management role; positive cases). Results
               showed that more than half of HCWs surveyed (52.5\%) screened
               positive (above cutoff) for traumatic stress, depression, or
               anxiety, with ~20\% reporting problematic alcohol use, and
               variable insufficient sleep from ~10\% off shift to ~50\% on
               shift. Clinical employees with an immunocompromised household
               member had increased odds of screening positive for a mental
               health problem. Non-clinical HCWs who were immunocompromised
               were at elevated risk for screening positive a mental health
               problem. Being female, minority status, and younger increased
               odds for mental health problems. Implications include
               alleviating a portion of the mental health burden of HCWs
               involved in response to the SARS-CoV-2 pandemic by considering
               policies to protect immunocompromised HCWs and their families
               (e.g., vaccine priorities, telework options).",
  journal   = "Brain Behav Immun Health",
  publisher = "Elsevier BV",
  volume    =  15,
  number    =  100285,
  pages     = "100285",
  month     =  aug,
  year      =  2021,
  keywords  = "Family members; Healthcare workers; Occupational stress;
               Pandemic; Traumatic stress; immunocompromised",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Pinana2022-lq,
  title     = "{SARS-CoV-2-reactive} antibody detection after {SARS-CoV-2}
               vaccination in hematopoietic stem cell transplant recipients:
               Prospective survey from the Spanish Hematopoietic Stem Cell
               Transplantation and Cell Therapy Group",
  author    = "Pi{\~n}ana, Jos{\'e} Luis and L{\'o}pez-Corral, Lucia and
               Martino, Rodrigo and Montoro, Juan and Vazquez, Lourdes and
               P{\'e}rez, Ariadna and Martin-Martin, Gabriel and Facal-Malvar,
               Ana and Ferrer, Elena and Pascual, Mar{\'\i}a-Jes{\'u}s and
               Sanz-Linares, Gabriela and Gago, Beatriz and Sanchez-Salinas,
               Andr{\'e}s and Villalon, Lucia and Conesa-Garcia, Venancio and
               Olave, Maria T and L{\'o}pez-Jimenez, Javier and
               Marcos-Corrales, Sara and Garc{\'\i}a-Bl{\'a}zquez, Marta and
               Garcia-Guti{\'e}rrez, Valent{\'\i}n and Hern{\'a}ndez-Rivas,
               Jos{\'e} {\'A}ngel and Saus, Ana and Espigado, Ildefonso and
               Alonso, Carmen and Hernani, Rafael and Solano, Carlos and
               Ferrer-Lores, Blanca and Guerreiro, Manuel and Ruiz-Garc{\'\i}a,
               Montserrat and Mu{\~n}oz-Bellido, Juan Luis and Navarro, David
               and Cedillo, Angel and Sureda, Anna and {Infectious
               Complications Subcommittee of the Spanish Hematopoietic Stem
               Cell Transplantation and Cell Therapy Group (GETH-TC)}",
  abstract  = "This is a multicenter prospective observational study that
               included a large cohort (n = 397) of allogeneic (allo-HSCT; (n =
               311) and autologous (ASCT) hematopoietic stem cell transplant (n
               = 86) recipients who were monitored for antibody detection
               within 3-6 weeks after complete severe acute respiratory
               syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1,
               2021, to July 20, 2021. Most patients (n = 387, 97.4\%) received
               mRNA-based vaccines. Most of the recipients (93\%) were
               vaccinated more than 1 year after transplant. Detectable
               SARS-CoV-2-reactive antibodies were observed in 242 (78\%) of
               allo-HSCT and in 73 (85\%) of ASCT recipients. Multivariate
               analysis in allo-HSCT recipients identified lymphopenia < 1
               $\times$ 109 /ml (odds ratio [OR] 0.33, 95\% confidence interval
               [95\% CI] 0.16-0.69, p = .003), active graft versus host disease
               (GvHD; OR 0.51, 95\% CI 0.27-0.98, p = .04) and vaccination
               within the first year of transplant (OR 0.3, 95\% CI 0.15-0.9, p
               = .04) associated with lower antibody detection whereas. In
               ASCT, non-Hodgkin's lymphoma (NHL; OR 0.09, 95\% CI 0.02-0.44, p
               = .003) and active corticosteroid therapy (OR 0.2, 95\% CI
               0.02-0.87, p = .03) were associated with lower detection rate.
               We report an encouraging rate of SARS-CoV-2-reactive antibodies
               detection in these severe immunocompromised patients.
               Lymphopenia, GvHD, the timing of vaccine, and NHL and
               corticosteroids therapy should be considered in allo-HSCT and
               ASCT, respectively, to identify candidates for SARS-CoV-2
               antibodies monitoring.",
  journal   = "Am. J. Hematol.",
  publisher = "Wiley",
  volume    =  97,
  number    =  1,
  pages     = "30--42",
  month     =  jan,
  year      =  2022,
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Gilliland2021-xw,
  title    = "Protection of human {ACE2} transgenic Syrian hamsters from {SARS}
              {CoV-2} variants by human polyclonal {IgG} from hyper-immunized
              transchromosomic bovines",
  author   = "Gilliland, Theron and Liu, Yanan and Li, Rong and Dunn, Matthew
              and Cottle, Emily and Terada, Yutaka and Ryckman, Zachary and
              Alcorn, Maria and Vasilatos, Shauna and Lundy, Jeneveve and
              Larson, Deanna and Wu, Hua and Luke, Thomas and Bausch, Christoph
              and Egland, Kristi and Sullivan, Eddie and Wang, Zhongde and
              Klimstra, William B",
  abstract = "Pandemic SARS CoV-2 has been undergoing rapid evolution during
              spread throughout the world resulting in the emergence of many
              Spike protein variants, some of which appear to either evade
              antibody neutralization, transmit more efficiently, or
              potentially exhibit increased virulence. This raises significant
              concerns regarding the long-term efficacy of protection elicited
              after primary infection and/or from vaccines derived from single
              virus Spike (S) genotypes, as well as the efficacy of anti-S
              monoclonal antibody based therapeutics. Here, we used fully human
              polyclonal human IgG (SAB-185), derived from hyperimmunization of
              transchromosomic bovines with DNA plasmids encoding the
              SARS-CoV-2 Wa-1 strain S protein or purified ectodomain of S
              protein, to examine the neutralizing capacity of SAB-185 in vitro
              and the protective efficacy of passive SAB-185 antibody (Ab)
              transfer in vivo . The Ab preparation was tested for
              neutralization against five variant SARS-CoV-2 strains: Munich
              (Spike D614G), UK (B.1.1.7), Brazil (P.1) and SA (B.1.3.5)
              variants, and a variant isolated from a chronically infected
              immunocompromised patient (Spike $\Delta$144-146). For the in
              vivo studies, we used a new human ACE2 (hACE2) transgenic Syrian
              hamster model that exhibits lethality after SARS-Cov-2 challenge
              and the Munich, UK, SA and $\Delta$144-146 variants. SAB-185
              neutralized each of the SARS-CoV-2 strains equivalently on Vero
              E6 cells, however, a control convalescent human serum sample was
              less effective at neutralizing the SA variant. In the hamster
              model, prophylactic SAB-185 treatment protected the hamsters from
              fatal disease and minimized clinical signs of infection. These
              results suggest that SAB-185 may be an effective treatment for
              patients infected with SARS CoV-2 variants.",
  journal  = "bioRxivorg",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Oguariri2021-mv,
  title    = "{S100A8} and {S100A9}, biomarkers of {SARS-Cov2-infected}
              patients, suppress {HIV} replication in primary macrophages",
  author   = "Oguariri, Raphael M and Brann, Terrence W and Adelsberger, Joseph
              W and Chen, Qian and Goswami, Suranjana and Mele, Anthony R and
              Imamichi, Tomozumi",
  abstract = "S100A8 and S100A9 are members of the Alarmin family; these
              proteins are abundantly expressed in neutrophils and form a
              heterodimer complex. Recently, both proteins were identified as
              novel biomarkers of SARS-CoV-2 infection and were shown to play
              key roles in inducing an aggressive inflammatory response by
              mediating the release of large amounts of pro-inflammatory
              cytokines, called the ``cytokine storm.'' Although co-infection
              with SARS-CoV-2 in people living with HIV-1 may result in an
              immunocompromised status, the role of the S100A8/A9 complex in
              HIV-1 replication in primary T cells and macrophages is still
              unclear. Here, we evaluated the roles of the proteins in HIV
              replication to elucidate their functions. We found that the
              complex had no impact on virus replication in both cell types;
              however, the subunits of S100A8 and S100A9 inhibits HIV in
              macrophages. These findings provide important insights into the
              regulation of HIV viral loads in SARS-CoV2 co-infection.",
  journal  = "bioRxivorg",
  month    =  oct,
  year     =  2021,
  language = "en"
}

@ARTICLE{Jordan2022-rv,
  title     = "Divergent immune responses to {SARS-CoV-2} vaccines in
               immunocompromised patients",
  author    = "Jordan, Stanley C and Shin, Bong-Ha and Gadsden, Terry-Ann M and
               Chu, Maggie and Petrosyan, Anna and Vo, Ashley and Ammerman,
               Noriko and Sethi, Supreet and Najjar, Reiad and Huang, Ed and
               Peng, Alice and Toyoda, Mieko and Kumar, Sanjeev and Zhang, Ruan",
  journal   = "Transplantation",
  publisher = "Ovid Technologies (Wolters Kluwer Health)",
  volume    =  106,
  number    =  1,
  pages     = "e90--e91",
  month     =  jan,
  year      =  2022,
  language  = "en"
}

@ARTICLE{Kesheh2021-lm,
  title     = "An overview on the seven pathogenic human coronaviruses",
  author    = "Kesheh, Mina Mobini and Hosseini, Parastoo and Soltani, Saber
               and Zandi, Milad",
  abstract  = "To date, seven human coronaviruses (HCoVs) have been detected:
               HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43, severe acute
               respiratory syndrome coronavirus (SARS-CoV), Middle East
               respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. Four
               of these viruses, including HCoV-NL63, -229E, -HKU1 and -OC43,
               usually cause mild-to-moderate respiratory diseases with a
               seasonal pattern. Since 2000, three new HCoVs have emerged with
               a significant mortality rate. Although SARS-CoV and MERS-CoV
               caused an epidemic in some countries, SARS-CoV-2 escalated into
               a pandemic. All HCoVs can cause severe complications in the
               elderly and immunocompromised individuals. The bat origin of
               HCoVs, the presence of intermediate hosts and the nature of
               their viral replication suggest that other new coronaviruses may
               emerge in the future. Despite the fact that all HCoVs share
               similarities in viral replication, they differ in their
               accessory proteins, incubation period and pathogenicity. This
               study aims to review these differences between the seven HCoVs.",
  journal   = "Rev. Med. Virol.",
  publisher = "Wiley",
  pages     = "e2282",
  month     =  aug,
  year      =  2021,
  keywords  = "HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; MERS-CoV; SARS-CoV;
               SARS-CoV-2; human coronaviruses",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Zhang2021-ir,
  title    = "{COVID-19} in the immunocompromised population: data from renal
              allograft recipients throughout full cycle of the outbreak in
              Hubei province, China",
  author   = "Zhang, Wei-Jie and Han, Fei and Wu, Xiong-Fei and Wang, Zhen-Di
              and Wang, Yan-Feng and Guo, Xiao-Jun and Chen, Song and Qiu, Tao
              and Li, Heng and Tu, Ya-Fang and Zhong, Zi-Biao and He, Jian-Nan
              and Liu, Bin and Zhang, Hui and Cai, Zhi-Tao and Zhang, Long and
              Lu, Xia and Zhu, Lan and Chen, Dong and Zhou, Jiang-Qiao and Sun,
              Qi-Quan and Chen, Zhi-Shui",
  journal  = "Chin. Med. J. (Engl.)",
  month    =  sep,
  year     =  2021,
  language = "en"
}

@ARTICLE{Thummler2021-al,
  title     = "Comparison of {SARS-CoV-2-} and {HCoV-specific} {T} cell
               response using {IFN-$\gamma$} {ELISpot}",
  author    = "Th{\"u}mmler, Laura and Schwarzkopf, Sina and Knop, Dietmar and
               Ross, J Alexander and Berg, Victoria and Horn, Peter A and
               Lindemann, Monika",
  abstract  = "Herd immunity is essential to control severe acute respiratory
               syndrome coronavirus type 2 (SARS-CoV-2), especially in
               immunocompromised patients. Convalescent individuals should be
               vaccinated later due to vaccine shortage, as studies show that
               neutralizing antibodies generated during infection are stable
               for at least 6 months. Cellular immunity is also detectable for
               months. However, there is evidence of cross-reactivity of T
               cells with human endemic coronaviruses (HCoVs). Here, we show
               that cross-reactivity-which may prevent the specific detection
               of SARS-CoV-2-specific T cell responses-can be avoided if cells
               are stimulated with the N-terminus of the spike protein in
               IFN-$\gamma$ ELISpot. In contrast to previous studies, we
               examined T-cell responses against all four known HCoVs using
               IFN-$\gamma$ ELISpot in 19 convalescent volunteers and 10 fully
               vaccinated volunteers. In addition, we performed Spearman
               analyses to detect cross-reactivity of T cells. We observed no
               correlation between T-cell responses against SARS-CoV-2 and
               human endemic coronaviruses, either in the whole cohort or in
               the individual groups. The use of the respective stimuli could
               lead to a more accurate assessment of cellular immunity in
               recovered individuals. This testing procedure could help to
               define the best time point at which convalescents should receive
               SARS-CoV-2 vaccination.",
  journal   = "Diagnostics (Basel)",
  publisher = "MDPI AG",
  volume    =  11,
  number    =  8,
  pages     = "1439",
  month     =  aug,
  year      =  2021,
  keywords  = "ELISpot; cross-reactivity; human endemic coronavirus",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Leung2021-ei,
  title     = "First reported case of late recurrence of pulmonary mucormycosis
               in a renal transplant recipient with poorly controlled diabetes
               mellitus",
  author    = "Leung, Cheuk Cheung Derek and Chan, Yu Hong and Ho, Man Ying and
               Chan, Ming Chiu and Chen, Chun Hoi and Kwok, Chin Tong and
               Yeung, Yiu Cheong",
  abstract  = "Pulmonary mucormycosis (PM) is a rare, life-threatening fungal
               infection usually affecting immunocompromised patients. Its
               incidence is rising, with a recent outbreak associated with
               COVID-19 co-infection. Amphotericin B along with early surgery
               are considered the standard treatment. Recurrence has been
               reported in patients without adequate treatment and without
               permanent reversal of predisposing factors. We report a case of
               late recurrence of PM in a renal transplant recipient. In 2012,
               he was diagnosed with PM. Imaging at the time showed a lingular
               mass. He was treated with antifungal for 1 year until complete
               radiological resolution. Surgical intervention was considered
               but no further follow-up action was taken. In 2020, he presented
               with fever and haemoptysis. Imaging again showed a lingular
               mass, which was confirmed to be PM by bronchoscopic lung biopsy.
               This case highlights the importance of secondary antifungal
               prophylaxis for PM if permanent reversal of immunosuppression is
               not possible.",
  journal   = "Respirol. Case Rep.",
  publisher = "Wiley",
  volume    =  9,
  number    =  12,
  pages     = "e0877",
  month     =  dec,
  year      =  2021,
  keywords  = "Rhizopus; diabetes mellitus; pulmonary mucormycosis; recurrence;
               renal transplant",
  copyright = "http://creativecommons.org/licenses/by-nc-nd/4.0/",
  language  = "en"
}

@ARTICLE{Nuara2021-ji,
  title     = "Telerehabilitation in response to constrained physical distance:
               an opportunity to rethink neurorehabilitative routines",
  author    = "Nuara, Arturo and Fabbri-Destro, Maddalena and Scalona, Emilia
               and Lenzi, Stefano Elio and Rizzolatti, Giacomo and Avanzini,
               Pietro",
  abstract  = "Ensuring proper dosage of treatment and repetition over time is
               a major challenge in neurorehabilitation. However, a requirement
               of physical distancing to date compromises their achievement.
               While mostly associated to COVID-19, physical distancing is not
               only required in a pandemic scenario, but also advised for
               several clinical conditions (e.g. immunocompromised individuals)
               or forced for specific social contexts (e.g. people living in
               remote areas worldwide). All these contexts advocate for the
               implementation of alternative healthcare models. The objective
               of this perspective is to highlight the benefits of remote
               administration of rehabilitative treatment, namely
               telerehabilitation, in counteracting physical distancing
               barriers in neurorehabilitation. Sustaining boosters of
               treatment outcome, such as compliance, sustainability, as well
               as motivation, telerehabilitation may adapt to multiple
               neurological conditions, with the further advantage of a high
               potential for individualization to patient's or pathology's
               specificities. The effectiveness of telerehabilitation can be
               potentiated by several technologies available to date: virtual
               reality can recreate realistic environments in which patients
               may bodily operate, wearable sensors allow to quantitatively
               monitor the patient's performance, and signal processing may
               contribute to the prediction of long-term dynamics of patient
               recovery. Telerehabilitation might spark its advantages far
               beyond the mere limitation of physical distancing effects,
               mitigating criticalities of daily neurorehabilitative practice,
               and thus paving the way to the envision of mixed models of care,
               where hospital-based procedures are complementarily integrated
               with telerehabilitative ones.",
  journal   = "J. Neurol.",
  publisher = "Springer Science and Business Media LLC",
  month     =  jan,
  year      =  2021,
  keywords  = "Action observation treatment; Physical distancing; Remote
               rehabilitation; Social distancing; Virtual reality",
  language  = "en"
}

@ARTICLE{Lodi2021-ci,
  title     = "Chronic asymptomatic {SARS-CoV-2} infection in the
               immunocompromised patient: new challenges and urgent needs",
  author    = "Lodi, Lorenzo and Moriondo, Maria and Pucci, Alessandra and
               Pisano, Laura and Ricci, Silvia and Indolfi, Giuseppe and
               Azzari, Chiara",
  journal   = "Clin. Infect. Dis.",
  publisher = "Oxford University Press (OUP)",
  month     =  jun,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Vellas2021-lc,
  title     = "Influence of treatment with neutralizing monoclonal antibodies
               on the {SARS-CoV-2} nasopharyngeal load and quasispecies",
  author    = "Vellas, Camille and Del Bello, Arnaud and Debard, Alexa and
               Steinmeyer, Zara and Tribaudeau, Laure and Ranger, No{\'e}mie
               and Jeanne, Nicolas and Martin-Blondel, Guillaume and Delobel,
               Pierre and Kamar, Nassim and Izopet, Jacques",
  abstract  = "OBJECTIVES: To evaluate the impact of neutralizing monoclonal
               antibody (mAb) treatment and to determine whether the selective
               pressure of mAbs could facilitate the proliferation of severe
               acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
               with spike protein mutations that might attenuate mAb
               effectiveness. PATIENTS AND METHODS: We evaluated the impact of
               mAbs on the nasopharyngeal (NP) viral load and virus
               quasispecies of mAb-treated patients using single-molecule
               real-time sequencing. The mAbs used were: Bamlanivimab alone
               (four patients), Bamlanivimab/Etesevimab (23 patients) and
               Casirivimab/Imdevimab (five patients). RESULTS: The NP
               SARS-CoV-2 viral load of mAb-treated patients decreased from 8.2
               log10 copies/mL before administration to 4.3 log10 copies/mL 7
               days after administration. Five immunocompromised patients given
               Bamlanivimab/Etesevimab were found to have mAb activity-reducing
               spike mutations. Two patients harboured SARS-CoV-2 variants with
               a Q493R spike mutation 7 days after administration, as did a
               third patient 14 days after administration. The fourth patient
               harboured a variant with a Q493K spike mutation 7 days
               post-treatment, and the fifth patient had a variant with a E484K
               spike mutation on day 21. The emergence of the spike mutation
               was accompanied by stabilization or rebound of the NP viral load
               in three of five patients. CONCLUSION: Two-mAb therapy can drive
               the selection of resistant SARS-CoV-2 variants in
               immunocompromised patients. Patients given mAbs should be
               closely monitored and measures to limit virus spread should be
               reinforced.",
  journal   = "Clin. Microbiol. Infect.",
  publisher = "Elsevier BV",
  volume    =  28,
  number    =  1,
  pages     = "139.e5--139.e8",
  month     =  sep,
  year      =  2021,
  keywords  = "Coronavirus disease 2019; Mutations; Neutralizing monoclonal
               antibodies; Quasispecies; Receptor-binding domain; Severe acute
               respiratory syndrome coronavirus 2; Single-molecular real-time
               sequencing; Spike protein",
  language  = "en"
}

@ARTICLE{Soltan2021-ui,
  title    = "In silico designing of a multitope vaccine against Rhizopus
              microsporus with potential activity against other mucormycosis
              causing fungi",
  author   = "Soltan, Mohamed A and Eldeen, Muhammad Alaa and Elbassiouny, Nada
              and Kamel, Hasnaa L and Abdelraheem, Kareem M and El-Gayyed,
              Hanaa Abd and Gouda, Ahmed M and Sheha, Mohammed F and Fayad,
              Eman and Ali, Ola A Abu and Ghany, Khalid Abd El and El-Damasy,
              Dalia A and Darwish, Khaled M and Elhady, Sameh S and Sileem,
              Ashraf E",
  abstract = "During the current era of the COVID-19 pandemic, the
              dissemination of Mucorales has been reported globally, with
              elevated rates of infection in India, and because of the high
              rate of mortality and morbidity, designing an effective vaccine
              against mucormycosis is a major health priority, especially for
              immunocompromised patients. In the current study, we studied
              shared Mucorales proteins, which have been reported as virulence
              factors, and after analysis of several virulent proteins for
              their antigenicity and subcellular localization, we selected
              spore coat (CotH) and serine protease (SP) proteins as the
              targets of epitope mapping. The current study proposes a vaccine
              constructed based on top-ranking cytotoxic T lymphocyte (CTL),
              helper T lymphocyte (HTL), and B cell lymphocyte (BCL) epitopes
              from filtered proteins. In addition to the selected epitopes,
              $\beta$-defensins adjuvant and PADRE peptide were included in the
              constructed vaccine to improve the stimulated immune response.
              Computational tools were used to estimate the physicochemical and
              immunological features of the proposed vaccine and validate its
              binding with TLR-2, where the output data of these assessments
              potentiate the probability of the constructed vaccine to
              stimulate a specific immune response against mucormycosis. Here,
              we demonstrate the approach of potential vaccine construction and
              assessment through computational tools, and to the best of our
              knowledge, this is the first study of a proposed vaccine against
              mucormycosis based on the immunoinformatics approach.",
  journal  = "Cells",
  volume   =  10,
  number   =  11,
  month    =  nov,
  year     =  2021,
  keywords = "COVID-19 pandemic; epitope mapping; immunoinformatics;
              mucormycosis; multitope vaccine",
  language = "en"
}

@ARTICLE{Ostrov2021-zr,
  title     = "Interplay of anti-viral vaccines with biologic agents and
               immunomodulators in individuals with autoimmune and
               autoinflammatory diseases",
  author    = "Ostrov, Barbara E and Amsterdam, Daniel",
  abstract  = "Vaccines are an essential part of a preventative healthcare
               strategy. However, response to vaccines may be less predictable
               in immunocompromised people. While outcomes for individuals with
               autoimmune and autoinflammatory diseases have dramatically
               improved with treatment using immunomodulating and biologic
               agents, infections have caused significant morbidity in these
               people today often more than due to their underlying diseases.
               Immune-based biologic therapies contribute to these infectious
               complications. This review addresses anti-viral vaccines, their
               effectiveness and safety in patients treated with approved
               biologic agents and immune targeted therapy with a focus on
               vaccines against influenza, human papillomavirus, hepatitis B
               virus and varicella zoster virus. Preliminary information
               regarding SARS-CoV-2 anti-viral vaccines is addressed.
               Additionally, we present recommendations regarding the safe use
               of vaccines in immunocompromised individuals with the goal to
               enhance awareness of the safety and efficacy of these anti-viral
               vaccines in these high-risk populations.",
  journal   = "Immunol. Invest.",
  publisher = "Informa UK Limited",
  volume    =  50,
  number    =  7,
  pages     = "833--856",
  month     =  oct,
  year      =  2021,
  keywords  = "Autoimmune diseases; anti-viral vaccines; biologic therapy;
               immunomodulating therapy",
  language  = "en"
}

@ARTICLE{Zeng2021-du,
  title     = "Impaired neutralizing antibody response to {COVID-19} {mRNA}
               vaccines in cancer patients",
  author    = "Zeng, Cong and Evans, John P and Reisinger, Sarah and Woyach,
               Jennifer and Liscynesky, Christina and Boghdadly, Zeinab El and
               Rubinstein, Mark P and Chakravarthy, Karthik and Saif, Linda and
               Oltz, Eugene M and Gumina, Richard J and Shields, Peter G and
               Li, Zihai and Liu, Shan-Lu",
  abstract  = "There is currently a critical need to determine the efficacy of
               SARS-CoV-2 vaccination for immunocompromised patients. In this
               study, we determined the neutralizing antibody response in 160
               cancer patients diagnosed with chronic lymphocytic leukemia
               (CLL), lung cancer, breast cancer, and various non-Hodgkin's
               lymphomas (NHL), after they received two doses of mRNA vaccines.
               Serum from 46 mRNA vaccinated health care workers (HCWs) served
               as healthy controls. We discovered that (1) cancer patients
               exhibited reduced neutralizing antibody titer (NT50) compared to
               HCWs; (2) CLL and NHL patients exhibited the lowest NT50 levels,
               with 50-60\% of them below the detection limit; (3) mean NT50
               levels in patients with CLL and NHL was ~2.6 fold lower than
               those with solid tumors; and (4) cancer patients who received
               anti-B cell therapy exhibited significantly reduced NT50 levels.
               Our results demonstrate an urgent need for novel immunization
               strategies for cancer patients against SARS-CoV-2, particularly
               those with hematological cancers and those on anti-B cell
               therapies.",
  journal   = "Cell Biosci.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  11,
  number    =  1,
  pages     = "197",
  month     =  nov,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{Beam2021-ga,
  title     = "False-negative nasopharyngeal severe acute respiratory
               coronavirus virus 2 ({SARS-CoV-2}) reverse-transcription
               polymerase chain reaction ({RT-PCR}) in immunocompromised
               patients resulting in healthcare worker exposures",
  author    = "Beam, Elena and Meyer, Michelle L and O' Horo, John C and
               Breeher, Laura E",
  journal   = "Infect. Control Hosp. Epidemiol.",
  publisher = "Cambridge University Press (CUP)",
  pages     = "1--2",
  month     =  nov,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Barrios2021-uf,
  title     = "Optimizing a protocol to assess immune responses after
               {SARS-CoV-2} vaccination in kidney-transplanted patients: In
               vivo {DTH} cutaneous test as the initial screening method",
  author    = "Barrios, Yvelise and Rodriguez, Aurelio and Franco, Andr{\'e}s
               and Alava-Cruz, Cristina and Marrero-Miranda, Domingo and
               Perez-Tamajon, Lourdes and Matheu, Victor",
  abstract  = "Previously, the delayed-type hypersensitivity (DTH) cutaneous
               test with the spike protein of SARS-CoV-2 has been shown to be a
               simple in vivo method to measure T-cell functionality after
               natural infection and in vaccinated individuals. METHODS:
               Twenty-five kidney-transplanted recipients were immunized with
               two doses of the mRNA-based Pfizer-BioNTech COVID19 vaccine
               three weeks apart. Cell-immune response (CIR) was evaluated ten
               weeks later using an in vivo DTH skin test and in vitro with an
               interferon gamma release assay (IGRA). Humoral Immune Response
               (HIR) was determined by the measurement of specific IgG anti-S1
               SARS-CoV-2. RESULTS: Ten weeks after the second dose of the
               vaccine, 23 out of 25 transplanted patients had a positive DTH
               skin test, while in vitro CIR was considered positive in 20
               patients. Unspecific stimulation was positive in all 25
               patients, showing no T-cell defect. Seven out of twenty-five
               patients had a negative specific anti-spike IgG. CIR was
               positive in all immune-competent control patients. CONCLUSIONS:
               DTH is a useful, simple, and cheaper tool that can be used to
               assess cellular immune response, with an excellent correlation
               with the in vitro CIR. CIR assessment after vaccination in these
               immunocompromised patients is an excellent complement to
               HIR-based methods. This skin test could be used if classical in
               vitro methods cannot be applied.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  9,
  number    =  11,
  pages     = "1315",
  month     =  nov,
  year      =  2021,
  keywords  = "DTH; SARS-CoV-2; T-cell response; delayed-type hypersensitivity;
               immunosuppression; kidney transplant; skin test; vaccination",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Marquez2021-yd,
  title     = "Reinfection with severe acute respiratory syndrome coronavirus 2
               ({SARS-CoV-2}) B.1.1.7 variant in an immunocompromised
               adolescent",
  author    = "Marquez, Lucila and Koy, Tjin and Spinler, Jennifer K and Luna,
               Ruth Ann and Tocco, Lisa and Fasciano, Lea and Dunn, James and
               Campbell, Judith R",
  journal   = "Infect. Control Hosp. Epidemiol.",
  publisher = "Cambridge University Press (CUP)",
  pages     = "1--2",
  month     =  may,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Wang2021-tq,
  title     = "Comparative assessment of favipiravir and remdesivir against
               human coronavirus {NL63} in molecular docking and cell culture
               models",
  author    = "Wang, Yining and Li, Pengfei and Rajpoot, Sajjan and Saqib, Uzma
               and Yu, Peifa and Li, Yunlong and Li, Yang and Ma, Zhongren and
               Baig, Mirza S and Pan, Qiuwei",
  abstract  = "Human coronavirus NL63 (HCoV-NL63) mainly affects young children
               and immunocompromised patients, causing morbidity and mortality
               in a subset of patients. Since no specific treatment is
               available, this study aims to explore the anti-SARS-CoV-2 agents
               including favipiravir and remdesivir for treating HCoV-NL63
               infection. We first successfully modelled the 3D structure of
               HCoV-NL63 RNA-dependent RNA polymerase (RdRp) based on the
               experimentally solved SARS-CoV-2 RdRp structure. Molecular
               docking indicated that favipiravir has similar binding
               affinities to SARS-CoV-2 and HCoV-NL63 RdRp with LibDock scores
               of 75 and 74, respectively. The LibDock scores of remdesivir to
               SARS-CoV-2 and HCoV-NL63 were 135 and 151, suggesting that
               remdesivir may have a higher affinity to HCoV-NL63 compared to
               SARS-CoV-2 RdRp. In cell culture models infected with HCoV-NL63,
               both favipiravir and remdesivir significantly inhibited viral
               replication and production of infectious viruses. Overall,
               remdesivir compared to favipiravir is more potent in inhibiting
               HCoV-NL63 in cell culture. Importantly, there is no evidence of
               resistance development upon long-term exposure to remdesivir.
               Furthermore, combining favipiravir or remdesivir with the
               clinically used antiviral cytokine interferon-alpha resulted in
               synergistic effects. These findings provided a proof-of-concept
               that anti-SARS-CoV-2 drugs, in particular remdesivir, have the
               potential to be repurposed for treating HCoV-NL63 infection.",
  journal   = "Sci. Rep.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  11,
  number    =  1,
  pages     = "23465",
  month     =  dec,
  year      =  2021,
  copyright = "https://creativecommons.org/licenses/by/4.0",
  language  = "en"
}

@ARTICLE{John2021-kh,
  title     = "Utilizing {CT} soft-tissue markers as a screening tool for acute
               invasive fungal sinusitis",
  author    = "John, Deepa Susan and Shyam, Karthik and Andrew, Dhilip and
               Cicilet, Soumya and Deepalam, Saikanth Reddy",
  abstract  = "OBJECTIVES: Acute invasive fungal sinusitis (AIFS) is a rapidly
               progressive disease, whose delayed identification results in
               poor outcomes, especially in immunocompromised individuals. A
               surge in of AIFS in the wake of the COVID-19 pandemic, has lent
               additional morbidity and mortality to an already precarious
               clinical scenario. Early detection of AIFS in individuals who
               are symptomatic/ at risk can allow early therapy, enabling
               better patient outcomes. Our study aims to determine optimal
               soft-tissue markers on CT for the early detection of AIFS.
               METHODS: In this case-control study, 142 patients with equal
               distribution of subjects were chosen based on histopathological
               diagnosis of AIFS; and their non-contrast CT scans were
               retrospectively assessed to determine the diagnostic utility of
               specific soft-tissue markers that would enable diagnosis of
               AIFS. RESULTS: A total of 9 markers with adequate sensitivity
               and specificity were identified, including pterygopalatine and
               sphenopalatine fossae, inferior orbital fissure and nasolacrimal
               duct involvement, premaxillary thickening, retro-antral and
               orbital stranding, and infratemporal muscle edema. It was
               determined that the combined occurrence of any 3 out of 9
               markers was 91.5\% sensitive and 95.9\% specific for diagnosis
               of AIFS (p < 0.005). CONCLUSION: Early, accurate detection of
               AIFS in predisposed individuals is possible with identification
               of soft-tissue markers on NECT, enabling early intervention.
               ADVANCES IN KNOWLEDGE: Being the aggressive disease that it is,
               AIFS may be managed early if the index of suspicion is held high
               via CT imaging; which our diagnostic checklist aims at enabling.",
  journal   = "Br. J. Radiol.",
  publisher = "British Institute of Radiology",
  pages     = "20210749",
  month     =  dec,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Lukacs2020-ya,
  title     = "Harnessing cellular immunity for vaccination against respiratory
               viruses",
  author    = "Lukacs, Nicholas W and Malinczak, Carrie-Anne",
  abstract  = "Severe respiratory viral infections, such as influenza,
               metapneumovirus (HMPV), respiratory syncytial virus (RSV),
               rhinovirus (RV), and coronaviruses, including severe acute
               respiratory syndrome coronavirus-2 (SARS-CoV-2), cause
               significant mortality and morbidity worldwide. These viruses
               have been identified as important causative agents of acute
               respiratory disease in infants, the elderly, and
               immunocompromised individuals. Clinical signs of infection range
               from mild upper respiratory illness to more serious lower
               respiratory illness, including bronchiolitis and pneumonia.
               Additionally, these illnesses can have long-lasting impact on
               patient health well beyond resolution of the viral infection.
               Aside from influenza, there are currently no licensed vaccines
               against these viruses. However, several research groups have
               tested various vaccine candidates, including those that utilize
               attenuated virus, virus-like particles (VLPs), protein subunits,
               and nanoparticles, as well as recent RNA vaccines, with several
               of these approaches showing promise. Historically, vaccine
               candidates have advanced, dependent upon the ability to activate
               the humoral immune response, specifically leading to strong B
               cell responses and neutralizing antibody production. More
               recently, it has been recognized that the cellular immune
               response is also critical in proper resolution of viral
               infection and protection against detrimental immunopathology
               associated with severe disease and therefore, must also be
               considered when analyzing the efficacy and safety of vaccine
               candidates. These candidates would ideally result in robust CD4+
               and CD8+ T cell responses as well as high-affinity neutralizing
               antibody. This review will aim to summarize established and new
               approaches that are being examined to harness the cellular
               immune response during respiratory viral vaccination.",
  journal   = "Vaccines (Basel)",
  publisher = "MDPI AG",
  volume    =  8,
  number    =  4,
  pages     = "783",
  month     =  dec,
  year      =  2020,
  keywords  = "RNA; RSV; SARS-CoV-2; cellular immunity; nanoparticles;
               respiratory viruses; vaccine; virus-like particles",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Dimkic2021-tm,
  title     = "The microbiome of bat guano: for what is this knowledge
               important?",
  author    = "Dimki{\'c}, Ivica and Fira, Djordje and Janakiev, Tamara and
               Kabi{\'c}, Jovana and Stupar, Milo{\v s} and Nenadi{\'c}, Marija
               and Unkovi{\'c}, Nikola and Grbi{\'c}, Milica Ljaljevi{\'c}",
  abstract  = "Bats as flying mammals are potent vectors and natural reservoir
               hosts for many infectious viruses, bacteria, and fungi, also
               detected in their excreta such as guano. Accelerated
               deforestation, urbanization, and anthropization hastily lead to
               overpopulation of the bats in urban areas allowing easy
               interaction with other animals, expansion, and emergence of new
               zoonotic disease outbreaks potentially harmful to humans.
               Therefore, getting new insights in the microbiome of bat guano
               from different places represents an imperative for the future.
               Furthermore, the use of novel high-throughput sequencing
               technologies allows better insight in guano microbiome and
               potentially indicated that some species could be typical
               guano-dwelling members. Bats are well known as a natural
               reservoir of many zoonotic viruses such as Ebola, Nipah,
               Marburg, lyssaviruses, rabies, henipaviruses, and many
               coronaviruses which caused a high number of outbreaks including
               ongoing COVID-19 pandemic. Additionally, many bacterial and
               fungal pathogens were identified as common guano residents.
               Thus, the presence of multi-drug-resistant bacteria as
               environmental reservoirs of extended spectrum $\beta$-lactamases
               and carbapenemase-producing strains has been confirmed. Bat
               guano is the most suitable substrate for fungal reproduction and
               dissemination, including pathogenic yeasts and keratinophilic
               and dimorphic human pathogenic fungi known as notorious
               causative agents of severe endemic mycoses like histoplasmosis
               and fatal cryptococcosis, especially deadly in immunocompromised
               individuals. This review provides an overview of bat guano
               microbiota diversity and the significance of autochthonous and
               pathogenic taxa for humans and the environment, highlighting
               better understanding in preventing emerging diseases. KEY
               POINTS: Bat guano as reservoir and source for spreading of
               autochthonous and pathogenic microbiota Bat guano vs. novel
               zoonotic disease outbreaks Destruction of bat natural habitats
               urgently demands increased human awareness.",
  journal   = "Appl. Microbiol. Biotechnol.",
  publisher = "Springer Science and Business Media LLC",
  volume    =  105,
  number    =  4,
  pages     = "1407--1419",
  month     =  feb,
  year      =  2021,
  keywords  = "Bat guano; Disease outbreaks; Microbiota; Pathogens; Zoonoses",
  language  = "en"
}

@ARTICLE{Xie2021-fz,
  title     = "Case report: Next-generation sequencing in diagnosis of
               pneumonia due to Pneumocystis jirovecii and Cytomegalovirus in a
               patient with {HIV} infection",
  author    = "Xie, Yirui and Ruan, Bing and Jin, Lingxiao and Zhu, Biao",
  abstract  = "Background: Pulmonary infections remain a significant cause of
               morbidity and mortality in immunocompromised patients. The
               pathogens spectrum of pulmonary infection that can affect
               patients with human immunodeficiency virus (HIV) is wide such as
               bacterial, fungal, viral, parasitic organisms, and so on. The
               risk of multi-pathogenic pneumonia is higher in HIV-infected
               patients. However, the fast and accurate diagnosis of
               multi-pathogenic pneumonia is challenging because of the
               limitations of current conventional tests. Case Presentation:
               Here, we report a case of pneumonia due to Pneumocystis
               jirovecii and cytomegalovirus (CMV) in a 22-year-old male with
               newly diagnosed HIV infection. Blood tests revealed a low CD4
               count, a chest computed tomography (CT) scan showed extensive
               ground-glass opacities in the bilateral lung with multiple
               cavity lesions in the left upper lung. Microscopic examination
               of stained sputum and bronchoalveolar lavage fluid (BALF) smear
               specimens did not find any pathogens. There was also no evidence
               of pathogens known to cause pneumonia in bacteria and fungi
               culture tests and virus antibodies such as EBV, CMV, and
               COVID-19. The nucleic acid of CMV in blood was reported by
               quantitative PCR. Next-generation sequencing (NGS) analysis of
               BALF specimens identified a large number of P. jirovecii and CMV
               reads, and confirmed the diagnosis of pneumonia due to P.
               jirovecii and CMV. Following the patient's treatment with
               anti-PCP and anti-CMV, the patient was cured and discharged.
               Conclusions: This case highlights the combined application of
               NGS in the clinical diagnosis of multi-pathogenic pneumonia in
               an HIV-infected patient. NGS is proposed as an important
               adjunctive diagnostic approach for identifying pathogens of
               multi-pathogenic pneumonia in HIV-infected patients.",
  journal   = "Front. Med. (Lausanne)",
  publisher = "Frontiers Media SA",
  volume    =  8,
  pages     = "653294",
  month     =  mar,
  year      =  2021,
  keywords  = "HIV; Pneumocystis jirovecii; bronchoalveolar lavage fluid;
               cytomegalovirus; next-generation sequencing; pneumonitis",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Mair2021-zv,
  title     = "Humoral immune response in hematooncological patients and health
               care workers who received {SARS-CoV-2} vaccinations",
  author    = "Mair, Maximilian J and Berger, Julia M and Berghoff, Anna S and
               Starzer, Angelika M and Ortmayr, Gregor and Puhr, Hannah C and
               Steindl, Ariane and Perkmann, Thomas and Haslacher, Helmuth and
               Strassl, Robert and Tobudic, Selma and Lamm, Wolfgang W and
               Raderer, Markus and Mitterer, Manfred and Fuereder, Thorsten and
               Fong, Dominic and Preusser, Matthias",
  abstract  = "Importance: To our knowledge, little is known about antibody
               development after SARS-CoV-2 vaccination in immunocompromised
               individuals, such as patients with cancer. Objective: To
               determine whether hematooncological patients develop
               anti-SARS-CoV-2 antibodies after vaccination. Design, Setting,
               and Participants: This retrospective cohort study included 2
               independent cohorts of patients who were treated for
               hematological and solid malignant tumors between October 2020
               and May 2021, comprising 901 samples from 595 patients and 58
               health care workers (HCWs). Serum samples were collected from
               patients who were treated at an academic center and a community
               hospital in a rural area and a control group of HCWs, all of
               whom received SARS-CoV-2 vaccination. Main Outcomes and
               Measures: Total anti-SARS-CoV-2 nucleocapsid (anti-NC) and
               antispike protein (anti-S) antibodies were measured
               retrospectively. Results: In total, 595 patients (320 women
               [53.8\%] and 275 men [46.2\%]; median [range] age, 67 [19-96]
               years) and 58 HCWs (40 women [69.0\%] and 18 men [31.0\%];
               median [range] age, 42 [24-60] years) were included. Previous
               SARS-CoV-2 infection was documented in 43 of 595 (7.2\%), while
               anti-NC antibodies that suggested previous infections were
               observed in 49 of 573 evaluable patients (8.6\%). In both
               cohorts, anti-S antibody levels were higher in fully vaccinated
               patients compared with patients who received 1 dose. After the
               first vaccination, patients with hematological cancer who
               received B cell-targeting agents had lower anti-S levels
               (median, 1.6 AU/mL; range: 0-17 244 AU/mL) than patients who
               received other therapies (median, 191.6 AU/mL; range, 0-40 000;
               P < .001) or patients with solid tumors (median, 246.4 AU/mL;
               range, 0-40 000 AU/mL; P < .001). Anti-S levels after the first
               vaccination differed according to ongoing antineoplastic
               treatment modalities, with the lowest median levels in patients
               who received chemotherapy alone (157.7 AU/mL; range, 0-40 000
               AU/mL) or in combination with immunotherapy (118.7 AU/mL; range,
               14.1-38 727 AU/mL) and the highest levels in patients with no
               ongoing antineoplastic treatment (median, 634.3 AU/mL; range,
               0-40 000 AU/mL; P = .01). Antibody levels after full
               immunization were higher in HCWs (median, 2500 U/mL; range,
               485-2500 U/mL) than in patients with cancer (median, 117.0 U/mL;
               range, 0-2500 U/mL; P < .001). Conclusions and Relevance: In
               this cohort study of patients with hematooncological diseases
               and a control group of HCWs, anti-SARS-CoV-2 antibodies after
               vaccination could be detected in patients with cancer. Lower
               antibody levels compared with HCWs and differences in
               seroconversion in specific subgroups underscore the need for
               further studies on SARS-CoV-2 vaccination in patients with
               hematooncological disease.",
  journal   = "JAMA Oncol.",
  publisher = "American Medical Association (AMA)",
  pages     = "1--8",
  month     =  sep,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Mencacci2021-ef,
  title     = "Role of nucleocapsid protein antigen detection for safe end of
               isolation of {SARS-CoV-2} infected patients with long
               persistence of viral {RNA} in respiratory samples",
  author    = "Mencacci, Antonella and Gili, Alessio and Gidari, Anna and
               Schiaroli, Elisabetta and Russo, Carla and Cenci, Elio and
               Camilloni, Barbara and Graziani, Alessandro and Melelli-Roia,
               Arduino and Francisci, Daniela and Stracci, Fabrizio",
  abstract  = "BACKGROUND: In SARS-CoV-2 infection, viral RNA may persist in
               respiratory samples for several weeks after the resolution of
               symptoms. Criteria to assess the end of infectivity are not
               unequivocally defined. In some countries, time from diagnosis is
               the unique criterion used, in addition to symptom cessation.
               This study evaluates the role of the Lumipulse\textregistered{}
               Antigen Assay (LAA) for the safe end of isolation of patients
               $\geq$21 days after the diagnosis of infection. METHODS: A total
               of 671 nasopharyngeal swabs from patients diagnosed with
               infection at least 21 days before were assessed by RT-PCR and
               LAA, and the role of LAA in predicting the absence of
               infectivity was evaluated by virus cell culture. RESULTS: Viable
               virus was present in 10/138 cultured samples. Eight out of ten
               infective patients suffered from a concomitant disease,
               predisposing them to long-term shedding of infective virus. In
               particular, infectious virus was isolated from 10/20
               RT-PCR+/LAA+ cultured samples, whereas no viable virus was found
               in all 118 RT-PCR+/LAA- cultured swabs. LLA and RT-PCR agreed in
               484/671 (72.1\%) samples, with 100\% and 26.7\% concordance in
               RT-PCR negative and positive samples, respectively. CONCLUSIONS:
               Viable virus can be found $\geq$21 days after diagnosis in
               immunocompromised or severely ill patients. LAA better than
               RT-PCR predicts non-infectivity of patients and can be safely
               used to end isolation in cases with long persistence of viral
               RNA in the respiratory tract.",
  journal   = "J. Clin. Med.",
  publisher = "MDPI AG",
  volume    =  10,
  number    =  18,
  pages     = "4037",
  month     =  sep,
  year      =  2021,
  keywords  = "RT-PCR; SARS-CoV-2; antigen test; isolation and discharge
               recommendations; virus culture",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Ghosh2021-kn,
  title     = "The rise in cases of mucormycosis, candidiasis and aspergillosis
               amidst {COVID19}",
  author    = "Ghosh, Asmita and Sarkar, Anusua and Paul, Pubali and Patel,
               Parth",
  abstract  = "The Coronavirus outbreak globally has changed the medical system
               and also led to a shortage of medical facilities in both
               developing and underdeveloped countries. The COVID19 disease,
               being novel in nature along with high infectivity and frequent
               mutational rate, has been termed to be fatal across the globe.
               The advent of infection by SARS-CoV-2 has brought a myriad of
               secondary complications and comorbidities resulting in
               additional challenges to the health care system induced by novel
               therapeutic procedures. The emerging variant with respect to the
               Indian subcontinent and the associated genetic mutations have
               worsened the situation at hand. Proper clinical management along
               with epidemiological studies and clinical presentations in
               scientific studies and trials is necessary in order to combat
               the simultaneous waves of emerging strains. This article
               summarizes three of the major fungal outbreaks in India namely
               mucormycosis, candidiasis and aspergillosis, and elaborates
               their subtypes, pathogenesis, symptoms and treatment and
               detection techniques. A detail of future therapeutics under
               consideration are also elaborated along with a general
               hypothesis on how COVID19 is related to immunological advances
               leading to major widespread fungal infection in the country. The
               factors that contribute in promoting virus proliferation and
               invasive fungal infections include cell-mediated immunity,
               associated immunocompromised conditions and treatment protocols
               that slows down immune mechanisms. To better comprehend a fungal
               or bacterial outbreak, it is very important to conduct audits
               mediated through multicenter national and state research teams
               for recognizing patterns and studying current cases of fungal
               infection in both healthy and comorbid groups of COVID19
               patients.",
  journal   = "Fungal Biol. Rev.",
  publisher = "Elsevier BV",
  volume    =  38,
  pages     = "67--91",
  month     =  dec,
  year      =  2021,
  keywords  = "Amphotericin-B; Aspergillosis; COVID19; Candidiasis; Fungus;
               Mucormycosis",
  language  = "en"
}

@ARTICLE{Mirhendi2021-ap,
  title     = "South Asian (Clade I) Candida auris meningitis in a paediatric
               patient in Iran with a review of the literature",
  author    = "Mirhendi, Hossein and Charsizadeh, Arezou and Aboutalebian,
               Shima and Mohammadpour, Masoud and Nikmanesh, Bahram and de
               Groot, Theun and Meis, Jacques F and Badali, Hamid",
  abstract  = "Candida meningitis is a rare life-threatening yeast infection
               mostly involving immunocompromised or paediatric patients
               undergoing neurosurgical procedures or shunt placement. Due to
               difficulties in diagnosis because of diverse clinical
               manifestations, the number of patients affected is most likely
               underestimated. Therefore, the correct diagnosis may be delayed
               for months, and accurate species identification is highly
               recommended for administering appropriate antifungal therapy. We
               report the first case of fluconazole-resistant Candida auris
               meningitis in a paediatric patient in Iran. This strain was
               probably imported, as it genotypically belonged to Clade I from
               South Asia. Furthermore, we include a literature review of C
               auris meningitis cases, as the number of cases with C auris
               meningitis has increased with reports from the United Kingdom,
               India and Iran. This problem might increase further in the era
               of COVID-19 due to attrition of experienced healthcare personnel
               and a high workload of hospital healthcare workers. To
               understand the precise prevalence of this emerging multidrug
               resistance pathogen, epidemiological surveillance studies are
               urgently warranted.",
  journal   = "Mycoses",
  publisher = "Wiley",
  month     =  nov,
  year      =  2021,
  keywords  = "Candida ; antifungal susceptibility; candidaemia; meningitis;
               typing",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Rubbiani2021-bs,
  title     = "In vivo active organometallic-containing antimycotic agents",
  author    = "Rubbiani, Riccardo and Weil, Tobias and Tocci, Noemi and
               Mastrobuoni, Luciano and Jeger, Severin and Moretto, Marco and
               Ng, James and Lin, Yan and Hess, Jeannine and Ferrari, Stefano
               and Kaech, Andres and Young, Luke and Spencer, John and Moore,
               Anthony L and Cariou, Kevin and Renga, Giorgia and Pariano,
               Marilena and Romani, Luigina and Gasser, Gilles",
  abstract  = "Fungal infections represent a global problem, notably for
               immunocompromised patients in hospital, COVID-19 patient wards
               and care home settings, and the ever-increasing emergence of
               multidrug resistant fungal strains is a sword of Damocles
               hanging over many healthcare systems. Azoles represent the
               mainstay of antifungal drugs, and their mode of action involves
               the binding mode of these molecules to the fungal lanosterol
               14$\alpha$-demethylase target enzyme. In this study, we have
               prepared and characterized four novel organometallic derivatives
               of the frontline antifungal drug fluconazole (1a-4a). Very
               importantly, enzyme inhibition and chemogenomic profiling
               demonstrated that lanosterol 14$\alpha$-demethylase, as for
               fluconazole, was the main target of the most active compound of
               the series,
               (N-(ferrocenylmethyl)-2-(2,4-difluorophenyl)-2-hydroxy-N-methyl-3-(1H-1,2,4-triazol-1-yl)propan-1-aminium
               chloride, 2a). Transmission electron microscopy (TEM) studies
               suggested that 2a induced a loss in cell wall integrity as well
               as intracellular features ascribable to late apoptosis or
               necrosis. The impressive activity of 2a was further confirmed on
               clinical isolates, where antimycotic potency up to 400 times
               higher than fluconazole was observed. Also, 2a showed activity
               towards azole-resistant strains. This finding is very
               interesting since the primary target of 2a is the same as that
               of fluconazole, emphasizing the role played by the
               organometallic moiety. In vivo experiments in a mice model of
               Candida infections revealed that 2a reduced the fungal growth
               and dissemination but also ameliorated immunopathology, a
               finding suggesting that 2a is active in vivo with added activity
               on the host innate immune response.",
  journal   = "RSC Chem Biol",
  publisher = "Royal Society of Chemistry (RSC)",
  volume    =  2,
  number    =  4,
  pages     = "1263--1273",
  month     =  aug,
  year      =  2021,
  copyright = "http://creativecommons.org/licenses/by-nc/3.0/",
  language  = "en"
}

@ARTICLE{De_Mello2021-za,
  title     = "Recovery of synthetic Zika virus based on {Rio-U1} isolate using
               a genetically stable two Plasmid system and {cDNA} amplification",
  author    = "de Mello, Iasmim Silva and Fernandes, D{\'e}berli Ruiz and
               Furtado, Nath{\'a}lia Dias and Dos Santos, Alexandre Ara{\'u}jo
               Cunha and Dos Santos, Marta Pereira and Ribeiro, Ieda Pereira
               and Raphael, Lidiane Menezes Souza and Nogueira, M{\^o}nica da
               Silva and da Cruz, Stephanie Oliveira Diaz and Rocha, Adalgiza
               da Silva and Manso, Pedro Paulo de Abreu and Pelajo-Machado,
               Marcelo and Bonaldo, Myrna Cristina",
  abstract  = "In 2016, the world experienced the unprecedented Zika epidemic.
               The ZIKV emerged as a major human pathogen due to its
               association with the impairment of perinatal development and
               Guillain-Barr{\'e} syndrome. The occurrence of these severe
               cases of Zika points to the significance of studies for
               understanding the molecular determinants of flavivirus
               pathogenesis. Reverse genetics is a powerful method for studying
               the replication and determinants of pathogenesis, virulence, and
               viral attenuation of flaviviruses, facilitating the design of
               vaccines and therapeutics. However, the main hurdle in the
               development of infectious clones is the instability of
               full-length cDNA in Escherichia coli. Here, we described the
               development of a genetically stable and efficient infectious
               clone based on the ZIKV Rio-U1 isolated in the 2016 epidemic in
               Brazil. The employed strategy consisted of cloning the viral
               cDNA genome into two stable plasmid subclones and obtaining a
               high-quality cDNA template with increment in DNA mass for in
               vitro transcription by PCR amplification. The strategy for
               developing a ZIKV infectious cDNA clone designed in this study
               was successful, yielding a replicative and efficient
               clone-derived virus with high similarities with its parental
               virus, Rio-U1, by comparison of the proliferation capacity in
               mammal and insect cells. The infection of AG129
               immunocompromised mice caused identical mortality rates, with
               similar disease progression and morbidity in the animals
               infected with the parental and the cDNA-derived virus.
               Histopathological analyses of mouse brains infected with the
               parental and the cDNA-derived viruses revealed a similar
               pathogenesis degree. We observed meningoencephalitis, cellular
               pyknosis, and neutrophilic invasion adjacent to the choroid
               plexus and perivascular cuffs with the presence of neutrophils.
               The developed infectious clone will be a tool for genetic and
               functional studies in vitro and in vivo to understand viral
               infection and pathogenesis better.",
  journal   = "Front. Microbiol.",
  publisher = "Frontiers Media SA",
  volume    =  12,
  pages     = "639655",
  month     =  feb,
  year      =  2021,
  keywords  = "AG129 mouse infection; Zika virus; cDNA amplification; cell
               infection; infectious clone; two-plasmid system",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Hughes2021-ff,
  title     = "Clinical illness with viable severe acute respiratory
               coronavirus virus 2 ({SARS-CoV-2}) virus presenting 72 days
               after infection in an immunocompromised patient",
  author    = "Hughes, Carly M and Gregory, Gareth P and Pierce, Anna B and
               Druce, Julian D and Catton, Mike and Chong, Brian and Sherry,
               Norelle L and Graham, Maryza and Chen, Melissa and Salvaris,
               Ross and Eise, Nicole and Lee, Jean Y H and McQuilten, Zoe and
               Crouch, Simon and Looker, Clare and Korman, Tony M and Stuart,
               Rhonda L",
  abstract  = "We present a case of late symptom onset of COVID-19 infection 72
               days after initial diagnosis in an immunocompromised 53-year-old
               man. SARS-CoV-2 was cultured from his sputum sample at this
               time, and genomic sequencing suggested reinfection was unlikely.
               After receipt of convalescent plasma, SARS-CoV-2 became
               undetectable by PCR 111 days after diagnosis, although
               SARS-CoV-2 antibodies remained not detectable. This case posed
               difficult public health management issues in a low prevalence
               COVID-19 setting as the person required extended home isolation
               given his prolonged SARS-CoV-2 PCR detection.",
  journal   = "Infect. Control Hosp. Epidemiol.",
  publisher = "Cambridge University Press (CUP)",
  pages     = "1--3",
  month     =  mar,
  year      =  2021,
  keywords  = "SARS-CoV-2; immunocompromise; public health",
  language  = "en"
}

@ARTICLE{Collins2021-bv,
  title     = "Reuse of disposable isolation gowns in rodent facilities during
               a pandemic",
  author    = "Collins, Toi A and Sparks, Amanda E and Walker, Mary M and
               Kendall, Lon V and Dobos, Karen M and Bergdall, Valerie K and
               Hickman-Davis, Judy M",
  abstract  = "Reuse of disposable personal protective equipment is
               traditionally discouraged, yet in times of heightened medical
               applications such as the SARS CoV-2 pandemic, it can be
               difficult to obtain. In this article we examine the reuse of
               disposable gowns with respect to still providing personnel
               protection. XR7, a fluorescent powder, was used to track
               contamination of gowns after manipulation of rodent cages. Mouse
               cages were treated with XR7 prior to manipulations. Disposable
               gowns were labeled for single person use and hung in common
               procedure spaces within the vivarium between usages. A simulated
               rack change of 140 cages was completed using XR7-treated cages.
               One individual changed all cages with a break occurring after
               the first 70 cages, requiring the gown to be removed and reused
               once. To simulate research activities, 5 individuals accessed 3
               XR7-treated cages daily for 5 d. Each mouse in the XR7-treated
               cages was manipulated at least once before returning cages to
               the housing room. Disposable gowns were reused 5 times per
               individual. Gowns, gloves, clothing, bare arms, and hands were
               scanned for fluorescence before and after removing PPE.
               Fluorescence was localized to gloves and gown sleeves in closest
               contact with animals and caging. No fluorescence was detected on
               underlying clothing, or bare arms and hands after removing PPE.
               Fluorescence was not detected in procedure spaces where gowns
               were hung. The lack of fluorescence on personnel or surfaces
               indicate that gowns can be reused 1 time for routine husbandry
               tasks and up to 5 times for research personnel. A method for
               decontamination of used gowns using Vaporized Hydrogen Peroxide
               (VHP) was also validated for use in areas where animals are
               considered high risk such as quarantine, or for fragile
               immunocompromised rodent colonies.",
  journal   = "J. Am. Assoc. Lab. Anim. Sci.",
  publisher = "American Association for Laboratory Animal Science",
  volume    =  60,
  number    =  4,
  pages     = "431--441",
  month     =  jul,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Bohmwald2021-qx,
  title     = "Contribution of pro-inflammatory molecules induced by
               respiratory virus infections to neurological disorders",
  author    = "Bohmwald, Karen and Andrade, Catalina A and Kalergis, Alexis M",
  abstract  = "Neurobehavioral alterations and cognitive impairment are common
               phenomena that represent neuropsychiatric disorders and can be
               triggered by an exacerbated immune response against pathogens,
               brain injury, or autoimmune diseases. Pro-inflammatory
               molecules, such as cytokines and chemokines, are produced in the
               brain by resident cells, mainly by microglia and astrocytes.
               Brain infiltrating immune cells constitutes another source of
               these molecules, contributing to an impaired neurological
               synapse function, affecting typical neurobehavioral and
               cognitive performance. Currently, there is increasing evidence
               supporting the notion that behavioral alterations and cognitive
               impairment can be associated with respiratory viral infections,
               such as human respiratory syncytial virus, influenza, and
               SARS-COV-2, which are responsible for endemic, epidemic, or
               pandemic outbreak mainly in the winter season. This article will
               review the brain's pro-inflammatory response due to infection by
               three highly contagious respiratory viruses that are the leading
               cause of acute respiratory illness, morbidity, and mobility in
               infants, immunocompromised and elderly population. How these
               respiratory viral pathogens induce increased secretion of
               pro-inflammatory molecules and their relationship with the
               alterations at a behavioral and cognitive level will be
               discussed.",
  journal   = "Pharmaceuticals (Basel)",
  publisher = "MDPI AG",
  volume    =  14,
  number    =  4,
  pages     = "340",
  month     =  apr,
  year      =  2021,
  keywords  = "brain; neuropsychiatric disorders; pro-inflammatory molecules;
               viral infection",
  copyright = "https://creativecommons.org/licenses/by/4.0/",
  language  = "en"
}

@ARTICLE{Pozzetto2021-rk,
  title     = "Immunogenicity and efficacy of heterologous {ChAdOx1-BNT162b2}
               vaccination",
  author    = "Pozzetto, Bruno and Legros, Vincent and Djebali, Sophia and
               Barateau, V{\'e}ronique and Guibert, Nicolas and Villard, Marine
               and Peyrot, Lo{\"\i}c and Allatif, Omran and Fassier,
               Jean-Baptiste and Massardier-Pilonch{\'e}ry, Am{\'e}lie and
               Brengel-Pesce, Karen and Yaugel-Novoa, Melyssa and Denolly,
               Sol{\`e}ne and Boson, Bertrand and Bourlet, Thomas and Bal,
               Antonin and Valette, Martine and Andrieu, Thibault and Lina,
               Bruno and {Covid-Ser study group} and Cosset, Fran{\c
               c}ois-Lo{\"\i}c and Paul, St{\'e}phane and Defrance, Thierry and
               Marvel, Jacqueline and Walzer, Thierry and Trouillet-Assant,
               Sophie",
  abstract  = "Following severe adverse reactions to the AstraZeneca
               ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities
               recommended that patients under the age of 55 years who received
               one dose of ChAdOx1-S-nCoV-19 receive a second dose of the
               Pfizer BNT162b2 vaccine as a booster. However, the effectiveness
               and the immunogenicity of this vaccination regimen have not been
               formally tested. Here we show that the heterologous
               ChAdOx1-S-nCoV-19 and BNT162b2 combination confers better
               protection against severe acute respiratory syndrome coronavirus
               2 (SARS-CoV-2) infection than the homologous BNT162b2 and
               BNT162b2 combination in a real-world observational study of
               healthcare workers (n = 13,121). To understand the underlying
               mechanism, we conducted a longitudinal survey of the anti-spike
               immunity conferred by each vaccine combination. Both
               combinations induced strong anti-spike antibody responses, but
               sera from heterologous vaccinated individuals displayed a
               stronger neutralizing activity regardless of the SARS-CoV-2
               variant. This enhanced neutralizing potential correlated with
               increased frequencies of switched and activated memory B cells
               that recognize the SARS-CoV-2 receptor binding domain. The
               ChAdOx1-S-nCoV-19 vaccine induced a weaker IgG response but a
               stronger T cell response than the BNT162b2 vaccine after the
               priming dose, which could explain the complementarity of both
               vaccines when used in combination. The heterologous vaccination
               regimen could therefore be particularly suitable for
               immunocompromised individuals.",
  journal   = "Nature",
  publisher = "Springer Science and Business Media LLC",
  month     =  oct,
  year      =  2021,
  language  = "en"
}

@ARTICLE{Schneider2021-hr,
  title     = "Autochthonous West Nile virus infection in Germany: Increasing
               numbers and a rare encephalitis case in a kidney transplant
               recipient",
  author    = "Schneider, Julia and Bachmann, Friederike and Choi, Mira and
               Kurvits, Lille and Schmidt, Marie Luisa and Bergfeld, Leon and
               Meier, Iris and Zuchowski, Marta and Werber, Dirk and Hofmann,
               J{\"o}rg and Ruprecht, Klemens and Eckardt, Kai-Uwe and Jones,
               Terry Carleton and Drosten, Christian and Corman, Victor Max",
  abstract  = "West Nile Virus (WNV) infections are increasingly detected in
               birds and horses in central Europe, with a first mosquito-borne
               autochthonous human infection detected in Germany in 2019. Human
               infections are typically asymptomatic, with occasional severe
               neurological disease. Because of a low number of cases in
               central Europe, awareness regarding potential cases is low and
               WNV diagnostic is neglected. We tested cerebrospinal fluid (CSF)
               samples from unsolved encephalitis and meningitis cases from
               Berlin from 2019 and 2020, and describe a WNV-encephalitis case
               in a 33-year old kidney transplant recipient. The infectious
               course was resolved by serology, RT-PCR, and sequencing of
               stored samples. Phylogenetic sequence analysis revealed a close
               relationship of the patient's WNV strain to German sequences
               from 2019 and 2020. A lack of travel history and patient
               self-isolation during the SARS-CoV-2 pandemic suggest the
               infection was acquired in the patient's home or garden.
               Serological tests of four people sharing the living space were
               negative. Retrospective RT-PCR and WNV-IgM testing of 671 CSF
               samples from unsolved encephalitis and meningitis cases from
               Berlin detected no additional infections. The recent increase of
               WNV cases illustrates the importance of considering WNV in cases
               of meningoencephalitis, especially in immunocompromised
               patients, as described here. Proper education and communication
               and a revised diagnostic strategy will help to raise awareness
               and to detect future WNV infections. This article is protected
               by copyright. All rights reserved.",
  journal   = "Transbound. Emerg. Dis.",
  publisher = "Wiley",
  month     =  nov,
  year      =  2021,
  keywords  = "Arboviruses; Diagnostics; Germany; West Nile virus; emerging
               disease; encephalitis",
  copyright = "http://onlinelibrary.wiley.com/termsAndConditions\#vor",
  language  = "en"
}

@ARTICLE{Walti2021-ry,
  title    = "Humoral immunogenicity of the seasonal influenza vaccine before
              and after {CAR-T-cell} therapy",
  author   = "Walti, Carla S and Loes, Andrea N and Shuey, Kiel and Krantz,
              Elizabeth M and Boonyaratanakornkit, Jim and Keane-Candib, Jacob
              and Loeffelholz, Tillie and Wolf, Caitlin R and Taylor, Justin J
              and Gardner, Rebecca A and Green, Damian J and Cowan, Andrew J
              and Maloney, David G and Turtle, Cameron J and Pergam, Steven A
              and Chu, Helen Y and Bloom, Jesse D and Hill, Joshua A",
  abstract = "Recipients of chimeric antigen receptor-modified T (CAR-T) cell
              therapies for B-cell malignancies are immunocompromised and at
              risk for serious infections. Vaccine immunogenicity is unknown in
              this population. We conducted a prospective observational study
              of the humoral immunogenicity of 2019-2020 inactivated influenza
              vaccines (IIV) in children and adults immediately prior to (n=7)
              or 13-57 months after (n=15) CD19-, CD20-, or BCMA-targeted
              CAR-T-cell therapy, as well as controls (n=8). Individuals
              post-CAR-T-cell therapy were in remission. We tested for
              antibodies to 4 vaccine strains at baseline and $\geq$1 time
              point after IIV using neutralization and hemagglutination
              inhibition assays. An antibody response was defined as a
              $\geq$4-fold titer increase from baseline at the first
              post-vaccine time point. Baseline A(H1N1) titers in the CAR-T
              cohorts were significantly lower compared to controls. Antibody
              responses to $\geq$1 vaccine strain occurred in 2 (29\%)
              individuals before CAR-T-cell therapy; one individual maintained
              a response for >3 months post-CAR-T-cell therapy. Antibody
              responses to $\geq$1 vaccine strain occurred in 6 (40\%)
              individuals vaccinated after CAR-T-cell therapy. An additional 2
              (29\%) and 6 (40\%) individuals had $\geq$2-fold increases (at
              any time) in the pre- and post-CAR-T cohorts, respectively. There
              were no identified clinical or immunologic predictors of antibody
              responses. Neither severe hypogammaglobulinemia nor B-cell
              aplasia precluded antibody responses. These data support
              consideration for vaccination before and after CAR-T-cell therapy
              for influenza and other relevant pathogens such as SARS-CoV-2,
              irrespective of hypogammaglobulinemia or B-cell aplasia. Larger
              studies are needed to determine correlates of vaccine
              immunogenicity and durability in CAR-T-cell therapy recipients.
              Key Points: Influenza vaccination was immunogenic pre- and
              post-CAR-T-cell therapy, despite hypogammaglobulinemia and B-cell
              aplasia.Vaccination with inactivated vaccines can be considered
              before CAR-T-cell therapy and in individuals with remission after
              therapy.",
  journal  = "medRxiv",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Walti2021-ja,
  title    = "Humoral immunogenicity of the seasonal influenza vaccine before
              and after {CAR-T-cell} therapy: a prospective observational study",
  author   = "Walti, Carla S and Loes, Andrea N and Shuey, Kiel and Krantz,
              Elizabeth M and Boonyaratanakornkit, Jim and Keane-Candib, Jacob
              and Loeffelholz, Tillie and Wolf, Caitlin R and Taylor, Justin J
              and Gardner, Rebecca A and Green, Damian J and Cowan, Andrew J
              and Maloney, David G and Turtle, Cameron J and Pergam, Steven A
              and Chu, Helen Y and Bloom, Jesse D and Hill, Joshua A",
  abstract = "Recipients of chimeric antigen receptor-modified T (CAR-T) cell
              therapies for B cell malignancies have profound and prolonged
              immunodeficiencies and are at risk for serious infections,
              including respiratory virus infections. Vaccination may be
              important for infection prevention, but there are limited data on
              vaccine immunogenicity in this population. We conducted a
              prospective observational study of the humoral immunogenicity of
              commercially available 2019-2020 inactivated influenza vaccines
              in adults immediately prior to or while in durable remission
              after CD19-, CD20-, or B cell maturation antigen-targeted
              CAR-T-cell therapy, as well as controls. We tested for antibodies
              to all four vaccine strains using neutralization and
              hemagglutination inhibition (HAI) assays. Antibody responses were
              defined as at least fourfold titer increases from baseline.
              Seroprotection was defined as a HAI titer $\geq$40. Enrolled
              CAR-T-cell recipients were vaccinated 14-29 days prior to (n=5)
              or 13-57 months following therapy (n=13), and the majority had
              hypogammaglobulinemia and cellular immunodeficiencies
              prevaccination. Eight non-immunocompromised adults served as
              controls. Antibody responses to $\geq$1 vaccine strain occurred
              in 2 (40\%) individuals before CAR-T-cell therapy and in 4 (31\%)
              individuals vaccinated after CAR-T-cell therapy. An additional 1
              (20\%) and 6 (46\%) individuals had at least twofold increases,
              respectively. One individual vaccinated prior to CAR-T-cell
              therapy maintained a response for >3 months following therapy.
              Across all tested vaccine strains, seroprotection was less
              frequent in CAR-T-cell recipients than in controls. There was
              evidence of immunogenicity even among individuals with low
              immunoglobulin, CD19+ B cell, and CD4+ T-cell counts. These data
              support consideration for vaccination before and after CAR-T-cell
              therapy for influenza and other relevant pathogens such as
              SARS-CoV-2, irrespective of hypogammaglobulinemia or B cell
              aplasia. However, relatively impaired humoral vaccine
              immunogenicity indicates the need for additional
              infection-prevention strategies. Larger studies are needed to
              refine our understanding of potential correlates of vaccine
              immunogenicity, and durability of immune responses, in CAR-T-cell
              therapy recipients.",
  journal  = "J. Immunother. Cancer",
  volume   =  9,
  number   =  10,
  month    =  oct,
  year     =  2021,
  keywords = "antibody formation; chimeric antigen; hematologic neoplasms;
              humoral; immunity; immunogenicity; receptors; vaccine",
  language = "en"
}
